[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fU4LnOOtK3d05CUL8oFNUxJok3AI9dds3PhjF0KwNVps":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":85,"rows":92},"Bristol-Myers Squibb",[4],1537,false,183,282,2974262,158,185,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Rheumatoid Arthritis",78,{"name":18,"count":19},"Healthy Participants",74,{"name":21,"count":22},"Melanoma",70,{"name":24,"count":25},"HIV Infections",68,{"name":27,"count":28},"Healthy Volunteers",53,{"name":30,"count":31},"Hepatitis C",47,{"name":33,"count":34},"Multiple Myeloma",32,{"name":36,"count":37},"Non-Small Cell Lung Cancer",27,[39,44,48,53,57,62,66,71,75,80],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT03141177","A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma","2020-02-12","Nivolumab",{"nctId":45,"briefTitle":46,"date":47,"intervention":43},"NCT02632409","An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer","2020-07-17",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT03470922","A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma","2021-01-25","Relatlimab",{"nctId":54,"briefTitle":55,"date":56,"intervention":43},"NCT04099251","Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB\u002FC Melanoma","2022-06-28",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT04909801","A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate","2023-06-14","Abatacept",{"nctId":63,"briefTitle":64,"date":65,"intervention":43},"NCT04025879","A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","2023-07-26",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT04446650","A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)","2023-10-05","Fedratinib",{"nctId":72,"briefTitle":73,"date":74,"intervention":43},"NCT04623775","A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)","2024-01-11",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT04908189","A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment","2024-02-06","Deucravacitinib",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT06549608","A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada","2024-05-06","Mavacamten",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,361,521,589,678,1070,1095,3142,3419,3561,3861,4554,4689,4787,4851,4950,5178,5232,5274,5326,5364,5487,5570,5735,5827,5908,5954,6003,6041,6079,6105,6131,6315,6349,6396,6505,6596,6626,6652,6678,6700,6722,6744,6813,6874,7000,7029,7129,7182,7229,7267,7301,7331,7365,7404,7426,7448,7470,7488,7506,7524,7542,7560,7578,7596,7614,7632,8048,8145,8177,8208,8230,8285,8336,8366,8392,8418,8552,8586,8626,8652,8688,8725,8758,8780,8806,8824,8842,8865,8883,8907,8925,8943,8961,8979,8997,9015,9033,9051,9069,9093,9111,9129,9147,9165,9183,9201,9219,9237,9255,9273,9315,9344,9370,9428,9458,9480,9513,9531,9549,9572,9595,9613,9638,9656,9674,9692,9710,9728,9752,9776,9807,9858,9899,9921,9939,9957,9975,9993,10011,10029,10052,10070,10094,10112,10130,10156,10174,10192,10215,10233,10251,10273,10291,10309,10327,10345,10368,10390,10504,10582,10625,10660,10709,10739,10778,10811,10841,10882,10917,10946,10981,11017,11048,11077,11110,11134,11152,11170,11193,11211,11234,11257,11280,11298,11316,11334,11352,11370,11388,11412,11430,11454,11476,11494,11517,11535,11558,11576,11598,11616,11718,11831,11948,12043,12107,12186,12278,12339,12387,12434,12503,12541,12594,12648,12688,12722,12769,12801,12835,12877,12912,12953,12987,13013,13043,13080,13116,13158,13191,13217,13239,13268,13299,13321,13354,13383,13405,13429,13451,13473,13504,13526,13548,13570,13598,13620,13642,13664,13687,13705,13723,13741,13759,13777,13795,13813,13831,13855,13873,13894,13912,13930,13948,13966,13984,14002,14020,14045,14063,14081,14107,14125,14143,14167,14185,14203,14221,14239,14257,14275,14293,14311,14329,14358,14376,14394,14412,14430,14451,14475,14493,14521,14539,14560,14578,14596,14614,14632,14656,14674,14692,14710,14733,14756,14774,14795,14818,14836,14854,14872,14890,14908,14926,14944,14966,14990,15008,15026,15048,15066,15084,15106,15124,15142,15160,15178,15290,15383,15493,15569,15625,15695,15750,15806,15853,15906,15951,16002,16053,16117,16161,16204,16253,16305,16354,16388,16426,16456,16498,16538,16583,16613,16643,16680,16709,16746,16772,16806,16839,16870,16909,16944,16970,17004,17037,17063,17089,17120,17149,17180,17207,17234,17256,17278,17300,17322,17352,17381,17405,17433,17458,17493,17521,17543,17565,17587,17612,17638,17667,17689,17711,17735,17763,17785,17807,17833,17855,17877,17899,17921,17943,17965,17987,18020,18038,18056,18074,18092,18110,18128,18149,18167,18185,18203,18221,18239,18257,18275,18293,18311,18329,18347,18365,18388,18406,18424,18449,18467,18485,18503,18521,18545,18563,18584,18605,18626,18644,18665,18688,18706,18724,18746,18764,18782,18805,18829,18847,18865,18883,18901,18925,18943,18961,18983,19001,19026,19044,19062,19080,19098,19119,19137,19155,19173,19194,19217,19235,19256,19281,19299,19317,19335,19353,19371,19389,19410,19428,19452,19470,19488,19511,19529,19547,19569,19592,19610,19628,19646,19667,19689,19707,19725,19747,19765,19783,19801,19823,19844,19862,19880,19898,19919,19945,19963,19981,19999,20017,20039,20057,20075,20093,20111,20129,20147,20165,20183,20201,20219,20242,20263,20281,20299,20317,20335,20353,20371,20393,20411,20433,20451,20469,20491,20509,20527,20548,20566,20584,20602,20675,20730,20794,20855,20896,20930,20966,21008,21047,21096,21134,21160,21190,21225,21263,21289,21315,21344,21376,21405,21442,21464,21486,21508,21530,21552,21584,21611,21633,21655,21677,21705,21736,21761,21783,21810,21832,21861,21886,21904,21929,21947,21965,21983,22006,22027,22050,22068,22092,22110,22128,22146,22164,22186,22208,22233,22251,22269,22287,22310,22331,22354,22372,22390,22408,22432,22450,22468,22490,22508,22530,22548,22566,22590,22608,22630,22652,22673,22691,22709,22727,22745,22767,22788,22806,22827,22850,22868,22891,22916,22934,22952,22970,22992,23010,23032,23053,23075,23093,23111,23129,23151,23169,23191,23214,23232,23250,23268,23293,23311,23329,23347,23365,23389,23407,23425,23443,23464,23486,23504,23522,23540,23558,23576,23594,23612,23630,23648,23666,23684,23702,23723,23748,23766,23784,23809,23827,23845,23863,23881,23899,23920,23941,23963,23985,24003,24027,24045,24063,24085,24106,24128,24146,24171,24189,24207,24228,24246,24267,24288,24306,24331,24349,24367,24389,24407,24428,24446,24464,24482,24500,24522,24540,24558,24579,24597,24620,24638,24656,24677,24695,24713,24731,24752,24775,24793,24811,24829,24850,24868,24891,24909,24927,24948,24966,24990,25008,25029,25050,25073,25091,25109,25130,25151,25173,25191,25209,25233,25251,25269,25290,25308,25326,25347,25370,25388,25406,25430,25452,25470,25488,25506,25529,25547,25570,25593,25611,25629,25653,25671,25693,25711,25729,25747,25765,25787,25808,25826,25850,25868,25886,25909,25927,25949,25967,25988,26006,26028,26046,26067,26088,26111,26129,26147,26165,26183,26201,26219,26237,26255,26273,26294,26312,26330,26348,26366,26389,26411,26429,26447,26465,26483,26504,26522,26540,26562,26580,26598,26621,26639,26661,26997,27273,27481,27651,27811,27933,28053,28138,28225,28290,28348,28402,28459,28501,28546,28588,28626,28660,28694,28726,28756,28790,28816,28853,28889,28915,28943,28973,28995,29013,29031,29052,29073,29095,29120,29138,29156,29178,29196,29217,29235,29257,29278,29301,29326,29348,29370,29392,29414,29432,29450,29472,29493,29511,29529,29547,29569,29590],{"intervention":84,"totalTrials":94,"cells":95},25,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":129,"PHASE3":152,"PHASE4":209,"NA":231},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[101,110,119],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":106,"start":107,"enrollment":11,"conditions":108,"interventions":109},"NCT05362045","A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants","COMPLETED",[87],"2022-08-19","2022-05-16",[18],[84],{"nctId":111,"briefTitle":112,"status":104,"phases":113,"primaryCompletion":114,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":118},"NCT05719805","A Study to Evaluate the Effects of Mavacamten in Healthy Participants",[87],"2023-07-25","2023-02-20",84,[18],[84],{"nctId":120,"briefTitle":121,"status":104,"phases":122,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":127},"NCT05320094","A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants",[87],"2022-09-11","2022-04-15",45,[18],[84,128],"Activated Charcoal with Sorbitol",{"trials":130,"activeCount":98},[131,142],{"nctId":132,"briefTitle":133,"status":104,"phases":134,"primaryCompletion":135,"completion":135,"start":136,"enrollment":137,"conditions":138,"interventions":140},"NCT03496168","Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER",[88],"2023-11-09","2018-04-26",13,[139],"Hypertrophic Cardiomyopathy",[141],"mavacamten",{"nctId":143,"briefTitle":144,"status":104,"phases":145,"primaryCompletion":146,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":151},"NCT04766892","A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT",[88],"2024-02-26","2021-03-30",30,[150],"Heart Failure With Preserved Ejection Fraction",[141],{"trials":153,"activeCount":208,"soonestReadout":181},[154,165,176,187,197],{"nctId":155,"briefTitle":156,"status":104,"phases":157,"primaryCompletion":158,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":164},"NCT03723655","A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM",[88,89],"2026-01-16","2018-09-27",314,[139,162,163],"Obstructive Hypertrophic Cardiomyopathy","Non-obstructive Hypertrophic Cardiomyopathy",[141],{"nctId":166,"briefTitle":167,"status":104,"phases":168,"primaryCompletion":169,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":175},"NCT05582395","A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy",[89],"2025-03-06","2025-10-20","2022-12-14",580,[174],"Cardiomyopathy, Hypertrophic",[84],{"nctId":177,"briefTitle":178,"status":179,"phases":180,"primaryCompletion":181,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":186},"NCT06253221","A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy","ACTIVE_NOT_RECRUITING",[89],"2025-11-25","2031-03-28","2024-04-17",44,[174],[84],{"nctId":188,"briefTitle":189,"status":104,"phases":190,"primaryCompletion":191,"completion":192,"start":106,"enrollment":193,"conditions":194,"interventions":196},"NCT05414175","A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy",[89],"2023-11-27","2025-12-11",38,[195],"Cardiomyopathy, Hypertrophic Obstructive",[84],{"nctId":198,"briefTitle":199,"status":104,"phases":200,"primaryCompletion":201,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":207},"NCT04349072","A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy",[89],"2022-02-07","2024-05-20","2020-07-06",112,[206],"HOCM, Hypertrophic Obstructive Cardiomyopathy",[84],1,{"trials":210,"activeCount":230,"soonestReadout":225},[211,221],{"nctId":212,"briefTitle":213,"status":179,"phases":214,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":220},"NCT07004972","A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)",[90],"2027-12-13","2025-09-04",50,[219],"Symptomatic Obstructive Hypertrophic Cardiomyopathy",[84],{"nctId":222,"briefTitle":223,"status":179,"phases":224,"primaryCompletion":225,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":229},"NCT06112743","A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy",[90],"2026-07-09","2024-01-24",63,[174],[84],2,{"trials":232,"activeCount":360,"soonestReadout":83},[233,245,255,265,274,284,293,305,314,324,334,341,351],{"nctId":234,"briefTitle":235,"status":236,"phases":237,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":244},"NCT07557498","Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US","RECRUITING",[],"2026-12-14","2027-06-17","2026-01-15",362,[243],"Obstructive Hypertrophic Cardiomyopathy (oHCM)",[84],{"nctId":246,"briefTitle":247,"status":236,"phases":248,"primaryCompletion":249,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":253},"NCT05489705","A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)",[],"2029-08-17","2022-08-16",1600,[162],[84,254],"Non-mavacamten symptomatic oHCM therapy",{"nctId":256,"briefTitle":257,"status":104,"phases":258,"primaryCompletion":259,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":264},"NCT07168655","Mavacamten in Obstructive Hypertrophic Cardiomyopathy",[],"2023-03-31","2025-03-25","2023-02-21",163,[243],[84],{"nctId":266,"briefTitle":267,"status":236,"phases":268,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":273},"NCT06146660","A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy",[],"2026-11-30","2024-07-24",600,[162],[84],{"nctId":275,"briefTitle":276,"status":104,"phases":277,"primaryCompletion":278,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":283},"NCT06338202","Real-World Effectiveness of Mavacamten in Canada",[],"2024-11-12","2024-12-19","2024-06-24",115,[243],[84],{"nctId":285,"briefTitle":286,"status":236,"phases":287,"primaryCompletion":288,"completion":289,"start":240,"enrollment":290,"conditions":291,"interventions":292},"NCT07361289","A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China",[],"2028-08-22","2028-08-28",500,[139],[84],{"nctId":294,"briefTitle":295,"status":179,"phases":296,"primaryCompletion":297,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":303},"NCT06372457","COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)",[],"2025-09-29","2026-06-30","2023-12-01",331,[302],"Hypertrophic Cardiomyopathy (HCM)",[304,84],"Approved Hypertrophic Cardiomyopathy drug treatments",{"nctId":306,"briefTitle":307,"status":236,"phases":308,"primaryCompletion":309,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":313},"NCT07383025","Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan",[],"2029-11-30","2025-05-21",200,[243],[84],{"nctId":315,"briefTitle":316,"status":236,"phases":317,"primaryCompletion":318,"completion":318,"start":135,"enrollment":319,"conditions":320,"interventions":323},"NCT05939700","Mavacamten Pregnancy Surveillance Program",[],"2027-04-30",20,[321,139,322],"Breastfeeding","Pregnancy Related",[84],{"nctId":325,"briefTitle":326,"status":179,"phases":327,"primaryCompletion":328,"completion":329,"start":330,"enrollment":331,"conditions":332,"interventions":333},"NCT07107373","A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US",[],"2024-07-26","2025-12-31","2023-12-22",150,[243],[84],{"nctId":81,"briefTitle":82,"status":179,"phases":335,"primaryCompletion":83,"completion":336,"start":337,"enrollment":338,"conditions":339,"interventions":340},[],"2025-04-18","2024-04-20",685,[139],[84],{"nctId":342,"briefTitle":343,"status":236,"phases":344,"primaryCompletion":345,"completion":345,"start":346,"enrollment":347,"conditions":348,"interventions":350},"NCT07541833","Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)",[],"2026-12-31","2026-02-05",36,[349],"Cardiomyopathy",[84],{"nctId":352,"briefTitle":353,"status":236,"phases":354,"primaryCompletion":345,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":359},"NCT06551129","Real-world Patient Reported Outcomes Among Patients Treated With Camzyos",[],"2027-06-30","2024-05-10",118,[162],[84],11,{"intervention":362,"totalTrials":363,"cells":364},"Luspatercept",14,{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":393,"PHASE4":416,"NA":427},{"trials":366,"activeCount":98},[],{"trials":368,"activeCount":98},[],{"trials":370,"activeCount":230,"soonestReadout":375},[371,382],{"nctId":372,"briefTitle":373,"status":179,"phases":374,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":381},"NCT05567458","A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.",[88],"2025-08-01","2026-08-01","2022-10-17",94,[380],"Beta-thalassemia",[362],{"nctId":383,"briefTitle":384,"status":236,"phases":385,"primaryCompletion":386,"completion":387,"start":388,"enrollment":389,"conditions":390,"interventions":392},"NCT05664737","A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia",[88],"2027-07-16","2034-08-14","2022-12-09",189,[391],"Anemia",[362],{"trials":394,"activeCount":230,"soonestReadout":411},[395,407],{"nctId":396,"briefTitle":397,"status":179,"phases":398,"primaryCompletion":399,"completion":400,"start":401,"enrollment":402,"conditions":403,"interventions":405},"NCT05949684","ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions",[89],"2027-06-25","2030-03-11","2023-10-24",360,[404],"Myelodysplastic Syndromes",[362,406],"Epoetin Alfa",{"nctId":408,"briefTitle":409,"status":179,"phases":410,"primaryCompletion":411,"completion":412,"start":69,"enrollment":413,"conditions":414,"interventions":415},"NCT06045689","A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants",[89],"2025-10-01","2027-12-30",106,[404],[362],{"trials":417,"activeCount":208,"soonestReadout":422},[418],{"nctId":419,"briefTitle":420,"status":179,"phases":421,"primaryCompletion":422,"completion":422,"start":423,"enrollment":424,"conditions":425,"interventions":426},"NCT05891249","A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India",[90],"2028-12-16","2023-06-05",85,[391],[362],{"trials":428,"activeCount":520,"soonestReadout":375},[429,444,455,464,474,482,492,501,509],{"nctId":430,"briefTitle":431,"status":179,"phases":432,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":437,"interventions":439},"NCT07465029","A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain",[],"2026-03-31","2026-05-31","2026-02-02",1300,[438],"Lower-risk Myelodysplastic Syndromes (TD LR-MDS)",[440,362,441,442,443],"Erythropoiesis-stimulating agents","Lenalidomide","Hypomethylating agents","Reb blood cell transfusion",{"nctId":445,"briefTitle":446,"status":179,"phases":447,"primaryCompletion":448,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":454},"NCT06596642","A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan",[],"2026-10-01","2026-12-17","2024-08-21",61,[453],"β-Thalassemia Major",[362],{"nctId":456,"briefTitle":457,"status":104,"phases":458,"primaryCompletion":459,"completion":459,"start":460,"enrollment":461,"conditions":462,"interventions":463},"NCT06851065","A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States",[],"2025-03-10","2024-08-22",418,[404],[362,440],{"nctId":465,"briefTitle":466,"status":467,"phases":468,"primaryCompletion":469,"completion":469,"start":470,"enrollment":98,"conditions":471,"interventions":473},"NCT06581055","A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes","WITHDRAWN",[],"2025-03-30","2024-11-30",[472],"Myelodysplastic Syndromes (MDS)",[362,406],{"nctId":475,"briefTitle":476,"status":104,"phases":477,"primaryCompletion":375,"completion":375,"start":478,"enrollment":479,"conditions":480,"interventions":481},"NCT07075406","A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept",[],"2024-11-01",250,[404],[362],{"nctId":483,"briefTitle":484,"status":236,"phases":485,"primaryCompletion":486,"completion":487,"start":488,"enrollment":311,"conditions":489,"interventions":491},"NCT07215975","A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East",[],"2030-02-28","2031-04-17","2026-06-25",[490],"β-thalassemia",[362],{"nctId":493,"briefTitle":494,"status":179,"phases":495,"primaryCompletion":375,"completion":375,"start":496,"enrollment":497,"conditions":498,"interventions":499},"NCT06971185","A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept",[],"2024-11-22",430,[472],[362,500],"Erythropoiesis-stimulating agent",{"nctId":502,"briefTitle":503,"status":104,"phases":504,"primaryCompletion":505,"completion":505,"start":336,"enrollment":506,"conditions":507,"interventions":508},"NCT07073690","Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China",[],"2026-05-12",88,[404],[362],{"nctId":510,"briefTitle":511,"status":236,"phases":512,"primaryCompletion":513,"completion":513,"start":514,"enrollment":515,"conditions":516,"interventions":519},"NCT06073860","A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia",[],"2027-12-21","2024-03-25",104,[517,518],"Myelodysplastic Syndrome","Beta Thalassemia",[362],5,{"intervention":522,"totalTrials":520,"cells":523},"Xanomeline\u002FTrospium Chloride",{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":539,"PHASE3":541,"PHASE4":575,"NA":587},{"trials":525,"activeCount":98},[],{"trials":527,"activeCount":208,"soonestReadout":532},[528],{"nctId":529,"briefTitle":530,"status":236,"phases":531,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":535,"interventions":536},"NCT07063342","A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult Participants",[87],"2026-08-15","2025-06-27",72,[27],[522,537,538],"Xanomeline Enteric","Trospium Chloride",{"trials":540,"activeCount":98},[],{"trials":542,"activeCount":574,"soonestReadout":558},[543,554,565],{"nctId":544,"briefTitle":545,"status":236,"phases":546,"primaryCompletion":547,"completion":548,"start":549,"enrollment":550,"conditions":551,"interventions":553},"NCT07011745","A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)",[89],"2028-11-03","2028-11-13","2025-07-16",352,[552],"Alzheimer Disease",[522,537],{"nctId":555,"briefTitle":556,"status":236,"phases":557,"primaryCompletion":558,"completion":558,"start":559,"enrollment":560,"conditions":561,"interventions":564},"NCT07140913","A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine",[89],"2027-06-28","2025-10-08",424,[562,563],"Mania","Bipolar Disorder",[522],{"nctId":566,"briefTitle":567,"status":236,"phases":568,"primaryCompletion":569,"completion":570,"start":571,"enrollment":550,"conditions":572,"interventions":573},"NCT07011732","A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)",[89],"2028-11-24","2028-12-08","2025-07-10",[552],[522,537],3,{"trials":576,"activeCount":208,"soonestReadout":412},[577],{"nctId":578,"briefTitle":579,"status":236,"phases":580,"primaryCompletion":412,"completion":412,"start":581,"enrollment":582,"conditions":583,"interventions":585},"NCT07221877","A Study to Evaluate the Effect of KarXT on Urological Safety",[90],"2026-01-20",60,[584],"Schizophrenia",[586],"Xanomeline\u002Ftrospium chloride",{"trials":588,"activeCount":98},[],{"intervention":590,"totalTrials":520,"cells":591},"Nivolumab + Relatlimab",{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":596,"PHASE3":624,"PHASE4":637,"NA":652},{"trials":593,"activeCount":98},[],{"trials":595,"activeCount":98},[],{"trials":597,"activeCount":208,"soonestReadout":602},[598],{"nctId":599,"briefTitle":600,"status":236,"phases":601,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":605,"interventions":607},"NCT03899155","Pan Tumor Rollover Study",[88],"2029-08-25","2019-08-09",1500,[606],"Cancer",[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],"Ipilimumab","Cabozantinib","Trametinib","Capecitabine","Bevacizumab","Temozolomide","Rucaparib","Daratumumab","Regorafinib","Leucovorin","Fluorouracil","Oxaliplatin","Enzalutamide","Sunitinib","Pemetrexed","Pembrolizumab",{"trials":625,"activeCount":208,"soonestReadout":630},[626],{"nctId":627,"briefTitle":628,"status":179,"phases":629,"primaryCompletion":630,"completion":631,"start":632,"enrollment":633,"conditions":634,"interventions":635},"NCT05625399","A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma",[89],"2025-08-04","2027-11-18","2023-03-06",579,[21],[590,636],"rHuPH20",{"trials":638,"activeCount":208,"soonestReadout":644},[639],{"nctId":640,"briefTitle":641,"status":642,"phases":643,"primaryCompletion":644,"completion":645,"start":646,"enrollment":148,"conditions":647,"interventions":651},"NCT07459543","A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India","NOT_YET_RECRUITING",[90],"2029-05-26","2029-05-28","2026-11-15",[648,649,650],"Untreated Melanoma","Unresectable Melanoma","Metastatic Melanoma",[590],{"trials":653,"activeCount":98},[654,665],{"nctId":655,"briefTitle":656,"status":104,"phases":657,"primaryCompletion":658,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":662},"NCT07091695","Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab",[],"2025-11-06","2025-05-11",100,[21],[663,664],"Nivolumab + relatlimab","Nivolumab + ipilimumab",{"nctId":666,"briefTitle":667,"status":104,"phases":668,"primaryCompletion":669,"completion":669,"start":670,"enrollment":671,"conditions":672,"interventions":674},"NCT07079644","Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database",[],"2025-03-31","2024-11-29",678,[673],"Advanced Melanoma",[590,675,676,677],"Nivolumab + Ipilimumab","Immunotherapy monotherapy","BRAF\u002FMEK inhibitors",{"intervention":679,"totalTrials":680,"cells":681},"BMS-986165",37,{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":930,"PHASE3":1006,"PHASE4":1055,"NA":1068},{"trials":683,"activeCount":98},[],{"trials":685,"activeCount":98},[686,697,707,718,729,741,751,762,773,783,797,806,815,824,833,842,853,864,875,884,894,903,912,920],{"nctId":687,"briefTitle":688,"status":104,"phases":689,"primaryCompletion":690,"completion":691,"start":692,"enrollment":693,"conditions":694,"interventions":695},"NCT04209699","A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers",[87],"2020-02-04","2020-02-11","2019-12-27",18,[18],[679,696],"Famotidine",{"nctId":698,"briefTitle":699,"status":104,"phases":700,"primaryCompletion":701,"completion":701,"start":702,"enrollment":703,"conditions":704,"interventions":706},"NCT03956953","Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects",[87],"2019-09-25","2019-04-04",135,[705],"Autoimmune Diseases",[679],{"nctId":708,"briefTitle":709,"status":104,"phases":710,"primaryCompletion":711,"completion":711,"start":712,"enrollment":713,"conditions":714,"interventions":716},"NCT04086719","An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.",[87],"2019-10-29","2019-09-12",16,[715],"Healthy Male Volunteers",[679,717],"Pyrimethamine",{"nctId":719,"briefTitle":720,"status":104,"phases":721,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":726,"interventions":727},"NCT04113668","The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants",[87],"2019-11-19","2019-11-25","2019-10-01",48,[18],[679,728],"diflunisal",{"nctId":730,"briefTitle":731,"status":104,"phases":732,"primaryCompletion":733,"completion":734,"start":735,"enrollment":736,"conditions":737,"interventions":739},"NCT04065932","A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets",[87],"2019-12-08","2019-12-10","2019-08-22",33,[738],"Lupus",[740,679,696],"BMS-986165-01",{"nctId":742,"briefTitle":743,"status":104,"phases":744,"primaryCompletion":745,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":750},"NCT03873415","Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males",[87],"2019-05-01","2019-01-25",9,[749],"Psoriasis",[679],{"nctId":752,"briefTitle":753,"status":104,"phases":754,"primaryCompletion":755,"completion":755,"start":756,"enrollment":757,"conditions":758,"interventions":760},"NCT03979248","A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants",[87],"2019-07-07","2019-05-16",21,[759],"Healthy",[679,761],"Rabeprazole",{"nctId":763,"briefTitle":764,"status":104,"phases":765,"primaryCompletion":766,"completion":767,"start":768,"enrollment":148,"conditions":769,"interventions":771},"NCT03402087","A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients",[87],"2018-03-20","2018-03-25","2018-01-08",[738,770],"Psoriatic Arthritis",[772,617,679],"Methotrexate",{"nctId":774,"briefTitle":775,"status":104,"phases":776,"primaryCompletion":777,"completion":777,"start":778,"enrollment":693,"conditions":779,"interventions":780},"NCT04249284","Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants",[87],"2020-03-15","2020-02-06",[18],[679,781,782],"BMS-986165 prototype 1","BMS-986165 prototype 2",{"nctId":784,"briefTitle":785,"status":104,"phases":786,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":791,"interventions":795},"NCT03262727","The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol\u002FNorethindrone) in Healthy Female Patients",[87],"2017-11-23","2017-12-19","2017-09-01",49,[792,793,749,794],"Systemic Lupus Erythematosus","Arthritic Psoriasis","Inflammatory Bowel Diseases",[679,796],"Loestrin 1.5\u002F30",{"nctId":798,"briefTitle":799,"status":104,"phases":800,"primaryCompletion":801,"completion":801,"start":802,"enrollment":116,"conditions":803,"interventions":804},"NCT03541564","An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects",[87],"2018-09-04","2018-05-30",[792,18],[679,805],"Moxifloxacin",{"nctId":807,"briefTitle":808,"status":104,"phases":809,"primaryCompletion":810,"completion":810,"start":811,"enrollment":34,"conditions":812,"interventions":814},"NCT03890809","An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage",[87],"2019-11-30","2019-02-26",[813,27],"Liver Dysfunction",[679],{"nctId":816,"briefTitle":817,"status":104,"phases":818,"primaryCompletion":819,"completion":147,"start":820,"enrollment":347,"conditions":821,"interventions":822},"NCT04671953","Effect of BMS-986165 on the Blood Levels of Metformin",[87],"2021-03-03","2020-12-18",[18],[679,823],"Metformin",{"nctId":825,"briefTitle":826,"status":104,"phases":827,"primaryCompletion":828,"completion":828,"start":829,"enrollment":830,"conditions":831,"interventions":832},"NCT03004768","Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants",[87],"2017-02-27","2017-01-26",6,[749],[679],{"nctId":834,"briefTitle":835,"status":104,"phases":836,"primaryCompletion":837,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":841},"NCT03739788","An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male Participants",[87],"2019-02-11","2018-12-05",8,[18],[679],{"nctId":843,"briefTitle":844,"status":104,"phases":845,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":849,"interventions":851},"NCT02534636","Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis",[87],"2016-11","2015-10",140,[850],"Healthy Subjects",[679,852,696],"Interferon alpha-2a recombinant",{"nctId":854,"briefTitle":855,"status":104,"phases":856,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":861,"interventions":862},"NCT03660436","An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants",[87],"2018-10-10","2018-10-18","2018-08-14",131,[18],[679,863],"MMF",{"nctId":865,"briefTitle":866,"status":104,"phases":867,"primaryCompletion":868,"completion":869,"start":870,"enrollment":319,"conditions":871,"interventions":873},"NCT03044873","Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin",[87],"2017-03-14","2017-03-27","2017-02-02",[705,872],"Inflammatory Diseases",[679,874],"Rosuvastatin",{"nctId":876,"briefTitle":877,"status":104,"phases":878,"primaryCompletion":879,"completion":879,"start":880,"enrollment":747,"conditions":881,"interventions":882},"NCT03751228","A Taste Assessment of BMS-986165 in Healthy Participants",[87],"2018-11-26","2018-10-11",[18],[679,883],"Active Pharmaceutical Ingredient",{"nctId":885,"briefTitle":886,"status":104,"phases":887,"primaryCompletion":888,"completion":888,"start":889,"enrollment":890,"conditions":891,"interventions":892},"NCT03419910","An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants",[87],"2018-05-04","2018-03-05",54,[749],[679,893],"Cyclosporine",{"nctId":895,"briefTitle":896,"status":104,"phases":897,"primaryCompletion":898,"completion":898,"start":899,"enrollment":713,"conditions":900,"interventions":901},"NCT04055506","A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants",[87],"2019-09-21","2019-08-14",[18],[679,902],"Ritonavir",{"nctId":904,"briefTitle":905,"status":104,"phases":906,"primaryCompletion":907,"completion":908,"start":909,"enrollment":790,"conditions":910,"interventions":911},"NCT03254784","A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat\u002F High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation",[87],"2017-11-04","2017-11-15","2017-09-13",[792,793,749,794],[679,679],{"nctId":913,"briefTitle":914,"status":104,"phases":915,"primaryCompletion":916,"completion":916,"start":745,"enrollment":713,"conditions":917,"interventions":918},"NCT03930602","Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165",[87],"2019-05-27",[759],[679,919],"Fluvoxamine",{"nctId":921,"briefTitle":922,"status":104,"phases":923,"primaryCompletion":924,"completion":925,"start":702,"enrollment":184,"conditions":926,"interventions":929},"NCT03890770","A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.",[87],"2020-02-07","2020-02-13",[927,928],"Renal Impairment","Healthy Volunteer",[679],{"trials":931,"activeCount":98},[932,941,950,960,972,982,992],{"nctId":933,"briefTitle":934,"status":104,"phases":935,"primaryCompletion":936,"completion":936,"start":937,"enrollment":938,"conditions":939,"interventions":940},"NCT03920267","Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus",[88],"2025-03-21","2019-03-26",261,[792],[679],{"nctId":942,"briefTitle":943,"status":104,"phases":944,"primaryCompletion":945,"completion":945,"start":946,"enrollment":947,"conditions":948,"interventions":949},"NCT02931838","Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis",[88],"2017-11-16","2016-11-15",268,[749],[679],{"nctId":951,"briefTitle":952,"status":104,"phases":953,"primaryCompletion":954,"completion":955,"start":956,"enrollment":193,"conditions":957,"interventions":959},"NCT04613518","A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis",[88],"2023-05-31","2023-11-29","2021-03-15",[958],"Colitis, Ulcerative",[679],{"nctId":961,"briefTitle":962,"status":963,"phases":964,"primaryCompletion":965,"completion":966,"start":967,"enrollment":713,"conditions":968,"interventions":970},"NCT03943147","An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis","TERMINATED",[88],"2020-10-29","2021-09-17","2019-07-15",[969],"Lupus Nephritis",[679,971],"Mycophenolate Mofetil",{"nctId":973,"briefTitle":974,"status":104,"phases":975,"primaryCompletion":976,"completion":977,"start":978,"enrollment":979,"conditions":980,"interventions":981},"NCT03252587","An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus",[88],"2021-06-29","2021-10-28","2017-09-21",363,[792],[679],{"nctId":983,"briefTitle":984,"status":104,"phases":985,"primaryCompletion":986,"completion":987,"start":988,"enrollment":860,"conditions":989,"interventions":991},"NCT03934216","Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis",[88],"2021-06-13","2023-04-04","2019-07-01",[990],"Ulcerative Colitis",[679],{"nctId":993,"briefTitle":994,"status":963,"phases":995,"primaryCompletion":996,"completion":997,"start":998,"enrollment":999,"conditions":1000,"interventions":1005},"NCT03599622","An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease",[88],"2022-12-12","2023-10-23","2018-07-16",239,[1001,1002,1003,1004],"Granulomatous Colitis","Crohn's Disease","Crohn's Enteritis","Granulomatous Enteritis",[679],{"trials":1007,"activeCount":208,"soonestReadout":1031},[1008,1018,1027,1037,1045],{"nctId":1009,"briefTitle":1010,"status":104,"phases":1011,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":1015,"interventions":1016},"NCT03624127","Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis",[89],"2020-09-02","2018-08-07",666,[749],[679,1017],"Apremilast",{"nctId":1019,"briefTitle":1020,"status":104,"phases":1021,"primaryCompletion":1022,"completion":1023,"start":723,"enrollment":1024,"conditions":1025,"interventions":1026},"NCT04167462","An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea",[89],"2021-03-08","2022-01-07",220,[749],[679],{"nctId":1028,"briefTitle":1029,"status":179,"phases":1030,"primaryCompletion":1031,"completion":1032,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1036},"NCT04036435","Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis",[89],"2026-07-25","2026-07-26","2019-08-12",1466,[749],[679],{"nctId":1038,"briefTitle":1039,"status":104,"phases":1040,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":19,"conditions":1043,"interventions":1044},"NCT03924427","An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis",[89],"2021-03-24","2019-04-10",[749],[679],{"nctId":1046,"briefTitle":1047,"status":104,"phases":1048,"primaryCompletion":1049,"completion":1050,"start":1051,"enrollment":1052,"conditions":1053,"interventions":1054},"NCT03611751","An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis",[89],"2020-11-29","2020-11-30","2018-07-26",1020,[749],[679,1017],{"trials":1056,"activeCount":208,"soonestReadout":1061},[1057],{"nctId":1058,"briefTitle":1059,"status":236,"phases":1060,"primaryCompletion":1061,"completion":1061,"start":1062,"enrollment":1063,"conditions":1064,"interventions":1067},"NCT06875960","A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and\u002For Subacute Cutaneous Lupus Erythematosus (DLE\u002FSCLE) Who Have Completed Study IM011074 or Study IM011132",[90],"2026-12-01","2026-02-24",35,[1065,1066],"Systemic Lupus Erythematosus (SLE)","Discoid and\u002For Subacute Cutaneous Lupus Erythematosus (DLE\u002FSCLE)",[679],{"trials":1069,"activeCount":98},[],{"intervention":1071,"totalTrials":208,"cells":1072},"BMS-986374",{"EARLY_PHASE1":1073,"PHASE1":1075,"PHASE2":1077,"PHASE3":1079,"PHASE4":1081,"NA":1093},{"trials":1074,"activeCount":98},[],{"trials":1076,"activeCount":98},[],{"trials":1078,"activeCount":98},[],{"trials":1080,"activeCount":98},[],{"trials":1082,"activeCount":208,"soonestReadout":1087},[1083],{"nctId":1084,"briefTitle":1085,"status":179,"phases":1086,"primaryCompletion":1087,"completion":1088,"start":1089,"enrollment":116,"conditions":1090,"interventions":1092},"NCT06396039","A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis",[90],"2028-12-29","2029-03-30","2024-05-15",[1091],"Relapsing Multiple Sclerosis",[1071],{"trials":1094,"activeCount":98},[],{"intervention":43,"totalTrials":1096,"cells":1097},202,{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1378,"PHASE3":2339,"PHASE4":2951,"NA":2993},{"trials":1099,"activeCount":98},[],{"trials":1101,"activeCount":230,"soonestReadout":1352},[1102,1112,1125,1134,1146,1159,1168,1178,1188,1198,1207,1215,1226,1236,1247,1256,1270,1279,1289,1301,1311,1320,1329,1338,1348,1359,1369],{"nctId":1103,"briefTitle":1104,"status":104,"phases":1105,"primaryCompletion":1106,"completion":1106,"start":1107,"enrollment":693,"conditions":1108,"interventions":1110},"NCT02534506","Study of Urelumab in Subjects With Advanced and\u002For Metastatic Malignant Tumors",[87],"2016-11-11","2015-11-06",[1109],"Malignant Tumors",[1111,43],"Urelumab",{"nctId":1113,"briefTitle":1114,"status":963,"phases":1115,"primaryCompletion":1116,"completion":1117,"start":1118,"enrollment":757,"conditions":1119,"interventions":1121},"NCT04311710","A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types",[87],"2021-01-14","2023-01-18","2020-06-25",[1120],"Tumor",[1122,1123,1124,1123],"ipilimumab","nivolumab","ENHANZE",{"nctId":1126,"briefTitle":1127,"status":104,"phases":1128,"primaryCompletion":1129,"completion":1129,"start":1130,"enrollment":830,"conditions":1131,"interventions":1133},"NCT05498480","Study of Relatlimab in Combination With Nivolumab in Chinese Participants",[87],"2024-01-18","2022-07-27",[1132],"Advanced Solid Tumors",[52,43],{"nctId":1135,"briefTitle":1136,"status":179,"phases":1137,"primaryCompletion":1138,"completion":1138,"start":260,"enrollment":1139,"conditions":1140,"interventions":1142},"NCT06764771","A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors",[87],"2027-10-15",437,[1141],"Advanced Malignant Tumors",[1143,1144,1145,43],"BMS-986488","Adagrasib","Cetuximab",{"nctId":1147,"briefTitle":1148,"status":104,"phases":1149,"primaryCompletion":1150,"completion":1150,"start":1151,"enrollment":1152,"conditions":1153,"interventions":1155},"NCT05298592","A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors",[87],"2024-08-16","2022-03-31",77,[1154],"Advanced Cancer",[1156,43,1157,622,1158],"BMS-986406","Carboplatin","Paclitaxel",{"nctId":1160,"briefTitle":1161,"status":104,"phases":1162,"primaryCompletion":1163,"completion":1163,"start":1164,"enrollment":574,"conditions":1165,"interventions":1166},"NCT03745807","An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors",[87],"2019-12-18","2019-04-09",[1154],[1167,43],"NKTR-214",{"nctId":1169,"briefTitle":1170,"status":104,"phases":1171,"primaryCompletion":1172,"completion":1173,"start":1174,"enrollment":1175,"conditions":1176,"interventions":1177},"NCT01621490","PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma",[87],"2017-09-12","2018-10-25","2012-09-27",170,[673,650],[43,608],{"nctId":1179,"briefTitle":1180,"status":104,"phases":1181,"primaryCompletion":1182,"completion":1182,"start":1183,"enrollment":1184,"conditions":1185,"interventions":1186},"NCT03203876","A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and\u002For Metastatic Solid Tumors",[87],"2020-08-06","2017-07-14",10,[1154],[1187,43,608],"Lirilumab",{"nctId":1189,"briefTitle":1190,"status":104,"phases":1191,"primaryCompletion":1192,"completion":1192,"start":1193,"enrollment":1063,"conditions":1194,"interventions":1196},"NCT02011945","A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia",[87],"2018-12-26","2014-02-07",[1195],"Chronic Myeloid Leukemia",[1197,43],"Dasatinib",{"nctId":1199,"briefTitle":1200,"status":104,"phases":1201,"primaryCompletion":1202,"completion":1202,"start":724,"enrollment":1203,"conditions":1204,"interventions":1205},"NCT04112498","A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab",[87],"2023-02-27",24,[606],[1206,1123,636],"relatlimab",{"nctId":1208,"briefTitle":1209,"status":104,"phases":1210,"primaryCompletion":1211,"completion":1211,"start":1212,"enrollment":1063,"conditions":1213,"interventions":1214},"NCT02966548","Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors",[87],"2024-07-09","2017-01-04",[606],[52,43],{"nctId":1216,"briefTitle":1217,"status":104,"phases":1218,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":1221,"conditions":1222,"interventions":1224},"NCT04132817","A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread",[87],"2022-08-15","2020-09-22",12,[1223],"Breast Cancer",[43,608,1225],"Nab-paclitaxel",{"nctId":1227,"briefTitle":1228,"status":963,"phases":1229,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":1232,"conditions":1233,"interventions":1234},"NCT03444753","An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed",[87],"2022-02-14","2018-04-05",82,[1154],[1235,43,608],"BMS-986299",{"nctId":1237,"briefTitle":1238,"status":104,"phases":1239,"primaryCompletion":1240,"completion":1241,"start":1242,"enrollment":319,"conditions":1243,"interventions":1244},"NCT03335540","An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment",[87],"2021-03-31","2021-08-25","2018-05-07",[1154],[43,52,1245,608,1246],"Cabiralizumab","IDO1 Inhibitor",{"nctId":1248,"briefTitle":1249,"status":104,"phases":1250,"primaryCompletion":1129,"completion":1129,"start":1251,"enrollment":148,"conditions":1252,"interventions":1254},"NCT04540705","A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread",[87],"2020-09-11",[1253],"Renal Cell Carcinoma",[43,1255,609],"Axitinib",{"nctId":1257,"briefTitle":1258,"status":104,"phases":1259,"primaryCompletion":1260,"completion":1261,"start":1262,"enrollment":1263,"conditions":1264,"interventions":1266},"NCT01454102","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine\u002FCisplatin, Pemetrexed\u002FCisplatin, Carboplatin\u002FPaclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB\u002FIV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",[87],"2016-07-20","2021-07-23","2011-12-16",472,[1265],"Non-small Cell Lung Cancer",[43,1267,1268,622,1158,1157,612,1269,608],"Gemcitabine","Cisplatin","Erlotinib",{"nctId":1271,"briefTitle":1272,"status":104,"phases":1273,"primaryCompletion":1274,"completion":1275,"start":1276,"enrollment":938,"conditions":1277,"interventions":1278},"NCT03980314","A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa\u002Fb\u002Fc\u002Fd or Stage IV Melanoma After Complete Resection",[87],"2021-03-04","2023-11-06","2019-06-24",[21],[43],{"nctId":1280,"briefTitle":1281,"status":104,"phases":1282,"primaryCompletion":1283,"completion":1283,"start":1284,"enrollment":1285,"conditions":1286,"interventions":1287},"NCT04943900","A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors",[87],"2025-02-27","2021-08-09",67,[1132],[1288,43],"BMS-986416",{"nctId":1290,"briefTitle":1291,"status":104,"phases":1292,"primaryCompletion":1293,"completion":1294,"start":1295,"enrollment":1296,"conditions":1297,"interventions":1299},"NCT01472081","Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)",[87],"2016-02-02","2021-06-03","2012-02-09",194,[1253,1298],"Clear-cell Metastatic Renal Cell Carcinoma",[43,1300,621,608],"Pazopanib",{"nctId":1302,"briefTitle":1303,"status":104,"phases":1304,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1307,"conditions":1308,"interventions":1310},"NCT03158272","A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread",[87],"2019-10-23","2017-05-25",19,[1309],"Advanced Malignancies",[1245,43],{"nctId":1312,"briefTitle":1313,"status":104,"phases":1314,"primaryCompletion":1315,"completion":1315,"start":1316,"enrollment":193,"conditions":1317,"interventions":1319},"NCT02960854","A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.",[87],"2018-01-05","2016-12-07",[1318],"Severe Sepsis",[43],{"nctId":1321,"briefTitle":1322,"status":104,"phases":1323,"primaryCompletion":1324,"completion":1324,"start":388,"enrollment":22,"conditions":1325,"interventions":1326},"NCT05625412","A Study of BMS-986360\u002FCC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors",[87],"2025-05-12",[1132],[1327,1328,43,611],"BMS-986360","Docetaxel",{"nctId":1330,"briefTitle":1331,"status":104,"phases":1332,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":360,"conditions":1335,"interventions":1336},"NCT03192943","A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors",[87],"2018-12-11","2017-06-23",[1154],[1337,43],"BMS-986205",{"nctId":1339,"briefTitle":1340,"status":104,"phases":1341,"primaryCompletion":1342,"completion":1342,"start":1343,"enrollment":736,"conditions":1344,"interventions":1346},"NCT01629758","Safety Study of IL-21\u002FAnti-PD-1 Combination in the Treatment of Solid Tumors",[87],"2014-12","2012-06",[1345],"Neoplasms by Site",[1347,43],"Denenicokin",{"nctId":1349,"briefTitle":1350,"status":179,"phases":1351,"primaryCompletion":1352,"completion":1352,"start":1353,"enrollment":1354,"conditions":1355,"interventions":1356},"NCT06544655","A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors",[87],"2027-10-14","2024-10-10",213,[1132],[1357,43,619,611,618,1358],"BMS-986484","Calcium folinate",{"nctId":1360,"briefTitle":1361,"status":104,"phases":1362,"primaryCompletion":1363,"completion":1364,"start":1365,"enrollment":37,"conditions":1366,"interventions":1367},"NCT03661632","An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors",[87],"2019-11-11","2020-12-29","2018-09-11",[1154],[1368,43],"BMS-986310",{"nctId":1370,"briefTitle":1371,"status":104,"phases":1372,"primaryCompletion":183,"completion":1373,"start":937,"enrollment":890,"conditions":1374,"interventions":1376},"NCT03956680","An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers",[87],"2024-04-24",[1375],"Advanced Solid Cancers",[1377,43,608],"BMS-986301",{"trials":1379,"activeCount":1750,"soonestReadout":74},[1380,1398,1408,1417,1428,1443,1454,1463,1475,1485,1495,1508,1518,1528,1539,1550,1561,1570,1580,1590,1600,1610,1619,1627,1638,1647,1661,1665,1679,1689,1699,1709,1722,1734,1744,1754,1762,1774,1786,1798,1809,1817,1828,1839,1848,1858,1871,1880,1891,1901,1910,1920,1930,1939,1950,1960,1972,1985,1994,2003,2013,2021,2032,2043,2056,2069,2078,2092,2101,2112,2123,2132,2142,2153,2165,2176,2185,2194,2207,2217,2226,2237,2246,2256,2268,2275,2283,2291,2302,2311,2321,2331],{"nctId":1381,"briefTitle":1382,"status":963,"phases":1383,"primaryCompletion":1384,"completion":1384,"start":1294,"enrollment":1385,"conditions":1386,"interventions":1397},"NCT04730349","A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer",[87,88],"2022-06-22",15,[1387,1388,1389,1390,1391,1392,1393,1394,1395,1396],"Ependymoma","Ewing Sarcoma","High-grade Glioma","Leukemia and Lymphoma","Medulloblastoma","Miscellaneous Brain Tumors","Miscellaneous Solid Tumors","Neuroblastoma","Relapsed, Refractory Malignant Neoplasms","Rhabdomyosarcoma",[43,1167],{"nctId":1399,"briefTitle":1400,"status":963,"phases":1401,"primaryCompletion":1402,"completion":1402,"start":1403,"enrollment":347,"conditions":1404,"interventions":1405},"NCT05543629","A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer",[87,88],"2024-09-12","2022-10-04",[1132,1265],[1406,43,1328,1157,1407,1158],"BMS-986442","Pemexetred",{"nctId":1409,"briefTitle":1410,"status":963,"phases":1411,"primaryCompletion":1412,"completion":1412,"start":1413,"enrollment":1414,"conditions":1415,"interventions":1416},"NCT02750514","An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer",[88],"2020-01-29","2016-05-09",295,[1154],[43,1197,52,608,1337],{"nctId":1418,"briefTitle":1419,"status":104,"phases":1420,"primaryCompletion":1421,"completion":1422,"start":1423,"enrollment":1424,"conditions":1425,"interventions":1427},"NCT02857426","A Study of Nivolumab in Relapsed\u002FRefractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed\u002FRefractory Primary Testicular Lymphoma (PTL)",[88],"2019-06-11","2020-11-24","2016-10-21",66,[1426],"Lymphoma",[43],{"nctId":1429,"briefTitle":1430,"status":467,"phases":1431,"primaryCompletion":1432,"completion":1433,"start":1434,"enrollment":98,"conditions":1435,"interventions":1440},"NCT03704077","An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma",[88],"2022-02-27","2024-09-30","2019-10-31",[1436,1437,1438,1439],"Gastric Cancer","Cancer of the Stomach","Stomach Cancer","Gastroesophageal Junction",[1441,43,1158,1442],"Relatlimab + Nivolumab","Ramucirumab",{"nctId":1444,"briefTitle":1445,"status":104,"phases":1446,"primaryCompletion":1447,"completion":1447,"start":1448,"enrollment":1449,"conditions":1450,"interventions":1452},"NCT02419417","Study of BMS-986158 in Subjects With Select Advanced Cancers",[87,88],"2021-03-17","2015-06-19",83,[1451],"Advanced Tumors",[1453,43],"BMS-986158",{"nctId":1455,"briefTitle":1456,"status":179,"phases":1457,"primaryCompletion":1458,"completion":1458,"start":1459,"enrollment":660,"conditions":1460,"interventions":1461},"NCT05888831","A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors",[87,88],"2026-09-30","2023-06-06",[1132],[1462,43],"BMS-986449",{"nctId":1464,"briefTitle":1465,"status":104,"phases":1466,"primaryCompletion":1467,"completion":1468,"start":1469,"enrollment":1470,"conditions":1471,"interventions":1473},"NCT01928394","A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors",[87,88],"2019-02-05","2024-11-18","2013-10-24",1163,[1472],"Advanced or Metastatic Solid Tumors",[43,608,1474],"Cobimetinib",{"nctId":1476,"briefTitle":1477,"status":963,"phases":1478,"primaryCompletion":1479,"completion":1479,"start":1480,"enrollment":451,"conditions":1481,"interventions":1483},"NCT02472977","Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors",[87,88],"2017-01-27","2015-07-13",[1482],"Solid Tumor",[1484,43],"Ulocuplumab",{"nctId":1486,"briefTitle":1487,"status":104,"phases":1488,"primaryCompletion":1489,"completion":1490,"start":1491,"enrollment":1492,"conditions":1493,"interventions":1494},"NCT01927419","Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma",[88],"2014-07-24","2021-02-26","2013-08-23",142,[649,650],[43,608],{"nctId":1496,"briefTitle":1497,"status":104,"phases":1498,"primaryCompletion":1499,"completion":1500,"start":1501,"enrollment":1502,"conditions":1503,"interventions":1505},"NCT02985957","A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)",[88],"2022-04-05","2025-01-07","2017-03-26",351,[1504],"Prostate Cancer",[43,608,1506,1507],"Cabazitaxel","Prednisone",{"nctId":1509,"briefTitle":1510,"status":104,"phases":1511,"primaryCompletion":1512,"completion":1512,"start":1513,"enrollment":1414,"conditions":1514,"interventions":1516},"NCT02598960","An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.",[87,88],"2019-12-16","2015-10-14",[1515],"Solid Tumors",[1517,43],"BMS-986156",{"nctId":72,"briefTitle":73,"status":179,"phases":1519,"primaryCompletion":74,"completion":1520,"start":1521,"enrollment":1522,"conditions":1523,"interventions":1526},[88],"2026-02-27","2021-02-17",468,[1265,1524,1525],"Recurrent Non-small Cell Lung Cancer","Metastatic Non-small Cell Lung Cancer",[43,52,1157,1268,1158,1527,622],"Nab-Paclitaxel",{"nctId":1529,"briefTitle":1530,"status":104,"phases":1531,"primaryCompletion":1532,"completion":1533,"start":1534,"enrollment":1535,"conditions":1536,"interventions":1538},"NCT02823574","Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",[88],"2019-01-23","2022-04-21","2016-11-08",425,[1537],"Head and Neck Cancer",[43,608],{"nctId":1540,"briefTitle":1541,"status":963,"phases":1542,"primaryCompletion":1543,"completion":1544,"start":1545,"enrollment":1492,"conditions":1546,"interventions":1548},"NCT03519256","A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder",[88],"2022-08-22","2022-08-24","2018-08-02",[1547],"Urinary Bladder Neoplasms",[43,1549,1337],"BCG",{"nctId":1551,"briefTitle":1552,"status":104,"phases":1553,"primaryCompletion":1554,"completion":1555,"start":1556,"enrollment":1557,"conditions":1558,"interventions":1560},"NCT01783938","Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)",[88],"2015-04-03","2020-08-12","2013-04-30",138,[1559],"Advanced or Metastatic Melanoma",[43,608],{"nctId":1562,"briefTitle":1563,"status":104,"phases":1564,"primaryCompletion":1565,"completion":1402,"start":1566,"enrollment":1567,"conditions":1568,"interventions":1569},"NCT03656718","A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)",[87,88],"2022-09-07","2018-10-29",139,[1345],[1123,636,1123],{"nctId":1571,"briefTitle":1572,"status":104,"phases":1573,"primaryCompletion":1574,"completion":1575,"start":1576,"enrollment":1577,"conditions":1578,"interventions":1579},"NCT03090737","Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer",[88],"2021-02-16","2022-03-14","2017-06-02",129,[36],[43],{"nctId":1581,"briefTitle":1582,"status":104,"phases":1583,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":1586,"conditions":1587,"interventions":1589},"NCT05136677","A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants",[88],"2025-11-12","2022-01-25",102,[1588],"Mesothelioma, Malignant",[43,608,622,1268,1157],{"nctId":1591,"briefTitle":1592,"status":104,"phases":1593,"primaryCompletion":1594,"completion":1595,"start":1596,"enrollment":1597,"conditions":1598,"interventions":1599},"NCT03001882","An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)",[88],"2022-02-17","2023-04-24","2017-03-29",230,[36],[43,608],{"nctId":1601,"briefTitle":1602,"status":104,"phases":1603,"primaryCompletion":278,"completion":278,"start":1604,"enrollment":1605,"conditions":1606,"interventions":1608},"NCT01658878","An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer",[87,88],"2012-10-30",657,[1607],"Hepatocellular Carcinoma",[43,1609,608,609],"Sorafenib",{"nctId":1611,"briefTitle":1612,"status":963,"phases":1613,"primaryCompletion":1614,"completion":1614,"start":191,"enrollment":208,"conditions":1615,"interventions":1617},"NCT06094296","A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)",[88],"2024-08-08",[1616],"NSCLC",[1618,43,622,1268,1157,1158],"BMS-986315",{"nctId":1620,"briefTitle":1621,"status":963,"phases":1622,"primaryCompletion":768,"completion":768,"start":1623,"enrollment":94,"conditions":1624,"interventions":1625},"NCT02828124","A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer",[87,88],"2016-08-23",[1607],[1626,43],"BMS-986183",{"nctId":1628,"briefTitle":1629,"status":104,"phases":1630,"primaryCompletion":1631,"completion":1632,"start":1633,"enrollment":1634,"conditions":1635,"interventions":1637},"NCT03130959","A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies",[88],"2020-03-10","2022-01-17","2017-06-12",166,[1636],"Various Advanced Cancer",[43,608],{"nctId":1639,"briefTitle":1640,"status":104,"phases":1641,"primaryCompletion":1642,"completion":1642,"start":1643,"enrollment":1644,"conditions":1645,"interventions":1646},"NCT02658890","An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread",[87,88],"2021-10-26","2016-04-14",627,[1154,21,36],[1337,43,608],{"nctId":1648,"briefTitle":1649,"status":104,"phases":1650,"primaryCompletion":1651,"completion":1652,"start":1653,"enrollment":1654,"conditions":1655,"interventions":1660},"NCT04567615","A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors",[88],"2023-08-31","2025-11-19","2021-02-04",266,[1607,1656,1657,1658,1659],"Hepatoma","Liver Cancer, Adult","Liver Cell Carcinoma","Liver Cell Carcinoma, Adult",[43,52],{"nctId":599,"briefTitle":600,"status":236,"phases":1662,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":1663,"interventions":1664},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"nctId":1666,"briefTitle":1667,"status":104,"phases":1668,"primaryCompletion":1669,"completion":60,"start":1670,"enrollment":1671,"conditions":1672,"interventions":1675},"NCT03184870","A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors",[87,88],"2023-04-06","2017-08-08",332,[1673,1674],"Colorectal Cancer","Pancreatic Cancer",[1676,43,1225,1267,1677,617,1678],"BMS-813160","5-fluorouracil","Irinotecan",{"nctId":1680,"briefTitle":1681,"status":179,"phases":1682,"primaryCompletion":1683,"completion":1684,"start":1685,"enrollment":1686,"conditions":1687,"interventions":1688},"NCT06946797","A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)",[88],"2027-02-05","2028-10-25","2025-09-19",76,[36],[43,608,1157,1158,622,1268],{"nctId":1690,"briefTitle":1691,"status":963,"phases":1692,"primaryCompletion":1693,"completion":1693,"start":1694,"enrollment":1695,"conditions":1696,"interventions":1697},"NCT03446040","An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread",[87,88],"2024-08-29","2018-03-08",92,[1154],[1698,43,636],"BMS-986258",{"nctId":1700,"briefTitle":1701,"status":963,"phases":1702,"primaryCompletion":1703,"completion":1704,"start":1448,"enrollment":1705,"conditions":1706,"interventions":1707},"NCT02341625","A Study of BMS-986148 in Patients With Select Advanced Solid Tumors",[87,88],"2019-02-25","2020-05-07",126,[1154],[1708,43],"BMS-986148",{"nctId":1710,"briefTitle":1711,"status":236,"phases":1712,"primaryCompletion":1713,"completion":1713,"start":1714,"enrollment":1715,"conditions":1716,"interventions":1718},"NCT06618287","A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors",[87,88],"2031-02-26","2025-02-04",416,[1717,1223],"Lung Cancer",[1719,1720,623,43,1721],"BMS-986507","Osimertinib","Pumitamig",{"nctId":1723,"briefTitle":1724,"status":236,"phases":1725,"primaryCompletion":1726,"completion":1727,"start":1728,"enrollment":1729,"conditions":1730,"interventions":1732},"NCT07325136","A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed\u002FRefractory Small Cell Lung Cancer",[87,88],"2029-04-23","2029-04-24","2026-02-03",240,[1731],"Relapsed\u002FRefractory Small Cell Lung Cancer",[1733,43],"BMS-986525",{"nctId":1735,"briefTitle":1736,"status":104,"phases":1737,"primaryCompletion":1738,"completion":1739,"start":1740,"enrollment":1449,"conditions":1741,"interventions":1743},"NCT05337137","A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer",[87,88],"2025-07-05","2025-11-18","2022-05-05",[1742],"Carcinoma, Hepatocellular",[52,43,612],{"nctId":1745,"briefTitle":1746,"status":963,"phases":1747,"primaryCompletion":1748,"completion":1748,"start":1749,"enrollment":1750,"conditions":1751,"interventions":1752},"NCT03351231","An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer",[87,88],"2018-08-28","2017-11-27",7,[606],[1753,43],"BMS-986242",{"nctId":1755,"briefTitle":1756,"status":104,"phases":1757,"primaryCompletion":203,"completion":203,"start":1758,"enrollment":1759,"conditions":1760,"interventions":1761},"NCT03098550","A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread",[87,88],"2017-06-15",105,[1154],[43,615],{"nctId":1763,"briefTitle":1764,"status":104,"phases":1765,"primaryCompletion":1766,"completion":1766,"start":1767,"enrollment":1634,"conditions":1768,"interventions":1769},"NCT02737475","An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and\u002For Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread",[87,88],"2020-11-02","2016-06-17",[1154],[1770,43,608,1771,1772,1773],"BMS-986178","Tetanus vaccine","DPV-001 vaccine","Cyclophosphamide",{"nctId":1775,"briefTitle":1776,"status":104,"phases":1777,"primaryCompletion":1778,"completion":1779,"start":1780,"enrollment":1781,"conditions":1782,"interventions":1784},"NCT02659059","Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer",[88],"2018-06-22","2022-03-07","2016-02-15",324,[1783],"Non-Small-Cell Lung Cancer",[43,608,1785],"Platinum Doublet Chemotherapy",{"nctId":1787,"briefTitle":1788,"status":104,"phases":1789,"primaryCompletion":1790,"completion":1790,"start":1791,"enrollment":1285,"conditions":1792,"interventions":1793},"NCT02719613","Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab",[88],"2026-02-23","2016-07-15",[33],[1794,1795,1795,441,1796,1797,43],"Elotuzumab","Dexamethasone","Bortezomib","Pomalidomide",{"nctId":1799,"briefTitle":1800,"status":104,"phases":1801,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":1805,"conditions":1806,"interventions":1807},"NCT03400332","A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers",[87,88],"2024-04-26","2025-12-04","2018-02-12",281,[606,21],[1808,43,608],"BMS-986253",{"nctId":1810,"briefTitle":1811,"status":104,"phases":1812,"primaryCompletion":1813,"completion":1813,"start":1814,"enrollment":680,"conditions":1815,"interventions":1816},"NCT03195478","A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors",[87,88],"2024-01-05","2017-08-02",[1482],[43,608],{"nctId":1818,"briefTitle":1819,"status":104,"phases":1820,"primaryCompletion":1821,"completion":1211,"start":1822,"enrollment":1823,"conditions":1824,"interventions":1827},"NCT01592370","An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma",[87,88],"2020-09-25","2012-08-02",320,[1825,1826,33],"Non-Hodgkin's Lymphoma","Hodgkin Lymphoma",[43,608,1187,615,1797,1795],{"nctId":1829,"briefTitle":1830,"status":104,"phases":1831,"primaryCompletion":1832,"completion":1833,"start":1834,"enrollment":1835,"conditions":1836,"interventions":1838},"NCT01721759","Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens",[88],"2014-01-22","2021-04-22","2012-11-16",117,[1837],"Squamous Cell Non-small Cell Lung Cancer",[43],{"nctId":1840,"briefTitle":1841,"status":104,"phases":1842,"primaryCompletion":1843,"completion":1843,"start":1844,"enrollment":208,"conditions":1845,"interventions":1846},"NCT05005273","A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer",[88],"2022-12-27","2022-10-03",[36],[43,608,1847],"BMS-986207",{"nctId":1849,"briefTitle":1850,"status":104,"phases":1851,"primaryCompletion":1852,"completion":1853,"start":1854,"enrollment":1855,"conditions":1856,"interventions":1857},"NCT02488759","An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors",[87,88],"2021-03-19","2022-10-24","2015-10-13",578,[1636],[43,608,52,615],{"nctId":1859,"briefTitle":1860,"status":963,"phases":1861,"primaryCompletion":1862,"completion":1862,"start":789,"enrollment":1863,"conditions":1864,"interventions":1868},"NCT03251924","A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors",[87,88],"2021-12-20",80,[606,1865,1866,1867],"Tumors","Neoplasm","Malignancy",[1869,43,608,1870],"BMS-986226","Tetanus Vaccine",{"nctId":1872,"briefTitle":1873,"status":104,"phases":1874,"primaryCompletion":1875,"completion":1875,"start":1876,"enrollment":1877,"conditions":1878,"interventions":1879},"NCT02320058","An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself",[88],"2020-09-08","2015-03-05",119,[21],[608,43],{"nctId":1881,"briefTitle":1882,"status":104,"phases":1883,"primaryCompletion":1884,"completion":1885,"start":1886,"enrollment":413,"conditions":1887,"interventions":1889},"NCT02247349","BMS-986012 in Relapsed\u002FRefractory SCLC",[87,88],"2022-12-21","2022-12-22","2014-11-14",[1888],"Small Cell Lung Cancer",[1890,43],"BMS-986012",{"nctId":1892,"briefTitle":1893,"status":104,"phases":1894,"primaryCompletion":1895,"completion":1896,"start":1897,"enrollment":1898,"conditions":1899,"interventions":1900},"NCT02038946","Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)",[88],"2017-05-17","2020-12-28","2014-03-26",116,[1426],[43],{"nctId":1902,"briefTitle":1903,"status":963,"phases":1904,"primaryCompletion":1905,"completion":1905,"start":1906,"enrollment":1184,"conditions":1907,"interventions":1908},"NCT03363776","An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers",[87,88],"2019-11-22","2017-12-06",[606],[1909,43],"BMS-986277",{"nctId":1911,"briefTitle":1912,"status":104,"phases":1913,"primaryCompletion":1914,"completion":1914,"start":1915,"enrollment":1916,"conditions":1917,"interventions":1919},"NCT02913313","A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors",[87,88],"2024-01-25","2016-11-30",101,[1918],"Broad Solid Tumor",[1847,43,608],{"nctId":1921,"briefTitle":1922,"status":104,"phases":1923,"primaryCompletion":1924,"completion":1925,"start":1447,"enrollment":703,"conditions":1926,"interventions":1928},"NCT04702880","A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer",[88],"2025-05-22","2025-11-28",[1927],"Extensive-stage Small Cell Lung Cancer",[1890,1157,1929,43],"Etoposide",{"nctId":1931,"briefTitle":1932,"status":104,"phases":1933,"primaryCompletion":1934,"completion":1935,"start":1936,"enrollment":999,"conditions":1937,"interventions":1938},"NCT02832167","An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread",[88],"2019-10-20","2021-06-24","2016-02-22",[606],[43],{"nctId":1940,"briefTitle":1941,"status":104,"phases":1942,"primaryCompletion":1943,"completion":1943,"start":1944,"enrollment":1945,"conditions":1946,"interventions":1947},"NCT03994601","An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers",[87,88],"2024-08-31","2019-09-06",219,[1154],[1948,43,1949],"BMS-986288","Regorafenib",{"nctId":1951,"briefTitle":1952,"status":104,"phases":1953,"primaryCompletion":1954,"completion":1954,"start":1955,"enrollment":1956,"conditions":1957,"interventions":1959},"NCT01714739","A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors",[87,88],"2019-12-13","2012-10-07",337,[1958],"CANCER,NOS",[1187,43,608],{"nctId":1961,"briefTitle":1962,"status":104,"phases":1963,"primaryCompletion":1964,"completion":1964,"start":1965,"enrollment":1966,"conditions":1967,"interventions":1971},"NCT03377361","An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread",[87,88],"2024-11-04","2018-01-31",325,[1673,1968,1969,1970],"Colorectal Tumors","Colorectal Carcinoma","Colorectal Neoplasm",[43,610,608,1949],{"nctId":1973,"briefTitle":1974,"status":104,"phases":1975,"primaryCompletion":1976,"completion":1977,"start":788,"enrollment":1978,"conditions":1979,"interventions":1980},"NCT03338790","An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer",[88],"2021-01-13","2025-01-10",292,[1504],[1123,1981,1982,1983,1984],"docetaxel","enzalutamide","rucaparib","prednisone",{"nctId":1986,"briefTitle":1987,"status":104,"phases":1988,"primaryCompletion":1989,"completion":1990,"start":1991,"enrollment":19,"conditions":1992,"interventions":1993},"NCT02612779","A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.",[88],"2019-07-29","2020-06-12","2016-02-09",[33],[1794,1797,1795,43],{"nctId":1995,"briefTitle":1996,"status":104,"phases":1997,"primaryCompletion":1998,"completion":1998,"start":1999,"enrollment":2000,"conditions":2001,"interventions":2002},"NCT02156804","A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)",[88],"2019-01-18","2014-10-07",1009,[21],[43],{"nctId":2004,"briefTitle":2005,"status":104,"phases":2006,"primaryCompletion":2007,"completion":2008,"start":2009,"enrollment":2010,"conditions":2011,"interventions":2012},"NCT02409368","An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb\u002FIV SqNSCLC",[88],"2018-03-07","2021-08-27","2015-04-29",812,[36],[43],{"nctId":2014,"briefTitle":2015,"status":467,"phases":2016,"primaryCompletion":2017,"completion":2018,"start":1240,"enrollment":98,"conditions":2019,"interventions":2020},"NCT04495010","Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants",[88],"2024-02-28","2027-10-23",[21],[43,608],{"nctId":2022,"briefTitle":2023,"status":104,"phases":2024,"primaryCompletion":2025,"completion":2026,"start":2027,"enrollment":2028,"conditions":2029,"interventions":2031},"NCT02038933","Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)",[88],"2016-04-08","2020-10-08","2014-03-05",121,[2030],"Lymphoma. Non-Hodgkin",[43],{"nctId":2033,"briefTitle":2034,"status":104,"phases":2035,"primaryCompletion":2036,"completion":2036,"start":2037,"enrollment":2038,"conditions":2039,"interventions":2040},"NCT04075604","A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer",[88],"2021-07-27","2019-10-18",23,[1223,606],[43,2041,2042],"Anastrozole","Palbociclib",{"nctId":2044,"briefTitle":2045,"status":104,"phases":2046,"primaryCompletion":2047,"completion":1843,"start":2048,"enrollment":2049,"conditions":2050,"interventions":2052},"NCT02181738","Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)",[88],"2017-08-31","2014-08-12",294,[2051],"Hodgkin Disease",[43,2053,2054,2055],"Doxorubicin","Vinblastine","Dacarbazine",{"nctId":2057,"briefTitle":2058,"status":467,"phases":2059,"primaryCompletion":2060,"completion":2061,"start":2062,"enrollment":98,"conditions":2063,"interventions":2065},"NCT04151563","A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1\u002F(L)1 Therapy and Chemotherapy",[87,88],"2023-12-17","2026-05-13","2021-04-15",[2064],"Carcinoma, Non-small Cell Lung Cancer",[1123,1122,2066,1981,2067,2068],"cabozantinib","ramucirumab","lucitanib",{"nctId":2070,"briefTitle":2071,"status":104,"phases":2072,"primaryCompletion":460,"completion":460,"start":2073,"enrollment":184,"conditions":2074,"interventions":2076},"NCT04349267","Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors",[87,88],"2020-07-14",[2075],"Advanced Solid Tumor",[1618,1123,2077],"cetuximab",{"nctId":2079,"briefTitle":2080,"status":104,"phases":2081,"primaryCompletion":2082,"completion":2082,"start":2083,"enrollment":2084,"conditions":2085,"interventions":2090},"NCT02060188","A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread",[88],"2024-10-22","2014-03-12",385,[2086,2087,2088,2089],"Microsatellite Unstable Colorectal Cancer","Microsatellite Stable Colorectal Cancer","Mismatch Repair Proficient Colorectal Cancer","Mismatch Repair Deficient Colorectal Cancer",[608,43,1474,615,2091],"BMS-986016",{"nctId":2093,"briefTitle":2094,"status":963,"phases":2095,"primaryCompletion":2096,"completion":2096,"start":1230,"enrollment":1184,"conditions":2097,"interventions":2099},"NCT05169684","A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer",[88],"2023-12-06",[2098],"Prostatic Neoplasms, Castration-Resistant",[2100,1328,43],"BMS-986218",{"nctId":2102,"briefTitle":2103,"status":104,"phases":2104,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":2108,"conditions":2109,"interventions":2111},"NCT03668119","A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)",[88],"2022-05-03","2023-08-02","2018-10-31",212,[2110],"Pan Tumor",[43,608],{"nctId":2113,"briefTitle":2114,"status":104,"phases":2115,"primaryCompletion":2116,"completion":2117,"start":2118,"enrollment":2119,"conditions":2120,"interventions":2121},"NCT01968109","An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors",[87,88],"2024-05-22","2025-02-03","2013-11-05",1482,[1345],[52,43,2122],"BMS-986213",{"nctId":2124,"briefTitle":2125,"status":104,"phases":2126,"primaryCompletion":2127,"completion":2062,"start":2128,"enrollment":2129,"conditions":2130,"interventions":2131},"NCT01354431","BMS-936558 (MDX-1106) In Subjects With Advanced\u002FMetastatic Clear-Cell Renal Cell Carcinoma (RCC)",[88],"2013-05-15","2011-05-31",168,[1253],[1123,1123,1123],{"nctId":2133,"briefTitle":2134,"status":104,"phases":2135,"primaryCompletion":460,"completion":2136,"start":2137,"enrollment":25,"conditions":2138,"interventions":2139},"NCT05407675","A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors",[87,88],"2025-07-24","2022-08-02",[1132],[2140,43,608,2141,761],"BMS-986408","Platinum-doublet chemotherapy",{"nctId":2143,"briefTitle":2144,"status":104,"phases":2145,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":2148,"conditions":2149,"interventions":2151},"NCT02754141","An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab",[87,88],"2021-10-12","2016-06-21",235,[2150],"Malignant Solid Tumor",[2152,43,636],"BMS-986179",{"nctId":2154,"briefTitle":2155,"status":467,"phases":2156,"primaryCompletion":2157,"completion":2158,"start":2159,"enrollment":98,"conditions":2160,"interventions":2163},"NCT03770299","An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease",[88],"2023-03-14","2024-03-14","2021-01-15",[36,2161,2162],"Non-Small-Cell Lung Carcinoma","Circulating Tumor DNA",[43,2164,1267,1328,622,1268,1157,1158],"Vinorelbine",{"nctId":2166,"briefTitle":2167,"status":104,"phases":2168,"primaryCompletion":2169,"completion":201,"start":2170,"enrollment":2171,"conditions":2172,"interventions":2174},"NCT02581631","An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas",[87,88],"2020-01-16","2016-02-11",145,[2173],"Non-Hodgkin's Disease",[43,2175],"Brentuximab Vedotin",{"nctId":2177,"briefTitle":2178,"status":467,"phases":2179,"primaryCompletion":280,"completion":2180,"start":954,"enrollment":98,"conditions":2181,"interventions":2183},"NCT05496192","A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer",[88],"2026-06-24",[21,2182],"Urothelial Carcinoma",[2184,43],"Nivolumab\u002FrHuPH20",{"nctId":2186,"briefTitle":2187,"status":104,"phases":2188,"primaryCompletion":2189,"completion":2189,"start":2190,"enrollment":520,"conditions":2191,"interventions":2193},"NCT05255601","A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma",[87,88],"2025-12-03","2022-09-13",[2192,2051],"Lymphoma, Non-Hodgkin",[52,43],{"nctId":2195,"briefTitle":2196,"status":104,"phases":2197,"primaryCompletion":2198,"completion":1129,"start":2199,"enrollment":2200,"conditions":2201,"interventions":2203},"NCT03662659","An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers",[88],"2020-08-27","2018-10-16",274,[1436,1437,2202],"Esophagogastric Junction",[2122,43,2204,2205,2206],"XELOX","FOLFOX","SOX",{"nctId":2208,"briefTitle":2209,"status":104,"phases":2210,"primaryCompletion":2211,"completion":2211,"start":2212,"enrollment":534,"conditions":2213,"interventions":2214},"NCT02927769","A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment",[88],"2024-05-28","2017-03-28",[2051],[43,2215,2216],"brentuximab vedotin","bendamustine",{"nctId":2218,"briefTitle":2219,"status":963,"phases":2220,"primaryCompletion":2221,"completion":2221,"start":2222,"enrollment":2223,"conditions":2224,"interventions":2225},"NCT03110107","First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors",[87,88],"2024-04-04","2017-05-04",376,[1154],[608,2100,43],{"nctId":2227,"briefTitle":2228,"status":104,"phases":2229,"primaryCompletion":2230,"completion":2230,"start":2231,"enrollment":2232,"conditions":2233,"interventions":2234},"NCT02574078","A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)",[87,88],"2020-04-15","2015-11-23",341,[36],[43,612,622,2235,1158,1328,1267,1269,2236,1157],"nab-Paclitaxel","Crizotinib",{"nctId":2238,"briefTitle":2239,"status":104,"phases":2240,"primaryCompletion":2241,"completion":2241,"start":1906,"enrollment":2242,"conditions":2243,"interventions":2244},"NCT03369223","A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors",[87,88],"2024-11-07",356,[1154],[2245,43,608],"BMS-986249",{"nctId":2247,"briefTitle":2248,"status":104,"phases":2249,"primaryCompletion":2250,"completion":2251,"start":2252,"enrollment":2253,"conditions":2254,"interventions":2255},"NCT02387996","A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer",[88],"2016-04-15","2021-11-12","2015-03-09",270,[1636],[43],{"nctId":2257,"briefTitle":2258,"status":104,"phases":2259,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":2262,"conditions":2263,"interventions":2265},"NCT03336216","A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer",[88],"2023-06-01","2017-12-18",205,[2264],"Advanced Pancreatic Cancer",[1245,1225,2266,43,618,1267,619,617,2267],"Onivyde","Irinotecan Hydrochloride",{"nctId":2269,"briefTitle":2270,"status":104,"phases":2271,"primaryCompletion":820,"completion":820,"start":2272,"enrollment":1221,"conditions":2273,"interventions":2274},"NCT03792750","A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors",[87,88],"2018-12-31",[1154],[1337,43],{"nctId":2276,"briefTitle":2277,"status":104,"phases":2278,"primaryCompletion":2279,"completion":2279,"start":870,"enrollment":2280,"conditions":2281,"interventions":2282},"NCT02996110","A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma",[88],"2021-11-23",182,[1154],[43,608,52,1337,1676],{"nctId":2284,"briefTitle":2285,"status":963,"phases":2286,"primaryCompletion":2287,"completion":2287,"start":2288,"enrollment":520,"conditions":2289,"interventions":2290},"NCT04088500","A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma",[88],"2021-11-15","2020-09-03",[1253],[43,608],{"nctId":2292,"briefTitle":2293,"status":179,"phases":2294,"primaryCompletion":2295,"completion":2296,"start":1275,"enrollment":660,"conditions":2297,"interventions":2298},"NCT06101134","A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations",[88],"2025-04-10","2027-08-31",[21],[2299,2300,1123,2301],"relatlimab+nivolumab","relatlimab+nivolumab+rHuPH20","nivolumab+rHuPH20",{"nctId":2303,"briefTitle":2304,"status":104,"phases":2305,"primaryCompletion":2306,"completion":2306,"start":2307,"enrollment":2308,"conditions":2309,"interventions":2310},"NCT02593786","A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors",[87,88],"2021-09-27","2016-01-07",58,[1515],[43],{"nctId":2312,"briefTitle":2313,"status":963,"phases":2314,"primaryCompletion":2315,"completion":2315,"start":2316,"enrollment":2317,"conditions":2318,"interventions":2320},"NCT02253992","An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma",[87,88],"2019-05-24","2014-09-29",232,[1132,2319],"Advanced B-cell NHL",[1111,43],{"nctId":2322,"briefTitle":2323,"status":104,"phases":2324,"primaryCompletion":2325,"completion":2325,"start":2326,"enrollment":2327,"conditions":2328,"interventions":2330},"NCT02935634","A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer",[88],"2022-05-11","2016-11-29",190,[2329],"Advanced Gastric Cancer",[43,608,52,1337,614],{"nctId":2332,"briefTitle":2333,"status":104,"phases":2334,"primaryCompletion":2335,"completion":2335,"start":802,"enrollment":2336,"conditions":2337,"interventions":2338},"NCT03459222","An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread",[87,88],"2025-02-19",229,[1154],[52,43,1337,608],{"trials":2340,"activeCount":363,"soonestReadout":42},[2341,2349,2359,2369,2380,2391,2399,2409,2419,2432,2442,2451,2465,2476,2484,2493,2500,2511,2521,2531,2541,2547,2557,2566,2575,2584,2592,2604,2613,2624,2633,2642,2652,2661,2670,2683,2692,2700,2707,2716,2723,2733,2743,2753,2763,2775,2783,2794,2802,2809,2819,2831,2842,2852,2865,2875,2884,2895,2903,2915,2925,2937],{"nctId":2342,"briefTitle":2343,"status":179,"phases":2344,"primaryCompletion":2345,"completion":2345,"start":2346,"enrollment":1139,"conditions":2347,"interventions":2348},"NCT03873402","A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer",[89],"2027-03-11","2019-06-21",[1253],[43,608],{"nctId":2350,"briefTitle":2351,"status":104,"phases":2352,"primaryCompletion":2353,"completion":2354,"start":1193,"enrollment":2355,"conditions":2356,"interventions":2358},"NCT02017717","A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients",[89],"2019-06-17","2024-06-21",529,[2357],"Recurrent Glioblastoma",[43,612,608],{"nctId":2360,"briefTitle":2361,"status":104,"phases":2362,"primaryCompletion":1107,"completion":2363,"start":2364,"enrollment":2365,"conditions":2366,"interventions":2368},"NCT02105636","Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)",[89],"2021-09-10","2014-05-29",361,[2367],"Squamous Cell Carcinoma of the Head and Neck",[43,1145,772,1328],{"nctId":2370,"briefTitle":2371,"status":104,"phases":2372,"primaryCompletion":2373,"completion":2374,"start":2375,"enrollment":2376,"conditions":2377,"interventions":2379},"NCT01844505","Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)",[89],"2016-08-01","2024-04-19","2013-06-11",945,[2378],"Unresectable or Metastatic Melanoma",[43,608],{"nctId":2381,"briefTitle":2382,"status":963,"phases":2383,"primaryCompletion":2384,"completion":2385,"start":2386,"enrollment":2387,"conditions":2388,"interventions":2389},"NCT05002569","A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma",[89],"2024-12-16","2025-04-02","2021-10-19",1093,[21],[43,2390],"Nivolumab + Relatlimab Fixed Dose Combination",{"nctId":2392,"briefTitle":2393,"status":104,"phases":2394,"primaryCompletion":967,"completion":2395,"start":2396,"enrollment":979,"conditions":2397,"interventions":2398},"NCT02713867","A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg\u002Fkg or 240 mg Every 2 Weeks",[89],"2022-01-18","2016-05-24",[1717],[43],{"nctId":2400,"briefTitle":2401,"status":104,"phases":2402,"primaryCompletion":2403,"completion":2404,"start":2405,"enrollment":2406,"conditions":2407,"interventions":2408},"NCT03635983","A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma",[89],"2021-11-19","2024-03-19","2018-09-21",783,[21],[1167,43],{"nctId":2410,"briefTitle":2411,"status":236,"phases":2412,"primaryCompletion":2413,"completion":2414,"start":2415,"enrollment":2416,"conditions":2417,"interventions":2418},"NCT06561386","A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV\u002FRecurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%",[89],"2030-07-30","2032-08-04","2024-10-07",1000,[1265],[43,52,623,1157,622,1268],{"nctId":2420,"briefTitle":2421,"status":104,"phases":2422,"primaryCompletion":2423,"completion":2423,"start":2424,"enrollment":2425,"conditions":2426,"interventions":2430},"NCT04209114","A Study of Nivolumab Plus Bempegaldesleukin (Bempeg\u002FNKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer",[89],"2023-06-07","2020-02-05",114,[2427,2428,2429],"Bladder Cancer","Bladder Tumor","Muscle-Invasive Bladder Cancer",[43,2431],"Bempegaldesleukin",{"nctId":2433,"briefTitle":2434,"status":104,"phases":2435,"primaryCompletion":2436,"completion":2437,"start":2438,"enrollment":2439,"conditions":2440,"interventions":2441},"NCT03143153","A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin",[89],"2021-01-18","2025-01-13","2017-06-29",970,[1636],[43,608,1268,618],{"nctId":2443,"briefTitle":2444,"status":104,"phases":2445,"primaryCompletion":2446,"completion":2446,"start":2447,"enrollment":2448,"conditions":2449,"interventions":2450},"NCT02599402","Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma",[89],"2020-02-10","2015-12-20",533,[21],[43,608],{"nctId":2452,"briefTitle":2453,"status":104,"phases":2454,"primaryCompletion":2455,"completion":2456,"start":2457,"enrollment":2458,"conditions":2459,"interventions":2460},"NCT02741570","Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",[89],"2021-05-10","2022-09-22","2016-10-05",947,[1537],[43,608,2461,2462,2463,2464],"Cetuximab\u002FErbitux","Cisplatin\u002FPlatinol","Carboplatin\u002FParaplatin","Fluorouracil\u002FAdrucil",{"nctId":2466,"briefTitle":2467,"status":104,"phases":2468,"primaryCompletion":2469,"completion":2470,"start":2471,"enrollment":2472,"conditions":2473,"interventions":2475},"NCT02041533","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",[89],"2016-07-01","2022-05-27","2014-03-27",541,[2474],"Stage IV or Recurrent Non-Small Cell Lung Cancer",[43,1267,1268,1157,1158,622],{"nctId":2477,"briefTitle":2478,"status":104,"phases":2479,"primaryCompletion":2480,"completion":2480,"start":2481,"enrollment":19,"conditions":2482,"interventions":2483},"NCT03349710","Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer",[89],"2019-10-14","2017-12-15",[2367],[43,1145,1268],{"nctId":2485,"briefTitle":2486,"status":179,"phases":2487,"primaryCompletion":2488,"completion":412,"start":2489,"enrollment":2490,"conditions":2491,"interventions":2492},"NCT03661320","A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer",[89],"2026-02-16","2018-11-06",855,[1547,2429],[43,1267,1268],{"nctId":2494,"briefTitle":2495,"status":104,"phases":2496,"primaryCompletion":2497,"completion":2497,"start":2137,"enrollment":363,"conditions":2498,"interventions":2499},"NCT05297565","A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection",[89],"2024-02-08",[21],[2184,43],{"nctId":2501,"briefTitle":2502,"status":104,"phases":2503,"primaryCompletion":2504,"completion":2505,"start":2506,"enrollment":2507,"conditions":2508,"interventions":2510},"NCT02617589","An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)",[89],"2019-01-17","2022-03-04","2016-03-01",560,[2509],"Brain Cancer",[43,613],{"nctId":2512,"briefTitle":2513,"status":104,"phases":2514,"primaryCompletion":2515,"completion":2516,"start":2326,"enrollment":2517,"conditions":2518,"interventions":2520},"NCT02899299","Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients",[89],"2020-03-25","2023-04-28",605,[2519],"Mesothelioma",[43,608,622,1268,1157],{"nctId":2522,"briefTitle":2523,"status":104,"phases":2524,"primaryCompletion":2525,"completion":2525,"start":2526,"enrollment":2527,"conditions":2528,"interventions":2530},"NCT04340193","A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer",[89],"2023-12-12","2020-09-14",26,[2529],"Cancer, Hepatocellular",[1123,1122],{"nctId":2532,"briefTitle":2533,"status":104,"phases":2534,"primaryCompletion":2535,"completion":2536,"start":2537,"enrollment":2538,"conditions":2539,"interventions":2540},"NCT03414983","An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread",[88,89],"2021-02-01","2022-12-28","2018-02-20",196,[1673],[43,619,617,618,612],{"nctId":40,"briefTitle":41,"status":179,"phases":2542,"primaryCompletion":42,"completion":158,"start":2543,"enrollment":2544,"conditions":2545,"interventions":2546},[89],"2017-07-23",701,[1253],[43,609,621,608],{"nctId":2548,"briefTitle":2549,"status":104,"phases":2550,"primaryCompletion":2551,"completion":2551,"start":2552,"enrollment":2553,"conditions":2554,"interventions":2556},"NCT02066636","A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen",[89],"2021-10-06","2014-04-09",1428,[2555],"Non Small Cell Lung Cancer (NSCLC)",[43],{"nctId":2558,"briefTitle":2559,"status":104,"phases":2560,"primaryCompletion":2561,"completion":2561,"start":2562,"enrollment":2563,"conditions":2564,"interventions":2565},"NCT03195491","A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia",[89],"2021-06-08","2017-12-25",400,[1717,36],[43],{"nctId":2567,"briefTitle":2568,"status":104,"phases":2569,"primaryCompletion":1990,"completion":2570,"start":2571,"enrollment":2572,"conditions":2573,"interventions":2574},"NCT03068455","An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb\u002Fc\u002Fd or Stage IV Melanoma",[89],"2021-02-02","2017-04-11",1844,[21],[1123,1122],{"nctId":2576,"briefTitle":2577,"status":104,"phases":2578,"primaryCompletion":2579,"completion":377,"start":2580,"enrollment":2581,"conditions":2582,"interventions":2583},"NCT02864251","A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy",[89],"2022-01-20","2017-03-17",367,[2161],[43,608,622,1268,1157],{"nctId":2585,"briefTitle":2586,"status":467,"phases":2587,"primaryCompletion":2588,"completion":2588,"start":2589,"enrollment":98,"conditions":2590,"interventions":2591},"NCT03386838","An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent\u002FMetastatic Squamous Cell Carcinoma of Head and Neck",[89],"2018-04-19","2018-03-28",[1537],[43,1337,1145,1268,1157,618],{"nctId":2593,"briefTitle":2594,"status":104,"phases":2595,"primaryCompletion":2596,"completion":2597,"start":2598,"enrollment":2599,"conditions":2600,"interventions":2603},"NCT02872116","Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach\u002FEsophagus Junction Cancer",[89],"2020-05-27","2024-06-06","2016-10-12",2031,[1436,2601,2602],"Gastroesophageal Junction Cancer","Esophageal Adenocarcinoma",[43,608,619,611,617,618],{"nctId":2605,"briefTitle":2606,"status":104,"phases":2607,"primaryCompletion":2608,"completion":2608,"start":2609,"enrollment":2610,"conditions":2611,"interventions":2612},"NCT02477826","An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)",[89],"2024-10-25","2015-08-05",2747,[36],[43,608,1157,1268,1267,622,1158],{"nctId":2614,"briefTitle":2615,"status":104,"phases":2616,"primaryCompletion":2617,"completion":2618,"start":2619,"enrollment":2620,"conditions":2621,"interventions":2623},"NCT02998528","A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)",[89],"2021-09-08","2024-12-06","2017-03-04",505,[2622],"Non Small Cell Lung Cancer",[43,1268,2164,1267,1328,622,1157,1158,608],{"nctId":2625,"briefTitle":2626,"status":104,"phases":2627,"primaryCompletion":879,"completion":2628,"start":2629,"enrollment":2630,"conditions":2631,"interventions":2632},"NCT02388906","Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb\u002Fc or Stage IV Melanoma",[89],"2024-10-16","2015-03-16",906,[21],[608,43],{"nctId":2634,"briefTitle":2635,"status":104,"phases":2636,"primaryCompletion":2637,"completion":2638,"start":1854,"enrollment":2639,"conditions":2640,"interventions":2641},"NCT02538666","An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy",[89],"2018-10-01","2021-11-11",907,[1717],[43,608],{"nctId":2643,"briefTitle":2644,"status":467,"phases":2645,"primaryCompletion":2646,"completion":2647,"start":2648,"enrollment":98,"conditions":2649,"interventions":2650},"NCT03417037","An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer",[89],"2021-04-25","2025-08-20","2018-05-24",[1717,36],[1337,43,2651],"Chemotherapy",{"nctId":2653,"briefTitle":2654,"status":179,"phases":2655,"primaryCompletion":225,"completion":225,"start":2656,"enrollment":2657,"conditions":2658,"interventions":2659},"NCT04039607","A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma",[89],"2019-09-30",732,[1607],[43,608,1609,2660],"lenvatinib",{"nctId":2662,"briefTitle":2663,"status":104,"phases":2664,"primaryCompletion":2665,"completion":2665,"start":2666,"enrollment":319,"conditions":2667,"interventions":2669},"NCT03329846","An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma",[89],"2020-07-02","2017-11-30",[21,2668],"Skin Cancer",[1337,43],{"nctId":2671,"briefTitle":2672,"status":104,"phases":2673,"primaryCompletion":2674,"completion":2675,"start":2676,"enrollment":2677,"conditions":2678,"interventions":2680},"NCT03138512","A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney",[89],"2023-09-28","2024-02-01","2017-07-07",1641,[2679],"Carcinoma, Renal Cell",[1123,1122,2681,2682],"nivolumab placebo","ipilimumab placebo",{"nctId":2684,"briefTitle":2685,"status":104,"phases":2686,"primaryCompletion":2687,"completion":2688,"start":2689,"enrollment":413,"conditions":2690,"interventions":2691},"NCT02905266","A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma",[89],"2017-10-23","2019-10-25","2016-10-27",[21],[43,608],{"nctId":2693,"briefTitle":2694,"status":104,"phases":2695,"primaryCompletion":2260,"completion":2696,"start":778,"enrollment":2697,"conditions":2698,"interventions":2699},"NCT04100018","A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer",[89],"2024-06-25",1030,[1504],[43,1507,1328],{"nctId":45,"briefTitle":46,"status":179,"phases":2701,"primaryCompletion":47,"completion":2702,"start":2703,"enrollment":2704,"conditions":2705,"interventions":2706},[89],"2027-05-27","2016-03-22",709,[1636],[43],{"nctId":2708,"briefTitle":2709,"status":963,"phases":2710,"primaryCompletion":2711,"completion":2711,"start":2712,"enrollment":137,"conditions":2713,"interventions":2714},"NCT04149574","A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)",[89],"2023-10-31","2020-01-15",[1547],[1123,2715],"Bacillus Calmette-Guérin",{"nctId":49,"briefTitle":50,"status":179,"phases":2717,"primaryCompletion":51,"completion":2718,"start":2719,"enrollment":2720,"conditions":2721,"interventions":2722},[88,89],"2030-12-15","2018-04-11",714,[21],[52,43],{"nctId":2724,"briefTitle":2725,"status":104,"phases":2726,"primaryCompletion":2727,"completion":2728,"start":2729,"enrollment":2730,"conditions":2731,"interventions":2732},"NCT02613507","Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer",[89],"2017-09-15","2023-11-24","2015-12-11",504,[36],[43,1328],{"nctId":2734,"briefTitle":2735,"status":104,"phases":2736,"primaryCompletion":2737,"completion":2738,"start":2739,"enrollment":2740,"conditions":2741,"interventions":2742},"NCT02576509","An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma",[89],"2019-05-30","2024-02-07","2015-12-07",743,[1607],[43,1609],{"nctId":2744,"briefTitle":2745,"status":179,"phases":2746,"primaryCompletion":1520,"completion":2747,"start":2748,"enrollment":2749,"conditions":2750,"interventions":2752},"NCT03383458","A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation",[89],"2031-02-27","2018-04-18",545,[1607,2751],"Liver Cancer",[43],{"nctId":2754,"briefTitle":2755,"status":963,"phases":2756,"primaryCompletion":2757,"completion":2757,"start":2758,"enrollment":2038,"conditions":2759,"interventions":2761},"NCT03138499","A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed\u002F Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,",[89],"2021-02-22","2017-06-26",[2760],"Hodgkin's Disease",[43,2762],"Brentuximab vedotin",{"nctId":2764,"briefTitle":2765,"status":179,"phases":2766,"primaryCompletion":2767,"completion":2768,"start":2769,"enrollment":2770,"conditions":2771,"interventions":2773},"NCT04810078","A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread",[89],"2025-07-29","2027-05-10","2021-05-21",681,[2772],"Clear Cell Renal Cell Carcinoma",[2774,43],"Nivolumab and rHuPH20",{"nctId":63,"briefTitle":64,"status":179,"phases":2776,"primaryCompletion":65,"completion":2777,"start":2778,"enrollment":2779,"conditions":2780,"interventions":2782},[89],"2027-07-30","2019-11-05",461,[2781],"Carcinoma, Non-Small-Cell Lung",[43,1157,1268,1158,622,1328],{"nctId":2784,"briefTitle":2785,"status":179,"phases":2786,"primaryCompletion":2787,"completion":2788,"start":2789,"enrollment":2790,"conditions":2791,"interventions":2793},"NCT03036098","Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer",[89],"2024-08-30","2026-05-15","2017-03-24",1314,[2792],"Urothelial Cancer",[43,608,1267,1268,1157],{"nctId":2795,"briefTitle":2796,"status":467,"phases":2797,"primaryCompletion":2798,"completion":2798,"start":2799,"enrollment":98,"conditions":2800,"interventions":2801},"NCT03048136","A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer",[89],"2019-09-29","2018-03-09",[36],[43,608],{"nctId":54,"briefTitle":55,"status":179,"phases":2803,"primaryCompletion":56,"completion":2804,"start":2805,"enrollment":2806,"conditions":2807,"interventions":2808},[89],"2027-06-29","2019-10-28",790,[21],[43],{"nctId":2810,"briefTitle":2811,"status":104,"phases":2812,"primaryCompletion":2758,"completion":936,"start":2813,"enrollment":2814,"conditions":2815,"interventions":2818},"NCT02231749","Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)",[89],"2014-10-16",1096,[2816,2817],"Advanced Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma",[43,608,621],{"nctId":2820,"briefTitle":2821,"status":104,"phases":2822,"primaryCompletion":2823,"completion":2824,"start":2825,"enrollment":2826,"conditions":2827,"interventions":2829},"NCT04026412","A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery",[89],"2024-03-22","2024-11-26","2019-10-08",925,[2828],"Non-Small Cell Lung Cancer (NSCLC)",[1123,1122,2830],"durvalumab",{"nctId":2832,"briefTitle":2833,"status":179,"phases":2834,"primaryCompletion":2835,"completion":2836,"start":2837,"enrollment":2838,"conditions":2839,"interventions":2841},"NCT04008030","A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)\u002FMicrosatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)",[89],"2024-08-28","2026-06-10","2019-08-05",839,[2840],"Metastatic Colorectal Cancer",[608,619,617,618,1678,612,1145,43],{"nctId":2843,"briefTitle":2844,"status":104,"phases":2845,"primaryCompletion":2846,"completion":2847,"start":2848,"enrollment":2849,"conditions":2850,"interventions":2851},"NCT01642004","Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)",[89],"2014-11-17","2021-08-16","2012-10-16",272,[1837],[43,1328],{"nctId":2853,"briefTitle":2854,"status":236,"phases":2855,"primaryCompletion":2856,"completion":2857,"start":2858,"enrollment":2859,"conditions":2860,"interventions":2862},"NCT07221149","A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)",[88,89],"2030-11-08","2032-09-11","2026-03-13",690,[2861],"Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma",[1721,2863,2864,43],"Folfox","Capox",{"nctId":2866,"briefTitle":2867,"status":104,"phases":2868,"primaryCompletion":2869,"completion":2870,"start":1413,"enrollment":2871,"conditions":2872,"interventions":2874},"NCT02667587","An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)",[89],"2020-12-22","2024-04-09",716,[2873],"Brain Neoplasms",[43,613],{"nctId":2876,"briefTitle":2877,"status":104,"phases":2878,"primaryCompletion":2879,"completion":2241,"start":2880,"enrollment":2881,"conditions":2882,"interventions":2883},"NCT02743494","An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer",[89],"2020-05-12","2016-07-14",794,[1154],[43],{"nctId":2885,"briefTitle":2886,"status":104,"phases":2887,"primaryCompletion":2888,"completion":2889,"start":2890,"enrollment":2891,"conditions":2892,"interventions":2894},"NCT01673867","Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC",[89],"2015-02-05","2021-12-17","2012-11-02",582,[2893],"Non-Squamous Cell Non-small Cell Lung Cancer",[43,1328],{"nctId":2896,"briefTitle":2897,"status":104,"phases":2898,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":1175,"conditions":2901,"interventions":2902},"NCT02726581","An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma",[89],"2022-03-09","2016-08-10",[33],[43,1794,1797,1795],{"nctId":2904,"briefTitle":2905,"status":104,"phases":2906,"primaryCompletion":2907,"completion":2908,"start":2909,"enrollment":2910,"conditions":2911,"interventions":2912},"NCT02481830","Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer",[89],"2018-08-17","2022-08-30","2015-09-14",569,[1717],[43,2913,2914],"Topotecan","Amrubicin",{"nctId":2916,"briefTitle":2917,"status":104,"phases":2918,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2922,"conditions":2923,"interventions":2924},"NCT03215706","A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC",[89],"2019-08-16","2024-10-18","2017-08-24",719,[36],[608,43,1157,1158,622,1268],{"nctId":2926,"briefTitle":2927,"status":104,"phases":2928,"primaryCompletion":2929,"completion":2930,"start":2931,"enrollment":2932,"conditions":2933,"interventions":2935},"NCT01668784","Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)",[89],"2015-05-06","2021-07-19","2012-10-09",821,[2934],"Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma",[43,2936],"Everolimus",{"nctId":2938,"briefTitle":2939,"status":104,"phases":2940,"primaryCompletion":2941,"completion":2942,"start":2943,"enrollment":2944,"conditions":2945,"interventions":2946},"NCT04109066","Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer",[89],"2023-01-16","2023-12-27","2019-11-18",521,[1223],[1123,2947,2948,2949,2950],"paclitaxel","anthracycline","cyclophosphamide","Endocrine Therapy",{"trials":2952,"activeCount":98},[2953,2962,2972,2981],{"nctId":2954,"briefTitle":2955,"status":104,"phases":2956,"primaryCompletion":2957,"completion":2957,"start":2958,"enrollment":1916,"conditions":2959,"interventions":2961},"NCT04513522","A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India",[90],"2024-01-04","2020-12-17",[2960],"Kidney Neoplasms",[43,608],{"nctId":2963,"briefTitle":2964,"status":104,"phases":2965,"primaryCompletion":2966,"completion":2967,"start":2968,"enrollment":2969,"conditions":2970,"interventions":2971},"NCT02596035","An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma",[90],"2018-03-19","2021-05-24","2016-01-08",197,[1253],[43],{"nctId":2973,"briefTitle":2974,"status":104,"phases":2975,"primaryCompletion":2976,"completion":2551,"start":2977,"enrollment":2978,"conditions":2979,"interventions":2980},"NCT02982954","A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer",[90],"2020-05-11","2017-01-16",211,[1253],[43,608],{"nctId":2982,"briefTitle":2983,"status":104,"phases":2984,"primaryCompletion":2985,"completion":2985,"start":2986,"enrollment":660,"conditions":2987,"interventions":2992},"NCT03444766","Study of Nivolumab for Advanced Cancers in India",[90],"2019-07-17","2018-03-06",[2828,2161,2988,2989,2960,2990,2991],"Nonsmall Cell Lung Cancer","Kidney Cancer","Renal Cancer","Renal Neoplasms",[43],{"trials":2994,"activeCount":98},[2995,3003,3011,3021,3030,3037,3043,3053,3063,3071,3080,3089,3096,3106,3116,3124,3133],{"nctId":2996,"briefTitle":2997,"status":2998,"phases":2999,"conditions":3000,"interventions":3002},"NCT03126643","Expanded Access to Nivolumab (Opdivo)","APPROVED_FOR_MARKETING",[],[3001],"Pediatric Cancer",[43],{"nctId":3004,"briefTitle":3005,"status":104,"phases":3006,"primaryCompletion":3007,"completion":3007,"start":3008,"enrollment":331,"conditions":3009,"interventions":3010},"NCT04146324","An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia",[],"2024-05-31","2019-12-12",[21],[1123],{"nctId":3012,"briefTitle":3013,"status":3014,"phases":3015,"primaryCompletion":3016,"completion":3016,"start":3017,"conditions":3018,"interventions":3020},"NCT02142218","Expanded Access Program With Nivolumab to Treat Melanoma","NO_LONGER_AVAILABLE",[],"2018-05","2014-06",[3019],"Stage III (Unresectable) or Stage IV Advanced Melanoma",[43],{"nctId":3022,"briefTitle":3023,"status":104,"phases":3024,"primaryCompletion":1914,"completion":1914,"start":3025,"enrollment":3026,"conditions":3027,"interventions":3029},"NCT06361576","Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada",[],"2023-09-05",700,[3028],"Upper Gastrointestinal Cancer",[43],{"nctId":3031,"briefTitle":3032,"status":3014,"phases":3033,"conditions":3034,"interventions":3036},"NCT02186249","Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma",[],[3035],"Malignant Melanoma",[43,608],{"nctId":3038,"briefTitle":3039,"status":104,"phases":3040,"primaryCompletion":1914,"completion":1914,"start":3025,"enrollment":479,"conditions":3041,"interventions":3042},"NCT06361563","Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada",[],[3028],[43],{"nctId":3044,"briefTitle":3045,"status":104,"phases":3046,"primaryCompletion":3047,"completion":3048,"start":3049,"enrollment":660,"conditions":3050,"interventions":3051},"NCT06163170","A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma",[],"2023-09-25","2023-11-10","2023-08-14",[21],[3052,43],"Nivolumab +\u002F- ipilimumab",{"nctId":3054,"briefTitle":3055,"status":104,"phases":3056,"primaryCompletion":3057,"completion":3057,"start":3058,"enrollment":3059,"conditions":3060,"interventions":3062},"NCT02856451","Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab",[],"2020-12-31","2015-12-09",486,[3061],"Encephalitis",[43],{"nctId":3064,"briefTitle":3065,"status":3014,"phases":3066,"conditions":3067,"interventions":3070},"NCT02475382","Expanded Access Program With Nivolumab Therapy for Treatment of Advanced\u002FMetastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen",[],[3068,3069],"Squamous Non-Small Cell Lung Cancer","Non-squamous Non-Small Cell Lung Cancer",[43],{"nctId":3072,"briefTitle":3073,"status":104,"phases":3074,"primaryCompletion":3075,"completion":3075,"start":1118,"enrollment":3076,"conditions":3077,"interventions":3079},"NCT04936399","A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom",[],"2021-12-03",87,[3078],"Esophageal Squamous Cell Carcinoma",[43],{"nctId":3081,"briefTitle":3082,"status":104,"phases":3083,"primaryCompletion":3084,"completion":3084,"start":3085,"enrollment":3086,"conditions":3087,"interventions":3088},"NCT05068609","A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)",[],"2021-10-18","2020-08-13",509,[2367],[43],{"nctId":3090,"briefTitle":3091,"status":104,"phases":3092,"primaryCompletion":2767,"completion":2767,"start":2017,"enrollment":3093,"conditions":3094,"interventions":3095},"NCT06452329","A Study to Evaluate Nivolumab in Patients With Unresectable Advanced\u002FMetastatic Gastric Cancer and Gastroesophageal Junction Cancer",[],260,[1436,2601],[43],{"nctId":3097,"briefTitle":3098,"status":104,"phases":3099,"primaryCompletion":3100,"completion":3100,"start":3101,"enrollment":3102,"conditions":3103,"interventions":3105},"NCT06499298","Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer\u002FGastroesophageal Junction Cancer",[],"2025-04-16","2024-12-03",64,[3104,2601],"Esophageal Cancer",[43],{"nctId":3107,"briefTitle":3108,"status":104,"phases":3109,"primaryCompletion":3110,"completion":3110,"start":3111,"enrollment":3112,"conditions":3113,"interventions":3115},"NCT04050761","A Study of Nivolumab in Patients With Head and Neck Cancer.",[],"2024-07-08","2019-06-26",502,[3114],"Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck",[43],{"nctId":3117,"briefTitle":3118,"status":104,"phases":3119,"primaryCompletion":3120,"completion":3120,"start":828,"enrollment":3121,"conditions":3122,"interventions":3123},"NCT03165409","Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread",[],"2017-09-30",1828,[21],[43,608],{"nctId":3125,"briefTitle":3126,"status":104,"phases":3127,"primaryCompletion":3128,"completion":3128,"start":3129,"enrollment":1916,"conditions":3130,"interventions":3132},"NCT06735781","Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France",[],"2024-10-01","2024-09-05",[3131],"Non-small Cell Lung Cancer (NSCLC)",[43],{"nctId":3134,"briefTitle":3135,"status":963,"phases":3136,"primaryCompletion":3137,"completion":3137,"start":3138,"enrollment":3139,"conditions":3140,"interventions":3141},"NCT06421311","Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France",[],"2025-04-04","2024-07-30",176,[2182],[1123],{"intervention":79,"totalTrials":3143,"cells":3144},29,{"EARLY_PHASE1":3145,"PHASE1":3147,"PHASE2":3172,"PHASE3":3203,"PHASE4":3288,"NA":3327},{"trials":3146,"activeCount":98},[],{"trials":3148,"activeCount":98},[3149,3157,3165],{"nctId":3150,"briefTitle":3151,"status":104,"phases":3152,"primaryCompletion":3153,"completion":3153,"start":3154,"enrollment":451,"conditions":3155,"interventions":3156},"NCT04949269","A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants",[87],"2022-01-03","2021-07-20",[18],[79,696],{"nctId":3158,"briefTitle":3159,"status":104,"phases":3160,"primaryCompletion":3161,"completion":3161,"start":2415,"enrollment":3162,"conditions":3163,"interventions":3164},"NCT06566768","Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants",[87],"2025-06-13",52,[18],[79],{"nctId":3166,"briefTitle":3167,"status":104,"phases":3168,"primaryCompletion":3137,"completion":3137,"start":3169,"enrollment":2527,"conditions":3170,"interventions":3171},"NCT06851871","A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults",[87],"2025-01-23",[18],[79,696],{"trials":3173,"activeCount":208,"soonestReadout":460},[3174,3183,3193],{"nctId":3175,"briefTitle":3176,"status":104,"phases":3177,"primaryCompletion":3178,"completion":3178,"start":3179,"enrollment":1285,"conditions":3180,"interventions":3182},"NCT04877990","A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis",[88],"2023-08-29","2021-05-07",[3181,990],"Crohn Disease",[79],{"nctId":3184,"briefTitle":3185,"status":179,"phases":3186,"primaryCompletion":460,"completion":3187,"start":3188,"enrollment":19,"conditions":3189,"interventions":3192},"NCT04857034","A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and\u002For Subacute Cutaneous Lupus Erythematosus (DLE\u002FSCLE)",[88],"2028-02-28","2021-07-12",[3190,3191],"Lupus Erythematosus, Discoid","Lupus Erythematosus, Subacute Cutaneous",[79],{"nctId":3194,"briefTitle":3195,"status":963,"phases":3196,"primaryCompletion":3197,"completion":3198,"start":3199,"enrollment":378,"conditions":3200,"interventions":3202},"NCT05556265","A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata",[88],"2024-01-06","2024-05-16","2022-11-08",[3201],"Alopecia Areata",[79],{"trials":3204,"activeCount":747,"soonestReadout":78},[3205,3215,3224,3233,3240,3247,3258,3267,3278],{"nctId":3206,"briefTitle":3207,"status":236,"phases":3208,"primaryCompletion":3209,"completion":3210,"start":3211,"enrollment":582,"conditions":3212,"interventions":3214},"NCT06869551","A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis",[89],"2030-03-06","2031-03-04","2025-03-13",[3213],"Juvenile Psoriatic Arthritis",[79],{"nctId":3216,"briefTitle":3217,"status":179,"phases":3218,"primaryCompletion":3129,"completion":3219,"start":3220,"enrollment":3221,"conditions":3222,"interventions":3223},"NCT04908202","A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs",[89],"2027-06-10","2021-07-13",670,[770],[79],{"nctId":3225,"briefTitle":3226,"status":179,"phases":3227,"primaryCompletion":3228,"completion":548,"start":3229,"enrollment":3230,"conditions":3231,"interventions":3232},"NCT05620407","A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus",[89],"2026-10-19","2023-01-12",513,[792],[79],{"nctId":3234,"briefTitle":3235,"status":179,"phases":3236,"primaryCompletion":3228,"completion":548,"start":3229,"enrollment":3237,"conditions":3238,"interventions":3239},"NCT05617677","A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)",[89],516,[792],[79],{"nctId":76,"briefTitle":77,"status":179,"phases":3241,"primaryCompletion":78,"completion":3242,"start":3243,"enrollment":3244,"conditions":3245,"interventions":3246},[89],"2026-11-12","2021-07-15",729,[770],[79,1017],{"nctId":3248,"briefTitle":3249,"status":236,"phases":3250,"primaryCompletion":3251,"completion":3252,"start":3253,"enrollment":3254,"conditions":3255,"interventions":3257},"NCT04772079","A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis",[89],"2029-01-01","2033-09-08","2021-03-23",153,[3256],"Plaque Psoriasis",[79],{"nctId":3259,"briefTitle":3260,"status":236,"phases":3261,"primaryCompletion":3262,"completion":3263,"start":2189,"enrollment":3264,"conditions":3265,"interventions":3266},"NCT06979453","A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis",[89],"2029-10-12","2034-08-12",366,[3256],[79],{"nctId":3268,"briefTitle":3269,"status":179,"phases":3270,"primaryCompletion":3271,"completion":3272,"start":3273,"enrollment":3274,"conditions":3275,"interventions":3277},"NCT05946941","A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome",[89],"2026-11-18","2028-11-16","2023-09-11",774,[3276],"Sjögren's Syndrome",[79],{"nctId":3279,"briefTitle":3280,"status":236,"phases":3281,"primaryCompletion":3282,"completion":3282,"start":3283,"enrollment":3284,"conditions":3285,"interventions":3286},"NCT07116967","Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)",[89],"2031-01-16","2025-09-22",3040,[3256],[79,3287],"Ustekinumab",{"trials":3289,"activeCount":98},[3290,3297,3306,3316],{"nctId":3291,"briefTitle":3292,"status":104,"phases":3293,"primaryCompletion":3294,"completion":3294,"start":280,"enrollment":839,"conditions":3295,"interventions":3296},"NCT06476834","A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants",[90],"2024-11-02",[27],[79],{"nctId":3298,"briefTitle":3299,"status":104,"phases":3300,"primaryCompletion":74,"completion":3301,"start":3302,"enrollment":3303,"conditions":3304,"interventions":3305},"NCT05478499","Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis",[90],"2024-10-17","2022-10-06",154,[749],[79],{"nctId":3307,"briefTitle":3308,"status":104,"phases":3309,"primaryCompletion":3310,"completion":3311,"start":3312,"enrollment":3313,"conditions":3314,"interventions":3315},"NCT05701995","A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting",[90],"2024-08-23","2025-05-29","2023-01-31",180,[749],[79],{"nctId":3317,"briefTitle":3318,"status":963,"phases":3319,"primaryCompletion":3320,"completion":3320,"start":3321,"enrollment":3322,"conditions":3323,"interventions":3326},"NCT06042920","A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis",[90],"2025-04-25","2023-10-09",130,[3324,3325],"Palmoplantar Psoriasis","Genital Psoriasis",[79],{"trials":3328,"activeCount":1184,"soonestReadout":3333},[3329,3339,3346,3354,3364,3373,3381,3392,3401,3411],{"nctId":3330,"briefTitle":3331,"status":179,"phases":3332,"primaryCompletion":3333,"completion":3334,"start":3335,"enrollment":3336,"conditions":3337,"interventions":3338},"NCT06104644","A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany",[],"2025-08-18","2030-05-31","2023-04-13",550,[3256],[79],{"nctId":3340,"briefTitle":3341,"status":179,"phases":3342,"primaryCompletion":2345,"completion":2345,"start":3343,"enrollment":3254,"conditions":3344,"interventions":3345},"NCT06512337","A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China",[],"2025-01-20",[3256],[79],{"nctId":3347,"briefTitle":3348,"status":236,"phases":3349,"primaryCompletion":3350,"completion":3350,"start":450,"enrollment":2620,"conditions":3351,"interventions":3353},"NCT06258668","Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea",[],"2028-09-30",[3352],"Moderate-to-severe Plaque Psoriasis",[79],{"nctId":3355,"briefTitle":3356,"status":179,"phases":3357,"primaryCompletion":3358,"completion":3358,"start":3359,"enrollment":3360,"conditions":3361,"interventions":3362},"NCT06952465","A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis",[],"2031-11-30","2025-01-24",2000,[749],[79,3363],"Any biologic treatment for psoriasis",{"nctId":3365,"briefTitle":3366,"status":236,"phases":3367,"primaryCompletion":3368,"completion":3368,"start":3369,"enrollment":3370,"conditions":3371,"interventions":3372},"NCT06701513","A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)",[],"2028-04-30","2025-01-29",350,[749],[79],{"nctId":3374,"briefTitle":3375,"status":236,"phases":3376,"primaryCompletion":3377,"completion":3377,"start":3378,"enrollment":271,"conditions":3379,"interventions":3380},"NCT06382987","A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)",[],"2029-12-31","2024-01-22",[3256],[79,1017],{"nctId":3382,"briefTitle":3383,"status":179,"phases":3384,"primaryCompletion":3385,"completion":3386,"start":3387,"enrollment":3388,"conditions":3389,"interventions":3390},"NCT06710470","A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring",[],"2027-01-31","2029-02-28","2024-08-02",833,[749],[79,3391],"Systemic psoriasis medications",{"nctId":3393,"briefTitle":3394,"status":236,"phases":3395,"primaryCompletion":3396,"completion":3397,"start":3398,"enrollment":311,"conditions":3399,"interventions":3400},"NCT07256015","Deucravacitinib for Patients With Moderate\u002FSevere Psoriasis: A Real-Life Experience in Italy",[],"2027-07-05","2027-08-05","2025-08-05",[749],[79],{"nctId":3402,"briefTitle":3403,"status":236,"phases":3404,"primaryCompletion":3405,"completion":3386,"start":936,"enrollment":3406,"conditions":3407,"interventions":3409},"NCT07017699","A Study to Assess Deucravacitinib Safety in Pregnancy",[],"2028-04-01",900,[3408],"Psoriasis (PsO)",[79,3410],"Other systemic treatments for PsO",{"nctId":3412,"briefTitle":3413,"status":236,"phases":3414,"primaryCompletion":3415,"completion":3415,"start":3416,"enrollment":604,"conditions":3417,"interventions":3418},"NCT05744466","A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis",[],"2027-12-10","2022-09-30",[749],[79,1017],{"intervention":3420,"totalTrials":363,"cells":3421},"KarXT",{"EARLY_PHASE1":3422,"PHASE1":3424,"PHASE2":3444,"PHASE3":3446,"PHASE4":3549,"NA":3551},{"trials":3423,"activeCount":98},[],{"trials":3425,"activeCount":208,"soonestReadout":3440},[3426,3436],{"nctId":3427,"briefTitle":3428,"status":104,"phases":3429,"primaryCompletion":3430,"completion":3430,"start":3431,"enrollment":1203,"conditions":3432,"interventions":3434},"NCT06853171","Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders",[87],"2025-07-22","2025-04-29",[3433],"Psychiatric Disorders",[3420,3435],"KarX-EC",{"nctId":3437,"briefTitle":3438,"status":236,"phases":3439,"primaryCompletion":3440,"completion":1138,"start":3441,"enrollment":725,"conditions":3442,"interventions":3443},"NCT07061288","A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia",[87],"2027-06-21","2025-09-03",[584],[3420],{"trials":3445,"activeCount":98},[],{"trials":3447,"activeCount":360,"soonestReadout":3495},[3448,3461,3472,3482,3491,3500,3507,3515,3524,3531,3539],{"nctId":3449,"briefTitle":3450,"status":236,"phases":3451,"primaryCompletion":3452,"completion":3452,"start":3453,"enrollment":3454,"conditions":3455,"interventions":3457},"NCT06929273","A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)",[89],"2028-06-13","2025-07-18",450,[3456],"Bipolar Disorder Type I With Mania",[3420,3458,3459,3460],"Lithium","Valproate","Lamotrigine",{"nctId":3462,"briefTitle":3463,"status":236,"phases":3464,"primaryCompletion":3465,"completion":3466,"start":3467,"enrollment":3468,"conditions":3469,"interventions":3471},"NCT06976216","A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease",[89],"2028-09-11","2029-02-23","2025-07-14",586,[3470],"Alzheimer's Disease",[3420,3435],{"nctId":3473,"briefTitle":3474,"status":236,"phases":3475,"primaryCompletion":3476,"completion":3477,"start":3478,"enrollment":1966,"conditions":3479,"interventions":3481},"NCT06947941","A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)",[89],"2028-02-21","2028-03-20","2026-03-25",[552,3480],"Psychosis",[3420,3435],{"nctId":3483,"briefTitle":3484,"status":642,"phases":3485,"primaryCompletion":3486,"completion":3486,"start":3487,"enrollment":3139,"conditions":3488,"interventions":3490},"NCT07284745","A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism",[89],"2029-07-05","2026-09-11",[3489],"Irritability Associated With Autism Spectrum Disorder",[3420,3435],{"nctId":3492,"briefTitle":3493,"status":236,"phases":3494,"primaryCompletion":3495,"completion":3495,"start":3496,"enrollment":2200,"conditions":3497,"interventions":3499},"NCT06951698","A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder",[89],"2026-11-01","2025-06-11",[3498],"Bipolar-I Disorder With Mania or Mania With Mixed Features",[3420],{"nctId":3501,"briefTitle":3502,"status":642,"phases":3503,"primaryCompletion":3504,"completion":3504,"start":3487,"enrollment":3139,"conditions":3505,"interventions":3506},"NCT07285798","A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder",[89],"2029-08-04",[3489],[3420,3435],{"nctId":3508,"briefTitle":3509,"status":236,"phases":3510,"primaryCompletion":3511,"completion":3511,"start":3512,"enrollment":1634,"conditions":3513,"interventions":3514},"NCT07288567","A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)",[89],"2029-12-18","2026-01-29",[584],[3420],{"nctId":3516,"briefTitle":3517,"status":236,"phases":3518,"primaryCompletion":3519,"completion":3520,"start":3521,"enrollment":479,"conditions":3522,"interventions":3523},"NCT06882785","A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia",[89],"2028-09-23","2029-08-23","2025-06-10",[584],[3420],{"nctId":3525,"briefTitle":3526,"status":236,"phases":3527,"primaryCompletion":3465,"completion":3466,"start":3528,"enrollment":3468,"conditions":3529,"interventions":3530},"NCT06976203","A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)",[89],"2025-07-21",[3470],[3420,3435],{"nctId":3532,"briefTitle":3533,"status":236,"phases":3534,"primaryCompletion":3535,"completion":3535,"start":3161,"enrollment":2200,"conditions":3536,"interventions":3538},"NCT06951711","A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)",[89],"2026-11-02",[3537],"Bipolar Disorder Type I With Mania or Mania With Mixed Features",[3420],{"nctId":3540,"briefTitle":3541,"status":236,"phases":3542,"primaryCompletion":3543,"completion":3544,"start":3545,"enrollment":271,"conditions":3546,"interventions":3548},"NCT06937229","A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)",[89],"2029-06-22","2029-07-20","2025-12-02",[552,3547],"Agitation",[3420,3435],{"trials":3550,"activeCount":98},[],{"trials":3552,"activeCount":208,"soonestReadout":3478},[3553],{"nctId":3554,"briefTitle":3555,"status":179,"phases":3556,"primaryCompletion":3478,"completion":3557,"start":158,"enrollment":3558,"conditions":3559,"interventions":3560},"NCT07571148","Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users",[],"2026-07-31",6876,[584],[3420],{"intervention":1157,"totalTrials":3562,"cells":3563},40,{"EARLY_PHASE1":3564,"PHASE1":3566,"PHASE2":3647,"PHASE3":3722,"PHASE4":3857,"NA":3859},{"trials":3565,"activeCount":98},[],{"trials":3567,"activeCount":98},[3568,3577,3581,3590,3600,3612,3622,3626,3636],{"nctId":3569,"briefTitle":3570,"status":104,"phases":3571,"primaryCompletion":1343,"completion":1343,"start":3572,"enrollment":757,"conditions":3573,"interventions":3575},"NCT00793897","Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors",[87],"2009-04",[1132,3574],"Metastatic Solid Tumors",[3576,1158,1157],"BMS-754807",{"nctId":1147,"briefTitle":1148,"status":104,"phases":3578,"primaryCompletion":1150,"completion":1150,"start":1151,"enrollment":1152,"conditions":3579,"interventions":3580},[87],[1154],[1156,43,1157,622,1158],{"nctId":3582,"briefTitle":3583,"status":104,"phases":3584,"primaryCompletion":3585,"completion":3586,"start":3587,"enrollment":534,"conditions":3588,"interventions":3589},"NCT00796991","Drug-Drug Interaction - 3 Arm - Carboplatin\u002FPaclitaxel, Dacarbazine",[87],"2009-11","2012-10","2009-02",[673],[608,1157,1158,2055],{"nctId":3591,"briefTitle":3592,"status":104,"phases":3593,"primaryCompletion":3594,"completion":3595,"start":3596,"enrollment":1221,"conditions":3597,"interventions":3598},"NCT02815592","Trial of BMS-986012 in Combination With Platinum and Etoposide",[87],"2019-12-15","2024-08-06","2016-11-28",[1888],[1890,1268,1929,3599,1157],"Platinum",{"nctId":3601,"briefTitle":3602,"status":104,"phases":3603,"primaryCompletion":3604,"completion":3605,"start":3606,"enrollment":3607,"conditions":3608,"interventions":3609},"NCT01653470","Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced \u002F Metastatic Solid Tumors",[87],"2017-05-03","2017-05-08","2012-10-12",141,[606],[1158,3610,1157,617,1678,1158,3611],"5-Fluorouracil","BMS-906024",{"nctId":3613,"briefTitle":3614,"status":104,"phases":3615,"primaryCompletion":3616,"completion":3616,"start":3617,"enrollment":520,"conditions":3618,"interventions":3620},"NCT00927875","A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer",[87],"2012-09","2010-02",[3619],"Small Cell Lung Carcinoma",[3621,1157,1929],"BMS-833923",{"nctId":1257,"briefTitle":1258,"status":104,"phases":3623,"primaryCompletion":1260,"completion":1261,"start":1262,"enrollment":1263,"conditions":3624,"interventions":3625},[87],[1265],[43,1267,1268,622,1158,1157,612,1269,608],{"nctId":3627,"briefTitle":3628,"status":104,"phases":3629,"primaryCompletion":3630,"completion":3630,"start":3631,"enrollment":1385,"conditions":3632,"interventions":3633},"NCT01165216","Japanese Study of Ipilimumab Administered in Combination With Paclitaxel\u002FCarboplatin in Patients With Nonsmall-cell Lung Cancer",[87],"2013-06","2010-09",[36],[3634,3635,1158,1157],"Ipilimumab, 3 mg","Ipilimumab, 10 mg",{"nctId":3637,"briefTitle":3638,"status":104,"phases":3639,"primaryCompletion":3640,"completion":3640,"start":3641,"conditions":3642,"interventions":3644},"NCT00024284","Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors",[87],"2003-12","2001-06",[3643],"Unspecified Childhood Solid Tumor, Protocol Specific",[3645,3646],"carboplatin","irinotecan hydrochloride",{"trials":3648,"activeCount":574,"soonestReadout":74},[3649,3653,3662,3666,3670,3674,3684,3688,3692,3703,3707,3718],{"nctId":1399,"briefTitle":1400,"status":963,"phases":3650,"primaryCompletion":1402,"completion":1402,"start":1403,"enrollment":347,"conditions":3651,"interventions":3652},[87,88],[1132,1265],[1406,43,1328,1157,1407,1158],{"nctId":3654,"briefTitle":3655,"status":104,"phases":3656,"primaryCompletion":3657,"completion":3657,"start":3658,"enrollment":319,"conditions":3659,"interventions":3661},"NCT00990912","A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)",[87,88],"2005-11","2004-01",[3660],"Pediatric Solid Tumors",[1157,1678,1678],{"nctId":72,"briefTitle":73,"status":179,"phases":3663,"primaryCompletion":74,"completion":1520,"start":1521,"enrollment":1522,"conditions":3664,"interventions":3665},[88],[1265,1524,1525],[43,52,1157,1268,1158,1527,622],{"nctId":1581,"briefTitle":1582,"status":104,"phases":3667,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":1586,"conditions":3668,"interventions":3669},[88],[1588],[43,608,622,1268,1157],{"nctId":1611,"briefTitle":1612,"status":963,"phases":3671,"primaryCompletion":1614,"completion":1614,"start":191,"enrollment":208,"conditions":3672,"interventions":3673},[88],[1616],[1618,43,622,1268,1157,1158],{"nctId":3675,"briefTitle":3676,"status":104,"phases":3677,"primaryCompletion":3678,"completion":3679,"start":3680,"enrollment":3681,"conditions":3682,"interventions":3683},"NCT00527735","Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)",[88],"2009-10","2011-12","2008-02",334,[1717,1888,2781],[608,1158,1157],{"nctId":1680,"briefTitle":1681,"status":179,"phases":3685,"primaryCompletion":1683,"completion":1684,"start":1685,"enrollment":1686,"conditions":3686,"interventions":3687},[88],[36],[43,608,1157,1158,622,1268],{"nctId":1921,"briefTitle":1922,"status":104,"phases":3689,"primaryCompletion":1924,"completion":1925,"start":1447,"enrollment":703,"conditions":3690,"interventions":3691},[88],[1927],[1890,1157,1929,43],{"nctId":3693,"briefTitle":3694,"status":642,"phases":3695,"primaryCompletion":3696,"completion":3696,"start":3697,"enrollment":3093,"conditions":3698,"interventions":3699},"NCT07492680","A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and\u002For Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)",[88],"2032-05-20","2026-07-17",[1515],[3700,3701,3702,613,1721,622,1157,1225,1267,1158],"BMS-986504","Daraxonrasib","Nivolumab + Relatlimab FDC",{"nctId":2154,"briefTitle":2155,"status":467,"phases":3704,"primaryCompletion":2157,"completion":2158,"start":2159,"enrollment":98,"conditions":3705,"interventions":3706},[88],[36,2161,2162],[43,2164,1267,1328,622,1268,1157,1158],{"nctId":3708,"briefTitle":3709,"status":963,"phases":3710,"primaryCompletion":3711,"completion":3711,"start":3712,"enrollment":3713,"conditions":3714,"interventions":3715},"NCT00850577","Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer",[88],"2013-08","2009-06",255,[3131],[1158,1157,3716,612,3717],"CT-322","Bevacizumab placebo",{"nctId":2227,"briefTitle":2228,"status":104,"phases":3719,"primaryCompletion":2230,"completion":2230,"start":2231,"enrollment":2232,"conditions":3720,"interventions":3721},[87,88],[36],[43,612,622,2235,1158,1328,1267,1269,2236,1157],{"trials":3723,"activeCount":839,"soonestReadout":65},[3724,3734,3738,3742,3752,3756,3765,3778,3782,3793,3803,3812,3816,3820,3824,3835,3845,3849,3853],{"nctId":3725,"briefTitle":3726,"status":236,"phases":3727,"primaryCompletion":3728,"completion":3728,"start":3729,"enrollment":3730,"conditions":3731,"interventions":3733},"NCT07063745","A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion",[88,89],"2031-08-12","2026-01-02",590,[3732],"Metastatic Non-small Cell Lung Cancer With MTAP Deletion",[3700,623,1268,1157,622,1158,1225],{"nctId":2410,"briefTitle":2411,"status":236,"phases":3735,"primaryCompletion":2413,"completion":2414,"start":2415,"enrollment":2416,"conditions":3736,"interventions":3737},[89],[1265],[43,52,623,1157,622,1268],{"nctId":2466,"briefTitle":2467,"status":104,"phases":3739,"primaryCompletion":2469,"completion":2470,"start":2471,"enrollment":2472,"conditions":3740,"interventions":3741},[89],[2474],[43,1267,1268,1157,1158,622],{"nctId":3743,"briefTitle":3744,"status":104,"phases":3745,"primaryCompletion":3746,"completion":1364,"start":3747,"enrollment":3748,"conditions":3749,"interventions":3750},"NCT01721746","A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)",[89],"2016-02-16","2012-12-21",405,[2378],[3751,2055,1157,1158],"BMS-936558",{"nctId":2512,"briefTitle":2513,"status":104,"phases":3753,"primaryCompletion":2515,"completion":2516,"start":2326,"enrollment":2517,"conditions":3754,"interventions":3755},[89],[2519],[43,608,622,1268,1157],{"nctId":3757,"briefTitle":3758,"status":104,"phases":3759,"primaryCompletion":3760,"completion":1895,"start":3761,"enrollment":3762,"conditions":3763,"interventions":3764},"NCT01450761","Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone",[89],"2015-03-19","2011-12-13",1351,[3619],[608,1929,1268,1157],{"nctId":3766,"briefTitle":3767,"status":236,"phases":3768,"primaryCompletion":3769,"completion":3770,"start":3771,"enrollment":3772,"conditions":3773,"interventions":3775},"NCT06646276","A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).",[89],"2028-04-06","2031-09-05","2025-02-25",530,[3774],"Extensive-Stage Small Cell Lung Cancer",[3776,3777,1157,1929],"BMS-986489","Atezolizumab",{"nctId":2576,"briefTitle":2577,"status":104,"phases":3779,"primaryCompletion":2579,"completion":377,"start":2580,"enrollment":2581,"conditions":3780,"interventions":3781},[89],[2161],[43,608,622,1268,1157],{"nctId":3783,"briefTitle":3784,"status":236,"phases":3785,"primaryCompletion":3786,"completion":3787,"start":3788,"enrollment":290,"conditions":3789,"interventions":3791},"NCT06926868","A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)",[88,89],"2028-03-13","2030-05-15","2025-09-11",[3790],"Breast Neoplasms",[3792,1225,1158,611,1157,1267],"Iza-bren",{"nctId":3794,"briefTitle":3795,"status":104,"phases":3796,"primaryCompletion":3797,"completion":3797,"start":3798,"enrollment":3799,"conditions":3800,"interventions":3802},"NCT02279732","Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin",[89],"2018-05-03","2014-10-13",342,[3801],"Lung Cancer (NSCLC)",[1158,1157,608],{"nctId":3804,"briefTitle":3805,"status":236,"phases":3806,"primaryCompletion":3807,"completion":3808,"start":3809,"enrollment":290,"conditions":3810,"interventions":3811},"NCT07100080","Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)",[88,89],"2028-12-15","2030-11-15","2025-11-05",[36],[3792,1157,1268,622],{"nctId":2585,"briefTitle":2586,"status":467,"phases":3813,"primaryCompletion":2588,"completion":2588,"start":2589,"enrollment":98,"conditions":3814,"interventions":3815},[89],[1537],[43,1337,1145,1268,1157,618],{"nctId":2605,"briefTitle":2606,"status":104,"phases":3817,"primaryCompletion":2608,"completion":2608,"start":2609,"enrollment":2610,"conditions":3818,"interventions":3819},[89],[36],[43,608,1157,1268,1267,622,1158],{"nctId":2614,"briefTitle":2615,"status":104,"phases":3821,"primaryCompletion":2617,"completion":2618,"start":2619,"enrollment":2620,"conditions":3822,"interventions":3823},[89],[2622],[43,1268,2164,1267,1328,622,1157,1158,608],{"nctId":3825,"briefTitle":3826,"status":104,"phases":3827,"primaryCompletion":3828,"completion":3829,"start":3830,"enrollment":3831,"conditions":3832,"interventions":3834},"NCT01285609","Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin",[89],"2015-06-09","2017-08-22","2011-01-16",1289,[3833],"Lung Cancer - Non Small Cell Squamous",[608,1158,1157],{"nctId":3836,"briefTitle":3837,"status":236,"phases":3838,"primaryCompletion":3839,"completion":3840,"start":3841,"enrollment":3842,"conditions":3843,"interventions":3844},"NCT07106762","Phase 2\u002F3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy",[88,89],"2029-01-26","2033-11-18","2025-09-30",470,[2792],[3792,1268,1267,1157],{"nctId":63,"briefTitle":64,"status":179,"phases":3846,"primaryCompletion":65,"completion":2777,"start":2778,"enrollment":2779,"conditions":3847,"interventions":3848},[89],[2781],[43,1157,1268,1158,622,1328],{"nctId":2784,"briefTitle":2785,"status":179,"phases":3850,"primaryCompletion":2787,"completion":2788,"start":2789,"enrollment":2790,"conditions":3851,"interventions":3852},[89],[2792],[43,608,1267,1268,1157],{"nctId":2916,"briefTitle":2917,"status":104,"phases":3854,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2922,"conditions":3855,"interventions":3856},[89],[36],[608,43,1157,1158,622,1268],{"trials":3858,"activeCount":98},[],{"trials":3860,"activeCount":98},[],{"intervention":608,"totalTrials":3862,"cells":3863},120,{"EARLY_PHASE1":3864,"PHASE1":3866,"PHASE2":4004,"PHASE3":4329,"PHASE4":4497,"NA":4507},{"trials":3865,"activeCount":98},[],{"trials":3867,"activeCount":98},[3868,3877,3881,3889,3898,3908,3912,3916,3923,3927,3934,3942,3946,3950,3954,3964,3968,3972,3982,3990,4000],{"nctId":3869,"briefTitle":3870,"status":104,"phases":3871,"primaryCompletion":3872,"completion":3586,"start":3873,"enrollment":3874,"conditions":3875,"interventions":3876},"NCT00920907","Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma",[87],"2010-04","2009-08",99,[673],[608],{"nctId":1113,"briefTitle":1114,"status":963,"phases":3878,"primaryCompletion":1116,"completion":1117,"start":1118,"enrollment":757,"conditions":3879,"interventions":3880},[87],[1120],[1122,1123,1124,1123],{"nctId":3882,"briefTitle":3883,"status":104,"phases":3884,"primaryCompletion":3885,"completion":3885,"start":3886,"enrollment":94,"conditions":3887,"interventions":3888},"NCT02516527","A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors",[87],"2018-09-20","2015-10-16",[21],[608],{"nctId":3890,"briefTitle":3891,"status":104,"phases":3892,"primaryCompletion":3893,"completion":3893,"start":3894,"enrollment":839,"conditions":3895,"interventions":3896},"NCT01245556","Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma",[87],"2012-11","2011-01",[21],[3897,3897,608,608],"BMS-908662",{"nctId":3899,"briefTitle":3900,"status":467,"phases":3901,"primaryCompletion":3902,"completion":3903,"start":3904,"enrollment":98,"conditions":3905,"interventions":3906},"NCT00803374","Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma",[87],"2012-07","2013-01","2010-11",[21],[3907,3907,3907,3907,3907,608],"AntiCD137",{"nctId":3582,"briefTitle":3583,"status":104,"phases":3909,"primaryCompletion":3585,"completion":3586,"start":3587,"enrollment":534,"conditions":3910,"interventions":3911},[87],[673],[608,1157,1158,2055],{"nctId":1169,"briefTitle":1170,"status":104,"phases":3913,"primaryCompletion":1172,"completion":1173,"start":1174,"enrollment":1175,"conditions":3914,"interventions":3915},[87],[673,650],[43,608],{"nctId":3917,"briefTitle":3918,"status":104,"phases":3919,"primaryCompletion":3678,"completion":3678,"start":3920,"enrollment":1221,"conditions":3921,"interventions":3922},"NCT00362713","Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection",[87],"2007-03",[2182],[608],{"nctId":1179,"briefTitle":1180,"status":104,"phases":3924,"primaryCompletion":1182,"completion":1182,"start":1183,"enrollment":1184,"conditions":3925,"interventions":3926},[87],[1154],[1187,43,608],{"nctId":3928,"briefTitle":3929,"status":963,"phases":3930,"primaryCompletion":65,"completion":65,"start":3931,"enrollment":360,"conditions":3932,"interventions":3933},"NCT03978611","A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment",[87],"2021-12-09",[21],[52,608],{"nctId":3935,"briefTitle":3936,"status":467,"phases":3937,"primaryCompletion":3938,"completion":3938,"start":3873,"enrollment":98,"conditions":3939,"interventions":3941},"NCT00732186","Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia",[87],"2011-02",[3940],"Leukemia, Myeloid, Chronic",[608],{"nctId":1216,"briefTitle":1217,"status":104,"phases":3943,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":1221,"conditions":3944,"interventions":3945},[87],[1223],[43,608,1225],{"nctId":1227,"briefTitle":1228,"status":963,"phases":3947,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":1232,"conditions":3948,"interventions":3949},[87],[1154],[1235,43,608],{"nctId":1237,"briefTitle":1238,"status":104,"phases":3951,"primaryCompletion":1240,"completion":1241,"start":1242,"enrollment":319,"conditions":3952,"interventions":3953},[87],[1154],[43,52,1245,608,1246],{"nctId":3955,"briefTitle":3956,"status":963,"phases":3957,"primaryCompletion":3958,"completion":3959,"start":3960,"enrollment":693,"conditions":3961,"interventions":3962},"NCT01400451","Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)",[87],"2013-04","2013-12","2011-11",[21],[608,3963],"Vemurafenib",{"nctId":1257,"briefTitle":1258,"status":104,"phases":3965,"primaryCompletion":1260,"completion":1261,"start":1262,"enrollment":1263,"conditions":3966,"interventions":3967},[87],[1265],[43,1267,1268,622,1158,1157,612,1269,608],{"nctId":1290,"briefTitle":1291,"status":104,"phases":3969,"primaryCompletion":1293,"completion":1294,"start":1295,"enrollment":1296,"conditions":3970,"interventions":3971},[87],[1253,1298],[43,1300,621,608],{"nctId":3973,"briefTitle":3974,"status":104,"phases":3975,"primaryCompletion":3976,"completion":3976,"start":3977,"enrollment":3978,"conditions":3979,"interventions":3981},"NCT01750580","Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor",[87],"2015-04","2012-12",22,[3980],"CANCER, NOS",[1187,608],{"nctId":3983,"briefTitle":3984,"status":104,"phases":3985,"primaryCompletion":3017,"completion":3017,"start":3679,"enrollment":3986,"conditions":3987,"interventions":3988},"NCT01489059","Safety Study of IL-21\u002FIpilimumab Combination in the Treatment of Melanoma",[87],42,[21],[3989,3989,3989,3989,608,608,608],"BMS-982470",{"nctId":3991,"briefTitle":3992,"status":104,"phases":3993,"primaryCompletion":3994,"completion":3995,"start":3996,"enrollment":3997,"conditions":3998,"interventions":3999},"NCT01024231","Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma",[87],"2014-02-04","2019-04-01","2009-12-14",127,[3035],[3751,608],{"nctId":1370,"briefTitle":1371,"status":104,"phases":4001,"primaryCompletion":183,"completion":1373,"start":937,"enrollment":890,"conditions":4002,"interventions":4003},[87],[1375],[1377,43,608],{"trials":4005,"activeCount":4328,"soonestReadout":1683},[4006,4015,4019,4030,4034,4051,4055,4059,4063,4067,4071,4075,4079,4090,4094,4098,4102,4106,4110,4118,4127,4131,4135,4139,4143,4147,4155,4163,4167,4171,4175,4183,4187,4191,4197,4201,4209,4213,4217,4225,4235,4239,4243,4247,4251,4258,4267,4271,4275,4285,4293,4304,4308,4312,4316,4324],{"nctId":4007,"briefTitle":4008,"status":104,"phases":4009,"primaryCompletion":4010,"completion":4010,"start":4011,"enrollment":4012,"conditions":4013,"interventions":4014},"NCT00289627","A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma",[88],"2007-07","2006-04",155,[21],[1122],{"nctId":1409,"briefTitle":1410,"status":963,"phases":4016,"primaryCompletion":1412,"completion":1412,"start":1413,"enrollment":1414,"conditions":4017,"interventions":4018},[88],[1154],[43,1197,52,608,1337],{"nctId":4020,"briefTitle":4021,"status":467,"phases":4022,"start":4023,"enrollment":98,"conditions":4024,"interventions":4026},"NCT00357461","Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma",[88],"2006-05",[4025],"Melanoma (Skin)",[4027,4028,4029,1122],"gp100:209-217(210M) peptide vaccine","gp100:280-288(288V) peptide vaccine","incomplete Freund's adjuvant",{"nctId":1464,"briefTitle":1465,"status":104,"phases":4031,"primaryCompletion":1467,"completion":1468,"start":1469,"enrollment":1470,"conditions":4032,"interventions":4033},[87,88],[1472],[43,608,1474],{"nctId":4035,"briefTitle":4036,"status":104,"phases":4037,"primaryCompletion":4038,"completion":3586,"start":4039,"enrollment":3874,"conditions":4040,"interventions":4041},"NCT00623766","Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases",[88],"2009-09","2008-07",[21],[608,4042,4043,4044,4045,4046,4047,4048,4049,4050],"Corticosteroid: Betamethasone","Corticosteroid: Dexamethasone","Corticosteroid: Fludrocortisone","Corticosteroid: Hydrocortisone","Corticosteroid: Meprednisone","Corticosteroid: Methylprednisolone","Corticosteroid: Prednisolone","Corticosteroid: Prednisone","Corticosteroid: Triamcinolone",{"nctId":1486,"briefTitle":1487,"status":104,"phases":4052,"primaryCompletion":1489,"completion":1490,"start":1491,"enrollment":1492,"conditions":4053,"interventions":4054},[88],[649,650],[43,608],{"nctId":1496,"briefTitle":1497,"status":104,"phases":4056,"primaryCompletion":1499,"completion":1500,"start":1501,"enrollment":1502,"conditions":4057,"interventions":4058},[88],[1504],[43,608,1506,1507],{"nctId":1529,"briefTitle":1530,"status":104,"phases":4060,"primaryCompletion":1532,"completion":1533,"start":1534,"enrollment":1535,"conditions":4061,"interventions":4062},[88],[1537],[43,608],{"nctId":1551,"briefTitle":1552,"status":104,"phases":4064,"primaryCompletion":1554,"completion":1555,"start":1556,"enrollment":1557,"conditions":4065,"interventions":4066},[88],[1559],[43,608],{"nctId":1581,"briefTitle":1582,"status":104,"phases":4068,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":1586,"conditions":4069,"interventions":4070},[88],[1588],[43,608,622,1268,1157],{"nctId":1591,"briefTitle":1592,"status":104,"phases":4072,"primaryCompletion":1594,"completion":1595,"start":1596,"enrollment":1597,"conditions":4073,"interventions":4074},[88],[36],[43,608],{"nctId":1601,"briefTitle":1602,"status":104,"phases":4076,"primaryCompletion":278,"completion":278,"start":1604,"enrollment":1605,"conditions":4077,"interventions":4078},[87,88],[1607],[43,1609,608,609],{"nctId":4080,"briefTitle":4081,"status":236,"phases":4082,"primaryCompletion":4083,"completion":4084,"start":4085,"enrollment":4086,"conditions":4087,"interventions":4089},"NCT07293351","A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)",[87,88],"2029-11-28","2031-11-26","2026-03-26",254,[4088],"Advanced Renal Cell Carcinoma (RCC)",[1721,608,609],{"nctId":1628,"briefTitle":1629,"status":104,"phases":4091,"primaryCompletion":1631,"completion":1632,"start":1633,"enrollment":1634,"conditions":4092,"interventions":4093},[88],[1636],[43,608],{"nctId":3675,"briefTitle":3676,"status":104,"phases":4095,"primaryCompletion":3678,"completion":3679,"start":3680,"enrollment":3681,"conditions":4096,"interventions":4097},[88],[1717,1888,2781],[608,1158,1157],{"nctId":1639,"briefTitle":1640,"status":104,"phases":4099,"primaryCompletion":1642,"completion":1642,"start":1643,"enrollment":1644,"conditions":4100,"interventions":4101},[87,88],[1154,21,36],[1337,43,608],{"nctId":599,"briefTitle":600,"status":236,"phases":4103,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":4104,"interventions":4105},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"nctId":1680,"briefTitle":1681,"status":179,"phases":4107,"primaryCompletion":1683,"completion":1684,"start":1685,"enrollment":1686,"conditions":4108,"interventions":4109},[88],[36],[43,608,1157,1158,622,1268],{"nctId":4111,"briefTitle":4112,"status":963,"phases":4113,"primaryCompletion":4114,"completion":4114,"start":3902,"enrollment":747,"conditions":4115,"interventions":4117},"NCT01471197","Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer",[88],"2013-02",[4116],"Lung Cancer - Non Small Cell",[608,622],{"nctId":4119,"briefTitle":4120,"status":963,"phases":4121,"primaryCompletion":4122,"completion":4122,"start":4123,"enrollment":4124,"conditions":4125,"interventions":4126},"NCT01709162","Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma",[88],"2014-07","2013-03",31,[21],[608,2651],{"nctId":1763,"briefTitle":1764,"status":104,"phases":4128,"primaryCompletion":1766,"completion":1766,"start":1767,"enrollment":1634,"conditions":4129,"interventions":4130},[87,88],[1154],[1770,43,608,1771,1772,1773],{"nctId":1775,"briefTitle":1776,"status":104,"phases":4132,"primaryCompletion":1778,"completion":1779,"start":1780,"enrollment":1781,"conditions":4133,"interventions":4134},[88],[1783],[43,608,1785],{"nctId":1799,"briefTitle":1800,"status":104,"phases":4136,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":1805,"conditions":4137,"interventions":4138},[87,88],[606,21],[1808,43,608],{"nctId":1810,"briefTitle":1811,"status":104,"phases":4140,"primaryCompletion":1813,"completion":1813,"start":1814,"enrollment":680,"conditions":4141,"interventions":4142},[87,88],[1482],[43,608],{"nctId":1818,"briefTitle":1819,"status":104,"phases":4144,"primaryCompletion":1821,"completion":1211,"start":1822,"enrollment":1823,"conditions":4145,"interventions":4146},[87,88],[1825,1826,33],[43,608,1187,615,1797,1795],{"nctId":4148,"briefTitle":4149,"status":104,"phases":4150,"primaryCompletion":4151,"completion":4151,"start":4152,"enrollment":1232,"conditions":4153,"interventions":4154},"NCT02279862","Safety and Efficacy Study of Ipilimumab 3 mg\u002Fkg Versus Ipilimumab 10 mg\u002Fkg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive",[88],"2016-12-15","2014-12-02",[1504],[608],{"nctId":4156,"briefTitle":4157,"status":104,"phases":4158,"primaryCompletion":4159,"completion":4160,"start":3959,"enrollment":319,"conditions":4161,"interventions":4162},"NCT01990859","Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients",[88],"2014-05","2015-02",[21],[608],{"nctId":1840,"briefTitle":1841,"status":104,"phases":4164,"primaryCompletion":1843,"completion":1843,"start":1844,"enrollment":208,"conditions":4165,"interventions":4166},[88],[36],[43,608,1847],{"nctId":1849,"briefTitle":1850,"status":104,"phases":4168,"primaryCompletion":1852,"completion":1853,"start":1854,"enrollment":1855,"conditions":4169,"interventions":4170},[87,88],[1636],[43,608,52,615],{"nctId":1859,"briefTitle":1860,"status":963,"phases":4172,"primaryCompletion":1862,"completion":1862,"start":789,"enrollment":1863,"conditions":4173,"interventions":4174},[87,88],[606,1865,1866,1867],[1869,43,608,1870],{"nctId":4176,"briefTitle":4177,"status":104,"phases":4178,"primaryCompletion":4179,"completion":4179,"start":3657,"enrollment":1863,"conditions":4180,"interventions":4182},"NCT00261365","Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)",[87,88],"2007-10",[4181],"Unresectable Stage III or IV Malignant Melanoma",[608,608],{"nctId":1872,"briefTitle":1873,"status":104,"phases":4184,"primaryCompletion":1875,"completion":1875,"start":1876,"enrollment":1877,"conditions":4185,"interventions":4186},[88],[21],[608,43],{"nctId":1911,"briefTitle":1912,"status":104,"phases":4188,"primaryCompletion":1914,"completion":1914,"start":1915,"enrollment":1916,"conditions":4189,"interventions":4190},[87,88],[1918],[1847,43,608],{"nctId":4192,"briefTitle":4193,"status":104,"phases":4194,"primaryCompletion":4159,"completion":4159,"start":3586,"enrollment":757,"conditions":4195,"interventions":4196},"NCT01681212","Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma",[88],[21],[608,2055],{"nctId":1951,"briefTitle":1952,"status":104,"phases":4198,"primaryCompletion":1954,"completion":1954,"start":1955,"enrollment":1956,"conditions":4199,"interventions":4200},[87,88],[1958],[1187,43,608],{"nctId":4202,"briefTitle":4203,"status":104,"phases":4204,"primaryCompletion":4205,"completion":4205,"start":4206,"enrollment":37,"conditions":4207,"interventions":4208},"NCT00112580","MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery",[88],"2009-06-30","2005-07-31",[1674],[1122],{"nctId":1961,"briefTitle":1962,"status":104,"phases":4210,"primaryCompletion":1964,"completion":1964,"start":1965,"enrollment":1966,"conditions":4211,"interventions":4212},[87,88],[1673,1968,1969,1970],[43,610,608,1949],{"nctId":2014,"briefTitle":2015,"status":467,"phases":4214,"primaryCompletion":2017,"completion":2018,"start":1240,"enrollment":98,"conditions":4215,"interventions":4216},[88],[21],[43,608],{"nctId":4218,"briefTitle":4219,"status":104,"phases":4220,"primaryCompletion":4122,"completion":3976,"start":3902,"enrollment":4221,"conditions":4222,"interventions":4224},"NCT01585987","An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy",[88],143,[4223],"Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction",[608],{"nctId":4226,"briefTitle":4227,"status":104,"phases":4228,"primaryCompletion":4229,"completion":4230,"start":4231,"enrollment":3562,"conditions":4232,"interventions":4234},"NCT01611558","Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer",[88],"2014-11-03","2019-07-03","2012-08-21",[4233],"Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line",[608],{"nctId":2057,"briefTitle":2058,"status":467,"phases":4236,"primaryCompletion":2060,"completion":2061,"start":2062,"enrollment":98,"conditions":4237,"interventions":4238},[87,88],[2064],[1123,1122,2066,1981,2067,2068],{"nctId":2079,"briefTitle":2080,"status":104,"phases":4240,"primaryCompletion":2082,"completion":2082,"start":2083,"enrollment":2084,"conditions":4241,"interventions":4242},[88],[2086,2087,2088,2089],[608,43,1474,615,2091],{"nctId":2102,"briefTitle":2103,"status":104,"phases":4244,"primaryCompletion":2105,"completion":2106,"start":2107,"enrollment":2108,"conditions":4245,"interventions":4246},[88],[2110],[43,608],{"nctId":2133,"briefTitle":2134,"status":104,"phases":4248,"primaryCompletion":460,"completion":2136,"start":2137,"enrollment":25,"conditions":4249,"interventions":4250},[87,88],[1132],[2140,43,608,2141,761],{"nctId":4252,"briefTitle":4253,"status":104,"phases":4254,"primaryCompletion":4010,"completion":4010,"start":4011,"enrollment":4255,"conditions":4256,"interventions":4257},"NCT00289640","Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma",[88],210,[21],[1122,608,608],{"nctId":4259,"briefTitle":4260,"status":104,"phases":4261,"primaryCompletion":4262,"completion":4263,"start":4264,"enrollment":22,"conditions":4265,"interventions":4266},"NCT01673854","Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma",[88],"2014-07-25","2015-05-12","2012-09-13",[21],[608,3963],{"nctId":2218,"briefTitle":2219,"status":963,"phases":4268,"primaryCompletion":2221,"completion":2221,"start":2222,"enrollment":2223,"conditions":4269,"interventions":4270},[87,88],[1154],[608,2100,43],{"nctId":2238,"briefTitle":2239,"status":104,"phases":4272,"primaryCompletion":2241,"completion":2241,"start":1906,"enrollment":2242,"conditions":4273,"interventions":4274},[87,88],[1154],[2245,43,608],{"nctId":4276,"briefTitle":4277,"status":104,"phases":4278,"primaryCompletion":4279,"completion":4279,"start":4280,"enrollment":1152,"conditions":4281,"interventions":4283},"NCT00084656","Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma",[88],"2009-10-31","2004-05-31",[4282,4025],"Intraocular Melanoma",[1122,4284],"Tyrosinase\u002Fgp100\u002FMART-1 Peptides",{"nctId":4286,"briefTitle":4287,"status":104,"phases":4288,"primaryCompletion":3616,"completion":4289,"start":4023,"enrollment":4290,"conditions":4291,"interventions":4292},"NCT00162123","A Companion Study for Patients Enrolled in Prior\u002FParent Ipilimumab Studies",[88],"2014-04",248,[21],[608],{"nctId":4294,"briefTitle":4295,"status":236,"phases":4296,"primaryCompletion":4297,"completion":4298,"start":4299,"enrollment":4300,"conditions":4301,"interventions":4303},"NCT07291076","A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)",[87,88],"2029-10-15","2031-10-14","2026-03-16",198,[4302],"Hepatocellular Carcinoma (HCC)",[1721,608],{"nctId":2276,"briefTitle":2277,"status":104,"phases":4305,"primaryCompletion":2279,"completion":2279,"start":870,"enrollment":2280,"conditions":4306,"interventions":4307},[88],[1154],[43,608,52,1337,1676],{"nctId":2284,"briefTitle":2285,"status":963,"phases":4309,"primaryCompletion":2287,"completion":2287,"start":2288,"enrollment":520,"conditions":4310,"interventions":4311},[88],[1253],[43,608],{"nctId":2322,"briefTitle":2323,"status":104,"phases":4313,"primaryCompletion":2325,"completion":2325,"start":2326,"enrollment":2327,"conditions":4314,"interventions":4315},[88],[2329],[43,608,52,1337,614],{"nctId":4317,"briefTitle":4318,"status":963,"phases":4319,"primaryCompletion":4320,"completion":4320,"start":4321,"enrollment":363,"conditions":4322,"interventions":4323},"NCT01696045","Phase 2 Study of Ipilimumab in Children and Adolescents (12 to \u003C 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma",[88],"2016-07-31","2012-11-12",[3035],[608],{"nctId":2332,"briefTitle":2333,"status":104,"phases":4325,"primaryCompletion":2335,"completion":2335,"start":802,"enrollment":2336,"conditions":4326,"interventions":4327},[87,88],[1154],[52,43,1337,608],4,{"trials":4330,"activeCount":520,"soonestReadout":42},[4331,4335,4339,4343,4352,4356,4360,4364,4374,4382,4386,4390,4394,4398,4402,4406,4410,4418,4422,4426,4430,4434,4438,4442,4446,4450,4454,4463,4473,4477,4481,4485,4489,4493],{"nctId":2342,"briefTitle":2343,"status":179,"phases":4332,"primaryCompletion":2345,"completion":2345,"start":2346,"enrollment":1139,"conditions":4333,"interventions":4334},[89],[1253],[43,608],{"nctId":2350,"briefTitle":2351,"status":104,"phases":4336,"primaryCompletion":2353,"completion":2354,"start":1193,"enrollment":2355,"conditions":4337,"interventions":4338},[89],[2357],[43,612,608],{"nctId":2370,"briefTitle":2371,"status":104,"phases":4340,"primaryCompletion":2373,"completion":2374,"start":2375,"enrollment":2376,"conditions":4341,"interventions":4342},[89],[2378],[43,608],{"nctId":4344,"briefTitle":4345,"status":104,"phases":4346,"primaryCompletion":3976,"completion":4347,"start":4348,"enrollment":4349,"conditions":4350,"interventions":4351},"NCT01057810","Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer",[89],"2015-07","2010-07",837,[1504],[608],{"nctId":2433,"briefTitle":2434,"status":104,"phases":4353,"primaryCompletion":2436,"completion":2437,"start":2438,"enrollment":2439,"conditions":4354,"interventions":4355},[89],[1636],[43,608,1268,618],{"nctId":2443,"briefTitle":2444,"status":104,"phases":4357,"primaryCompletion":2446,"completion":2446,"start":2447,"enrollment":2448,"conditions":4358,"interventions":4359},[89],[21],[43,608],{"nctId":2452,"briefTitle":2453,"status":104,"phases":4361,"primaryCompletion":2455,"completion":2456,"start":2457,"enrollment":2458,"conditions":4362,"interventions":4363},[89],[1537],[43,608,2461,2462,2463,2464],{"nctId":4365,"briefTitle":4366,"status":104,"phases":4367,"primaryCompletion":4368,"completion":879,"start":4369,"enrollment":4370,"conditions":4371,"interventions":4373},"NCT00636168","Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma",[89],"2013-07-26","2008-06-30",1211,[4372],"High Risk Stage III Melanoma",[1122],{"nctId":4375,"briefTitle":4376,"status":104,"phases":4377,"primaryCompletion":3894,"completion":4378,"start":4379,"enrollment":2770,"conditions":4380,"interventions":4381},"NCT00324155","Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma",[89],"2013-10","2006-08",[21],[608,2055],{"nctId":2512,"briefTitle":2513,"status":104,"phases":4383,"primaryCompletion":2515,"completion":2516,"start":2326,"enrollment":2517,"conditions":4384,"interventions":4385},[89],[2519],[43,608,622,1268,1157],{"nctId":2522,"briefTitle":2523,"status":104,"phases":4387,"primaryCompletion":2525,"completion":2525,"start":2526,"enrollment":2527,"conditions":4388,"interventions":4389},[89],[2529],[1123,1122],{"nctId":3757,"briefTitle":3758,"status":104,"phases":4391,"primaryCompletion":3760,"completion":1895,"start":3761,"enrollment":3762,"conditions":4392,"interventions":4393},[89],[3619],[608,1929,1268,1157],{"nctId":40,"briefTitle":41,"status":179,"phases":4395,"primaryCompletion":42,"completion":158,"start":2543,"enrollment":2544,"conditions":4396,"interventions":4397},[89],[1253],[43,609,621,608],{"nctId":2567,"briefTitle":2568,"status":104,"phases":4399,"primaryCompletion":1990,"completion":2570,"start":2571,"enrollment":2572,"conditions":4400,"interventions":4401},[89],[21],[1123,1122],{"nctId":2576,"briefTitle":2577,"status":104,"phases":4403,"primaryCompletion":2579,"completion":377,"start":2580,"enrollment":2581,"conditions":4404,"interventions":4405},[89],[2161],[43,608,622,1268,1157],{"nctId":3794,"briefTitle":3795,"status":104,"phases":4407,"primaryCompletion":3797,"completion":3797,"start":3798,"enrollment":3799,"conditions":4408,"interventions":4409},[89],[3801],[1158,1157,608],{"nctId":4411,"briefTitle":4412,"status":104,"phases":4413,"primaryCompletion":4414,"completion":4414,"start":4415,"enrollment":2280,"conditions":4416,"interventions":4417},"NCT02545075","A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg\u002Fkg) vs. Dacarbazine",[89],"2019-04-19","2015-10-31",[21],[608,2055],{"nctId":2593,"briefTitle":2594,"status":104,"phases":4419,"primaryCompletion":2596,"completion":2597,"start":2598,"enrollment":2599,"conditions":4420,"interventions":4421},[89],[1436,2601,2602],[43,608,619,611,617,618],{"nctId":2605,"briefTitle":2606,"status":104,"phases":4423,"primaryCompletion":2608,"completion":2608,"start":2609,"enrollment":2610,"conditions":4424,"interventions":4425},[89],[36],[43,608,1157,1268,1267,622,1158],{"nctId":2614,"briefTitle":2615,"status":104,"phases":4427,"primaryCompletion":2617,"completion":2618,"start":2619,"enrollment":2620,"conditions":4428,"interventions":4429},[89],[2622],[43,1268,2164,1267,1328,622,1157,1158,608],{"nctId":2625,"briefTitle":2626,"status":104,"phases":4431,"primaryCompletion":879,"completion":2628,"start":2629,"enrollment":2630,"conditions":4432,"interventions":4433},[89],[21],[608,43],{"nctId":2634,"briefTitle":2635,"status":104,"phases":4435,"primaryCompletion":2637,"completion":2638,"start":1854,"enrollment":2639,"conditions":4436,"interventions":4437},[89],[1717],[43,608],{"nctId":2653,"briefTitle":2654,"status":179,"phases":4439,"primaryCompletion":225,"completion":225,"start":2656,"enrollment":2657,"conditions":4440,"interventions":4441},[89],[1607],[43,608,1609,2660],{"nctId":3825,"briefTitle":3826,"status":104,"phases":4443,"primaryCompletion":3828,"completion":3829,"start":3830,"enrollment":3831,"conditions":4444,"interventions":4445},[89],[3833],[608,1158,1157],{"nctId":2671,"briefTitle":2672,"status":104,"phases":4447,"primaryCompletion":2674,"completion":2675,"start":2676,"enrollment":2677,"conditions":4448,"interventions":4449},[89],[2679],[1123,1122,2681,2682],{"nctId":2684,"briefTitle":2685,"status":104,"phases":4451,"primaryCompletion":2687,"completion":2688,"start":2689,"enrollment":413,"conditions":4452,"interventions":4453},[89],[21],[43,608],{"nctId":4455,"briefTitle":4456,"status":104,"phases":4457,"primaryCompletion":3893,"completion":4458,"start":4459,"enrollment":4460,"conditions":4461,"interventions":4462},"NCT00861614","Study of Immunotherapy to Treat Advanced Prostate Cancer",[89],"2015-08","2009-05",988,[1504],[608],{"nctId":4464,"briefTitle":4465,"status":104,"phases":4466,"primaryCompletion":4467,"completion":4468,"start":4469,"enrollment":4470,"conditions":4471,"interventions":4472},"NCT01515189","Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg\u002Fkg Ipilimumab Versus 10 mg\u002Fkg Ipilimumab",[89],"2016-02-06","2017-08-17","2012-02-17",831,[21],[608],{"nctId":2784,"briefTitle":2785,"status":179,"phases":4474,"primaryCompletion":2787,"completion":2788,"start":2789,"enrollment":2790,"conditions":4475,"interventions":4476},[89],[2792],[43,608,1267,1268,1157],{"nctId":2795,"briefTitle":2796,"status":467,"phases":4478,"primaryCompletion":2798,"completion":2798,"start":2799,"enrollment":98,"conditions":4479,"interventions":4480},[89],[36],[43,608],{"nctId":2810,"briefTitle":2811,"status":104,"phases":4482,"primaryCompletion":2758,"completion":936,"start":2813,"enrollment":2814,"conditions":4483,"interventions":4484},[89],[2816,2817],[43,608,621],{"nctId":2820,"briefTitle":2821,"status":104,"phases":4486,"primaryCompletion":2823,"completion":2824,"start":2825,"enrollment":2826,"conditions":4487,"interventions":4488},[89],[2828],[1123,1122,2830],{"nctId":2832,"briefTitle":2833,"status":179,"phases":4490,"primaryCompletion":2835,"completion":2836,"start":2837,"enrollment":2838,"conditions":4491,"interventions":4492},[89],[2840],[608,619,617,618,1678,612,1145,43],{"nctId":2916,"briefTitle":2917,"status":104,"phases":4494,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2922,"conditions":4495,"interventions":4496},[89],[36],[608,43,1157,1158,622,1268],{"trials":4498,"activeCount":98},[4499,4503],{"nctId":2954,"briefTitle":2955,"status":104,"phases":4500,"primaryCompletion":2957,"completion":2957,"start":2958,"enrollment":1916,"conditions":4501,"interventions":4502},[90],[2960],[43,608],{"nctId":2973,"briefTitle":2974,"status":104,"phases":4504,"primaryCompletion":2976,"completion":2551,"start":2977,"enrollment":2978,"conditions":4505,"interventions":4506},[90],[1253],[43,608],{"trials":4508,"activeCount":208,"soonestReadout":4539},[4509,4515,4524,4531,4535,4543,4547],{"nctId":4510,"briefTitle":4511,"status":3014,"phases":4512,"conditions":4513,"interventions":4514},"NCT00495066","Compassionate Use Trial for Unresectable Melanoma With Ipilimumab",[],[21],[608],{"nctId":4516,"briefTitle":4517,"status":104,"phases":4518,"primaryCompletion":4519,"completion":4519,"start":4520,"enrollment":4521,"conditions":4522,"interventions":4523},"NCT02739386","Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases",[],"2017-03-30","2016-02-29",370,[21],[608],{"nctId":4525,"briefTitle":4526,"status":104,"phases":4527,"primaryCompletion":4528,"completion":4528,"start":4347,"enrollment":11,"conditions":4529,"interventions":4530},"NCT02224768","YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey",[],"2015-11",[673],[608],{"nctId":3031,"briefTitle":3032,"status":3014,"phases":4532,"conditions":4533,"interventions":4534},[],[3035],[43,608],{"nctId":4536,"briefTitle":4537,"status":179,"phases":4538,"primaryCompletion":4539,"completion":4540,"start":1033,"enrollment":1184,"conditions":4541,"interventions":4542},"NCT04196452","A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)",[],"2034-02-20","2034-07-24",[21],[608],{"nctId":3117,"briefTitle":3118,"status":104,"phases":4544,"primaryCompletion":3120,"completion":3120,"start":828,"enrollment":3121,"conditions":4545,"interventions":4546},[],[21],[43,608],{"nctId":4548,"briefTitle":4549,"status":104,"phases":4550,"primaryCompletion":4160,"completion":4160,"start":4551,"enrollment":830,"conditions":4552,"interventions":4553},"NCT02050594","Ipilimumab 12-month Intensive Pharmacovigilance Protocol",[],"2014-02",[21],[608],{"intervention":1268,"totalTrials":37,"cells":4555},{"EARLY_PHASE1":4556,"PHASE1":4558,"PHASE2":4584,"PHASE3":4606,"PHASE4":4685,"NA":4687},{"trials":4557,"activeCount":98},[],{"trials":4559,"activeCount":98},[4560,4564,4571,4575],{"nctId":3591,"briefTitle":3592,"status":104,"phases":4561,"primaryCompletion":3594,"completion":3595,"start":3596,"enrollment":1221,"conditions":4562,"interventions":4563},[87],[1888],[1890,1268,1929,3599,1157],{"nctId":4565,"briefTitle":4566,"status":104,"phases":4567,"primaryCompletion":4568,"completion":4568,"start":2326,"enrollment":1750,"conditions":4569,"interventions":4570},"NCT02949895","Study of BMS-986012 in Subjects With Small Cell Lung Caner",[87],"2017-08-29",[1888],[1890,1268,1929],{"nctId":1257,"briefTitle":1258,"status":104,"phases":4572,"primaryCompletion":1260,"completion":1261,"start":1262,"enrollment":1263,"conditions":4573,"interventions":4574},[87],[1265],[43,1267,1268,622,1158,1157,612,1269,608],{"nctId":4576,"briefTitle":4577,"status":104,"phases":4578,"primaryCompletion":3893,"completion":3893,"start":3585,"enrollment":4579,"conditions":4580,"interventions":4583},"NCT00909402","A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas",[87],39,[4581,4582],"Stomach Neoplasms","Esophageal Neoplasms",[3621,1268,611],{"trials":4585,"activeCount":230,"soonestReadout":74},[4586,4590,4594,4598,4602],{"nctId":72,"briefTitle":73,"status":179,"phases":4587,"primaryCompletion":74,"completion":1520,"start":1521,"enrollment":1522,"conditions":4588,"interventions":4589},[88],[1265,1524,1525],[43,52,1157,1268,1158,1527,622],{"nctId":1581,"briefTitle":1582,"status":104,"phases":4591,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":1586,"conditions":4592,"interventions":4593},[88],[1588],[43,608,622,1268,1157],{"nctId":1611,"briefTitle":1612,"status":963,"phases":4595,"primaryCompletion":1614,"completion":1614,"start":191,"enrollment":208,"conditions":4596,"interventions":4597},[88],[1616],[1618,43,622,1268,1157,1158],{"nctId":1680,"briefTitle":1681,"status":179,"phases":4599,"primaryCompletion":1683,"completion":1684,"start":1685,"enrollment":1686,"conditions":4600,"interventions":4601},[88],[36],[43,608,1157,1158,622,1268],{"nctId":2154,"briefTitle":2155,"status":467,"phases":4603,"primaryCompletion":2157,"completion":2158,"start":2159,"enrollment":98,"conditions":4604,"interventions":4605},[88],[36,2161,2162],[43,2164,1267,1328,622,1268,1157,1158],{"trials":4607,"activeCount":1750,"soonestReadout":65},[4608,4612,4616,4620,4624,4628,4632,4636,4640,4644,4648,4652,4656,4660,4669,4673,4677,4681],{"nctId":3725,"briefTitle":3726,"status":236,"phases":4609,"primaryCompletion":3728,"completion":3728,"start":3729,"enrollment":3730,"conditions":4610,"interventions":4611},[88,89],[3732],[3700,623,1268,1157,622,1158,1225],{"nctId":2410,"briefTitle":2411,"status":236,"phases":4613,"primaryCompletion":2413,"completion":2414,"start":2415,"enrollment":2416,"conditions":4614,"interventions":4615},[89],[1265],[43,52,623,1157,622,1268],{"nctId":2433,"briefTitle":2434,"status":104,"phases":4617,"primaryCompletion":2436,"completion":2437,"start":2438,"enrollment":2439,"conditions":4618,"interventions":4619},[89],[1636],[43,608,1268,618],{"nctId":2466,"briefTitle":2467,"status":104,"phases":4621,"primaryCompletion":2469,"completion":2470,"start":2471,"enrollment":2472,"conditions":4622,"interventions":4623},[89],[2474],[43,1267,1268,1157,1158,622],{"nctId":2477,"briefTitle":2478,"status":104,"phases":4625,"primaryCompletion":2480,"completion":2480,"start":2481,"enrollment":19,"conditions":4626,"interventions":4627},[89],[2367],[43,1145,1268],{"nctId":2485,"briefTitle":2486,"status":179,"phases":4629,"primaryCompletion":2488,"completion":412,"start":2489,"enrollment":2490,"conditions":4630,"interventions":4631},[89],[1547,2429],[43,1267,1268],{"nctId":2512,"briefTitle":2513,"status":104,"phases":4633,"primaryCompletion":2515,"completion":2516,"start":2326,"enrollment":2517,"conditions":4634,"interventions":4635},[89],[2519],[43,608,622,1268,1157],{"nctId":3757,"briefTitle":3758,"status":104,"phases":4637,"primaryCompletion":3760,"completion":1895,"start":3761,"enrollment":3762,"conditions":4638,"interventions":4639},[89],[3619],[608,1929,1268,1157],{"nctId":2576,"briefTitle":2577,"status":104,"phases":4641,"primaryCompletion":2579,"completion":377,"start":2580,"enrollment":2581,"conditions":4642,"interventions":4643},[89],[2161],[43,608,622,1268,1157],{"nctId":3804,"briefTitle":3805,"status":236,"phases":4645,"primaryCompletion":3807,"completion":3808,"start":3809,"enrollment":290,"conditions":4646,"interventions":4647},[88,89],[36],[3792,1157,1268,622],{"nctId":2585,"briefTitle":2586,"status":467,"phases":4649,"primaryCompletion":2588,"completion":2588,"start":2589,"enrollment":98,"conditions":4650,"interventions":4651},[89],[1537],[43,1337,1145,1268,1157,618],{"nctId":2605,"briefTitle":2606,"status":104,"phases":4653,"primaryCompletion":2608,"completion":2608,"start":2609,"enrollment":2610,"conditions":4654,"interventions":4655},[89],[36],[43,608,1157,1268,1267,622,1158],{"nctId":2614,"briefTitle":2615,"status":104,"phases":4657,"primaryCompletion":2617,"completion":2618,"start":2619,"enrollment":2620,"conditions":4658,"interventions":4659},[89],[2622],[43,1268,2164,1267,1328,622,1157,1158,608],{"nctId":4661,"briefTitle":4662,"status":104,"phases":4663,"primaryCompletion":4664,"completion":4664,"start":4665,"enrollment":217,"conditions":4666,"interventions":4667},"NCT00337532","A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer",[88,89],"2007-06","2005-05",[1537],[1158,4668],"cisplatin",{"nctId":3836,"briefTitle":3837,"status":236,"phases":4670,"primaryCompletion":3839,"completion":3840,"start":3841,"enrollment":3842,"conditions":4671,"interventions":4672},[88,89],[2792],[3792,1268,1267,1157],{"nctId":63,"briefTitle":64,"status":179,"phases":4674,"primaryCompletion":65,"completion":2777,"start":2778,"enrollment":2779,"conditions":4675,"interventions":4676},[89],[2781],[43,1157,1268,1158,622,1328],{"nctId":2784,"briefTitle":2785,"status":179,"phases":4678,"primaryCompletion":2787,"completion":2788,"start":2789,"enrollment":2790,"conditions":4679,"interventions":4680},[89],[2792],[43,608,1267,1268,1157],{"nctId":2916,"briefTitle":2917,"status":104,"phases":4682,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2922,"conditions":4683,"interventions":4684},[89],[36],[608,43,1157,1158,622,1268],{"trials":4686,"activeCount":98},[],{"trials":4688,"activeCount":98},[],{"intervention":622,"totalTrials":757,"cells":4690},{"EARLY_PHASE1":4691,"PHASE1":4693,"PHASE2":4703,"PHASE3":4741,"PHASE4":4783,"NA":4785},{"trials":4692,"activeCount":98},[],{"trials":4694,"activeCount":98},[4695,4699],{"nctId":1147,"briefTitle":1148,"status":104,"phases":4696,"primaryCompletion":1150,"completion":1150,"start":1151,"enrollment":1152,"conditions":4697,"interventions":4698},[87],[1154],[1156,43,1157,622,1158],{"nctId":1257,"briefTitle":1258,"status":104,"phases":4700,"primaryCompletion":1260,"completion":1261,"start":1262,"enrollment":1263,"conditions":4701,"interventions":4702},[87],[1265],[43,1267,1268,622,1158,1157,612,1269,608],{"trials":4704,"activeCount":4328,"soonestReadout":74},[4705,4709,4713,4717,4721,4725,4729,4733,4737],{"nctId":72,"briefTitle":73,"status":179,"phases":4706,"primaryCompletion":74,"completion":1520,"start":1521,"enrollment":1522,"conditions":4707,"interventions":4708},[88],[1265,1524,1525],[43,52,1157,1268,1158,1527,622],{"nctId":1581,"briefTitle":1582,"status":104,"phases":4710,"primaryCompletion":1584,"completion":1584,"start":1585,"enrollment":1586,"conditions":4711,"interventions":4712},[88],[1588],[43,608,622,1268,1157],{"nctId":1611,"briefTitle":1612,"status":963,"phases":4714,"primaryCompletion":1614,"completion":1614,"start":191,"enrollment":208,"conditions":4715,"interventions":4716},[88],[1616],[1618,43,622,1268,1157,1158],{"nctId":599,"briefTitle":600,"status":236,"phases":4718,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":4719,"interventions":4720},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"nctId":1680,"briefTitle":1681,"status":179,"phases":4722,"primaryCompletion":1683,"completion":1684,"start":1685,"enrollment":1686,"conditions":4723,"interventions":4724},[88],[36],[43,608,1157,1158,622,1268],{"nctId":4111,"briefTitle":4112,"status":963,"phases":4726,"primaryCompletion":4114,"completion":4114,"start":3902,"enrollment":747,"conditions":4727,"interventions":4728},[88],[4116],[608,622],{"nctId":3693,"briefTitle":3694,"status":642,"phases":4730,"primaryCompletion":3696,"completion":3696,"start":3697,"enrollment":3093,"conditions":4731,"interventions":4732},[88],[1515],[3700,3701,3702,613,1721,622,1157,1225,1267,1158],{"nctId":2154,"briefTitle":2155,"status":467,"phases":4734,"primaryCompletion":2157,"completion":2158,"start":2159,"enrollment":98,"conditions":4735,"interventions":4736},[88],[36,2161,2162],[43,2164,1267,1328,622,1268,1157,1158],{"nctId":2227,"briefTitle":2228,"status":104,"phases":4738,"primaryCompletion":2230,"completion":2230,"start":2231,"enrollment":2232,"conditions":4739,"interventions":4740},[87,88],[36],[43,612,622,2235,1158,1328,1267,1269,2236,1157],{"trials":4742,"activeCount":4328,"soonestReadout":65},[4743,4747,4751,4755,4759,4763,4767,4771,4775,4779],{"nctId":3725,"briefTitle":3726,"status":236,"phases":4744,"primaryCompletion":3728,"completion":3728,"start":3729,"enrollment":3730,"conditions":4745,"interventions":4746},[88,89],[3732],[3700,623,1268,1157,622,1158,1225],{"nctId":2410,"briefTitle":2411,"status":236,"phases":4748,"primaryCompletion":2413,"completion":2414,"start":2415,"enrollment":2416,"conditions":4749,"interventions":4750},[89],[1265],[43,52,623,1157,622,1268],{"nctId":2466,"briefTitle":2467,"status":104,"phases":4752,"primaryCompletion":2469,"completion":2470,"start":2471,"enrollment":2472,"conditions":4753,"interventions":4754},[89],[2474],[43,1267,1268,1157,1158,622],{"nctId":2512,"briefTitle":2513,"status":104,"phases":4756,"primaryCompletion":2515,"completion":2516,"start":2326,"enrollment":2517,"conditions":4757,"interventions":4758},[89],[2519],[43,608,622,1268,1157],{"nctId":2576,"briefTitle":2577,"status":104,"phases":4760,"primaryCompletion":2579,"completion":377,"start":2580,"enrollment":2581,"conditions":4761,"interventions":4762},[89],[2161],[43,608,622,1268,1157],{"nctId":3804,"briefTitle":3805,"status":236,"phases":4764,"primaryCompletion":3807,"completion":3808,"start":3809,"enrollment":290,"conditions":4765,"interventions":4766},[88,89],[36],[3792,1157,1268,622],{"nctId":2605,"briefTitle":2606,"status":104,"phases":4768,"primaryCompletion":2608,"completion":2608,"start":2609,"enrollment":2610,"conditions":4769,"interventions":4770},[89],[36],[43,608,1157,1268,1267,622,1158],{"nctId":2614,"briefTitle":2615,"status":104,"phases":4772,"primaryCompletion":2617,"completion":2618,"start":2619,"enrollment":2620,"conditions":4773,"interventions":4774},[89],[2622],[43,1268,2164,1267,1328,622,1157,1158,608],{"nctId":63,"briefTitle":64,"status":179,"phases":4776,"primaryCompletion":65,"completion":2777,"start":2778,"enrollment":2779,"conditions":4777,"interventions":4778},[89],[2781],[43,1157,1268,1158,622,1328],{"nctId":2916,"briefTitle":2917,"status":104,"phases":4780,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2922,"conditions":4781,"interventions":4782},[89],[36],[608,43,1157,1158,622,1268],{"trials":4784,"activeCount":98},[],{"trials":4786,"activeCount":98},[],{"intervention":1721,"totalTrials":839,"cells":4788},{"EARLY_PHASE1":4789,"PHASE1":4791,"PHASE2":4793,"PHASE3":4811,"PHASE4":4847,"NA":4849},{"trials":4790,"activeCount":98},[],{"trials":4792,"activeCount":98},[],{"trials":4794,"activeCount":4328,"soonestReadout":4297},[4795,4799,4803,4807],{"nctId":4080,"briefTitle":4081,"status":236,"phases":4796,"primaryCompletion":4083,"completion":4084,"start":4085,"enrollment":4086,"conditions":4797,"interventions":4798},[87,88],[4088],[1721,608,609],{"nctId":1710,"briefTitle":1711,"status":236,"phases":4800,"primaryCompletion":1713,"completion":1713,"start":1714,"enrollment":1715,"conditions":4801,"interventions":4802},[87,88],[1717,1223],[1719,1720,623,43,1721],{"nctId":3693,"briefTitle":3694,"status":642,"phases":4804,"primaryCompletion":3696,"completion":3696,"start":3697,"enrollment":3093,"conditions":4805,"interventions":4806},[88],[1515],[3700,3701,3702,613,1721,622,1157,1225,1267,1158],{"nctId":4294,"briefTitle":4295,"status":236,"phases":4808,"primaryCompletion":4297,"completion":4298,"start":4299,"enrollment":4300,"conditions":4809,"interventions":4810},[87,88],[4302],[1721,608],{"trials":4812,"activeCount":4328,"soonestReadout":4835},[4813,4821,4831,4843],{"nctId":4814,"briefTitle":4815,"status":236,"phases":4816,"primaryCompletion":4298,"completion":4298,"start":4817,"enrollment":4818,"conditions":4819,"interventions":4820},"NCT07361510","A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)",[89],"2026-03-12",750,[2828],[1721,623],{"nctId":4822,"briefTitle":4823,"status":236,"phases":4824,"primaryCompletion":4825,"completion":4826,"start":4299,"enrollment":4827,"conditions":4828,"interventions":4829},"NCT07361497","A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)",[89],"2030-09-18","2033-12-31",850,[3131],[1721,4830],"Durvalumab",{"nctId":4832,"briefTitle":4833,"status":236,"phases":4834,"primaryCompletion":4835,"completion":4836,"start":329,"enrollment":4837,"conditions":4838,"interventions":4840},"NCT07221357","A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer",[88,89],"2030-02-02","2034-03-11",990,[4839],"Untreated, Unresectable, or Metastatic Colorectal Cancer",[1721,2205,4841,612,4842],"FOLFIRI","CAPOX",{"nctId":2853,"briefTitle":2854,"status":236,"phases":4844,"primaryCompletion":2856,"completion":2857,"start":2858,"enrollment":2859,"conditions":4845,"interventions":4846},[88,89],[2861],[1721,2863,2864,43],{"trials":4848,"activeCount":98},[],{"trials":4850,"activeCount":98},[],{"intervention":1267,"totalTrials":713,"cells":4852},{"EARLY_PHASE1":4853,"PHASE1":4855,"PHASE2":4861,"PHASE3":4895,"PHASE4":4946,"NA":4948},{"trials":4854,"activeCount":98},[],{"trials":4856,"activeCount":98},[4857],{"nctId":1257,"briefTitle":1258,"status":104,"phases":4858,"primaryCompletion":1260,"completion":1261,"start":1262,"enrollment":1263,"conditions":4859,"interventions":4860},[87],[1265],[43,1267,1268,622,1158,1157,612,1269,608],{"trials":4862,"activeCount":230,"soonestReadout":4871},[4863,4867,4879,4883,4887,4891],{"nctId":1666,"briefTitle":1667,"status":104,"phases":4864,"primaryCompletion":1669,"completion":60,"start":1670,"enrollment":1671,"conditions":4865,"interventions":4866},[87,88],[1673,1674],[1676,43,1225,1267,1677,617,1678],{"nctId":4868,"briefTitle":4869,"status":236,"phases":4870,"primaryCompletion":4871,"completion":4871,"start":181,"enrollment":4872,"conditions":4873,"interventions":4877},"NCT07223047","A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies",[87,88],"2028-10-13",252,[4874,3131,4875,4876],"Advanced Solid Malignancies","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)",[4878,1267,1527,1145,623],"BMS-986523",{"nctId":3693,"briefTitle":3694,"status":642,"phases":4880,"primaryCompletion":3696,"completion":3696,"start":3697,"enrollment":3093,"conditions":4881,"interventions":4882},[88],[1515],[3700,3701,3702,613,1721,622,1157,1225,1267,1158],{"nctId":2154,"briefTitle":2155,"status":467,"phases":4884,"primaryCompletion":2157,"completion":2158,"start":2159,"enrollment":98,"conditions":4885,"interventions":4886},[88],[36,2161,2162],[43,2164,1267,1328,622,1268,1157,1158],{"nctId":2227,"briefTitle":2228,"status":104,"phases":4888,"primaryCompletion":2230,"completion":2230,"start":2231,"enrollment":2232,"conditions":4889,"interventions":4890},[87,88],[36],[43,612,622,2235,1158,1328,1267,1269,2236,1157],{"nctId":2257,"briefTitle":2258,"status":104,"phases":4892,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":2262,"conditions":4893,"interventions":4894},[88],[2264],[1245,1225,2266,43,618,1267,619,617,2267],{"trials":4896,"activeCount":520,"soonestReadout":2787},[4897,4901,4905,4909,4918,4922,4926,4938,4942],{"nctId":2466,"briefTitle":2467,"status":104,"phases":4898,"primaryCompletion":2469,"completion":2470,"start":2471,"enrollment":2472,"conditions":4899,"interventions":4900},[89],[2474],[43,1267,1268,1157,1158,622],{"nctId":2485,"briefTitle":2486,"status":179,"phases":4902,"primaryCompletion":2488,"completion":412,"start":2489,"enrollment":2490,"conditions":4903,"interventions":4904},[89],[1547,2429],[43,1267,1268],{"nctId":3783,"briefTitle":3784,"status":236,"phases":4906,"primaryCompletion":3786,"completion":3787,"start":3788,"enrollment":290,"conditions":4907,"interventions":4908},[88,89],[3790],[3792,1225,1158,611,1157,1267],{"nctId":4910,"briefTitle":4911,"status":236,"phases":4912,"primaryCompletion":4913,"completion":4913,"start":4914,"enrollment":3842,"conditions":4915,"interventions":4917},"NCT07076121","A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)",[88,89],"2029-05-03","2025-10-23",[4916],"Pancreatic Ductal Adenocarcinoma",[3700,1267,1225],{"nctId":2605,"briefTitle":2606,"status":104,"phases":4919,"primaryCompletion":2608,"completion":2608,"start":2609,"enrollment":2610,"conditions":4920,"interventions":4921},[89],[36],[43,608,1157,1268,1267,622,1158],{"nctId":2614,"briefTitle":2615,"status":104,"phases":4923,"primaryCompletion":2617,"completion":2618,"start":2619,"enrollment":2620,"conditions":4924,"interventions":4925},[89],[2622],[43,1268,2164,1267,1328,622,1157,1158,608],{"nctId":4927,"briefTitle":4928,"status":104,"phases":4929,"primaryCompletion":4930,"completion":4930,"start":4931,"enrollment":4932,"conditions":4933,"interventions":4936},"NCT00389155","First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy",[88,89],"2008-01","2007-01",34,[2427,4934,4935],"Transitional Cell Carcinoma","Metastasis",[4937,1267],"Vinflunine",{"nctId":3836,"briefTitle":3837,"status":236,"phases":4939,"primaryCompletion":3839,"completion":3840,"start":3841,"enrollment":3842,"conditions":4940,"interventions":4941},[88,89],[2792],[3792,1268,1267,1157],{"nctId":2784,"briefTitle":2785,"status":179,"phases":4943,"primaryCompletion":2787,"completion":2788,"start":2789,"enrollment":2790,"conditions":4944,"interventions":4945},[89],[2792],[43,608,1267,1268,1157],{"trials":4947,"activeCount":98},[],{"trials":4949,"activeCount":98},[],{"intervention":1158,"totalTrials":3562,"cells":4951},{"EARLY_PHASE1":4952,"PHASE1":4954,"PHASE2":5000,"PHASE3":5124,"PHASE4":5174,"NA":5176},{"trials":4953,"activeCount":98},[],{"trials":4955,"activeCount":98},[4956,4960,4964,4968,4972,4976,4987,4991],{"nctId":3569,"briefTitle":3570,"status":104,"phases":4957,"primaryCompletion":1343,"completion":1343,"start":3572,"enrollment":757,"conditions":4958,"interventions":4959},[87],[1132,3574],[3576,1158,1157],{"nctId":1147,"briefTitle":1148,"status":104,"phases":4961,"primaryCompletion":1150,"completion":1150,"start":1151,"enrollment":1152,"conditions":4962,"interventions":4963},[87],[1154],[1156,43,1157,622,1158],{"nctId":3582,"briefTitle":3583,"status":104,"phases":4965,"primaryCompletion":3585,"completion":3586,"start":3587,"enrollment":534,"conditions":4966,"interventions":4967},[87],[673],[608,1157,1158,2055],{"nctId":3601,"briefTitle":3602,"status":104,"phases":4969,"primaryCompletion":3604,"completion":3605,"start":3606,"enrollment":3607,"conditions":4970,"interventions":4971},[87],[606],[1158,3610,1157,617,1678,1158,3611],{"nctId":1257,"briefTitle":1258,"status":104,"phases":4973,"primaryCompletion":1260,"completion":1261,"start":1262,"enrollment":1263,"conditions":4974,"interventions":4975},[87],[1265],[43,1267,1268,622,1158,1157,612,1269,608],{"nctId":4977,"briefTitle":4978,"status":104,"phases":4979,"primaryCompletion":4980,"completion":4980,"start":4981,"enrollment":4982,"conditions":4983,"interventions":4984},"NCT00798252","Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers",[87],"2015-05","2009-03",111,[1154],[611,2053,4985,1328,1158,4986],"Ixabepilone","Brivanib alaninate",{"nctId":3627,"briefTitle":3628,"status":104,"phases":4988,"primaryCompletion":3630,"completion":3630,"start":3631,"enrollment":1385,"conditions":4989,"interventions":4990},[87],[36],[3634,3635,1158,1157],{"nctId":4992,"briefTitle":4993,"status":104,"phases":4994,"primaryCompletion":3873,"completion":3873,"start":4995,"enrollment":3143,"conditions":4996,"interventions":4997},"NCT00803556","Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy",[87],"2006-01",[1482,1223],[4998,4999,1158],"Alvespimycin","Trastuzumab",{"trials":5001,"activeCount":574,"soonestReadout":74},[5002,5006,5010,5018,5026,5030,5038,5046,5054,5058,5062,5070,5074,5082,5094,5101,5105,5109,5113,5120],{"nctId":1399,"briefTitle":1400,"status":963,"phases":5003,"primaryCompletion":1402,"completion":1402,"start":1403,"enrollment":347,"conditions":5004,"interventions":5005},[87,88],[1132,1265],[1406,43,1328,1157,1407,1158],{"nctId":1429,"briefTitle":1430,"status":467,"phases":5007,"primaryCompletion":1432,"completion":1433,"start":1434,"enrollment":98,"conditions":5008,"interventions":5009},[88],[1436,1437,1438,1439],[1441,43,1158,1442],{"nctId":5011,"briefTitle":5012,"status":104,"phases":5013,"primaryCompletion":5014,"completion":5014,"start":4179,"enrollment":5015,"conditions":5016,"interventions":5017},"NCT00455533","Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer",[88],"2009-12",384,[1223],[4985,1158,1773,2053],{"nctId":5019,"briefTitle":5020,"status":104,"phases":5021,"primaryCompletion":5022,"completion":5022,"start":5023,"enrollment":208,"conditions":5024,"interventions":5025},"NCT00971841","Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer",[88],"2012-04","2008-03",[3104],[1158],{"nctId":72,"briefTitle":73,"status":179,"phases":5027,"primaryCompletion":74,"completion":1520,"start":1521,"enrollment":1522,"conditions":5028,"interventions":5029},[88],[1265,1524,1525],[43,52,1157,1268,1158,1527,622],{"nctId":5031,"briefTitle":5032,"status":104,"phases":5033,"primaryCompletion":5034,"completion":5034,"start":5035,"enrollment":360,"conditions":5036,"interventions":5037},"NCT00971867","Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer",[88],"2008-11-26","2006-08-04",[1537],[1158],{"nctId":5039,"briefTitle":5040,"status":104,"phases":5041,"primaryCompletion":5042,"completion":5042,"start":5043,"enrollment":347,"conditions":5044,"interventions":5045},"NCT00855764","Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer",[88],"2006-10","2005-10",[1537],[1158],{"nctId":5047,"briefTitle":5048,"status":104,"phases":5049,"primaryCompletion":5050,"completion":5050,"start":5051,"enrollment":582,"conditions":5052,"interventions":5053},"NCT01024062","Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)",[88],"2005-03","2002-12",[36],[1158],{"nctId":1611,"briefTitle":1612,"status":963,"phases":5055,"primaryCompletion":1614,"completion":1614,"start":191,"enrollment":208,"conditions":5056,"interventions":5057},[88],[1616],[1618,43,622,1268,1157,1158],{"nctId":3675,"briefTitle":3676,"status":104,"phases":5059,"primaryCompletion":3678,"completion":3679,"start":3680,"enrollment":3681,"conditions":5060,"interventions":5061},[88],[1717,1888,2781],[608,1158,1157],{"nctId":5063,"briefTitle":5064,"status":104,"phases":5065,"primaryCompletion":5066,"completion":5066,"start":5067,"enrollment":830,"conditions":5068,"interventions":5069},"NCT00971945","Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer",[88],"2008-03-31","2005-06-30",[1223],[1158],{"nctId":1680,"briefTitle":1681,"status":179,"phases":5071,"primaryCompletion":1683,"completion":1684,"start":1685,"enrollment":1686,"conditions":5072,"interventions":5073},[88],[36],[43,608,1157,1158,622,1268],{"nctId":5075,"briefTitle":5076,"status":104,"phases":5077,"primaryCompletion":5078,"completion":5078,"start":5079,"enrollment":25,"conditions":5080,"interventions":5081},"NCT01023204","Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer",[88],"2005-07","2002-10",[1223],[1158],{"nctId":5083,"briefTitle":5084,"status":104,"phases":5085,"primaryCompletion":5086,"completion":5087,"start":5088,"enrollment":413,"conditions":5089,"interventions":5091},"NCT05613088","A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[88],"2024-06-17","2025-09-10","2023-02-01",[5090],"Neoplasms, Ovarian",[5092,1158,5093,2913],"MORAb-202","Pegylated Liposomal Doxorubicin",{"nctId":5095,"briefTitle":5096,"status":104,"phases":5097,"primaryCompletion":5098,"completion":5098,"start":3658,"enrollment":347,"conditions":5099,"interventions":5100},"NCT01024101","Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer",[88],"2005-12",[1537],[1158],{"nctId":3693,"briefTitle":3694,"status":642,"phases":5102,"primaryCompletion":3696,"completion":3696,"start":3697,"enrollment":3093,"conditions":5103,"interventions":5104},[88],[1515],[3700,3701,3702,613,1721,622,1157,1225,1267,1158],{"nctId":2154,"briefTitle":2155,"status":467,"phases":5106,"primaryCompletion":2157,"completion":2158,"start":2159,"enrollment":98,"conditions":5107,"interventions":5108},[88],[36,2161,2162],[43,2164,1267,1328,622,1268,1157,1158],{"nctId":3708,"briefTitle":3709,"status":963,"phases":5110,"primaryCompletion":3711,"completion":3711,"start":3712,"enrollment":3713,"conditions":5111,"interventions":5112},[88],[3131],[1158,1157,3716,612,3717],{"nctId":5114,"briefTitle":5115,"status":104,"phases":5116,"primaryCompletion":5023,"completion":5023,"start":5117,"enrollment":28,"conditions":5118,"interventions":5119},"NCT00344552","Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer",[88],"2006-06",[3104],[1158],{"nctId":2227,"briefTitle":2228,"status":104,"phases":5121,"primaryCompletion":2230,"completion":2230,"start":2231,"enrollment":2232,"conditions":5122,"interventions":5123},[87,88],[36],[43,612,622,2235,1158,1328,1267,1269,2236,1157],{"trials":5125,"activeCount":574,"soonestReadout":65},[5126,5130,5134,5138,5142,5146,5150,5154,5158,5162,5166,5170],{"nctId":3725,"briefTitle":3726,"status":236,"phases":5127,"primaryCompletion":3728,"completion":3728,"start":3729,"enrollment":3730,"conditions":5128,"interventions":5129},[88,89],[3732],[3700,623,1268,1157,622,1158,1225],{"nctId":2466,"briefTitle":2467,"status":104,"phases":5131,"primaryCompletion":2469,"completion":2470,"start":2471,"enrollment":2472,"conditions":5132,"interventions":5133},[89],[2474],[43,1267,1268,1157,1158,622],{"nctId":3743,"briefTitle":3744,"status":104,"phases":5135,"primaryCompletion":3746,"completion":1364,"start":3747,"enrollment":3748,"conditions":5136,"interventions":5137},[89],[2378],[3751,2055,1157,1158],{"nctId":3783,"briefTitle":3784,"status":236,"phases":5139,"primaryCompletion":3786,"completion":3787,"start":3788,"enrollment":290,"conditions":5140,"interventions":5141},[88,89],[3790],[3792,1225,1158,611,1157,1267],{"nctId":3794,"briefTitle":3795,"status":104,"phases":5143,"primaryCompletion":3797,"completion":3797,"start":3798,"enrollment":3799,"conditions":5144,"interventions":5145},[89],[3801],[1158,1157,608],{"nctId":2605,"briefTitle":2606,"status":104,"phases":5147,"primaryCompletion":2608,"completion":2608,"start":2609,"enrollment":2610,"conditions":5148,"interventions":5149},[89],[36],[43,608,1157,1268,1267,622,1158],{"nctId":2614,"briefTitle":2615,"status":104,"phases":5151,"primaryCompletion":2617,"completion":2618,"start":2619,"enrollment":2620,"conditions":5152,"interventions":5153},[89],[2622],[43,1268,2164,1267,1328,622,1157,1158,608],{"nctId":4661,"briefTitle":4662,"status":104,"phases":5155,"primaryCompletion":4664,"completion":4664,"start":4665,"enrollment":217,"conditions":5156,"interventions":5157},[88,89],[1537],[1158,4668],{"nctId":3825,"briefTitle":3826,"status":104,"phases":5159,"primaryCompletion":3828,"completion":3829,"start":3830,"enrollment":3831,"conditions":5160,"interventions":5161},[89],[3833],[608,1158,1157],{"nctId":63,"briefTitle":64,"status":179,"phases":5163,"primaryCompletion":65,"completion":2777,"start":2778,"enrollment":2779,"conditions":5164,"interventions":5165},[89],[2781],[43,1157,1268,1158,622,1328],{"nctId":2916,"briefTitle":2917,"status":104,"phases":5167,"primaryCompletion":2919,"completion":2920,"start":2921,"enrollment":2922,"conditions":5168,"interventions":5169},[89],[36],[608,43,1157,1158,622,1268],{"nctId":2938,"briefTitle":2939,"status":104,"phases":5171,"primaryCompletion":2941,"completion":2942,"start":2943,"enrollment":2944,"conditions":5172,"interventions":5173},[89],[1223],[1123,2947,2948,2949,2950],{"trials":5175,"activeCount":98},[],{"trials":5177,"activeCount":98},[],{"intervention":1225,"totalTrials":1184,"cells":5179},{"EARLY_PHASE1":5180,"PHASE1":5182,"PHASE2":5188,"PHASE3":5214,"PHASE4":5228,"NA":5230},{"trials":5181,"activeCount":98},[],{"trials":5183,"activeCount":98},[5184],{"nctId":1216,"briefTitle":1217,"status":104,"phases":5185,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":1221,"conditions":5186,"interventions":5187},[87],[1223],[43,608,1225],{"trials":5189,"activeCount":574,"soonestReadout":74},[5190,5194,5198,5202,5206,5210],{"nctId":72,"briefTitle":73,"status":179,"phases":5191,"primaryCompletion":74,"completion":1520,"start":1521,"enrollment":1522,"conditions":5192,"interventions":5193},[88],[1265,1524,1525],[43,52,1157,1268,1158,1527,622],{"nctId":1666,"briefTitle":1667,"status":104,"phases":5195,"primaryCompletion":1669,"completion":60,"start":1670,"enrollment":1671,"conditions":5196,"interventions":5197},[87,88],[1673,1674],[1676,43,1225,1267,1677,617,1678],{"nctId":4868,"briefTitle":4869,"status":236,"phases":5199,"primaryCompletion":4871,"completion":4871,"start":181,"enrollment":4872,"conditions":5200,"interventions":5201},[87,88],[4874,3131,4875,4876],[4878,1267,1527,1145,623],{"nctId":3693,"briefTitle":3694,"status":642,"phases":5203,"primaryCompletion":3696,"completion":3696,"start":3697,"enrollment":3093,"conditions":5204,"interventions":5205},[88],[1515],[3700,3701,3702,613,1721,622,1157,1225,1267,1158],{"nctId":2227,"briefTitle":2228,"status":104,"phases":5207,"primaryCompletion":2230,"completion":2230,"start":2231,"enrollment":2232,"conditions":5208,"interventions":5209},[87,88],[36],[43,612,622,2235,1158,1328,1267,1269,2236,1157],{"nctId":2257,"briefTitle":2258,"status":104,"phases":5211,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":2262,"conditions":5212,"interventions":5213},[88],[2264],[1245,1225,2266,43,618,1267,619,617,2267],{"trials":5215,"activeCount":574,"soonestReadout":3786},[5216,5220,5224],{"nctId":3725,"briefTitle":3726,"status":236,"phases":5217,"primaryCompletion":3728,"completion":3728,"start":3729,"enrollment":3730,"conditions":5218,"interventions":5219},[88,89],[3732],[3700,623,1268,1157,622,1158,1225],{"nctId":3783,"briefTitle":3784,"status":236,"phases":5221,"primaryCompletion":3786,"completion":3787,"start":3788,"enrollment":290,"conditions":5222,"interventions":5223},[88,89],[3790],[3792,1225,1158,611,1157,1267],{"nctId":4910,"briefTitle":4911,"status":236,"phases":5225,"primaryCompletion":4913,"completion":4913,"start":4914,"enrollment":3842,"conditions":5226,"interventions":5227},[88,89],[4916],[3700,1267,1225],{"trials":5229,"activeCount":98},[],{"trials":5231,"activeCount":98},[],{"intervention":3435,"totalTrials":1750,"cells":5233},{"EARLY_PHASE1":5234,"PHASE1":5236,"PHASE2":5242,"PHASE3":5244,"PHASE4":5270,"NA":5272},{"trials":5235,"activeCount":98},[],{"trials":5237,"activeCount":98},[5238],{"nctId":3427,"briefTitle":3428,"status":104,"phases":5239,"primaryCompletion":3430,"completion":3430,"start":3431,"enrollment":1203,"conditions":5240,"interventions":5241},[87],[3433],[3420,3435],{"trials":5243,"activeCount":98},[],{"trials":5245,"activeCount":830,"soonestReadout":3476},[5246,5250,5254,5258,5262,5266],{"nctId":3462,"briefTitle":3463,"status":236,"phases":5247,"primaryCompletion":3465,"completion":3466,"start":3467,"enrollment":3468,"conditions":5248,"interventions":5249},[89],[3470],[3420,3435],{"nctId":3473,"briefTitle":3474,"status":236,"phases":5251,"primaryCompletion":3476,"completion":3477,"start":3478,"enrollment":1966,"conditions":5252,"interventions":5253},[89],[552,3480],[3420,3435],{"nctId":3483,"briefTitle":3484,"status":642,"phases":5255,"primaryCompletion":3486,"completion":3486,"start":3487,"enrollment":3139,"conditions":5256,"interventions":5257},[89],[3489],[3420,3435],{"nctId":3501,"briefTitle":3502,"status":642,"phases":5259,"primaryCompletion":3504,"completion":3504,"start":3487,"enrollment":3139,"conditions":5260,"interventions":5261},[89],[3489],[3420,3435],{"nctId":3525,"briefTitle":3526,"status":236,"phases":5263,"primaryCompletion":3465,"completion":3466,"start":3528,"enrollment":3468,"conditions":5264,"interventions":5265},[89],[3470],[3420,3435],{"nctId":3540,"briefTitle":3541,"status":236,"phases":5267,"primaryCompletion":3543,"completion":3544,"start":3545,"enrollment":271,"conditions":5268,"interventions":5269},[89],[552,3547],[3420,3435],{"trials":5271,"activeCount":98},[],{"trials":5273,"activeCount":98},[],{"intervention":3700,"totalTrials":830,"cells":5275},{"EARLY_PHASE1":5276,"PHASE1":5278,"PHASE2":5298,"PHASE3":5312,"PHASE4":5322,"NA":5324},{"trials":5277,"activeCount":98},[],{"trials":5279,"activeCount":230,"soonestReadout":5292},[5280,5288],{"nctId":5281,"briefTitle":5282,"status":236,"phases":5283,"primaryCompletion":5284,"completion":5284,"start":5285,"enrollment":34,"conditions":5286,"interventions":5287},"NCT07077434","A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors",[87],"2027-01-19","2025-10-15",[1132],[3700],{"nctId":5289,"briefTitle":5290,"status":236,"phases":5291,"primaryCompletion":5292,"completion":5292,"start":5293,"enrollment":839,"conditions":5294,"interventions":5296},"NCT06672523","A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion",[87],"2026-04-20","2025-03-24",[5295],"Advanced Solid Tumors With Homozygous MTAP Deletion",[3700,5297],"[14C]-BMS-986504",{"trials":5299,"activeCount":230,"soonestReadout":1087},[5300,5304],{"nctId":3693,"briefTitle":3694,"status":642,"phases":5301,"primaryCompletion":3696,"completion":3696,"start":3697,"enrollment":3093,"conditions":5302,"interventions":5303},[88],[1515],[3700,3701,3702,613,1721,622,1157,1225,1267,1158],{"nctId":5305,"briefTitle":5306,"status":236,"phases":5307,"primaryCompletion":1087,"completion":5308,"start":5309,"enrollment":3322,"conditions":5310,"interventions":5311},"NCT06855771","A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)",[88],"2031-12-30","2025-09-09",[2781],[3700],{"trials":5313,"activeCount":230,"soonestReadout":4913},[5314,5318],{"nctId":3725,"briefTitle":3726,"status":236,"phases":5315,"primaryCompletion":3728,"completion":3728,"start":3729,"enrollment":3730,"conditions":5316,"interventions":5317},[88,89],[3732],[3700,623,1268,1157,622,1158,1225],{"nctId":4910,"briefTitle":4911,"status":236,"phases":5319,"primaryCompletion":4913,"completion":4913,"start":4914,"enrollment":3842,"conditions":5320,"interventions":5321},[88,89],[4916],[3700,1267,1225],{"trials":5323,"activeCount":98},[],{"trials":5325,"activeCount":98},[],{"intervention":623,"totalTrials":830,"cells":5327},{"EARLY_PHASE1":5328,"PHASE1":5330,"PHASE2":5332,"PHASE3":5346,"PHASE4":5360,"NA":5362},{"trials":5329,"activeCount":98},[],{"trials":5331,"activeCount":98},[],{"trials":5333,"activeCount":574,"soonestReadout":4871},[5334,5338,5342],{"nctId":599,"briefTitle":600,"status":236,"phases":5335,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":5336,"interventions":5337},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"nctId":1710,"briefTitle":1711,"status":236,"phases":5339,"primaryCompletion":1713,"completion":1713,"start":1714,"enrollment":1715,"conditions":5340,"interventions":5341},[87,88],[1717,1223],[1719,1720,623,43,1721],{"nctId":4868,"briefTitle":4869,"status":236,"phases":5343,"primaryCompletion":4871,"completion":4871,"start":181,"enrollment":4872,"conditions":5344,"interventions":5345},[87,88],[4874,3131,4875,4876],[4878,1267,1527,1145,623],{"trials":5347,"activeCount":574,"soonestReadout":2413},[5348,5352,5356],{"nctId":3725,"briefTitle":3726,"status":236,"phases":5349,"primaryCompletion":3728,"completion":3728,"start":3729,"enrollment":3730,"conditions":5350,"interventions":5351},[88,89],[3732],[3700,623,1268,1157,622,1158,1225],{"nctId":2410,"briefTitle":2411,"status":236,"phases":5353,"primaryCompletion":2413,"completion":2414,"start":2415,"enrollment":2416,"conditions":5354,"interventions":5355},[89],[1265],[43,52,623,1157,622,1268],{"nctId":4814,"briefTitle":4815,"status":236,"phases":5357,"primaryCompletion":4298,"completion":4298,"start":4817,"enrollment":4818,"conditions":5358,"interventions":5359},[89],[2828],[1721,623],{"trials":5361,"activeCount":98},[],{"trials":5363,"activeCount":98},[],{"intervention":5365,"totalTrials":1221,"cells":5366},"Ozanimod",{"EARLY_PHASE1":5367,"PHASE1":5369,"PHASE2":5378,"PHASE3":5380,"PHASE4":5417,"NA":5428},{"trials":5368,"activeCount":98},[],{"trials":5370,"activeCount":98},[5371],{"nctId":5372,"briefTitle":5373,"status":104,"phases":5374,"primaryCompletion":966,"completion":2306,"start":5375,"enrollment":1750,"conditions":5376,"interventions":5377},"NCT05001152","Taste Assessment of Ozanimod",[87],"2021-09-09",[27],[5365],{"trials":5379,"activeCount":98},[],{"trials":5381,"activeCount":230,"soonestReadout":5412},[5382,5393,5401,5408],{"nctId":5383,"briefTitle":5384,"status":236,"phases":5385,"primaryCompletion":5386,"completion":5387,"start":5388,"enrollment":1296,"conditions":5389,"interventions":5391},"NCT06408259","Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis",[89],"2031-04-11","2036-07-13","2025-04-08",[5390],"Multiple Sclerosis, Relapsing-Remitting",[5365,5392],"Fingolimod",{"nctId":5394,"briefTitle":5395,"status":963,"phases":5396,"primaryCompletion":5397,"completion":5397,"start":5398,"enrollment":520,"conditions":5399,"interventions":5400},"NCT05470985","A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy",[88,89],"2024-09-13","2023-08-22",[3181],[5365],{"nctId":5402,"briefTitle":5403,"status":963,"phases":5404,"primaryCompletion":5405,"completion":5405,"start":388,"enrollment":860,"conditions":5406,"interventions":5407},"NCT05644665","A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)",[89],"2025-03-07",[990],[5365],{"nctId":5409,"briefTitle":5410,"status":236,"phases":5411,"primaryCompletion":5412,"completion":5413,"start":5414,"enrollment":3862,"conditions":5415,"interventions":5416},"NCT05076175","A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis",[88,89],"2026-05-22","2031-08-14","2022-05-30",[958],[5365],{"trials":5418,"activeCount":98},[5419],{"nctId":5420,"briefTitle":5421,"status":963,"phases":5422,"primaryCompletion":5423,"completion":5424,"start":5425,"enrollment":1567,"conditions":5426,"interventions":5427},"NCT05369832","An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice",[90],"2025-01-21","2025-04-11","2022-12-16",[958],[5365],{"trials":5429,"activeCount":4328,"soonestReadout":5474},[5430,5437,5450,5458,5470,5480],{"nctId":5431,"briefTitle":5432,"status":104,"phases":5433,"primaryCompletion":5434,"completion":5434,"start":819,"enrollment":3454,"conditions":5435,"interventions":5436},"NCT05335031","A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)",[],"2025-06-30",[5390],[5365],{"nctId":5438,"briefTitle":5439,"status":179,"phases":5440,"primaryCompletion":5441,"completion":5442,"start":5443,"enrollment":5444,"conditions":5445,"interventions":5447},"NCT06133049","A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants",[],"2031-03-31","2031-08-31","2021-03-16",2961,[5446],"Multiple Sclerosis",[5365,5448,5449],"Select DMTs other than ozanimod","No DMTs",{"nctId":5451,"briefTitle":5452,"status":963,"phases":5453,"primaryCompletion":5454,"completion":5454,"start":5414,"enrollment":5455,"conditions":5456,"interventions":5457},"NCT05382715","A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative Colitis",[],"2025-05-31",175,[958],[5365],{"nctId":5459,"briefTitle":5460,"status":179,"phases":5461,"primaryCompletion":5462,"completion":5463,"start":5464,"enrollment":5465,"conditions":5466,"interventions":5467},"NCT06126835","A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants",[],"2031-05-31","2032-06-30","2024-08-26",2828,[990],[5365,5468,5469],"Conventional therapy","Advanced therapy",{"nctId":5471,"briefTitle":5472,"status":236,"phases":5473,"primaryCompletion":5474,"completion":5475,"start":3512,"enrollment":331,"conditions":5476,"interventions":5478},"NCT07271069","Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis",[],"2027-03-31","2027-12-31",[5477],"Ulcerative Colitis (UC)",[5365,5479],"Azathioprine",{"nctId":5481,"briefTitle":5482,"status":236,"phases":5483,"primaryCompletion":3405,"completion":3405,"start":2374,"enrollment":5484,"conditions":5485,"interventions":5486},"NCT06073873","A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea",[],3000,[990],[5365],{"intervention":612,"totalTrials":1221,"cells":5488},{"EARLY_PHASE1":5489,"PHASE1":5491,"PHASE2":5497,"PHASE3":5548,"PHASE4":5566,"NA":5568},{"trials":5490,"activeCount":98},[],{"trials":5492,"activeCount":98},[5493],{"nctId":1257,"briefTitle":1258,"status":104,"phases":5494,"primaryCompletion":1260,"completion":1261,"start":1262,"enrollment":1263,"conditions":5495,"interventions":5496},[87],[1265],[43,1267,1268,622,1158,1157,612,1269,608],{"trials":5498,"activeCount":574,"soonestReadout":5523},[5499,5503,5507,5519,5529,5533,5537],{"nctId":599,"briefTitle":600,"status":236,"phases":5500,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":5501,"interventions":5502},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"nctId":1735,"briefTitle":1736,"status":104,"phases":5504,"primaryCompletion":1738,"completion":1739,"start":1740,"enrollment":1449,"conditions":5505,"interventions":5506},[87,88],[1742],[52,43,612],{"nctId":5508,"briefTitle":5509,"status":236,"phases":5510,"primaryCompletion":5511,"completion":5512,"start":5513,"enrollment":5514,"conditions":5515,"interventions":5516},"NCT06697197","A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors",[87,88],"2029-01-04","2029-01-05","2025-02-17",413,[1132],[5517,2774,5518,612],"BMS-986482","Nivolumab\u002Frelatlimab\u002FrHuPH20",{"nctId":5520,"briefTitle":5521,"status":236,"phases":5522,"primaryCompletion":5523,"completion":5524,"start":5525,"enrollment":402,"conditions":5526,"interventions":5527},"NCT06730750","A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors",[87,88],"2026-09-05","2029-12-09","2025-02-12",[1132],[5528,612],"BMS-986490",{"nctId":3708,"briefTitle":3709,"status":963,"phases":5530,"primaryCompletion":3711,"completion":3711,"start":3712,"enrollment":3713,"conditions":5531,"interventions":5532},[88],[3131],[1158,1157,3716,612,3717],{"nctId":2227,"briefTitle":2228,"status":104,"phases":5534,"primaryCompletion":2230,"completion":2230,"start":2231,"enrollment":2232,"conditions":5535,"interventions":5536},[87,88],[36],[43,612,622,2235,1158,1328,1267,1269,2236,1157],{"nctId":5538,"briefTitle":5539,"status":104,"phases":5540,"primaryCompletion":5541,"completion":5542,"start":3678,"enrollment":5543,"conditions":5544,"interventions":5545},"NCT00851045","Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer",[88],"2011-09","2011-10",17,[4875],[1678,3610,3610,5546,3716,612,5547],"Leucovorin calcium","Bevacizumab Placebo",{"trials":5549,"activeCount":230,"soonestReadout":2835},[5550,5554,5558,5562],{"nctId":2350,"briefTitle":2351,"status":104,"phases":5551,"primaryCompletion":2353,"completion":2354,"start":1193,"enrollment":2355,"conditions":5552,"interventions":5553},[89],[2357],[43,612,608],{"nctId":2532,"briefTitle":2533,"status":104,"phases":5555,"primaryCompletion":2535,"completion":2536,"start":2537,"enrollment":2538,"conditions":5556,"interventions":5557},[88,89],[1673],[43,619,617,618,612],{"nctId":4832,"briefTitle":4833,"status":236,"phases":5559,"primaryCompletion":4835,"completion":4836,"start":329,"enrollment":4837,"conditions":5560,"interventions":5561},[88,89],[4839],[1721,2205,4841,612,4842],{"nctId":2832,"briefTitle":2833,"status":179,"phases":5563,"primaryCompletion":2835,"completion":2836,"start":2837,"enrollment":2838,"conditions":5564,"interventions":5565},[89],[2840],[608,619,617,618,1678,612,1145,43],{"trials":5567,"activeCount":98},[],{"trials":5569,"activeCount":98},[],{"intervention":5571,"totalTrials":713,"cells":5572},"BMS-986278",{"EARLY_PHASE1":5573,"PHASE1":5575,"PHASE2":5684,"PHASE3":5697,"PHASE4":5731,"NA":5733},{"trials":5574,"activeCount":98},[],{"trials":5576,"activeCount":208,"soonestReadout":5680},[5577,5587,5596,5605,5614,5624,5635,5643,5650,5659,5668,5676],{"nctId":5578,"briefTitle":5579,"status":104,"phases":5580,"primaryCompletion":997,"completion":997,"start":5581,"enrollment":31,"conditions":5582,"interventions":5583},"NCT05932303","A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants",[87],"2023-07-12",[18],[5571,5584,5585,5586],"Itraconazole","Gemfibrozil","Carbamazepine",{"nctId":5588,"briefTitle":5589,"status":104,"phases":5590,"primaryCompletion":5591,"completion":5591,"start":5592,"enrollment":680,"conditions":5593,"interventions":5594},"NCT05985590","A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants",[87],"2023-12-11","2023-08-18",[27],[5571,5595],"Drospirenone\u002FEthinyl Estradiol",{"nctId":5597,"briefTitle":5598,"status":104,"phases":5599,"primaryCompletion":5600,"completion":5600,"start":5601,"enrollment":680,"conditions":5602,"interventions":5604},"NCT06425198","Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment",[87],"2024-12-30","2024-06-10",[5603,18],"Hepatic Impairment",[5571],{"nctId":5606,"briefTitle":5607,"status":104,"phases":5608,"primaryCompletion":5609,"completion":1685,"start":5610,"enrollment":37,"conditions":5611,"interventions":5613},"NCT06723535","A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis",[87],"2025-09-16","2024-12-07",[5612,27,927],"Kidney Failure, Chronic",[5571],{"nctId":5615,"briefTitle":5616,"status":104,"phases":5617,"primaryCompletion":5618,"completion":5618,"start":5619,"enrollment":1203,"conditions":5620,"interventions":5621},"NCT04468815","A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)",[87],"2020-10-07","2020-07-10",[18],[5571,5622,5623],"Esomeprazole","BMS-986278 suspension",{"nctId":5625,"briefTitle":5626,"status":104,"phases":5627,"primaryCompletion":5628,"completion":5629,"start":5630,"enrollment":3978,"conditions":5631,"interventions":5633},"NCT03981094","A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants",[87],"2019-07-27","2019-07-30","2019-05-10",[5632],"Idiopathic Pulmonary Fibrosis (IPF)",[5571,5634],"Pirfenidone",{"nctId":5636,"briefTitle":5637,"status":104,"phases":5638,"primaryCompletion":5639,"completion":5639,"start":5640,"enrollment":204,"conditions":5641,"interventions":5642},"NCT03429933","A Study of Experimental Medication BMS-986278 Given to Healthy Participants",[87],"2019-03-02","2018-02-07",[18],[5571],{"nctId":5644,"briefTitle":5645,"status":104,"phases":5646,"primaryCompletion":3788,"completion":3788,"start":5647,"enrollment":3986,"conditions":5648,"interventions":5649},"NCT06746402","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants",[87],"2025-02-10",[27],[5571,805],{"nctId":5651,"briefTitle":5652,"status":104,"phases":5653,"primaryCompletion":5654,"completion":5654,"start":5655,"enrollment":4579,"conditions":5656,"interventions":5657},"NCT03712540","An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy Participants",[87],"2018-11-08","2018-09-06",[18],[5571,5658],"Rifampin",{"nctId":5660,"briefTitle":5661,"status":104,"phases":5662,"primaryCompletion":5663,"completion":5663,"start":5664,"enrollment":451,"conditions":5665,"interventions":5666},"NCT05684289","A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)",[87],"2023-05-02","2023-01-03",[18],[5571,5667],"Sildenafil",{"nctId":5669,"briefTitle":5670,"status":104,"phases":5671,"primaryCompletion":5672,"completion":5672,"start":5673,"enrollment":1203,"conditions":5674,"interventions":5675},"NCT05805904","A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants",[87],"2023-05-23","2023-03-29",[27],[5571],{"nctId":5677,"briefTitle":5678,"status":236,"phases":5679,"primaryCompletion":5680,"completion":5680,"start":5681,"enrollment":34,"conditions":5682,"interventions":5683},"NCT07422298","A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants",[87],"2026-06-15","2026-02-19",[27],[5571,805],{"trials":5685,"activeCount":98},[5686],{"nctId":5687,"briefTitle":5688,"status":104,"phases":5689,"primaryCompletion":5690,"completion":5691,"start":5692,"enrollment":5693,"conditions":5694,"interventions":5696},"NCT04308681","A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis",[88],"2022-08-04","2023-09-22","2020-07-29",403,[5695],"Pulmonary Fibrosis",[5571],{"trials":5698,"activeCount":574,"soonestReadout":5724},[5699,5709,5720],{"nctId":5700,"briefTitle":5701,"status":642,"phases":5702,"primaryCompletion":5703,"completion":5704,"start":5705,"enrollment":5706,"conditions":5707,"interventions":5708},"NCT07441408","Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis",[89],"2029-11-22","2030-03-30","2026-12-16",2277,[5695],[5571],{"nctId":5710,"briefTitle":5711,"status":179,"phases":5712,"primaryCompletion":5713,"completion":5713,"start":5714,"enrollment":5715,"conditions":5716,"interventions":5718},"NCT06025578","A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis",[89],"2027-12-27","2023-10-25",1057,[5717],"Progressive Pulmonary Fibrosis",[5571,5719],"BMS-986278 Placebo",{"nctId":5721,"briefTitle":5722,"status":179,"phases":5723,"primaryCompletion":5724,"completion":5725,"start":5726,"enrollment":5727,"conditions":5728,"interventions":5730},"NCT06003426","A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis",[89],"2026-10-06","2027-06-04","2023-09-14",1255,[5729],"Idiopathic Pulmonary Fibrosis",[5571,5719],{"trials":5732,"activeCount":98},[],{"trials":5734,"activeCount":98},[],{"intervention":52,"totalTrials":1307,"cells":5736},{"EARLY_PHASE1":5737,"PHASE1":5739,"PHASE2":5761,"PHASE3":5807,"PHASE4":5817,"NA":5819},{"trials":5738,"activeCount":98},[],{"trials":5740,"activeCount":98},[5741,5745,5749,5753,5757],{"nctId":1126,"briefTitle":1127,"status":104,"phases":5742,"primaryCompletion":1129,"completion":1129,"start":1130,"enrollment":830,"conditions":5743,"interventions":5744},[87],[1132],[52,43],{"nctId":3928,"briefTitle":3929,"status":963,"phases":5746,"primaryCompletion":65,"completion":65,"start":3931,"enrollment":360,"conditions":5747,"interventions":5748},[87],[21],[52,608],{"nctId":1199,"briefTitle":1200,"status":104,"phases":5750,"primaryCompletion":1202,"completion":1202,"start":724,"enrollment":1203,"conditions":5751,"interventions":5752},[87],[606],[1206,1123,636],{"nctId":1208,"briefTitle":1209,"status":104,"phases":5754,"primaryCompletion":1211,"completion":1211,"start":1212,"enrollment":1063,"conditions":5755,"interventions":5756},[87],[606],[52,43],{"nctId":1237,"briefTitle":1238,"status":104,"phases":5758,"primaryCompletion":1240,"completion":1241,"start":1242,"enrollment":319,"conditions":5759,"interventions":5760},[87],[1154],[43,52,1245,608,1246],{"trials":5762,"activeCount":230,"soonestReadout":74},[5763,5767,5771,5775,5779,5783,5787,5791,5795,5799,5803],{"nctId":1409,"briefTitle":1410,"status":963,"phases":5764,"primaryCompletion":1412,"completion":1412,"start":1413,"enrollment":1414,"conditions":5765,"interventions":5766},[88],[1154],[43,1197,52,608,1337],{"nctId":72,"briefTitle":73,"status":179,"phases":5768,"primaryCompletion":74,"completion":1520,"start":1521,"enrollment":1522,"conditions":5769,"interventions":5770},[88],[1265,1524,1525],[43,52,1157,1268,1158,1527,622],{"nctId":1648,"briefTitle":1649,"status":104,"phases":5772,"primaryCompletion":1651,"completion":1652,"start":1653,"enrollment":1654,"conditions":5773,"interventions":5774},[88],[1607,1656,1657,1658,1659],[43,52],{"nctId":599,"briefTitle":600,"status":236,"phases":5776,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":5777,"interventions":5778},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"nctId":1735,"briefTitle":1736,"status":104,"phases":5780,"primaryCompletion":1738,"completion":1739,"start":1740,"enrollment":1449,"conditions":5781,"interventions":5782},[87,88],[1742],[52,43,612],{"nctId":1849,"briefTitle":1850,"status":104,"phases":5784,"primaryCompletion":1852,"completion":1853,"start":1854,"enrollment":1855,"conditions":5785,"interventions":5786},[87,88],[1636],[43,608,52,615],{"nctId":2113,"briefTitle":2114,"status":104,"phases":5788,"primaryCompletion":2116,"completion":2117,"start":2118,"enrollment":2119,"conditions":5789,"interventions":5790},[87,88],[1345],[52,43,2122],{"nctId":2186,"briefTitle":2187,"status":104,"phases":5792,"primaryCompletion":2189,"completion":2189,"start":2190,"enrollment":520,"conditions":5793,"interventions":5794},[87,88],[2192,2051],[52,43],{"nctId":2276,"briefTitle":2277,"status":104,"phases":5796,"primaryCompletion":2279,"completion":2279,"start":870,"enrollment":2280,"conditions":5797,"interventions":5798},[88],[1154],[43,608,52,1337,1676],{"nctId":2322,"briefTitle":2323,"status":104,"phases":5800,"primaryCompletion":2325,"completion":2325,"start":2326,"enrollment":2327,"conditions":5801,"interventions":5802},[88],[2329],[43,608,52,1337,614],{"nctId":2332,"briefTitle":2333,"status":104,"phases":5804,"primaryCompletion":2335,"completion":2335,"start":802,"enrollment":2336,"conditions":5805,"interventions":5806},[87,88],[1154],[52,43,1337,608],{"trials":5808,"activeCount":230,"soonestReadout":51},[5809,5813],{"nctId":2410,"briefTitle":2411,"status":236,"phases":5810,"primaryCompletion":2413,"completion":2414,"start":2415,"enrollment":2416,"conditions":5811,"interventions":5812},[89],[1265],[43,52,623,1157,622,1268],{"nctId":49,"briefTitle":50,"status":179,"phases":5814,"primaryCompletion":51,"completion":2718,"start":2719,"enrollment":2720,"conditions":5815,"interventions":5816},[88,89],[21],[52,43],{"trials":5818,"activeCount":98},[],{"trials":5820,"activeCount":98},[5821],{"nctId":5822,"briefTitle":5823,"status":3014,"phases":5824,"conditions":5825,"interventions":5826},"NCT05170659","Expanded Access for Relatlimab",[],[],[52],{"intervention":1145,"totalTrials":1221,"cells":5828},{"EARLY_PHASE1":5829,"PHASE1":5831,"PHASE2":5844,"PHASE3":5886,"PHASE4":5904,"NA":5906},{"trials":5830,"activeCount":98},[],{"trials":5832,"activeCount":208,"soonestReadout":1138},[5833,5837],{"nctId":1135,"briefTitle":1136,"status":179,"phases":5834,"primaryCompletion":1138,"completion":1138,"start":260,"enrollment":1139,"conditions":5835,"interventions":5836},[87],[1141],[1143,1144,1145,43],{"nctId":5838,"briefTitle":5839,"status":104,"phases":5840,"primaryCompletion":5841,"completion":5841,"start":4289,"enrollment":1424,"conditions":5842,"interventions":5843},"NCT02110082","Combination Study of Urelumab and Cetuximab in Patients With Advanced\u002FMetastatic Colorectal Cancer or Advanced\u002FMetastatic Head and Neck Cancer",[87],"2016-12",[1673,1537],[1111,1145],{"trials":5845,"activeCount":208,"soonestReadout":4871},[5846,5853,5857,5865,5869,5879],{"nctId":5847,"briefTitle":5848,"status":104,"phases":5849,"primaryCompletion":5850,"completion":5850,"start":4348,"enrollment":5543,"conditions":5851,"interventions":5852},"NCT01086267","Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer",[87,88],"2011-08",[1673],[3897,3897,1145],{"nctId":4868,"briefTitle":4869,"status":236,"phases":5854,"primaryCompletion":4871,"completion":4871,"start":181,"enrollment":4872,"conditions":5855,"interventions":5856},[87,88],[4874,3131,4875,4876],[4878,1267,1527,1145,623],{"nctId":5858,"briefTitle":5859,"status":963,"phases":5860,"primaryCompletion":5861,"completion":5861,"start":135,"enrollment":520,"conditions":5862,"interventions":5863},"NCT06024174","A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors",[87,88],"2024-05-13",[1132],[5864,1144,1145],"BMS-986466",{"nctId":2070,"briefTitle":2071,"status":104,"phases":5866,"primaryCompletion":460,"completion":460,"start":2073,"enrollment":184,"conditions":5867,"interventions":5868},[87,88],[2075],[1618,1123,2077],{"nctId":5870,"briefTitle":5871,"status":104,"phases":5872,"primaryCompletion":3977,"completion":3977,"start":5873,"enrollment":193,"conditions":5874,"interventions":5876},"NCT00594984","Phase I\u002FII Combination With Irinotecan- Erbitux",[87,88],"2008-05",[5875],"Metastatic Colorectal Cancer (MCRC)",[1145,1678,5877,5877,5878],"Brivanib","Brivanib Placebo",{"nctId":5880,"briefTitle":5881,"status":963,"phases":5882,"primaryCompletion":3977,"completion":3977,"start":3678,"enrollment":890,"conditions":5883,"interventions":5885},"NCT00908024","Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors",[87,88],[1673,1537,5884],"Neoplasm Metastasis",[3576,2077],{"trials":5887,"activeCount":208,"soonestReadout":2835},[5888,5892,5896,5900],{"nctId":2360,"briefTitle":2361,"status":104,"phases":5889,"primaryCompletion":1107,"completion":2363,"start":2364,"enrollment":2365,"conditions":5890,"interventions":5891},[89],[2367],[43,1145,772,1328],{"nctId":2477,"briefTitle":2478,"status":104,"phases":5893,"primaryCompletion":2480,"completion":2480,"start":2481,"enrollment":19,"conditions":5894,"interventions":5895},[89],[2367],[43,1145,1268],{"nctId":2585,"briefTitle":2586,"status":467,"phases":5897,"primaryCompletion":2588,"completion":2588,"start":2589,"enrollment":98,"conditions":5898,"interventions":5899},[89],[1537],[43,1337,1145,1268,1157,618],{"nctId":2832,"briefTitle":2833,"status":179,"phases":5901,"primaryCompletion":2835,"completion":2836,"start":2837,"enrollment":2838,"conditions":5902,"interventions":5903},[89],[2840],[608,619,617,618,1678,612,1145,43],{"trials":5905,"activeCount":98},[],{"trials":5907,"activeCount":98},[],{"intervention":618,"totalTrials":839,"cells":5909},{"EARLY_PHASE1":5910,"PHASE1":5912,"PHASE2":5918,"PHASE3":5928,"PHASE4":5950,"NA":5952},{"trials":5911,"activeCount":98},[],{"trials":5913,"activeCount":208,"soonestReadout":1352},[5914],{"nctId":1349,"briefTitle":1350,"status":179,"phases":5915,"primaryCompletion":1352,"completion":1352,"start":1353,"enrollment":1354,"conditions":5916,"interventions":5917},[87],[1132],[1357,43,619,611,618,1358],{"trials":5919,"activeCount":208,"soonestReadout":602},[5920,5924],{"nctId":599,"briefTitle":600,"status":236,"phases":5921,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":5922,"interventions":5923},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"nctId":2257,"briefTitle":2258,"status":104,"phases":5925,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":2262,"conditions":5926,"interventions":5927},[88],[2264],[1245,1225,2266,43,618,1267,619,617,2267],{"trials":5929,"activeCount":208,"soonestReadout":2835},[5930,5934,5938,5942,5946],{"nctId":2433,"briefTitle":2434,"status":104,"phases":5931,"primaryCompletion":2436,"completion":2437,"start":2438,"enrollment":2439,"conditions":5932,"interventions":5933},[89],[1636],[43,608,1268,618],{"nctId":2532,"briefTitle":2533,"status":104,"phases":5935,"primaryCompletion":2535,"completion":2536,"start":2537,"enrollment":2538,"conditions":5936,"interventions":5937},[88,89],[1673],[43,619,617,618,612],{"nctId":2585,"briefTitle":2586,"status":467,"phases":5939,"primaryCompletion":2588,"completion":2588,"start":2589,"enrollment":98,"conditions":5940,"interventions":5941},[89],[1537],[43,1337,1145,1268,1157,618],{"nctId":2593,"briefTitle":2594,"status":104,"phases":5943,"primaryCompletion":2596,"completion":2597,"start":2598,"enrollment":2599,"conditions":5944,"interventions":5945},[89],[1436,2601,2602],[43,608,619,611,617,618],{"nctId":2832,"briefTitle":2833,"status":179,"phases":5947,"primaryCompletion":2835,"completion":2836,"start":2837,"enrollment":2838,"conditions":5948,"interventions":5949},[89],[2840],[608,619,617,618,1678,612,1145,43],{"trials":5951,"activeCount":98},[],{"trials":5953,"activeCount":98},[],{"intervention":611,"totalTrials":839,"cells":5955},{"EARLY_PHASE1":5956,"PHASE1":5958,"PHASE2":5983,"PHASE3":5989,"PHASE4":5999,"NA":6001},{"trials":5957,"activeCount":98},[],{"trials":5959,"activeCount":208,"soonestReadout":1352},[5960,5967,5971,5975,5979],{"nctId":5961,"briefTitle":5962,"status":104,"phases":5963,"primaryCompletion":3586,"completion":3586,"start":4664,"enrollment":3162,"conditions":5964,"interventions":5966},"NCT00452673","Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer",[87],[5965],"Advanced Breast Cancer",[1197,611],{"nctId":4977,"briefTitle":4978,"status":104,"phases":5968,"primaryCompletion":4980,"completion":4980,"start":4981,"enrollment":4982,"conditions":5969,"interventions":5970},[87],[1154],[611,2053,4985,1328,1158,4986],{"nctId":1321,"briefTitle":1322,"status":104,"phases":5972,"primaryCompletion":1324,"completion":1324,"start":388,"enrollment":22,"conditions":5973,"interventions":5974},[87],[1132],[1327,1328,43,611],{"nctId":4576,"briefTitle":4577,"status":104,"phases":5976,"primaryCompletion":3893,"completion":3893,"start":3585,"enrollment":4579,"conditions":5977,"interventions":5978},[87],[4581,4582],[3621,1268,611],{"nctId":1349,"briefTitle":1350,"status":179,"phases":5980,"primaryCompletion":1352,"completion":1352,"start":1353,"enrollment":1354,"conditions":5981,"interventions":5982},[87],[1132],[1357,43,619,611,618,1358],{"trials":5984,"activeCount":208,"soonestReadout":602},[5985],{"nctId":599,"briefTitle":600,"status":236,"phases":5986,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":5987,"interventions":5988},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"trials":5990,"activeCount":208,"soonestReadout":3786},[5991,5995],{"nctId":3783,"briefTitle":3784,"status":236,"phases":5992,"primaryCompletion":3786,"completion":3787,"start":3788,"enrollment":290,"conditions":5993,"interventions":5994},[88,89],[3790],[3792,1225,1158,611,1157,1267],{"nctId":2593,"briefTitle":2594,"status":104,"phases":5996,"primaryCompletion":2596,"completion":2597,"start":2598,"enrollment":2599,"conditions":5997,"interventions":5998},[89],[1436,2601,2602],[43,608,619,611,617,618],{"trials":6000,"activeCount":98},[],{"trials":6002,"activeCount":98},[],{"intervention":609,"totalTrials":830,"cells":6004},{"EARLY_PHASE1":6005,"PHASE1":6007,"PHASE2":6013,"PHASE3":6031,"PHASE4":6037,"NA":6039},{"trials":6006,"activeCount":98},[],{"trials":6008,"activeCount":98},[6009],{"nctId":1248,"briefTitle":1249,"status":104,"phases":6010,"primaryCompletion":1129,"completion":1129,"start":1251,"enrollment":148,"conditions":6011,"interventions":6012},[87],[1253],[43,1255,609],{"trials":6014,"activeCount":230,"soonestReadout":602},[6015,6019,6023,6027],{"nctId":1601,"briefTitle":1602,"status":104,"phases":6016,"primaryCompletion":278,"completion":278,"start":1604,"enrollment":1605,"conditions":6017,"interventions":6018},[87,88],[1607],[43,1609,608,609],{"nctId":4080,"briefTitle":4081,"status":236,"phases":6020,"primaryCompletion":4083,"completion":4084,"start":4085,"enrollment":4086,"conditions":6021,"interventions":6022},[87,88],[4088],[1721,608,609],{"nctId":599,"briefTitle":600,"status":236,"phases":6024,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":6025,"interventions":6026},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"nctId":2057,"briefTitle":2058,"status":467,"phases":6028,"primaryCompletion":2060,"completion":2061,"start":2062,"enrollment":98,"conditions":6029,"interventions":6030},[87,88],[2064],[1123,1122,2066,1981,2067,2068],{"trials":6032,"activeCount":208,"soonestReadout":42},[6033],{"nctId":40,"briefTitle":41,"status":179,"phases":6034,"primaryCompletion":42,"completion":158,"start":2543,"enrollment":2544,"conditions":6035,"interventions":6036},[89],[1253],[43,609,621,608],{"trials":6038,"activeCount":98},[],{"trials":6040,"activeCount":98},[],{"intervention":619,"totalTrials":830,"cells":6042},{"EARLY_PHASE1":6043,"PHASE1":6045,"PHASE2":6051,"PHASE3":6061,"PHASE4":6075,"NA":6077},{"trials":6044,"activeCount":98},[],{"trials":6046,"activeCount":208,"soonestReadout":1352},[6047],{"nctId":1349,"briefTitle":1350,"status":179,"phases":6048,"primaryCompletion":1352,"completion":1352,"start":1353,"enrollment":1354,"conditions":6049,"interventions":6050},[87],[1132],[1357,43,619,611,618,1358],{"trials":6052,"activeCount":208,"soonestReadout":602},[6053,6057],{"nctId":599,"briefTitle":600,"status":236,"phases":6054,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":6055,"interventions":6056},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"nctId":2257,"briefTitle":2258,"status":104,"phases":6058,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":2262,"conditions":6059,"interventions":6060},[88],[2264],[1245,1225,2266,43,618,1267,619,617,2267],{"trials":6062,"activeCount":208,"soonestReadout":2835},[6063,6067,6071],{"nctId":2532,"briefTitle":2533,"status":104,"phases":6064,"primaryCompletion":2535,"completion":2536,"start":2537,"enrollment":2538,"conditions":6065,"interventions":6066},[88,89],[1673],[43,619,617,618,612],{"nctId":2593,"briefTitle":2594,"status":104,"phases":6068,"primaryCompletion":2596,"completion":2597,"start":2598,"enrollment":2599,"conditions":6069,"interventions":6070},[89],[1436,2601,2602],[43,608,619,611,617,618],{"nctId":2832,"briefTitle":2833,"status":179,"phases":6072,"primaryCompletion":2835,"completion":2836,"start":2837,"enrollment":2838,"conditions":6073,"interventions":6074},[89],[2840],[608,619,617,618,1678,612,1145,43],{"trials":6076,"activeCount":98},[],{"trials":6078,"activeCount":98},[],{"intervention":537,"totalTrials":574,"cells":6080},{"EARLY_PHASE1":6081,"PHASE1":6083,"PHASE2":6089,"PHASE3":6091,"PHASE4":6101,"NA":6103},{"trials":6082,"activeCount":98},[],{"trials":6084,"activeCount":208,"soonestReadout":532},[6085],{"nctId":529,"briefTitle":530,"status":236,"phases":6086,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":6087,"interventions":6088},[87],[27],[522,537,538],{"trials":6090,"activeCount":98},[],{"trials":6092,"activeCount":230,"soonestReadout":547},[6093,6097],{"nctId":544,"briefTitle":545,"status":236,"phases":6094,"primaryCompletion":547,"completion":548,"start":549,"enrollment":550,"conditions":6095,"interventions":6096},[89],[552],[522,537],{"nctId":566,"briefTitle":567,"status":236,"phases":6098,"primaryCompletion":569,"completion":570,"start":571,"enrollment":550,"conditions":6099,"interventions":6100},[89],[552],[522,537],{"trials":6102,"activeCount":98},[],{"trials":6104,"activeCount":98},[],{"intervention":3792,"totalTrials":574,"cells":6106},{"EARLY_PHASE1":6107,"PHASE1":6109,"PHASE2":6111,"PHASE3":6113,"PHASE4":6127,"NA":6129},{"trials":6108,"activeCount":98},[],{"trials":6110,"activeCount":98},[],{"trials":6112,"activeCount":98},[],{"trials":6114,"activeCount":574,"soonestReadout":3786},[6115,6119,6123],{"nctId":3783,"briefTitle":3784,"status":236,"phases":6116,"primaryCompletion":3786,"completion":3787,"start":3788,"enrollment":290,"conditions":6117,"interventions":6118},[88,89],[3790],[3792,1225,1158,611,1157,1267],{"nctId":3804,"briefTitle":3805,"status":236,"phases":6120,"primaryCompletion":3807,"completion":3808,"start":3809,"enrollment":290,"conditions":6121,"interventions":6122},[88,89],[36],[3792,1157,1268,622],{"nctId":3836,"briefTitle":3837,"status":236,"phases":6124,"primaryCompletion":3839,"completion":3840,"start":3841,"enrollment":3842,"conditions":6125,"interventions":6126},[88,89],[2792],[3792,1268,1267,1157],{"trials":6128,"activeCount":98},[],{"trials":6130,"activeCount":98},[],{"intervention":1795,"totalTrials":757,"cells":6132},{"EARLY_PHASE1":6133,"PHASE1":6135,"PHASE2":6189,"PHASE3":6259,"PHASE4":6305,"NA":6307},{"trials":6134,"activeCount":98},[],{"trials":6136,"activeCount":208,"soonestReadout":6150},[6137,6146,6156,6165,6174,6180],{"nctId":6138,"briefTitle":6139,"status":104,"phases":6140,"primaryCompletion":6141,"completion":6142,"start":6143,"enrollment":1063,"conditions":6144,"interventions":6145},"NCT01393964","Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function",[87],"2014-03-21","2016-07-18","2012-01-06",[33],[441,1795,1795,1795,1794],{"nctId":6147,"briefTitle":6148,"status":179,"phases":6149,"primaryCompletion":6150,"completion":6150,"start":6151,"enrollment":1221,"conditions":6152,"interventions":6154},"NCT05688475","A Rollover Study of CC-122",[87],"2026-10-31","2023-04-11",[6153],"Non-Hodgkin Lymphoma",[6155,1795],"CC-122",{"nctId":6157,"briefTitle":6158,"status":104,"phases":6159,"primaryCompletion":5640,"completion":5640,"start":6160,"enrollment":4124,"conditions":6161,"interventions":6164},"NCT01363817","Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma",[87],"2011-09-28",[6162,6163],"Lymphoblastic Leukemia, Acute T-cell","Precursor T-Cell Lymphoblastic Lymphoma",[3611,1795],{"nctId":6166,"briefTitle":6167,"status":104,"phases":6168,"primaryCompletion":6169,"completion":6169,"start":6170,"enrollment":37,"conditions":6171,"interventions":6173},"NCT00884546","Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma",[87],"2012-03","2009-07",[6172],"Advanced Cancer, Various, NOS",[3621,441,1795,1796],{"nctId":6175,"briefTitle":6176,"status":963,"phases":6177,"primaryCompletion":3938,"completion":3938,"start":3680,"enrollment":713,"conditions":6178,"interventions":6179},"NCT00560352","Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma",[87],[33],[1197,1796,1795],{"nctId":6181,"briefTitle":6182,"status":104,"phases":6183,"primaryCompletion":6184,"completion":6184,"start":5541,"enrollment":6185,"conditions":6186,"interventions":6187},"NCT01359657","Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide\u002FDexamethasone or Bortezomib\u002FDexamethasone in Relapsed\u002FRefractory Multiple Myeloma",[87],"2016-03",46,[33],[6188,441,1795,6188,1796,1795],"Anti-CXCR4",{"trials":6190,"activeCount":208,"soonestReadout":6253},[6191,6200,6209,6213,6217,6221,6231,6240,6249],{"nctId":6192,"briefTitle":6193,"status":104,"phases":6194,"primaryCompletion":6195,"completion":6196,"start":6197,"enrollment":116,"conditions":6198,"interventions":6199},"NCT02159365","Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed\u002FRefractory Multiple Myeloma Patients",[88],"2016-06-30","2018-07-11","2014-03-08",[33],[1794,441,1795],{"nctId":6201,"briefTitle":6202,"status":104,"phases":6203,"primaryCompletion":6204,"completion":6205,"start":6206,"enrollment":12,"conditions":6207,"interventions":6208},"NCT01478048","Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma",[88],"2014-05-30","2017-04-21","2011-11-30",[33],[1794,1796,1795,1795,1795,1795],{"nctId":1787,"briefTitle":1788,"status":104,"phases":6210,"primaryCompletion":1790,"completion":1790,"start":1791,"enrollment":1285,"conditions":6211,"interventions":6212},[88],[33],[1794,1795,1795,441,1796,1797,43],{"nctId":1818,"briefTitle":1819,"status":104,"phases":6214,"primaryCompletion":1821,"completion":1211,"start":1822,"enrollment":1823,"conditions":6215,"interventions":6216},[87,88],[1825,1826,33],[43,608,1187,615,1797,1795],{"nctId":1986,"briefTitle":1987,"status":104,"phases":6218,"primaryCompletion":1989,"completion":1990,"start":1991,"enrollment":19,"conditions":6219,"interventions":6220},[88],[33],[1794,1797,1795,43],{"nctId":6222,"briefTitle":6223,"status":104,"phases":6224,"primaryCompletion":4378,"completion":6184,"start":6225,"enrollment":6226,"conditions":6227,"interventions":6229},"NCT01632150","Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and\u002For Refractory Multiple Myeloma",[88],"2012-05",51,[6228],"Relapsed and\u002For Refractory Multiple Myeloma",[1794,6230,1795,1773],"Thalidomide",{"nctId":6232,"briefTitle":6233,"status":104,"phases":6234,"primaryCompletion":6235,"completion":6236,"start":6237,"enrollment":1835,"conditions":6238,"interventions":6239},"NCT02654132","An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)",[88],"2018-01-17","2021-10-21","2016-03-18",[33],[1794,1797,1795],{"nctId":6241,"briefTitle":6242,"status":104,"phases":6243,"primaryCompletion":6244,"completion":6245,"start":6246,"enrollment":1232,"conditions":6247,"interventions":6248},"NCT02272803","Phase II Study of Lenalidomide\u002FDexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan",[88],"2017-02-09","2021-07-21","2015-02-20",[33],[441,1795,1794],{"nctId":6250,"briefTitle":6251,"status":236,"phases":6252,"primaryCompletion":6253,"completion":6253,"start":6254,"enrollment":3093,"conditions":6255,"interventions":6256},"NCT05372354","A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma",[87,88],"2026-10-12","2022-10-18",[33],[6257,6258,1453,610,1795],"CC-92480","Tazemetostat",{"trials":6260,"activeCount":208,"soonestReadout":6282},[6261,6269,6278,6291,6301],{"nctId":6262,"briefTitle":6263,"status":963,"phases":6264,"primaryCompletion":1118,"completion":1118,"start":6265,"enrollment":2038,"conditions":6266,"interventions":6268},"NCT01891643","PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)",[89],"2013-09-30",[6267],"Newly Diagnosed, Previously Untreated Multiple Myeloma",[441,1795,1794],{"nctId":6270,"briefTitle":6271,"status":104,"phases":6272,"primaryCompletion":724,"completion":6273,"start":6274,"enrollment":6275,"conditions":6276,"interventions":6277},"NCT01335399","Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma",[89],"2021-09-03","2011-08-04",748,[33],[441,1795,1795,1795,1795,1794,1794],{"nctId":6279,"briefTitle":6280,"status":179,"phases":6281,"primaryCompletion":6282,"completion":6283,"start":6284,"enrollment":6285,"conditions":6286,"interventions":6288},"NCT05552976","A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)",[89],"2026-07-18","2029-07-25","2023-01-10",606,[6287],"Relapsed or Refractory Multiple Myeloma",[6289,6290,1795],"Mezigdomide","Carfilzomib",{"nctId":6292,"briefTitle":6293,"status":104,"phases":6294,"primaryCompletion":6295,"completion":6296,"start":6297,"enrollment":6298,"conditions":6299,"interventions":6300},"NCT01239797","Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma",[89],"2014-09-02","2021-04-21","2011-06-20",646,[1426,33],[441,1795,1795,1795,1794],{"nctId":2896,"briefTitle":2897,"status":104,"phases":6302,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":1175,"conditions":6303,"interventions":6304},[89],[33],[43,1794,1797,1795],{"trials":6306,"activeCount":98},[],{"trials":6308,"activeCount":98},[6309],{"nctId":6310,"briefTitle":6311,"status":3014,"phases":6312,"conditions":6313,"interventions":6314},"NCT02856438","Early Patient Access Treatment Use Protocol CA204-220",[],[33],[1794,441,1795],{"intervention":1017,"totalTrials":520,"cells":6316},{"EARLY_PHASE1":6317,"PHASE1":6319,"PHASE2":6321,"PHASE3":6323,"PHASE4":6337,"NA":6339},{"trials":6318,"activeCount":98},[],{"trials":6320,"activeCount":98},[],{"trials":6322,"activeCount":98},[],{"trials":6324,"activeCount":208,"soonestReadout":78},[6325,6329,6333],{"nctId":1009,"briefTitle":1010,"status":104,"phases":6326,"primaryCompletion":1012,"completion":1012,"start":1013,"enrollment":1014,"conditions":6327,"interventions":6328},[89],[749],[679,1017],{"nctId":76,"briefTitle":77,"status":179,"phases":6330,"primaryCompletion":78,"completion":3242,"start":3243,"enrollment":3244,"conditions":6331,"interventions":6332},[89],[770],[79,1017],{"nctId":1046,"briefTitle":1047,"status":104,"phases":6334,"primaryCompletion":1049,"completion":1050,"start":1051,"enrollment":1052,"conditions":6335,"interventions":6336},[89],[749],[679,1017],{"trials":6338,"activeCount":98},[],{"trials":6340,"activeCount":230,"soonestReadout":3415},[6341,6345],{"nctId":3374,"briefTitle":3375,"status":236,"phases":6342,"primaryCompletion":3377,"completion":3377,"start":3378,"enrollment":271,"conditions":6343,"interventions":6344},[],[3256],[79,1017],{"nctId":3412,"briefTitle":3413,"status":236,"phases":6346,"primaryCompletion":3415,"completion":3415,"start":3416,"enrollment":604,"conditions":6347,"interventions":6348},[],[749],[79,1017],{"intervention":6350,"totalTrials":4328,"cells":6351},"Oral azacitidine",{"EARLY_PHASE1":6352,"PHASE1":6354,"PHASE2":6356,"PHASE3":6368,"PHASE4":6377,"NA":6379},{"trials":6353,"activeCount":98},[],{"trials":6355,"activeCount":98},[],{"trials":6357,"activeCount":208,"soonestReadout":6362},[6358],{"nctId":6359,"briefTitle":6360,"status":179,"phases":6361,"primaryCompletion":6362,"completion":6363,"start":1632,"enrollment":1307,"conditions":6364,"interventions":6366},"NCT05197426","A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission",[88],"2025-01-27","2026-04-30",[6365],"Acute Myeloid Leukemia",[6367],"Oral Azacitidine",{"trials":6369,"activeCount":208,"soonestReadout":6374},[6370],{"nctId":6371,"briefTitle":6372,"status":179,"phases":6373,"primaryCompletion":6374,"completion":6374,"start":171,"enrollment":1597,"conditions":6375,"interventions":6376},"NCT05469737","A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)",[88,89],"2028-07-31",[404],[6367],{"trials":6378,"activeCount":98},[],{"trials":6380,"activeCount":208,"soonestReadout":2777},[6381,6389],{"nctId":6382,"briefTitle":6383,"status":104,"phases":6384,"primaryCompletion":6385,"completion":6385,"start":5672,"enrollment":204,"conditions":6386,"interventions":6388},"NCT06565975","Characteristics and Outcomes of Acute Myeloid Leukemia (AML) Patients Treated With Oral-Azacitidine Maintenance Therapy in France",[],"2026-01-26",[6387],"Acute Myeloid Leukemia (AML)",[6350],{"nctId":6390,"briefTitle":6391,"status":236,"phases":6392,"primaryCompletion":2777,"completion":2777,"start":6393,"enrollment":3303,"conditions":6394,"interventions":6395},"NCT06073769","A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia",[],"2023-11-15",[6365],[6350],{"intervention":1328,"totalTrials":693,"cells":6397},{"EARLY_PHASE1":6398,"PHASE1":6400,"PHASE2":6410,"PHASE3":6461,"PHASE4":6501,"NA":6503},{"trials":6399,"activeCount":98},[],{"trials":6401,"activeCount":98},[6402,6406],{"nctId":4977,"briefTitle":4978,"status":104,"phases":6403,"primaryCompletion":4980,"completion":4980,"start":4981,"enrollment":4982,"conditions":6404,"interventions":6405},[87],[1154],[611,2053,4985,1328,1158,4986],{"nctId":1321,"briefTitle":1322,"status":104,"phases":6407,"primaryCompletion":1324,"completion":1324,"start":388,"enrollment":22,"conditions":6408,"interventions":6409},[87],[1132],[1327,1328,43,611],{"trials":6411,"activeCount":208,"soonestReadout":6420},[6412,6416,6433,6441,6445,6449,6453,6457],{"nctId":1399,"briefTitle":1400,"status":963,"phases":6413,"primaryCompletion":1402,"completion":1402,"start":1403,"enrollment":347,"conditions":6414,"interventions":6415},[87,88],[1132,1265],[1406,43,1328,1157,1407,1158],{"nctId":6417,"briefTitle":6418,"status":236,"phases":6419,"primaryCompletion":6420,"completion":6420,"start":6421,"enrollment":6422,"conditions":6423,"interventions":6430},"NCT04895709","A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors",[87,88],"2028-07-07","2021-05-27",949,[6424,6425,2087,1783,6426,2679,2182,6427,21,6428,6429],"Cervical Cancer","Gastric\u002FGastroesophageal Junction Adenocarcinoma","Squamous Cell Carcinoma of Head and Neck","Pancreatic Adenocarcinoma","Ovarian Neoplasms","Triple Negative Breast Neoplasms",[6431,6432,1328],"BMS-986340","BMS-936558-01",{"nctId":6434,"briefTitle":6435,"status":104,"phases":6436,"primaryCompletion":6437,"completion":3903,"start":4010,"enrollment":790,"conditions":6438,"interventions":6440},"NCT00439270","Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer",[87,88],"2012-02",[6439],"Metastatic Prostate Cancer",[1197,1328],{"nctId":1973,"briefTitle":1974,"status":104,"phases":6442,"primaryCompletion":1976,"completion":1977,"start":788,"enrollment":1978,"conditions":6443,"interventions":6444},[88],[1504],[1123,1981,1982,1983,1984],{"nctId":2057,"briefTitle":2058,"status":467,"phases":6446,"primaryCompletion":2060,"completion":2061,"start":2062,"enrollment":98,"conditions":6447,"interventions":6448},[87,88],[2064],[1123,1122,2066,1981,2067,2068],{"nctId":2093,"briefTitle":2094,"status":963,"phases":6450,"primaryCompletion":2096,"completion":2096,"start":1230,"enrollment":1184,"conditions":6451,"interventions":6452},[88],[2098],[2100,1328,43],{"nctId":2154,"briefTitle":2155,"status":467,"phases":6454,"primaryCompletion":2157,"completion":2158,"start":2159,"enrollment":98,"conditions":6455,"interventions":6456},[88],[36,2161,2162],[43,2164,1267,1328,622,1268,1157,1158],{"nctId":2227,"briefTitle":2228,"status":104,"phases":6458,"primaryCompletion":2230,"completion":2230,"start":2231,"enrollment":2232,"conditions":6459,"interventions":6460},[87,88],[36],[43,612,622,2235,1158,1328,1267,1269,2236,1157],{"trials":6462,"activeCount":208,"soonestReadout":65},[6463,6467,6471,6475,6485,6489,6493,6497],{"nctId":2360,"briefTitle":2361,"status":104,"phases":6464,"primaryCompletion":1107,"completion":2363,"start":2364,"enrollment":2365,"conditions":6465,"interventions":6466},[89],[2367],[43,1145,772,1328],{"nctId":2614,"briefTitle":2615,"status":104,"phases":6468,"primaryCompletion":2617,"completion":2618,"start":2619,"enrollment":2620,"conditions":6469,"interventions":6470},[89],[2622],[43,1268,2164,1267,1328,622,1157,1158,608],{"nctId":2693,"briefTitle":2694,"status":104,"phases":6472,"primaryCompletion":2260,"completion":2696,"start":778,"enrollment":2697,"conditions":6473,"interventions":6474},[89],[1504],[43,1507,1328],{"nctId":6476,"briefTitle":6477,"status":104,"phases":6478,"primaryCompletion":6479,"completion":4347,"start":6480,"enrollment":6481,"conditions":6482,"interventions":6484},"NCT00744497","Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer",[89],"2012-08","2008-10",1930,[6483],"Prostatic Neoplasms",[1197,1328,1507],{"nctId":2724,"briefTitle":2725,"status":104,"phases":6486,"primaryCompletion":2727,"completion":2728,"start":2729,"enrollment":2730,"conditions":6487,"interventions":6488},[89],[36],[43,1328],{"nctId":63,"briefTitle":64,"status":179,"phases":6490,"primaryCompletion":65,"completion":2777,"start":2778,"enrollment":2779,"conditions":6491,"interventions":6492},[89],[2781],[43,1157,1268,1158,622,1328],{"nctId":2843,"briefTitle":2844,"status":104,"phases":6494,"primaryCompletion":2846,"completion":2847,"start":2848,"enrollment":2849,"conditions":6495,"interventions":6496},[89],[1837],[43,1328],{"nctId":2885,"briefTitle":2886,"status":104,"phases":6498,"primaryCompletion":2888,"completion":2889,"start":2890,"enrollment":2891,"conditions":6499,"interventions":6500},[89],[2893],[43,1328],{"trials":6502,"activeCount":98},[],{"trials":6504,"activeCount":98},[],{"intervention":617,"totalTrials":1221,"cells":6506},{"EARLY_PHASE1":6507,"PHASE1":6509,"PHASE2":6564,"PHASE3":6578,"PHASE4":6592,"NA":6594},{"trials":6508,"activeCount":98},[],{"trials":6510,"activeCount":98},[6511,6520,6537,6548,6552,6556],{"nctId":6512,"briefTitle":6513,"status":104,"phases":6514,"primaryCompletion":6515,"completion":6515,"start":6516,"enrollment":1686,"conditions":6517,"interventions":6518},"NCT05615012","A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants",[87],"2023-12-13","2022-11-11",[18],[6519,874,823,772,617],"BMS-986322",{"nctId":6521,"briefTitle":6522,"status":104,"phases":6523,"primaryCompletion":6524,"completion":6525,"start":6526,"enrollment":2527,"conditions":6527,"interventions":6528},"NCT03131973","Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin",[87],"2017-11-05","2017-11-10","2017-05-13",[15],[6529,772,617,6530,6531,6532,6533,6534,6535,6536],"BMS-986195","Caffeine","Montelukast","Flurbiprofen","Omeprazole","Midazolam","Digoxin","Pravastatin",{"nctId":6538,"briefTitle":6539,"status":104,"phases":6540,"primaryCompletion":6541,"completion":6542,"start":6543,"enrollment":148,"conditions":6544,"interventions":6545},"NCT05445440","A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine",[87],"2022-11-17","2022-11-23","2022-09-06",[18],[772,617,6546,6547],"BMS-986371","Sulfasalazine",{"nctId":763,"briefTitle":764,"status":104,"phases":6549,"primaryCompletion":766,"completion":767,"start":768,"enrollment":148,"conditions":6550,"interventions":6551},[87],[738,770],[772,617,679],{"nctId":3601,"briefTitle":3602,"status":104,"phases":6553,"primaryCompletion":3604,"completion":3605,"start":3606,"enrollment":3607,"conditions":6554,"interventions":6555},[87],[606],[1158,3610,1157,617,1678,1158,3611],{"nctId":6557,"briefTitle":6558,"status":104,"phases":6559,"primaryCompletion":3017,"completion":3017,"start":3617,"enrollment":790,"conditions":6560,"interventions":6562},"NCT01046864","Combination of Brivanib With 5-Fluorouracil\u002FLeucovorin (5FU\u002FLV) and 5-Fluorouracil\u002FLeucovorin\u002FIrinotecan (FOLFIRI)",[87],[6561],"Gastro-Intestinal Cancer",[6563,617,6563,1678,5877,5877,5877],"5-FU",{"trials":6565,"activeCount":208,"soonestReadout":602},[6566,6570,6574],{"nctId":599,"briefTitle":600,"status":236,"phases":6567,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":6568,"interventions":6569},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"nctId":1666,"briefTitle":1667,"status":104,"phases":6571,"primaryCompletion":1669,"completion":60,"start":1670,"enrollment":1671,"conditions":6572,"interventions":6573},[87,88],[1673,1674],[1676,43,1225,1267,1677,617,1678],{"nctId":2257,"briefTitle":2258,"status":104,"phases":6575,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":2262,"conditions":6576,"interventions":6577},[88],[2264],[1245,1225,2266,43,618,1267,619,617,2267],{"trials":6579,"activeCount":208,"soonestReadout":2835},[6580,6584,6588],{"nctId":2532,"briefTitle":2533,"status":104,"phases":6581,"primaryCompletion":2535,"completion":2536,"start":2537,"enrollment":2538,"conditions":6582,"interventions":6583},[88,89],[1673],[43,619,617,618,612],{"nctId":2593,"briefTitle":2594,"status":104,"phases":6585,"primaryCompletion":2596,"completion":2597,"start":2598,"enrollment":2599,"conditions":6586,"interventions":6587},[89],[1436,2601,2602],[43,608,619,611,617,618],{"nctId":2832,"briefTitle":2833,"status":179,"phases":6589,"primaryCompletion":2835,"completion":2836,"start":2837,"enrollment":2838,"conditions":6590,"interventions":6591},[89],[2840],[608,619,617,618,1678,612,1145,43],{"trials":6593,"activeCount":98},[],{"trials":6595,"activeCount":98},[],{"intervention":621,"totalTrials":4328,"cells":6597},{"EARLY_PHASE1":6598,"PHASE1":6600,"PHASE2":6606,"PHASE3":6612,"PHASE4":6622,"NA":6624},{"trials":6599,"activeCount":98},[],{"trials":6601,"activeCount":98},[6602],{"nctId":1290,"briefTitle":1291,"status":104,"phases":6603,"primaryCompletion":1293,"completion":1294,"start":1295,"enrollment":1296,"conditions":6604,"interventions":6605},[87],[1253,1298],[43,1300,621,608],{"trials":6607,"activeCount":208,"soonestReadout":602},[6608],{"nctId":599,"briefTitle":600,"status":236,"phases":6609,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":6610,"interventions":6611},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"trials":6613,"activeCount":208,"soonestReadout":42},[6614,6618],{"nctId":40,"briefTitle":41,"status":179,"phases":6615,"primaryCompletion":42,"completion":158,"start":2543,"enrollment":2544,"conditions":6616,"interventions":6617},[89],[1253],[43,609,621,608],{"nctId":2810,"briefTitle":2811,"status":104,"phases":6619,"primaryCompletion":2758,"completion":936,"start":2813,"enrollment":2814,"conditions":6620,"interventions":6621},[89],[2816,2817],[43,608,621],{"trials":6623,"activeCount":98},[],{"trials":6625,"activeCount":98},[],{"intervention":2205,"totalTrials":574,"cells":6627},{"EARLY_PHASE1":6628,"PHASE1":6630,"PHASE2":6632,"PHASE3":6638,"PHASE4":6648,"NA":6650},{"trials":6629,"activeCount":98},[],{"trials":6631,"activeCount":98},[],{"trials":6633,"activeCount":98},[6634],{"nctId":2195,"briefTitle":2196,"status":104,"phases":6635,"primaryCompletion":2198,"completion":1129,"start":2199,"enrollment":2200,"conditions":6636,"interventions":6637},[88],[1436,1437,2202],[2122,43,2204,2205,2206],{"trials":6639,"activeCount":230,"soonestReadout":4835},[6640,6644],{"nctId":4832,"briefTitle":4833,"status":236,"phases":6641,"primaryCompletion":4835,"completion":4836,"start":329,"enrollment":4837,"conditions":6642,"interventions":6643},[88,89],[4839],[1721,2205,4841,612,4842],{"nctId":2853,"briefTitle":2854,"status":236,"phases":6645,"primaryCompletion":2856,"completion":2857,"start":2858,"enrollment":2859,"conditions":6646,"interventions":6647},[88,89],[2861],[1721,2863,2864,43],{"trials":6649,"activeCount":98},[],{"trials":6651,"activeCount":98},[],{"intervention":3776,"totalTrials":230,"cells":6653},{"EARLY_PHASE1":6654,"PHASE1":6656,"PHASE2":6666,"PHASE3":6668,"PHASE4":6674,"NA":6676},{"trials":6655,"activeCount":98},[],{"trials":6657,"activeCount":208,"soonestReadout":6662},[6658],{"nctId":6659,"briefTitle":6660,"status":179,"phases":6661,"primaryCompletion":6662,"completion":6662,"start":6663,"enrollment":1184,"conditions":6664,"interventions":6665},"NCT06799286","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed\u002FRefractory Small Cell Lung Cancer",[87],"2027-05-26","2025-05-07",[3619],[3776],{"trials":6667,"activeCount":98},[],{"trials":6669,"activeCount":208,"soonestReadout":3769},[6670],{"nctId":3766,"briefTitle":3767,"status":236,"phases":6671,"primaryCompletion":3769,"completion":3770,"start":3771,"enrollment":3772,"conditions":6672,"interventions":6673},[89],[3774],[3776,3777,1157,1929],{"trials":6675,"activeCount":98},[],{"trials":6677,"activeCount":98},[],{"intervention":2774,"totalTrials":230,"cells":6679},{"EARLY_PHASE1":6680,"PHASE1":6682,"PHASE2":6684,"PHASE3":6690,"PHASE4":6696,"NA":6698},{"trials":6681,"activeCount":98},[],{"trials":6683,"activeCount":98},[],{"trials":6685,"activeCount":208,"soonestReadout":5511},[6686],{"nctId":5508,"briefTitle":5509,"status":236,"phases":6687,"primaryCompletion":5511,"completion":5512,"start":5513,"enrollment":5514,"conditions":6688,"interventions":6689},[87,88],[1132],[5517,2774,5518,612],{"trials":6691,"activeCount":208,"soonestReadout":2767},[6692],{"nctId":2764,"briefTitle":2765,"status":179,"phases":6693,"primaryCompletion":2767,"completion":2768,"start":2769,"enrollment":2770,"conditions":6694,"interventions":6695},[89],[2772],[2774,43],{"trials":6697,"activeCount":98},[],{"trials":6699,"activeCount":98},[],{"intervention":4842,"totalTrials":230,"cells":6701},{"EARLY_PHASE1":6702,"PHASE1":6704,"PHASE2":6706,"PHASE3":6708,"PHASE4":6718,"NA":6720},{"trials":6703,"activeCount":98},[],{"trials":6705,"activeCount":98},[],{"trials":6707,"activeCount":98},[],{"trials":6709,"activeCount":230,"soonestReadout":4835},[6710,6714],{"nctId":4832,"briefTitle":4833,"status":236,"phases":6711,"primaryCompletion":4835,"completion":4836,"start":329,"enrollment":4837,"conditions":6712,"interventions":6713},[88,89],[4839],[1721,2205,4841,612,4842],{"nctId":2853,"briefTitle":2854,"status":236,"phases":6715,"primaryCompletion":2856,"completion":2857,"start":2858,"enrollment":2859,"conditions":6716,"interventions":6717},[88,89],[2861],[1721,2863,2864,43],{"trials":6719,"activeCount":98},[],{"trials":6721,"activeCount":98},[],{"intervention":5719,"totalTrials":230,"cells":6723},{"EARLY_PHASE1":6724,"PHASE1":6726,"PHASE2":6728,"PHASE3":6730,"PHASE4":6740,"NA":6742},{"trials":6725,"activeCount":98},[],{"trials":6727,"activeCount":98},[],{"trials":6729,"activeCount":98},[],{"trials":6731,"activeCount":230,"soonestReadout":5724},[6732,6736],{"nctId":5710,"briefTitle":5711,"status":179,"phases":6733,"primaryCompletion":5713,"completion":5713,"start":5714,"enrollment":5715,"conditions":6734,"interventions":6735},[89],[5717],[5571,5719],{"nctId":5721,"briefTitle":5722,"status":179,"phases":6737,"primaryCompletion":5724,"completion":5725,"start":5726,"enrollment":5727,"conditions":6738,"interventions":6739},[89],[5729],[5571,5719],{"trials":6741,"activeCount":98},[],{"trials":6743,"activeCount":98},[],{"intervention":441,"totalTrials":1221,"cells":6745},{"EARLY_PHASE1":6746,"PHASE1":6748,"PHASE2":6762,"PHASE3":6776,"PHASE4":6801,"NA":6803},{"trials":6747,"activeCount":98},[],{"trials":6749,"activeCount":98},[6750,6754,6758],{"nctId":6138,"briefTitle":6139,"status":104,"phases":6751,"primaryCompletion":6141,"completion":6142,"start":6143,"enrollment":1063,"conditions":6752,"interventions":6753},[87],[33],[441,1795,1795,1795,1794],{"nctId":6166,"briefTitle":6167,"status":104,"phases":6755,"primaryCompletion":6169,"completion":6169,"start":6170,"enrollment":37,"conditions":6756,"interventions":6757},[87],[6172],[3621,441,1795,1796],{"nctId":6181,"briefTitle":6182,"status":104,"phases":6759,"primaryCompletion":6184,"completion":6184,"start":5541,"enrollment":6185,"conditions":6760,"interventions":6761},[87],[33],[6188,441,1795,6188,1796,1795],{"trials":6763,"activeCount":98},[6764,6768,6772],{"nctId":6192,"briefTitle":6193,"status":104,"phases":6765,"primaryCompletion":6195,"completion":6196,"start":6197,"enrollment":116,"conditions":6766,"interventions":6767},[88],[33],[1794,441,1795],{"nctId":1787,"briefTitle":1788,"status":104,"phases":6769,"primaryCompletion":1790,"completion":1790,"start":1791,"enrollment":1285,"conditions":6770,"interventions":6771},[88],[33],[1794,1795,1795,441,1796,1797,43],{"nctId":6241,"briefTitle":6242,"status":104,"phases":6773,"primaryCompletion":6244,"completion":6245,"start":6246,"enrollment":1232,"conditions":6774,"interventions":6775},[88],[33],[441,1795,1794],{"trials":6777,"activeCount":208,"soonestReadout":6782},[6778,6789,6793,6797],{"nctId":6779,"briefTitle":6780,"status":236,"phases":6781,"primaryCompletion":6782,"completion":6783,"start":6784,"enrollment":6785,"conditions":6786,"interventions":6787},"NCT05827016","A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma",[89],"2029-03-15","2036-01-01","2023-06-22",1216,[33],[6788,441],"Iberdomide",{"nctId":6262,"briefTitle":6263,"status":963,"phases":6790,"primaryCompletion":1118,"completion":1118,"start":6265,"enrollment":2038,"conditions":6791,"interventions":6792},[89],[6267],[441,1795,1794],{"nctId":6270,"briefTitle":6271,"status":104,"phases":6794,"primaryCompletion":724,"completion":6273,"start":6274,"enrollment":6275,"conditions":6795,"interventions":6796},[89],[33],[441,1795,1795,1795,1795,1794,1794],{"nctId":6292,"briefTitle":6293,"status":104,"phases":6798,"primaryCompletion":6295,"completion":6296,"start":6297,"enrollment":6298,"conditions":6799,"interventions":6800},[89],[1426,33],[441,1795,1795,1795,1794],{"trials":6802,"activeCount":98},[],{"trials":6804,"activeCount":208,"soonestReadout":433},[6805,6809],{"nctId":430,"briefTitle":431,"status":179,"phases":6806,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":6807,"interventions":6808},[],[438],[440,362,441,442,443],{"nctId":6310,"briefTitle":6311,"status":3014,"phases":6810,"conditions":6811,"interventions":6812},[],[33],[1794,441,1795],{"intervention":6814,"totalTrials":830,"cells":6815},"Repotrectinib",{"EARLY_PHASE1":6816,"PHASE1":6818,"PHASE2":6843,"PHASE3":6845,"PHASE4":6855,"NA":6857},{"trials":6817,"activeCount":98},[],{"trials":6819,"activeCount":98},[6820,6828,6836],{"nctId":6821,"briefTitle":6822,"status":104,"phases":6823,"primaryCompletion":5610,"completion":5610,"start":5464,"enrollment":34,"conditions":6824,"interventions":6825},"NCT06493409","A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants",[87],[27],[6814,6826,6827],"Voriconazole","Quinidine",{"nctId":6829,"briefTitle":6830,"status":104,"phases":6831,"primaryCompletion":5681,"completion":6832,"start":329,"enrollment":148,"conditions":6833,"interventions":6834},"NCT07223671","Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants",[87],"2026-03-19",[27],[6814,823,6535,874,6835,6532,6533],"Bupropion",{"nctId":6837,"briefTitle":6838,"status":104,"phases":6839,"primaryCompletion":5609,"completion":5609,"start":6840,"enrollment":693,"conditions":6841,"interventions":6842},"NCT06352528","A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment",[87],"2024-04-29",[5603,27],[6814],{"trials":6844,"activeCount":98},[],{"trials":6846,"activeCount":208,"soonestReadout":2858},[6847],{"nctId":6848,"briefTitle":6849,"status":179,"phases":6850,"primaryCompletion":2858,"completion":6851,"start":6852,"enrollment":2327,"conditions":6853,"interventions":6854},"NCT06140836","A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)",[89],"2027-03-15","2023-12-21",[2781],[6814,2236],{"trials":6856,"activeCount":98},[],{"trials":6858,"activeCount":208,"soonestReadout":412},[6859,6867],{"nctId":6860,"briefTitle":6861,"status":642,"phases":6862,"primaryCompletion":412,"completion":6863,"start":6864,"enrollment":1184,"conditions":6865,"interventions":6866},"NCT07599007","Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion",[],"2028-01-31","2026-05-24",[36],[6814],{"nctId":6868,"briefTitle":6869,"status":6870,"phases":6871,"conditions":6872,"interventions":6873},"NCT05926232","Expanded Access for Repotrectinib","AVAILABLE",[],[],[6814],{"intervention":772,"totalTrials":713,"cells":6875},{"EARLY_PHASE1":6876,"PHASE1":6878,"PHASE2":6896,"PHASE3":6906,"PHASE4":6980,"NA":6998},{"trials":6877,"activeCount":98},[],{"trials":6879,"activeCount":98},[6880,6884,6888,6892],{"nctId":6512,"briefTitle":6513,"status":104,"phases":6881,"primaryCompletion":6515,"completion":6515,"start":6516,"enrollment":1686,"conditions":6882,"interventions":6883},[87],[18],[6519,874,823,772,617],{"nctId":6521,"briefTitle":6522,"status":104,"phases":6885,"primaryCompletion":6524,"completion":6525,"start":6526,"enrollment":2527,"conditions":6886,"interventions":6887},[87],[15],[6529,772,617,6530,6531,6532,6533,6534,6535,6536],{"nctId":6538,"briefTitle":6539,"status":104,"phases":6889,"primaryCompletion":6541,"completion":6542,"start":6543,"enrollment":148,"conditions":6890,"interventions":6891},[87],[18],[772,617,6546,6547],{"nctId":763,"briefTitle":764,"status":104,"phases":6893,"primaryCompletion":766,"completion":767,"start":768,"enrollment":148,"conditions":6894,"interventions":6895},[87],[738,770],[772,617,679],{"trials":6897,"activeCount":98},[6898],{"nctId":6899,"briefTitle":6900,"status":104,"phases":6901,"primaryCompletion":3797,"completion":3797,"start":3746,"enrollment":6902,"conditions":6903,"interventions":6904},"NCT02638948","Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis",[88],508,[15],[6905,772],"BMS-986142",{"trials":6907,"activeCount":208,"soonestReadout":60},[6908,6912,6924,6933,6941,6949,6956,6964,6973],{"nctId":2360,"briefTitle":2361,"status":104,"phases":6909,"primaryCompletion":1107,"completion":2363,"start":2364,"enrollment":2365,"conditions":6910,"interventions":6911},[89],[2367],[43,1145,772,1328],{"nctId":6913,"briefTitle":6914,"status":104,"phases":6915,"primaryCompletion":6916,"completion":6917,"start":6918,"enrollment":6919,"conditions":6920,"interventions":6921},"NCT01142726","Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis",[89],"2013-09","2014-10","2010-12",511,[15],[61,772,6922,6923],"Abatacept placebo","Methotrexate placebo",{"nctId":6925,"briefTitle":6926,"status":104,"phases":6927,"primaryCompletion":2977,"completion":6928,"start":6929,"enrollment":6930,"conditions":6931,"interventions":6932},"NCT02504268","Effects of Abatacept in Patients With Early Rheumatoid Arthritis",[89],"2020-03-19","2015-09-03",994,[15],[61,772],{"nctId":58,"briefTitle":59,"status":179,"phases":6934,"primaryCompletion":60,"completion":6935,"start":6936,"enrollment":6937,"conditions":6938,"interventions":6939},[89],"2027-09-01","2021-09-15",338,[15],[61,6940,772],"Adalimumab",{"nctId":6942,"briefTitle":6943,"status":104,"phases":6944,"primaryCompletion":3680,"completion":3587,"start":5078,"enrollment":6945,"conditions":6946,"interventions":6947},"NCT00122382","Remission and Joint Damage Progression in Early Rheumatoid Arthritis",[89],1052,[15],[61,6948],"methotrexate",{"nctId":6950,"briefTitle":6951,"status":104,"phases":6952,"primaryCompletion":5542,"completion":5542,"start":6953,"enrollment":515,"conditions":6954,"interventions":6955},"NCT00767325","A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography",[89],"2008-12",[15],[61,772],{"nctId":6957,"briefTitle":6958,"status":104,"phases":6959,"primaryCompletion":4039,"completion":3679,"start":6960,"enrollment":6961,"conditions":6962,"interventions":6963},"NCT00409838","A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate",[89],"2007-04",113,[15],[61,772,61,772],{"nctId":6965,"briefTitle":6966,"status":104,"phases":6967,"primaryCompletion":6953,"completion":4551,"start":6968,"enrollment":1877,"conditions":6969,"interventions":6971},"NCT00547521","Phase IIIB Subcutaneous Abatacept Monotherapy Study",[89],"2007-12",[6970],"Rheumatoid Arthritis (RA)",[6972,772],"abatacept",{"nctId":6974,"briefTitle":6975,"status":104,"phases":6976,"primaryCompletion":3678,"completion":3678,"start":5051,"enrollment":6977,"conditions":6978,"interventions":6979},"NCT00048568","A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate",[89],1250,[15],[61,772],{"trials":6981,"activeCount":98},[6982,6990],{"nctId":6983,"briefTitle":6984,"status":104,"phases":6985,"primaryCompletion":6986,"completion":6986,"start":6987,"enrollment":3748,"conditions":6988,"interventions":6989},"NCT01758198","Abatacept Post-marketing Clinical Study in Japan",[90],"2016-12-26","2013-04-11",[15],[61,772],{"nctId":6991,"briefTitle":6992,"status":104,"phases":6993,"primaryCompletion":6994,"completion":6994,"start":6995,"enrollment":1863,"conditions":6996,"interventions":6997},"NCT02557100","Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis",[90],"2019-03-28","2015-11-19",[15],[61,6940,772],{"trials":6999,"activeCount":98},[],{"intervention":6940,"totalTrials":574,"cells":7001},{"EARLY_PHASE1":7002,"PHASE1":7004,"PHASE2":7006,"PHASE3":7008,"PHASE4":7021,"NA":7027},{"trials":7003,"activeCount":98},[],{"trials":7005,"activeCount":98},[],{"trials":7007,"activeCount":98},[],{"trials":7009,"activeCount":208,"soonestReadout":60},[7010,7014],{"nctId":58,"briefTitle":59,"status":179,"phases":7011,"primaryCompletion":60,"completion":6935,"start":6936,"enrollment":6937,"conditions":7012,"interventions":7013},[89],[15],[61,6940,772],{"nctId":7015,"briefTitle":7016,"status":104,"phases":7017,"primaryCompletion":5542,"completion":3893,"start":3678,"enrollment":7018,"conditions":7019,"interventions":7020},"NCT00929864","Abatacept Versus Adalimumab Head-to-Head",[89],869,[15],[61,6940],{"trials":7022,"activeCount":98},[7023],{"nctId":6991,"briefTitle":6992,"status":104,"phases":7024,"primaryCompletion":6994,"completion":6994,"start":6995,"enrollment":1863,"conditions":7025,"interventions":7026},[90],[15],[61,6940,772],{"trials":7028,"activeCount":98},[],{"intervention":971,"totalTrials":747,"cells":7030},{"EARLY_PHASE1":7031,"PHASE1":7033,"PHASE2":7045,"PHASE3":7096,"PHASE4":7125,"NA":7127},{"trials":7032,"activeCount":98},[],{"trials":7034,"activeCount":98},[7035],{"nctId":7036,"briefTitle":7037,"status":104,"phases":7038,"primaryCompletion":7039,"completion":7040,"start":7041,"enrollment":1385,"conditions":7042,"interventions":7043},"NCT04039373","Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil",[87],"2019-09-18","2019-10-16","2019-07-22",[18],[7044,971],"BMS-986256",{"trials":7046,"activeCount":98},[7047,7061,7071,7080,7084],{"nctId":7048,"briefTitle":7049,"status":104,"phases":7050,"primaryCompletion":7051,"completion":7051,"start":7052,"enrollment":2308,"conditions":7053,"interventions":7055},"NCT02137239","Regimen Optimization Study",[88],"2019-05-02","2015-12-31",[7054],"Kidney Transplantation",[7056,7057,7058,7059,2936,7060],"Thymoglobulin","Belatacept","mycophenolate mofetil","Corticosteroids","Tacrolimus",{"nctId":7062,"briefTitle":7063,"status":104,"phases":7064,"primaryCompletion":3658,"completion":3902,"start":7065,"enrollment":1597,"conditions":7066,"interventions":7069},"NCT00035555","Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney",[88],"2001-03",[7067,7054,7068],"Graft Rejection","Renal Transplantation",[7057,893,7070,7059],"Mycophenolate mofetil",{"nctId":7072,"briefTitle":7073,"status":104,"phases":7074,"primaryCompletion":6480,"completion":6479,"start":4010,"enrollment":7075,"conditions":7076,"interventions":7078},"NCT00455013","A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation",[88],93,[7077],"Disorder Related to Renal Transplantation",[7056,7057,7079,7060,971],"Sirolimus",{"nctId":961,"briefTitle":962,"status":963,"phases":7081,"primaryCompletion":965,"completion":966,"start":967,"enrollment":713,"conditions":7082,"interventions":7083},[88],[969],[679,971],{"nctId":7085,"briefTitle":7086,"status":963,"phases":7087,"primaryCompletion":7088,"completion":7089,"start":4930,"enrollment":3093,"conditions":7090,"interventions":7092},"NCT00555321","Belatacept in Liver Transplant Recipients",[88],"2010-03","2011-06",[7091],"Immunosuppression in Solid Organ Transplant",[7060,7093,7094,7095,971],"Basiliximab","Belatacept More Intensive","Belatacept Less Intensive",{"trials":7097,"activeCount":208,"soonestReadout":7102},[7098,7109,7119],{"nctId":7099,"briefTitle":7100,"status":236,"phases":7101,"primaryCompletion":7102,"completion":7103,"start":6245,"enrollment":1586,"conditions":7104,"interventions":7106},"NCT04877288","A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to \u003C18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications",[89],"2032-12-30","2034-06-30",[7105],"Renal Allograft Recipients",[7057,7060,7107,971,7108,7059],"Cyclosporine A","Enteric Coated Mycophenolate Sodium",{"nctId":7110,"briefTitle":7111,"status":963,"phases":7112,"primaryCompletion":7113,"completion":802,"start":7114,"enrollment":7115,"conditions":7116,"interventions":7117},"NCT01714817","Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis",[89],"2016-11-21","2013-01-22",695,[969],[7118,7070,1507],"BMS-188667",{"nctId":7120,"briefTitle":7111,"status":963,"phases":7121,"primaryCompletion":3631,"completion":5850,"start":4664,"enrollment":7122,"conditions":7123,"interventions":7124},"NCT00430677",[88,89],423,[792],[7059,61,61,7070,61],{"trials":7126,"activeCount":98},[],{"trials":7128,"activeCount":98},[],{"intervention":1678,"totalTrials":839,"cells":7130},{"EARLY_PHASE1":7131,"PHASE1":7133,"PHASE2":7143,"PHASE3":7172,"PHASE4":7178,"NA":7180},{"trials":7132,"activeCount":98},[],{"trials":7134,"activeCount":98},[7135,7139],{"nctId":3601,"briefTitle":3602,"status":104,"phases":7136,"primaryCompletion":3604,"completion":3605,"start":3606,"enrollment":3607,"conditions":7137,"interventions":7138},[87],[606],[1158,3610,1157,617,1678,1158,3611],{"nctId":6557,"briefTitle":6558,"status":104,"phases":7140,"primaryCompletion":3017,"completion":3017,"start":3617,"enrollment":790,"conditions":7141,"interventions":7142},[87],[6561],[6563,617,6563,1678,5877,5877,5877],{"trials":7144,"activeCount":98},[7145,7149,7160,7164,7168],{"nctId":3654,"briefTitle":3655,"status":104,"phases":7146,"primaryCompletion":3657,"completion":3657,"start":3658,"enrollment":319,"conditions":7147,"interventions":7148},[87,88],[3660],[1157,1678,1678],{"nctId":7150,"briefTitle":7151,"status":104,"phases":7152,"primaryCompletion":7153,"completion":7153,"start":7154,"conditions":7155,"interventions":7157},"NCT00057473","A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors",[88],"2004-02","2003-02",[7156],"Neoplasms",[7158,7159],"carboplatin + irinotecan","irinotecan",{"nctId":1666,"briefTitle":1667,"status":104,"phases":7161,"primaryCompletion":1669,"completion":60,"start":1670,"enrollment":1671,"conditions":7162,"interventions":7163},[87,88],[1673,1674],[1676,43,1225,1267,1677,617,1678],{"nctId":5870,"briefTitle":5871,"status":104,"phases":7165,"primaryCompletion":3977,"completion":3977,"start":5873,"enrollment":193,"conditions":7166,"interventions":7167},[87,88],[5875],[1145,1678,5877,5877,5878],{"nctId":5538,"briefTitle":5539,"status":104,"phases":7169,"primaryCompletion":5541,"completion":5542,"start":3678,"enrollment":5543,"conditions":7170,"interventions":7171},[88],[4875],[1678,3610,3610,5546,3716,612,5547],{"trials":7173,"activeCount":208,"soonestReadout":2835},[7174],{"nctId":2832,"briefTitle":2833,"status":179,"phases":7175,"primaryCompletion":2835,"completion":2836,"start":2837,"enrollment":2838,"conditions":7176,"interventions":7177},[89],[2840],[608,619,617,618,1678,612,1145,43],{"trials":7179,"activeCount":98},[],{"trials":7181,"activeCount":98},[],{"intervention":7060,"totalTrials":830,"cells":7183},{"EARLY_PHASE1":7184,"PHASE1":7186,"PHASE2":7188,"PHASE3":7210,"PHASE4":7225,"NA":7227},{"trials":7185,"activeCount":98},[],{"trials":7187,"activeCount":98},[],{"trials":7189,"activeCount":98},[7190,7194,7202,7206],{"nctId":7048,"briefTitle":7049,"status":104,"phases":7191,"primaryCompletion":7051,"completion":7051,"start":7052,"enrollment":2308,"conditions":7192,"interventions":7193},[88],[7054],[7056,7057,7058,7059,2936,7060],{"nctId":7195,"briefTitle":7196,"status":104,"phases":7197,"primaryCompletion":3712,"completion":3630,"start":4931,"enrollment":7198,"conditions":7199,"interventions":7201},"NCT00402168","A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids",[88],173,[7200],"Renal Transplant",[7057,7107,7060],{"nctId":7072,"briefTitle":7073,"status":104,"phases":7203,"primaryCompletion":6480,"completion":6479,"start":4010,"enrollment":7075,"conditions":7204,"interventions":7205},[88],[7077],[7056,7057,7079,7060,971],{"nctId":7085,"briefTitle":7086,"status":963,"phases":7207,"primaryCompletion":7088,"completion":7089,"start":4930,"enrollment":3093,"conditions":7208,"interventions":7209},[88],[7091],[7060,7093,7094,7095,971],{"trials":7211,"activeCount":208,"soonestReadout":7102},[7212,7216],{"nctId":7099,"briefTitle":7100,"status":236,"phases":7213,"primaryCompletion":7102,"completion":7103,"start":6245,"enrollment":1586,"conditions":7214,"interventions":7215},[89],[7105],[7057,7060,7107,971,7108,7059],{"nctId":7217,"briefTitle":7218,"status":104,"phases":7219,"primaryCompletion":7220,"completion":7220,"start":7221,"enrollment":7222,"conditions":7223,"interventions":7224},"NCT01820572","A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based",[89],"2019-10-24","2013-03-27",446,[7054],[7057,7060,893],{"trials":7226,"activeCount":98},[],{"trials":7228,"activeCount":98},[],{"intervention":1929,"totalTrials":830,"cells":7230},{"EARLY_PHASE1":7231,"PHASE1":7233,"PHASE2":7247,"PHASE3":7253,"PHASE4":7263,"NA":7265},{"trials":7232,"activeCount":98},[],{"trials":7234,"activeCount":98},[7235,7239,7243],{"nctId":3591,"briefTitle":3592,"status":104,"phases":7236,"primaryCompletion":3594,"completion":3595,"start":3596,"enrollment":1221,"conditions":7237,"interventions":7238},[87],[1888],[1890,1268,1929,3599,1157],{"nctId":4565,"briefTitle":4566,"status":104,"phases":7240,"primaryCompletion":4568,"completion":4568,"start":2326,"enrollment":1750,"conditions":7241,"interventions":7242},[87],[1888],[1890,1268,1929],{"nctId":3613,"briefTitle":3614,"status":104,"phases":7244,"primaryCompletion":3616,"completion":3616,"start":3617,"enrollment":520,"conditions":7245,"interventions":7246},[87],[3619],[3621,1157,1929],{"trials":7248,"activeCount":98},[7249],{"nctId":1921,"briefTitle":1922,"status":104,"phases":7250,"primaryCompletion":1924,"completion":1925,"start":1447,"enrollment":703,"conditions":7251,"interventions":7252},[88],[1927],[1890,1157,1929,43],{"trials":7254,"activeCount":208,"soonestReadout":3769},[7255,7259],{"nctId":3757,"briefTitle":3758,"status":104,"phases":7256,"primaryCompletion":3760,"completion":1895,"start":3761,"enrollment":3762,"conditions":7257,"interventions":7258},[89],[3619],[608,1929,1268,1157],{"nctId":3766,"briefTitle":3767,"status":236,"phases":7260,"primaryCompletion":3769,"completion":3770,"start":3771,"enrollment":3772,"conditions":7261,"interventions":7262},[89],[3774],[3776,3777,1157,1929],{"trials":7264,"activeCount":98},[],{"trials":7266,"activeCount":98},[],{"intervention":636,"totalTrials":520,"cells":7268},{"EARLY_PHASE1":7269,"PHASE1":7271,"PHASE2":7277,"PHASE3":7291,"PHASE4":7297,"NA":7299},{"trials":7270,"activeCount":98},[],{"trials":7272,"activeCount":98},[7273],{"nctId":1199,"briefTitle":1200,"status":104,"phases":7274,"primaryCompletion":1202,"completion":1202,"start":724,"enrollment":1203,"conditions":7275,"interventions":7276},[87],[606],[1206,1123,636],{"trials":7278,"activeCount":98},[7279,7283,7287],{"nctId":1562,"briefTitle":1563,"status":104,"phases":7280,"primaryCompletion":1565,"completion":1402,"start":1566,"enrollment":1567,"conditions":7281,"interventions":7282},[87,88],[1345],[1123,636,1123],{"nctId":1690,"briefTitle":1691,"status":963,"phases":7284,"primaryCompletion":1693,"completion":1693,"start":1694,"enrollment":1695,"conditions":7285,"interventions":7286},[87,88],[1154],[1698,43,636],{"nctId":2143,"briefTitle":2144,"status":104,"phases":7288,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":2148,"conditions":7289,"interventions":7290},[87,88],[2150],[2152,43,636],{"trials":7292,"activeCount":208,"soonestReadout":630},[7293],{"nctId":627,"briefTitle":628,"status":179,"phases":7294,"primaryCompletion":630,"completion":631,"start":632,"enrollment":633,"conditions":7295,"interventions":7296},[89],[21],[590,636],{"trials":7298,"activeCount":98},[],{"trials":7300,"activeCount":98},[],{"intervention":7059,"totalTrials":4328,"cells":7302},{"EARLY_PHASE1":7303,"PHASE1":7305,"PHASE2":7307,"PHASE3":7317,"PHASE4":7327,"NA":7329},{"trials":7304,"activeCount":98},[],{"trials":7306,"activeCount":98},[],{"trials":7308,"activeCount":98},[7309,7313],{"nctId":7048,"briefTitle":7049,"status":104,"phases":7310,"primaryCompletion":7051,"completion":7051,"start":7052,"enrollment":2308,"conditions":7311,"interventions":7312},[88],[7054],[7056,7057,7058,7059,2936,7060],{"nctId":7062,"briefTitle":7063,"status":104,"phases":7314,"primaryCompletion":3658,"completion":3902,"start":7065,"enrollment":1597,"conditions":7315,"interventions":7316},[88],[7067,7054,7068],[7057,893,7070,7059],{"trials":7318,"activeCount":208,"soonestReadout":7102},[7319,7323],{"nctId":7099,"briefTitle":7100,"status":236,"phases":7320,"primaryCompletion":7102,"completion":7103,"start":6245,"enrollment":1586,"conditions":7321,"interventions":7322},[89],[7105],[7057,7060,7107,971,7108,7059],{"nctId":7120,"briefTitle":7111,"status":963,"phases":7324,"primaryCompletion":3631,"completion":5850,"start":4664,"enrollment":7122,"conditions":7325,"interventions":7326},[88,89],[792],[7059,61,61,7070,61],{"trials":7328,"activeCount":98},[],{"trials":7330,"activeCount":98},[],{"intervention":1609,"totalTrials":4328,"cells":7332},{"EARLY_PHASE1":7333,"PHASE1":7335,"PHASE2":7337,"PHASE3":7343,"PHASE4":7361,"NA":7363},{"trials":7334,"activeCount":98},[],{"trials":7336,"activeCount":98},[],{"trials":7338,"activeCount":98},[7339],{"nctId":1601,"briefTitle":1602,"status":104,"phases":7340,"primaryCompletion":278,"completion":278,"start":1604,"enrollment":1605,"conditions":7341,"interventions":7342},[87,88],[1607],[43,1609,608,609],{"trials":7344,"activeCount":208,"soonestReadout":225},[7345,7353,7357],{"nctId":7346,"briefTitle":7347,"status":104,"phases":7348,"primaryCompletion":1343,"completion":6916,"start":4459,"enrollment":7349,"conditions":7350,"interventions":7352},"NCT00858871","First Line Hepato Cellular Carcinoma (HCC)",[89],1714,[7351],"Hepato Cellular Carcinoma (HCC)",[5877,1609],{"nctId":2653,"briefTitle":2654,"status":179,"phases":7354,"primaryCompletion":225,"completion":225,"start":2656,"enrollment":2657,"conditions":7355,"interventions":7356},[89],[1607],[43,608,1609,2660],{"nctId":2734,"briefTitle":2735,"status":104,"phases":7358,"primaryCompletion":2737,"completion":2738,"start":2739,"enrollment":2740,"conditions":7359,"interventions":7360},[89],[1607],[43,1609],{"trials":7362,"activeCount":98},[],{"trials":7364,"activeCount":98},[],{"intervention":3287,"totalTrials":574,"cells":7366},{"EARLY_PHASE1":7367,"PHASE1":7369,"PHASE2":7380,"PHASE3":7394,"PHASE4":7400,"NA":7402},{"trials":7368,"activeCount":98},[],{"trials":7370,"activeCount":98},[7371],{"nctId":7372,"briefTitle":7373,"status":104,"phases":7374,"primaryCompletion":4151,"completion":4151,"start":7375,"enrollment":7376,"conditions":7377,"interventions":7378},"NCT02763969","Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis",[87],"2016-05-18",357,[749],[7379,852,696,3287],"BMS-986202",{"trials":7381,"activeCount":98},[7382],{"nctId":7383,"briefTitle":7384,"status":104,"phases":7385,"primaryCompletion":7386,"completion":7387,"start":3995,"enrollment":7388,"conditions":7389,"interventions":7391},"NCT03881059","Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)",[88],"2020-04-27","2021-01-27",203,[7390],"Active Psoriatic Arthritis",[7392,7393,3287],"BMS-986165 Dose A","BMS-986165 Dose B",{"trials":7395,"activeCount":208,"soonestReadout":3282},[7396],{"nctId":3279,"briefTitle":3280,"status":236,"phases":7397,"primaryCompletion":3282,"completion":3282,"start":3283,"enrollment":3284,"conditions":7398,"interventions":7399},[89],[3256],[79,3287],{"trials":7401,"activeCount":98},[],{"trials":7403,"activeCount":98},[],{"intervention":7107,"totalTrials":230,"cells":7405},{"EARLY_PHASE1":7406,"PHASE1":7408,"PHASE2":7410,"PHASE3":7416,"PHASE4":7422,"NA":7424},{"trials":7407,"activeCount":98},[],{"trials":7409,"activeCount":98},[],{"trials":7411,"activeCount":98},[7412],{"nctId":7195,"briefTitle":7196,"status":104,"phases":7413,"primaryCompletion":3712,"completion":3630,"start":4931,"enrollment":7198,"conditions":7414,"interventions":7415},[88],[7200],[7057,7107,7060],{"trials":7417,"activeCount":208,"soonestReadout":7102},[7418],{"nctId":7099,"briefTitle":7100,"status":236,"phases":7419,"primaryCompletion":7102,"completion":7103,"start":6245,"enrollment":1586,"conditions":7420,"interventions":7421},[89],[7105],[7057,7060,7107,971,7108,7059],{"trials":7423,"activeCount":98},[],{"trials":7425,"activeCount":98},[],{"intervention":2236,"totalTrials":230,"cells":7427},{"EARLY_PHASE1":7428,"PHASE1":7430,"PHASE2":7432,"PHASE3":7438,"PHASE4":7444,"NA":7446},{"trials":7429,"activeCount":98},[],{"trials":7431,"activeCount":98},[],{"trials":7433,"activeCount":98},[7434],{"nctId":2227,"briefTitle":2228,"status":104,"phases":7435,"primaryCompletion":2230,"completion":2230,"start":2231,"enrollment":2232,"conditions":7436,"interventions":7437},[87,88],[36],[43,612,622,2235,1158,1328,1267,1269,2236,1157],{"trials":7439,"activeCount":208,"soonestReadout":2858},[7440],{"nctId":6848,"briefTitle":6849,"status":179,"phases":7441,"primaryCompletion":2858,"completion":6851,"start":6852,"enrollment":2327,"conditions":7442,"interventions":7443},[89],[2781],[6814,2236],{"trials":7445,"activeCount":98},[],{"trials":7447,"activeCount":98},[],{"intervention":4830,"totalTrials":230,"cells":7449},{"EARLY_PHASE1":7450,"PHASE1":7452,"PHASE2":7454,"PHASE3":7456,"PHASE4":7466,"NA":7468},{"trials":7451,"activeCount":98},[],{"trials":7453,"activeCount":98},[],{"trials":7455,"activeCount":98},[],{"trials":7457,"activeCount":208,"soonestReadout":4825},[7458,7462],{"nctId":4822,"briefTitle":4823,"status":236,"phases":7459,"primaryCompletion":4825,"completion":4826,"start":4299,"enrollment":4827,"conditions":7460,"interventions":7461},[89],[3131],[1721,4830],{"nctId":2820,"briefTitle":2821,"status":104,"phases":7463,"primaryCompletion":2823,"completion":2824,"start":2825,"enrollment":2826,"conditions":7464,"interventions":7465},[89],[2828],[1123,1122,2830],{"trials":7467,"activeCount":98},[],{"trials":7469,"activeCount":98},[],{"intervention":7108,"totalTrials":208,"cells":7471},{"EARLY_PHASE1":7472,"PHASE1":7474,"PHASE2":7476,"PHASE3":7478,"PHASE4":7484,"NA":7486},{"trials":7473,"activeCount":98},[],{"trials":7475,"activeCount":98},[],{"trials":7477,"activeCount":98},[],{"trials":7479,"activeCount":208,"soonestReadout":7102},[7480],{"nctId":7099,"briefTitle":7100,"status":236,"phases":7481,"primaryCompletion":7102,"completion":7103,"start":6245,"enrollment":1586,"conditions":7482,"interventions":7483},[89],[7105],[7057,7060,7107,971,7108,7059],{"trials":7485,"activeCount":98},[],{"trials":7487,"activeCount":98},[],{"intervention":3458,"totalTrials":208,"cells":7489},{"EARLY_PHASE1":7490,"PHASE1":7492,"PHASE2":7494,"PHASE3":7496,"PHASE4":7502,"NA":7504},{"trials":7491,"activeCount":98},[],{"trials":7493,"activeCount":98},[],{"trials":7495,"activeCount":98},[],{"trials":7497,"activeCount":208,"soonestReadout":3452},[7498],{"nctId":3449,"briefTitle":3450,"status":236,"phases":7499,"primaryCompletion":3452,"completion":3452,"start":3453,"enrollment":3454,"conditions":7500,"interventions":7501},[89],[3456],[3420,3458,3459,3460],{"trials":7503,"activeCount":98},[],{"trials":7505,"activeCount":98},[],{"intervention":3459,"totalTrials":208,"cells":7507},{"EARLY_PHASE1":7508,"PHASE1":7510,"PHASE2":7512,"PHASE3":7514,"PHASE4":7520,"NA":7522},{"trials":7509,"activeCount":98},[],{"trials":7511,"activeCount":98},[],{"trials":7513,"activeCount":98},[],{"trials":7515,"activeCount":208,"soonestReadout":3452},[7516],{"nctId":3449,"briefTitle":3450,"status":236,"phases":7517,"primaryCompletion":3452,"completion":3452,"start":3453,"enrollment":3454,"conditions":7518,"interventions":7519},[89],[3456],[3420,3458,3459,3460],{"trials":7521,"activeCount":98},[],{"trials":7523,"activeCount":98},[],{"intervention":3460,"totalTrials":208,"cells":7525},{"EARLY_PHASE1":7526,"PHASE1":7528,"PHASE2":7530,"PHASE3":7532,"PHASE4":7538,"NA":7540},{"trials":7527,"activeCount":98},[],{"trials":7529,"activeCount":98},[],{"trials":7531,"activeCount":98},[],{"trials":7533,"activeCount":208,"soonestReadout":3452},[7534],{"nctId":3449,"briefTitle":3450,"status":236,"phases":7535,"primaryCompletion":3452,"completion":3452,"start":3453,"enrollment":3454,"conditions":7536,"interventions":7537},[89],[3456],[3420,3458,3459,3460],{"trials":7539,"activeCount":98},[],{"trials":7541,"activeCount":98},[],{"intervention":3777,"totalTrials":208,"cells":7543},{"EARLY_PHASE1":7544,"PHASE1":7546,"PHASE2":7548,"PHASE3":7550,"PHASE4":7556,"NA":7558},{"trials":7545,"activeCount":98},[],{"trials":7547,"activeCount":98},[],{"trials":7549,"activeCount":98},[],{"trials":7551,"activeCount":208,"soonestReadout":3769},[7552],{"nctId":3766,"briefTitle":3767,"status":236,"phases":7553,"primaryCompletion":3769,"completion":3770,"start":3771,"enrollment":3772,"conditions":7554,"interventions":7555},[89],[3774],[3776,3777,1157,1929],{"trials":7557,"activeCount":98},[],{"trials":7559,"activeCount":98},[],{"intervention":4841,"totalTrials":208,"cells":7561},{"EARLY_PHASE1":7562,"PHASE1":7564,"PHASE2":7566,"PHASE3":7568,"PHASE4":7574,"NA":7576},{"trials":7563,"activeCount":98},[],{"trials":7565,"activeCount":98},[],{"trials":7567,"activeCount":98},[],{"trials":7569,"activeCount":208,"soonestReadout":4835},[7570],{"nctId":4832,"briefTitle":4833,"status":236,"phases":7571,"primaryCompletion":4835,"completion":4836,"start":329,"enrollment":4837,"conditions":7572,"interventions":7573},[88,89],[4839],[1721,2205,4841,612,4842],{"trials":7575,"activeCount":98},[],{"trials":7577,"activeCount":98},[],{"intervention":5392,"totalTrials":208,"cells":7579},{"EARLY_PHASE1":7580,"PHASE1":7582,"PHASE2":7584,"PHASE3":7586,"PHASE4":7592,"NA":7594},{"trials":7581,"activeCount":98},[],{"trials":7583,"activeCount":98},[],{"trials":7585,"activeCount":98},[],{"trials":7587,"activeCount":208,"soonestReadout":5386},[7588],{"nctId":5383,"briefTitle":5384,"status":236,"phases":7589,"primaryCompletion":5386,"completion":5387,"start":5388,"enrollment":1296,"conditions":7590,"interventions":7591},[89],[5390],[5365,5392],{"trials":7593,"activeCount":98},[],{"trials":7595,"activeCount":98},[],{"intervention":2660,"totalTrials":208,"cells":7597},{"EARLY_PHASE1":7598,"PHASE1":7600,"PHASE2":7602,"PHASE3":7604,"PHASE4":7610,"NA":7612},{"trials":7599,"activeCount":98},[],{"trials":7601,"activeCount":98},[],{"trials":7603,"activeCount":98},[],{"trials":7605,"activeCount":208,"soonestReadout":225},[7606],{"nctId":2653,"briefTitle":2654,"status":179,"phases":7607,"primaryCompletion":225,"completion":225,"start":2656,"enrollment":2657,"conditions":7608,"interventions":7609},[89],[1607],[43,608,1609,2660],{"trials":7611,"activeCount":98},[],{"trials":7613,"activeCount":98},[],{"intervention":6290,"totalTrials":208,"cells":7615},{"EARLY_PHASE1":7616,"PHASE1":7618,"PHASE2":7620,"PHASE3":7622,"PHASE4":7628,"NA":7630},{"trials":7617,"activeCount":98},[],{"trials":7619,"activeCount":98},[],{"trials":7621,"activeCount":98},[],{"trials":7623,"activeCount":208,"soonestReadout":6282},[7624],{"nctId":6279,"briefTitle":6280,"status":179,"phases":7625,"primaryCompletion":6282,"completion":6283,"start":6284,"enrollment":6285,"conditions":7626,"interventions":7627},[89],[6287],[6289,6290,1795],{"trials":7629,"activeCount":98},[],{"trials":7631,"activeCount":98},[],{"intervention":61,"totalTrials":7633,"cells":7634},55,{"EARLY_PHASE1":7635,"PHASE1":7637,"PHASE2":7718,"PHASE3":7817,"PHASE4":7998,"NA":8008},{"trials":7636,"activeCount":98},[],{"trials":7638,"activeCount":98},[7639,7646,7655,7663,7670,7678,7686,7694,7702,7709],{"nctId":7640,"briefTitle":7641,"status":104,"phases":7642,"primaryCompletion":5051,"completion":5051,"start":7643,"enrollment":148,"conditions":7644,"interventions":7645},"NCT00277199","Comparability DE vs CD-CHO1",[87],"2002-09",[850],[61],{"nctId":7647,"briefTitle":7648,"status":104,"phases":7649,"primaryCompletion":7650,"completion":7650,"start":7651,"enrollment":125,"conditions":7652,"interventions":7654},"NCT00306878","Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris",[87],"1997-05","1995-08",[7653],"Psoriasis Vulgaris",[61],{"nctId":7656,"briefTitle":7657,"status":104,"phases":7658,"primaryCompletion":7659,"completion":7659,"start":7660,"enrollment":848,"conditions":7661,"interventions":7662},"NCT03714022","A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes",[87],"2019-04-02","2018-11-09",[15],[61],{"nctId":7664,"briefTitle":7665,"status":104,"phases":7666,"primaryCompletion":6437,"completion":6437,"start":5542,"enrollment":7667,"conditions":7668,"interventions":7669},"NCT01439204","Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb",[87],223,[15],[61],{"nctId":7671,"briefTitle":7672,"status":104,"phases":7673,"primaryCompletion":7674,"completion":7674,"start":7675,"enrollment":713,"conditions":7676,"interventions":7677},"NCT00162201","An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy",[87],"2005-04","2003-10",[15],[61],{"nctId":7679,"briefTitle":7680,"status":104,"phases":7681,"primaryCompletion":7682,"completion":7682,"start":7683,"enrollment":34,"conditions":7684,"interventions":7685},"NCT00277225","A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris",[87],"1996-06","1995-11",[7653],[61],{"nctId":7687,"briefTitle":7688,"status":104,"phases":7689,"primaryCompletion":7690,"completion":7690,"start":7691,"enrollment":2242,"conditions":7692,"interventions":7693},"NCT01890473","Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe",[87],"2014-11","2013-07",[15],[61],{"nctId":7695,"briefTitle":7696,"status":104,"phases":7697,"primaryCompletion":7698,"completion":7698,"start":5592,"enrollment":7699,"conditions":7700,"interventions":7701},"NCT05981976","A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants",[87],"2023-12-14",174,[18],[61],{"nctId":7703,"briefTitle":7704,"status":467,"phases":7705,"primaryCompletion":3938,"completion":3938,"start":7706,"enrollment":98,"conditions":7707,"interventions":7708},"NCT01221636","Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept",[87],"2010-10",[15],[61],{"nctId":7710,"briefTitle":7711,"status":104,"phases":7712,"primaryCompletion":7713,"completion":7714,"start":7715,"enrollment":137,"conditions":7716,"interventions":7717},"NCT00705367","Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg\u002Fkg",[87],"2009-01","2011-07","2008-08",[969],[61,61],{"trials":7719,"activeCount":98},[7720,7727,7738,7746,7754,7761,7772,7780,7788,7795,7807],{"nctId":7721,"briefTitle":7722,"status":104,"phases":7723,"primaryCompletion":7724,"enrollment":4255,"conditions":7725,"interventions":7726},"NCT00279760","Phase I\u002FII Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis",[87,88],"2002-03",[15],[7057,61],{"nctId":7728,"briefTitle":7729,"status":104,"phases":7730,"primaryCompletion":7731,"completion":7731,"start":7732,"enrollment":347,"conditions":7733,"interventions":7737},"NCT02592798","Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)",[88],"2020-01-28","2016-03-09",[7734,7735,7736],"Nephrotic Syndrome","Focal Segmental Glomerulosclerosis","Minimal Change Disease",[61],{"nctId":7739,"briefTitle":7740,"status":104,"phases":7741,"primaryCompletion":7742,"completion":3902,"start":4995,"enrollment":3076,"conditions":7743,"interventions":7744},"NCT00254293","Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)",[87,88],"2007-05",[15],[7745,7745,7745,7745,7745,61],"Abatacept or Placebo",{"nctId":7747,"briefTitle":7748,"status":104,"phases":7749,"primaryCompletion":7750,"completion":7750,"start":7751,"enrollment":3607,"conditions":7752,"interventions":7753},"NCT00162279","The Study of Abatacept in Combination With Etanercept",[88],"2007-02","2000-10",[15],[61],{"nctId":7755,"briefTitle":7756,"status":104,"phases":7757,"primaryCompletion":7758,"completion":7758,"start":5117,"enrollment":1296,"conditions":7759,"interventions":7760},"NCT00345748","A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate",[88],"2007-11",[15],[61],{"nctId":7762,"briefTitle":7763,"status":963,"phases":7764,"primaryCompletion":7765,"completion":7766,"start":7767,"enrollment":451,"conditions":7768,"interventions":7771},"NCT04472494","Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise",[88],"2021-08-12","2021-09-13","2020-10-14",[7769,7770],"COVID-19","SARS-CoV-2",[61],{"nctId":7773,"briefTitle":7774,"status":963,"phases":7775,"primaryCompletion":6953,"completion":7776,"start":7758,"enrollment":7777,"conditions":7778,"interventions":7779},"NCT00534313","Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis",[88],"2011-05",191,[770],[61],{"nctId":7781,"briefTitle":7782,"status":104,"phases":7783,"primaryCompletion":7784,"completion":7784,"start":7785,"enrollment":8,"conditions":7786,"interventions":7787},"NCT00119678","Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone",[88],"2008-11","2005-09",[792],[61,1507,61],{"nctId":7789,"briefTitle":7790,"status":104,"phases":7791,"primaryCompletion":4038,"completion":4038,"start":7751,"enrollment":7792,"conditions":7793,"interventions":7794},"NCT00162266","Abatacept With Methotrexate- Phase IIB",[88],524,[15],[61,61,61],{"nctId":7796,"briefTitle":7797,"status":104,"phases":7798,"primaryCompletion":7799,"completion":7799,"start":7800,"enrollment":1877,"conditions":7801,"interventions":7804},"NCT04186871","Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis",[88],"2022-12-05","2020-01-07",[7802,15,792,7803],"Autoimmune Disorder","Primary Sjögren's Syndrome",[7805,6972,7806],"branebrutinib","branebrutinib placebo",{"nctId":7808,"briefTitle":7809,"status":104,"phases":7810,"primaryCompletion":7742,"completion":7811,"start":7812,"enrollment":7813,"conditions":7814,"interventions":7816},"NCT00124449","Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients",[88],"2008-04","2005-02",56,[7815],"Arthritis, Rheumatoid",[61],{"trials":7818,"activeCount":208,"soonestReadout":60},[7819,7829,7836,7842,7850,7854,7858,7867,7871,7880,7884,7888,7894,7898,7905,7909,7919,7923,7931,7940,7948,7952,7962,7969,7973,7983,7991],{"nctId":7820,"briefTitle":7821,"status":104,"phases":7822,"primaryCompletion":6170,"completion":6170,"start":7812,"enrollment":7823,"conditions":7824,"interventions":7825},"NCT00095147","Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis",[89],431,[15],[61,7826,7827,7828],"Infliximab (INF) + MTX, DB","PLA + MTX switched to ABA+ MTX, DB","ABA, open-label",{"nctId":7830,"briefTitle":7831,"status":104,"phases":7832,"primaryCompletion":3678,"completion":3678,"start":6960,"enrollment":7833,"conditions":7834,"interventions":7835},"NCT00989235","Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis",[89],108,[15],[61,61],{"nctId":7837,"briefTitle":7838,"status":104,"phases":7839,"primaryCompletion":4122,"completion":4122,"start":3958,"enrollment":3862,"conditions":7840,"interventions":7841},"NCT01844895","Methotrexate-Inadequate Response Autoinjector Device Sub Study",[89],[15],[61],{"nctId":7843,"briefTitle":7844,"status":104,"phases":7845,"primaryCompletion":6918,"completion":6918,"start":7846,"enrollment":7847,"conditions":7848,"interventions":7849},"NCT00484289","A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis",[89],"2006-12",217,[15],[61],{"nctId":6913,"briefTitle":6914,"status":104,"phases":7851,"primaryCompletion":6916,"completion":6917,"start":6918,"enrollment":6919,"conditions":7852,"interventions":7853},[89],[15],[61,772,6922,6923],{"nctId":6925,"briefTitle":6926,"status":104,"phases":7855,"primaryCompletion":2977,"completion":6928,"start":6929,"enrollment":6930,"conditions":7856,"interventions":7857},[89],[15],[61,772],{"nctId":7859,"briefTitle":7860,"status":104,"phases":7861,"primaryCompletion":3873,"completion":3873,"start":7674,"enrollment":7862,"conditions":7863,"interventions":7864},"NCT00124982","Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy",[89],1286,[15],[61,7865,7866],"Non-biologic Disease Modifying Anti-Rheumatic Drug","Anti-Tumor Necrosing Factor (TNF) Therapy",{"nctId":58,"briefTitle":59,"status":179,"phases":7868,"primaryCompletion":60,"completion":6935,"start":6936,"enrollment":6937,"conditions":7869,"interventions":7870},[89],[15],[61,6940,772],{"nctId":7872,"briefTitle":7873,"status":104,"phases":7874,"primaryCompletion":7875,"completion":5088,"start":7876,"enrollment":1945,"conditions":7877,"interventions":7879},"NCT01844518","Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)",[89],"2015-03-12","2013-08-30",[7878],"Active Polyarticular Juvenile Idiopathic Arthritis",[61],{"nctId":7120,"briefTitle":7111,"status":963,"phases":7881,"primaryCompletion":3631,"completion":5850,"start":4664,"enrollment":7122,"conditions":7882,"interventions":7883},[88,89],[792],[7059,61,61,7070,61],{"nctId":7015,"briefTitle":7016,"status":104,"phases":7885,"primaryCompletion":5542,"completion":3893,"start":3678,"enrollment":7018,"conditions":7886,"interventions":7887},[89],[15],[61,6940],{"nctId":7889,"briefTitle":7890,"status":104,"phases":7891,"primaryCompletion":6953,"completion":4551,"start":7758,"enrollment":2253,"conditions":7892,"interventions":7893},"NCT00533897","Phase IIIB Subcutaneous Missed Dose Study",[89],[15],[61],{"nctId":6942,"briefTitle":6943,"status":104,"phases":7895,"primaryCompletion":3680,"completion":3587,"start":5078,"enrollment":6945,"conditions":7896,"interventions":7897},[89],[15],[61,6948],{"nctId":7899,"briefTitle":7900,"status":104,"phases":7901,"primaryCompletion":3712,"completion":3585,"start":7846,"enrollment":7902,"conditions":7903,"interventions":7904},"NCT00410410","A Study of Abatacept in Patients With Active Ulcerative Colitis",[89],591,[990],[6972,6972],{"nctId":6950,"briefTitle":6951,"status":104,"phases":7906,"primaryCompletion":5542,"completion":5542,"start":6953,"enrollment":515,"conditions":7907,"interventions":7908},[89],[15],[61,772],{"nctId":7910,"briefTitle":7911,"status":104,"phases":7912,"primaryCompletion":7913,"completion":7914,"start":7915,"enrollment":7916,"conditions":7917,"interventions":7918},"NCT01860976","Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis",[89],"2015-07-14","2020-06-30","2013-06-17",489,[770],[61],{"nctId":6957,"briefTitle":6958,"status":104,"phases":7920,"primaryCompletion":4039,"completion":3679,"start":6960,"enrollment":6961,"conditions":7921,"interventions":7922},[89],[15],[61,772,61,772],{"nctId":7924,"briefTitle":7925,"status":104,"phases":7926,"primaryCompletion":5014,"completion":7927,"start":5873,"enrollment":7928,"conditions":7929,"interventions":7930},"NCT00663702","Phase IIIB Switching From Intravenous to Subcutaneous Study",[89],"2012-01",123,[7815],[61],{"nctId":7932,"briefTitle":7933,"status":104,"phases":7934,"primaryCompletion":1013,"completion":7935,"start":7936,"enrollment":479,"conditions":7937,"interventions":7939},"NCT02915159","A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome",[89],"2019-07-23","2016-12-06",[7938],"Sjogrens Disease",[61],{"nctId":7941,"briefTitle":7942,"status":104,"phases":7943,"primaryCompletion":3873,"completion":7944,"start":7742,"enrollment":217,"conditions":7945,"interventions":7947},"NCT00420199","A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate",[89],"2010-05",[7946],"Active Rheumatoid Arthritis",[61],{"nctId":6965,"briefTitle":6966,"status":104,"phases":7949,"primaryCompletion":6953,"completion":4551,"start":6968,"enrollment":1877,"conditions":7950,"interventions":7951},[89],[6970],[6972,772],{"nctId":7953,"briefTitle":7954,"status":104,"phases":7955,"primaryCompletion":7956,"completion":7957,"start":7958,"enrollment":2038,"conditions":7959,"interventions":7961},"NCT01835470","Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan",[89],"2015-11-24","2018-07-30","2013-08-09",[7960],"Juvenile Idiopathic Arthritis",[61],{"nctId":7963,"briefTitle":7964,"status":963,"phases":7965,"primaryCompletion":3585,"completion":3585,"start":7846,"enrollment":7966,"conditions":7967,"interventions":7968},"NCT00406653","A Study of Abatacept in Patients With Active Crohn's Disease",[89],451,[1002],[6972,6972],{"nctId":6974,"briefTitle":6975,"status":104,"phases":7970,"primaryCompletion":3678,"completion":3678,"start":5051,"enrollment":6977,"conditions":7971,"interventions":7972},[89],[15],[61,772],{"nctId":7974,"briefTitle":7975,"status":467,"phases":7976,"primaryCompletion":7977,"completion":2279,"start":7978,"enrollment":98,"conditions":7979,"interventions":7981},"NCT03192969","A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)",[89],"2020-06-07","2017-07-15",[7980],"Giant Cell Arteritis",[61,7982],"Glucocorticoid Treatment",{"nctId":7984,"briefTitle":7985,"status":104,"phases":7986,"primaryCompletion":5117,"completion":3960,"start":3640,"enrollment":7987,"conditions":7988,"interventions":7990},"NCT00095173","BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis",[89],214,[7989],"Juvenile Rheumatoid Arthritis",[61,61],{"nctId":7992,"briefTitle":7993,"status":104,"phases":7994,"primaryCompletion":4038,"completion":4038,"start":5051,"enrollment":7995,"conditions":7996,"interventions":7997},"NCT00048581","Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.",[89],738,[15],[61,61],{"trials":7999,"activeCount":98},[8000,8004],{"nctId":6983,"briefTitle":6984,"status":104,"phases":8001,"primaryCompletion":6986,"completion":6986,"start":6987,"enrollment":3748,"conditions":8002,"interventions":8003},[90],[15],[61,772],{"nctId":6991,"briefTitle":6992,"status":104,"phases":8005,"primaryCompletion":6994,"completion":6994,"start":6995,"enrollment":1863,"conditions":8006,"interventions":8007},[90],[15],[61,6940,772],{"trials":8009,"activeCount":98},[8010,8019,8026,8034,8042],{"nctId":8011,"briefTitle":8012,"status":104,"phases":8013,"primaryCompletion":8014,"completion":8014,"start":8015,"enrollment":8016,"conditions":8017,"interventions":8018},"NCT02169544","Post-marketing Study Assessing the Long-Term Safety of Abatacept",[],"2017-02-28","2014-01-31",100000,[15],[61],{"nctId":8020,"briefTitle":8021,"status":104,"phases":8022,"primaryCompletion":1965,"completion":1965,"start":8023,"enrollment":3254,"conditions":8024,"interventions":8025},"NCT02037737","Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting",[],"2016-09-30",[15],[61],{"nctId":8027,"briefTitle":8028,"status":104,"phases":8029,"primaryCompletion":8030,"completion":8030,"start":5023,"enrollment":8031,"conditions":8032,"interventions":8033},"NCT02109666","Long Term Experience With Abatacept in Routine Clinical Practice",[],"2016-02",2364,[15],[61],{"nctId":8035,"briefTitle":8036,"status":104,"phases":8037,"primaryCompletion":8038,"completion":8038,"start":4347,"enrollment":8039,"conditions":8040,"interventions":8041},"NCT02598466","Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa",[],"2016-01",69,[15],[61],{"nctId":8043,"briefTitle":8044,"status":3014,"phases":8045,"conditions":8046,"interventions":8047},"NCT05170672","Expanded Access for Abatacept",[],[],[61],{"intervention":7057,"totalTrials":363,"cells":8049},{"EARLY_PHASE1":8050,"PHASE1":8052,"PHASE2":8070,"PHASE3":8106,"PHASE4":8116,"NA":8127},{"trials":8051,"activeCount":98},[],{"trials":8053,"activeCount":98},[8054,8062],{"nctId":8055,"briefTitle":8056,"status":104,"phases":8057,"primaryCompletion":7715,"completion":7715,"start":6968,"enrollment":3254,"conditions":8058,"interventions":8060},"NCT00569803","Subcutaneous Pharmacokinetics of Belatacept",[87],[8059],"Transplantation",[8061],"belatacept",{"nctId":8063,"briefTitle":8064,"status":104,"phases":8065,"primaryCompletion":8066,"completion":7659,"start":8067,"enrollment":116,"conditions":8068,"interventions":8069},"NCT03375138","A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes",[87],"2018-05-08","2017-12-04",[27],[8061],{"trials":8071,"activeCount":98},[8072,8076,8080,8084,8088,8094,8098],{"nctId":7721,"briefTitle":7722,"status":104,"phases":8073,"primaryCompletion":7724,"enrollment":4255,"conditions":8074,"interventions":8075},[87,88],[15],[7057,61],{"nctId":7048,"briefTitle":7049,"status":104,"phases":8077,"primaryCompletion":7051,"completion":7051,"start":7052,"enrollment":2308,"conditions":8078,"interventions":8079},[88],[7054],[7056,7057,7058,7059,2936,7060],{"nctId":7062,"briefTitle":7063,"status":104,"phases":8081,"primaryCompletion":3658,"completion":3902,"start":7065,"enrollment":1597,"conditions":8082,"interventions":8083},[88],[7067,7054,7068],[7057,893,7070,7059],{"nctId":7195,"briefTitle":7196,"status":104,"phases":8085,"primaryCompletion":3712,"completion":3630,"start":4931,"enrollment":7198,"conditions":8086,"interventions":8087},[88],[7200],[7057,7107,7060],{"nctId":8089,"briefTitle":8090,"status":104,"phases":8091,"primaryCompletion":4981,"completion":3616,"start":5023,"enrollment":363,"conditions":8092,"interventions":8093},"NCT00578448","Belatacept Pharmacokinetic Trial in Renal Transplantation",[88],[7068],[7057],{"nctId":7072,"briefTitle":7073,"status":104,"phases":8095,"primaryCompletion":6480,"completion":6479,"start":4010,"enrollment":7075,"conditions":8096,"interventions":8097},[88],[7077],[7056,7057,7079,7060,971],{"nctId":8099,"briefTitle":8100,"status":104,"phases":8101,"primaryCompletion":7936,"completion":7936,"start":8102,"enrollment":713,"conditions":8103,"interventions":8105},"NCT01791491","Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients",[88],"2013-05-09",[8104],"Kidney Transplant",[7057],{"trials":8107,"activeCount":208,"soonestReadout":7102},[8108,8112],{"nctId":7099,"briefTitle":7100,"status":236,"phases":8109,"primaryCompletion":7102,"completion":7103,"start":6245,"enrollment":1586,"conditions":8110,"interventions":8111},[89],[7105],[7057,7060,7107,971,7108,7059],{"nctId":7217,"briefTitle":7218,"status":104,"phases":8113,"primaryCompletion":7220,"completion":7220,"start":7221,"enrollment":7222,"conditions":8114,"interventions":8115},[89],[7054],[7057,7060,893],{"trials":8117,"activeCount":98},[8118],{"nctId":8119,"briefTitle":8120,"status":104,"phases":8121,"primaryCompletion":3958,"completion":3958,"start":3903,"enrollment":125,"conditions":8122,"interventions":8124},"NCT01766050","Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers",[90],[8123],"Transplant Rejection",[6530,8125,6533,8126,6534,7057],"Losartan","Dextromethorphan",{"trials":8128,"activeCount":98},[8129,8139],{"nctId":8130,"briefTitle":8131,"status":104,"phases":8132,"primaryCompletion":2837,"completion":2837,"start":8133,"enrollment":8134,"conditions":8135,"interventions":8137},"NCT01656343","Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients",[],"2011-10-31",775,[7054,8136],"Transplantation, Kidney",[8138,7057],"Calcineurin inhibitors",{"nctId":8140,"briefTitle":8141,"status":3014,"phases":8142,"conditions":8143,"interventions":8144},"NCT00719225","A Belatacept Compassionate Use Study for Patients With a Kidney Transplant",[],[7068],[7057],{"intervention":6788,"totalTrials":574,"cells":8146},{"EARLY_PHASE1":8147,"PHASE1":8149,"PHASE2":8159,"PHASE3":8161,"PHASE4":8167,"NA":8169},{"trials":8148,"activeCount":98},[],{"trials":8150,"activeCount":98},[8151],{"nctId":8152,"briefTitle":8153,"status":104,"phases":8154,"primaryCompletion":8155,"completion":8155,"start":8156,"enrollment":34,"conditions":8157,"interventions":8158},"NCT05899738","A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants",[87],"2023-07-06","2023-05-18",[27],[6788],{"trials":8160,"activeCount":98},[],{"trials":8162,"activeCount":208,"soonestReadout":6782},[8163],{"nctId":6779,"briefTitle":6780,"status":236,"phases":8164,"primaryCompletion":6782,"completion":6783,"start":6784,"enrollment":6785,"conditions":8165,"interventions":8166},[89],[33],[6788,441],{"trials":8168,"activeCount":98},[],{"trials":8170,"activeCount":98},[8171],{"nctId":8172,"briefTitle":8173,"status":6870,"phases":8174,"conditions":8175,"interventions":8176},"NCT07434960","Expanded Access for Iberdomide",[],[],[6788],{"intervention":6289,"totalTrials":574,"cells":8178},{"EARLY_PHASE1":8179,"PHASE1":8181,"PHASE2":8190,"PHASE3":8192,"PHASE4":8198,"NA":8200},{"trials":8180,"activeCount":98},[],{"trials":8182,"activeCount":98},[8183],{"nctId":8184,"briefTitle":8185,"status":104,"phases":8186,"primaryCompletion":8187,"completion":8187,"start":115,"enrollment":34,"conditions":8188,"interventions":8189},"NCT05707390","A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment",[87],"2023-09-13",[5603],[6289],{"trials":8191,"activeCount":98},[],{"trials":8193,"activeCount":208,"soonestReadout":6282},[8194],{"nctId":6279,"briefTitle":6280,"status":179,"phases":8195,"primaryCompletion":6282,"completion":6283,"start":6284,"enrollment":6285,"conditions":8196,"interventions":8197},[89],[6287],[6289,6290,1795],{"trials":8199,"activeCount":98},[],{"trials":8201,"activeCount":98},[8202],{"nctId":8203,"briefTitle":8204,"status":6870,"phases":8205,"conditions":8206,"interventions":8207},"NCT06994117","Expanded Access for Mezigdomide",[],[],[6289],{"intervention":406,"totalTrials":230,"cells":8209},{"EARLY_PHASE1":8210,"PHASE1":8212,"PHASE2":8214,"PHASE3":8216,"PHASE4":8222,"NA":8224},{"trials":8211,"activeCount":98},[],{"trials":8213,"activeCount":98},[],{"trials":8215,"activeCount":98},[],{"trials":8217,"activeCount":208,"soonestReadout":399},[8218],{"nctId":396,"briefTitle":397,"status":179,"phases":8219,"primaryCompletion":399,"completion":400,"start":401,"enrollment":402,"conditions":8220,"interventions":8221},[89],[404],[362,406],{"trials":8223,"activeCount":98},[],{"trials":8225,"activeCount":98},[8226],{"nctId":465,"briefTitle":466,"status":467,"phases":8227,"primaryCompletion":469,"completion":469,"start":470,"enrollment":98,"conditions":8228,"interventions":8229},[],[472],[362,406],{"intervention":8231,"totalTrials":520,"cells":8232},"BMS-986435",{"EARLY_PHASE1":8233,"PHASE1":8235,"PHASE2":8267,"PHASE3":8279,"PHASE4":8281,"NA":8283},{"trials":8234,"activeCount":98},[],{"trials":8236,"activeCount":230,"soonestReadout":8241},[8237,8245,8252,8259],{"nctId":8238,"briefTitle":8239,"status":642,"phases":8240,"primaryCompletion":8241,"completion":8241,"start":8242,"enrollment":1203,"conditions":8243,"interventions":8244},"NCT07248839","A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment",[87],"2026-04-06","2025-12-15",[27,5603],[8231],{"nctId":8246,"briefTitle":8247,"status":236,"phases":8248,"primaryCompletion":8249,"completion":8249,"start":1584,"enrollment":848,"conditions":8250,"interventions":8251},"NCT07226817","A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants",[87],"2026-07-01",[27],[8231],{"nctId":8253,"briefTitle":8254,"status":104,"phases":8255,"primaryCompletion":2335,"completion":2335,"start":8256,"enrollment":94,"conditions":8257,"interventions":8258},"NCT06577259","Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants",[87],"2024-09-03",[18],[8231],{"nctId":8260,"briefTitle":8261,"status":104,"phases":8262,"primaryCompletion":8263,"completion":8263,"start":8264,"enrollment":319,"conditions":8265,"interventions":8266},"NCT06476821","A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of Single Doses of BMS-986435 (MYK-224) in Healthy Chinese Participants",[87],"2024-10-11","2024-06-27",[27],[8231],{"trials":8268,"activeCount":208,"soonestReadout":8273},[8269],{"nctId":8270,"briefTitle":8271,"status":236,"phases":8272,"primaryCompletion":8273,"completion":8273,"start":8274,"enrollment":8275,"conditions":8276,"interventions":8278},"NCT06122779","Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435\u002FMYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)",[88],"2026-07-03","2023-11-07",208,[8277],"Heart Failure",[8231],{"trials":8280,"activeCount":98},[],{"trials":8282,"activeCount":98},[],{"trials":8284,"activeCount":98},[],{"intervention":70,"totalTrials":4328,"cells":8286},{"EARLY_PHASE1":8287,"PHASE1":8289,"PHASE2":8300,"PHASE3":8319,"PHASE4":8321,"NA":8323},{"trials":8288,"activeCount":98},[],{"trials":8290,"activeCount":98},[8291],{"nctId":8292,"briefTitle":8293,"status":104,"phases":8294,"primaryCompletion":8295,"completion":8296,"start":8297,"enrollment":2308,"conditions":8298,"interventions":8299},"NCT05051553","A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants",[87],"2021-12-23","2022-04-08","2021-09-21",[27],[70],{"trials":8301,"activeCount":230,"soonestReadout":69},[8302,8308],{"nctId":67,"briefTitle":68,"status":179,"phases":8303,"primaryCompletion":69,"completion":269,"start":8304,"enrollment":4124,"conditions":8305,"interventions":8307},[87,88],"2020-10-12",[8306],"Primary Myelofibrosis",[70],{"nctId":8309,"briefTitle":8310,"status":179,"phases":8311,"primaryCompletion":8312,"completion":8312,"start":8313,"enrollment":8314,"conditions":8315,"interventions":8317},"NCT04817007","A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)",[87,88],"2028-08-31","2021-03-22",216,[8316],"Myelofibrosis",[1453,8318,70],"Ruxolitinib",{"trials":8320,"activeCount":98},[],{"trials":8322,"activeCount":98},[],{"trials":8324,"activeCount":208,"soonestReadout":8329},[8325],{"nctId":8326,"briefTitle":8327,"status":236,"phases":8328,"primaryCompletion":8329,"completion":8329,"start":8330,"enrollment":8331,"conditions":8332,"interventions":8335},"NCT06073847","A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis",[],"2027-12-20","2023-06-13",137,[8306,8333,8334],"Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis",[70],{"intervention":613,"totalTrials":4328,"cells":8337},{"EARLY_PHASE1":8338,"PHASE1":8340,"PHASE2":8342,"PHASE3":8352,"PHASE4":8362,"NA":8364},{"trials":8339,"activeCount":98},[],{"trials":8341,"activeCount":98},[],{"trials":8343,"activeCount":230,"soonestReadout":602},[8344,8348],{"nctId":599,"briefTitle":600,"status":236,"phases":8345,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":8346,"interventions":8347},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"nctId":3693,"briefTitle":3694,"status":642,"phases":8349,"primaryCompletion":3696,"completion":3696,"start":3697,"enrollment":3093,"conditions":8350,"interventions":8351},[88],[1515],[3700,3701,3702,613,1721,622,1157,1225,1267,1158],{"trials":8353,"activeCount":98},[8354,8358],{"nctId":2501,"briefTitle":2502,"status":104,"phases":8355,"primaryCompletion":2504,"completion":2505,"start":2506,"enrollment":2507,"conditions":8356,"interventions":8357},[89],[2509],[43,613],{"nctId":2866,"briefTitle":2867,"status":104,"phases":8359,"primaryCompletion":2869,"completion":2870,"start":1413,"enrollment":2871,"conditions":8360,"interventions":8361},[89],[2873],[43,613],{"trials":8363,"activeCount":98},[],{"trials":8365,"activeCount":98},[],{"intervention":1453,"totalTrials":574,"cells":8367},{"EARLY_PHASE1":8368,"PHASE1":8370,"PHASE2":8372,"PHASE3":8386,"PHASE4":8388,"NA":8390},{"trials":8369,"activeCount":98},[],{"trials":8371,"activeCount":98},[],{"trials":8373,"activeCount":230,"soonestReadout":6253},[8374,8378,8382],{"nctId":1444,"briefTitle":1445,"status":104,"phases":8375,"primaryCompletion":1447,"completion":1447,"start":1448,"enrollment":1449,"conditions":8376,"interventions":8377},[87,88],[1451],[1453,43],{"nctId":8309,"briefTitle":8310,"status":179,"phases":8379,"primaryCompletion":8312,"completion":8312,"start":8313,"enrollment":8314,"conditions":8380,"interventions":8381},[87,88],[8316],[1453,8318,70],{"nctId":6250,"briefTitle":6251,"status":236,"phases":8383,"primaryCompletion":6253,"completion":6253,"start":6254,"enrollment":3093,"conditions":8384,"interventions":8385},[87,88],[33],[6257,6258,1453,610,1795],{"trials":8387,"activeCount":98},[],{"trials":8389,"activeCount":98},[],{"trials":8391,"activeCount":98},[],{"intervention":610,"totalTrials":574,"cells":8393},{"EARLY_PHASE1":8394,"PHASE1":8396,"PHASE2":8398,"PHASE3":8412,"PHASE4":8414,"NA":8416},{"trials":8395,"activeCount":98},[],{"trials":8397,"activeCount":98},[],{"trials":8399,"activeCount":230,"soonestReadout":6253},[8400,8404,8408],{"nctId":599,"briefTitle":600,"status":236,"phases":8401,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":8402,"interventions":8403},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"nctId":1961,"briefTitle":1962,"status":104,"phases":8405,"primaryCompletion":1964,"completion":1964,"start":1965,"enrollment":1966,"conditions":8406,"interventions":8407},[87,88],[1673,1968,1969,1970],[43,610,608,1949],{"nctId":6250,"briefTitle":6251,"status":236,"phases":8409,"primaryCompletion":6253,"completion":6253,"start":6254,"enrollment":3093,"conditions":8410,"interventions":8411},[87,88],[33],[6257,6258,1453,610,1795],{"trials":8413,"activeCount":98},[],{"trials":8415,"activeCount":98},[],{"trials":8417,"activeCount":98},[],{"intervention":696,"totalTrials":713,"cells":8419},{"EARLY_PHASE1":8420,"PHASE1":8422,"PHASE2":8522,"PHASE3":8536,"PHASE4":8538,"NA":8550},{"trials":8421,"activeCount":98},[],{"trials":8423,"activeCount":98},[8424,8432,8436,8440,8451,8455,8459,8467,8476,8480,8490,8494,8503,8513],{"nctId":8425,"briefTitle":8426,"status":104,"phases":8427,"primaryCompletion":8428,"completion":8428,"start":8429,"enrollment":3978,"conditions":8430,"interventions":8431},"NCT04941755","A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants",[87],"2021-09-24","2021-06-25",[18],[7044,696],{"nctId":687,"briefTitle":688,"status":104,"phases":8433,"primaryCompletion":690,"completion":691,"start":692,"enrollment":693,"conditions":8434,"interventions":8435},[87],[18],[679,696],{"nctId":7372,"briefTitle":7373,"status":104,"phases":8437,"primaryCompletion":4151,"completion":4151,"start":7375,"enrollment":7376,"conditions":8438,"interventions":8439},[87],[749],[7379,852,696,3287],{"nctId":8441,"briefTitle":8442,"status":104,"phases":8443,"primaryCompletion":8444,"completion":8444,"start":8445,"enrollment":736,"conditions":8446,"interventions":8448},"NCT03142165","A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants",[87],"2017-11-29","2017-05-11",[8447],"Fibrosis",[8449,8450,696],"BMS-986263","Diphenhydramine",{"nctId":730,"briefTitle":731,"status":104,"phases":8452,"primaryCompletion":733,"completion":734,"start":735,"enrollment":736,"conditions":8453,"interventions":8454},[87],[738],[740,679,696],{"nctId":3150,"briefTitle":3151,"status":104,"phases":8456,"primaryCompletion":3153,"completion":3153,"start":3154,"enrollment":451,"conditions":8457,"interventions":8458},[87],[18],[79,696],{"nctId":8460,"briefTitle":8461,"status":104,"phases":8462,"primaryCompletion":819,"completion":819,"start":8463,"enrollment":2527,"conditions":8464,"interventions":8465},"NCT04550195","A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants",[87],"2020-09-17",[27],[8466,696],"BMS-986337",{"nctId":8468,"briefTitle":8469,"status":104,"phases":8470,"primaryCompletion":3220,"completion":3220,"start":8471,"enrollment":8472,"conditions":8473,"interventions":8474},"NCT04175925","A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants",[87],"2019-11-15",171,[18],[6519,8475],"famotidine",{"nctId":843,"briefTitle":844,"status":104,"phases":8477,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":8478,"interventions":8479},[87],[850],[679,852,696],{"nctId":8481,"briefTitle":8482,"status":104,"phases":8483,"primaryCompletion":8484,"completion":8484,"start":8485,"enrollment":7813,"conditions":8486,"interventions":8487},"NCT04536961","A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants",[87],"2020-12-25","2020-09-10",[27],[8488,8489,696],"Reference Treatment- BMS-986165-01","Prototype BMS-986165",{"nctId":3166,"briefTitle":3167,"status":104,"phases":8491,"primaryCompletion":3137,"completion":3137,"start":3169,"enrollment":2527,"conditions":8492,"interventions":8493},[87],[18],[79,696],{"nctId":8495,"briefTitle":8496,"status":104,"phases":8497,"primaryCompletion":8498,"completion":8499,"start":8500,"enrollment":1063,"conditions":8501,"interventions":8502},"NCT04470778","Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants",[87],"2021-03-21","2021-03-28","2020-07-20",[18],[7044,696],{"nctId":8504,"briefTitle":8505,"status":963,"phases":8506,"primaryCompletion":2628,"completion":2628,"start":8507,"enrollment":8508,"conditions":8509,"interventions":8510},"NCT06144697","A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants",[87],"2024-01-29",267,[18],[8511,8512,696],"BMS-986465","Pegasys",{"nctId":8514,"briefTitle":8515,"status":104,"phases":8516,"primaryCompletion":8517,"completion":8517,"start":8518,"enrollment":34,"conditions":8519,"interventions":8520},"NCT05866627","A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants",[87],"2023-09-29","2023-07-04",[27],[696,8521],"Afimetoran",{"trials":8523,"activeCount":208,"soonestReadout":8528},[8524],{"nctId":8525,"briefTitle":8526,"status":236,"phases":8527,"primaryCompletion":8528,"completion":8529,"start":8530,"enrollment":8531,"conditions":8532,"interventions":8534},"NCT06481306","A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease",[87,88],"2027-01-06","2027-11-16","2024-07-17",184,[8533,27],"Anemia, Sickle Cell",[8535,696],"BMS-986470",{"trials":8537,"activeCount":98},[],{"trials":8539,"activeCount":98},[8540],{"nctId":8541,"briefTitle":8542,"status":104,"phases":8543,"primaryCompletion":7089,"completion":7089,"start":3938,"enrollment":94,"conditions":8544,"interventions":8546},"NCT01232127","Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection",[90],[8545],"HIV",[8547,8547,902,902,8548,8548,8549,8549,696,696],"Atazanavir","Tenofovir","Nucleoside Reverse Transcriptase Inhibitor",{"trials":8551,"activeCount":98},[],{"intervention":615,"totalTrials":520,"cells":8553},{"EARLY_PHASE1":8554,"PHASE1":8556,"PHASE2":8558,"PHASE3":8580,"PHASE4":8582,"NA":8584},{"trials":8555,"activeCount":98},[],{"trials":8557,"activeCount":98},[],{"trials":8559,"activeCount":208,"soonestReadout":602},[8560,8564,8568,8572,8576],{"nctId":599,"briefTitle":600,"status":236,"phases":8561,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":8562,"interventions":8563},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"nctId":1755,"briefTitle":1756,"status":104,"phases":8565,"primaryCompletion":203,"completion":203,"start":1758,"enrollment":1759,"conditions":8566,"interventions":8567},[87,88],[1154],[43,615],{"nctId":1818,"briefTitle":1819,"status":104,"phases":8569,"primaryCompletion":1821,"completion":1211,"start":1822,"enrollment":1823,"conditions":8570,"interventions":8571},[87,88],[1825,1826,33],[43,608,1187,615,1797,1795],{"nctId":1849,"briefTitle":1850,"status":104,"phases":8573,"primaryCompletion":1852,"completion":1853,"start":1854,"enrollment":1855,"conditions":8574,"interventions":8575},[87,88],[1636],[43,608,52,615],{"nctId":2079,"briefTitle":2080,"status":104,"phases":8577,"primaryCompletion":2082,"completion":2082,"start":2083,"enrollment":2084,"conditions":8578,"interventions":8579},[88],[2086,2087,2088,2089],[608,43,1474,615,2091],{"trials":8581,"activeCount":98},[],{"trials":8583,"activeCount":98},[],{"trials":8585,"activeCount":98},[],{"intervention":8587,"totalTrials":574,"cells":8588},"BMS-986369",{"EARLY_PHASE1":8589,"PHASE1":8591,"PHASE2":8608,"PHASE3":8620,"PHASE4":8622,"NA":8624},{"trials":8590,"activeCount":98},[],{"trials":8592,"activeCount":98},[8593,8601],{"nctId":8594,"briefTitle":8595,"status":104,"phases":8596,"primaryCompletion":8597,"completion":8597,"start":8598,"enrollment":25,"conditions":8599,"interventions":8600},"NCT05350800","A Study to Evaluate the Drug Exposure of Single Ascending Doses of BMS-986369 and the Effect of Food on the BMS-986369 in Healthy Participants",[87],"2023-05-04","2022-09-12",[928],[8587],{"nctId":8602,"briefTitle":8603,"status":104,"phases":8604,"primaryCompletion":1843,"completion":1843,"start":8605,"enrollment":839,"conditions":8606,"interventions":8607},"NCT05567510","A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants",[87],"2022-10-20",[18],[8587],{"trials":8609,"activeCount":208,"soonestReadout":8614},[8610],{"nctId":8611,"briefTitle":8612,"status":179,"phases":8613,"primaryCompletion":8614,"completion":8615,"start":8616,"enrollment":424,"conditions":8617,"interventions":8619},"NCT06035497","A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)",[87,88],"2027-01-30","2030-10-10","2023-11-20",[8618],"Relapsed or Refractory T-cell Lymphomas",[8587],{"trials":8621,"activeCount":98},[],{"trials":8623,"activeCount":98},[],{"trials":8625,"activeCount":98},[],{"intervention":614,"totalTrials":574,"cells":8627},{"EARLY_PHASE1":8628,"PHASE1":8630,"PHASE2":8632,"PHASE3":8646,"PHASE4":8648,"NA":8650},{"trials":8629,"activeCount":98},[],{"trials":8631,"activeCount":98},[],{"trials":8633,"activeCount":208,"soonestReadout":602},[8634,8638,8642],{"nctId":599,"briefTitle":600,"status":236,"phases":8635,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":8636,"interventions":8637},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"nctId":1973,"briefTitle":1974,"status":104,"phases":8639,"primaryCompletion":1976,"completion":1977,"start":788,"enrollment":1978,"conditions":8640,"interventions":8641},[88],[1504],[1123,1981,1982,1983,1984],{"nctId":2322,"briefTitle":2323,"status":104,"phases":8643,"primaryCompletion":2325,"completion":2325,"start":2326,"enrollment":2327,"conditions":8644,"interventions":8645},[88],[2329],[43,608,52,1337,614],{"trials":8647,"activeCount":98},[],{"trials":8649,"activeCount":98},[],{"trials":8651,"activeCount":98},[],{"intervention":8521,"totalTrials":574,"cells":8653},{"EARLY_PHASE1":8654,"PHASE1":8656,"PHASE2":8671,"PHASE3":8682,"PHASE4":8684,"NA":8686},{"trials":8655,"activeCount":98},[],{"trials":8657,"activeCount":98},[8658,8667],{"nctId":8659,"briefTitle":8660,"status":104,"phases":8661,"primaryCompletion":8662,"completion":8662,"start":60,"enrollment":8663,"conditions":8664,"interventions":8665},"NCT05901714","A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam",[87],"2024-04-11",65,[18],[8521,8666,6534],"Phenytoin",{"nctId":8514,"briefTitle":8515,"status":104,"phases":8668,"primaryCompletion":8517,"completion":8517,"start":8518,"enrollment":34,"conditions":8669,"interventions":8670},[87],[27],[696,8521],{"trials":8672,"activeCount":208,"soonestReadout":8677},[8673],{"nctId":8674,"briefTitle":8675,"status":179,"phases":8676,"primaryCompletion":8677,"completion":8678,"start":8679,"enrollment":947,"conditions":8680,"interventions":8681},"NCT04895696","A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)",[88],"2026-06-18","2029-04-22","2021-10-11",[792],[8521],{"trials":8683,"activeCount":98},[],{"trials":8685,"activeCount":98},[],{"trials":8687,"activeCount":98},[],{"intervention":8689,"totalTrials":230,"cells":8690},"Rituximab",{"EARLY_PHASE1":8691,"PHASE1":8693,"PHASE2":8703,"PHASE3":8719,"PHASE4":8721,"NA":8723},{"trials":8692,"activeCount":98},[],{"trials":8694,"activeCount":98},[8695],{"nctId":8696,"briefTitle":8697,"status":104,"phases":8698,"primaryCompletion":8699,"completion":8699,"start":4123,"enrollment":31,"conditions":8700,"interventions":8702},"NCT01775631","Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma",[87],"2016-08",[8701],"B-Cell Malignancies",[1111,8689],{"trials":8704,"activeCount":208,"soonestReadout":8709},[8705],{"nctId":8706,"briefTitle":8707,"status":236,"phases":8708,"primaryCompletion":8709,"completion":8710,"start":8711,"enrollment":8712,"conditions":8713,"interventions":8715},"NCT06090539","A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed\u002FRefractory Non-Hodgkin Lymphomas",[87,88],"2027-10-28","2028-10-28","2023-12-29",308,[8714],"Relapsed\u002FRefractory Non-Hodgkin Lymphoma",[8716,8689,8717,8718],"BMS-986458","Glofitamab\u002FObinutuzumab","Mosunetuzumab",{"trials":8720,"activeCount":98},[],{"trials":8722,"activeCount":98},[],{"trials":8724,"activeCount":98},[],{"intervention":8726,"totalTrials":230,"cells":8727},"BMS-986446",{"EARLY_PHASE1":8728,"PHASE1":8730,"PHASE2":8740,"PHASE3":8752,"PHASE4":8754,"NA":8756},{"trials":8729,"activeCount":98},[],{"trials":8731,"activeCount":98},[8732],{"nctId":8733,"briefTitle":8734,"status":104,"phases":8735,"primaryCompletion":8736,"completion":8736,"start":8737,"enrollment":1203,"conditions":8738,"interventions":8739},"NCT06084598","A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity",[87],"2024-03-08","2023-10-12",[18],[8726],{"trials":8741,"activeCount":208,"soonestReadout":8746},[8742],{"nctId":8743,"briefTitle":8744,"status":179,"phases":8745,"primaryCompletion":8746,"completion":8746,"start":8747,"enrollment":8748,"conditions":8749,"interventions":8751},"NCT06268886","Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease",[88],"2027-03-18","2024-03-20",310,[8750],"Alzheimer Disease, Early Onset",[8726],{"trials":8753,"activeCount":98},[],{"trials":8755,"activeCount":98},[],{"trials":8757,"activeCount":98},[],{"intervention":620,"totalTrials":230,"cells":8759},{"EARLY_PHASE1":8760,"PHASE1":8762,"PHASE2":8764,"PHASE3":8774,"PHASE4":8776,"NA":8778},{"trials":8761,"activeCount":98},[],{"trials":8763,"activeCount":98},[],{"trials":8765,"activeCount":208,"soonestReadout":602},[8766,8770],{"nctId":599,"briefTitle":600,"status":236,"phases":8767,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":8768,"interventions":8769},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"nctId":1973,"briefTitle":1974,"status":104,"phases":8771,"primaryCompletion":1976,"completion":1977,"start":788,"enrollment":1978,"conditions":8772,"interventions":8773},[88],[1504],[1123,1981,1982,1983,1984],{"trials":8775,"activeCount":98},[],{"trials":8777,"activeCount":98},[],{"trials":8779,"activeCount":98},[],{"intervention":6257,"totalTrials":230,"cells":8781},{"EARLY_PHASE1":8782,"PHASE1":8784,"PHASE2":8794,"PHASE3":8800,"PHASE4":8802,"NA":8804},{"trials":8783,"activeCount":98},[],{"trials":8785,"activeCount":98},[8786],{"nctId":8787,"briefTitle":8788,"status":104,"phases":8789,"primaryCompletion":8790,"completion":8790,"start":8791,"enrollment":1203,"conditions":8792,"interventions":8793},"NCT05389722","A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants",[87],"2022-11-12","2022-06-09",[27],[6257,5658,5584,6535,874],{"trials":8795,"activeCount":208,"soonestReadout":6253},[8796],{"nctId":6250,"briefTitle":6251,"status":236,"phases":8797,"primaryCompletion":6253,"completion":6253,"start":6254,"enrollment":3093,"conditions":8798,"interventions":8799},[87,88],[33],[6257,6258,1453,610,1795],{"trials":8801,"activeCount":98},[],{"trials":8803,"activeCount":98},[],{"trials":8805,"activeCount":98},[],{"intervention":6431,"totalTrials":208,"cells":8807},{"EARLY_PHASE1":8808,"PHASE1":8810,"PHASE2":8812,"PHASE3":8818,"PHASE4":8820,"NA":8822},{"trials":8809,"activeCount":98},[],{"trials":8811,"activeCount":98},[],{"trials":8813,"activeCount":208,"soonestReadout":6420},[8814],{"nctId":6417,"briefTitle":6418,"status":236,"phases":8815,"primaryCompletion":6420,"completion":6420,"start":6421,"enrollment":6422,"conditions":8816,"interventions":8817},[87,88],[6424,6425,2087,1783,6426,2679,2182,6427,21,6428,6429],[6431,6432,1328],{"trials":8819,"activeCount":98},[],{"trials":8821,"activeCount":98},[],{"trials":8823,"activeCount":98},[],{"intervention":6432,"totalTrials":208,"cells":8825},{"EARLY_PHASE1":8826,"PHASE1":8828,"PHASE2":8830,"PHASE3":8836,"PHASE4":8838,"NA":8840},{"trials":8827,"activeCount":98},[],{"trials":8829,"activeCount":98},[],{"trials":8831,"activeCount":208,"soonestReadout":6420},[8832],{"nctId":6417,"briefTitle":6418,"status":236,"phases":8833,"primaryCompletion":6420,"completion":6420,"start":6421,"enrollment":6422,"conditions":8834,"interventions":8835},[87,88],[6424,6425,2087,1783,6426,2679,2182,6427,21,6428,6429],[6431,6432,1328],{"trials":8837,"activeCount":98},[],{"trials":8839,"activeCount":98},[],{"trials":8841,"activeCount":98},[],{"intervention":8843,"totalTrials":208,"cells":8844},"CC-486",{"EARLY_PHASE1":8845,"PHASE1":8847,"PHASE2":8849,"PHASE3":8859,"PHASE4":8861,"NA":8863},{"trials":8846,"activeCount":98},[],{"trials":8848,"activeCount":98},[],{"trials":8850,"activeCount":208,"soonestReadout":8855},[8851],{"nctId":8852,"briefTitle":8853,"status":179,"phases":8854,"primaryCompletion":8855,"completion":6150,"start":106,"enrollment":4932,"conditions":8856,"interventions":8858},"NCT05413018","An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission",[88],"2025-10-31",[8857],"Leukemia, Myeloid, Acute",[8843],{"trials":8860,"activeCount":98},[],{"trials":8862,"activeCount":98},[],{"trials":8864,"activeCount":98},[],{"intervention":1462,"totalTrials":208,"cells":8866},{"EARLY_PHASE1":8867,"PHASE1":8869,"PHASE2":8871,"PHASE3":8877,"PHASE4":8879,"NA":8881},{"trials":8868,"activeCount":98},[],{"trials":8870,"activeCount":98},[],{"trials":8872,"activeCount":208,"soonestReadout":1458},[8873],{"nctId":1455,"briefTitle":1456,"status":179,"phases":8874,"primaryCompletion":1458,"completion":1458,"start":1459,"enrollment":660,"conditions":8875,"interventions":8876},[87,88],[1132],[1462,43],{"trials":8878,"activeCount":98},[],{"trials":8880,"activeCount":98},[],{"trials":8882,"activeCount":98},[],{"intervention":8884,"totalTrials":208,"cells":8885},"BMS-986528",{"EARLY_PHASE1":8886,"PHASE1":8888,"PHASE2":8890,"PHASE3":8901,"PHASE4":8903,"NA":8905},{"trials":8887,"activeCount":98},[],{"trials":8889,"activeCount":98},[],{"trials":8891,"activeCount":208,"soonestReadout":8896},[8892],{"nctId":8893,"briefTitle":8894,"status":642,"phases":8895,"primaryCompletion":8896,"completion":8897,"start":8898,"enrollment":116,"conditions":8899,"interventions":8900},"NCT07412704","A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis",[87,88],"2029-10-30","2030-09-02","2026-05-28",[7815],[8884],{"trials":8902,"activeCount":98},[],{"trials":8904,"activeCount":98},[],{"trials":8906,"activeCount":98},[],{"intervention":616,"totalTrials":208,"cells":8908},{"EARLY_PHASE1":8909,"PHASE1":8911,"PHASE2":8913,"PHASE3":8919,"PHASE4":8921,"NA":8923},{"trials":8910,"activeCount":98},[],{"trials":8912,"activeCount":98},[],{"trials":8914,"activeCount":208,"soonestReadout":602},[8915],{"nctId":599,"briefTitle":600,"status":236,"phases":8916,"primaryCompletion":602,"completion":602,"start":603,"enrollment":604,"conditions":8917,"interventions":8918},[88],[606],[43,608,609,610,52,590,611,612,613,614,615,616,617,618,619,620,621,622,623],{"trials":8920,"activeCount":98},[],{"trials":8922,"activeCount":98},[],{"trials":8924,"activeCount":98},[],{"intervention":1719,"totalTrials":208,"cells":8926},{"EARLY_PHASE1":8927,"PHASE1":8929,"PHASE2":8931,"PHASE3":8937,"PHASE4":8939,"NA":8941},{"trials":8928,"activeCount":98},[],{"trials":8930,"activeCount":98},[],{"trials":8932,"activeCount":208,"soonestReadout":1713},[8933],{"nctId":1710,"briefTitle":1711,"status":236,"phases":8934,"primaryCompletion":1713,"completion":1713,"start":1714,"enrollment":1715,"conditions":8935,"interventions":8936},[87,88],[1717,1223],[1719,1720,623,43,1721],{"trials":8938,"activeCount":98},[],{"trials":8940,"activeCount":98},[],{"trials":8942,"activeCount":98},[],{"intervention":1720,"totalTrials":208,"cells":8944},{"EARLY_PHASE1":8945,"PHASE1":8947,"PHASE2":8949,"PHASE3":8955,"PHASE4":8957,"NA":8959},{"trials":8946,"activeCount":98},[],{"trials":8948,"activeCount":98},[],{"trials":8950,"activeCount":208,"soonestReadout":1713},[8951],{"nctId":1710,"briefTitle":1711,"status":236,"phases":8952,"primaryCompletion":1713,"completion":1713,"start":1714,"enrollment":1715,"conditions":8953,"interventions":8954},[87,88],[1717,1223],[1719,1720,623,43,1721],{"trials":8956,"activeCount":98},[],{"trials":8958,"activeCount":98},[],{"trials":8960,"activeCount":98},[],{"intervention":1733,"totalTrials":208,"cells":8962},{"EARLY_PHASE1":8963,"PHASE1":8965,"PHASE2":8967,"PHASE3":8973,"PHASE4":8975,"NA":8977},{"trials":8964,"activeCount":98},[],{"trials":8966,"activeCount":98},[],{"trials":8968,"activeCount":208,"soonestReadout":1726},[8969],{"nctId":1723,"briefTitle":1724,"status":236,"phases":8970,"primaryCompletion":1726,"completion":1727,"start":1728,"enrollment":1729,"conditions":8971,"interventions":8972},[87,88],[1731],[1733,43],{"trials":8974,"activeCount":98},[],{"trials":8976,"activeCount":98},[],{"trials":8978,"activeCount":98},[],{"intervention":4878,"totalTrials":208,"cells":8980},{"EARLY_PHASE1":8981,"PHASE1":8983,"PHASE2":8985,"PHASE3":8991,"PHASE4":8993,"NA":8995},{"trials":8982,"activeCount":98},[],{"trials":8984,"activeCount":98},[],{"trials":8986,"activeCount":208,"soonestReadout":4871},[8987],{"nctId":4868,"briefTitle":4869,"status":236,"phases":8988,"primaryCompletion":4871,"completion":4871,"start":181,"enrollment":4872,"conditions":8989,"interventions":8990},[87,88],[4874,3131,4875,4876],[4878,1267,1527,1145,623],{"trials":8992,"activeCount":98},[],{"trials":8994,"activeCount":98},[],{"trials":8996,"activeCount":98},[],{"intervention":5517,"totalTrials":208,"cells":8998},{"EARLY_PHASE1":8999,"PHASE1":9001,"PHASE2":9003,"PHASE3":9009,"PHASE4":9011,"NA":9013},{"trials":9000,"activeCount":98},[],{"trials":9002,"activeCount":98},[],{"trials":9004,"activeCount":208,"soonestReadout":5511},[9005],{"nctId":5508,"briefTitle":5509,"status":236,"phases":9006,"primaryCompletion":5511,"completion":5512,"start":5513,"enrollment":5514,"conditions":9007,"interventions":9008},[87,88],[1132],[5517,2774,5518,612],{"trials":9010,"activeCount":98},[],{"trials":9012,"activeCount":98},[],{"trials":9014,"activeCount":98},[],{"intervention":5518,"totalTrials":208,"cells":9016},{"EARLY_PHASE1":9017,"PHASE1":9019,"PHASE2":9021,"PHASE3":9027,"PHASE4":9029,"NA":9031},{"trials":9018,"activeCount":98},[],{"trials":9020,"activeCount":98},[],{"trials":9022,"activeCount":208,"soonestReadout":5511},[9023],{"nctId":5508,"briefTitle":5509,"status":236,"phases":9024,"primaryCompletion":5511,"completion":5512,"start":5513,"enrollment":5514,"conditions":9025,"interventions":9026},[87,88],[1132],[5517,2774,5518,612],{"trials":9028,"activeCount":98},[],{"trials":9030,"activeCount":98},[],{"trials":9032,"activeCount":98},[],{"intervention":8318,"totalTrials":208,"cells":9034},{"EARLY_PHASE1":9035,"PHASE1":9037,"PHASE2":9039,"PHASE3":9045,"PHASE4":9047,"NA":9049},{"trials":9036,"activeCount":98},[],{"trials":9038,"activeCount":98},[],{"trials":9040,"activeCount":208,"soonestReadout":8312},[9041],{"nctId":8309,"briefTitle":8310,"status":179,"phases":9042,"primaryCompletion":8312,"completion":8312,"start":8313,"enrollment":8314,"conditions":9043,"interventions":9044},[87,88],[8316],[1453,8318,70],{"trials":9046,"activeCount":98},[],{"trials":9048,"activeCount":98},[],{"trials":9050,"activeCount":98},[],{"intervention":8535,"totalTrials":208,"cells":9052},{"EARLY_PHASE1":9053,"PHASE1":9055,"PHASE2":9057,"PHASE3":9063,"PHASE4":9065,"NA":9067},{"trials":9054,"activeCount":98},[],{"trials":9056,"activeCount":98},[],{"trials":9058,"activeCount":208,"soonestReadout":8528},[9059],{"nctId":8525,"briefTitle":8526,"status":236,"phases":9060,"primaryCompletion":8528,"completion":8529,"start":8530,"enrollment":8531,"conditions":9061,"interventions":9062},[87,88],[8533,27],[8535,696],{"trials":9064,"activeCount":98},[],{"trials":9066,"activeCount":98},[],{"trials":9068,"activeCount":98},[],{"intervention":9070,"totalTrials":208,"cells":9071},"BMS-986517",{"EARLY_PHASE1":9072,"PHASE1":9074,"PHASE2":9076,"PHASE3":9087,"PHASE4":9089,"NA":9091},{"trials":9073,"activeCount":98},[],{"trials":9075,"activeCount":98},[],{"trials":9077,"activeCount":208,"soonestReadout":6374},[9078],{"nctId":9079,"briefTitle":9080,"status":236,"phases":9081,"primaryCompletion":6374,"completion":9082,"start":5285,"enrollment":9083,"conditions":9084,"interventions":9086},"NCT07160725","A Phase 1\u002F2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors",[87,88],"2028-08-01",315,[9085],"Solid Tumours",[9070],{"trials":9088,"activeCount":98},[],{"trials":9090,"activeCount":98},[],{"trials":9092,"activeCount":98},[],{"intervention":3701,"totalTrials":208,"cells":9094},{"EARLY_PHASE1":9095,"PHASE1":9097,"PHASE2":9099,"PHASE3":9105,"PHASE4":9107,"NA":9109},{"trials":9096,"activeCount":98},[],{"trials":9098,"activeCount":98},[],{"trials":9100,"activeCount":208,"soonestReadout":3696},[9101],{"nctId":3693,"briefTitle":3694,"status":642,"phases":9102,"primaryCompletion":3696,"completion":3696,"start":3697,"enrollment":3093,"conditions":9103,"interventions":9104},[88],[1515],[3700,3701,3702,613,1721,622,1157,1225,1267,1158],{"trials":9106,"activeCount":98},[],{"trials":9108,"activeCount":98},[],{"trials":9110,"activeCount":98},[],{"intervention":3702,"totalTrials":208,"cells":9112},{"EARLY_PHASE1":9113,"PHASE1":9115,"PHASE2":9117,"PHASE3":9123,"PHASE4":9125,"NA":9127},{"trials":9114,"activeCount":98},[],{"trials":9116,"activeCount":98},[],{"trials":9118,"activeCount":208,"soonestReadout":3696},[9119],{"nctId":3693,"briefTitle":3694,"status":642,"phases":9120,"primaryCompletion":3696,"completion":3696,"start":3697,"enrollment":3093,"conditions":9121,"interventions":9122},[88],[1515],[3700,3701,3702,613,1721,622,1157,1225,1267,1158],{"trials":9124,"activeCount":98},[],{"trials":9126,"activeCount":98},[],{"trials":9128,"activeCount":98},[],{"intervention":5528,"totalTrials":208,"cells":9130},{"EARLY_PHASE1":9131,"PHASE1":9133,"PHASE2":9135,"PHASE3":9141,"PHASE4":9143,"NA":9145},{"trials":9132,"activeCount":98},[],{"trials":9134,"activeCount":98},[],{"trials":9136,"activeCount":208,"soonestReadout":5523},[9137],{"nctId":5520,"briefTitle":5521,"status":236,"phases":9138,"primaryCompletion":5523,"completion":5524,"start":5525,"enrollment":402,"conditions":9139,"interventions":9140},[87,88],[1132],[5528,612],{"trials":9142,"activeCount":98},[],{"trials":9144,"activeCount":98},[],{"trials":9146,"activeCount":98},[],{"intervention":2299,"totalTrials":208,"cells":9148},{"EARLY_PHASE1":9149,"PHASE1":9151,"PHASE2":9153,"PHASE3":9159,"PHASE4":9161,"NA":9163},{"trials":9150,"activeCount":98},[],{"trials":9152,"activeCount":98},[],{"trials":9154,"activeCount":208,"soonestReadout":2295},[9155],{"nctId":2292,"briefTitle":2293,"status":179,"phases":9156,"primaryCompletion":2295,"completion":2296,"start":1275,"enrollment":660,"conditions":9157,"interventions":9158},[88],[21],[2299,2300,1123,2301],{"trials":9160,"activeCount":98},[],{"trials":9162,"activeCount":98},[],{"trials":9164,"activeCount":98},[],{"intervention":2300,"totalTrials":208,"cells":9166},{"EARLY_PHASE1":9167,"PHASE1":9169,"PHASE2":9171,"PHASE3":9177,"PHASE4":9179,"NA":9181},{"trials":9168,"activeCount":98},[],{"trials":9170,"activeCount":98},[],{"trials":9172,"activeCount":208,"soonestReadout":2295},[9173],{"nctId":2292,"briefTitle":2293,"status":179,"phases":9174,"primaryCompletion":2295,"completion":2296,"start":1275,"enrollment":660,"conditions":9175,"interventions":9176},[88],[21],[2299,2300,1123,2301],{"trials":9178,"activeCount":98},[],{"trials":9180,"activeCount":98},[],{"trials":9182,"activeCount":98},[],{"intervention":2301,"totalTrials":208,"cells":9184},{"EARLY_PHASE1":9185,"PHASE1":9187,"PHASE2":9189,"PHASE3":9195,"PHASE4":9197,"NA":9199},{"trials":9186,"activeCount":98},[],{"trials":9188,"activeCount":98},[],{"trials":9190,"activeCount":208,"soonestReadout":2295},[9191],{"nctId":2292,"briefTitle":2293,"status":179,"phases":9192,"primaryCompletion":2295,"completion":2296,"start":1275,"enrollment":660,"conditions":9193,"interventions":9194},[88],[21],[2299,2300,1123,2301],{"trials":9196,"activeCount":98},[],{"trials":9198,"activeCount":98},[],{"trials":9200,"activeCount":98},[],{"intervention":8716,"totalTrials":208,"cells":9202},{"EARLY_PHASE1":9203,"PHASE1":9205,"PHASE2":9207,"PHASE3":9213,"PHASE4":9215,"NA":9217},{"trials":9204,"activeCount":98},[],{"trials":9206,"activeCount":98},[],{"trials":9208,"activeCount":208,"soonestReadout":8709},[9209],{"nctId":8706,"briefTitle":8707,"status":236,"phases":9210,"primaryCompletion":8709,"completion":8710,"start":8711,"enrollment":8712,"conditions":9211,"interventions":9212},[87,88],[8714],[8716,8689,8717,8718],{"trials":9214,"activeCount":98},[],{"trials":9216,"activeCount":98},[],{"trials":9218,"activeCount":98},[],{"intervention":8717,"totalTrials":208,"cells":9220},{"EARLY_PHASE1":9221,"PHASE1":9223,"PHASE2":9225,"PHASE3":9231,"PHASE4":9233,"NA":9235},{"trials":9222,"activeCount":98},[],{"trials":9224,"activeCount":98},[],{"trials":9226,"activeCount":208,"soonestReadout":8709},[9227],{"nctId":8706,"briefTitle":8707,"status":236,"phases":9228,"primaryCompletion":8709,"completion":8710,"start":8711,"enrollment":8712,"conditions":9229,"interventions":9230},[87,88],[8714],[8716,8689,8717,8718],{"trials":9232,"activeCount":98},[],{"trials":9234,"activeCount":98},[],{"trials":9236,"activeCount":98},[],{"intervention":8718,"totalTrials":208,"cells":9238},{"EARLY_PHASE1":9239,"PHASE1":9241,"PHASE2":9243,"PHASE3":9249,"PHASE4":9251,"NA":9253},{"trials":9240,"activeCount":98},[],{"trials":9242,"activeCount":98},[],{"trials":9244,"activeCount":208,"soonestReadout":8709},[9245],{"nctId":8706,"briefTitle":8707,"status":236,"phases":9246,"primaryCompletion":8709,"completion":8710,"start":8711,"enrollment":8712,"conditions":9247,"interventions":9248},[87,88],[8714],[8716,8689,8717,8718],{"trials":9250,"activeCount":98},[],{"trials":9252,"activeCount":98},[],{"trials":9254,"activeCount":98},[],{"intervention":6258,"totalTrials":208,"cells":9256},{"EARLY_PHASE1":9257,"PHASE1":9259,"PHASE2":9261,"PHASE3":9267,"PHASE4":9269,"NA":9271},{"trials":9258,"activeCount":98},[],{"trials":9260,"activeCount":98},[],{"trials":9262,"activeCount":208,"soonestReadout":6253},[9263],{"nctId":6250,"briefTitle":6251,"status":236,"phases":9264,"primaryCompletion":6253,"completion":6253,"start":6254,"enrollment":3093,"conditions":9265,"interventions":9266},[87,88],[33],[6257,6258,1453,610,1795],{"trials":9268,"activeCount":98},[],{"trials":9270,"activeCount":98},[],{"trials":9272,"activeCount":98},[],{"intervention":9274,"totalTrials":574,"cells":9275},"Azacitidine",{"EARLY_PHASE1":9276,"PHASE1":9278,"PHASE2":9299,"PHASE3":9301,"PHASE4":9303,"NA":9305},{"trials":9277,"activeCount":98},[],{"trials":9279,"activeCount":208,"soonestReadout":9293},[9280,9289],{"nctId":9281,"briefTitle":9282,"status":963,"phases":9283,"primaryCompletion":3138,"completion":3138,"start":9284,"enrollment":7813,"conditions":9285,"interventions":9286},"NCT05168202","A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes",[87],"2022-01-19",[8857,404],[9287,9274,9288],"CC-95251","Venetoclax",{"nctId":9290,"briefTitle":9291,"status":236,"phases":9292,"primaryCompletion":9293,"completion":9294,"start":9295,"enrollment":1759,"conditions":9296,"interventions":9297},"NCT06419634","Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",[87],"2027-02-01","2030-09-16","2024-05-29",[6365,517],[9298,9274,9288],"BMS-986497",{"trials":9300,"activeCount":98},[],{"trials":9302,"activeCount":98},[],{"trials":9304,"activeCount":98},[],{"trials":9306,"activeCount":208,"soonestReadout":9311},[9307],{"nctId":9308,"briefTitle":9309,"status":179,"phases":9310,"primaryCompletion":9311,"completion":433,"start":9312,"enrollment":184,"conditions":9313,"interventions":9314},"NCT07458542","Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia",[],"2026-01-09","2025-12-09",[6387],[9274],{"intervention":2042,"totalTrials":230,"cells":9316},{"EARLY_PHASE1":9317,"PHASE1":9319,"PHASE2":9332,"PHASE3":9338,"PHASE4":9340,"NA":9342},{"trials":9318,"activeCount":98},[],{"trials":9320,"activeCount":208,"soonestReadout":9325},[9321],{"nctId":9322,"briefTitle":9323,"status":236,"phases":9324,"primaryCompletion":9325,"completion":9325,"start":375,"enrollment":9326,"conditions":9327,"interventions":9329},"NCT06997029","A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors",[87],"2028-12-14",234,[2075,5965,9328],"Advanced Ovarian Cancer",[9330,2042,9331],"BMS-986500","Fulvestrant",{"trials":9333,"activeCount":98},[9334],{"nctId":2033,"briefTitle":2034,"status":104,"phases":9335,"primaryCompletion":2036,"completion":2036,"start":2037,"enrollment":2038,"conditions":9336,"interventions":9337},[88],[1223,606],[43,2041,2042],{"trials":9339,"activeCount":98},[],{"trials":9341,"activeCount":98},[],{"trials":9343,"activeCount":98},[],{"intervention":9331,"totalTrials":230,"cells":9345},{"EARLY_PHASE1":9346,"PHASE1":9348,"PHASE2":9354,"PHASE3":9364,"PHASE4":9366,"NA":9368},{"trials":9347,"activeCount":98},[],{"trials":9349,"activeCount":208,"soonestReadout":9325},[9350],{"nctId":9322,"briefTitle":9323,"status":236,"phases":9351,"primaryCompletion":9325,"completion":9325,"start":375,"enrollment":9326,"conditions":9352,"interventions":9353},[87],[2075,5965,9328],[9330,2042,9331],{"trials":9355,"activeCount":98},[9356],{"nctId":9357,"briefTitle":9358,"status":104,"phases":9359,"primaryCompletion":3960,"completion":9360,"start":9361,"enrollment":660,"conditions":9362,"interventions":9363},"NCT00754325","Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor",[88],"2014-01","2008-09",[5965],[1197,9331],{"trials":9365,"activeCount":98},[],{"trials":9367,"activeCount":98},[],{"trials":9369,"activeCount":98},[],{"intervention":805,"totalTrials":1750,"cells":9371},{"EARLY_PHASE1":9372,"PHASE1":9374,"PHASE2":9420,"PHASE3":9422,"PHASE4":9424,"NA":9426},{"trials":9373,"activeCount":98},[],{"trials":9375,"activeCount":208,"soonestReadout":5680},[9376,9384,9392,9396,9404,9412,9416],{"nctId":9377,"briefTitle":9378,"status":104,"phases":9379,"primaryCompletion":4458,"completion":4458,"start":4122,"enrollment":2308,"conditions":9380,"interventions":9382},"NCT02164812","Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects",[87],[9381],"HIV\u002FAIDS",[805,9383],"Efavirenz",{"nctId":9385,"briefTitle":9386,"status":104,"phases":9387,"primaryCompletion":4159,"completion":4159,"start":4289,"enrollment":9388,"conditions":9389,"interventions":9390},"NCT02084953","Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects",[87],59,[30],[9391,805],"BMS-791325",{"nctId":798,"briefTitle":799,"status":104,"phases":9393,"primaryCompletion":801,"completion":801,"start":802,"enrollment":116,"conditions":9394,"interventions":9395},[87],[792,18],[679,805],{"nctId":9397,"briefTitle":9398,"status":104,"phases":9399,"primaryCompletion":9400,"completion":9400,"start":1283,"enrollment":19,"conditions":9401,"interventions":9402},"NCT06846866","A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants",[87],"2025-10-21",[27],[9403,805],"BMS-986419",{"nctId":9405,"briefTitle":9406,"status":104,"phases":9407,"primaryCompletion":3617,"completion":3617,"start":4038,"enrollment":9408,"conditions":9409,"interventions":9410},"NCT00979316","Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects",[87],62,[552],[9411,9411,805],"BMS-708163",{"nctId":5644,"briefTitle":5645,"status":104,"phases":9413,"primaryCompletion":3788,"completion":3788,"start":5647,"enrollment":3986,"conditions":9414,"interventions":9415},[87],[27],[5571,805],{"nctId":5677,"briefTitle":5678,"status":236,"phases":9417,"primaryCompletion":5680,"completion":5680,"start":5681,"enrollment":34,"conditions":9418,"interventions":9419},[87],[27],[5571,805],{"trials":9421,"activeCount":98},[],{"trials":9423,"activeCount":98},[],{"trials":9425,"activeCount":98},[],{"trials":9427,"activeCount":98},[],{"intervention":9429,"totalTrials":230,"cells":9430},"BMS-986454",{"EARLY_PHASE1":9431,"PHASE1":9433,"PHASE2":9450,"PHASE3":9452,"PHASE4":9454,"NA":9456},{"trials":9432,"activeCount":98},[],{"trials":9434,"activeCount":208,"soonestReadout":558},[9435,9443],{"nctId":9436,"briefTitle":9437,"status":104,"phases":9438,"primaryCompletion":9439,"completion":9439,"start":9440,"enrollment":227,"conditions":9441,"interventions":9442},"NCT06086886","A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants",[87],"2024-12-20","2023-11-16",[18],[9429],{"nctId":9444,"briefTitle":9445,"status":236,"phases":9446,"primaryCompletion":558,"completion":9447,"start":1520,"enrollment":6185,"conditions":9448,"interventions":9449},"NCT07171983","A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis",[87],"2027-08-25",[15],[9429],{"trials":9451,"activeCount":98},[],{"trials":9453,"activeCount":98},[],{"trials":9455,"activeCount":98},[],{"trials":9457,"activeCount":98},[],{"intervention":9288,"totalTrials":230,"cells":9459},{"EARLY_PHASE1":9460,"PHASE1":9462,"PHASE2":9472,"PHASE3":9474,"PHASE4":9476,"NA":9478},{"trials":9461,"activeCount":98},[],{"trials":9463,"activeCount":208,"soonestReadout":9293},[9464,9468],{"nctId":9281,"briefTitle":9282,"status":963,"phases":9465,"primaryCompletion":3138,"completion":3138,"start":9284,"enrollment":7813,"conditions":9466,"interventions":9467},[87],[8857,404],[9287,9274,9288],{"nctId":9290,"briefTitle":9291,"status":236,"phases":9469,"primaryCompletion":9293,"completion":9294,"start":9295,"enrollment":1759,"conditions":9470,"interventions":9471},[87],[6365,517],[9298,9274,9288],{"trials":9473,"activeCount":98},[],{"trials":9475,"activeCount":98},[],{"trials":9477,"activeCount":98},[],{"trials":9479,"activeCount":98},[],{"intervention":9481,"totalTrials":230,"cells":9482},"BMS-986460",{"EARLY_PHASE1":9483,"PHASE1":9485,"PHASE2":9505,"PHASE3":9507,"PHASE4":9509,"NA":9511},{"trials":9484,"activeCount":98},[],{"trials":9486,"activeCount":208,"soonestReadout":9491},[9487,9497],{"nctId":9488,"briefTitle":9489,"status":236,"phases":9490,"primaryCompletion":9491,"completion":9492,"start":9493,"enrollment":848,"conditions":9494,"interventions":9496},"NCT06067841","A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer",[87],"2029-08-24","2031-07-27","2023-10-18",[9495],"Metastatic Castration-resistant Prostate Cancer",[9481],{"nctId":9498,"briefTitle":9499,"status":104,"phases":9500,"primaryCompletion":9501,"completion":9501,"start":9502,"enrollment":424,"conditions":9503,"interventions":9504},"NCT06877702","A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants",[87],"2025-12-17","2025-03-19",[27],[9481],{"trials":9506,"activeCount":98},[],{"trials":9508,"activeCount":98},[],{"trials":9510,"activeCount":98},[],{"trials":9512,"activeCount":98},[],{"intervention":1143,"totalTrials":208,"cells":9514},{"EARLY_PHASE1":9515,"PHASE1":9517,"PHASE2":9523,"PHASE3":9525,"PHASE4":9527,"NA":9529},{"trials":9516,"activeCount":98},[],{"trials":9518,"activeCount":208,"soonestReadout":1138},[9519],{"nctId":1135,"briefTitle":1136,"status":179,"phases":9520,"primaryCompletion":1138,"completion":1138,"start":260,"enrollment":1139,"conditions":9521,"interventions":9522},[87],[1141],[1143,1144,1145,43],{"trials":9524,"activeCount":98},[],{"trials":9526,"activeCount":98},[],{"trials":9528,"activeCount":98},[],{"trials":9530,"activeCount":98},[],{"intervention":6155,"totalTrials":208,"cells":9532},{"EARLY_PHASE1":9533,"PHASE1":9535,"PHASE2":9541,"PHASE3":9543,"PHASE4":9545,"NA":9547},{"trials":9534,"activeCount":98},[],{"trials":9536,"activeCount":208,"soonestReadout":6150},[9537],{"nctId":6147,"briefTitle":6148,"status":179,"phases":9538,"primaryCompletion":6150,"completion":6150,"start":6151,"enrollment":1221,"conditions":9539,"interventions":9540},[87],[6153],[6155,1795],{"trials":9542,"activeCount":98},[],{"trials":9544,"activeCount":98},[],{"trials":9546,"activeCount":98},[],{"trials":9548,"activeCount":98},[],{"intervention":9550,"totalTrials":208,"cells":9551},"MRTX1719",{"EARLY_PHASE1":9552,"PHASE1":9554,"PHASE2":9564,"PHASE3":9566,"PHASE4":9568,"NA":9570},{"trials":9553,"activeCount":98},[],{"trials":9555,"activeCount":208,"soonestReadout":3415},[9556],{"nctId":9557,"briefTitle":9558,"status":236,"phases":9559,"primaryCompletion":3415,"completion":3415,"start":8791,"enrollment":9560,"conditions":9561,"interventions":9563},"NCT05245500","Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion",[87],336,[2519,2622,9562,1482,6427,2075],"Malignant Peripheral Nerve Sheath Tumors",[9550],{"trials":9565,"activeCount":98},[],{"trials":9567,"activeCount":98},[],{"trials":9569,"activeCount":98},[],{"trials":9571,"activeCount":98},[],{"intervention":9573,"totalTrials":208,"cells":9574},"BMS-985521",{"EARLY_PHASE1":9575,"PHASE1":9577,"PHASE2":9587,"PHASE3":9589,"PHASE4":9591,"NA":9593},{"trials":9576,"activeCount":98},[],{"trials":9578,"activeCount":208,"soonestReadout":9583},[9579],{"nctId":9580,"briefTitle":9581,"status":236,"phases":9582,"primaryCompletion":9583,"completion":9583,"start":9584,"enrollment":413,"conditions":9585,"interventions":9586},"NCT07283263","A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.",[87],"2026-11-17","2025-12-23",[27],[9573],{"trials":9588,"activeCount":98},[],{"trials":9590,"activeCount":98},[],{"trials":9592,"activeCount":98},[],{"trials":9594,"activeCount":98},[],{"intervention":5297,"totalTrials":208,"cells":9596},{"EARLY_PHASE1":9597,"PHASE1":9599,"PHASE2":9605,"PHASE3":9607,"PHASE4":9609,"NA":9611},{"trials":9598,"activeCount":98},[],{"trials":9600,"activeCount":208,"soonestReadout":5292},[9601],{"nctId":5289,"briefTitle":5290,"status":236,"phases":9602,"primaryCompletion":5292,"completion":5292,"start":5293,"enrollment":839,"conditions":9603,"interventions":9604},[87],[5295],[3700,5297],{"trials":9606,"activeCount":98},[],{"trials":9608,"activeCount":98},[],{"trials":9610,"activeCount":98},[],{"trials":9612,"activeCount":98},[],{"intervention":9614,"totalTrials":208,"cells":9615},"BMS-986463",{"EARLY_PHASE1":9616,"PHASE1":9618,"PHASE2":9630,"PHASE3":9632,"PHASE4":9634,"NA":9636},{"trials":9617,"activeCount":98},[],{"trials":9619,"activeCount":208,"soonestReadout":9624},[9620],{"nctId":9621,"briefTitle":9622,"status":236,"phases":9623,"primaryCompletion":9624,"completion":9624,"start":9625,"enrollment":1729,"conditions":9626,"interventions":9629},"NCT06476808","A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.",[87],"2028-12-19","2024-09-06",[9627,9628,3131],"High-grade Serous Ovarian Carcinoma (HGSOC)","Uterine Serous Carcinoma (USC)",[9614],{"trials":9631,"activeCount":98},[],{"trials":9633,"activeCount":98},[],{"trials":9635,"activeCount":98},[],{"trials":9637,"activeCount":98},[],{"intervention":538,"totalTrials":208,"cells":9639},{"EARLY_PHASE1":9640,"PHASE1":9642,"PHASE2":9648,"PHASE3":9650,"PHASE4":9652,"NA":9654},{"trials":9641,"activeCount":98},[],{"trials":9643,"activeCount":208,"soonestReadout":532},[9644],{"nctId":529,"briefTitle":530,"status":236,"phases":9645,"primaryCompletion":532,"completion":532,"start":533,"enrollment":534,"conditions":9646,"interventions":9647},[87],[27],[522,537,538],{"trials":9649,"activeCount":98},[],{"trials":9651,"activeCount":98},[],{"trials":9653,"activeCount":98},[],{"trials":9655,"activeCount":98},[],{"intervention":1357,"totalTrials":208,"cells":9657},{"EARLY_PHASE1":9658,"PHASE1":9660,"PHASE2":9666,"PHASE3":9668,"PHASE4":9670,"NA":9672},{"trials":9659,"activeCount":98},[],{"trials":9661,"activeCount":208,"soonestReadout":1352},[9662],{"nctId":1349,"briefTitle":1350,"status":179,"phases":9663,"primaryCompletion":1352,"completion":1352,"start":1353,"enrollment":1354,"conditions":9664,"interventions":9665},[87],[1132],[1357,43,619,611,618,1358],{"trials":9667,"activeCount":98},[],{"trials":9669,"activeCount":98},[],{"trials":9671,"activeCount":98},[],{"trials":9673,"activeCount":98},[],{"intervention":1358,"totalTrials":208,"cells":9675},{"EARLY_PHASE1":9676,"PHASE1":9678,"PHASE2":9684,"PHASE3":9686,"PHASE4":9688,"NA":9690},{"trials":9677,"activeCount":98},[],{"trials":9679,"activeCount":208,"soonestReadout":1352},[9680],{"nctId":1349,"briefTitle":1350,"status":179,"phases":9681,"primaryCompletion":1352,"completion":1352,"start":1353,"enrollment":1354,"conditions":9682,"interventions":9683},[87],[1132],[1357,43,619,611,618,1358],{"trials":9685,"activeCount":98},[],{"trials":9687,"activeCount":98},[],{"trials":9689,"activeCount":98},[],{"trials":9691,"activeCount":98},[],{"intervention":9330,"totalTrials":208,"cells":9693},{"EARLY_PHASE1":9694,"PHASE1":9696,"PHASE2":9702,"PHASE3":9704,"PHASE4":9706,"NA":9708},{"trials":9695,"activeCount":98},[],{"trials":9697,"activeCount":208,"soonestReadout":9325},[9698],{"nctId":9322,"briefTitle":9323,"status":236,"phases":9699,"primaryCompletion":9325,"completion":9325,"start":375,"enrollment":9326,"conditions":9700,"interventions":9701},[87],[2075,5965,9328],[9330,2042,9331],{"trials":9703,"activeCount":98},[],{"trials":9705,"activeCount":98},[],{"trials":9707,"activeCount":98},[],{"trials":9709,"activeCount":98},[],{"intervention":9298,"totalTrials":208,"cells":9711},{"EARLY_PHASE1":9712,"PHASE1":9714,"PHASE2":9720,"PHASE3":9722,"PHASE4":9724,"NA":9726},{"trials":9713,"activeCount":98},[],{"trials":9715,"activeCount":208,"soonestReadout":9293},[9716],{"nctId":9290,"briefTitle":9291,"status":236,"phases":9717,"primaryCompletion":9293,"completion":9294,"start":9295,"enrollment":1759,"conditions":9718,"interventions":9719},[87],[6365,517],[9298,9274,9288],{"trials":9721,"activeCount":98},[],{"trials":9723,"activeCount":98},[],{"trials":9725,"activeCount":98},[],{"trials":9727,"activeCount":98},[],{"intervention":9729,"totalTrials":208,"cells":9730},"BMS-986506",{"EARLY_PHASE1":9731,"PHASE1":9733,"PHASE2":9744,"PHASE3":9746,"PHASE4":9748,"NA":9750},{"trials":9732,"activeCount":98},[],{"trials":9734,"activeCount":208,"soonestReadout":9739},[9735],{"nctId":9736,"briefTitle":9737,"status":236,"phases":9738,"primaryCompletion":9739,"completion":9740,"start":240,"enrollment":9741,"conditions":9742,"interventions":9743},"NCT07195682","A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)",[87],"2030-05-03","2031-04-03",125,[1253],[9729],{"trials":9745,"activeCount":98},[],{"trials":9747,"activeCount":98},[],{"trials":9749,"activeCount":98},[],{"trials":9751,"activeCount":98},[],{"intervention":9753,"totalTrials":208,"cells":9754},"Navlimetostat",{"EARLY_PHASE1":9755,"PHASE1":9757,"PHASE2":9768,"PHASE3":9770,"PHASE4":9772,"NA":9774},{"trials":9756,"activeCount":98},[],{"trials":9758,"activeCount":208,"soonestReadout":9763},[9759],{"nctId":9760,"briefTitle":9761,"status":236,"phases":9762,"primaryCompletion":9763,"completion":9764,"start":9765,"enrollment":3102,"conditions":9766,"interventions":9767},"NCT07544628","A Phase 1 Study of Navlimetostat Tablet Formulations",[87],"2026-08-31","2026-10-15","2026-04-27",[18],[9753],{"trials":9769,"activeCount":98},[],{"trials":9771,"activeCount":98},[],{"trials":9773,"activeCount":98},[],{"trials":9775,"activeCount":98},[],{"intervention":1144,"totalTrials":574,"cells":9777},{"EARLY_PHASE1":9778,"PHASE1":9780,"PHASE2":9786,"PHASE3":9792,"PHASE4":9794,"NA":9796},{"trials":9779,"activeCount":98},[],{"trials":9781,"activeCount":208,"soonestReadout":1138},[9782],{"nctId":1135,"briefTitle":1136,"status":179,"phases":9783,"primaryCompletion":1138,"completion":1138,"start":260,"enrollment":1139,"conditions":9784,"interventions":9785},[87],[1141],[1143,1144,1145,43],{"trials":9787,"activeCount":98},[9788],{"nctId":5858,"briefTitle":5859,"status":963,"phases":9789,"primaryCompletion":5861,"completion":5861,"start":135,"enrollment":520,"conditions":9790,"interventions":9791},[87,88],[1132],[5864,1144,1145],{"trials":9793,"activeCount":98},[],{"trials":9795,"activeCount":98},[],{"trials":9797,"activeCount":98},[9798],{"nctId":9799,"briefTitle":9800,"status":2998,"phases":9801,"conditions":9802,"interventions":9805},"NCT05162443","Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation",[],[1154,9803,9804],"Metastatic Cancer","Malignant Neoplasm",[9806],"adagrasib",{"intervention":664,"totalTrials":520,"cells":9808},{"EARLY_PHASE1":9809,"PHASE1":9811,"PHASE2":9813,"PHASE3":9815,"PHASE4":9817,"NA":9819},{"trials":9810,"activeCount":98},[],{"trials":9812,"activeCount":98},[],{"trials":9814,"activeCount":98},[],{"trials":9816,"activeCount":98},[],{"trials":9818,"activeCount":98},[],{"trials":9820,"activeCount":574,"soonestReadout":5434},[9821,9829,9833,9842,9846],{"nctId":9822,"briefTitle":9823,"status":179,"phases":9824,"primaryCompletion":5434,"completion":5434,"start":9825,"enrollment":660,"conditions":9826,"interventions":9827},"NCT07024862","Long-term Outcomes Among Patients With Programmed Death-ligand 1 \u003C1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy",[],"2024-10-24",[1525],[9828],"nivolumab + ipilimumab",{"nctId":655,"briefTitle":656,"status":104,"phases":9830,"primaryCompletion":658,"completion":658,"start":659,"enrollment":660,"conditions":9831,"interventions":9832},[],[21],[663,664],{"nctId":9834,"briefTitle":9835,"status":179,"phases":9836,"primaryCompletion":9837,"completion":9837,"start":9838,"enrollment":9839,"conditions":9840,"interventions":9841},"NCT06487156","A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[],"2030-10-11","2023-10-11",404,[3131],[664],{"nctId":666,"briefTitle":667,"status":104,"phases":9843,"primaryCompletion":669,"completion":669,"start":670,"enrollment":671,"conditions":9844,"interventions":9845},[],[673],[590,675,676,677],{"nctId":9847,"briefTitle":9848,"status":179,"phases":9849,"primaryCompletion":9850,"completion":9851,"start":496,"enrollment":9852,"conditions":9853,"interventions":9854},"NCT07215962","Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) \u003C1%",[],"2025-07-01","2026-03-01",300,[3131],[664,9855,9856,9857],"Nivolumab + ipilimumab + platinum-based chemotherapy","Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy","Other dual-immuno-oncology therapy with chemotherapy",{"intervention":9859,"totalTrials":574,"cells":9860},"Idecabtagene vicleucel",{"EARLY_PHASE1":9861,"PHASE1":9863,"PHASE2":9865,"PHASE3":9867,"PHASE4":9869,"NA":9871},{"trials":9862,"activeCount":98},[],{"trials":9864,"activeCount":98},[],{"trials":9866,"activeCount":98},[],{"trials":9868,"activeCount":98},[],{"trials":9870,"activeCount":98},[],{"trials":9872,"activeCount":574,"soonestReadout":9887},[9873,9883,9891],{"nctId":9874,"briefTitle":9875,"status":236,"phases":9876,"primaryCompletion":9877,"completion":9877,"start":9878,"enrollment":217,"conditions":9879,"interventions":9881},"NCT06357754","Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy",[],"2038-10-06","2023-10-06",[6153,9880,33],"Chronic Lymphocytic Leukaemia",[9859,9882],"Lisocabtagene maraleucel",{"nctId":9884,"briefTitle":9885,"status":179,"phases":9886,"primaryCompletion":9887,"completion":5475,"start":9888,"enrollment":3370,"conditions":9889,"interventions":9890},"NCT06154902","Real-World Outcomes in Relapsed\u002FRefractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel",[],"2027-07-31","2022-07-29",[33],[9859],{"nctId":9892,"briefTitle":9893,"status":236,"phases":9894,"primaryCompletion":9895,"completion":9895,"start":9896,"enrollment":1385,"conditions":9897,"interventions":9898},"NCT06698887","A Study to Evaluate the Long-Term Safety of Idecabtagene Vicleucel Treatment in Adults With Newly Diagnosed Multiple Myeloma in Korea",[],"2031-03-27","2024-09-11",[33],[9859],{"intervention":440,"totalTrials":230,"cells":9900},{"EARLY_PHASE1":9901,"PHASE1":9903,"PHASE2":9905,"PHASE3":9907,"PHASE4":9909,"NA":9911},{"trials":9902,"activeCount":98},[],{"trials":9904,"activeCount":98},[],{"trials":9906,"activeCount":98},[],{"trials":9908,"activeCount":98},[],{"trials":9910,"activeCount":98},[],{"trials":9912,"activeCount":208,"soonestReadout":433},[9913,9917],{"nctId":430,"briefTitle":431,"status":179,"phases":9914,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":9915,"interventions":9916},[],[438],[440,362,441,442,443],{"nctId":456,"briefTitle":457,"status":104,"phases":9918,"primaryCompletion":459,"completion":459,"start":460,"enrollment":461,"conditions":9919,"interventions":9920},[],[404],[362,440],{"intervention":9882,"totalTrials":208,"cells":9922},{"EARLY_PHASE1":9923,"PHASE1":9925,"PHASE2":9927,"PHASE3":9929,"PHASE4":9931,"NA":9933},{"trials":9924,"activeCount":98},[],{"trials":9926,"activeCount":98},[],{"trials":9928,"activeCount":98},[],{"trials":9930,"activeCount":98},[],{"trials":9932,"activeCount":98},[],{"trials":9934,"activeCount":208,"soonestReadout":9877},[9935],{"nctId":9874,"briefTitle":9875,"status":236,"phases":9936,"primaryCompletion":9877,"completion":9877,"start":9878,"enrollment":217,"conditions":9937,"interventions":9938},[],[6153,9880,33],[9859,9882],{"intervention":442,"totalTrials":208,"cells":9940},{"EARLY_PHASE1":9941,"PHASE1":9943,"PHASE2":9945,"PHASE3":9947,"PHASE4":9949,"NA":9951},{"trials":9942,"activeCount":98},[],{"trials":9944,"activeCount":98},[],{"trials":9946,"activeCount":98},[],{"trials":9948,"activeCount":98},[],{"trials":9950,"activeCount":98},[],{"trials":9952,"activeCount":208,"soonestReadout":433},[9953],{"nctId":430,"briefTitle":431,"status":179,"phases":9954,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":9955,"interventions":9956},[],[438],[440,362,441,442,443],{"intervention":443,"totalTrials":208,"cells":9958},{"EARLY_PHASE1":9959,"PHASE1":9961,"PHASE2":9963,"PHASE3":9965,"PHASE4":9967,"NA":9969},{"trials":9960,"activeCount":98},[],{"trials":9962,"activeCount":98},[],{"trials":9964,"activeCount":98},[],{"trials":9966,"activeCount":98},[],{"trials":9968,"activeCount":98},[],{"trials":9970,"activeCount":208,"soonestReadout":433},[9971],{"nctId":430,"briefTitle":431,"status":179,"phases":9972,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":9973,"interventions":9974},[],[438],[440,362,441,442,443],{"intervention":254,"totalTrials":208,"cells":9976},{"EARLY_PHASE1":9977,"PHASE1":9979,"PHASE2":9981,"PHASE3":9983,"PHASE4":9985,"NA":9987},{"trials":9978,"activeCount":98},[],{"trials":9980,"activeCount":98},[],{"trials":9982,"activeCount":98},[],{"trials":9984,"activeCount":98},[],{"trials":9986,"activeCount":98},[],{"trials":9988,"activeCount":208,"soonestReadout":249},[9989],{"nctId":246,"briefTitle":247,"status":236,"phases":9990,"primaryCompletion":249,"completion":249,"start":250,"enrollment":251,"conditions":9991,"interventions":9992},[],[162],[84,254],{"intervention":5448,"totalTrials":208,"cells":9994},{"EARLY_PHASE1":9995,"PHASE1":9997,"PHASE2":9999,"PHASE3":10001,"PHASE4":10003,"NA":10005},{"trials":9996,"activeCount":98},[],{"trials":9998,"activeCount":98},[],{"trials":10000,"activeCount":98},[],{"trials":10002,"activeCount":98},[],{"trials":10004,"activeCount":98},[],{"trials":10006,"activeCount":208,"soonestReadout":5441},[10007],{"nctId":5438,"briefTitle":5439,"status":179,"phases":10008,"primaryCompletion":5441,"completion":5442,"start":5443,"enrollment":5444,"conditions":10009,"interventions":10010},[],[5446],[5365,5448,5449],{"intervention":5449,"totalTrials":208,"cells":10012},{"EARLY_PHASE1":10013,"PHASE1":10015,"PHASE2":10017,"PHASE3":10019,"PHASE4":10021,"NA":10023},{"trials":10014,"activeCount":98},[],{"trials":10016,"activeCount":98},[],{"trials":10018,"activeCount":98},[],{"trials":10020,"activeCount":98},[],{"trials":10022,"activeCount":98},[],{"trials":10024,"activeCount":208,"soonestReadout":5441},[10025],{"nctId":5438,"briefTitle":5439,"status":179,"phases":10026,"primaryCompletion":5441,"completion":5442,"start":5443,"enrollment":5444,"conditions":10027,"interventions":10028},[],[5446],[5365,5448,5449],{"intervention":10030,"totalTrials":208,"cells":10031},"Current standard of care treatment options",{"EARLY_PHASE1":10032,"PHASE1":10034,"PHASE2":10036,"PHASE3":10038,"PHASE4":10040,"NA":10042},{"trials":10033,"activeCount":98},[],{"trials":10035,"activeCount":98},[],{"trials":10037,"activeCount":98},[],{"trials":10039,"activeCount":98},[],{"trials":10041,"activeCount":98},[],{"trials":10043,"activeCount":208,"soonestReadout":10048},[10044],{"nctId":10045,"briefTitle":10046,"status":236,"phases":10047,"primaryCompletion":10048,"completion":10049,"start":559,"enrollment":7667,"conditions":10050,"interventions":10051},"NCT07175285","A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants",[],"2028-03-24","2032-10-05",[1065],[10030],{"intervention":3363,"totalTrials":208,"cells":10053},{"EARLY_PHASE1":10054,"PHASE1":10056,"PHASE2":10058,"PHASE3":10060,"PHASE4":10062,"NA":10064},{"trials":10055,"activeCount":98},[],{"trials":10057,"activeCount":98},[],{"trials":10059,"activeCount":98},[],{"trials":10061,"activeCount":98},[],{"trials":10063,"activeCount":98},[],{"trials":10065,"activeCount":208,"soonestReadout":3358},[10066],{"nctId":3355,"briefTitle":3356,"status":179,"phases":10067,"primaryCompletion":3358,"completion":3358,"start":3359,"enrollment":3360,"conditions":10068,"interventions":10069},[],[749],[79,3363],{"intervention":10071,"totalTrials":208,"cells":10072},"Neoadjuvant nivolumab in combination with platinum-based chemotherapy",{"EARLY_PHASE1":10073,"PHASE1":10075,"PHASE2":10077,"PHASE3":10079,"PHASE4":10081,"NA":10083},{"trials":10074,"activeCount":98},[],{"trials":10076,"activeCount":98},[],{"trials":10078,"activeCount":98},[],{"trials":10080,"activeCount":98},[],{"trials":10082,"activeCount":98},[],{"trials":10084,"activeCount":208,"soonestReadout":10089},[10085],{"nctId":10086,"briefTitle":10087,"status":236,"phases":10088,"primaryCompletion":10089,"completion":10089,"start":10090,"enrollment":2563,"conditions":10091,"interventions":10093},"NCT06169956","An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany",[],"2030-09-30","2023-11-30",[10092],"Resectable Non-small Cell Lung Cancer",[10071],{"intervention":5468,"totalTrials":208,"cells":10095},{"EARLY_PHASE1":10096,"PHASE1":10098,"PHASE2":10100,"PHASE3":10102,"PHASE4":10104,"NA":10106},{"trials":10097,"activeCount":98},[],{"trials":10099,"activeCount":98},[],{"trials":10101,"activeCount":98},[],{"trials":10103,"activeCount":98},[],{"trials":10105,"activeCount":98},[],{"trials":10107,"activeCount":208,"soonestReadout":5462},[10108],{"nctId":5459,"briefTitle":5460,"status":179,"phases":10109,"primaryCompletion":5462,"completion":5463,"start":5464,"enrollment":5465,"conditions":10110,"interventions":10111},[],[990],[5365,5468,5469],{"intervention":5469,"totalTrials":208,"cells":10113},{"EARLY_PHASE1":10114,"PHASE1":10116,"PHASE2":10118,"PHASE3":10120,"PHASE4":10122,"NA":10124},{"trials":10115,"activeCount":98},[],{"trials":10117,"activeCount":98},[],{"trials":10119,"activeCount":98},[],{"trials":10121,"activeCount":98},[],{"trials":10123,"activeCount":98},[],{"trials":10125,"activeCount":208,"soonestReadout":5462},[10126],{"nctId":5459,"briefTitle":5460,"status":179,"phases":10127,"primaryCompletion":5462,"completion":5463,"start":5464,"enrollment":5465,"conditions":10128,"interventions":10129},[],[990],[5365,5468,5469],{"intervention":10131,"totalTrials":208,"cells":10132},"nivolumab + chemotherapy",{"EARLY_PHASE1":10133,"PHASE1":10135,"PHASE2":10137,"PHASE3":10139,"PHASE4":10141,"NA":10143},{"trials":10134,"activeCount":98},[],{"trials":10136,"activeCount":98},[],{"trials":10138,"activeCount":98},[],{"trials":10140,"activeCount":98},[],{"trials":10142,"activeCount":98},[],{"trials":10144,"activeCount":208,"soonestReadout":8312},[10145],{"nctId":10146,"briefTitle":10147,"status":179,"phases":10148,"primaryCompletion":8312,"completion":8312,"start":10149,"enrollment":8275,"conditions":10150,"interventions":10155},"NCT06504615","Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France",[],"2024-12-10",[10151,10152,10153,10154],"Gastric Adenocarcinoma","Gastro-esophageal Junction Adenocarcinoma","Esophageal Adenocarcinoma (EAC)","Esophageal Squamous Cell Carcinoma (ESCC)",[10131],{"intervention":5479,"totalTrials":208,"cells":10157},{"EARLY_PHASE1":10158,"PHASE1":10160,"PHASE2":10162,"PHASE3":10164,"PHASE4":10166,"NA":10168},{"trials":10159,"activeCount":98},[],{"trials":10161,"activeCount":98},[],{"trials":10163,"activeCount":98},[],{"trials":10165,"activeCount":98},[],{"trials":10167,"activeCount":98},[],{"trials":10169,"activeCount":208,"soonestReadout":5474},[10170],{"nctId":5471,"briefTitle":5472,"status":236,"phases":10171,"primaryCompletion":5474,"completion":5475,"start":3512,"enrollment":331,"conditions":10172,"interventions":10173},[],[5477],[5365,5479],{"intervention":3391,"totalTrials":208,"cells":10175},{"EARLY_PHASE1":10176,"PHASE1":10178,"PHASE2":10180,"PHASE3":10182,"PHASE4":10184,"NA":10186},{"trials":10177,"activeCount":98},[],{"trials":10179,"activeCount":98},[],{"trials":10181,"activeCount":98},[],{"trials":10183,"activeCount":98},[],{"trials":10185,"activeCount":98},[],{"trials":10187,"activeCount":208,"soonestReadout":3385},[10188],{"nctId":3382,"briefTitle":3383,"status":179,"phases":10189,"primaryCompletion":3385,"completion":3386,"start":3387,"enrollment":3388,"conditions":10190,"interventions":10191},[],[749],[79,3391],{"intervention":10193,"totalTrials":208,"cells":10194},"xanomeline and trospium chloride (X\u002FT) therapy",{"EARLY_PHASE1":10195,"PHASE1":10197,"PHASE2":10199,"PHASE3":10201,"PHASE4":10203,"NA":10205},{"trials":10196,"activeCount":98},[],{"trials":10198,"activeCount":98},[],{"trials":10200,"activeCount":98},[],{"trials":10202,"activeCount":98},[],{"trials":10204,"activeCount":98},[],{"trials":10206,"activeCount":208,"soonestReadout":10211},[10207],{"nctId":10208,"briefTitle":10209,"status":236,"phases":10210,"primaryCompletion":10211,"completion":10212,"start":3283,"enrollment":9852,"conditions":10213,"interventions":10214},"NCT07101094","Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)",[],"2029-01-31","2029-05-14",[584],[10193],{"intervention":304,"totalTrials":208,"cells":10216},{"EARLY_PHASE1":10217,"PHASE1":10219,"PHASE2":10221,"PHASE3":10223,"PHASE4":10225,"NA":10227},{"trials":10218,"activeCount":98},[],{"trials":10220,"activeCount":98},[],{"trials":10222,"activeCount":98},[],{"trials":10224,"activeCount":98},[],{"trials":10226,"activeCount":98},[],{"trials":10228,"activeCount":208,"soonestReadout":297},[10229],{"nctId":294,"briefTitle":295,"status":179,"phases":10230,"primaryCompletion":297,"completion":298,"start":299,"enrollment":300,"conditions":10231,"interventions":10232},[],[302],[304,84],{"intervention":500,"totalTrials":208,"cells":10234},{"EARLY_PHASE1":10235,"PHASE1":10237,"PHASE2":10239,"PHASE3":10241,"PHASE4":10243,"NA":10245},{"trials":10236,"activeCount":98},[],{"trials":10238,"activeCount":98},[],{"trials":10240,"activeCount":98},[],{"trials":10242,"activeCount":98},[],{"trials":10244,"activeCount":98},[],{"trials":10246,"activeCount":208,"soonestReadout":375},[10247],{"nctId":493,"briefTitle":494,"status":179,"phases":10248,"primaryCompletion":375,"completion":375,"start":496,"enrollment":497,"conditions":10249,"interventions":10250},[],[472],[362,500],{"intervention":10252,"totalTrials":208,"cells":10253},"Prescribed treatments for myelodysplastic syndromes",{"EARLY_PHASE1":10254,"PHASE1":10256,"PHASE2":10258,"PHASE3":10260,"PHASE4":10262,"NA":10264},{"trials":10255,"activeCount":98},[],{"trials":10257,"activeCount":98},[],{"trials":10259,"activeCount":98},[],{"trials":10261,"activeCount":98},[],{"trials":10263,"activeCount":98},[],{"trials":10265,"activeCount":208,"soonestReadout":6150},[10266],{"nctId":10267,"briefTitle":10268,"status":642,"phases":10269,"primaryCompletion":6150,"completion":10270,"start":4085,"enrollment":290,"conditions":10271,"interventions":10272},"NCT07355478","Asia Myelodysplastic Syndrome (MDS) Registry",[],"2027-09-30",[472],[10252],{"intervention":3410,"totalTrials":208,"cells":10274},{"EARLY_PHASE1":10275,"PHASE1":10277,"PHASE2":10279,"PHASE3":10281,"PHASE4":10283,"NA":10285},{"trials":10276,"activeCount":98},[],{"trials":10278,"activeCount":98},[],{"trials":10280,"activeCount":98},[],{"trials":10282,"activeCount":98},[],{"trials":10284,"activeCount":98},[],{"trials":10286,"activeCount":208,"soonestReadout":3405},[10287],{"nctId":3402,"briefTitle":3403,"status":236,"phases":10288,"primaryCompletion":3405,"completion":3386,"start":936,"enrollment":3406,"conditions":10289,"interventions":10290},[],[3408],[79,3410],{"intervention":9855,"totalTrials":208,"cells":10292},{"EARLY_PHASE1":10293,"PHASE1":10295,"PHASE2":10297,"PHASE3":10299,"PHASE4":10301,"NA":10303},{"trials":10294,"activeCount":98},[],{"trials":10296,"activeCount":98},[],{"trials":10298,"activeCount":98},[],{"trials":10300,"activeCount":98},[],{"trials":10302,"activeCount":98},[],{"trials":10304,"activeCount":208,"soonestReadout":9850},[10305],{"nctId":9847,"briefTitle":9848,"status":179,"phases":10306,"primaryCompletion":9850,"completion":9851,"start":496,"enrollment":9852,"conditions":10307,"interventions":10308},[],[3131],[664,9855,9856,9857],{"intervention":9856,"totalTrials":208,"cells":10310},{"EARLY_PHASE1":10311,"PHASE1":10313,"PHASE2":10315,"PHASE3":10317,"PHASE4":10319,"NA":10321},{"trials":10312,"activeCount":98},[],{"trials":10314,"activeCount":98},[],{"trials":10316,"activeCount":98},[],{"trials":10318,"activeCount":98},[],{"trials":10320,"activeCount":98},[],{"trials":10322,"activeCount":208,"soonestReadout":9850},[10323],{"nctId":9847,"briefTitle":9848,"status":179,"phases":10324,"primaryCompletion":9850,"completion":9851,"start":496,"enrollment":9852,"conditions":10325,"interventions":10326},[],[3131],[664,9855,9856,9857],{"intervention":9857,"totalTrials":208,"cells":10328},{"EARLY_PHASE1":10329,"PHASE1":10331,"PHASE2":10333,"PHASE3":10335,"PHASE4":10337,"NA":10339},{"trials":10330,"activeCount":98},[],{"trials":10332,"activeCount":98},[],{"trials":10334,"activeCount":98},[],{"trials":10336,"activeCount":98},[],{"trials":10338,"activeCount":98},[],{"trials":10340,"activeCount":208,"soonestReadout":9850},[10341],{"nctId":9847,"briefTitle":9848,"status":179,"phases":10342,"primaryCompletion":9850,"completion":9851,"start":496,"enrollment":9852,"conditions":10343,"interventions":10344},[],[3131],[664,9855,9856,9857],{"intervention":10346,"totalTrials":208,"cells":10347},"Xanomeline and trospium chloride",{"EARLY_PHASE1":10348,"PHASE1":10350,"PHASE2":10352,"PHASE3":10354,"PHASE4":10356,"NA":10358},{"trials":10349,"activeCount":98},[],{"trials":10351,"activeCount":98},[],{"trials":10353,"activeCount":98},[],{"trials":10355,"activeCount":98},[],{"trials":10357,"activeCount":98},[],{"trials":10359,"activeCount":208,"soonestReadout":10364},[10360],{"nctId":10361,"briefTitle":10362,"status":236,"phases":10363,"primaryCompletion":10364,"completion":10364,"start":10365,"enrollment":604,"conditions":10366,"interventions":10367},"NCT07379827","Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)",[],"2028-06-20","2026-02-26",[584],[10346],{"intervention":10369,"totalTrials":208,"cells":10370},"Approved Non-small Cell Lung Cancer (NSCLC) therapies",{"EARLY_PHASE1":10371,"PHASE1":10373,"PHASE2":10375,"PHASE3":10377,"PHASE4":10379,"NA":10381},{"trials":10372,"activeCount":98},[],{"trials":10374,"activeCount":98},[],{"trials":10376,"activeCount":98},[],{"trials":10378,"activeCount":98},[],{"trials":10380,"activeCount":98},[],{"trials":10382,"activeCount":208,"soonestReadout":298},[10383],{"nctId":10384,"briefTitle":10385,"status":236,"phases":10386,"primaryCompletion":298,"completion":298,"start":10387,"enrollment":7633,"conditions":10388,"interventions":10389},"NCT06448793","Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments",[],"2024-11-25",[3131],[10369],{"intervention":902,"totalTrials":1221,"cells":10391},{"EARLY_PHASE1":10392,"PHASE1":10394,"PHASE2":10416,"PHASE3":10437,"PHASE4":10478,"NA":10502},{"trials":10393,"activeCount":98},[],{"trials":10395,"activeCount":98},[10396,10405,10412],{"nctId":10397,"briefTitle":10398,"status":104,"phases":10399,"primaryCompletion":4122,"completion":4122,"start":3017,"enrollment":790,"conditions":10400,"interventions":10401},"NCT02159352","Study Assessing the Effects of Darunavir\u002FRitonavir or Lopinavir\u002FRitonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants",[87],[30],[10402,10403,902,10404],"Daclatasvir","Darunavir","Lopinavir\u002FRitonavir",{"nctId":10406,"briefTitle":10407,"status":104,"phases":10408,"primaryCompletion":4348,"completion":3938,"start":4038,"enrollment":12,"conditions":10409,"interventions":10411},"NCT00833482","Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir\u002FRitonavir in Healthy Participants",[87],[10410,24],"Human Immunodeficiency Virus Type 1 (HIV-1)",[6826,8547,902],{"nctId":895,"briefTitle":896,"status":104,"phases":10413,"primaryCompletion":898,"completion":898,"start":899,"enrollment":713,"conditions":10414,"interventions":10415},[87],[18],[679,902],{"trials":10417,"activeCount":98},[10418,10427],{"nctId":10419,"briefTitle":10420,"status":104,"phases":10421,"primaryCompletion":10422,"completion":10422,"start":10423,"conditions":10424,"interventions":10425},"NCT00004584","Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment",[88],"2002-01","1999-12",[24],[8547,902,10426],"Saquinavir",{"nctId":10428,"briefTitle":10429,"status":963,"phases":10430,"primaryCompletion":10431,"completion":7944,"start":7784,"enrollment":10432,"conditions":10433,"interventions":10434},"NCT00768989","Phase IIB Pilot of Atazanavir + Raltegravir",[88],"2010-01",167,[8545],[8547,10435,8547,902,10436],"Raltegravir","Tenofovir\u002FEmtricitabine",{"trials":10438,"activeCount":98},[10439,10448,10459,10467],{"nctId":10440,"briefTitle":10441,"status":467,"phases":10442,"primaryCompletion":10443,"completion":10443,"start":10444,"enrollment":98,"conditions":10445,"interventions":10446},"NCT01605084","Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone",[89],"2014-08-31","2012-06-30",[8545],[8547,10403,902,10447],"Optimized NRTI backbone",{"nctId":10449,"briefTitle":10450,"status":104,"phases":10451,"primaryCompletion":10452,"completion":10453,"start":10454,"enrollment":1232,"conditions":10455,"interventions":10456},"NCT01099579","PRINCE: Study of Atazanavir (ATV)\u002FRitonavir (RTV)",[89],"2012-10-04","2017-09-11","2010-10-13",[24],[10457,10458,8547,902],"Atazanavir powder","Ritonavir oral solution",{"nctId":10460,"briefTitle":10461,"status":963,"phases":10462,"primaryCompletion":7114,"completion":7114,"start":10463,"enrollment":574,"conditions":10464,"interventions":10465},"NCT01620944","Open-Label Study Comparing Efficacy and Safety of ATV\u002FRTV+3TC With ATV\u002FRTV+TDF\u002FFTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV\u002FRTV+3TC",[89],"2012-07-31",[8545],[8547,902,10466,10436],"Lamivudine",{"nctId":10468,"briefTitle":10469,"status":104,"phases":10470,"primaryCompletion":10471,"completion":10472,"start":10473,"enrollment":10474,"conditions":10475,"interventions":10476},"NCT01335698","Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients",[89],"2014-09-10","2018-01-22","2011-05-27",160,[8545],[10477,902],"Atazanavir Sulphate",{"trials":10479,"activeCount":98},[10480,10488,10492],{"nctId":10481,"briefTitle":10482,"status":104,"phases":10483,"primaryCompletion":6916,"completion":4551,"start":5542,"enrollment":10484,"conditions":10485,"interventions":10487},"NCT01332227","Atazanavir\u002FRitonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients",[90],132,[10486],"HIV, Combination Therapy",[8547,902,10435,10436],{"nctId":8541,"briefTitle":8542,"status":104,"phases":10489,"primaryCompletion":7089,"completion":7089,"start":3938,"enrollment":94,"conditions":10490,"interventions":10491},[90],[8545],[8547,8547,902,902,8548,8548,8549,8549,696,696],{"nctId":10493,"briefTitle":10494,"status":104,"phases":10495,"primaryCompletion":10496,"completion":10497,"start":10498,"enrollment":7833,"conditions":10499,"interventions":10501},"NCT01691794","Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients",[90],"2014-10-31","2017-02-20","2012-11-30",[10500],"HIV, Pediatric",[8547,902],{"trials":10503,"activeCount":98},[],{"intervention":6534,"totalTrials":747,"cells":10505},{"EARLY_PHASE1":10506,"PHASE1":10508,"PHASE2":10570,"PHASE3":10572,"PHASE4":10574,"NA":10580},{"trials":10507,"activeCount":98},[],{"trials":10509,"activeCount":98},[10510,10514,10521,10530,10540,10544,10552,10562],{"nctId":6521,"briefTitle":6522,"status":104,"phases":10511,"primaryCompletion":6524,"completion":6525,"start":6526,"enrollment":2527,"conditions":10512,"interventions":10513},[87],[15],[6529,772,617,6530,6531,6532,6533,6534,6535,6536],{"nctId":10515,"briefTitle":10516,"status":104,"phases":10517,"primaryCompletion":6916,"completion":6916,"start":10518,"enrollment":725,"conditions":10519,"interventions":10520},"NCT00996879","Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects",[87],"2013-05",[30],[6534,9391],{"nctId":10522,"briefTitle":10523,"status":104,"phases":10524,"primaryCompletion":4160,"completion":4160,"start":10525,"enrollment":1203,"conditions":10526,"interventions":10528},"NCT02208882","Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120",[87],"2014-08",[10527],"Healthy Adult Volunteers",[10529,6534],"BMS-986120",{"nctId":10531,"briefTitle":10532,"status":104,"phases":10533,"primaryCompletion":10534,"completion":2404,"start":10535,"enrollment":137,"conditions":10536,"interventions":10538},"NCT05952089","A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure",[87],"2024-03-15","2023-08-17",[10537],"Heart Failure With Reduced Ejection Fraction",[10539,6534],"Danicamtiv",{"nctId":8659,"briefTitle":8660,"status":104,"phases":10541,"primaryCompletion":8662,"completion":8662,"start":60,"enrollment":8663,"conditions":10542,"interventions":10543},[87],[18],[8521,8666,6534],{"nctId":10545,"briefTitle":10546,"status":104,"phases":10547,"primaryCompletion":10548,"completion":10548,"start":954,"enrollment":693,"conditions":10549,"interventions":10550},"NCT05852769","A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants",[87],"2023-08-24",[27],[10551,6530,6531,6532,6533,6534,6535,6536],"BMS-986196",{"nctId":10553,"briefTitle":10554,"status":104,"phases":10555,"primaryCompletion":4123,"completion":4123,"start":1343,"enrollment":713,"conditions":10556,"interventions":10557},"NCT01585623","Drug Interaction Study of SAR302503 in Patients With Solid Tumor",[87],[1482],[10558,10559,10560,10561],"SAR302503","omeprazol","metoprolol","midazolam",{"nctId":10563,"briefTitle":10564,"status":104,"phases":10565,"primaryCompletion":8187,"completion":8187,"start":10566,"enrollment":3978,"conditions":10567,"interventions":10568},"NCT05932277","A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants",[87],"2023-06-29",[27],[9403,6530,6835,6532,6533,6534,10569],"Fexofenadine",{"trials":10571,"activeCount":98},[],{"trials":10573,"activeCount":98},[],{"trials":10575,"activeCount":98},[10576],{"nctId":8119,"briefTitle":8120,"status":104,"phases":10577,"primaryCompletion":3958,"completion":3958,"start":3903,"enrollment":125,"conditions":10578,"interventions":10579},[90],[8123],[6530,8125,6533,8126,6534,7057],{"trials":10581,"activeCount":98},[],{"intervention":6533,"totalTrials":830,"cells":10583},{"EARLY_PHASE1":10584,"PHASE1":10586,"PHASE2":10613,"PHASE3":10615,"PHASE4":10617,"NA":10623},{"trials":10585,"activeCount":98},[],{"trials":10587,"activeCount":98},[10588,10597,10601,10605,10609],{"nctId":10589,"briefTitle":10590,"status":104,"phases":10591,"primaryCompletion":10592,"completion":10592,"start":10593,"enrollment":713,"conditions":10594,"interventions":10595},"NCT03936374","A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants",[87],"2019-07-20","2019-05-08",[759],[1337,10596],"omeprazole",{"nctId":6521,"briefTitle":6522,"status":104,"phases":10598,"primaryCompletion":6524,"completion":6525,"start":6526,"enrollment":2527,"conditions":10599,"interventions":10600},[87],[15],[6529,772,617,6530,6531,6532,6533,6534,6535,6536],{"nctId":6829,"briefTitle":6830,"status":104,"phases":10602,"primaryCompletion":5681,"completion":6832,"start":329,"enrollment":148,"conditions":10603,"interventions":10604},[87],[27],[6814,823,6535,874,6835,6532,6533],{"nctId":10545,"briefTitle":10546,"status":104,"phases":10606,"primaryCompletion":10548,"completion":10548,"start":954,"enrollment":693,"conditions":10607,"interventions":10608},[87],[27],[10551,6530,6531,6532,6533,6534,6535,6536],{"nctId":10563,"briefTitle":10564,"status":104,"phases":10610,"primaryCompletion":8187,"completion":8187,"start":10566,"enrollment":3978,"conditions":10611,"interventions":10612},[87],[27],[9403,6530,6835,6532,6533,6534,10569],{"trials":10614,"activeCount":98},[],{"trials":10616,"activeCount":98},[],{"trials":10618,"activeCount":98},[10619],{"nctId":8119,"briefTitle":8120,"status":104,"phases":10620,"primaryCompletion":3958,"completion":3958,"start":3903,"enrollment":125,"conditions":10621,"interventions":10622},[90],[8123],[6530,8125,6533,8126,6534,7057],{"trials":10624,"activeCount":98},[],{"intervention":10436,"totalTrials":4328,"cells":10626},{"EARLY_PHASE1":10627,"PHASE1":10629,"PHASE2":10631,"PHASE3":10637,"PHASE4":10652,"NA":10658},{"trials":10628,"activeCount":98},[],{"trials":10630,"activeCount":98},[],{"trials":10632,"activeCount":98},[10633],{"nctId":10428,"briefTitle":10429,"status":963,"phases":10634,"primaryCompletion":10431,"completion":7944,"start":7784,"enrollment":10432,"conditions":10635,"interventions":10636},[88],[8545],[8547,10435,8547,902,10436],{"trials":10638,"activeCount":98},[10639,10648],{"nctId":10640,"briefTitle":10641,"status":104,"phases":10642,"primaryCompletion":8030,"completion":8030,"start":5079,"enrollment":10643,"conditions":10644,"interventions":10645},"NCT01003990","Roll-Over Protocol To Provide Atv And\u002FOr Truvada For Extended Access",[89],710,[8545],[8547,10646,10436,10647],"Atazanavir\u002FRitonavir","Lopinavir\u002Fritonavir",{"nctId":10460,"briefTitle":10461,"status":963,"phases":10649,"primaryCompletion":7114,"completion":7114,"start":10463,"enrollment":574,"conditions":10650,"interventions":10651},[89],[8545],[8547,902,10466,10436],{"trials":10653,"activeCount":98},[10654],{"nctId":10481,"briefTitle":10482,"status":104,"phases":10655,"primaryCompletion":6916,"completion":4551,"start":5542,"enrollment":10484,"conditions":10656,"interventions":10657},[90],[10486],[8547,902,10435,10436],{"trials":10659,"activeCount":98},[],{"intervention":10661,"totalTrials":4328,"cells":10662},"Adefovir",{"EARLY_PHASE1":10663,"PHASE1":10665,"PHASE2":10667,"PHASE3":10669,"PHASE4":10699,"NA":10707},{"trials":10664,"activeCount":98},[],{"trials":10666,"activeCount":98},[],{"trials":10668,"activeCount":98},[],{"trials":10670,"activeCount":98},[10671,10681,10689],{"nctId":10672,"briefTitle":10673,"status":104,"phases":10674,"primaryCompletion":6480,"completion":10518,"start":10675,"enrollment":10676,"conditions":10677,"interventions":10679},"NCT00065507","Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation",[89],"2003-08",195,[10678],"Hepatitis B",[10680,10661],"Entecavir",{"nctId":10682,"briefTitle":10683,"status":104,"phases":10684,"primaryCompletion":3894,"completion":3902,"start":5023,"enrollment":10685,"conditions":10686,"interventions":10688},"NCT00410202","Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus",[89],629,[10687],"Hepatitis B, Chronic",[10680,8548,10661,10466],{"nctId":10690,"briefTitle":10691,"status":104,"phases":10692,"primaryCompletion":4995,"completion":7811,"start":10693,"enrollment":8039,"conditions":10694,"interventions":10696},"NCT00096785","Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection",[89],"2004-12",[10678,10695],"Chronic Disease",[10697,10698],"entecavir","adefovir",{"trials":10700,"activeCount":98},[10701],{"nctId":10702,"briefTitle":10703,"status":467,"phases":10704,"primaryCompletion":3977,"completion":3017,"start":5014,"enrollment":98,"conditions":10705,"interventions":10706},"NCT00986778","Entecavir Plus Adefovir in Lamivudine-Resistant Patients",[90],[10687],[10466,10680,10661],{"trials":10708,"activeCount":98},[],{"intervention":6530,"totalTrials":4328,"cells":10710},{"EARLY_PHASE1":10711,"PHASE1":10713,"PHASE2":10727,"PHASE3":10729,"PHASE4":10731,"NA":10737},{"trials":10712,"activeCount":98},[],{"trials":10714,"activeCount":98},[10715,10719,10723],{"nctId":6521,"briefTitle":6522,"status":104,"phases":10716,"primaryCompletion":6524,"completion":6525,"start":6526,"enrollment":2527,"conditions":10717,"interventions":10718},[87],[15],[6529,772,617,6530,6531,6532,6533,6534,6535,6536],{"nctId":10545,"briefTitle":10546,"status":104,"phases":10720,"primaryCompletion":10548,"completion":10548,"start":954,"enrollment":693,"conditions":10721,"interventions":10722},[87],[27],[10551,6530,6531,6532,6533,6534,6535,6536],{"nctId":10563,"briefTitle":10564,"status":104,"phases":10724,"primaryCompletion":8187,"completion":8187,"start":10566,"enrollment":3978,"conditions":10725,"interventions":10726},[87],[27],[9403,6530,6835,6532,6533,6534,10569],{"trials":10728,"activeCount":98},[],{"trials":10730,"activeCount":98},[],{"trials":10732,"activeCount":98},[10733],{"nctId":8119,"briefTitle":8120,"status":104,"phases":10734,"primaryCompletion":3958,"completion":3958,"start":3903,"enrollment":125,"conditions":10735,"interventions":10736},[90],[8123],[6530,8125,6533,8126,6534,7057],{"trials":10738,"activeCount":98},[],{"intervention":8548,"totalTrials":4328,"cells":10740},{"EARLY_PHASE1":10741,"PHASE1":10743,"PHASE2":10745,"PHASE3":10756,"PHASE4":10770,"NA":10776},{"trials":10742,"activeCount":98},[],{"trials":10744,"activeCount":98},[],{"trials":10746,"activeCount":98},[10747],{"nctId":10748,"briefTitle":10749,"status":963,"phases":10750,"primaryCompletion":4123,"completion":4122,"start":3938,"enrollment":10751,"conditions":10752,"interventions":10754},"NCT01489046","Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive",[88],297,[10753],"HIV-1 Infection",[10755,10755,10755,9383,10466,8548],"BMS-986001",{"trials":10757,"activeCount":98},[10758,10766],{"nctId":10759,"briefTitle":10760,"status":104,"phases":10761,"primaryCompletion":3893,"completion":4551,"start":7944,"enrollment":10762,"conditions":10763,"interventions":10765},"NCT01063036","Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment",[89],144,[10764],"Chronic Hepatitis B",[10680,8548],{"nctId":10682,"briefTitle":10683,"status":104,"phases":10767,"primaryCompletion":3894,"completion":3902,"start":5023,"enrollment":10685,"conditions":10768,"interventions":10769},[89],[10687],[10680,8548,10661,10466],{"trials":10771,"activeCount":98},[10772],{"nctId":8541,"briefTitle":8542,"status":104,"phases":10773,"primaryCompletion":7089,"completion":7089,"start":3938,"enrollment":94,"conditions":10774,"interventions":10775},[90],[8545],[8547,8547,902,902,8548,8548,8549,8549,696,696],{"trials":10777,"activeCount":98},[],{"intervention":10646,"totalTrials":574,"cells":10779},{"EARLY_PHASE1":10780,"PHASE1":10782,"PHASE2":10791,"PHASE3":10793,"PHASE4":10799,"NA":10809},{"trials":10781,"activeCount":98},[],{"trials":10783,"activeCount":98},[10784],{"nctId":10785,"briefTitle":10786,"status":104,"phases":10787,"primaryCompletion":4379,"completion":4379,"start":5117,"enrollment":7813,"conditions":10788,"interventions":10789},"NCT00357240","Drug Interaction Study With Proton Pump Inhibitor",[87],[24],[8547,10646,10790,10790,8547,10646,10790,10790],"Atazanavir\u002FRitonavir+Omeprazole",{"trials":10792,"activeCount":98},[],{"trials":10794,"activeCount":98},[10795],{"nctId":10640,"briefTitle":10641,"status":104,"phases":10796,"primaryCompletion":8030,"completion":8030,"start":5079,"enrollment":10643,"conditions":10797,"interventions":10798},[89],[8545],[8547,10646,10436,10647],{"trials":10800,"activeCount":98},[10801],{"nctId":10802,"briefTitle":10803,"status":104,"phases":10804,"primaryCompletion":6968,"completion":6968,"start":7846,"enrollment":3562,"conditions":10805,"interventions":10806},"NCT00384904","Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients",[90],[24],[10646,10807,10807,10646,10808,10808],"Atazanavir\u002FRitonavir + Famotidine","Atazanavir\u002FRitonavir + Tenofovir Disproxil Fumrarate + Famotidine",{"trials":10810,"activeCount":98},[],{"intervention":10435,"totalTrials":574,"cells":10812},{"EARLY_PHASE1":10813,"PHASE1":10815,"PHASE2":10825,"PHASE3":10831,"PHASE4":10833,"NA":10839},{"trials":10814,"activeCount":98},[],{"trials":10816,"activeCount":98},[10817],{"nctId":10818,"briefTitle":10819,"status":104,"phases":10820,"primaryCompletion":6968,"completion":6968,"start":10821,"enrollment":3978,"conditions":10822,"interventions":10823},"NCT00518297","DDI HV (ATV - Merck)",[87],"2007-08",[24],[10435,8547,10824],"Atazanavir + Raltegravir",{"trials":10826,"activeCount":98},[10827],{"nctId":10428,"briefTitle":10429,"status":963,"phases":10828,"primaryCompletion":10431,"completion":7944,"start":7784,"enrollment":10432,"conditions":10829,"interventions":10830},[88],[8545],[8547,10435,8547,902,10436],{"trials":10832,"activeCount":98},[],{"trials":10834,"activeCount":98},[10835],{"nctId":10481,"briefTitle":10482,"status":104,"phases":10836,"primaryCompletion":6916,"completion":4551,"start":5542,"enrollment":10484,"conditions":10837,"interventions":10838},[90],[10486],[8547,902,10435,10436],{"trials":10840,"activeCount":98},[],{"intervention":10842,"totalTrials":574,"cells":10843},"Irbesartan",{"EARLY_PHASE1":10844,"PHASE1":10846,"PHASE2":10848,"PHASE3":10850,"PHASE4":10869,"NA":10880},{"trials":10845,"activeCount":98},[],{"trials":10847,"activeCount":98},[],{"trials":10849,"activeCount":98},[],{"trials":10851,"activeCount":98},[10852,10860],{"nctId":10853,"briefTitle":10854,"status":104,"phases":10855,"primaryCompletion":4664,"completion":4664,"start":10856,"enrollment":184,"conditions":10857,"interventions":10859},"NCT00352560","Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)",[89],"2006-07",[10858],"Atrial Fibrillation",[10842],{"nctId":10861,"briefTitle":10862,"status":104,"phases":10863,"primaryCompletion":4039,"completion":4039,"start":10864,"enrollment":10865,"conditions":10866,"interventions":10868},"NCT00095238","Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)",[89],"2002-06",4128,[10867],"Congestive Heart Failure",[10842],{"trials":10870,"activeCount":98},[10871],{"nctId":10872,"briefTitle":10873,"status":104,"phases":10874,"primaryCompletion":7750,"completion":7750,"start":3657,"enrollment":2563,"conditions":10875,"interventions":10878},"NCT00110422","Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome",[90],[10876,10877],"Metabolic Syndrome","Hypertension",[10842,10879],"Hydrochlorothiazide",{"trials":10881,"activeCount":98},[],{"intervention":10883,"totalTrials":574,"cells":10884},"Megestrol acetate",{"EARLY_PHASE1":10885,"PHASE1":10887,"PHASE2":10889,"PHASE3":10899,"PHASE4":10907,"NA":10915},{"trials":10886,"activeCount":98},[],{"trials":10888,"activeCount":98},[],{"trials":10890,"activeCount":98},[10891],{"nctId":10892,"briefTitle":10893,"status":104,"phases":10894,"conditions":10895,"interventions":10898},"NCT00002300","A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and Malnutrition",[88],[10896,10897,24],"Anorexia","Cachexia",[10883],{"trials":10900,"activeCount":98},[10901],{"nctId":10902,"briefTitle":10903,"status":104,"phases":10904,"conditions":10905,"interventions":10906},"NCT00002067","A Study Comparing Megestrol Acetate at 800 mg\u002FDay, and Placebo in AIDS Patients With Anorexia and Cachexia",[89],[10896,10897,24],[10883],{"trials":10908,"activeCount":98},[10909],{"nctId":10910,"briefTitle":10911,"status":104,"phases":10912,"enrollment":3562,"conditions":10913,"interventions":10914},"NCT00002345","The Safety and Effectiveness of Megace in HIV-Infected Women",[90],[10896,10897,24],[10883],{"trials":10916,"activeCount":98},[],{"intervention":6536,"totalTrials":574,"cells":10918},{"EARLY_PHASE1":10919,"PHASE1":10921,"PHASE2":10931,"PHASE3":10933,"PHASE4":10935,"NA":10944},{"trials":10920,"activeCount":98},[],{"trials":10922,"activeCount":98},[10923,10927],{"nctId":6521,"briefTitle":6522,"status":104,"phases":10924,"primaryCompletion":6524,"completion":6525,"start":6526,"enrollment":2527,"conditions":10925,"interventions":10926},[87],[15],[6529,772,617,6530,6531,6532,6533,6534,6535,6536],{"nctId":10545,"briefTitle":10546,"status":104,"phases":10928,"primaryCompletion":10548,"completion":10548,"start":954,"enrollment":693,"conditions":10929,"interventions":10930},[87],[27],[10551,6530,6531,6532,6533,6534,6535,6536],{"trials":10932,"activeCount":98},[],{"trials":10934,"activeCount":98},[],{"trials":10936,"activeCount":98},[10937],{"nctId":10938,"briefTitle":10939,"status":104,"phases":10940,"primaryCompletion":5050,"completion":5050,"start":5051,"enrollment":2317,"conditions":10941,"interventions":10943},"NCT00529178","Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease",[90],[10942],"Hypercholesterolemia",[6536],{"trials":10945,"activeCount":98},[],{"intervention":10947,"totalTrials":230,"cells":10948},"Glucovance",{"EARLY_PHASE1":10949,"PHASE1":10951,"PHASE2":10953,"PHASE3":10955,"PHASE4":10967,"NA":10979},{"trials":10950,"activeCount":98},[],{"trials":10952,"activeCount":98},[],{"trials":10954,"activeCount":98},[],{"trials":10956,"activeCount":98},[10957],{"nctId":10958,"briefTitle":10959,"status":104,"phases":10960,"primaryCompletion":7675,"completion":7675,"start":10961,"conditions":10962,"interventions":10964},"NCT00035542","A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.",[89],"2001-12",[10963],"Diabetes Mellitus, Non-Insulin-Dependent",[10947,10965,10966],"metformin HCl","glyburide",{"trials":10968,"activeCount":98},[10969],{"nctId":10970,"briefTitle":10971,"status":104,"phases":10972,"primaryCompletion":10973,"completion":10973,"start":10974,"conditions":10975,"interventions":10976},"NCT00035568","A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes",[90],"2003-06","2002-02",[10963],[10947,10977,10978],"or Metformin HCl alone","or Glyburide alone.",{"trials":10980,"activeCount":98},[],{"intervention":10982,"totalTrials":230,"cells":10983},"Acetylsalicylic acid",{"EARLY_PHASE1":10984,"PHASE1":10986,"PHASE2":10988,"PHASE3":10990,"PHASE4":11002,"NA":11015},{"trials":10985,"activeCount":98},[],{"trials":10987,"activeCount":98},[],{"trials":10989,"activeCount":98},[],{"trials":10991,"activeCount":98},[10992],{"nctId":10993,"briefTitle":10994,"status":104,"phases":10995,"primaryCompletion":10996,"completion":1306,"start":10997,"enrollment":10998,"conditions":10999,"interventions":11000},"NCT00496769","A Phase III Study of Apixaban in Patients With Atrial Fibrillation",[89],"2010-11-30","2007-08-31",6421,[10858],[11001,10982],"Apixaban",{"trials":11003,"activeCount":98},[11004],{"nctId":11005,"briefTitle":11006,"status":104,"phases":11007,"primaryCompletion":11008,"completion":11008,"start":11009,"enrollment":11010,"conditions":11011,"interventions":11013},"NCT02415400","A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart",[90],"2018-11-10","2015-06-04",4614,[11012],"Acute Coronary Syndromes",[11001,11014,10982],"vitamin K antagonist",{"trials":11016,"activeCount":98},[],{"intervention":11018,"totalTrials":230,"cells":11019},"Aripiprazole",{"EARLY_PHASE1":11020,"PHASE1":11022,"PHASE2":11024,"PHASE3":11026,"PHASE4":11028,"NA":11046},{"trials":11021,"activeCount":98},[],{"trials":11023,"activeCount":98},[],{"trials":11025,"activeCount":98},[],{"trials":11027,"activeCount":98},[],{"trials":11029,"activeCount":98},[11030,11039],{"nctId":11031,"briefTitle":11032,"status":104,"phases":11033,"primaryCompletion":1343,"completion":1343,"start":11034,"enrollment":11035,"conditions":11036,"interventions":11038},"NCT01227668","Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder",[90],"2011-03",215,[11037],"Irritability Associated With Autistic Disorder",[11018],{"nctId":11040,"briefTitle":11041,"status":963,"phases":11042,"primaryCompletion":4981,"completion":4981,"start":7758,"enrollment":9741,"conditions":11043,"interventions":11044},"NCT00508157","A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome",[90],[10876,584],[11018,11045],"Continued Antipsychotic",{"trials":11047,"activeCount":98},[],{"intervention":11014,"totalTrials":230,"cells":11049},{"EARLY_PHASE1":11050,"PHASE1":11052,"PHASE2":11054,"PHASE3":11067,"PHASE4":11069,"NA":11075},{"trials":11051,"activeCount":98},[],{"trials":11053,"activeCount":98},[],{"trials":11055,"activeCount":98},[11056],{"nctId":11057,"briefTitle":11058,"status":104,"phases":11059,"primaryCompletion":3084,"completion":3084,"start":11060,"enrollment":11061,"conditions":11062,"interventions":11064},"NCT02981472","A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation",[88],"2017-01-19",192,[11063],"Thrombosis",[11001,11065,11066],"Vitamin K Antagonist","Low Molecular Weight Heparin",{"trials":11068,"activeCount":98},[],{"trials":11070,"activeCount":98},[11071],{"nctId":11005,"briefTitle":11006,"status":104,"phases":11072,"primaryCompletion":11008,"completion":11008,"start":11009,"enrollment":11010,"conditions":11073,"interventions":11074},[90],[11012],[11001,11014,10982],{"trials":11076,"activeCount":98},[],{"intervention":11078,"totalTrials":230,"cells":11079},"Metformin XR",{"EARLY_PHASE1":11080,"PHASE1":11082,"PHASE2":11084,"PHASE3":11086,"PHASE4":11088,"NA":11108},{"trials":11081,"activeCount":98},[],{"trials":11083,"activeCount":98},[],{"trials":11085,"activeCount":98},[],{"trials":11087,"activeCount":98},[],{"trials":11089,"activeCount":98},[11090,11101],{"nctId":11091,"briefTitle":11092,"status":104,"phases":11093,"primaryCompletion":11094,"completion":11094,"start":11095,"enrollment":11096,"conditions":11097,"interventions":11099},"NCT01864174","Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes",[90],"2016-06-01","2013-06-20",1736,[11098],"Type 2 Diabetes Mellitus",[11078,11100],"Metformin IR",{"nctId":11102,"briefTitle":11103,"status":104,"phases":11104,"primaryCompletion":11034,"completion":11034,"start":3585,"enrollment":11105,"conditions":11106,"interventions":11107},"NCT00778622","Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients",[90],371,[11098],[11078],{"trials":11109,"activeCount":98},[],{"intervention":11111,"totalTrials":208,"cells":11112},"Standard of Care",{"EARLY_PHASE1":11113,"PHASE1":11115,"PHASE2":11117,"PHASE3":11119,"PHASE4":11121,"NA":11132},{"trials":11114,"activeCount":98},[],{"trials":11116,"activeCount":98},[],{"trials":11118,"activeCount":98},[],{"trials":11120,"activeCount":98},[],{"trials":11122,"activeCount":98},[11123],{"nctId":11124,"briefTitle":11125,"status":104,"phases":11126,"primaryCompletion":11127,"completion":11127,"start":11128,"enrollment":2336,"conditions":11129,"interventions":11131},"NCT02464969","Apixaban for the Acute Treatment of Venous Thromboembolism in Children",[90],"2024-04-30","2015-11-22",[11130],"Venous Thromboembolism",[11001,11111],{"trials":11133,"activeCount":98},[],{"intervention":10807,"totalTrials":208,"cells":11135},{"EARLY_PHASE1":11136,"PHASE1":11138,"PHASE2":11140,"PHASE3":11142,"PHASE4":11144,"NA":11150},{"trials":11137,"activeCount":98},[],{"trials":11139,"activeCount":98},[],{"trials":11141,"activeCount":98},[],{"trials":11143,"activeCount":98},[],{"trials":11145,"activeCount":98},[11146],{"nctId":10802,"briefTitle":10803,"status":104,"phases":11147,"primaryCompletion":6968,"completion":6968,"start":7846,"enrollment":3562,"conditions":11148,"interventions":11149},[90],[24],[10646,10807,10807,10646,10808,10808],{"trials":11151,"activeCount":98},[],{"intervention":10808,"totalTrials":208,"cells":11153},{"EARLY_PHASE1":11154,"PHASE1":11156,"PHASE2":11158,"PHASE3":11160,"PHASE4":11162,"NA":11168},{"trials":11155,"activeCount":98},[],{"trials":11157,"activeCount":98},[],{"trials":11159,"activeCount":98},[],{"trials":11161,"activeCount":98},[],{"trials":11163,"activeCount":98},[11164],{"nctId":10802,"briefTitle":10803,"status":104,"phases":11165,"primaryCompletion":6968,"completion":6968,"start":7846,"enrollment":3562,"conditions":11166,"interventions":11167},[90],[24],[10646,10807,10807,10646,10808,10808],{"trials":11169,"activeCount":98},[],{"intervention":11171,"totalTrials":208,"cells":11172},"Atazanavir\u002F Stavidine \u002F Lamivudine",{"EARLY_PHASE1":11173,"PHASE1":11175,"PHASE2":11177,"PHASE3":11179,"PHASE4":11181,"NA":11191},{"trials":11174,"activeCount":98},[],{"trials":11176,"activeCount":98},[],{"trials":11178,"activeCount":98},[],{"trials":11180,"activeCount":98},[],{"trials":11182,"activeCount":98},[11183],{"nctId":11184,"briefTitle":11185,"status":104,"phases":11186,"primaryCompletion":4379,"start":11187,"enrollment":311,"conditions":11188,"interventions":11189},"NCT00084253","Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients",[90],"2004-06",[24],[11171,11190],"Atazanavir-Ritonavir\u002F Stavidine \u002F Lamivudine",{"trials":11192,"activeCount":98},[],{"intervention":11190,"totalTrials":208,"cells":11194},{"EARLY_PHASE1":11195,"PHASE1":11197,"PHASE2":11199,"PHASE3":11201,"PHASE4":11203,"NA":11209},{"trials":11196,"activeCount":98},[],{"trials":11198,"activeCount":98},[],{"trials":11200,"activeCount":98},[],{"trials":11202,"activeCount":98},[],{"trials":11204,"activeCount":98},[11205],{"nctId":11184,"briefTitle":11185,"status":104,"phases":11206,"primaryCompletion":4379,"start":11187,"enrollment":311,"conditions":11207,"interventions":11208},[90],[24],[11171,11190],{"trials":11210,"activeCount":98},[],{"intervention":11212,"totalTrials":208,"cells":11213},"Nivolumab in combination with Ipilimumab",{"EARLY_PHASE1":11214,"PHASE1":11216,"PHASE2":11218,"PHASE3":11220,"PHASE4":11222,"NA":11232},{"trials":11215,"activeCount":98},[],{"trials":11217,"activeCount":98},[],{"trials":11219,"activeCount":98},[],{"trials":11221,"activeCount":98},[],{"trials":11223,"activeCount":98},[11224],{"nctId":11225,"briefTitle":11226,"status":104,"phases":11227,"primaryCompletion":11228,"completion":11228,"start":2457,"enrollment":11229,"conditions":11230,"interventions":11231},"NCT02869789","An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers",[90],"2022-05-13",1041,[1717],[11212],{"trials":11233,"activeCount":98},[],{"intervention":11235,"totalTrials":208,"cells":11236},"efavirenz, stavudine extended release, lamivudine",{"EARLY_PHASE1":11237,"PHASE1":11239,"PHASE2":11241,"PHASE3":11243,"PHASE4":11245,"NA":11255},{"trials":11238,"activeCount":98},[],{"trials":11240,"activeCount":98},[],{"trials":11242,"activeCount":98},[],{"trials":11244,"activeCount":98},[],{"trials":11246,"activeCount":98},[11247],{"nctId":11248,"briefTitle":11249,"status":104,"phases":11250,"primaryCompletion":11251,"completion":11251,"start":7724,"enrollment":22,"conditions":11252,"interventions":11254},"NCT00116116","DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy",[90],"2005-06",[24,11253],"AIDS",[11235],{"trials":11256,"activeCount":98},[],{"intervention":11258,"totalTrials":208,"cells":11259},"Paracetamol",{"EARLY_PHASE1":11260,"PHASE1":11262,"PHASE2":11264,"PHASE3":11266,"PHASE4":11268,"NA":11278},{"trials":11261,"activeCount":98},[],{"trials":11263,"activeCount":98},[],{"trials":11265,"activeCount":98},[],{"trials":11267,"activeCount":98},[],{"trials":11269,"activeCount":98},[11270],{"nctId":11271,"briefTitle":11272,"status":104,"phases":11273,"primaryCompletion":3680,"completion":3680,"start":4011,"enrollment":11274,"conditions":11275,"interventions":11277},"NCT00344045","Study to Evaluate The Analgesic Efficacy and Safety of Intravenous Paracetamol in Subjects With Postoperative Pain After Total Hip Arthroplasty",[90],86,[11276],"Pain",[11258],{"trials":11279,"activeCount":98},[],{"intervention":10879,"totalTrials":208,"cells":11281},{"EARLY_PHASE1":11282,"PHASE1":11284,"PHASE2":11286,"PHASE3":11288,"PHASE4":11290,"NA":11296},{"trials":11283,"activeCount":98},[],{"trials":11285,"activeCount":98},[],{"trials":11287,"activeCount":98},[],{"trials":11289,"activeCount":98},[],{"trials":11291,"activeCount":98},[11292],{"nctId":10872,"briefTitle":10873,"status":104,"phases":11293,"primaryCompletion":7750,"completion":7750,"start":3657,"enrollment":2563,"conditions":11294,"interventions":11295},[90],[10876,10877],[10842,10879],{"trials":11297,"activeCount":98},[],{"intervention":10977,"totalTrials":208,"cells":11299},{"EARLY_PHASE1":11300,"PHASE1":11302,"PHASE2":11304,"PHASE3":11306,"PHASE4":11308,"NA":11314},{"trials":11301,"activeCount":98},[],{"trials":11303,"activeCount":98},[],{"trials":11305,"activeCount":98},[],{"trials":11307,"activeCount":98},[],{"trials":11309,"activeCount":98},[11310],{"nctId":10970,"briefTitle":10971,"status":104,"phases":11311,"primaryCompletion":10973,"completion":10973,"start":10974,"conditions":11312,"interventions":11313},[90],[10963],[10947,10977,10978],{"trials":11315,"activeCount":98},[],{"intervention":10978,"totalTrials":208,"cells":11317},{"EARLY_PHASE1":11318,"PHASE1":11320,"PHASE2":11322,"PHASE3":11324,"PHASE4":11326,"NA":11332},{"trials":11319,"activeCount":98},[],{"trials":11321,"activeCount":98},[],{"trials":11323,"activeCount":98},[],{"trials":11325,"activeCount":98},[],{"trials":11327,"activeCount":98},[11328],{"nctId":10970,"briefTitle":10971,"status":104,"phases":11329,"primaryCompletion":10973,"completion":10973,"start":10974,"conditions":11330,"interventions":11331},[90],[10963],[10947,10977,10978],{"trials":11333,"activeCount":98},[],{"intervention":8549,"totalTrials":208,"cells":11335},{"EARLY_PHASE1":11336,"PHASE1":11338,"PHASE2":11340,"PHASE3":11342,"PHASE4":11344,"NA":11350},{"trials":11337,"activeCount":98},[],{"trials":11339,"activeCount":98},[],{"trials":11341,"activeCount":98},[],{"trials":11343,"activeCount":98},[],{"trials":11345,"activeCount":98},[11346],{"nctId":8541,"briefTitle":8542,"status":104,"phases":11347,"primaryCompletion":7089,"completion":7089,"start":3938,"enrollment":94,"conditions":11348,"interventions":11349},[90],[8545],[8547,8547,902,902,8548,8548,8549,8549,696,696],{"trials":11351,"activeCount":98},[],{"intervention":8125,"totalTrials":208,"cells":11353},{"EARLY_PHASE1":11354,"PHASE1":11356,"PHASE2":11358,"PHASE3":11360,"PHASE4":11362,"NA":11368},{"trials":11355,"activeCount":98},[],{"trials":11357,"activeCount":98},[],{"trials":11359,"activeCount":98},[],{"trials":11361,"activeCount":98},[],{"trials":11363,"activeCount":98},[11364],{"nctId":8119,"briefTitle":8120,"status":104,"phases":11365,"primaryCompletion":3958,"completion":3958,"start":3903,"enrollment":125,"conditions":11366,"interventions":11367},[90],[8123],[6530,8125,6533,8126,6534,7057],{"trials":11369,"activeCount":98},[],{"intervention":8126,"totalTrials":208,"cells":11371},{"EARLY_PHASE1":11372,"PHASE1":11374,"PHASE2":11376,"PHASE3":11378,"PHASE4":11380,"NA":11386},{"trials":11373,"activeCount":98},[],{"trials":11375,"activeCount":98},[],{"trials":11377,"activeCount":98},[],{"trials":11379,"activeCount":98},[],{"trials":11381,"activeCount":98},[11382],{"nctId":8119,"briefTitle":8120,"status":104,"phases":11383,"primaryCompletion":3958,"completion":3958,"start":3903,"enrollment":125,"conditions":11384,"interventions":11385},[90],[8123],[6530,8125,6533,8126,6534,7057],{"trials":11387,"activeCount":98},[],{"intervention":11389,"totalTrials":208,"cells":11390},"Ramipril + Irbesartan",{"EARLY_PHASE1":11391,"PHASE1":11393,"PHASE2":11395,"PHASE3":11397,"PHASE4":11399,"NA":11410},{"trials":11392,"activeCount":98},[],{"trials":11394,"activeCount":98},[],{"trials":11396,"activeCount":98},[],{"trials":11398,"activeCount":98},[],{"trials":11400,"activeCount":98},[11401],{"nctId":11402,"briefTitle":11403,"status":104,"phases":11404,"primaryCompletion":3657,"completion":3657,"start":11405,"enrollment":2563,"conditions":11406,"interventions":11408},"NCT00095290","Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria",[90],"2004-09",[11407],"Albuminuria",[11389,11409],"Ramipril + Placebo",{"trials":11411,"activeCount":98},[],{"intervention":11409,"totalTrials":208,"cells":11413},{"EARLY_PHASE1":11414,"PHASE1":11416,"PHASE2":11418,"PHASE3":11420,"PHASE4":11422,"NA":11428},{"trials":11415,"activeCount":98},[],{"trials":11417,"activeCount":98},[],{"trials":11419,"activeCount":98},[],{"trials":11421,"activeCount":98},[],{"trials":11423,"activeCount":98},[11424],{"nctId":11402,"briefTitle":11403,"status":104,"phases":11425,"primaryCompletion":3657,"completion":3657,"start":11405,"enrollment":2563,"conditions":11426,"interventions":11427},[90],[11407],[11389,11409],{"trials":11429,"activeCount":98},[],{"intervention":11431,"totalTrials":208,"cells":11432},"PRAVASTATIN SODIUM",{"EARLY_PHASE1":11433,"PHASE1":11435,"PHASE2":11437,"PHASE3":11439,"PHASE4":11441,"NA":11452},{"trials":11434,"activeCount":98},[],{"trials":11436,"activeCount":98},[],{"trials":11438,"activeCount":98},[],{"trials":11440,"activeCount":98},[],{"trials":11442,"activeCount":98},[11443],{"nctId":11444,"briefTitle":11445,"status":104,"phases":11446,"primaryCompletion":3640,"completion":3640,"start":11447,"enrollment":11448,"conditions":11449,"interventions":11451},"NCT00382460","Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22)",[90],"2000-11",4000,[11450],"Actue Coronary Syndromes",[11431],{"trials":11453,"activeCount":98},[],{"intervention":11455,"totalTrials":208,"cells":11456},"Atazanavir + 2 NRTIs",{"EARLY_PHASE1":11457,"PHASE1":11459,"PHASE2":11461,"PHASE3":11463,"PHASE4":11465,"NA":11474},{"trials":11458,"activeCount":98},[],{"trials":11460,"activeCount":98},[],{"trials":11462,"activeCount":98},[],{"trials":11464,"activeCount":98},[],{"trials":11466,"activeCount":98},[11467],{"nctId":11468,"briefTitle":11469,"status":104,"phases":11470,"primaryCompletion":10821,"completion":4930,"start":3657,"enrollment":4872,"conditions":11471,"interventions":11472},"NCT00207142","Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)",[90],[24],[11455,11473],"Atazanavir + Ritonavir + 2 NRTIs",{"trials":11475,"activeCount":98},[],{"intervention":11473,"totalTrials":208,"cells":11477},{"EARLY_PHASE1":11478,"PHASE1":11480,"PHASE2":11482,"PHASE3":11484,"PHASE4":11486,"NA":11492},{"trials":11479,"activeCount":98},[],{"trials":11481,"activeCount":98},[],{"trials":11483,"activeCount":98},[],{"trials":11485,"activeCount":98},[],{"trials":11487,"activeCount":98},[11488],{"nctId":11468,"briefTitle":11469,"status":104,"phases":11489,"primaryCompletion":10821,"completion":4930,"start":3657,"enrollment":4872,"conditions":11490,"interventions":11491},[90],[24],[11455,11473],{"trials":11493,"activeCount":98},[],{"intervention":11495,"totalTrials":208,"cells":11496},"continuation of current HAART",{"EARLY_PHASE1":11497,"PHASE1":11499,"PHASE2":11501,"PHASE3":11503,"PHASE4":11505,"NA":11515},{"trials":11498,"activeCount":98},[],{"trials":11500,"activeCount":98},[],{"trials":11502,"activeCount":98},[],{"trials":11504,"activeCount":98},[],{"trials":11506,"activeCount":98},[11507],{"nctId":11508,"briefTitle":11509,"status":104,"phases":11510,"primaryCompletion":4010,"completion":11511,"start":5078,"enrollment":1945,"conditions":11512,"interventions":11514},"NCT00135356","Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome",[90],"2008-06",[11513],"HIV-Associated Lipodystrophy Syndrome",[8547,11495],{"trials":11516,"activeCount":98},[],{"intervention":11100,"totalTrials":208,"cells":11518},{"EARLY_PHASE1":11519,"PHASE1":11521,"PHASE2":11523,"PHASE3":11525,"PHASE4":11527,"NA":11533},{"trials":11520,"activeCount":98},[],{"trials":11522,"activeCount":98},[],{"trials":11524,"activeCount":98},[],{"trials":11526,"activeCount":98},[],{"trials":11528,"activeCount":98},[11529],{"nctId":11091,"briefTitle":11092,"status":104,"phases":11530,"primaryCompletion":11094,"completion":11094,"start":11095,"enrollment":11096,"conditions":11531,"interventions":11532},[90],[11098],[11078,11100],{"trials":11534,"activeCount":98},[],{"intervention":11536,"totalTrials":208,"cells":11537},"Lamivudine Placebo",{"EARLY_PHASE1":11538,"PHASE1":11540,"PHASE2":11542,"PHASE3":11544,"PHASE4":11546,"NA":11556},{"trials":11539,"activeCount":98},[],{"trials":11541,"activeCount":98},[],{"trials":11543,"activeCount":98},[],{"trials":11545,"activeCount":98},[],{"trials":11547,"activeCount":98},[11548],{"nctId":11549,"briefTitle":11550,"status":104,"phases":11551,"primaryCompletion":7713,"completion":6916,"start":7750,"enrollment":11552,"conditions":11553,"interventions":11554},"NCT00393484","A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection",[90],122,[10764],[10680,11536,10466,11555],"Entecavir Placebo",{"trials":11557,"activeCount":98},[],{"intervention":11555,"totalTrials":208,"cells":11559},{"EARLY_PHASE1":11560,"PHASE1":11562,"PHASE2":11564,"PHASE3":11566,"PHASE4":11568,"NA":11574},{"trials":11561,"activeCount":98},[],{"trials":11563,"activeCount":98},[],{"trials":11565,"activeCount":98},[],{"trials":11567,"activeCount":98},[],{"trials":11569,"activeCount":98},[11570],{"nctId":11549,"briefTitle":11550,"status":104,"phases":11571,"primaryCompletion":7713,"completion":6916,"start":7750,"enrollment":11552,"conditions":11572,"interventions":11573},[90],[10764],[10680,11536,10466,11555],{"trials":11575,"activeCount":98},[],{"intervention":11577,"totalTrials":208,"cells":11578},"Adefovir\u002FEntecavir",{"EARLY_PHASE1":11579,"PHASE1":11581,"PHASE2":11583,"PHASE3":11585,"PHASE4":11587,"NA":11596},{"trials":11580,"activeCount":98},[],{"trials":11582,"activeCount":98},[],{"trials":11584,"activeCount":98},[],{"trials":11586,"activeCount":98},[],{"trials":11588,"activeCount":98},[11589],{"nctId":11590,"briefTitle":11591,"status":104,"phases":11592,"primaryCompletion":5014,"completion":3894,"start":4039,"enrollment":11593,"conditions":11594,"interventions":11595},"NCT00718887","Suboptimal Responders to Adefovir Switching to Entecavir",[90],228,[10687],[10680,11577],{"trials":11597,"activeCount":98},[],{"intervention":11045,"totalTrials":208,"cells":11599},{"EARLY_PHASE1":11600,"PHASE1":11602,"PHASE2":11604,"PHASE3":11606,"PHASE4":11608,"NA":11614},{"trials":11601,"activeCount":98},[],{"trials":11603,"activeCount":98},[],{"trials":11605,"activeCount":98},[],{"trials":11607,"activeCount":98},[],{"trials":11609,"activeCount":98},[11610],{"nctId":11040,"briefTitle":11041,"status":963,"phases":11611,"primaryCompletion":4981,"completion":4981,"start":7758,"enrollment":9741,"conditions":11612,"interventions":11613},[90],[10876,584],[11018,11045],{"trials":11615,"activeCount":98},[],{"intervention":1337,"totalTrials":5543,"cells":11617},{"EARLY_PHASE1":11618,"PHASE1":11620,"PHASE2":11670,"PHASE3":11700,"PHASE4":11714,"NA":11716},{"trials":11619,"activeCount":98},[],{"trials":11621,"activeCount":98},[11622,11630,11634,11642,11650,11658,11662],{"nctId":11623,"briefTitle":11624,"status":104,"phases":11625,"primaryCompletion":11626,"completion":11626,"start":11627,"enrollment":747,"conditions":11628,"interventions":11629},"NCT03247283","Pharmacokinetics and Metabolism Study in Healthy Male Participants",[87],"2017-10-15","2017-07-19",[606],[1337],{"nctId":10589,"briefTitle":10590,"status":104,"phases":11631,"primaryCompletion":10592,"completion":10592,"start":10593,"enrollment":713,"conditions":11632,"interventions":11633},[87],[759],[1337,10596],{"nctId":11635,"briefTitle":11636,"status":104,"phases":11637,"primaryCompletion":11638,"completion":11638,"start":11639,"enrollment":34,"conditions":11640,"interventions":11641},"NCT03312426","An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants",[87],"2017-11-22","2017-10-09",[27],[1337],{"nctId":11643,"briefTitle":11644,"status":104,"phases":11645,"primaryCompletion":11646,"completion":11646,"start":11638,"enrollment":28,"conditions":11647,"interventions":11649},"NCT03346837","A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects",[87],"2017-12-20",[11648],"Malignancies Multiple",[1337,5584,5658],{"nctId":11651,"briefTitle":11652,"status":104,"phases":11653,"primaryCompletion":11654,"completion":11654,"start":11655,"enrollment":1750,"conditions":11656,"interventions":11657},"NCT03374228","A Study to Evaluate the Bioavailability of BMS-986205",[87],"2018-02-16","2018-01-04",[18],[1337],{"nctId":1330,"briefTitle":1331,"status":104,"phases":11659,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":360,"conditions":11660,"interventions":11661},[87],[1154],[1337,43],{"nctId":11663,"briefTitle":11664,"status":104,"phases":11665,"primaryCompletion":11666,"completion":11666,"start":11667,"enrollment":3562,"conditions":11668,"interventions":11669},"NCT03362411","A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a Tablet",[87],"2018-02-01","2017-11-09",[27],[1337],{"trials":11671,"activeCount":98},[11672,11676,11680,11684,11688,11692,11696],{"nctId":1409,"briefTitle":1410,"status":963,"phases":11673,"primaryCompletion":1412,"completion":1412,"start":1413,"enrollment":1414,"conditions":11674,"interventions":11675},[88],[1154],[43,1197,52,608,1337],{"nctId":1540,"briefTitle":1541,"status":963,"phases":11677,"primaryCompletion":1543,"completion":1544,"start":1545,"enrollment":1492,"conditions":11678,"interventions":11679},[88],[1547],[43,1549,1337],{"nctId":1639,"briefTitle":1640,"status":104,"phases":11681,"primaryCompletion":1642,"completion":1642,"start":1643,"enrollment":1644,"conditions":11682,"interventions":11683},[87,88],[1154,21,36],[1337,43,608],{"nctId":2269,"briefTitle":2270,"status":104,"phases":11685,"primaryCompletion":820,"completion":820,"start":2272,"enrollment":1221,"conditions":11686,"interventions":11687},[87,88],[1154],[1337,43],{"nctId":2276,"briefTitle":2277,"status":104,"phases":11689,"primaryCompletion":2279,"completion":2279,"start":870,"enrollment":2280,"conditions":11690,"interventions":11691},[88],[1154],[43,608,52,1337,1676],{"nctId":2322,"briefTitle":2323,"status":104,"phases":11693,"primaryCompletion":2325,"completion":2325,"start":2326,"enrollment":2327,"conditions":11694,"interventions":11695},[88],[2329],[43,608,52,1337,614],{"nctId":2332,"briefTitle":2333,"status":104,"phases":11697,"primaryCompletion":2335,"completion":2335,"start":802,"enrollment":2336,"conditions":11698,"interventions":11699},[87,88],[1154],[52,43,1337,608],{"trials":11701,"activeCount":98},[11702,11706,11710],{"nctId":2585,"briefTitle":2586,"status":467,"phases":11703,"primaryCompletion":2588,"completion":2588,"start":2589,"enrollment":98,"conditions":11704,"interventions":11705},[89],[1537],[43,1337,1145,1268,1157,618],{"nctId":2643,"briefTitle":2644,"status":467,"phases":11707,"primaryCompletion":2646,"completion":2647,"start":2648,"enrollment":98,"conditions":11708,"interventions":11709},[89],[1717,36],[1337,43,2651],{"nctId":2662,"briefTitle":2663,"status":104,"phases":11711,"primaryCompletion":2665,"completion":2665,"start":2666,"enrollment":319,"conditions":11712,"interventions":11713},[89],[21,2668],[1337,43],{"trials":11715,"activeCount":98},[],{"trials":11717,"activeCount":98},[],{"intervention":5877,"totalTrials":363,"cells":11719},{"EARLY_PHASE1":11720,"PHASE1":11722,"PHASE2":11769,"PHASE3":11795,"PHASE4":11827,"NA":11829},{"trials":11721,"activeCount":98},[],{"trials":11723,"activeCount":98},[11724,11731,11738,11745,11751,11758,11765],{"nctId":11725,"briefTitle":11726,"status":104,"phases":11727,"primaryCompletion":11511,"completion":11511,"start":11728,"enrollment":4328,"conditions":11729,"interventions":11730},"NCT00435669","A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)",[87],"2007-09",[1865],[5877,5877],{"nctId":11732,"briefTitle":11733,"status":104,"phases":11734,"primaryCompletion":5873,"completion":4114,"start":11735,"enrollment":3143,"conditions":11736,"interventions":11737},"NCT00437437","A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)",[87],"2000-05",[1865],[5877],{"nctId":11739,"briefTitle":11740,"status":104,"phases":11741,"primaryCompletion":11742,"completion":11742,"start":6169,"enrollment":5543,"conditions":11743,"interventions":11744},"NCT01540461","Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)",[87],"2013-11",[1607],[5877],{"nctId":11746,"briefTitle":11747,"status":104,"phases":11748,"primaryCompletion":7088,"completion":7088,"start":4179,"enrollment":137,"conditions":11749,"interventions":11750},"NCT00390936","A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors",[87],[1515],[5877],{"nctId":11752,"briefTitle":11753,"status":104,"phases":11754,"primaryCompletion":4179,"completion":9361,"start":11405,"enrollment":25,"conditions":11755,"interventions":11756},"NCT00207103","MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors",[87],[1865,5884],[5877,5877,5877,5877,5877,11757],"Brivanab",{"nctId":11759,"briefTitle":11760,"status":104,"phases":11761,"primaryCompletion":11762,"completion":11762,"start":4010,"enrollment":1203,"conditions":11763,"interventions":11764},"NCT00437424","A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction",[87],"2010-06",[1742],[5877],{"nctId":6557,"briefTitle":6558,"status":104,"phases":11766,"primaryCompletion":3017,"completion":3017,"start":3617,"enrollment":790,"conditions":11767,"interventions":11768},[87],[6561],[6563,617,6563,1678,5877,5877,5877],{"trials":11770,"activeCount":98},[11771,11780,11791],{"nctId":11772,"briefTitle":11773,"status":104,"phases":11774,"primaryCompletion":11775,"completion":11775,"start":11776,"enrollment":8331,"conditions":11777,"interventions":11778},"NCT00355238","A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer",[88],"2010-04-30","2006-12-31",[4302],[11779],"brivanib",{"nctId":11781,"briefTitle":11782,"status":104,"phases":11783,"primaryCompletion":6437,"completion":3977,"start":11511,"enrollment":11784,"conditions":11785,"interventions":11790},"NCT00633789","Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types",[88],597,[11786,4934,11787,11788,11789],"Advanced Non-small Cell Lung Cancer","Soft Tissue Sarcoma","Gastric\u002FEsophageal Adenocarcinoma","Pancreatic Cancer Including Ampulla of Vater",[11779],{"nctId":5870,"briefTitle":5871,"status":104,"phases":11792,"primaryCompletion":3977,"completion":3977,"start":5873,"enrollment":193,"conditions":11793,"interventions":11794},[87,88],[5875],[1145,1678,5877,5877,5878],{"trials":11796,"activeCount":98},[11797,11803,11813,11817],{"nctId":11798,"briefTitle":11799,"status":963,"phases":11800,"primaryCompletion":4378,"completion":4378,"start":7944,"enrollment":3076,"conditions":11801,"interventions":11802},"NCT01108705","Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment",[89],[1742],[5877],{"nctId":11804,"briefTitle":11805,"status":104,"phases":11806,"primaryCompletion":11807,"completion":11808,"start":11809,"enrollment":11810,"conditions":11811,"interventions":11812},"NCT00825955","Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment",[89],"2011-11-15","2017-08-25","2009-02-17",587,[2751],[5877],{"nctId":7346,"briefTitle":7347,"status":104,"phases":11814,"primaryCompletion":1343,"completion":6916,"start":4459,"enrollment":7349,"conditions":11815,"interventions":11816},[89],[7351],[5877,1609],{"nctId":11818,"briefTitle":11819,"status":104,"phases":11820,"primaryCompletion":11821,"completion":11822,"start":11823,"enrollment":11824,"conditions":11825,"interventions":11826},"NCT00908752","Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC",[89],"2012-09-28","2018-01-26","2009-07-20",734,[1607],[5877],{"trials":11828,"activeCount":98},[],{"trials":11830,"activeCount":98},[],{"intervention":9391,"totalTrials":363,"cells":11832},{"EARLY_PHASE1":11833,"PHASE1":11835,"PHASE2":11908,"PHASE3":11935,"PHASE4":11944,"NA":11946},{"trials":11834,"activeCount":98},[],{"trials":11836,"activeCount":98},[11837,11844,11851,11861,11865,11869,11876,11883,11891,11899],{"nctId":11838,"briefTitle":11839,"status":467,"phases":11840,"primaryCompletion":4160,"completion":4160,"start":6917,"enrollment":98,"conditions":11841,"interventions":11843},"NCT00947245","Japanese Bridging Study Conducted in the United States",[87],[11842],"Hepatitis C Virus",[9391,9391,9391,9391,9391,9391],{"nctId":11845,"briefTitle":11846,"status":104,"phases":11847,"primaryCompletion":4159,"completion":4159,"start":4289,"enrollment":693,"conditions":11848,"interventions":11849},"NCT02104843","Drug Interaction Between Daclatasvir\u002FAsunaprevir\u002FBMS-791325 and Rosuvastatin",[87],[30],[11850,9391,874],"Daclatasvir, Asunaprevir and BMS-791325 FDC",{"nctId":11852,"briefTitle":11853,"status":104,"phases":11854,"primaryCompletion":4289,"completion":4289,"start":4551,"enrollment":34,"conditions":11855,"interventions":11856},"NCT02045693","Drug Interaction & Methadone & Buprenorphine",[87],[30],[11857,11858,9391,11859,11860],"Methadone","DCV 3DAA FDC","Buprenorphine","Naloxone",{"nctId":9385,"briefTitle":9386,"status":104,"phases":11862,"primaryCompletion":4159,"completion":4159,"start":4289,"enrollment":9388,"conditions":11863,"interventions":11864},[87],[30],[9391,805],{"nctId":10515,"briefTitle":10516,"status":104,"phases":11866,"primaryCompletion":6916,"completion":6916,"start":10518,"enrollment":725,"conditions":11867,"interventions":11868},[87],[30],[6534,9391],{"nctId":11870,"briefTitle":11871,"status":104,"phases":11872,"primaryCompletion":3017,"completion":3017,"start":4289,"enrollment":11873,"conditions":11874,"interventions":11875},"NCT02108639","To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet",[87],41,[30],[11858,9391],{"nctId":11877,"briefTitle":11878,"status":104,"phases":11879,"primaryCompletion":4289,"completion":4289,"start":4551,"enrollment":713,"conditions":11880,"interventions":11881},"NCT02045966","Study to Determine the Potential DDIs When the Daclatasvir\u002FAsunaprevir\u002FBMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects",[87],[30],[11882,11858,9391],"Cocktail",{"nctId":11884,"briefTitle":11885,"status":104,"phases":11886,"primaryCompletion":4122,"completion":4122,"start":4289,"enrollment":319,"conditions":11887,"interventions":11888},"NCT02103569","Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325",[87],[30],[11889,11890,9391],"FDC of Daclatasvir, Asunaprevir and BMS-791325","FDC of Norethindrone and Ethinyl Estradiol",{"nctId":11892,"briefTitle":11893,"status":104,"phases":11894,"primaryCompletion":4159,"completion":4159,"start":4289,"enrollment":839,"conditions":11895,"interventions":11897},"NCT02112110","Absolute Bioavailability of BMS-791325",[87],[11896],"Hepatitis C Virus Infection",[9391,11898],"[13C]-BMS-791325",{"nctId":11900,"briefTitle":11901,"status":104,"phases":11902,"primaryCompletion":10525,"start":3017,"enrollment":11873,"conditions":11903,"interventions":11905},"NCT02175602","Study of Drug Combination on Pharmacokinetics in Healthy Volunteers",[87],[11904],"Hepatitis C Infection",[11906,11907,11858,9391],"Escitalopram","Sertraline",{"trials":11909,"activeCount":98},[11910,11918,11925],{"nctId":11911,"briefTitle":11912,"status":104,"phases":11913,"primaryCompletion":7089,"completion":3893,"start":7706,"enrollment":4579,"conditions":11914,"interventions":11915},"NCT01193361","Ph IIA Study (SOC +\u002F- NS5B)",[88],[11842],[9391,9391,11916,11917],"Peg-interferon alfa-2a","Ribavirin",{"nctId":11919,"briefTitle":11920,"status":104,"phases":11921,"primaryCompletion":3712,"completion":3712,"start":5873,"enrollment":1203,"conditions":11922,"interventions":11924},"NCT00664625","A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects",[87,88],[11923],"Chronic Hepatitis C",[9391],{"nctId":11926,"briefTitle":11927,"status":104,"phases":11928,"primaryCompletion":11929,"completion":11930,"start":6206,"enrollment":1823,"conditions":11931,"interventions":11932},"NCT01455090","Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications",[88],"2014-03-31","2015-07-31",[11923],[11933,11934,9391,11917],"BMS-650032","BMS-790052",{"trials":11936,"activeCount":98},[11937],{"nctId":11938,"briefTitle":11939,"status":104,"phases":11940,"primaryCompletion":10525,"completion":7690,"start":3959,"enrollment":1096,"conditions":11941,"interventions":11942},"NCT01973049","UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis",[89],[30],[10402,11943,9391,11917],"Asunaprevir",{"trials":11945,"activeCount":98},[],{"trials":11947,"activeCount":98},[],{"intervention":11934,"totalTrials":360,"cells":11949},{"EARLY_PHASE1":11950,"PHASE1":11952,"PHASE2":11975,"PHASE3":12022,"PHASE4":12039,"NA":12041},{"trials":11951,"activeCount":98},[],{"trials":11953,"activeCount":98},[11954,11961,11968],{"nctId":11955,"briefTitle":11956,"status":104,"phases":11957,"primaryCompletion":6170,"completion":6170,"start":4459,"enrollment":11958,"conditions":11959,"interventions":11960},"NCT00904059","Drug-Drug Interaction Study in Healthy Subjects",[87],28,[30],[11933,11934,11933,11934],{"nctId":11962,"briefTitle":11963,"status":104,"phases":11964,"primaryCompletion":3617,"completion":3617,"start":3678,"enrollment":31,"conditions":11965,"interventions":11966},"NCT00983957","Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects",[87],[11923],[11934,11967],"Ortho Tri-Cyclen®",{"nctId":11969,"briefTitle":11970,"status":104,"phases":11971,"primaryCompletion":4038,"completion":4038,"start":4981,"enrollment":6185,"conditions":11972,"interventions":11974},"NCT00859053","Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment",[87],[11973],"Hepatic Insufficiency",[11934],{"trials":11976,"activeCount":98},[11977,11987,11994,12004,12008,12015],{"nctId":11978,"briefTitle":11979,"status":104,"phases":11980,"primaryCompletion":4122,"completion":11981,"start":11034,"enrollment":11982,"conditions":11983,"interventions":11984},"NCT01309932","Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin",[88],"2014-09",165,[30],[11985,11934,11917,11933,11986,11985,11917,11985,11917,11934,11933],"Pegylated Interferon Lambda","Pegylated Interferon Alfa-2a",{"nctId":11988,"briefTitle":11989,"status":104,"phases":11990,"primaryCompletion":5541,"completion":6225,"start":3872,"enrollment":11991,"conditions":11992,"interventions":11993},"NCT01051414","An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject",[88],43,[11904],[11934,11933],{"nctId":11995,"briefTitle":11996,"status":104,"phases":11997,"primaryCompletion":1343,"completion":3977,"start":11998,"enrollment":11999,"conditions":12000,"interventions":12001},"NCT01170962","Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment",[88],"2010-08",512,[11842],[11934,11934,12002,12003],"peginterferon alfa-2a","ribavirin",{"nctId":11926,"briefTitle":11927,"status":104,"phases":12005,"primaryCompletion":11929,"completion":11930,"start":6206,"enrollment":1823,"conditions":12006,"interventions":12007},[88],[11923],[11933,11934,9391,11917],{"nctId":12009,"briefTitle":12010,"status":104,"phases":12011,"primaryCompletion":3586,"completion":4551,"start":5014,"enrollment":11035,"conditions":12012,"interventions":12013},"NCT01012895","Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care",[88],[11923],[11934,11933,11933,11933,12014,11917],"Pegylated-interferon alfa-2a",{"nctId":12016,"briefTitle":12017,"status":104,"phases":12018,"primaryCompletion":3631,"completion":3631,"start":5014,"enrollment":6226,"conditions":12019,"interventions":12020},"NCT01016912","Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients",[88],[11904],[11934,11934,12021,11917],"Peginterferon alfa-2b",{"trials":12023,"activeCount":98},[12024,12031],{"nctId":12025,"briefTitle":12026,"status":104,"phases":12027,"primaryCompletion":3958,"completion":3630,"start":7927,"enrollment":12028,"conditions":12029,"interventions":12030},"NCT01497834","A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients",[89],224,[30],[11934,11933],{"nctId":12032,"briefTitle":12033,"status":104,"phases":12034,"primaryCompletion":4378,"completion":9360,"start":3679,"enrollment":12035,"conditions":12036,"interventions":12037},"NCT01448044","Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C",[89],152,[30],[11934,12038,11917],"Pegylated-interferon alfa 2a",{"trials":12040,"activeCount":98},[],{"trials":12042,"activeCount":98},[],{"intervention":11933,"totalTrials":1184,"cells":12044},{"EARLY_PHASE1":12045,"PHASE1":12047,"PHASE2":12065,"PHASE3":12097,"PHASE4":12103,"NA":12105},{"trials":12046,"activeCount":98},[],{"trials":12048,"activeCount":98},[12049,12055,12061],{"nctId":12050,"briefTitle":12051,"status":104,"phases":12052,"primaryCompletion":11762,"completion":11762,"start":10431,"enrollment":319,"conditions":12053,"interventions":12054},"NCT01063023","Drug Interaction Oral Contraceptive Pill (OCP)",[87],[11842],[11967,11933],{"nctId":12056,"briefTitle":12057,"status":104,"phases":12058,"primaryCompletion":5850,"completion":5850,"start":5014,"enrollment":11958,"conditions":12059,"interventions":12060},"NCT01019070","Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032",[87],[11973],[11933],{"nctId":11955,"briefTitle":11956,"status":104,"phases":12062,"primaryCompletion":6170,"completion":6170,"start":4459,"enrollment":11958,"conditions":12063,"interventions":12064},[87],[30],[11933,11934,11933,11934],{"trials":12066,"activeCount":98},[12067,12071,12075,12081,12085,12089],{"nctId":11978,"briefTitle":11979,"status":104,"phases":12068,"primaryCompletion":4122,"completion":11981,"start":11034,"enrollment":11982,"conditions":12069,"interventions":12070},[88],[30],[11985,11934,11917,11933,11986,11985,11917,11985,11917,11934,11933],{"nctId":11988,"briefTitle":11989,"status":104,"phases":12072,"primaryCompletion":5541,"completion":6225,"start":3872,"enrollment":11991,"conditions":12073,"interventions":12074},[88],[11904],[11934,11933],{"nctId":12076,"briefTitle":12077,"status":104,"phases":12078,"primaryCompletion":5014,"completion":5014,"start":6953,"enrollment":1385,"conditions":12079,"interventions":12080},"NCT00722358","A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects",[88],[11923],[11933],{"nctId":11926,"briefTitle":11927,"status":104,"phases":12082,"primaryCompletion":11929,"completion":11930,"start":6206,"enrollment":1823,"conditions":12083,"interventions":12084},[88],[11923],[11933,11934,9391,11917],{"nctId":12009,"briefTitle":12010,"status":104,"phases":12086,"primaryCompletion":3586,"completion":4551,"start":5014,"enrollment":11035,"conditions":12087,"interventions":12088},[88],[11923],[11934,11933,11933,11933,12014,11917],{"nctId":12090,"briefTitle":12091,"status":104,"phases":12092,"primaryCompletion":3586,"completion":3586,"start":3617,"enrollment":12093,"conditions":12094,"interventions":12095},"NCT01030432","Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin",[88],285,[11842],[11933,11933,12096,12096,11917,11917],"Peginterferon Alfa-2a",{"trials":12098,"activeCount":98},[12099],{"nctId":12025,"briefTitle":12026,"status":104,"phases":12100,"primaryCompletion":3958,"completion":3630,"start":7927,"enrollment":12028,"conditions":12101,"interventions":12102},[89],[30],[11934,11933],{"trials":12104,"activeCount":98},[],{"trials":12106,"activeCount":98},[],{"intervention":10558,"totalTrials":1184,"cells":12108},{"EARLY_PHASE1":12109,"PHASE1":12111,"PHASE2":12137,"PHASE3":12173,"PHASE4":12182,"NA":12184},{"trials":12110,"activeCount":98},[],{"trials":12112,"activeCount":98},[12113,12119,12125,12133],{"nctId":12114,"briefTitle":12115,"status":104,"phases":12116,"primaryCompletion":4123,"completion":4123,"start":3977,"enrollment":5543,"conditions":12117,"interventions":12118},"NCT01762462","Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment",[87],[5603],[10558],{"nctId":12120,"briefTitle":12121,"status":104,"phases":12122,"primaryCompletion":7691,"completion":7691,"start":3893,"enrollment":347,"conditions":12123,"interventions":12124},"NCT01763190","Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment",[87],[927],[10558],{"nctId":12126,"briefTitle":12127,"status":104,"phases":12128,"primaryCompletion":11742,"completion":4159,"start":10518,"enrollment":582,"conditions":12129,"interventions":12131},"NCT01836705","Effect of SAR302503 on ECG Activity in Patients With Solid Tumors",[87],[12130],"Neoplasm Malignant",[10558,12132],"Panolosetron",{"nctId":10553,"briefTitle":10554,"status":104,"phases":12134,"primaryCompletion":4123,"completion":4123,"start":1343,"enrollment":713,"conditions":12135,"interventions":12136},[87],[1482],[10558,10559,10560,10561],{"trials":12138,"activeCount":98},[12139,12146,12152,12159,12166],{"nctId":12140,"briefTitle":12141,"status":104,"phases":12142,"primaryCompletion":4289,"completion":4289,"start":5850,"enrollment":148,"conditions":12143,"interventions":12145},"NCT01420770","Phase 2 Study of SAR302503 in Patients With Myelofibrosis",[88],[12144],"Hematopoietic Neoplasm",[10558],{"nctId":12147,"briefTitle":12148,"status":104,"phases":12149,"primaryCompletion":4159,"completion":4159,"start":4039,"enrollment":3986,"conditions":12150,"interventions":12151},"NCT00724334","A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis",[87,88],[8316],[10558],{"nctId":12153,"briefTitle":12154,"status":104,"phases":12155,"primaryCompletion":4289,"completion":4289,"start":5022,"enrollment":12156,"conditions":12157,"interventions":12158},"NCT01523171","Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib",[88],97,[12144],[10558],{"nctId":12160,"briefTitle":12161,"status":104,"phases":12162,"primaryCompletion":3893,"completion":4159,"start":5542,"enrollment":12163,"conditions":12164,"interventions":12165},"NCT01420783","Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia",[88],81,[12144],[10558],{"nctId":12167,"briefTitle":12168,"status":104,"phases":12169,"primaryCompletion":12170,"completion":12170,"start":3893,"enrollment":839,"conditions":12171,"interventions":12172},"NCT01692366","Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly",[88],"2014-03",[8316],[10558],{"trials":12174,"activeCount":98},[12175],{"nctId":12176,"briefTitle":12177,"status":104,"phases":12178,"primaryCompletion":3017,"completion":3017,"start":3679,"enrollment":12179,"conditions":12180,"interventions":12181},"NCT01437787","Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis",[89],289,[12144],[10558],{"trials":12183,"activeCount":98},[],{"trials":12185,"activeCount":98},[],{"intervention":12187,"totalTrials":747,"cells":12188},"Muraglitazar",{"EARLY_PHASE1":12189,"PHASE1":12191,"PHASE2":12193,"PHASE3":12195,"PHASE4":12274,"NA":12276},{"trials":12190,"activeCount":98},[],{"trials":12192,"activeCount":98},[],{"trials":12194,"activeCount":98},[],{"trials":12196,"activeCount":98},[12197,12206,12216,12226,12233,12242,12250,12257,12265],{"nctId":12198,"briefTitle":12199,"status":104,"phases":12200,"primaryCompletion":3657,"completion":3657,"start":12201,"enrollment":12202,"conditions":12203,"interventions":12205},"NCT00162175","PPAR-COMBO With Sulfonylurea",[89],"2003-07",534,[12204],"Metabolics Diabetes Nos",[12187],{"nctId":12207,"briefTitle":12208,"status":104,"phases":12209,"completion":12210,"start":12211,"enrollment":12212,"conditions":12213,"interventions":12215},"NCT00245388","Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia",[88,89],"2002-07","2002-04",330,[12214],"Dyslipidemia",[12187],{"nctId":12217,"briefTitle":12218,"status":104,"phases":12219,"primaryCompletion":12220,"completion":12220,"start":7153,"enrollment":12221,"conditions":12222,"interventions":12224},"NCT00095030","Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone",[89],"2006-03",1752,[12223],"Diabetes Mellitus, Type 2",[12225],"muraglitazar",{"nctId":12227,"briefTitle":12228,"status":104,"phases":12229,"primaryCompletion":4023,"completion":4023,"start":12230,"enrollment":3986,"conditions":12231,"interventions":12232},"NCT00094991","Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes",[89],"2004-05",[12223],[12187],{"nctId":12234,"briefTitle":12235,"status":104,"phases":12236,"primaryCompletion":4379,"completion":4379,"start":12237,"enrollment":12238,"conditions":12239,"interventions":12240},"NCT00106808","Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes",[89],"2005-08",1440,[11098],[12187,12241],"Pioglitazone",{"nctId":12243,"briefTitle":12244,"status":104,"phases":12245,"primaryCompletion":5050,"start":7675,"enrollment":12246,"conditions":12247,"interventions":12249},"NCT00240370","A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics",[89],1159,[12248],"Type 2 Diabetes",[12187],{"nctId":12251,"briefTitle":12252,"status":104,"phases":12253,"completion":12230,"start":10973,"enrollment":12202,"conditions":12254,"interventions":12256},"NCT00162240","PPAR - Combination With Metformin",[89],[12255],"Diabetes Mellitus",[12187],{"nctId":12258,"briefTitle":12259,"status":104,"phases":12260,"completion":12261,"start":10973,"enrollment":2232,"conditions":12262,"interventions":12264},"NCT00246987","A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control",[89],"2004-04",[12263],"Diabetes, Type 2",[12187],{"nctId":12266,"briefTitle":12267,"status":104,"phases":12268,"primaryCompletion":5117,"completion":5117,"start":12269,"enrollment":12270,"conditions":12271,"interventions":12273},"NCT00240383","Dose Ranging Study With LT, Monotherapy, PPAR",[88,89],"2002-05",1260,[12272],"Diabetes Mellitus II",[12187],{"trials":12275,"activeCount":98},[],{"trials":12277,"activeCount":98},[],{"intervention":12096,"totalTrials":1750,"cells":12279},{"EARLY_PHASE1":12280,"PHASE1":12282,"PHASE2":12284,"PHASE3":12301,"PHASE4":12335,"NA":12337},{"trials":12281,"activeCount":98},[],{"trials":12283,"activeCount":98},[],{"trials":12285,"activeCount":98},[12286,12290,12294],{"nctId":11995,"briefTitle":11996,"status":104,"phases":12287,"primaryCompletion":1343,"completion":3977,"start":11998,"enrollment":11999,"conditions":12288,"interventions":12289},[88],[11842],[11934,11934,12002,12003],{"nctId":12090,"briefTitle":12091,"status":104,"phases":12291,"primaryCompletion":3586,"completion":3586,"start":3617,"enrollment":12093,"conditions":12292,"interventions":12293},[88],[11842],[11933,11933,12096,12096,11917,11917],{"nctId":12295,"briefTitle":12296,"status":104,"phases":12297,"primaryCompletion":5542,"completion":5542,"start":5014,"enrollment":7633,"conditions":12298,"interventions":12299},"NCT01017575","Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)",[88],[11904],[10402,10402,12300,11917],"Peginterferon alfa-2a",{"trials":12302,"activeCount":98},[12303,12315,12321,12328],{"nctId":12304,"briefTitle":12305,"status":104,"phases":12306,"primaryCompletion":12307,"completion":12308,"start":12309,"enrollment":12310,"conditions":12311,"interventions":12312},"NCT01598090","Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir",[89],"2015-02-04","2015-05-15","2012-06-14",881,[11842],[12313,12096,11917,12314],"Peginterferon Lambda-1a","Telaprevir",{"nctId":12316,"briefTitle":12317,"status":104,"phases":12318,"primaryCompletion":3959,"completion":12170,"start":7927,"enrollment":2517,"conditions":12319,"interventions":12320},"NCT01492426","Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection",[89],[30],[10402,12314,12300,11917],{"nctId":12322,"briefTitle":12323,"status":104,"phases":12324,"primaryCompletion":11981,"completion":11981,"start":4123,"enrollment":3562,"conditions":12325,"interventions":12327},"NCT01754974","Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C",[89],[12326],"Hepatitis C Virus (HCV)",[12313,11917,12300],{"nctId":12329,"briefTitle":12330,"status":104,"phases":12331,"primaryCompletion":6917,"completion":6917,"start":3903,"enrollment":12332,"conditions":12333,"interventions":12334},"NCT01718158","Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy",[89],444,[30],[12313,12096,11917,10402,12314],{"trials":12336,"activeCount":98},[],{"trials":12338,"activeCount":98},[],{"intervention":1796,"totalTrials":1750,"cells":12340},{"EARLY_PHASE1":12341,"PHASE1":12343,"PHASE2":12357,"PHASE3":12367,"PHASE4":12383,"NA":12385},{"trials":12342,"activeCount":98},[],{"trials":12344,"activeCount":98},[12345,12349,12353],{"nctId":6166,"briefTitle":6167,"status":104,"phases":12346,"primaryCompletion":6169,"completion":6169,"start":6170,"enrollment":37,"conditions":12347,"interventions":12348},[87],[6172],[3621,441,1795,1796],{"nctId":6175,"briefTitle":6176,"status":963,"phases":12350,"primaryCompletion":3938,"completion":3938,"start":3680,"enrollment":713,"conditions":12351,"interventions":12352},[87],[33],[1197,1796,1795],{"nctId":6181,"briefTitle":6182,"status":104,"phases":12354,"primaryCompletion":6184,"completion":6184,"start":5541,"enrollment":6185,"conditions":12355,"interventions":12356},[87],[33],[6188,441,1795,6188,1796,1795],{"trials":12358,"activeCount":98},[12359,12363],{"nctId":6201,"briefTitle":6202,"status":104,"phases":12360,"primaryCompletion":6204,"completion":6205,"start":6206,"enrollment":12,"conditions":12361,"interventions":12362},[88],[33],[1794,1796,1795,1795,1795,1795],{"nctId":1787,"briefTitle":1788,"status":104,"phases":12364,"primaryCompletion":1790,"completion":1790,"start":1791,"enrollment":1285,"conditions":12365,"interventions":12366},[88],[33],[1794,1795,1795,441,1796,1797,43],{"trials":12368,"activeCount":98},[12369,12376],{"nctId":12370,"briefTitle":12371,"status":104,"phases":12372,"primaryCompletion":3587,"completion":3587,"start":10821,"enrollment":3978,"conditions":12373,"interventions":12374},"NCT00514371","A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma",[88,89],[33],[12375,1796],"tanespimycin",{"nctId":12377,"briefTitle":12378,"status":104,"phases":12379,"primaryCompletion":7088,"completion":7088,"start":3680,"enrollment":4124,"conditions":12380,"interventions":12381},"NCT00546780","A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse",[89],[33],[12382,1796],"Tanespimycin",{"trials":12384,"activeCount":98},[],{"trials":12386,"activeCount":98},[],{"intervention":2055,"totalTrials":1750,"cells":12388},{"EARLY_PHASE1":12389,"PHASE1":12391,"PHASE2":12397,"PHASE3":12407,"PHASE4":12430,"NA":12432},{"trials":12390,"activeCount":98},[],{"trials":12392,"activeCount":98},[12393],{"nctId":3582,"briefTitle":3583,"status":104,"phases":12394,"primaryCompletion":3585,"completion":3586,"start":3587,"enrollment":534,"conditions":12395,"interventions":12396},[87],[673],[608,1157,1158,2055],{"trials":12398,"activeCount":98},[12399,12403],{"nctId":4192,"briefTitle":4193,"status":104,"phases":12400,"primaryCompletion":4159,"completion":4159,"start":3586,"enrollment":757,"conditions":12401,"interventions":12402},[88],[21],[608,2055],{"nctId":2044,"briefTitle":2045,"status":104,"phases":12404,"primaryCompletion":2047,"completion":1843,"start":2048,"enrollment":2049,"conditions":12405,"interventions":12406},[88],[2051],[43,2053,2054,2055],{"trials":12408,"activeCount":98},[12409,12413,12417,12426],{"nctId":3743,"briefTitle":3744,"status":104,"phases":12410,"primaryCompletion":3746,"completion":1364,"start":3747,"enrollment":3748,"conditions":12411,"interventions":12412},[89],[2378],[3751,2055,1157,1158],{"nctId":4375,"briefTitle":4376,"status":104,"phases":12414,"primaryCompletion":3894,"completion":4378,"start":4379,"enrollment":2770,"conditions":12415,"interventions":12416},[89],[21],[608,2055],{"nctId":12418,"briefTitle":12419,"status":104,"phases":12420,"primaryCompletion":12421,"completion":12422,"start":12423,"enrollment":461,"conditions":12424,"interventions":12425},"NCT01721772","Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma",[89],"2014-06-24","2021-05-14","2013-01-18",[21],[3751,2055],{"nctId":4411,"briefTitle":4412,"status":104,"phases":12427,"primaryCompletion":4414,"completion":4414,"start":4415,"enrollment":2280,"conditions":12428,"interventions":12429},[89],[21],[608,2055],{"trials":12431,"activeCount":98},[],{"trials":12433,"activeCount":98},[],{"intervention":12435,"totalTrials":830,"cells":12436},"Enoxaparin",{"EARLY_PHASE1":12437,"PHASE1":12439,"PHASE2":12441,"PHASE3":12453,"PHASE4":12499,"NA":12501},{"trials":12438,"activeCount":98},[],{"trials":12440,"activeCount":98},[],{"trials":12442,"activeCount":98},[12443],{"nctId":12444,"briefTitle":12445,"status":104,"phases":12446,"primaryCompletion":2687,"completion":2687,"start":12447,"enrollment":34,"conditions":12448,"interventions":12450},"NCT03000673","A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis",[87,88],"2017-05-23",[12449],"Antithrombotic",[12435,12451,12452],"unfractionated heparin","BMS-986177",{"trials":12454,"activeCount":98},[12455,12464,12475,12483,12492],{"nctId":12456,"briefTitle":12457,"status":104,"phases":12458,"primaryCompletion":7776,"completion":7776,"start":4664,"enrollment":12459,"conditions":12460,"interventions":12463},"NCT00457002","Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness",[89],6758,[12461,12462],"Venous Thrombosis","Pulmonary Embolism",[11001,12435],{"nctId":12465,"briefTitle":12466,"status":104,"phases":12467,"primaryCompletion":5098,"completion":5098,"start":12468,"enrollment":12469,"conditions":12470,"interventions":12471},"NCT00097357","BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery",[88,89],"2004-10",1238,[12461,12462],[11001,12435,12472,12473,12474],"Warfarin","Enoxaparin Placebo","Apixaban Placebo",{"nctId":12476,"briefTitle":12477,"status":104,"phases":12478,"primaryCompletion":7713,"completion":7713,"start":4664,"enrollment":12479,"conditions":12480,"interventions":12482},"NCT00452530","Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery",[89],3221,[12481,12462],"Deep Vein Thrombosis",[12435,11001],{"nctId":12484,"briefTitle":12485,"status":104,"phases":12486,"primaryCompletion":4123,"completion":4123,"start":4039,"enrollment":12487,"conditions":12488,"interventions":12489},"NCT00643201","Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism",[89],5614,[12461],[12435,12490,12491],"warfarin","apixaban",{"nctId":12493,"briefTitle":12494,"status":104,"phases":12495,"primaryCompletion":4038,"completion":4038,"start":3920,"enrollment":12496,"conditions":12497,"interventions":12498},"NCT00423319","Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)",[89],5407,[12481,12462],[12435,11001],{"trials":12500,"activeCount":98},[],{"trials":12502,"activeCount":98},[],{"intervention":1507,"totalTrials":830,"cells":12504},{"EARLY_PHASE1":12505,"PHASE1":12507,"PHASE2":12509,"PHASE3":12523,"PHASE4":12537,"NA":12539},{"trials":12506,"activeCount":98},[],{"trials":12508,"activeCount":98},[],{"trials":12510,"activeCount":98},[12511,12515,12519],{"nctId":1496,"briefTitle":1497,"status":104,"phases":12512,"primaryCompletion":1499,"completion":1500,"start":1501,"enrollment":1502,"conditions":12513,"interventions":12514},[88],[1504],[43,608,1506,1507],{"nctId":1973,"briefTitle":1974,"status":104,"phases":12516,"primaryCompletion":1976,"completion":1977,"start":788,"enrollment":1978,"conditions":12517,"interventions":12518},[88],[1504],[1123,1981,1982,1983,1984],{"nctId":7781,"briefTitle":7782,"status":104,"phases":12520,"primaryCompletion":7784,"completion":7784,"start":7785,"enrollment":8,"conditions":12521,"interventions":12522},[88],[792],[61,1507,61],{"trials":12524,"activeCount":98},[12525,12529,12533],{"nctId":7110,"briefTitle":7111,"status":963,"phases":12526,"primaryCompletion":7113,"completion":802,"start":7114,"enrollment":7115,"conditions":12527,"interventions":12528},[89],[969],[7118,7070,1507],{"nctId":2693,"briefTitle":2694,"status":104,"phases":12530,"primaryCompletion":2260,"completion":2696,"start":778,"enrollment":2697,"conditions":12531,"interventions":12532},[89],[1504],[43,1507,1328],{"nctId":6476,"briefTitle":6477,"status":104,"phases":12534,"primaryCompletion":6479,"completion":4347,"start":6480,"enrollment":6481,"conditions":12535,"interventions":12536},[89],[6483],[1197,1328,1507],{"trials":12538,"activeCount":98},[],{"trials":12540,"activeCount":98},[],{"intervention":12542,"totalTrials":830,"cells":12543},"Pegylated interferon alfa-2a",{"EARLY_PHASE1":12544,"PHASE1":12546,"PHASE2":12548,"PHASE3":12574,"PHASE4":12590,"NA":12592},{"trials":12545,"activeCount":98},[],{"trials":12547,"activeCount":98},[],{"trials":12549,"activeCount":98},[12550,12554,12561,12568],{"nctId":11978,"briefTitle":11979,"status":104,"phases":12551,"primaryCompletion":4122,"completion":11981,"start":11034,"enrollment":11982,"conditions":12552,"interventions":12553},[88],[30],[11985,11934,11917,11933,11986,11985,11917,11985,11917,11934,11933],{"nctId":12555,"briefTitle":12556,"status":104,"phases":12557,"primaryCompletion":11981,"completion":1342,"start":5541,"enrollment":12558,"conditions":12559,"interventions":12560},"NCT01428063","Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials",[88],276,[11896],[10402,11943,12542,11917],{"nctId":12562,"briefTitle":12563,"status":963,"phases":12564,"primaryCompletion":3711,"completion":3711,"start":6225,"enrollment":4255,"conditions":12565,"interventions":12566},"NCT01425970","Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and\u002For Ribavirin",[88],[30],[12567,12567,12567,12542,11917,12567,10402],"INX-08189",{"nctId":12569,"briefTitle":12570,"status":104,"phases":12571,"primaryCompletion":6225,"completion":3616,"start":6918,"enrollment":2538,"conditions":12572,"interventions":12573},"NCT01257204","Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection",[88],[11842],[10402,12542,11917],{"trials":12575,"activeCount":98},[12576,12584],{"nctId":12577,"briefTitle":12578,"status":104,"phases":12579,"primaryCompletion":3017,"completion":11981,"start":3902,"enrollment":12580,"conditions":12581,"interventions":12582},"NCT01616524","Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3",[89],880,[12326],[12583,12583,12542,11917,11917,10402],"Pegylated interferon lambda",{"nctId":12585,"briefTitle":12586,"status":467,"phases":12587,"primaryCompletion":12170,"completion":10525,"start":6169,"enrollment":98,"conditions":12588,"interventions":12589},"NCT01447394","Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C",[89],[12326],[11985,11986,11917],{"trials":12591,"activeCount":98},[],{"trials":12593,"activeCount":98},[],{"intervention":3751,"totalTrials":830,"cells":12595},{"EARLY_PHASE1":12596,"PHASE1":12598,"PHASE2":12623,"PHASE3":12634,"PHASE4":12644,"NA":12646},{"trials":12597,"activeCount":98},[],{"trials":12599,"activeCount":98},[12600,12610,12619],{"nctId":12601,"briefTitle":12602,"status":104,"phases":12603,"primaryCompletion":12604,"completion":2869,"start":12605,"enrollment":12606,"conditions":12607,"interventions":12609},"NCT00730639","A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies",[87],"2013-02-04","2008-10-30",395,[12608,1253,650,1265],"Metastatic Castration-resistant Prostrate Cancer",[3751,3751,3751,3751,3751],{"nctId":12611,"briefTitle":12612,"status":104,"phases":12613,"primaryCompletion":12614,"completion":12615,"start":12616,"enrollment":1877,"conditions":12617,"interventions":12618},"NCT01358721","Phase I Biomarker Study (BMS-936558)",[87],"2014-12-01","2019-05-22","2011-09-23",[1253],[3751,3751,3751],{"nctId":3991,"briefTitle":3992,"status":104,"phases":12620,"primaryCompletion":3994,"completion":3995,"start":3996,"enrollment":3997,"conditions":12621,"interventions":12622},[87],[3035],[3751,608],{"trials":12624,"activeCount":98},[12625],{"nctId":12626,"briefTitle":12627,"status":104,"phases":12628,"primaryCompletion":12629,"completion":12629,"start":12630,"enrollment":413,"conditions":12631,"interventions":12633},"NCT02061761","A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies",[87,88],"2022-02-16","2014-03-13",[12632],"Hematologic Neoplasms",[2091,3751],{"trials":12635,"activeCount":98},[12636,12640],{"nctId":3743,"briefTitle":3744,"status":104,"phases":12637,"primaryCompletion":3746,"completion":1364,"start":3747,"enrollment":3748,"conditions":12638,"interventions":12639},[89],[2378],[3751,2055,1157,1158],{"nctId":12418,"briefTitle":12419,"status":104,"phases":12641,"primaryCompletion":12421,"completion":12422,"start":12423,"enrollment":461,"conditions":12642,"interventions":12643},[89],[21],[3751,2055],{"trials":12645,"activeCount":98},[],{"trials":12647,"activeCount":98},[],{"intervention":1773,"totalTrials":520,"cells":12649},{"EARLY_PHASE1":12650,"PHASE1":12652,"PHASE2":12664,"PHASE3":12678,"PHASE4":12684,"NA":12686},{"trials":12651,"activeCount":98},[],{"trials":12653,"activeCount":98},[12654],{"nctId":12655,"briefTitle":12656,"status":963,"phases":12657,"primaryCompletion":8597,"completion":8597,"start":12658,"enrollment":520,"conditions":12659,"interventions":12661},"NCT05244070","A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and\u002For Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[87],"2022-09-14",[12660,1426],"Leukemia, Lymphocytic, Chronic, B-Cell",[12662,12663,1773],"BMS-986403","Fludarabine",{"trials":12665,"activeCount":98},[12666,12670,12674],{"nctId":5011,"briefTitle":5012,"status":104,"phases":12667,"primaryCompletion":5014,"completion":5014,"start":4179,"enrollment":5015,"conditions":12668,"interventions":12669},[88],[1223],[4985,1158,1773,2053],{"nctId":1763,"briefTitle":1764,"status":104,"phases":12671,"primaryCompletion":1766,"completion":1766,"start":1767,"enrollment":1634,"conditions":12672,"interventions":12673},[87,88],[1154],[1770,43,608,1771,1772,1773],{"nctId":6222,"briefTitle":6223,"status":104,"phases":12675,"primaryCompletion":4378,"completion":6184,"start":6225,"enrollment":6226,"conditions":12676,"interventions":12677},[88],[6228],[1794,6230,1795,1773],{"trials":12679,"activeCount":98},[12680],{"nctId":2938,"briefTitle":2939,"status":104,"phases":12681,"primaryCompletion":2941,"completion":2942,"start":2943,"enrollment":2944,"conditions":12682,"interventions":12683},[89],[1223],[1123,2947,2948,2949,2950],{"trials":12685,"activeCount":98},[],{"trials":12687,"activeCount":98},[],{"intervention":1797,"totalTrials":520,"cells":12689},{"EARLY_PHASE1":12690,"PHASE1":12692,"PHASE2":12694,"PHASE3":12712,"PHASE4":12718,"NA":12720},{"trials":12691,"activeCount":98},[],{"trials":12693,"activeCount":98},[],{"trials":12695,"activeCount":98},[12696,12700,12704,12708],{"nctId":1787,"briefTitle":1788,"status":104,"phases":12697,"primaryCompletion":1790,"completion":1790,"start":1791,"enrollment":1285,"conditions":12698,"interventions":12699},[88],[33],[1794,1795,1795,441,1796,1797,43],{"nctId":1818,"briefTitle":1819,"status":104,"phases":12701,"primaryCompletion":1821,"completion":1211,"start":1822,"enrollment":1823,"conditions":12702,"interventions":12703},[87,88],[1825,1826,33],[43,608,1187,615,1797,1795],{"nctId":1986,"briefTitle":1987,"status":104,"phases":12705,"primaryCompletion":1989,"completion":1990,"start":1991,"enrollment":19,"conditions":12706,"interventions":12707},[88],[33],[1794,1797,1795,43],{"nctId":6232,"briefTitle":6233,"status":104,"phases":12709,"primaryCompletion":6235,"completion":6236,"start":6237,"enrollment":1835,"conditions":12710,"interventions":12711},[88],[33],[1794,1797,1795],{"trials":12713,"activeCount":98},[12714],{"nctId":2896,"briefTitle":2897,"status":104,"phases":12715,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":1175,"conditions":12716,"interventions":12717},[89],[33],[43,1794,1797,1795],{"trials":12719,"activeCount":98},[],{"trials":12721,"activeCount":98},[],{"intervention":11906,"totalTrials":4328,"cells":12723},{"EARLY_PHASE1":12724,"PHASE1":12726,"PHASE2":12732,"PHASE3":12754,"PHASE4":12765,"NA":12767},{"trials":12725,"activeCount":98},[],{"trials":12727,"activeCount":98},[12728],{"nctId":11900,"briefTitle":11901,"status":104,"phases":12729,"primaryCompletion":10525,"start":3017,"enrollment":11873,"conditions":12730,"interventions":12731},[87],[11904],[11906,11907,11858,9391],{"trials":12733,"activeCount":98},[12734,12743],{"nctId":12735,"briefTitle":12736,"status":104,"phases":12737,"primaryCompletion":4179,"completion":4179,"start":3657,"enrollment":12738,"conditions":12739,"interventions":12741},"NCT00135421","Study of BMS-562086 in the Treatment of Outpatients With Major Depressive Disorder",[87,88],271,[12740],"Major Depressive Disorder",[12742,11906],"Pexacerfont",{"nctId":12744,"briefTitle":12745,"status":104,"phases":12746,"primaryCompletion":10518,"completion":10518,"start":7714,"enrollment":12747,"conditions":12748,"interventions":12750},"NCT01369095","Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression",[88],976,[12749],"Depression",[12751,11906,12752,12753,12753,12753,12753],"Duloxetine","BMS-820836 Placebo","BMS-820836",{"trials":12755,"activeCount":98},[12756],{"nctId":12757,"briefTitle":12758,"status":104,"phases":12759,"primaryCompletion":5023,"completion":5023,"start":4010,"enrollment":3093,"conditions":12760,"interventions":12762},"NCT00481325","Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder",[88,89],[12761],"Generalized Anxiety Disorder",[12763,12764],"pexacerfont","escitalopram",{"trials":12766,"activeCount":98},[],{"trials":12768,"activeCount":98},[],{"intervention":11985,"totalTrials":4328,"cells":12770},{"EARLY_PHASE1":12771,"PHASE1":12773,"PHASE2":12775,"PHASE3":12787,"PHASE4":12797,"NA":12799},{"trials":12772,"activeCount":98},[],{"trials":12774,"activeCount":98},[],{"trials":12776,"activeCount":98},[12777,12783],{"nctId":12778,"briefTitle":11979,"status":104,"phases":12779,"primaryCompletion":4289,"completion":11981,"start":4123,"enrollment":11982,"conditions":12780,"interventions":12781},"NCT01795911",[88],[30],[11985,12782,10402],"Ribasphere",{"nctId":11978,"briefTitle":11979,"status":104,"phases":12784,"primaryCompletion":4122,"completion":11981,"start":11034,"enrollment":11982,"conditions":12785,"interventions":12786},[88],[30],[11985,11934,11917,11933,11986,11985,11917,11985,11917,11934,11933],{"trials":12788,"activeCount":98},[12789,12793],{"nctId":12577,"briefTitle":12578,"status":104,"phases":12790,"primaryCompletion":3017,"completion":11981,"start":3902,"enrollment":12580,"conditions":12791,"interventions":12792},[89],[12326],[12583,12583,12542,11917,11917,10402],{"nctId":12585,"briefTitle":12586,"status":467,"phases":12794,"primaryCompletion":12170,"completion":10525,"start":6169,"enrollment":98,"conditions":12795,"interventions":12796},[89],[12326],[11985,11986,11917],{"trials":12798,"activeCount":98},[],{"trials":12800,"activeCount":98},[],{"intervention":12314,"totalTrials":4328,"cells":12802},{"EARLY_PHASE1":12803,"PHASE1":12805,"PHASE2":12807,"PHASE3":12809,"PHASE4":12831,"NA":12833},{"trials":12804,"activeCount":98},[],{"trials":12806,"activeCount":98},[],{"trials":12808,"activeCount":98},[],{"trials":12810,"activeCount":98},[12811,12815,12819,12827],{"nctId":12304,"briefTitle":12305,"status":104,"phases":12812,"primaryCompletion":12307,"completion":12308,"start":12309,"enrollment":12310,"conditions":12813,"interventions":12814},[89],[11842],[12313,12096,11917,12314],{"nctId":12316,"briefTitle":12317,"status":104,"phases":12816,"primaryCompletion":3959,"completion":12170,"start":7927,"enrollment":2517,"conditions":12817,"interventions":12818},[89],[30],[10402,12314,12300,11917],{"nctId":12820,"briefTitle":12821,"status":104,"phases":12822,"primaryCompletion":3959,"completion":1342,"start":3893,"enrollment":12823,"conditions":12824,"interventions":12825},"NCT01718145","A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects",[89],258,[11896],[10402,11943,11917,12826,12314],"pegIFNα-2b",{"nctId":12329,"briefTitle":12330,"status":104,"phases":12828,"primaryCompletion":6917,"completion":6917,"start":3903,"enrollment":12332,"conditions":12829,"interventions":12830},[89],[30],[12313,12096,11917,10402,12314],{"trials":12832,"activeCount":98},[],{"trials":12834,"activeCount":98},[],{"intervention":12836,"totalTrials":4328,"cells":12837},"peg-interferon alfa-2a",{"EARLY_PHASE1":12838,"PHASE1":12840,"PHASE2":12842,"PHASE3":12855,"PHASE4":12873,"NA":12875},{"trials":12839,"activeCount":98},[],{"trials":12841,"activeCount":98},[],{"trials":12843,"activeCount":98},[12844,12851],{"nctId":12845,"briefTitle":12846,"status":104,"phases":12847,"primaryCompletion":5022,"completion":6479,"start":4348,"enrollment":12848,"conditions":12849,"interventions":12850},"NCT01125189","Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients",[88],558,[11842],[10402,10402,12836,12003],{"nctId":11911,"briefTitle":11912,"status":104,"phases":12852,"primaryCompletion":7089,"completion":3893,"start":7706,"enrollment":4579,"conditions":12853,"interventions":12854},[88],[11842],[9391,9391,11916,11917],{"trials":12856,"activeCount":98},[12857,12865],{"nctId":12858,"briefTitle":12859,"status":104,"phases":12860,"primaryCompletion":6916,"completion":3959,"start":6225,"enrollment":12861,"conditions":12862,"interventions":12863},"NCT01573351","Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls\u002FPartials)",[89],398,[11842],[11943,10402,12864,11917],"Peg-interferon Alfa-2a",{"nctId":12866,"briefTitle":12867,"status":104,"phases":12868,"primaryCompletion":6916,"completion":9360,"start":5541,"enrollment":12869,"conditions":12870,"interventions":12871},"NCT01389323","BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black\u002FAfrican-Americans, Latinos and White\u002FCaucasians With Hepatitis C",[89],448,[30],[10402,12872,11917],"Peg-Interferon Alfa-2a",{"trials":12874,"activeCount":98},[],{"trials":12876,"activeCount":98},[],{"intervention":893,"totalTrials":4328,"cells":12878},{"EARLY_PHASE1":12879,"PHASE1":12881,"PHASE2":12887,"PHASE3":12893,"PHASE4":12908,"NA":12910},{"trials":12880,"activeCount":98},[],{"trials":12882,"activeCount":98},[12883],{"nctId":885,"briefTitle":886,"status":104,"phases":12884,"primaryCompletion":888,"completion":888,"start":889,"enrollment":890,"conditions":12885,"interventions":12886},[87],[749],[679,893],{"trials":12888,"activeCount":98},[12889],{"nctId":7062,"briefTitle":7063,"status":104,"phases":12890,"primaryCompletion":3658,"completion":3902,"start":7065,"enrollment":1597,"conditions":12891,"interventions":12892},[88],[7067,7054,7068],[7057,893,7070,7059],{"trials":12894,"activeCount":98},[12895,12904],{"nctId":12896,"briefTitle":12897,"status":104,"phases":12898,"primaryCompletion":11511,"completion":3976,"start":5050,"enrollment":7995,"conditions":12899,"interventions":12901},"NCT00256750","Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)",[89],[7054,12900],"Chronic Kidney Failure",[893,12902,12903],"Belatacept LI","Belatacept MI",{"nctId":7217,"briefTitle":7218,"status":104,"phases":12905,"primaryCompletion":7220,"completion":7220,"start":7221,"enrollment":7222,"conditions":12906,"interventions":12907},[89],[7054],[7057,7060,893],{"trials":12909,"activeCount":98},[],{"trials":12911,"activeCount":98},[],{"intervention":4937,"totalTrials":4328,"cells":12913},{"EARLY_PHASE1":12914,"PHASE1":12916,"PHASE2":12924,"PHASE3":12937,"PHASE4":12949,"NA":12951},{"trials":12915,"activeCount":98},[],{"trials":12917,"activeCount":98},[12918],{"nctId":12919,"briefTitle":12920,"status":467,"phases":12921,"primaryCompletion":7784,"completion":7784,"start":11728,"enrollment":98,"conditions":12922,"interventions":12923},"NCT00534807","A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer",[87],[606],[4937,5658],{"trials":12925,"activeCount":98},[12926],{"nctId":12927,"briefTitle":12928,"status":104,"phases":12929,"primaryCompletion":6960,"completion":6960,"start":12930,"enrollment":331,"conditions":12931,"interventions":12935},"NCT00101608","Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium",[88],"2005-01",[4934,12932,2960,12933,2427,12934],"Bladder Neoplasms","Ureter Neoplasms","Neoplasm, Bladder",[12936],"vinflunine",{"trials":12938,"activeCount":98},[12939,12945],{"nctId":12940,"briefTitle":12941,"status":963,"phases":12942,"primaryCompletion":4179,"completion":7758,"start":3920,"enrollment":7633,"conditions":12943,"interventions":12944},"NCT00359476","A Study of Vinflunine in Patients With Gastric Cancer",[88,89],[1438],[4937],{"nctId":4927,"briefTitle":4928,"status":104,"phases":12946,"primaryCompletion":4930,"completion":4930,"start":4931,"enrollment":4932,"conditions":12947,"interventions":12948},[88,89],[2427,4934,4935],[4937,1267],{"trials":12950,"activeCount":98},[],{"trials":12952,"activeCount":98},[],{"intervention":12382,"totalTrials":4328,"cells":12954},{"EARLY_PHASE1":12955,"PHASE1":12957,"PHASE2":12959,"PHASE3":12973,"PHASE4":12983,"NA":12985},{"trials":12956,"activeCount":98},[],{"trials":12958,"activeCount":98},[],{"trials":12960,"activeCount":98},[12961,12967],{"nctId":12962,"briefTitle":12963,"status":104,"phases":12964,"primaryCompletion":4123,"completion":7691,"start":10856,"enrollment":830,"conditions":12965,"interventions":12966},"NCT00779428","Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin",[88],[1309],[12382],{"nctId":12968,"briefTitle":12969,"status":104,"phases":12970,"primaryCompletion":4459,"completion":3873,"start":5098,"enrollment":94,"conditions":12971,"interventions":12972},"NCT00773344","Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin",[87,88],[1515,1223],[12382],{"trials":12974,"activeCount":98},[12975,12979],{"nctId":12370,"briefTitle":12371,"status":104,"phases":12976,"primaryCompletion":3587,"completion":3587,"start":10821,"enrollment":3978,"conditions":12977,"interventions":12978},[88,89],[33],[12375,1796],{"nctId":12377,"briefTitle":12378,"status":104,"phases":12980,"primaryCompletion":7088,"completion":7088,"start":3680,"enrollment":4124,"conditions":12981,"interventions":12982},[89],[33],[12382,1796],{"trials":12984,"activeCount":98},[],{"trials":12986,"activeCount":98},[],{"intervention":1167,"totalTrials":574,"cells":12988},{"EARLY_PHASE1":12989,"PHASE1":12991,"PHASE2":12997,"PHASE3":13003,"PHASE4":13009,"NA":13011},{"trials":12990,"activeCount":98},[],{"trials":12992,"activeCount":98},[12993],{"nctId":1160,"briefTitle":1161,"status":104,"phases":12994,"primaryCompletion":1163,"completion":1163,"start":1164,"enrollment":574,"conditions":12995,"interventions":12996},[87],[1154],[1167,43],{"trials":12998,"activeCount":98},[12999],{"nctId":1381,"briefTitle":1382,"status":963,"phases":13000,"primaryCompletion":1384,"completion":1384,"start":1294,"enrollment":1385,"conditions":13001,"interventions":13002},[87,88],[1387,1388,1389,1390,1391,1392,1393,1394,1395,1396],[43,1167],{"trials":13004,"activeCount":98},[13005],{"nctId":2400,"briefTitle":2401,"status":104,"phases":13006,"primaryCompletion":2403,"completion":2404,"start":2405,"enrollment":2406,"conditions":13007,"interventions":13008},[89],[21],[1167,43],{"trials":13010,"activeCount":98},[],{"trials":13012,"activeCount":98},[],{"intervention":10404,"totalTrials":574,"cells":13014},{"EARLY_PHASE1":13015,"PHASE1":13017,"PHASE2":13023,"PHASE3":13025,"PHASE4":13039,"NA":13041},{"trials":13016,"activeCount":98},[],{"trials":13018,"activeCount":98},[13019],{"nctId":10397,"briefTitle":10398,"status":104,"phases":13020,"primaryCompletion":4122,"completion":4122,"start":3017,"enrollment":790,"conditions":13021,"interventions":13022},[87],[30],[10402,10403,902,10404],{"trials":13024,"activeCount":98},[],{"trials":13026,"activeCount":98},[13027,13031],{"nctId":10640,"briefTitle":10641,"status":104,"phases":13028,"primaryCompletion":8030,"completion":8030,"start":5079,"enrollment":10643,"conditions":13029,"interventions":13030},[89],[8545],[8547,10646,10436,10647],{"nctId":13032,"briefTitle":13033,"status":104,"phases":13034,"primaryCompletion":13035,"completion":13035,"start":13036,"conditions":13037,"interventions":13038},"NCT00028301","Atazanavir Versus Lopinavir\u002FRitonavir (LPV\u002FRTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)",[89],"2003-09","2001-02",[24],[8547,10404],{"trials":13040,"activeCount":98},[],{"trials":13042,"activeCount":98},[],{"intervention":10477,"totalTrials":574,"cells":13044},{"EARLY_PHASE1":13045,"PHASE1":13047,"PHASE2":13068,"PHASE3":13070,"PHASE4":13076,"NA":13078},{"trials":13046,"activeCount":98},[],{"trials":13048,"activeCount":98},[13049,13057],{"nctId":13050,"briefTitle":13051,"status":104,"phases":13052,"primaryCompletion":13053,"completion":13053,"start":5117,"enrollment":693,"conditions":13054,"interventions":13056},"NCT00357721","Atazanavir Twice Daily",[87],"2006-09",[24,13055],"Protease Inhibitor",[10477,10477,10477],{"nctId":13058,"briefTitle":13059,"status":104,"phases":13060,"primaryCompletion":13061,"completion":13061,"start":13053,"enrollment":363,"conditions":13062,"interventions":13063},"NCT00362726","Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone",[87],"2006-11",[24],[13064,10477,13065,13066,13067],"Rosiglitazone maleate","Atazanavir Sulphate + Rosiglitazone maleate","Atazanavir Sulphate + Ritonavir","Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate",{"trials":13069,"activeCount":98},[],{"trials":13071,"activeCount":98},[13072],{"nctId":10468,"briefTitle":10469,"status":104,"phases":13073,"primaryCompletion":10471,"completion":10472,"start":10473,"enrollment":10474,"conditions":13074,"interventions":13075},[89],[8545],[10477,902],{"trials":13077,"activeCount":98},[],{"trials":13079,"activeCount":98},[],{"intervention":13081,"totalTrials":574,"cells":13082},"Atazanavir + Ritonavir",{"EARLY_PHASE1":13083,"PHASE1":13085,"PHASE2":13101,"PHASE3":13103,"PHASE4":13112,"NA":13114},{"trials":13084,"activeCount":98},[],{"trials":13086,"activeCount":98},[13087,13093],{"nctId":13088,"briefTitle":13089,"status":104,"phases":13090,"primaryCompletion":7846,"completion":7846,"start":13061,"enrollment":6185,"conditions":13091,"interventions":13092},"NCT00393328","Bioequivalence Study of Atazanavir 300 mg Capsule",[87],[24],[13081,13081],{"nctId":13094,"briefTitle":13095,"status":104,"phases":13096,"primaryCompletion":10856,"completion":10856,"start":5043,"enrollment":6185,"conditions":13097,"interventions":13098},"NCT00162149","ATV\u002FRitonavir Nevirapine Interaction (USPAC)",[87],[24],[13099,13100,13100,13081],"Nevirapine","Nevirapine + Atazanavir\u002FRitonavir",{"trials":13102,"activeCount":98},[],{"trials":13104,"activeCount":98},[13105],{"nctId":13106,"briefTitle":13107,"status":104,"phases":13108,"primaryCompletion":5873,"completion":4459,"start":5117,"enrollment":451,"conditions":13109,"interventions":13111},"NCT00337467","Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir\u002FRitonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression",[89],[13110],"Human Immunodeficiency Virus (HIV) Infections",[13081],{"trials":13113,"activeCount":98},[],{"trials":13115,"activeCount":98},[],{"intervention":13117,"totalTrials":574,"cells":13118},"DCV\u002FASV\u002FBMS-791325",{"EARLY_PHASE1":13119,"PHASE1":13121,"PHASE2":13123,"PHASE3":13136,"PHASE4":13154,"NA":13156},{"trials":13120,"activeCount":98},[],{"trials":13122,"activeCount":98},[],{"trials":13124,"activeCount":98},[13125],{"nctId":13126,"briefTitle":13127,"status":104,"phases":13128,"primaryCompletion":13129,"completion":13130,"start":13131,"enrollment":1063,"conditions":13132,"interventions":13133},"NCT02175966","Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)",[88],"2015-01-28","2015-12-17","2014-07-28",[30],[13117,11917,13134,13135],"Sofosbuvir","Peginterferon α-2a",{"trials":13137,"activeCount":98},[13138,13148],{"nctId":13139,"briefTitle":13140,"status":104,"phases":13141,"primaryCompletion":13142,"completion":13143,"start":13144,"enrollment":13145,"conditions":13146,"interventions":13147},"NCT02170727","A Phase 3 Study of a Daclatasvir\u002FAsunaprevir\u002FBMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1",[89],"2015-06-12","2015-09-09","2014-06-26",199,[11842],[13117],{"nctId":13149,"briefTitle":13150,"status":104,"phases":13151,"primaryCompletion":10525,"completion":7690,"start":3959,"enrollment":1715,"conditions":13152,"interventions":13153},"NCT01979939","UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects",[89],[30],[13117],{"trials":13155,"activeCount":98},[],{"trials":13157,"activeCount":98},[],{"intervention":1949,"totalTrials":574,"cells":13159},{"EARLY_PHASE1":13160,"PHASE1":13162,"PHASE2":13164,"PHASE3":13174,"PHASE4":13187,"NA":13189},{"trials":13161,"activeCount":98},[],{"trials":13163,"activeCount":98},[],{"trials":13165,"activeCount":98},[13166,13170],{"nctId":1940,"briefTitle":1941,"status":104,"phases":13167,"primaryCompletion":1943,"completion":1943,"start":1944,"enrollment":1945,"conditions":13168,"interventions":13169},[87,88],[1154],[1948,43,1949],{"nctId":1961,"briefTitle":1962,"status":104,"phases":13171,"primaryCompletion":1964,"completion":1964,"start":1965,"enrollment":1966,"conditions":13172,"interventions":13173},[87,88],[1673,1968,1969,1970],[43,610,608,1949],{"trials":13175,"activeCount":98},[13176],{"nctId":13177,"briefTitle":13178,"status":963,"phases":13179,"primaryCompletion":3467,"completion":3467,"start":13180,"enrollment":13181,"conditions":13182,"interventions":13184},"NCT05328908","A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer",[89],"2022-04-28",770,[13183],"Colorectal Neoplasms",[13185,1949,13186],"Nivolumab-relatlimab FDC","TAS-102",{"trials":13188,"activeCount":98},[],{"trials":13190,"activeCount":98},[],{"intervention":2762,"totalTrials":574,"cells":13192},{"EARLY_PHASE1":13193,"PHASE1":13195,"PHASE2":13197,"PHASE3":13207,"PHASE4":13213,"NA":13215},{"trials":13194,"activeCount":98},[],{"trials":13196,"activeCount":98},[],{"trials":13198,"activeCount":98},[13199,13203],{"nctId":2166,"briefTitle":2167,"status":104,"phases":13200,"primaryCompletion":2169,"completion":201,"start":2170,"enrollment":2171,"conditions":13201,"interventions":13202},[87,88],[2173],[43,2175],{"nctId":2208,"briefTitle":2209,"status":104,"phases":13204,"primaryCompletion":2211,"completion":2211,"start":2212,"enrollment":534,"conditions":13205,"interventions":13206},[88],[2051],[43,2215,2216],{"trials":13208,"activeCount":98},[13209],{"nctId":2754,"briefTitle":2755,"status":963,"phases":13210,"primaryCompletion":2757,"completion":2757,"start":2758,"enrollment":2038,"conditions":13211,"interventions":13212},[89],[2760],[43,2762],{"trials":13214,"activeCount":98},[],{"trials":13216,"activeCount":98},[],{"intervention":12763,"totalTrials":230,"cells":13218},{"EARLY_PHASE1":13219,"PHASE1":13221,"PHASE2":13223,"PHASE3":13229,"PHASE4":13235,"NA":13237},{"trials":13220,"activeCount":98},[],{"trials":13222,"activeCount":98},[],{"trials":13224,"activeCount":98},[13225],{"nctId":12735,"briefTitle":12736,"status":104,"phases":13226,"primaryCompletion":4179,"completion":4179,"start":3657,"enrollment":12738,"conditions":13227,"interventions":13228},[87,88],[12740],[12742,11906],{"trials":13230,"activeCount":98},[13231],{"nctId":12757,"briefTitle":12758,"status":104,"phases":13232,"primaryCompletion":5023,"completion":5023,"start":4010,"enrollment":3093,"conditions":13233,"interventions":13234},[88,89],[12761],[12763,12764],{"trials":13236,"activeCount":98},[],{"trials":13238,"activeCount":98},[],{"intervention":12782,"totalTrials":230,"cells":13240},{"EARLY_PHASE1":13241,"PHASE1":13243,"PHASE2":13245,"PHASE3":13251,"PHASE4":13264,"NA":13266},{"trials":13242,"activeCount":98},[],{"trials":13244,"activeCount":98},[],{"trials":13246,"activeCount":98},[13247],{"nctId":12778,"briefTitle":11979,"status":104,"phases":13248,"primaryCompletion":4289,"completion":11981,"start":4123,"enrollment":11982,"conditions":13249,"interventions":13250},[88],[30],[11985,12782,10402],{"trials":13252,"activeCount":98},[13253],{"nctId":13254,"briefTitle":13255,"status":963,"phases":13256,"primaryCompletion":13257,"completion":13257,"start":13258,"enrollment":13259,"conditions":13260,"interventions":13262},"NCT01866930","Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV",[89],"2015-08-27","2013-07-11",453,[13261],"Chronic Hepatitis C Infection",[13263,10402,12782],"Pegylated Interferon Lambda-1a",{"trials":13265,"activeCount":98},[],{"trials":13267,"activeCount":98},[],{"intervention":13269,"totalTrials":230,"cells":13270},"Intravenous (IV) abatacept",{"EARLY_PHASE1":13271,"PHASE1":13273,"PHASE2":13275,"PHASE3":13277,"PHASE4":13295,"NA":13297},{"trials":13272,"activeCount":98},[],{"trials":13274,"activeCount":98},[],{"trials":13276,"activeCount":98},[],{"trials":13278,"activeCount":98},[13279,13286],{"nctId":13280,"briefTitle":13281,"status":104,"phases":13282,"primaryCompletion":3938,"completion":3586,"start":5014,"enrollment":357,"conditions":13283,"interventions":13284},"NCT01001832","Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients",[88,89],[15],[13269,13285],"Subcutaneous (SC) abatacept",{"nctId":13287,"briefTitle":13288,"status":104,"phases":13289,"primaryCompletion":3585,"completion":11981,"start":4930,"enrollment":13290,"conditions":13291,"interventions":13292},"NCT00559585","Methotrexate-Inadequate Response Study",[89],2492,[6970],[13293,13294],"Subcutaneous (SC) Abatacept","Intravenous (IV) Abatacept",{"trials":13296,"activeCount":98},[],{"trials":13298,"activeCount":98},[],{"intervention":13285,"totalTrials":230,"cells":13300},{"EARLY_PHASE1":13301,"PHASE1":13303,"PHASE2":13305,"PHASE3":13307,"PHASE4":13317,"NA":13319},{"trials":13302,"activeCount":98},[],{"trials":13304,"activeCount":98},[],{"trials":13306,"activeCount":98},[],{"trials":13308,"activeCount":98},[13309,13313],{"nctId":13280,"briefTitle":13281,"status":104,"phases":13310,"primaryCompletion":3938,"completion":3586,"start":5014,"enrollment":357,"conditions":13311,"interventions":13312},[88,89],[15],[13269,13285],{"nctId":13287,"briefTitle":13288,"status":104,"phases":13314,"primaryCompletion":3585,"completion":11981,"start":4930,"enrollment":13290,"conditions":13315,"interventions":13316},[89],[6970],[13293,13294],{"trials":13318,"activeCount":98},[],{"trials":13320,"activeCount":98},[],{"intervention":13322,"totalTrials":230,"cells":13323},"Lamivudine\u002FZidovudine",{"EARLY_PHASE1":13324,"PHASE1":13326,"PHASE2":13328,"PHASE3":13330,"PHASE4":13350,"NA":13352},{"trials":13325,"activeCount":98},[],{"trials":13327,"activeCount":98},[],{"trials":13329,"activeCount":98},[],{"trials":13331,"activeCount":98},[13332,13343],{"nctId":13333,"briefTitle":13334,"status":104,"phases":13335,"primaryCompletion":13336,"completion":13336,"start":13337,"enrollment":290,"conditions":13338,"interventions":13339},"NCT00002429","Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen",[89],"2001-01","1999-07",[24],[13322,13340,13341,13342],"Nelfinavir mesylate","Stavudine","Didanosine",{"nctId":13344,"briefTitle":13345,"status":104,"phases":13346,"primaryCompletion":13347,"completion":13347,"start":13036,"conditions":13348,"interventions":13349},"NCT00013897","A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine",[89],"2003-04",[24],[8547,13322,9383],{"trials":13351,"activeCount":98},[],{"trials":13353,"activeCount":98},[],{"intervention":13355,"totalTrials":230,"cells":13356},"Entecavir + Tenofovir",{"EARLY_PHASE1":13357,"PHASE1":13359,"PHASE2":13361,"PHASE3":13363,"PHASE4":13379,"NA":13381},{"trials":13358,"activeCount":98},[],{"trials":13360,"activeCount":98},[],{"trials":13362,"activeCount":98},[],{"trials":13364,"activeCount":98},[13365,13372],{"nctId":13366,"briefTitle":13367,"status":104,"phases":13368,"primaryCompletion":7706,"completion":7706,"start":6960,"enrollment":13369,"conditions":13370,"interventions":13371},"NCT00410072","Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B",[89],669,[10687],[10680,13355],{"nctId":13373,"briefTitle":13374,"status":963,"phases":13375,"primaryCompletion":3587,"completion":3587,"start":7715,"enrollment":4328,"conditions":13376,"interventions":13377},"NCT00605384","A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection",[89],[10764],[13355,13378],"Adefovir + continuing Lamivudine",{"trials":13380,"activeCount":98},[],{"trials":13382,"activeCount":98},[],{"intervention":10403,"totalTrials":230,"cells":13384},{"EARLY_PHASE1":13385,"PHASE1":13387,"PHASE2":13393,"PHASE3":13395,"PHASE4":13401,"NA":13403},{"trials":13386,"activeCount":98},[],{"trials":13388,"activeCount":98},[13389],{"nctId":10397,"briefTitle":10398,"status":104,"phases":13390,"primaryCompletion":4122,"completion":4122,"start":3017,"enrollment":790,"conditions":13391,"interventions":13392},[87],[30],[10402,10403,902,10404],{"trials":13394,"activeCount":98},[],{"trials":13396,"activeCount":98},[13397],{"nctId":10440,"briefTitle":10441,"status":467,"phases":13398,"primaryCompletion":10443,"completion":10443,"start":10444,"enrollment":98,"conditions":13399,"interventions":13400},[89],[8545],[8547,10403,902,10447],{"trials":13402,"activeCount":98},[],{"trials":13404,"activeCount":98},[],{"intervention":12038,"totalTrials":230,"cells":13406},{"EARLY_PHASE1":13407,"PHASE1":13409,"PHASE2":13411,"PHASE3":13413,"PHASE4":13425,"NA":13427},{"trials":13408,"activeCount":98},[],{"trials":13410,"activeCount":98},[],{"trials":13412,"activeCount":98},[],{"trials":13414,"activeCount":98},[13415,13419],{"nctId":12032,"briefTitle":12033,"status":104,"phases":13416,"primaryCompletion":4378,"completion":9360,"start":3679,"enrollment":12035,"conditions":13417,"interventions":13418},[89],[30],[11934,12038,11917],{"nctId":13420,"briefTitle":13421,"status":104,"phases":13422,"primaryCompletion":4378,"completion":11981,"start":6225,"enrollment":6275,"conditions":13423,"interventions":13424},"NCT01581203","Phase III Hallmark DUAL: ASV+DCV (Nulls\u002FPartials, Intolerants\u002FIneligibles. Naives)",[89],[11842],[11943,10402,12038,11917],{"trials":13426,"activeCount":98},[],{"trials":13428,"activeCount":98},[],{"intervention":2184,"totalTrials":230,"cells":13430},{"EARLY_PHASE1":13431,"PHASE1":13433,"PHASE2":13435,"PHASE3":13441,"PHASE4":13447,"NA":13449},{"trials":13432,"activeCount":98},[],{"trials":13434,"activeCount":98},[],{"trials":13436,"activeCount":98},[13437],{"nctId":2177,"briefTitle":2178,"status":467,"phases":13438,"primaryCompletion":280,"completion":2180,"start":954,"enrollment":98,"conditions":13439,"interventions":13440},[88],[21,2182],[2184,43],{"trials":13442,"activeCount":98},[13443],{"nctId":2494,"briefTitle":2495,"status":104,"phases":13444,"primaryCompletion":2497,"completion":2497,"start":2137,"enrollment":363,"conditions":13445,"interventions":13446},[89],[21],[2184,43],{"trials":13448,"activeCount":98},[],{"trials":13450,"activeCount":98},[],{"intervention":2936,"totalTrials":230,"cells":13452},{"EARLY_PHASE1":13453,"PHASE1":13455,"PHASE2":13457,"PHASE3":13463,"PHASE4":13469,"NA":13471},{"trials":13454,"activeCount":98},[],{"trials":13456,"activeCount":98},[],{"trials":13458,"activeCount":98},[13459],{"nctId":7048,"briefTitle":7049,"status":104,"phases":13460,"primaryCompletion":7051,"completion":7051,"start":7052,"enrollment":2308,"conditions":13461,"interventions":13462},[88],[7054],[7056,7057,7058,7059,2936,7060],{"trials":13464,"activeCount":98},[13465],{"nctId":2926,"briefTitle":2927,"status":104,"phases":13466,"primaryCompletion":2929,"completion":2930,"start":2931,"enrollment":2932,"conditions":13467,"interventions":13468},[89],[2934],[43,2936],{"trials":13470,"activeCount":98},[],{"trials":13472,"activeCount":98},[],{"intervention":13474,"totalTrials":230,"cells":13475},"Irbesartan\u002FHCTZ",{"EARLY_PHASE1":13476,"PHASE1":13478,"PHASE2":13480,"PHASE3":13482,"PHASE4":13500,"NA":13502},{"trials":13477,"activeCount":98},[],{"trials":13479,"activeCount":98},[],{"trials":13481,"activeCount":98},[],{"trials":13483,"activeCount":98},[13484,13492],{"nctId":13485,"briefTitle":13486,"status":104,"phases":13487,"primaryCompletion":4665,"completion":4665,"start":11405,"enrollment":13488,"conditions":13489,"interventions":13490},"NCT00095394","Irbesartan\u002FHydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension",[89],645,[10877],[13474,13491],"Irbesartan monotherapy",{"nctId":13493,"briefTitle":13494,"status":104,"phases":13495,"primaryCompletion":11251,"completion":11251,"start":12468,"enrollment":13496,"conditions":13497,"interventions":13498},"NCT00095550","Irbesartan\u002FHydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension",[89],496,[10877],[13474,13491,13499],"HCTZ monotherapy",{"trials":13501,"activeCount":98},[],{"trials":13503,"activeCount":98},[],{"intervention":13491,"totalTrials":230,"cells":13505},{"EARLY_PHASE1":13506,"PHASE1":13508,"PHASE2":13510,"PHASE3":13512,"PHASE4":13522,"NA":13524},{"trials":13507,"activeCount":98},[],{"trials":13509,"activeCount":98},[],{"trials":13511,"activeCount":98},[],{"trials":13513,"activeCount":98},[13514,13518],{"nctId":13485,"briefTitle":13486,"status":104,"phases":13515,"primaryCompletion":4665,"completion":4665,"start":11405,"enrollment":13488,"conditions":13516,"interventions":13517},[89],[10877],[13474,13491],{"nctId":13493,"briefTitle":13494,"status":104,"phases":13519,"primaryCompletion":11251,"completion":11251,"start":12468,"enrollment":13496,"conditions":13520,"interventions":13521},[89],[10877],[13474,13491,13499],{"trials":13523,"activeCount":98},[],{"trials":13525,"activeCount":98},[],{"intervention":2913,"totalTrials":230,"cells":13527},{"EARLY_PHASE1":13528,"PHASE1":13530,"PHASE2":13532,"PHASE3":13538,"PHASE4":13544,"NA":13546},{"trials":13529,"activeCount":98},[],{"trials":13531,"activeCount":98},[],{"trials":13533,"activeCount":98},[13534],{"nctId":5083,"briefTitle":5084,"status":104,"phases":13535,"primaryCompletion":5086,"completion":5087,"start":5088,"enrollment":413,"conditions":13536,"interventions":13537},[88],[5090],[5092,1158,5093,2913],{"trials":13539,"activeCount":98},[13540],{"nctId":2904,"briefTitle":2905,"status":104,"phases":13541,"primaryCompletion":2907,"completion":2908,"start":2909,"enrollment":2910,"conditions":13542,"interventions":13543},[89],[1717],[43,2913,2914],{"trials":13545,"activeCount":98},[],{"trials":13547,"activeCount":98},[],{"intervention":2651,"totalTrials":230,"cells":13549},{"EARLY_PHASE1":13550,"PHASE1":13552,"PHASE2":13554,"PHASE3":13560,"PHASE4":13566,"NA":13568},{"trials":13551,"activeCount":98},[],{"trials":13553,"activeCount":98},[],{"trials":13555,"activeCount":98},[13556],{"nctId":4119,"briefTitle":4120,"status":963,"phases":13557,"primaryCompletion":4122,"completion":4122,"start":4123,"enrollment":4124,"conditions":13558,"interventions":13559},[88],[21],[608,2651],{"trials":13561,"activeCount":98},[13562],{"nctId":2643,"briefTitle":2644,"status":467,"phases":13563,"primaryCompletion":2646,"completion":2647,"start":2648,"enrollment":98,"conditions":13564,"interventions":13565},[89],[1717,36],[1337,43,2651],{"trials":13567,"activeCount":98},[],{"trials":13569,"activeCount":98},[],{"intervention":13571,"totalTrials":230,"cells":13572},"Antidepressant + Placebo",{"EARLY_PHASE1":13573,"PHASE1":13575,"PHASE2":13577,"PHASE3":13579,"PHASE4":13594,"NA":13596},{"trials":13574,"activeCount":98},[],{"trials":13576,"activeCount":98},[],{"trials":13578,"activeCount":98},[],{"trials":13580,"activeCount":98},[13581,13589],{"nctId":13582,"briefTitle":13583,"status":104,"phases":13584,"primaryCompletion":4379,"completion":4379,"start":11187,"enrollment":13585,"conditions":13586,"interventions":13587},"NCT00095823","A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder",[89],1200,[12740],[13571,13588],"Antidepressant + Aripiprazole",{"nctId":13590,"briefTitle":13583,"status":104,"phases":13591,"primaryCompletion":7846,"completion":7846,"start":11405,"enrollment":13585,"conditions":13592,"interventions":13593},"NCT00095758",[89],[12740],[13571,13588],{"trials":13595,"activeCount":98},[],{"trials":13597,"activeCount":98},[],{"intervention":13588,"totalTrials":230,"cells":13599},{"EARLY_PHASE1":13600,"PHASE1":13602,"PHASE2":13604,"PHASE3":13606,"PHASE4":13616,"NA":13618},{"trials":13601,"activeCount":98},[],{"trials":13603,"activeCount":98},[],{"trials":13605,"activeCount":98},[],{"trials":13607,"activeCount":98},[13608,13612],{"nctId":13582,"briefTitle":13583,"status":104,"phases":13609,"primaryCompletion":4379,"completion":4379,"start":11187,"enrollment":13585,"conditions":13610,"interventions":13611},[89],[12740],[13571,13588],{"nctId":13590,"briefTitle":13583,"status":104,"phases":13613,"primaryCompletion":7846,"completion":7846,"start":11405,"enrollment":13585,"conditions":13614,"interventions":13615},[89],[12740],[13571,13588],{"trials":13617,"activeCount":98},[],{"trials":13619,"activeCount":98},[],{"intervention":2164,"totalTrials":230,"cells":13621},{"EARLY_PHASE1":13622,"PHASE1":13624,"PHASE2":13626,"PHASE3":13632,"PHASE4":13638,"NA":13640},{"trials":13623,"activeCount":98},[],{"trials":13625,"activeCount":98},[],{"trials":13627,"activeCount":98},[13628],{"nctId":2154,"briefTitle":2155,"status":467,"phases":13629,"primaryCompletion":2157,"completion":2158,"start":2159,"enrollment":98,"conditions":13630,"interventions":13631},[88],[36,2161,2162],[43,2164,1267,1328,622,1268,1157,1158],{"trials":13633,"activeCount":98},[13634],{"nctId":2614,"briefTitle":2615,"status":104,"phases":13635,"primaryCompletion":2617,"completion":2618,"start":2619,"enrollment":2620,"conditions":13636,"interventions":13637},[89],[2622],[43,1268,2164,1267,1328,622,1157,1158,608],{"trials":13639,"activeCount":98},[],{"trials":13641,"activeCount":98},[],{"intervention":13643,"totalTrials":208,"cells":13644},"Sorivudine",{"EARLY_PHASE1":13645,"PHASE1":13647,"PHASE2":13649,"PHASE3":13651,"PHASE4":13660,"NA":13662},{"trials":13646,"activeCount":98},[],{"trials":13648,"activeCount":98},[],{"trials":13650,"activeCount":98},[],{"trials":13652,"activeCount":98},[13653],{"nctId":13654,"briefTitle":13655,"status":104,"phases":13656,"conditions":13657,"interventions":13659},"NCT00002358","A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV",[89],[24,13658],"Chickenpox",[13643],{"trials":13661,"activeCount":98},[],{"trials":13663,"activeCount":98},[],{"intervention":13665,"totalTrials":208,"cells":13666},"Atazanavir+ritonavir",{"EARLY_PHASE1":13667,"PHASE1":13669,"PHASE2":13671,"PHASE3":13673,"PHASE4":13683,"NA":13685},{"trials":13668,"activeCount":98},[],{"trials":13670,"activeCount":98},[],{"trials":13672,"activeCount":98},[],{"trials":13674,"activeCount":98},[13675],{"nctId":13676,"briefTitle":13677,"status":104,"phases":13678,"primaryCompletion":13679,"completion":13679,"start":12230,"enrollment":311,"conditions":13680,"interventions":13681},"NCT00135395","A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen",[89],"2006-02",[24],[13665,13682],"Lopinavir+ritonavir",{"trials":13684,"activeCount":98},[],{"trials":13686,"activeCount":98},[],{"intervention":13682,"totalTrials":208,"cells":13688},{"EARLY_PHASE1":13689,"PHASE1":13691,"PHASE2":13693,"PHASE3":13695,"PHASE4":13701,"NA":13703},{"trials":13690,"activeCount":98},[],{"trials":13692,"activeCount":98},[],{"trials":13694,"activeCount":98},[],{"trials":13696,"activeCount":98},[13697],{"nctId":13676,"briefTitle":13677,"status":104,"phases":13698,"primaryCompletion":13679,"completion":13679,"start":12230,"enrollment":311,"conditions":13699,"interventions":13700},[89],[24],[13665,13682],{"trials":13702,"activeCount":98},[],{"trials":13704,"activeCount":98},[],{"intervention":7826,"totalTrials":208,"cells":13706},{"EARLY_PHASE1":13707,"PHASE1":13709,"PHASE2":13711,"PHASE3":13713,"PHASE4":13719,"NA":13721},{"trials":13708,"activeCount":98},[],{"trials":13710,"activeCount":98},[],{"trials":13712,"activeCount":98},[],{"trials":13714,"activeCount":98},[13715],{"nctId":7820,"briefTitle":7821,"status":104,"phases":13716,"primaryCompletion":6170,"completion":6170,"start":7812,"enrollment":7823,"conditions":13717,"interventions":13718},[89],[15],[61,7826,7827,7828],{"trials":13720,"activeCount":98},[],{"trials":13722,"activeCount":98},[],{"intervention":7827,"totalTrials":208,"cells":13724},{"EARLY_PHASE1":13725,"PHASE1":13727,"PHASE2":13729,"PHASE3":13731,"PHASE4":13737,"NA":13739},{"trials":13726,"activeCount":98},[],{"trials":13728,"activeCount":98},[],{"trials":13730,"activeCount":98},[],{"trials":13732,"activeCount":98},[13733],{"nctId":7820,"briefTitle":7821,"status":104,"phases":13734,"primaryCompletion":6170,"completion":6170,"start":7812,"enrollment":7823,"conditions":13735,"interventions":13736},[89],[15],[61,7826,7827,7828],{"trials":13738,"activeCount":98},[],{"trials":13740,"activeCount":98},[],{"intervention":7828,"totalTrials":208,"cells":13742},{"EARLY_PHASE1":13743,"PHASE1":13745,"PHASE2":13747,"PHASE3":13749,"PHASE4":13755,"NA":13757},{"trials":13744,"activeCount":98},[],{"trials":13746,"activeCount":98},[],{"trials":13748,"activeCount":98},[],{"trials":13750,"activeCount":98},[13751],{"nctId":7820,"briefTitle":7821,"status":104,"phases":13752,"primaryCompletion":6170,"completion":6170,"start":7812,"enrollment":7823,"conditions":13753,"interventions":13754},[89],[15],[61,7826,7827,7828],{"trials":13756,"activeCount":98},[],{"trials":13758,"activeCount":98},[],{"intervention":2390,"totalTrials":208,"cells":13760},{"EARLY_PHASE1":13761,"PHASE1":13763,"PHASE2":13765,"PHASE3":13767,"PHASE4":13773,"NA":13775},{"trials":13762,"activeCount":98},[],{"trials":13764,"activeCount":98},[],{"trials":13766,"activeCount":98},[],{"trials":13768,"activeCount":98},[13769],{"nctId":2381,"briefTitle":2382,"status":963,"phases":13770,"primaryCompletion":2384,"completion":2385,"start":2386,"enrollment":2387,"conditions":13771,"interventions":13772},[89],[21],[43,2390],{"trials":13774,"activeCount":98},[],{"trials":13776,"activeCount":98},[],{"intervention":13263,"totalTrials":208,"cells":13778},{"EARLY_PHASE1":13779,"PHASE1":13781,"PHASE2":13783,"PHASE3":13785,"PHASE4":13791,"NA":13793},{"trials":13780,"activeCount":98},[],{"trials":13782,"activeCount":98},[],{"trials":13784,"activeCount":98},[],{"trials":13786,"activeCount":98},[13787],{"nctId":13254,"briefTitle":13255,"status":963,"phases":13788,"primaryCompletion":13257,"completion":13257,"start":13258,"enrollment":13259,"conditions":13789,"interventions":13790},[89],[13261],[13263,10402,12782],{"trials":13792,"activeCount":98},[],{"trials":13794,"activeCount":98},[],{"intervention":12902,"totalTrials":208,"cells":13796},{"EARLY_PHASE1":13797,"PHASE1":13799,"PHASE2":13801,"PHASE3":13803,"PHASE4":13809,"NA":13811},{"trials":13798,"activeCount":98},[],{"trials":13800,"activeCount":98},[],{"trials":13802,"activeCount":98},[],{"trials":13804,"activeCount":98},[13805],{"nctId":12896,"briefTitle":12897,"status":104,"phases":13806,"primaryCompletion":11511,"completion":3976,"start":5050,"enrollment":7995,"conditions":13807,"interventions":13808},[89],[7054,12900],[893,12902,12903],{"trials":13810,"activeCount":98},[],{"trials":13812,"activeCount":98},[],{"intervention":12903,"totalTrials":208,"cells":13814},{"EARLY_PHASE1":13815,"PHASE1":13817,"PHASE2":13819,"PHASE3":13821,"PHASE4":13827,"NA":13829},{"trials":13816,"activeCount":98},[],{"trials":13818,"activeCount":98},[],{"trials":13820,"activeCount":98},[],{"trials":13822,"activeCount":98},[13823],{"nctId":12896,"briefTitle":12897,"status":104,"phases":13824,"primaryCompletion":11511,"completion":3976,"start":5050,"enrollment":7995,"conditions":13825,"interventions":13826},[89],[7054,12900],[893,12902,12903],{"trials":13828,"activeCount":98},[],{"trials":13830,"activeCount":98},[],{"intervention":13832,"totalTrials":208,"cells":13833},"MDX-010 (anti-CTLA4) monoclonal antibody",{"EARLY_PHASE1":13834,"PHASE1":13836,"PHASE2":13838,"PHASE3":13840,"PHASE4":13851,"NA":13853},{"trials":13835,"activeCount":98},[],{"trials":13837,"activeCount":98},[],{"trials":13839,"activeCount":98},[],{"trials":13841,"activeCount":98},[13842],{"nctId":13843,"briefTitle":13844,"status":104,"phases":13845,"primaryCompletion":3873,"completion":3678,"start":11405,"enrollment":13846,"conditions":13847,"interventions":13849},"NCT00094653","MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010\u002FMDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma",[89],1783,[21,13848],"Metastases",[13832,13850],"MDX-1379 (gp100) Melanoma Peptide Vaccine",{"trials":13852,"activeCount":98},[],{"trials":13854,"activeCount":98},[],{"intervention":13850,"totalTrials":208,"cells":13856},{"EARLY_PHASE1":13857,"PHASE1":13859,"PHASE2":13861,"PHASE3":13863,"PHASE4":13869,"NA":13871},{"trials":13858,"activeCount":98},[],{"trials":13860,"activeCount":98},[],{"trials":13862,"activeCount":98},[],{"trials":13864,"activeCount":98},[13865],{"nctId":13843,"briefTitle":13844,"status":104,"phases":13866,"primaryCompletion":3873,"completion":3678,"start":11405,"enrollment":13846,"conditions":13867,"interventions":13868},[89],[21,13848],[13832,13850],{"trials":13870,"activeCount":98},[],{"trials":13872,"activeCount":98},[],{"intervention":13874,"totalTrials":208,"cells":13875},"stavudine extended-release, lamivudine, efavirenz",{"EARLY_PHASE1":13876,"PHASE1":13878,"PHASE2":13880,"PHASE3":13882,"PHASE4":13890,"NA":13892},{"trials":13877,"activeCount":98},[],{"trials":13879,"activeCount":98},[],{"trials":13881,"activeCount":98},[],{"trials":13883,"activeCount":98},[13884],{"nctId":13885,"briefTitle":13886,"status":104,"phases":13887,"primaryCompletion":5078,"completion":5078,"start":7643,"enrollment":9852,"conditions":13888,"interventions":13889},"NCT00135369","Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen",[89],[24],[13874],{"trials":13891,"activeCount":98},[],{"trials":13893,"activeCount":98},[],{"intervention":10447,"totalTrials":208,"cells":13895},{"EARLY_PHASE1":13896,"PHASE1":13898,"PHASE2":13900,"PHASE3":13902,"PHASE4":13908,"NA":13910},{"trials":13897,"activeCount":98},[],{"trials":13899,"activeCount":98},[],{"trials":13901,"activeCount":98},[],{"trials":13903,"activeCount":98},[13904],{"nctId":10440,"briefTitle":10441,"status":467,"phases":13905,"primaryCompletion":10443,"completion":10443,"start":10444,"enrollment":98,"conditions":13906,"interventions":13907},[89],[8545],[8547,10403,902,10447],{"trials":13909,"activeCount":98},[],{"trials":13911,"activeCount":98},[],{"intervention":2431,"totalTrials":208,"cells":13913},{"EARLY_PHASE1":13914,"PHASE1":13916,"PHASE2":13918,"PHASE3":13920,"PHASE4":13926,"NA":13928},{"trials":13915,"activeCount":98},[],{"trials":13917,"activeCount":98},[],{"trials":13919,"activeCount":98},[],{"trials":13921,"activeCount":98},[13922],{"nctId":2420,"briefTitle":2421,"status":104,"phases":13923,"primaryCompletion":2423,"completion":2423,"start":2424,"enrollment":2425,"conditions":13924,"interventions":13925},[89],[2427,2428,2429],[43,2431],{"trials":13927,"activeCount":98},[],{"trials":13929,"activeCount":98},[],{"intervention":13378,"totalTrials":208,"cells":13931},{"EARLY_PHASE1":13932,"PHASE1":13934,"PHASE2":13936,"PHASE3":13938,"PHASE4":13944,"NA":13946},{"trials":13933,"activeCount":98},[],{"trials":13935,"activeCount":98},[],{"trials":13937,"activeCount":98},[],{"trials":13939,"activeCount":98},[13940],{"nctId":13373,"briefTitle":13374,"status":963,"phases":13941,"primaryCompletion":3587,"completion":3587,"start":7715,"enrollment":4328,"conditions":13942,"interventions":13943},[89],[10764],[13355,13378],{"trials":13945,"activeCount":98},[],{"trials":13947,"activeCount":98},[],{"intervention":2461,"totalTrials":208,"cells":13949},{"EARLY_PHASE1":13950,"PHASE1":13952,"PHASE2":13954,"PHASE3":13956,"PHASE4":13962,"NA":13964},{"trials":13951,"activeCount":98},[],{"trials":13953,"activeCount":98},[],{"trials":13955,"activeCount":98},[],{"trials":13957,"activeCount":98},[13958],{"nctId":2452,"briefTitle":2453,"status":104,"phases":13959,"primaryCompletion":2455,"completion":2456,"start":2457,"enrollment":2458,"conditions":13960,"interventions":13961},[89],[1537],[43,608,2461,2462,2463,2464],{"trials":13963,"activeCount":98},[],{"trials":13965,"activeCount":98},[],{"intervention":2462,"totalTrials":208,"cells":13967},{"EARLY_PHASE1":13968,"PHASE1":13970,"PHASE2":13972,"PHASE3":13974,"PHASE4":13980,"NA":13982},{"trials":13969,"activeCount":98},[],{"trials":13971,"activeCount":98},[],{"trials":13973,"activeCount":98},[],{"trials":13975,"activeCount":98},[13976],{"nctId":2452,"briefTitle":2453,"status":104,"phases":13977,"primaryCompletion":2455,"completion":2456,"start":2457,"enrollment":2458,"conditions":13978,"interventions":13979},[89],[1537],[43,608,2461,2462,2463,2464],{"trials":13981,"activeCount":98},[],{"trials":13983,"activeCount":98},[],{"intervention":2463,"totalTrials":208,"cells":13985},{"EARLY_PHASE1":13986,"PHASE1":13988,"PHASE2":13990,"PHASE3":13992,"PHASE4":13998,"NA":14000},{"trials":13987,"activeCount":98},[],{"trials":13989,"activeCount":98},[],{"trials":13991,"activeCount":98},[],{"trials":13993,"activeCount":98},[13994],{"nctId":2452,"briefTitle":2453,"status":104,"phases":13995,"primaryCompletion":2455,"completion":2456,"start":2457,"enrollment":2458,"conditions":13996,"interventions":13997},[89],[1537],[43,608,2461,2462,2463,2464],{"trials":13999,"activeCount":98},[],{"trials":14001,"activeCount":98},[],{"intervention":2464,"totalTrials":208,"cells":14003},{"EARLY_PHASE1":14004,"PHASE1":14006,"PHASE2":14008,"PHASE3":14010,"PHASE4":14016,"NA":14018},{"trials":14005,"activeCount":98},[],{"trials":14007,"activeCount":98},[],{"trials":14009,"activeCount":98},[],{"trials":14011,"activeCount":98},[14012],{"nctId":2452,"briefTitle":2453,"status":104,"phases":14013,"primaryCompletion":2455,"completion":2456,"start":2457,"enrollment":2458,"conditions":14014,"interventions":14015},[89],[1537],[43,608,2461,2462,2463,2464],{"trials":14017,"activeCount":98},[],{"trials":14019,"activeCount":98},[],{"intervention":14021,"totalTrials":208,"cells":14022},"Atazanavir + ritonavir + tenofovir + nucleoside",{"EARLY_PHASE1":14023,"PHASE1":14025,"PHASE2":14027,"PHASE3":14029,"PHASE4":14041,"NA":14043},{"trials":14024,"activeCount":98},[],{"trials":14026,"activeCount":98},[],{"trials":14028,"activeCount":98},[],{"trials":14030,"activeCount":98},[14031],{"nctId":14032,"briefTitle":14033,"status":104,"phases":14034,"primaryCompletion":12201,"completion":4981,"start":14035,"enrollment":14036,"conditions":14037,"interventions":14038},"NCT00035932","Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir\u002FRitonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",[89],"2001-11",571,[24],[14021,14039,14040],"Atazanavir + saquinavir + tenofovir + nucleoside","Lopinavir\u002Fritonavir + tenofovir + nucleoside",{"trials":14042,"activeCount":98},[],{"trials":14044,"activeCount":98},[],{"intervention":14039,"totalTrials":208,"cells":14046},{"EARLY_PHASE1":14047,"PHASE1":14049,"PHASE2":14051,"PHASE3":14053,"PHASE4":14059,"NA":14061},{"trials":14048,"activeCount":98},[],{"trials":14050,"activeCount":98},[],{"trials":14052,"activeCount":98},[],{"trials":14054,"activeCount":98},[14055],{"nctId":14032,"briefTitle":14033,"status":104,"phases":14056,"primaryCompletion":12201,"completion":4981,"start":14035,"enrollment":14036,"conditions":14057,"interventions":14058},[89],[24],[14021,14039,14040],{"trials":14060,"activeCount":98},[],{"trials":14062,"activeCount":98},[],{"intervention":14040,"totalTrials":208,"cells":14064},{"EARLY_PHASE1":14065,"PHASE1":14067,"PHASE2":14069,"PHASE3":14071,"PHASE4":14077,"NA":14079},{"trials":14066,"activeCount":98},[],{"trials":14068,"activeCount":98},[],{"trials":14070,"activeCount":98},[],{"trials":14072,"activeCount":98},[14073],{"nctId":14032,"briefTitle":14033,"status":104,"phases":14074,"primaryCompletion":12201,"completion":4981,"start":14035,"enrollment":14036,"conditions":14075,"interventions":14076},[89],[24],[14021,14039,14040],{"trials":14078,"activeCount":98},[],{"trials":14080,"activeCount":98},[],{"intervention":14082,"totalTrials":208,"cells":14083},"DCV",{"EARLY_PHASE1":14084,"PHASE1":14086,"PHASE2":14088,"PHASE3":14090,"PHASE4":14103,"NA":14105},{"trials":14085,"activeCount":98},[],{"trials":14087,"activeCount":98},[],{"trials":14089,"activeCount":98},[],{"trials":14091,"activeCount":98},[14092],{"nctId":14093,"briefTitle":14094,"status":104,"phases":14095,"primaryCompletion":14096,"completion":14097,"start":14098,"enrollment":413,"conditions":14099,"interventions":14100},"NCT02673489","A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection",[89],"2017-03-02","2017-05-26","2016-03-15",[30],[14082,14101,14102],"SOF","RBV",{"trials":14104,"activeCount":98},[],{"trials":14106,"activeCount":98},[],{"intervention":14101,"totalTrials":208,"cells":14108},{"EARLY_PHASE1":14109,"PHASE1":14111,"PHASE2":14113,"PHASE3":14115,"PHASE4":14121,"NA":14123},{"trials":14110,"activeCount":98},[],{"trials":14112,"activeCount":98},[],{"trials":14114,"activeCount":98},[],{"trials":14116,"activeCount":98},[14117],{"nctId":14093,"briefTitle":14094,"status":104,"phases":14118,"primaryCompletion":14096,"completion":14097,"start":14098,"enrollment":413,"conditions":14119,"interventions":14120},[89],[30],[14082,14101,14102],{"trials":14122,"activeCount":98},[],{"trials":14124,"activeCount":98},[],{"intervention":14102,"totalTrials":208,"cells":14126},{"EARLY_PHASE1":14127,"PHASE1":14129,"PHASE2":14131,"PHASE3":14133,"PHASE4":14139,"NA":14141},{"trials":14128,"activeCount":98},[],{"trials":14130,"activeCount":98},[],{"trials":14132,"activeCount":98},[],{"trials":14134,"activeCount":98},[14135],{"nctId":14093,"briefTitle":14094,"status":104,"phases":14136,"primaryCompletion":14096,"completion":14097,"start":14098,"enrollment":413,"conditions":14137,"interventions":14138},[89],[30],[14082,14101,14102],{"trials":14140,"activeCount":98},[],{"trials":14142,"activeCount":98},[],{"intervention":14144,"totalTrials":208,"cells":14145},"Cyclosporin A",{"EARLY_PHASE1":14146,"PHASE1":14148,"PHASE2":14150,"PHASE3":14152,"PHASE4":14163,"NA":14165},{"trials":14147,"activeCount":98},[],{"trials":14149,"activeCount":98},[],{"trials":14151,"activeCount":98},[],{"trials":14153,"activeCount":98},[14154],{"nctId":14155,"briefTitle":14156,"status":104,"phases":14157,"primaryCompletion":5873,"completion":11981,"start":7812,"enrollment":14158,"conditions":14159,"interventions":14160},"NCT00114777","Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant",[89],595,[7068],[14144,14161,14162],"Belatacept Less Intensive Regimen","Belatacept More Intensive Regimen",{"trials":14164,"activeCount":98},[],{"trials":14166,"activeCount":98},[],{"intervention":14161,"totalTrials":208,"cells":14168},{"EARLY_PHASE1":14169,"PHASE1":14171,"PHASE2":14173,"PHASE3":14175,"PHASE4":14181,"NA":14183},{"trials":14170,"activeCount":98},[],{"trials":14172,"activeCount":98},[],{"trials":14174,"activeCount":98},[],{"trials":14176,"activeCount":98},[14177],{"nctId":14155,"briefTitle":14156,"status":104,"phases":14178,"primaryCompletion":5873,"completion":11981,"start":7812,"enrollment":14158,"conditions":14179,"interventions":14180},[89],[7068],[14144,14161,14162],{"trials":14182,"activeCount":98},[],{"trials":14184,"activeCount":98},[],{"intervention":14162,"totalTrials":208,"cells":14186},{"EARLY_PHASE1":14187,"PHASE1":14189,"PHASE2":14191,"PHASE3":14193,"PHASE4":14199,"NA":14201},{"trials":14188,"activeCount":98},[],{"trials":14190,"activeCount":98},[],{"trials":14192,"activeCount":98},[],{"trials":14194,"activeCount":98},[14195],{"nctId":14155,"briefTitle":14156,"status":104,"phases":14196,"primaryCompletion":5873,"completion":11981,"start":7812,"enrollment":14158,"conditions":14197,"interventions":14198},[89],[7068],[14144,14161,14162],{"trials":14200,"activeCount":98},[],{"trials":14202,"activeCount":98},[],{"intervention":12473,"totalTrials":208,"cells":14204},{"EARLY_PHASE1":14205,"PHASE1":14207,"PHASE2":14209,"PHASE3":14211,"PHASE4":14217,"NA":14219},{"trials":14206,"activeCount":98},[],{"trials":14208,"activeCount":98},[],{"trials":14210,"activeCount":98},[],{"trials":14212,"activeCount":98},[14213],{"nctId":12465,"briefTitle":12466,"status":104,"phases":14214,"primaryCompletion":5098,"completion":5098,"start":12468,"enrollment":12469,"conditions":14215,"interventions":14216},[88,89],[12461,12462],[11001,12435,12472,12473,12474],{"trials":14218,"activeCount":98},[],{"trials":14220,"activeCount":98},[],{"intervention":12474,"totalTrials":208,"cells":14222},{"EARLY_PHASE1":14223,"PHASE1":14225,"PHASE2":14227,"PHASE3":14229,"PHASE4":14235,"NA":14237},{"trials":14224,"activeCount":98},[],{"trials":14226,"activeCount":98},[],{"trials":14228,"activeCount":98},[],{"trials":14230,"activeCount":98},[14231],{"nctId":12465,"briefTitle":12466,"status":104,"phases":14232,"primaryCompletion":5098,"completion":5098,"start":12468,"enrollment":12469,"conditions":14233,"interventions":14234},[88,89],[12461,12462],[11001,12435,12472,12473,12474],{"trials":14236,"activeCount":98},[],{"trials":14238,"activeCount":98},[],{"intervention":6922,"totalTrials":208,"cells":14240},{"EARLY_PHASE1":14241,"PHASE1":14243,"PHASE2":14245,"PHASE3":14247,"PHASE4":14253,"NA":14255},{"trials":14242,"activeCount":98},[],{"trials":14244,"activeCount":98},[],{"trials":14246,"activeCount":98},[],{"trials":14248,"activeCount":98},[14249],{"nctId":6913,"briefTitle":6914,"status":104,"phases":14250,"primaryCompletion":6916,"completion":6917,"start":6918,"enrollment":6919,"conditions":14251,"interventions":14252},[89],[15],[61,772,6922,6923],{"trials":14254,"activeCount":98},[],{"trials":14256,"activeCount":98},[],{"intervention":6923,"totalTrials":208,"cells":14258},{"EARLY_PHASE1":14259,"PHASE1":14261,"PHASE2":14263,"PHASE3":14265,"PHASE4":14271,"NA":14273},{"trials":14260,"activeCount":98},[],{"trials":14262,"activeCount":98},[],{"trials":14264,"activeCount":98},[],{"trials":14266,"activeCount":98},[14267],{"nctId":6913,"briefTitle":6914,"status":104,"phases":14268,"primaryCompletion":6916,"completion":6917,"start":6918,"enrollment":6919,"conditions":14269,"interventions":14270},[89],[15],[61,772,6922,6923],{"trials":14272,"activeCount":98},[],{"trials":14274,"activeCount":98},[],{"intervention":7118,"totalTrials":208,"cells":14276},{"EARLY_PHASE1":14277,"PHASE1":14279,"PHASE2":14281,"PHASE3":14283,"PHASE4":14289,"NA":14291},{"trials":14278,"activeCount":98},[],{"trials":14280,"activeCount":98},[],{"trials":14282,"activeCount":98},[],{"trials":14284,"activeCount":98},[14285],{"nctId":7110,"briefTitle":7111,"status":963,"phases":14286,"primaryCompletion":7113,"completion":802,"start":7114,"enrollment":7115,"conditions":14287,"interventions":14288},[89],[969],[7118,7070,1507],{"trials":14290,"activeCount":98},[],{"trials":14292,"activeCount":98},[],{"intervention":10457,"totalTrials":208,"cells":14294},{"EARLY_PHASE1":14295,"PHASE1":14297,"PHASE2":14299,"PHASE3":14301,"PHASE4":14307,"NA":14309},{"trials":14296,"activeCount":98},[],{"trials":14298,"activeCount":98},[],{"trials":14300,"activeCount":98},[],{"trials":14302,"activeCount":98},[14303],{"nctId":10449,"briefTitle":10450,"status":104,"phases":14304,"primaryCompletion":10452,"completion":10453,"start":10454,"enrollment":1232,"conditions":14305,"interventions":14306},[89],[24],[10457,10458,8547,902],{"trials":14308,"activeCount":98},[],{"trials":14310,"activeCount":98},[],{"intervention":10458,"totalTrials":208,"cells":14312},{"EARLY_PHASE1":14313,"PHASE1":14315,"PHASE2":14317,"PHASE3":14319,"PHASE4":14325,"NA":14327},{"trials":14314,"activeCount":98},[],{"trials":14316,"activeCount":98},[],{"trials":14318,"activeCount":98},[],{"trials":14320,"activeCount":98},[14321],{"nctId":10449,"briefTitle":10450,"status":104,"phases":14322,"primaryCompletion":10452,"completion":10453,"start":10454,"enrollment":1232,"conditions":14323,"interventions":14324},[89],[24],[10457,10458,8547,902],{"trials":14326,"activeCount":98},[],{"trials":14328,"activeCount":98},[],{"intervention":14330,"totalTrials":208,"cells":14331},"Nivolumab 3 mg\u002Fkg IV",{"EARLY_PHASE1":14332,"PHASE1":14334,"PHASE2":14336,"PHASE3":14338,"PHASE4":14354,"NA":14356},{"trials":14333,"activeCount":98},[],{"trials":14335,"activeCount":98},[],{"trials":14337,"activeCount":98},[],{"trials":14339,"activeCount":98},[14340],{"nctId":14341,"briefTitle":14342,"status":104,"phases":14343,"primaryCompletion":14344,"completion":14345,"start":14346,"enrollment":14347,"conditions":14348,"interventions":14349},"NCT02714218","A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma",[89],"2017-04-20","2021-05-28","2016-04-04",387,[21],[14330,14350,14351,14352,14353],"Ipilimumab 1 mg\u002Fkg IV","Nivolumab 1 mg\u002Fkg IV","Ipilimumab 3 mg\u002Fkg IV","Nivolumab 6 mg\u002Fkg IV",{"trials":14355,"activeCount":98},[],{"trials":14357,"activeCount":98},[],{"intervention":14350,"totalTrials":208,"cells":14359},{"EARLY_PHASE1":14360,"PHASE1":14362,"PHASE2":14364,"PHASE3":14366,"PHASE4":14372,"NA":14374},{"trials":14361,"activeCount":98},[],{"trials":14363,"activeCount":98},[],{"trials":14365,"activeCount":98},[],{"trials":14367,"activeCount":98},[14368],{"nctId":14341,"briefTitle":14342,"status":104,"phases":14369,"primaryCompletion":14344,"completion":14345,"start":14346,"enrollment":14347,"conditions":14370,"interventions":14371},[89],[21],[14330,14350,14351,14352,14353],{"trials":14373,"activeCount":98},[],{"trials":14375,"activeCount":98},[],{"intervention":14351,"totalTrials":208,"cells":14377},{"EARLY_PHASE1":14378,"PHASE1":14380,"PHASE2":14382,"PHASE3":14384,"PHASE4":14390,"NA":14392},{"trials":14379,"activeCount":98},[],{"trials":14381,"activeCount":98},[],{"trials":14383,"activeCount":98},[],{"trials":14385,"activeCount":98},[14386],{"nctId":14341,"briefTitle":14342,"status":104,"phases":14387,"primaryCompletion":14344,"completion":14345,"start":14346,"enrollment":14347,"conditions":14388,"interventions":14389},[89],[21],[14330,14350,14351,14352,14353],{"trials":14391,"activeCount":98},[],{"trials":14393,"activeCount":98},[],{"intervention":14352,"totalTrials":208,"cells":14395},{"EARLY_PHASE1":14396,"PHASE1":14398,"PHASE2":14400,"PHASE3":14402,"PHASE4":14408,"NA":14410},{"trials":14397,"activeCount":98},[],{"trials":14399,"activeCount":98},[],{"trials":14401,"activeCount":98},[],{"trials":14403,"activeCount":98},[14404],{"nctId":14341,"briefTitle":14342,"status":104,"phases":14405,"primaryCompletion":14344,"completion":14345,"start":14346,"enrollment":14347,"conditions":14406,"interventions":14407},[89],[21],[14330,14350,14351,14352,14353],{"trials":14409,"activeCount":98},[],{"trials":14411,"activeCount":98},[],{"intervention":14353,"totalTrials":208,"cells":14413},{"EARLY_PHASE1":14414,"PHASE1":14416,"PHASE2":14418,"PHASE3":14420,"PHASE4":14426,"NA":14428},{"trials":14415,"activeCount":98},[],{"trials":14417,"activeCount":98},[],{"trials":14419,"activeCount":98},[],{"trials":14421,"activeCount":98},[14422],{"nctId":14341,"briefTitle":14342,"status":104,"phases":14423,"primaryCompletion":14344,"completion":14345,"start":14346,"enrollment":14347,"conditions":14424,"interventions":14425},[89],[21],[14330,14350,14351,14352,14353],{"trials":14427,"activeCount":98},[],{"trials":14429,"activeCount":98},[],{"intervention":14431,"totalTrials":208,"cells":14432},"Peginterferon alfa 2a",{"EARLY_PHASE1":14433,"PHASE1":14435,"PHASE2":14437,"PHASE3":14439,"PHASE4":14447,"NA":14449},{"trials":14434,"activeCount":98},[],{"trials":14436,"activeCount":98},[],{"trials":14438,"activeCount":98},[],{"trials":14440,"activeCount":98},[14441],{"nctId":14442,"briefTitle":14443,"status":467,"phases":14444,"primaryCompletion":846,"completion":846,"start":3017,"enrollment":98,"conditions":14445,"interventions":14446},"NCT01797848","Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients",[89],[30],[14431,11917,10402],{"trials":14448,"activeCount":98},[],{"trials":14450,"activeCount":98},[],{"intervention":14452,"totalTrials":208,"cells":14453},"Pegylated-Interferon-lambda",{"EARLY_PHASE1":14454,"PHASE1":14456,"PHASE2":14458,"PHASE3":14460,"PHASE4":14471,"NA":14473},{"trials":14455,"activeCount":98},[],{"trials":14457,"activeCount":98},[],{"trials":14459,"activeCount":98},[],{"trials":14461,"activeCount":98},[14462],{"nctId":14463,"briefTitle":14464,"status":104,"phases":14465,"primaryCompletion":14466,"completion":14466,"start":14467,"enrollment":14468,"conditions":14469,"interventions":14470},"NCT01741545","Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia",[89],"2015-01-31","2013-03-31",71,[11842],[14452,11917,10402],{"trials":14472,"activeCount":98},[],{"trials":14474,"activeCount":98},[],{"intervention":12826,"totalTrials":208,"cells":14476},{"EARLY_PHASE1":14477,"PHASE1":14479,"PHASE2":14481,"PHASE3":14483,"PHASE4":14489,"NA":14491},{"trials":14478,"activeCount":98},[],{"trials":14480,"activeCount":98},[],{"trials":14482,"activeCount":98},[],{"trials":14484,"activeCount":98},[14485],{"nctId":12820,"briefTitle":12821,"status":104,"phases":14486,"primaryCompletion":3959,"completion":1342,"start":3893,"enrollment":12823,"conditions":14487,"interventions":14488},[89],[11896],[10402,11943,11917,12826,12314],{"trials":14490,"activeCount":98},[],{"trials":14492,"activeCount":98},[],{"intervention":14494,"totalTrials":208,"cells":14495},"Abatacept subcutaneous",{"EARLY_PHASE1":14496,"PHASE1":14498,"PHASE2":14500,"PHASE3":14502,"PHASE4":14517,"NA":14519},{"trials":14497,"activeCount":98},[],{"trials":14499,"activeCount":98},[],{"trials":14501,"activeCount":98},[],{"trials":14503,"activeCount":98},[14504],{"nctId":14505,"briefTitle":14506,"status":104,"phases":14507,"primaryCompletion":14508,"completion":2137,"start":2222,"enrollment":14509,"conditions":14510,"interventions":14516},"NCT02971683","Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy",[89],"2020-07-27",149,[14511,14512,14513,14514,14515],"Polymyositis","Dermatomyositis","Autoimmune Necrotizing Myopathy","Overlap Myositis","Juvenile Myositis Above the Age of 18",[14494],{"trials":14518,"activeCount":98},[],{"trials":14520,"activeCount":98},[],{"intervention":12241,"totalTrials":208,"cells":14522},{"EARLY_PHASE1":14523,"PHASE1":14525,"PHASE2":14527,"PHASE3":14529,"PHASE4":14535,"NA":14537},{"trials":14524,"activeCount":98},[],{"trials":14526,"activeCount":98},[],{"trials":14528,"activeCount":98},[],{"trials":14530,"activeCount":98},[14531],{"nctId":12234,"briefTitle":12235,"status":104,"phases":14532,"primaryCompletion":4379,"completion":4379,"start":12237,"enrollment":12238,"conditions":14533,"interventions":14534},[89],[11098],[12187,12241],{"trials":14536,"activeCount":98},[],{"trials":14538,"activeCount":98},[],{"intervention":14540,"totalTrials":208,"cells":14541},"Atazanvir\u002Fritonavir + efavirenz",{"EARLY_PHASE1":14542,"PHASE1":14544,"PHASE2":14546,"PHASE3":14548,"PHASE4":14556,"NA":14558},{"trials":14543,"activeCount":98},[],{"trials":14545,"activeCount":98},[],{"trials":14547,"activeCount":98},[],{"trials":14549,"activeCount":98},[14550],{"nctId":14551,"briefTitle":14552,"status":104,"phases":14553,"primaryCompletion":5043,"completion":5043,"start":12261,"enrollment":582,"conditions":14554,"interventions":14555},"NCT00135343","A Pilot Study of Atazanavir\u002FRitonavir\u002FEfavirenz as a Nucleoside Sparing Regimen",[89],[24],[14540,14540],{"trials":14557,"activeCount":98},[],{"trials":14559,"activeCount":98},[],{"intervention":13185,"totalTrials":208,"cells":14561},{"EARLY_PHASE1":14562,"PHASE1":14564,"PHASE2":14566,"PHASE3":14568,"PHASE4":14574,"NA":14576},{"trials":14563,"activeCount":98},[],{"trials":14565,"activeCount":98},[],{"trials":14567,"activeCount":98},[],{"trials":14569,"activeCount":98},[14570],{"nctId":13177,"briefTitle":13178,"status":963,"phases":14571,"primaryCompletion":3467,"completion":3467,"start":13180,"enrollment":13181,"conditions":14572,"interventions":14573},[89],[13183],[13185,1949,13186],{"trials":14575,"activeCount":98},[],{"trials":14577,"activeCount":98},[],{"intervention":13186,"totalTrials":208,"cells":14579},{"EARLY_PHASE1":14580,"PHASE1":14582,"PHASE2":14584,"PHASE3":14586,"PHASE4":14592,"NA":14594},{"trials":14581,"activeCount":98},[],{"trials":14583,"activeCount":98},[],{"trials":14585,"activeCount":98},[],{"trials":14587,"activeCount":98},[14588],{"nctId":13177,"briefTitle":13178,"status":963,"phases":14589,"primaryCompletion":3467,"completion":3467,"start":13180,"enrollment":13181,"conditions":14590,"interventions":14591},[89],[13183],[13185,1949,13186],{"trials":14593,"activeCount":98},[],{"trials":14595,"activeCount":98},[],{"intervention":7865,"totalTrials":208,"cells":14597},{"EARLY_PHASE1":14598,"PHASE1":14600,"PHASE2":14602,"PHASE3":14604,"PHASE4":14610,"NA":14612},{"trials":14599,"activeCount":98},[],{"trials":14601,"activeCount":98},[],{"trials":14603,"activeCount":98},[],{"trials":14605,"activeCount":98},[14606],{"nctId":7859,"briefTitle":7860,"status":104,"phases":14607,"primaryCompletion":3873,"completion":3873,"start":7674,"enrollment":7862,"conditions":14608,"interventions":14609},[89],[15],[61,7865,7866],{"trials":14611,"activeCount":98},[],{"trials":14613,"activeCount":98},[],{"intervention":7866,"totalTrials":208,"cells":14615},{"EARLY_PHASE1":14616,"PHASE1":14618,"PHASE2":14620,"PHASE3":14622,"PHASE4":14628,"NA":14630},{"trials":14617,"activeCount":98},[],{"trials":14619,"activeCount":98},[],{"trials":14621,"activeCount":98},[],{"trials":14623,"activeCount":98},[14624],{"nctId":7859,"briefTitle":7860,"status":104,"phases":14625,"primaryCompletion":3873,"completion":3873,"start":7674,"enrollment":7862,"conditions":14626,"interventions":14627},[89],[15],[61,7865,7866],{"trials":14629,"activeCount":98},[],{"trials":14631,"activeCount":98},[],{"intervention":14633,"totalTrials":208,"cells":14634},"ATV",{"EARLY_PHASE1":14635,"PHASE1":14637,"PHASE2":14639,"PHASE3":14641,"PHASE4":14652,"NA":14654},{"trials":14636,"activeCount":98},[],{"trials":14638,"activeCount":98},[],{"trials":14640,"activeCount":98},[],{"trials":14642,"activeCount":98},[14643],{"nctId":14644,"briefTitle":14645,"status":104,"phases":14646,"primaryCompletion":4664,"completion":6480,"start":3657,"enrollment":5715,"conditions":14647,"interventions":14648},"NCT00272779","BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada",[89],[24],[14633,14649,14650,14651],"RTV","Tenofovi-Emtricitabine (TDF\u002FFTC)","LPV",{"trials":14653,"activeCount":98},[],{"trials":14655,"activeCount":98},[],{"intervention":14649,"totalTrials":208,"cells":14657},{"EARLY_PHASE1":14658,"PHASE1":14660,"PHASE2":14662,"PHASE3":14664,"PHASE4":14670,"NA":14672},{"trials":14659,"activeCount":98},[],{"trials":14661,"activeCount":98},[],{"trials":14663,"activeCount":98},[],{"trials":14665,"activeCount":98},[14666],{"nctId":14644,"briefTitle":14645,"status":104,"phases":14667,"primaryCompletion":4664,"completion":6480,"start":3657,"enrollment":5715,"conditions":14668,"interventions":14669},[89],[24],[14633,14649,14650,14651],{"trials":14671,"activeCount":98},[],{"trials":14673,"activeCount":98},[],{"intervention":14650,"totalTrials":208,"cells":14675},{"EARLY_PHASE1":14676,"PHASE1":14678,"PHASE2":14680,"PHASE3":14682,"PHASE4":14688,"NA":14690},{"trials":14677,"activeCount":98},[],{"trials":14679,"activeCount":98},[],{"trials":14681,"activeCount":98},[],{"trials":14683,"activeCount":98},[14684],{"nctId":14644,"briefTitle":14645,"status":104,"phases":14685,"primaryCompletion":4664,"completion":6480,"start":3657,"enrollment":5715,"conditions":14686,"interventions":14687},[89],[24],[14633,14649,14650,14651],{"trials":14689,"activeCount":98},[],{"trials":14691,"activeCount":98},[],{"intervention":14651,"totalTrials":208,"cells":14693},{"EARLY_PHASE1":14694,"PHASE1":14696,"PHASE2":14698,"PHASE3":14700,"PHASE4":14706,"NA":14708},{"trials":14695,"activeCount":98},[],{"trials":14697,"activeCount":98},[],{"trials":14699,"activeCount":98},[],{"trials":14701,"activeCount":98},[14702],{"nctId":14644,"briefTitle":14645,"status":104,"phases":14703,"primaryCompletion":4664,"completion":6480,"start":3657,"enrollment":5715,"conditions":14704,"interventions":14705},[89],[24],[14633,14649,14650,14651],{"trials":14707,"activeCount":98},[],{"trials":14709,"activeCount":98},[],{"intervention":14711,"totalTrials":208,"cells":14712},"PEG-Interferon alfa 2a",{"EARLY_PHASE1":14713,"PHASE1":14715,"PHASE2":14717,"PHASE3":14719,"PHASE4":14729,"NA":14731},{"trials":14714,"activeCount":98},[],{"trials":14716,"activeCount":98},[],{"trials":14718,"activeCount":98},[],{"trials":14720,"activeCount":98},[14721],{"nctId":14722,"briefTitle":14723,"status":104,"phases":14724,"primaryCompletion":3017,"completion":11981,"start":3679,"enrollment":14725,"conditions":14726,"interventions":14728},"NCT01471574","Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus",[89],549,[14727],"Hepatitis C, Genotype 1",[10402,11917,14711],{"trials":14730,"activeCount":98},[],{"trials":14732,"activeCount":98},[],{"intervention":14734,"totalTrials":208,"cells":14735},"Enoxaparin + Placebo",{"EARLY_PHASE1":14736,"PHASE1":14738,"PHASE2":14740,"PHASE3":14742,"PHASE4":14752,"NA":14754},{"trials":14737,"activeCount":98},[],{"trials":14739,"activeCount":98},[],{"trials":14741,"activeCount":98},[],{"trials":14743,"activeCount":98},[14744],{"nctId":14745,"briefTitle":14746,"status":104,"phases":14747,"primaryCompletion":5873,"completion":5873,"start":13061,"enrollment":14748,"conditions":14749,"interventions":14750},"NCT00371683","Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery",[89],3608,[12481,12462],[14734,14751],"Apixaban + Placebo",{"trials":14753,"activeCount":98},[],{"trials":14755,"activeCount":98},[],{"intervention":14751,"totalTrials":208,"cells":14757},{"EARLY_PHASE1":14758,"PHASE1":14760,"PHASE2":14762,"PHASE3":14764,"PHASE4":14770,"NA":14772},{"trials":14759,"activeCount":98},[],{"trials":14761,"activeCount":98},[],{"trials":14763,"activeCount":98},[],{"trials":14765,"activeCount":98},[14766],{"nctId":14745,"briefTitle":14746,"status":104,"phases":14767,"primaryCompletion":5873,"completion":5873,"start":13061,"enrollment":14748,"conditions":14768,"interventions":14769},[89],[12481,12462],[14734,14751],{"trials":14771,"activeCount":98},[],{"trials":14773,"activeCount":98},[],{"intervention":14775,"totalTrials":208,"cells":14776},"stavudine, efavirenz, lamivudine",{"EARLY_PHASE1":14777,"PHASE1":14779,"PHASE2":14781,"PHASE3":14783,"PHASE4":14791,"NA":14793},{"trials":14778,"activeCount":98},[],{"trials":14780,"activeCount":98},[],{"trials":14782,"activeCount":98},[],{"trials":14784,"activeCount":98},[14785],{"nctId":14786,"briefTitle":14787,"status":104,"phases":14788,"primaryCompletion":12930,"completion":12930,"start":13336,"enrollment":3406,"conditions":14789,"interventions":14790},"NCT00116298","Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)",[89],[24,11253],[14775],{"trials":14792,"activeCount":98},[],{"trials":14794,"activeCount":98},[],{"intervention":14796,"totalTrials":208,"cells":14797},"Videx EC",{"EARLY_PHASE1":14798,"PHASE1":14800,"PHASE2":14802,"PHASE3":14804,"PHASE4":14814,"NA":14816},{"trials":14799,"activeCount":98},[],{"trials":14801,"activeCount":98},[],{"trials":14803,"activeCount":98},[],{"trials":14805,"activeCount":98},[14806],{"nctId":14807,"briefTitle":14808,"status":104,"phases":14809,"primaryCompletion":5043,"completion":5043,"start":10864,"enrollment":4086,"conditions":14810,"interventions":14811},"NCT00135382","Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen",[89],[24],[14796,14812,14813],"Epivir","Sustiva",{"trials":14815,"activeCount":98},[],{"trials":14817,"activeCount":98},[],{"intervention":14812,"totalTrials":208,"cells":14819},{"EARLY_PHASE1":14820,"PHASE1":14822,"PHASE2":14824,"PHASE3":14826,"PHASE4":14832,"NA":14834},{"trials":14821,"activeCount":98},[],{"trials":14823,"activeCount":98},[],{"trials":14825,"activeCount":98},[],{"trials":14827,"activeCount":98},[14828],{"nctId":14807,"briefTitle":14808,"status":104,"phases":14829,"primaryCompletion":5043,"completion":5043,"start":10864,"enrollment":4086,"conditions":14830,"interventions":14831},[89],[24],[14796,14812,14813],{"trials":14833,"activeCount":98},[],{"trials":14835,"activeCount":98},[],{"intervention":14813,"totalTrials":208,"cells":14837},{"EARLY_PHASE1":14838,"PHASE1":14840,"PHASE2":14842,"PHASE3":14844,"PHASE4":14850,"NA":14852},{"trials":14839,"activeCount":98},[],{"trials":14841,"activeCount":98},[],{"trials":14843,"activeCount":98},[],{"trials":14845,"activeCount":98},[14846],{"nctId":14807,"briefTitle":14808,"status":104,"phases":14847,"primaryCompletion":5043,"completion":5043,"start":10864,"enrollment":4086,"conditions":14848,"interventions":14849},[89],[24],[14796,14812,14813],{"trials":14851,"activeCount":98},[],{"trials":14853,"activeCount":98},[],{"intervention":10965,"totalTrials":208,"cells":14855},{"EARLY_PHASE1":14856,"PHASE1":14858,"PHASE2":14860,"PHASE3":14862,"PHASE4":14868,"NA":14870},{"trials":14857,"activeCount":98},[],{"trials":14859,"activeCount":98},[],{"trials":14861,"activeCount":98},[],{"trials":14863,"activeCount":98},[14864],{"nctId":10958,"briefTitle":10959,"status":104,"phases":14865,"primaryCompletion":7675,"completion":7675,"start":10961,"conditions":14866,"interventions":14867},[89],[10963],[10947,10965,10966],{"trials":14869,"activeCount":98},[],{"trials":14871,"activeCount":98},[],{"intervention":10966,"totalTrials":208,"cells":14873},{"EARLY_PHASE1":14874,"PHASE1":14876,"PHASE2":14878,"PHASE3":14880,"PHASE4":14886,"NA":14888},{"trials":14875,"activeCount":98},[],{"trials":14877,"activeCount":98},[],{"trials":14879,"activeCount":98},[],{"trials":14881,"activeCount":98},[14882],{"nctId":10958,"briefTitle":10959,"status":104,"phases":14883,"primaryCompletion":7675,"completion":7675,"start":10961,"conditions":14884,"interventions":14885},[89],[10963],[10947,10965,10966],{"trials":14887,"activeCount":98},[],{"trials":14889,"activeCount":98},[],{"intervention":2681,"totalTrials":208,"cells":14891},{"EARLY_PHASE1":14892,"PHASE1":14894,"PHASE2":14896,"PHASE3":14898,"PHASE4":14904,"NA":14906},{"trials":14893,"activeCount":98},[],{"trials":14895,"activeCount":98},[],{"trials":14897,"activeCount":98},[],{"trials":14899,"activeCount":98},[14900],{"nctId":2671,"briefTitle":2672,"status":104,"phases":14901,"primaryCompletion":2674,"completion":2675,"start":2676,"enrollment":2677,"conditions":14902,"interventions":14903},[89],[2679],[1123,1122,2681,2682],{"trials":14905,"activeCount":98},[],{"trials":14907,"activeCount":98},[],{"intervention":2682,"totalTrials":208,"cells":14909},{"EARLY_PHASE1":14910,"PHASE1":14912,"PHASE2":14914,"PHASE3":14916,"PHASE4":14922,"NA":14924},{"trials":14911,"activeCount":98},[],{"trials":14913,"activeCount":98},[],{"trials":14915,"activeCount":98},[],{"trials":14917,"activeCount":98},[14918],{"nctId":2671,"briefTitle":2672,"status":104,"phases":14919,"primaryCompletion":2674,"completion":2675,"start":2676,"enrollment":2677,"conditions":14920,"interventions":14921},[89],[2679],[1123,1122,2681,2682],{"trials":14923,"activeCount":98},[],{"trials":14925,"activeCount":98},[],{"intervention":2715,"totalTrials":208,"cells":14927},{"EARLY_PHASE1":14928,"PHASE1":14930,"PHASE2":14932,"PHASE3":14934,"PHASE4":14940,"NA":14942},{"trials":14929,"activeCount":98},[],{"trials":14931,"activeCount":98},[],{"trials":14933,"activeCount":98},[],{"trials":14935,"activeCount":98},[14936],{"nctId":2708,"briefTitle":2709,"status":963,"phases":14937,"primaryCompletion":2711,"completion":2711,"start":2712,"enrollment":137,"conditions":14938,"interventions":14939},[89],[1547],[1123,2715],{"trials":14941,"activeCount":98},[],{"trials":14943,"activeCount":98},[],{"intervention":14945,"totalTrials":208,"cells":14946},"DCV 3DAA",{"EARLY_PHASE1":14947,"PHASE1":14949,"PHASE2":14951,"PHASE3":14953,"PHASE4":14962,"NA":14964},{"trials":14948,"activeCount":98},[],{"trials":14950,"activeCount":98},[],{"trials":14952,"activeCount":98},[],{"trials":14954,"activeCount":98},[14955],{"nctId":14956,"briefTitle":14957,"status":104,"phases":14958,"primaryCompletion":14959,"completion":4458,"start":4289,"enrollment":10751,"conditions":14960,"interventions":14961},"NCT02123654","UNITY 3: A Japanese Phase 3 Study of a Daclatasvir\u002FAsunaprevir\u002FBMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C",[89],"2015-01",[11896],[10402,11943,14945],{"trials":14963,"activeCount":98},[],{"trials":14965,"activeCount":98},[],{"intervention":14967,"totalTrials":208,"cells":14968},"Double-blind Abatacept",{"EARLY_PHASE1":14969,"PHASE1":14971,"PHASE2":14973,"PHASE3":14975,"PHASE4":14986,"NA":14988},{"trials":14970,"activeCount":98},[],{"trials":14972,"activeCount":98},[],{"trials":14974,"activeCount":98},[],{"trials":14976,"activeCount":98},[14977],{"nctId":14978,"briefTitle":14979,"status":104,"phases":14980,"primaryCompletion":3678,"completion":3678,"start":5051,"enrollment":14981,"conditions":14982,"interventions":14983},"NCT00048932","A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis",[89],1795,[15],[14967,14984,14985],"Double-blind Placebo","Open-label Abatacept",{"trials":14987,"activeCount":98},[],{"trials":14989,"activeCount":98},[],{"intervention":14984,"totalTrials":208,"cells":14991},{"EARLY_PHASE1":14992,"PHASE1":14994,"PHASE2":14996,"PHASE3":14998,"PHASE4":15004,"NA":15006},{"trials":14993,"activeCount":98},[],{"trials":14995,"activeCount":98},[],{"trials":14997,"activeCount":98},[],{"trials":14999,"activeCount":98},[15000],{"nctId":14978,"briefTitle":14979,"status":104,"phases":15001,"primaryCompletion":3678,"completion":3678,"start":5051,"enrollment":14981,"conditions":15002,"interventions":15003},[89],[15],[14967,14984,14985],{"trials":15005,"activeCount":98},[],{"trials":15007,"activeCount":98},[],{"intervention":14985,"totalTrials":208,"cells":15009},{"EARLY_PHASE1":15010,"PHASE1":15012,"PHASE2":15014,"PHASE3":15016,"PHASE4":15022,"NA":15024},{"trials":15011,"activeCount":98},[],{"trials":15013,"activeCount":98},[],{"trials":15015,"activeCount":98},[],{"trials":15017,"activeCount":98},[15018],{"nctId":14978,"briefTitle":14979,"status":104,"phases":15019,"primaryCompletion":3678,"completion":3678,"start":5051,"enrollment":14981,"conditions":15020,"interventions":15021},[89],[15],[14967,14984,14985],{"trials":15023,"activeCount":98},[],{"trials":15025,"activeCount":98},[],{"intervention":15027,"totalTrials":208,"cells":15028},"Paclitaxel and carboplatin",{"EARLY_PHASE1":15029,"PHASE1":15031,"PHASE2":15033,"PHASE3":15035,"PHASE4":15044,"NA":15046},{"trials":15030,"activeCount":98},[],{"trials":15032,"activeCount":98},[],{"trials":15034,"activeCount":98},[],{"trials":15036,"activeCount":98},[15037],{"nctId":15038,"briefTitle":15039,"status":104,"phases":15040,"completion":10693,"start":15041,"enrollment":12332,"conditions":15042,"interventions":15043},"NCT00035152","Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer",[89],"2000-06",[2781],[15027],{"trials":15045,"activeCount":98},[],{"trials":15047,"activeCount":98},[],{"intervention":13499,"totalTrials":208,"cells":15049},{"EARLY_PHASE1":15050,"PHASE1":15052,"PHASE2":15054,"PHASE3":15056,"PHASE4":15062,"NA":15064},{"trials":15051,"activeCount":98},[],{"trials":15053,"activeCount":98},[],{"trials":15055,"activeCount":98},[],{"trials":15057,"activeCount":98},[15058],{"nctId":13493,"briefTitle":13494,"status":104,"phases":15059,"primaryCompletion":11251,"completion":11251,"start":12468,"enrollment":13496,"conditions":15060,"interventions":15061},[89],[10877],[13474,13491,13499],{"trials":15063,"activeCount":98},[],{"trials":15065,"activeCount":98},[],{"intervention":2914,"totalTrials":208,"cells":15067},{"EARLY_PHASE1":15068,"PHASE1":15070,"PHASE2":15072,"PHASE3":15074,"PHASE4":15080,"NA":15082},{"trials":15069,"activeCount":98},[],{"trials":15071,"activeCount":98},[],{"trials":15073,"activeCount":98},[],{"trials":15075,"activeCount":98},[15076],{"nctId":2904,"briefTitle":2905,"status":104,"phases":15077,"primaryCompletion":2907,"completion":2908,"start":2909,"enrollment":2910,"conditions":15078,"interventions":15079},[89],[1717],[43,2913,2914],{"trials":15081,"activeCount":98},[],{"trials":15083,"activeCount":98},[],{"intervention":15085,"totalTrials":208,"cells":15086},"atazanavir\u002Fritonavir +2 NRTIs",{"EARLY_PHASE1":15087,"PHASE1":15089,"PHASE2":15091,"PHASE3":15093,"PHASE4":15102,"NA":15104},{"trials":15088,"activeCount":98},[],{"trials":15090,"activeCount":98},[],{"trials":15092,"activeCount":98},[],{"trials":15094,"activeCount":98},[15095],{"nctId":15096,"briefTitle":15097,"status":104,"phases":15098,"primaryCompletion":4023,"completion":4023,"start":3658,"enrollment":11061,"conditions":15099,"interventions":15100},"NCT00120393","Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir\u002FRitonavir",[89],[24],[15085,15101],"LPV\u002Fr +2 NRTIs",{"trials":15103,"activeCount":98},[],{"trials":15105,"activeCount":98},[],{"intervention":15101,"totalTrials":208,"cells":15107},{"EARLY_PHASE1":15108,"PHASE1":15110,"PHASE2":15112,"PHASE3":15114,"PHASE4":15120,"NA":15122},{"trials":15109,"activeCount":98},[],{"trials":15111,"activeCount":98},[],{"trials":15113,"activeCount":98},[],{"trials":15115,"activeCount":98},[15116],{"nctId":15096,"briefTitle":15097,"status":104,"phases":15117,"primaryCompletion":4023,"completion":4023,"start":3658,"enrollment":11061,"conditions":15118,"interventions":15119},[89],[24],[15085,15101],{"trials":15121,"activeCount":98},[],{"trials":15123,"activeCount":98},[],{"intervention":7982,"totalTrials":208,"cells":15125},{"EARLY_PHASE1":15126,"PHASE1":15128,"PHASE2":15130,"PHASE3":15132,"PHASE4":15138,"NA":15140},{"trials":15127,"activeCount":98},[],{"trials":15129,"activeCount":98},[],{"trials":15131,"activeCount":98},[],{"trials":15133,"activeCount":98},[15134],{"nctId":7974,"briefTitle":7975,"status":467,"phases":15135,"primaryCompletion":7977,"completion":2279,"start":7978,"enrollment":98,"conditions":15136,"interventions":15137},[89],[7980],[61,7982],{"trials":15139,"activeCount":98},[],{"trials":15141,"activeCount":98},[],{"intervention":2948,"totalTrials":208,"cells":15143},{"EARLY_PHASE1":15144,"PHASE1":15146,"PHASE2":15148,"PHASE3":15150,"PHASE4":15156,"NA":15158},{"trials":15145,"activeCount":98},[],{"trials":15147,"activeCount":98},[],{"trials":15149,"activeCount":98},[],{"trials":15151,"activeCount":98},[15152],{"nctId":2938,"briefTitle":2939,"status":104,"phases":15153,"primaryCompletion":2941,"completion":2942,"start":2943,"enrollment":2944,"conditions":15154,"interventions":15155},[89],[1223],[1123,2947,2948,2949,2950],{"trials":15157,"activeCount":98},[],{"trials":15159,"activeCount":98},[],{"intervention":2950,"totalTrials":208,"cells":15161},{"EARLY_PHASE1":15162,"PHASE1":15164,"PHASE2":15166,"PHASE3":15168,"PHASE4":15174,"NA":15176},{"trials":15163,"activeCount":98},[],{"trials":15165,"activeCount":98},[],{"trials":15167,"activeCount":98},[],{"trials":15169,"activeCount":98},[15170],{"nctId":2938,"briefTitle":2939,"status":104,"phases":15171,"primaryCompletion":2941,"completion":2942,"start":2943,"enrollment":2944,"conditions":15172,"interventions":15173},[89],[1223],[1123,2947,2948,2949,2950],{"trials":15175,"activeCount":98},[],{"trials":15177,"activeCount":98},[],{"intervention":12452,"totalTrials":137,"cells":15179},{"EARLY_PHASE1":15180,"PHASE1":15182,"PHASE2":15268,"PHASE3":15284,"PHASE4":15286,"NA":15288},{"trials":15181,"activeCount":98},[],{"trials":15183,"activeCount":98},[15184,15192,15200,15207,15216,15222,15231,15238,15246,15254,15262],{"nctId":15185,"briefTitle":15186,"status":104,"phases":15187,"primaryCompletion":8699,"completion":8699,"start":15188,"enrollment":11958,"conditions":15189,"interventions":15190},"NCT02807909","A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy Subjects",[87],"2016-07",[11063],[12452,5584,15191],"Diltiazem ER",{"nctId":15193,"briefTitle":15194,"status":104,"phases":15195,"primaryCompletion":945,"completion":945,"start":15196,"enrollment":319,"conditions":15197,"interventions":15198},"NCT03341390","An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants",[87],"2017-10-18",[27],[15199,12452],"Aspirin",{"nctId":15201,"briefTitle":15202,"status":104,"phases":15203,"primaryCompletion":15204,"completion":15204,"start":908,"enrollment":1221,"conditions":15205,"interventions":15206},"NCT03362437","Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants",[87],"2017-12-28",[11063],[12452,12452],{"nctId":15208,"briefTitle":15209,"status":104,"phases":15210,"primaryCompletion":15211,"completion":15211,"start":15212,"enrollment":6961,"conditions":15213,"interventions":15214},"NCT03698513","A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects",[87],"2019-02-19","2018-10-04",[27],[12452,15215,15199],"Clopidogrel",{"nctId":15217,"briefTitle":15218,"status":104,"phases":15219,"primaryCompletion":2543,"completion":2543,"start":7052,"enrollment":515,"conditions":15220,"interventions":15221},"NCT02608970","Safety and Tolerability Study of BMS-986177 in Healthy Subjects",[87],[11063],[12452],{"nctId":15223,"briefTitle":15224,"status":104,"phases":15225,"primaryCompletion":15226,"completion":15226,"start":846,"enrollment":830,"conditions":15227,"interventions":15230},"NCT02902679","A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment",[87],"2017-06",[11063,15228,927,15229],"Factor XI","ESRD (End-Stage Renal Disease)",[12452],{"nctId":15232,"briefTitle":15233,"status":104,"phases":15234,"primaryCompletion":15235,"completion":15235,"start":7051,"enrollment":747,"conditions":15236,"interventions":15237},"NCT03939702","Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants",[87],"2019-07-11",[11063],[12452],{"nctId":15239,"briefTitle":15240,"status":104,"phases":15241,"primaryCompletion":15242,"completion":15242,"start":15243,"enrollment":736,"conditions":15244,"interventions":15245},"NCT03224260","To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants",[87],"2017-11-07","2017-06-28",[11063],[12452],{"nctId":15247,"briefTitle":15248,"status":104,"phases":15249,"primaryCompletion":15250,"completion":15250,"start":15251,"enrollment":1203,"conditions":15252,"interventions":15253},"NCT03196206","Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment",[87],"2018-03-04","2017-07-13",[11063],[12452],{"nctId":15255,"briefTitle":15256,"status":104,"phases":15257,"primaryCompletion":15258,"completion":15258,"start":15259,"enrollment":2527,"conditions":15260,"interventions":15261},"NCT02982707","Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants",[87],"2018-09-28","2018-03-01",[11063],[12452],{"nctId":15263,"briefTitle":15264,"status":104,"phases":15265,"primaryCompletion":5841,"completion":5841,"start":846,"enrollment":713,"conditions":15266,"interventions":15267},"NCT02959060","A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy Subjects",[87],[11063],[12452,5658],{"trials":15269,"activeCount":98},[15270,15274],{"nctId":12444,"briefTitle":12445,"status":104,"phases":15271,"primaryCompletion":2687,"completion":2687,"start":12447,"enrollment":34,"conditions":15272,"interventions":15273},[87,88],[12449],[12435,12451,12452],{"nctId":15275,"briefTitle":15276,"status":104,"phases":15277,"primaryCompletion":1151,"completion":1151,"start":15278,"enrollment":15279,"conditions":15280,"interventions":15283},"NCT03766581","A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel",[88],"2019-01-27",2366,[15281,15282],"Acute Ischemic Stroke","Transient Ischemic Attack (TIA)",[12452,15215,15199],{"trials":15285,"activeCount":98},[],{"trials":15287,"activeCount":98},[],{"trials":15289,"activeCount":98},[],{"intervention":9411,"totalTrials":1221,"cells":15291},{"EARLY_PHASE1":15292,"PHASE1":15294,"PHASE2":15368,"PHASE3":15377,"PHASE4":15379,"NA":15381},{"trials":15293,"activeCount":98},[],{"trials":15295,"activeCount":98},[15296,15302,15310,15316,15326,15332,15338,15345,15351,15358,15364],{"nctId":15297,"briefTitle":15298,"status":104,"phases":15299,"primaryCompletion":6170,"completion":6170,"start":4459,"enrollment":347,"conditions":15300,"interventions":15301},"NCT00901498","Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease",[87],[3470,759],[9411,9411,9411,9411,9411],{"nctId":15303,"briefTitle":15304,"status":104,"phases":15305,"primaryCompletion":6480,"completion":6480,"start":7715,"enrollment":3978,"conditions":15306,"interventions":15307},"NCT00726726","Drug Interaction Study With a Potential Alzheimer's Disease Compound",[87],[552],[15308,9411,15309],"Interacting drugs - Cooperstown Cocktail","BMS-708163 + Cooperstown Cocktail",{"nctId":15311,"briefTitle":15312,"status":104,"phases":15313,"primaryCompletion":11762,"completion":11762,"start":7088,"enrollment":3978,"conditions":15314,"interventions":15315},"NCT01057030","Multiple Dose Japanese Bridging Study",[87],[552],[9411],{"nctId":15317,"briefTitle":15318,"status":104,"phases":15319,"primaryCompletion":3712,"completion":3712,"start":3572,"enrollment":148,"conditions":15320,"interventions":15321},"NCT00860275","Drug-Drug Interaction (DDI) w\u002FKetoconazole or Fluconazole",[87],[552],[9411,15322,15323,15324,15325],"BMS-708163 + Ketoconazole","Ketoconazole","Fluconazole","BMS-708163 + Fluconazole",{"nctId":15327,"briefTitle":15328,"status":104,"phases":15329,"primaryCompletion":6170,"completion":6170,"start":6480,"enrollment":34,"conditions":15330,"interventions":15331},"NCT00828646","Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly Japanese",[87],[759],[9411,9411,9411],{"nctId":15333,"briefTitle":15334,"status":104,"phases":15335,"primaryCompletion":7706,"completion":7706,"start":11998,"enrollment":319,"conditions":15336,"interventions":15337},"NCT01002079","Drug-Drug Interaction Study With Rifampin",[87],[552],[9411,5658,5658],{"nctId":15339,"briefTitle":15340,"status":104,"phases":15341,"primaryCompletion":3872,"completion":3872,"start":10431,"enrollment":693,"conditions":15342,"interventions":15343},"NCT01042314","Drug-Drug Interaction Study With Aricept® (Donepezil)",[87],[552],[15344,9411],"Donepezil",{"nctId":15346,"briefTitle":15347,"status":104,"phases":15348,"primaryCompletion":4981,"completion":4981,"start":4664,"enrollment":1898,"conditions":15349,"interventions":15350},"NCT01454115","Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163",[87],[3470],[9411,9411,9411,9411,9411,9411,9411,9411,9411,9411],{"nctId":15352,"briefTitle":15353,"status":104,"phases":15354,"primaryCompletion":3872,"completion":3872,"start":10431,"enrollment":693,"conditions":15355,"interventions":15356},"NCT01039194","Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)",[87],[552],[15357,15357,9411],"galantamine",{"nctId":15359,"briefTitle":15360,"status":104,"phases":15361,"primaryCompletion":6918,"completion":6918,"start":3872,"enrollment":34,"conditions":15362,"interventions":15363},"NCT01079819","Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163",[87],[3470],[9411,9411],{"nctId":9405,"briefTitle":9406,"status":104,"phases":15365,"primaryCompletion":3617,"completion":3617,"start":4038,"enrollment":9408,"conditions":15366,"interventions":15367},[87],[552],[9411,9411,805],{"trials":15369,"activeCount":98},[15370],{"nctId":15371,"briefTitle":15372,"status":104,"phases":15373,"primaryCompletion":11762,"completion":11762,"start":3587,"enrollment":15374,"conditions":15375,"interventions":15376},"NCT00810147","A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease",[88],209,[3470],[9411,9411,9411,9411],{"trials":15378,"activeCount":98},[],{"trials":15380,"activeCount":98},[],{"trials":15382,"activeCount":98},[],{"intervention":15384,"totalTrials":360,"cells":15385},"BMS-986036",{"EARLY_PHASE1":15386,"PHASE1":15388,"PHASE2":15442,"PHASE3":15487,"PHASE4":15489,"NA":15491},{"trials":15387,"activeCount":98},[],{"trials":15389,"activeCount":98},[15390,15398,15410,15417,15427,15434],{"nctId":15391,"briefTitle":15392,"status":104,"phases":15393,"primaryCompletion":15394,"completion":15394,"start":15243,"enrollment":227,"conditions":15395,"interventions":15397},"NCT03198182","A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese Subjects",[87],"2017-09-22",[15396],"Metabolics",[15384],{"nctId":15399,"briefTitle":15400,"status":104,"phases":15401,"primaryCompletion":15402,"completion":15402,"start":15403,"enrollment":148,"conditions":15404,"interventions":15409},"NCT03445208","A Study of Experimental Medication BMS-986036 Given to Healthy Participants",[87],"2018-05-02","2018-02-14",[15405,15406,15407,15408],"Hepatic Cirrhosis","Liver Fibrosis","Nonalcoholic Fatty Liver Disease","Nonalcoholic Steatohepatitis",[15384],{"nctId":15411,"briefTitle":15412,"status":104,"phases":15413,"primaryCompletion":1276,"completion":1276,"start":1365,"enrollment":3562,"conditions":15414,"interventions":15416},"NCT03674476","An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function",[87],[15415,15407,15408],"NAFLD",[15384],{"nctId":15418,"briefTitle":15419,"status":104,"phases":15420,"primaryCompletion":15421,"completion":15421,"start":15422,"enrollment":713,"conditions":15423,"interventions":15426},"NCT04634149","A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment",[87],"2022-06-02","2020-11-23",[15424,15425],"Moderate Liver Impairment","Severe Liver Impairment",[15384],{"nctId":15428,"briefTitle":15429,"status":104,"phases":15430,"primaryCompletion":15431,"completion":15431,"start":5692,"enrollment":1586,"conditions":15432,"interventions":15433},"NCT04493567","Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe",[87],"2021-06-11",[18],[15384],{"nctId":15435,"briefTitle":15436,"status":467,"phases":15437,"primaryCompletion":8297,"completion":15438,"start":15439,"enrollment":98,"conditions":15440,"interventions":15441},"NCT04649710","A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants",[87],"2021-09-22","2021-06-21",[18],[15384],{"trials":15443,"activeCount":98},[15444,15454,15464,15473,15481],{"nctId":15445,"briefTitle":15446,"status":104,"phases":15447,"primaryCompletion":15448,"completion":15449,"start":15450,"enrollment":8531,"conditions":15451,"interventions":15453},"NCT02413372","A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)",[88],"2017-01-18","2017-06-19","2015-05-08",[15452],"Non-Alcoholic Steatohepatitis",[15384,15384],{"nctId":15455,"briefTitle":15456,"status":104,"phases":15457,"primaryCompletion":15458,"completion":15459,"start":15460,"enrollment":1945,"conditions":15461,"interventions":15463},"NCT02097277","A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes",[88],"2015-09-22","2016-05-17","2014-04-15",[15462],"Diabetes Mellitus Type 2",[15384],{"nctId":15465,"briefTitle":15466,"status":104,"phases":15467,"primaryCompletion":2026,"completion":15468,"start":15469,"enrollment":4012,"conditions":15470,"interventions":15472},"NCT03486912","A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis",[88],"2021-09-14","2018-06-12",[15405,15406,15471,15408],"Nonalcoholic Fatty Liver Disease (NAFLD)",[15384],{"nctId":15474,"briefTitle":15475,"status":104,"phases":15476,"primaryCompletion":2526,"completion":15477,"start":15478,"enrollment":2969,"conditions":15479,"interventions":15480},"NCT03486899","A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis",[88],"2021-08-17","2018-06-19",[15406,15471,15408],[15384],{"nctId":15482,"briefTitle":15483,"status":104,"phases":15484,"primaryCompletion":15448,"completion":15449,"start":15450,"enrollment":574,"conditions":15485,"interventions":15486},"NCT03400163","A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)",[88],[15452],[15384],{"trials":15488,"activeCount":98},[],{"trials":15490,"activeCount":98},[],{"trials":15492,"activeCount":98},[],{"intervention":15199,"totalTrials":747,"cells":15494},{"EARLY_PHASE1":15495,"PHASE1":15497,"PHASE2":15539,"PHASE3":15563,"PHASE4":15565,"NA":15567},{"trials":15496,"activeCount":98},[],{"trials":15498,"activeCount":98},[15499,15506,15513,15517,15521,15529],{"nctId":15500,"briefTitle":15501,"status":104,"phases":15502,"primaryCompletion":3678,"completion":3678,"start":6170,"enrollment":1385,"conditions":15503,"interventions":15505},"NCT00935506","Ex Vivo Human Thrombosis Chamber Study",[87],[15504],"Cardiovascular Disease",[15215,15199],{"nctId":15507,"briefTitle":15508,"status":104,"phases":15509,"primaryCompletion":6184,"completion":6184,"start":15510,"enrollment":3986,"conditions":15511,"interventions":15512},"NCT02439190","CV004-007 Thrombosis Chamber Study",[87],"2015-09",[11063],[10529,15199,15215],{"nctId":15193,"briefTitle":15194,"status":104,"phases":15514,"primaryCompletion":945,"completion":945,"start":15196,"enrollment":319,"conditions":15515,"interventions":15516},[87],[27],[15199,12452],{"nctId":15208,"briefTitle":15209,"status":104,"phases":15518,"primaryCompletion":15211,"completion":15211,"start":15212,"enrollment":6961,"conditions":15519,"interventions":15520},[87],[27],[12452,15215,15199],{"nctId":15522,"briefTitle":15523,"status":104,"phases":15524,"primaryCompletion":15510,"completion":15510,"start":11981,"enrollment":15525,"conditions":15526,"interventions":15527},"NCT02341638","Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects",[87],148,[11063],[15528,15199,5584],"BMS-986141",{"nctId":15530,"briefTitle":15531,"status":104,"phases":15532,"primaryCompletion":1293,"completion":15533,"start":15534,"enrollment":15535,"conditions":15536,"interventions":15537},"NCT03197779","A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects",[87],"2017-01-24","2013-11-18",691,[11063],[15538,15199],"BMS-962212",{"trials":15540,"activeCount":98},[15541,15551,15555],{"nctId":15542,"briefTitle":15543,"status":104,"phases":15544,"primaryCompletion":15545,"completion":15545,"start":15546,"enrollment":2308,"conditions":15547,"interventions":15549},"NCT05093790","A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants",[88],"2022-11-14","2022-03-25",[15548,18],"Coronary Artery Disease",[15550,15528,15199],"Ticagrelor",{"nctId":15275,"briefTitle":15276,"status":104,"phases":15552,"primaryCompletion":1151,"completion":1151,"start":15278,"enrollment":15279,"conditions":15553,"interventions":15554},[88],[15281,15282],[12452,15215,15199],{"nctId":15556,"briefTitle":15557,"status":104,"phases":15558,"primaryCompletion":15559,"completion":15559,"start":15560,"enrollment":713,"conditions":15561,"interventions":15562},"NCT02671461","Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or \"Mini Strokes\"",[88],"2017-03-31","2016-04-25",[11063],[15528,15199],{"trials":15564,"activeCount":98},[],{"trials":15566,"activeCount":98},[],{"trials":15568,"activeCount":98},[],{"intervention":3576,"totalTrials":1750,"cells":15570},{"EARLY_PHASE1":15571,"PHASE1":15573,"PHASE2":15597,"PHASE3":15619,"PHASE4":15621,"NA":15623},{"trials":15572,"activeCount":98},[],{"trials":15574,"activeCount":98},[15575,15579,15585,15591],{"nctId":3569,"briefTitle":3570,"status":104,"phases":15576,"primaryCompletion":1343,"completion":1343,"start":3572,"enrollment":757,"conditions":15577,"interventions":15578},[87],[1132,3574],[3576,1158,1157],{"nctId":15580,"briefTitle":15581,"status":104,"phases":15582,"primaryCompletion":5022,"completion":5022,"start":6437,"enrollment":2527,"conditions":15583,"interventions":15584},"NCT01525823","Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With Metformin",[87],[27],[3576,823],{"nctId":15586,"briefTitle":15587,"status":104,"phases":15588,"primaryCompletion":7714,"completion":7714,"start":4038,"enrollment":1385,"conditions":15589,"interventions":15590},"NCT00898716","Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan",[87],[7156],[3576],{"nctId":15592,"briefTitle":15593,"status":104,"phases":15594,"primaryCompletion":3958,"completion":3958,"start":7811,"enrollment":227,"conditions":15595,"interventions":15596},"NCT00569036","Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors",[87],[7156,1515,13848],[3576],{"trials":15598,"activeCount":98},[15599,15608,15612],{"nctId":15600,"briefTitle":15601,"status":963,"phases":15602,"primaryCompletion":15603,"completion":15603,"start":15604,"enrollment":1152,"conditions":15605,"interventions":15606},"NCT01225172","Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors",[88],"2014-11-30","2010-12-31",[1223],[3576,15607],"letrozole",{"nctId":5880,"briefTitle":5881,"status":963,"phases":15609,"primaryCompletion":3977,"completion":3977,"start":3678,"enrollment":890,"conditions":15610,"interventions":15611},[87,88],[1673,1537,5884],[3576,2077],{"nctId":15613,"briefTitle":15614,"status":104,"phases":15615,"primaryCompletion":3960,"completion":3960,"start":6170,"enrollment":3562,"conditions":15616,"interventions":15617},"NCT00788333","Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer",[87,88],[1223],[3576,15618],"trastuzumab",{"trials":15620,"activeCount":98},[],{"trials":15622,"activeCount":98},[],{"trials":15624,"activeCount":98},[],{"intervention":15626,"totalTrials":1750,"cells":15627},"BMS-986166",{"EARLY_PHASE1":15628,"PHASE1":15630,"PHASE2":15679,"PHASE3":15689,"PHASE4":15691,"NA":15693},{"trials":15629,"activeCount":98},[],{"trials":15631,"activeCount":98},[15632,15640,15648,15657,15666,15673],{"nctId":15633,"briefTitle":15634,"status":104,"phases":15635,"primaryCompletion":15636,"completion":15636,"start":15637,"enrollment":1354,"conditions":15638,"interventions":15639},"NCT03038711","A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers",[87],"2017-08-10","2017-02-01",[990],[15626],{"nctId":15641,"briefTitle":15642,"status":104,"phases":15643,"primaryCompletion":1585,"completion":1585,"start":15644,"enrollment":94,"conditions":15645,"interventions":15646},"NCT04934696","A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential",[87],"2021-08-03",[18],[15626,15647],"Oral contraceptive",{"nctId":15649,"briefTitle":15650,"status":104,"phases":15651,"primaryCompletion":15652,"completion":15652,"start":15653,"enrollment":1750,"conditions":15654,"interventions":15655},"NCT05409157","A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male Participants",[87],"2022-10-15","2022-06-17",[18],[15626,15656],"Bisacodyl",{"nctId":15658,"briefTitle":15659,"status":104,"phases":15660,"primaryCompletion":15661,"completion":15661,"start":15662,"enrollment":1385,"conditions":15663,"interventions":15664},"NCT04956627","A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants",[87],"2022-04-27","2021-07-28",[18],[15626,5584,15665,5585],"Extended Phenytoin Sodium",{"nctId":15667,"briefTitle":15668,"status":104,"phases":15669,"primaryCompletion":15242,"completion":15242,"start":15670,"enrollment":1424,"conditions":15671,"interventions":15672},"NCT02790125","A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects",[87],"2016-07-28",[759],[15626],{"nctId":15674,"briefTitle":15675,"status":104,"phases":15676,"primaryCompletion":201,"completion":201,"start":3243,"enrollment":2038,"conditions":15677,"interventions":15678},"NCT04965402","A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese Participants",[87],[27],[15626],{"trials":15680,"activeCount":98},[15681],{"nctId":15682,"briefTitle":15683,"status":104,"phases":15684,"primaryCompletion":1543,"completion":1543,"start":15477,"enrollment":5543,"conditions":15685,"interventions":15687},"NCT05014438","A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis",[88],[15686],"Dermatitis, Atopic",[15626,15688],"Branebrutinib",{"trials":15690,"activeCount":98},[],{"trials":15692,"activeCount":98},[],{"trials":15694,"activeCount":98},[],{"intervention":3621,"totalTrials":1750,"cells":15696},{"EARLY_PHASE1":15697,"PHASE1":15699,"PHASE2":15729,"PHASE3":15744,"PHASE4":15746,"NA":15748},{"trials":15698,"activeCount":98},[],{"trials":15700,"activeCount":98},[15701,15705,15709,15719,15723],{"nctId":6166,"briefTitle":6167,"status":104,"phases":15702,"primaryCompletion":6169,"completion":6169,"start":6170,"enrollment":37,"conditions":15703,"interventions":15704},[87],[6172],[3621,441,1795,1796],{"nctId":3613,"briefTitle":3614,"status":104,"phases":15706,"primaryCompletion":3616,"completion":3616,"start":3617,"enrollment":520,"conditions":15707,"interventions":15708},[87],[3619],[3621,1157,1929],{"nctId":15710,"briefTitle":15711,"status":104,"phases":15712,"primaryCompletion":4289,"completion":4159,"start":4039,"enrollment":28,"conditions":15713,"interventions":15718},"NCT00670189","A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer",[87],[15714,15715,15716,15717],"Hedgehog Pathway","Smoothened","Basal Cell Carcinoma (BCC)","Basal Cell Nevoid Syndrome (BCNS)",[3621],{"nctId":4576,"briefTitle":4577,"status":104,"phases":15720,"primaryCompletion":3893,"completion":3893,"start":3585,"enrollment":4579,"conditions":15721,"interventions":15722},[87],[4581,4582],[3621,1268,611],{"nctId":15724,"briefTitle":15725,"status":104,"phases":15726,"primaryCompletion":3893,"completion":3893,"start":3960,"enrollment":1221,"conditions":15727,"interventions":15728},"NCT01413906","Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors",[87],[606],[3621],{"trials":15730,"activeCount":98},[15731,15738],{"nctId":15732,"briefTitle":15733,"status":104,"phases":15734,"primaryCompletion":3958,"completion":3958,"start":3894,"enrollment":736,"conditions":15735,"interventions":15737},"NCT01218477","Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)",[87,88],[15736],"Leukemia",[1197,3621],{"nctId":15739,"briefTitle":15740,"status":963,"phases":15741,"primaryCompletion":8038,"completion":8038,"start":5541,"enrollment":22,"conditions":15742,"interventions":15743},"NCT01357655","Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)",[88],[15736],[1197,3621],{"trials":15745,"activeCount":98},[],{"trials":15747,"activeCount":98},[],{"trials":15749,"activeCount":98},[],{"intervention":15751,"totalTrials":830,"cells":15752},"BMS-690514",{"EARLY_PHASE1":15753,"PHASE1":15755,"PHASE2":15777,"PHASE3":15800,"PHASE4":15802,"NA":15804},{"trials":15754,"activeCount":98},[],{"trials":15756,"activeCount":98},[15757,15764,15771],{"nctId":15758,"briefTitle":15759,"status":104,"phases":15760,"primaryCompletion":6437,"completion":6437,"start":4179,"enrollment":680,"conditions":15761,"interventions":15763},"NCT00420186","A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin",[87],[15762],"Cancer (Solid Tumors)",[15751],{"nctId":15765,"briefTitle":15766,"status":104,"phases":15767,"primaryCompletion":6170,"completion":6170,"start":4379,"enrollment":15768,"conditions":15769,"interventions":15770},"NCT00329004","A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors",[87],89,[606,1120],[15751],{"nctId":15772,"briefTitle":15773,"status":104,"phases":15774,"primaryCompletion":4039,"completion":4039,"start":7758,"enrollment":747,"conditions":15775,"interventions":15776},"NCT00516451","Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors",[87],[606],[15751],{"trials":15778,"activeCount":98},[15779,15786,15792],{"nctId":15780,"briefTitle":15781,"status":104,"phases":15782,"primaryCompletion":15783,"completion":15783,"start":11998,"enrollment":360,"conditions":15784,"interventions":15785},"NCT01167244","Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response",[88],"2011-04",[2161],[15751],{"nctId":15787,"briefTitle":15788,"status":104,"phases":15789,"primaryCompletion":11998,"completion":1343,"start":4981,"enrollment":3607,"conditions":15790,"interventions":15791},"NCT00743938","A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC",[88],[2622],[15751,1269],{"nctId":15793,"briefTitle":15794,"status":104,"phases":15795,"primaryCompletion":6918,"completion":6918,"start":11762,"enrollment":4328,"conditions":15796,"interventions":15797},"NCT01068704","Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer",[88],[1223],[15751,15798,15799],"Lapatinib","Letrozole",{"trials":15801,"activeCount":98},[],{"trials":15803,"activeCount":98},[],{"trials":15805,"activeCount":98},[],{"intervention":1111,"totalTrials":830,"cells":15807},{"EARLY_PHASE1":15808,"PHASE1":15810,"PHASE2":15841,"PHASE3":15847,"PHASE4":15849,"NA":15851},{"trials":15809,"activeCount":98},[],{"trials":15811,"activeCount":98},[15812,15816,15820,15824,15832],{"nctId":1103,"briefTitle":1104,"status":104,"phases":15813,"primaryCompletion":1106,"completion":1106,"start":1107,"enrollment":693,"conditions":15814,"interventions":15815},[87],[1109],[1111,43],{"nctId":8696,"briefTitle":8697,"status":104,"phases":15817,"primaryCompletion":8699,"completion":8699,"start":4123,"enrollment":31,"conditions":15818,"interventions":15819},[87],[8701],[1111,8689],{"nctId":5838,"briefTitle":5839,"status":104,"phases":15821,"primaryCompletion":5841,"completion":5841,"start":4289,"enrollment":1424,"conditions":15822,"interventions":15823},[87],[1673,1537],[1111,1145],{"nctId":15825,"briefTitle":15826,"status":104,"phases":15827,"primaryCompletion":15828,"completion":15828,"start":15829,"enrollment":184,"conditions":15830,"interventions":15831},"NCT02252263","A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma",[87],"2017-10-10","2014-12-09",[33],[1794,1187,1111],{"nctId":15833,"briefTitle":15834,"status":104,"phases":15835,"primaryCompletion":15836,"completion":15836,"start":6437,"enrollment":15837,"conditions":15838,"interventions":15840},"NCT01471210","Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and\u002For Metastatic Solid Tumors and Relapsed\u002FRefractory B-cell Non-Hodgkin's Lymphoma",[87],"2016-04",124,[15839],"Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma",[1111],{"trials":15842,"activeCount":98},[15843],{"nctId":2312,"briefTitle":2313,"status":963,"phases":15844,"primaryCompletion":2315,"completion":2315,"start":2316,"enrollment":2317,"conditions":15845,"interventions":15846},[87,88],[1132,2319],[1111,43],{"trials":15848,"activeCount":98},[],{"trials":15850,"activeCount":98},[],{"trials":15852,"activeCount":98},[],{"intervention":6519,"totalTrials":830,"cells":15854},{"EARLY_PHASE1":15855,"PHASE1":15857,"PHASE2":15890,"PHASE3":15900,"PHASE4":15902,"NA":15904},{"trials":15856,"activeCount":98},[],{"trials":15858,"activeCount":98},[15859,15867,15871,15878,15886],{"nctId":15860,"briefTitle":15861,"status":104,"phases":15862,"primaryCompletion":15863,"completion":15863,"start":15864,"enrollment":1203,"conditions":15865,"interventions":15866},"NCT05546151","A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent",[87],"2023-04-07","2022-09-28",[18],[6519],{"nctId":6512,"briefTitle":6513,"status":104,"phases":15868,"primaryCompletion":6515,"completion":6515,"start":6516,"enrollment":1686,"conditions":15869,"interventions":15870},[87],[18],[6519,874,823,772,617],{"nctId":15872,"briefTitle":15873,"status":104,"phases":15874,"primaryCompletion":330,"completion":330,"start":2711,"enrollment":839,"conditions":15875,"interventions":15877},"NCT06088264","A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants",[87],[15876],"Healthy Male Participants",[6519],{"nctId":15879,"briefTitle":15880,"status":104,"phases":15881,"primaryCompletion":2260,"completion":2260,"start":15882,"enrollment":3986,"conditions":15883,"interventions":15884},"NCT05579574","A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]\u002FNorethindrone [NET]) in Healthy Female Participants",[87],"2022-10-21",[18],[6519,15885],"Loestrin",{"nctId":8468,"briefTitle":8469,"status":104,"phases":15887,"primaryCompletion":3220,"completion":3220,"start":8471,"enrollment":8472,"conditions":15888,"interventions":15889},[87],[18],[6519,8475],{"trials":15891,"activeCount":98},[15892],{"nctId":15893,"briefTitle":15894,"status":104,"phases":15895,"primaryCompletion":3595,"completion":3595,"start":15896,"enrollment":15897,"conditions":15898,"interventions":15899},"NCT05730725","A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis",[88],"2023-04-03",109,[749],[6519],{"trials":15901,"activeCount":98},[],{"trials":15903,"activeCount":98},[],{"trials":15905,"activeCount":98},[],{"intervention":823,"totalTrials":830,"cells":15907},{"EARLY_PHASE1":15908,"PHASE1":15910,"PHASE2":15928,"PHASE3":15945,"PHASE4":15947,"NA":15949},{"trials":15909,"activeCount":98},[],{"trials":15911,"activeCount":98},[15912,15916,15920,15924],{"nctId":6512,"briefTitle":6513,"status":104,"phases":15913,"primaryCompletion":6515,"completion":6515,"start":6516,"enrollment":1686,"conditions":15914,"interventions":15915},[87],[18],[6519,874,823,772,617],{"nctId":15580,"briefTitle":15581,"status":104,"phases":15917,"primaryCompletion":5022,"completion":5022,"start":6437,"enrollment":2527,"conditions":15918,"interventions":15919},[87],[27],[3576,823],{"nctId":816,"briefTitle":817,"status":104,"phases":15921,"primaryCompletion":819,"completion":147,"start":820,"enrollment":347,"conditions":15922,"interventions":15923},[87],[18],[679,823],{"nctId":6829,"briefTitle":6830,"status":104,"phases":15925,"primaryCompletion":5681,"completion":6832,"start":329,"enrollment":148,"conditions":15926,"interventions":15927},[87],[27],[6814,823,6535,874,6835,6532,6533],{"trials":15929,"activeCount":98},[15930,15937],{"nctId":15931,"briefTitle":15932,"status":104,"phases":15933,"primaryCompletion":3894,"completion":3894,"start":4348,"enrollment":9408,"conditions":15934,"interventions":15935},"NCT01111955","Safety Study of BMS-823778 in Subjects With Type 2 Diabetes",[88],[12223],[15936,15936,15936,823],"BMS-823778",{"nctId":15938,"briefTitle":15939,"status":104,"phases":15940,"primaryCompletion":3894,"completion":3894,"start":7944,"enrollment":1686,"conditions":15941,"interventions":15943},"NCT01046422","Safety Study of BMS-770767 in Subjects With Type 2 Diabetes",[88],[15942],"Diabetes Type 2",[15944,15944,15944,15944,823],"BMS-770767",{"trials":15946,"activeCount":98},[],{"trials":15948,"activeCount":98},[],{"trials":15950,"activeCount":98},[],{"intervention":12753,"totalTrials":830,"cells":15952},{"EARLY_PHASE1":15953,"PHASE1":15955,"PHASE2":15976,"PHASE3":15996,"PHASE4":15998,"NA":16000},{"trials":15954,"activeCount":98},[],{"trials":15956,"activeCount":98},[15957,15964,15970],{"nctId":15958,"briefTitle":15959,"status":104,"phases":15960,"primaryCompletion":3904,"completion":3904,"start":4459,"enrollment":15961,"conditions":15962,"interventions":15963},"NCT00892840","Multiple-Ascending Dose Study",[87],57,[12749],[12753],{"nctId":15965,"briefTitle":15966,"status":104,"phases":15967,"primaryCompletion":6225,"completion":6225,"start":5541,"enrollment":15961,"conditions":15968,"interventions":15969},"NCT01396252","Japanese Phase 1 Multiple Ascending Dose (MAD) Study",[87],[12749],[12753,12753,12753,12753],{"nctId":15971,"briefTitle":15972,"status":104,"phases":15973,"primaryCompletion":3572,"completion":3572,"start":4039,"enrollment":25,"conditions":15974,"interventions":15975},"NCT00964912","Single Dose Study of BMS-820836",[87],[12749],[12753,12753,12753,12753,12753,12753,12753,12753,12753,12753,12753],{"trials":15977,"activeCount":98},[15978,15985,15992],{"nctId":15979,"briefTitle":15980,"status":104,"phases":15981,"primaryCompletion":3903,"completion":3903,"start":15783,"enrollment":15982,"conditions":15983,"interventions":15984},"NCT01309945","Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression",[88],889,[12749],[12751,12753,12751],{"nctId":15986,"briefTitle":15987,"status":963,"phases":15988,"primaryCompletion":4378,"completion":4378,"start":5850,"enrollment":15989,"conditions":15990,"interventions":15991},"NCT01361555","Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression",[88],789,[12749],[12753,12753,12753],{"nctId":12744,"briefTitle":12745,"status":104,"phases":15993,"primaryCompletion":10518,"completion":10518,"start":7714,"enrollment":12747,"conditions":15994,"interventions":15995},[88],[12749],[12751,11906,12752,12753,12753,12753,12753],{"trials":15997,"activeCount":98},[],{"trials":15999,"activeCount":98},[],{"trials":16001,"activeCount":98},[],{"intervention":16003,"totalTrials":520,"cells":16004},"MDX-010",{"EARLY_PHASE1":16005,"PHASE1":16007,"PHASE2":16024,"PHASE3":16047,"PHASE4":16049,"NA":16051},{"trials":16006,"activeCount":98},[],{"trials":16008,"activeCount":98},[16009,16018],{"nctId":16010,"briefTitle":16011,"status":104,"phases":16012,"primaryCompletion":16013,"completion":16013,"start":16014,"enrollment":1203,"conditions":16015,"interventions":16017},"NCT03407105","A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)",[87],"2006-02-21","2003-04-21",[16016],"Human Immunodeficiency Virus (HIV)",[16003],{"nctId":16019,"briefTitle":16020,"status":104,"phases":16021,"primaryCompletion":5043,"completion":4664,"start":12201,"enrollment":1695,"conditions":16022,"interventions":16023},"NCT00729950","Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma",[87],[3035],[16003],{"trials":16025,"activeCount":98},[16026,16032,16040],{"nctId":16027,"briefTitle":16028,"status":104,"phases":16029,"primaryCompletion":7153,"completion":7153,"start":5079,"conditions":16030,"interventions":16031},"NCT00050102","Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma",[88],[21],[16003],{"nctId":16033,"briefTitle":16034,"status":104,"phases":16035,"completion":13679,"start":16036,"enrollment":736,"conditions":16037,"interventions":16039},"NCT00083278","Study of MDX-010 in Stage IV Breast Cancer",[88],"2003-05",[1223,16038],"Adenocarcinoma",[16003],{"nctId":16041,"briefTitle":16042,"status":104,"phases":16043,"primaryCompletion":4038,"completion":7691,"start":4995,"enrollment":16044,"conditions":16045,"interventions":16046},"NCT00323882","Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer",[87,88],75,[1504,5884],[16003],{"trials":16048,"activeCount":98},[],{"trials":16050,"activeCount":98},[],{"trials":16052,"activeCount":98},[],{"intervention":16054,"totalTrials":520,"cells":16055},"BMS-986231",{"EARLY_PHASE1":16056,"PHASE1":16058,"PHASE2":16100,"PHASE3":16111,"PHASE4":16113,"NA":16115},{"trials":16057,"activeCount":98},[],{"trials":16059,"activeCount":98},[16060,16069,16082,16092],{"nctId":16061,"briefTitle":16062,"status":104,"phases":16063,"primaryCompletion":14097,"completion":14097,"start":16064,"enrollment":7813,"conditions":16065,"interventions":16067},"NCT02932969","Study With Healthy Japanese and Non-Asian Participants With BMS-986231",[87],"2016-10-04",[16066],"Heart Decompensation, Acute",[16054,16068],"BMS-986231 Placebo",{"nctId":16070,"briefTitle":16071,"status":104,"phases":16072,"primaryCompletion":16073,"completion":16073,"start":16074,"enrollment":1686,"conditions":16075,"interventions":16081},"NCT03515980","An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function",[87],"2019-08-29","2018-05-25",[813,16076,16077,16078,16079,10867,16080],"Liver Insufficiency","Hepatic Failure","Myocardial Failure","Cardiac Failure","Heart Decompensation",[16054],{"nctId":16083,"briefTitle":16084,"status":104,"phases":16085,"primaryCompletion":16086,"completion":16086,"start":16087,"enrollment":725,"conditions":16088,"interventions":16091},"NCT03332186","A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function",[87],"2018-10-22","2018-03-15",[16078,16079,10867,16089,16090],"Kidney Failure","Renal Failure",[16054],{"nctId":16093,"briefTitle":16094,"status":104,"phases":16095,"primaryCompletion":16096,"completion":16096,"start":16097,"enrollment":520,"conditions":16098,"interventions":16099},"NCT03210909","Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants",[87],"2017-07-20","2017-06-22",[16066],[16054],{"trials":16101,"activeCount":98},[16102],{"nctId":16103,"briefTitle":16104,"status":104,"phases":16105,"primaryCompletion":16106,"completion":16107,"start":2504,"enrollment":2038,"conditions":16108,"interventions":16109},"NCT03730961","An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic",[88],"2019-12-11","2020-01-09",[16079,16078,10867,16080],[16054,16110],"Furosemide",{"trials":16112,"activeCount":98},[],{"trials":16114,"activeCount":98},[],{"trials":16116,"activeCount":98},[],{"intervention":15936,"totalTrials":520,"cells":16118},{"EARLY_PHASE1":16119,"PHASE1":16121,"PHASE2":16129,"PHASE3":16155,"PHASE4":16157,"NA":16159},{"trials":16120,"activeCount":98},[],{"trials":16122,"activeCount":98},[16123],{"nctId":16124,"briefTitle":16125,"status":104,"phases":16126,"primaryCompletion":3616,"completion":3616,"start":6169,"enrollment":3562,"conditions":16127,"interventions":16128},"NCT01515202","Japanese Phase 1 Multiple Ascending Dose Study",[87],[11098],[15936,15936,15936,15936],{"trials":16130,"activeCount":98},[16131,16139,16143,16149],{"nctId":16132,"briefTitle":16133,"status":467,"phases":16134,"primaryCompletion":847,"completion":16135,"start":4289,"enrollment":98,"conditions":16136,"interventions":16138},"NCT01666704","Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis",[88],"2016-05",[16137],"Atherosclerotic Cardiovascular Disease",[15936,15936],{"nctId":15931,"briefTitle":15932,"status":104,"phases":16140,"primaryCompletion":3894,"completion":3894,"start":4348,"enrollment":9408,"conditions":16141,"interventions":16142},[88],[12223],[15936,15936,15936,823],{"nctId":16144,"briefTitle":16145,"status":104,"phases":16146,"primaryCompletion":6918,"completion":6918,"start":11762,"enrollment":582,"conditions":16147,"interventions":16148},"NCT01112423","Safety Study of BMS-823778 in Subjects With Hypercholesterolemia",[88],[12214],[15936,15936,15936],{"nctId":16150,"briefTitle":16151,"status":963,"phases":16152,"primaryCompletion":3893,"completion":3893,"start":3902,"enrollment":1750,"conditions":16153,"interventions":16154},"NCT01602367","Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients",[88],[10877],[15936,15936,15936],{"trials":16156,"activeCount":98},[],{"trials":16158,"activeCount":98},[],{"trials":16160,"activeCount":98},[],{"intervention":15528,"totalTrials":520,"cells":16162},{"EARLY_PHASE1":16163,"PHASE1":16165,"PHASE2":16188,"PHASE3":16198,"PHASE4":16200,"NA":16202},{"trials":16164,"activeCount":98},[],{"trials":16166,"activeCount":98},[16167,16175,16184],{"nctId":16168,"briefTitle":16169,"status":467,"phases":16170,"primaryCompletion":16171,"completion":2676,"start":16172,"enrollment":98,"conditions":16173,"interventions":16174},"NCT02985632","A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants",[87],"2017-05-18","2017-01-11",[5603],[15528],{"nctId":16176,"briefTitle":16177,"status":104,"phases":16178,"primaryCompletion":846,"completion":846,"start":16179,"enrollment":713,"conditions":16180,"interventions":16182},"NCT02922452","A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects",[87],"2016-09",[16181],"Ischemic Stroke",[15528,16183],"Dilitazem",{"nctId":15522,"briefTitle":15523,"status":104,"phases":16185,"primaryCompletion":15510,"completion":15510,"start":11981,"enrollment":15525,"conditions":16186,"interventions":16187},[87],[11063],[15528,15199,5584],{"trials":16189,"activeCount":98},[16190,16194],{"nctId":15542,"briefTitle":15543,"status":104,"phases":16191,"primaryCompletion":15545,"completion":15545,"start":15546,"enrollment":2308,"conditions":16192,"interventions":16193},[88],[15548,18],[15550,15528,15199],{"nctId":15556,"briefTitle":15557,"status":104,"phases":16195,"primaryCompletion":15559,"completion":15559,"start":15560,"enrollment":713,"conditions":16196,"interventions":16197},[88],[11063],[15528,15199],{"trials":16199,"activeCount":98},[],{"trials":16201,"activeCount":98},[],{"trials":16203,"activeCount":98},[],{"intervention":6905,"totalTrials":520,"cells":16205},{"EARLY_PHASE1":16206,"PHASE1":16208,"PHASE2":16232,"PHASE3":16247,"PHASE4":16249,"NA":16251},{"trials":16207,"activeCount":98},[],{"trials":16209,"activeCount":98},[16210,16219,16226],{"nctId":16211,"briefTitle":16212,"status":104,"phases":16213,"primaryCompletion":16214,"completion":16214,"start":16135,"enrollment":94,"conditions":16215,"interventions":16217},"NCT02832180","The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects",[87],"2016-10",[16216],"Arthritis",[16218,6905],"OC containing EE and NET",{"nctId":16220,"briefTitle":16221,"status":104,"phases":16222,"primaryCompletion":4458,"completion":4458,"start":11981,"enrollment":357,"conditions":16223,"interventions":16225},"NCT02257151","Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects",[87],[16224],"Healthy Adult",[6905],{"nctId":16227,"briefTitle":16228,"status":104,"phases":16229,"primaryCompletion":16179,"completion":16179,"start":8699,"enrollment":747,"conditions":16230,"interventions":16231},"NCT02880670","Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects",[87],[16216],[6905],{"trials":16233,"activeCount":98},[16234,16243],{"nctId":16235,"briefTitle":16236,"status":963,"phases":16237,"primaryCompletion":16238,"completion":16238,"start":16239,"enrollment":125,"conditions":16240,"interventions":16241},"NCT02843659","Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome",[88],"2017-07-24","2016-10-18",[3276],[16242,6905],"BMS-931699",{"nctId":6899,"briefTitle":6900,"status":104,"phases":16244,"primaryCompletion":3797,"completion":3797,"start":3746,"enrollment":6902,"conditions":16245,"interventions":16246},[88],[15],[6905,772],{"trials":16248,"activeCount":98},[],{"trials":16250,"activeCount":98},[],{"trials":16252,"activeCount":98},[],{"intervention":16254,"totalTrials":520,"cells":16255},"BMS-986020",{"EARLY_PHASE1":16256,"PHASE1":16258,"PHASE2":16282,"PHASE3":16299,"PHASE4":16301,"NA":16303},{"trials":16257,"activeCount":98},[],{"trials":16259,"activeCount":98},[16260,16268,16275],{"nctId":16261,"briefTitle":16262,"status":104,"phases":16263,"primaryCompletion":14959,"completion":14959,"start":9360,"enrollment":319,"conditions":16264,"interventions":16266},"NCT02017730","To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers",[87],[16265],"Immunology",[16254,16267],"[11C]BMT-136088",{"nctId":16269,"briefTitle":16270,"status":104,"phases":16271,"primaryCompletion":7690,"completion":7690,"start":11981,"enrollment":319,"conditions":16272,"interventions":16274},"NCT02227173","A Phase 1 Drug-drug Interaction Study in Healthy Volunteers",[87],[16273],"Drug-drug Interaction Study",[16254,6531,6532,6535],{"nctId":16276,"briefTitle":16277,"status":104,"phases":16278,"primaryCompletion":4159,"completion":4159,"start":12170,"enrollment":2527,"conditions":16279,"interventions":16281},"NCT02101125","Drug Interaction Study With Rosuvastatin",[87],[16280],"Immunosuppression For Disease",[16254,874],{"trials":16283,"activeCount":98},[16284,16292],{"nctId":16285,"briefTitle":16286,"status":467,"phases":16287,"primaryCompletion":16288,"completion":16288,"start":8030,"enrollment":98,"conditions":16289,"interventions":16291},"NCT02588625","A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)",[88],"2019-10",[16290],"Scleroderma",[16254],{"nctId":16293,"briefTitle":16294,"status":104,"phases":16295,"primaryCompletion":4520,"completion":4520,"start":16296,"enrollment":1966,"conditions":16297,"interventions":16298},"NCT01766817","Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis",[88],"2013-01-31",[5729],[16254],{"trials":16300,"activeCount":98},[],{"trials":16302,"activeCount":98},[],{"trials":16304,"activeCount":98},[],{"intervention":10539,"totalTrials":520,"cells":16306},{"EARLY_PHASE1":16307,"PHASE1":16309,"PHASE2":16336,"PHASE3":16348,"PHASE4":16350,"NA":16352},{"trials":16308,"activeCount":98},[],{"trials":16310,"activeCount":98},[16311,16317,16321,16327],{"nctId":16312,"briefTitle":16313,"status":104,"phases":16314,"primaryCompletion":3048,"completion":3048,"start":3025,"enrollment":757,"conditions":16315,"interventions":16316},"NCT06027437","A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants",[87],[27],[10539],{"nctId":10531,"briefTitle":10532,"status":104,"phases":16318,"primaryCompletion":10534,"completion":2404,"start":10535,"enrollment":137,"conditions":16319,"interventions":16320},[87],[10537],[10539,6534],{"nctId":16322,"briefTitle":16323,"status":104,"phases":16324,"primaryCompletion":3049,"completion":3049,"start":259,"enrollment":736,"conditions":16325,"interventions":16326},"NCT05806359","A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants",[87],[27],[10539],{"nctId":16328,"briefTitle":16329,"status":104,"phases":16330,"primaryCompletion":16331,"completion":16331,"start":16332,"enrollment":148,"conditions":16333,"interventions":16334},"NCT05162222","A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy Participants",[87],"2022-07-08","2021-12-15",[18],[10539,5584,16335],"Diltiazem",{"trials":16337,"activeCount":98},[16338],{"nctId":16339,"briefTitle":16340,"status":963,"phases":16341,"primaryCompletion":16342,"completion":16342,"start":16343,"enrollment":11873,"conditions":16344,"interventions":16346},"NCT04572893","Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities",[88],"2024-02-22","2020-08-04",[16345],"Primary Familial Dilated Cardiomyopathy",[16347],"danicamtiv",{"trials":16349,"activeCount":98},[],{"trials":16351,"activeCount":98},[],{"trials":16353,"activeCount":98},[],{"intervention":1187,"totalTrials":520,"cells":16355},{"EARLY_PHASE1":16356,"PHASE1":16358,"PHASE2":16372,"PHASE3":16382,"PHASE4":16384,"NA":16386},{"trials":16357,"activeCount":98},[],{"trials":16359,"activeCount":98},[16360,16364,16368],{"nctId":1179,"briefTitle":1180,"status":104,"phases":16361,"primaryCompletion":1182,"completion":1182,"start":1183,"enrollment":1184,"conditions":16362,"interventions":16363},[87],[1154],[1187,43,608],{"nctId":3973,"briefTitle":3974,"status":104,"phases":16365,"primaryCompletion":3976,"completion":3976,"start":3977,"enrollment":3978,"conditions":16366,"interventions":16367},[87],[3980],[1187,608],{"nctId":15825,"briefTitle":15826,"status":104,"phases":16369,"primaryCompletion":15828,"completion":15828,"start":15829,"enrollment":184,"conditions":16370,"interventions":16371},[87],[33],[1794,1187,1111],{"trials":16373,"activeCount":98},[16374,16378],{"nctId":1818,"briefTitle":1819,"status":104,"phases":16375,"primaryCompletion":1821,"completion":1211,"start":1822,"enrollment":1823,"conditions":16376,"interventions":16377},[87,88],[1825,1826,33],[43,608,1187,615,1797,1795],{"nctId":1951,"briefTitle":1952,"status":104,"phases":16379,"primaryCompletion":1954,"completion":1954,"start":1955,"enrollment":1956,"conditions":16380,"interventions":16381},[87,88],[1958],[1187,43,608],{"trials":16383,"activeCount":98},[],{"trials":16385,"activeCount":98},[],{"trials":16387,"activeCount":98},[],{"intervention":15688,"totalTrials":4328,"cells":16389},{"EARLY_PHASE1":16390,"PHASE1":16392,"PHASE2":16410,"PHASE3":16420,"PHASE4":16422,"NA":16424},{"trials":16391,"activeCount":98},[],{"trials":16393,"activeCount":98},[16394,16401],{"nctId":16395,"briefTitle":16396,"status":104,"phases":16397,"primaryCompletion":16398,"completion":16398,"start":8296,"enrollment":7813,"conditions":16399,"interventions":16400},"NCT05303220","A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants",[87],"2022-08-18",[27],[15688],{"nctId":16402,"briefTitle":16403,"status":104,"phases":16404,"primaryCompletion":16405,"completion":16406,"start":16407,"enrollment":3978,"conditions":16408,"interventions":16409},"NCT04515628","Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants",[87],"2020-10-18","2020-10-26","2020-08-02",[18],[874,15688],{"trials":16411,"activeCount":98},[16412,16416],{"nctId":15682,"briefTitle":15683,"status":104,"phases":16413,"primaryCompletion":1543,"completion":1543,"start":15477,"enrollment":5543,"conditions":16414,"interventions":16415},[88],[15686],[15626,15688],{"nctId":7796,"briefTitle":7797,"status":104,"phases":16417,"primaryCompletion":7799,"completion":7799,"start":7800,"enrollment":1877,"conditions":16418,"interventions":16419},[88],[7802,15,792,7803],[7805,6972,7806],{"trials":16421,"activeCount":98},[],{"trials":16423,"activeCount":98},[],{"trials":16425,"activeCount":98},[],{"intervention":15215,"totalTrials":4328,"cells":16427},{"EARLY_PHASE1":16428,"PHASE1":16430,"PHASE2":16444,"PHASE3":16450,"PHASE4":16452,"NA":16454},{"trials":16429,"activeCount":98},[],{"trials":16431,"activeCount":98},[16432,16436,16440],{"nctId":15500,"briefTitle":15501,"status":104,"phases":16433,"primaryCompletion":3678,"completion":3678,"start":6170,"enrollment":1385,"conditions":16434,"interventions":16435},[87],[15504],[15215,15199],{"nctId":15507,"briefTitle":15508,"status":104,"phases":16437,"primaryCompletion":6184,"completion":6184,"start":15510,"enrollment":3986,"conditions":16438,"interventions":16439},[87],[11063],[10529,15199,15215],{"nctId":15208,"briefTitle":15209,"status":104,"phases":16441,"primaryCompletion":15211,"completion":15211,"start":15212,"enrollment":6961,"conditions":16442,"interventions":16443},[87],[27],[12452,15215,15199],{"trials":16445,"activeCount":98},[16446],{"nctId":15275,"briefTitle":15276,"status":104,"phases":16447,"primaryCompletion":1151,"completion":1151,"start":15278,"enrollment":15279,"conditions":16448,"interventions":16449},[88],[15281,15282],[12452,15215,15199],{"trials":16451,"activeCount":98},[],{"trials":16453,"activeCount":98},[],{"trials":16455,"activeCount":98},[],{"intervention":8449,"totalTrials":4328,"cells":16457},{"EARLY_PHASE1":16458,"PHASE1":16460,"PHASE2":16473,"PHASE3":16492,"PHASE4":16494,"NA":16496},{"trials":16459,"activeCount":98},[],{"trials":16461,"activeCount":98},[16462,16466],{"nctId":8441,"briefTitle":8442,"status":104,"phases":16463,"primaryCompletion":8444,"completion":8444,"start":8445,"enrollment":736,"conditions":16464,"interventions":16465},[87],[8447],[8449,8450,696],{"nctId":16467,"briefTitle":16468,"status":104,"phases":16469,"primaryCompletion":16470,"completion":16470,"start":2169,"enrollment":3562,"conditions":16471,"interventions":16472},"NCT04225936","A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment",[87],"2021-06-01",[5603],[8449],{"trials":16474,"activeCount":98},[16475,16483],{"nctId":16476,"briefTitle":16477,"status":104,"phases":16478,"primaryCompletion":16479,"completion":16480,"start":15403,"enrollment":451,"conditions":16481,"interventions":16482},"NCT03420768","A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C",[88],"2018-12-10","2019-05-28",[15405,15406],[8449],{"nctId":16484,"briefTitle":16485,"status":963,"phases":16486,"primaryCompletion":16487,"completion":16488,"start":1447,"enrollment":15837,"conditions":16489,"interventions":16491},"NCT04267393","Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)",[88],"2023-08-16","2024-02-09",[16490],"Nonalcoholic Steatohepatitis (NASH)",[8449],{"trials":16493,"activeCount":98},[],{"trials":16495,"activeCount":98},[],{"trials":16497,"activeCount":98},[],{"intervention":1676,"totalTrials":4328,"cells":16499},{"EARLY_PHASE1":16500,"PHASE1":16502,"PHASE2":16512,"PHASE3":16532,"PHASE4":16534,"NA":16536},{"trials":16501,"activeCount":98},[],{"trials":16503,"activeCount":98},[16504],{"nctId":16505,"briefTitle":16506,"status":104,"phases":16507,"primaryCompletion":3904,"completion":3904,"start":3617,"enrollment":22,"conditions":16508,"interventions":16510},"NCT01049165","Single Ascending Dose (BMS-813160) Study",[87],[16509],"Accelerated Intimal Hyperplasia",[1676,1676,1676,1676,1676,1676,16511,1676,1676],"[14C] BMS-813160",{"trials":16513,"activeCount":98},[16514,16524,16528],{"nctId":16515,"briefTitle":16516,"status":963,"phases":16517,"primaryCompletion":16518,"completion":16518,"start":16519,"enrollment":16520,"conditions":16521,"interventions":16523},"NCT01752985","Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease",[88],"2015-06-30","2013-03-18",319,[16522],"Diabetic Kidney Disease",[1676],{"nctId":1666,"briefTitle":1667,"status":104,"phases":16525,"primaryCompletion":1669,"completion":60,"start":1670,"enrollment":1671,"conditions":16526,"interventions":16527},[87,88],[1673,1674],[1676,43,1225,1267,1677,617,1678],{"nctId":2276,"briefTitle":2277,"status":104,"phases":16529,"primaryCompletion":2279,"completion":2279,"start":870,"enrollment":2280,"conditions":16530,"interventions":16531},[88],[1154],[43,608,52,1337,1676],{"trials":16533,"activeCount":98},[],{"trials":16535,"activeCount":98},[],{"trials":16537,"activeCount":98},[],{"intervention":16539,"totalTrials":4328,"cells":16540},"MYK-224",{"EARLY_PHASE1":16541,"PHASE1":16543,"PHASE2":16568,"PHASE3":16577,"PHASE4":16579,"NA":16581},{"trials":16542,"activeCount":98},[],{"trials":16544,"activeCount":98},[16545,16552,16560],{"nctId":16546,"briefTitle":16547,"status":104,"phases":16548,"primaryCompletion":16549,"completion":16549,"start":2941,"enrollment":1750,"conditions":16550,"interventions":16551},"NCT05686096","A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435",[87],"2023-04-08",[27],[16539],{"nctId":16553,"briefTitle":16554,"status":104,"phases":16555,"primaryCompletion":16556,"completion":388,"start":16557,"enrollment":347,"conditions":16558,"interventions":16559},"NCT05405543","A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese Participants",[87],"2022-11-16","2022-07-12",[27],[16539],{"nctId":16561,"briefTitle":16562,"status":104,"phases":16563,"primaryCompletion":15545,"completion":16564,"start":1533,"enrollment":125,"conditions":16565,"interventions":16566},"NCT05304533","A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants",[87],"2022-11-29",[18],[16539,5584,16567],"Verapamil",{"trials":16569,"activeCount":98},[16570],{"nctId":16571,"briefTitle":16572,"status":963,"phases":16573,"primaryCompletion":16574,"completion":1283,"start":1117,"enrollment":693,"conditions":16575,"interventions":16576},"NCT05556343","A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy",[88],"2024-08-19",[174],[16539],{"trials":16578,"activeCount":98},[],{"trials":16580,"activeCount":98},[],{"trials":16582,"activeCount":98},[],{"intervention":1890,"totalTrials":4328,"cells":16584},{"EARLY_PHASE1":16585,"PHASE1":16587,"PHASE2":16597,"PHASE3":16607,"PHASE4":16609,"NA":16611},{"trials":16586,"activeCount":98},[],{"trials":16588,"activeCount":98},[16589,16593],{"nctId":3591,"briefTitle":3592,"status":104,"phases":16590,"primaryCompletion":3594,"completion":3595,"start":3596,"enrollment":1221,"conditions":16591,"interventions":16592},[87],[1888],[1890,1268,1929,3599,1157],{"nctId":4565,"briefTitle":4566,"status":104,"phases":16594,"primaryCompletion":4568,"completion":4568,"start":2326,"enrollment":1750,"conditions":16595,"interventions":16596},[87],[1888],[1890,1268,1929],{"trials":16598,"activeCount":98},[16599,16603],{"nctId":1881,"briefTitle":1882,"status":104,"phases":16600,"primaryCompletion":1884,"completion":1885,"start":1886,"enrollment":413,"conditions":16601,"interventions":16602},[87,88],[1888],[1890,43],{"nctId":1921,"briefTitle":1922,"status":104,"phases":16604,"primaryCompletion":1924,"completion":1925,"start":1447,"enrollment":703,"conditions":16605,"interventions":16606},[88],[1927],[1890,1157,1929,43],{"trials":16608,"activeCount":98},[],{"trials":16610,"activeCount":98},[],{"trials":16612,"activeCount":98},[],{"intervention":4985,"totalTrials":574,"cells":16614},{"EARLY_PHASE1":16615,"PHASE1":16617,"PHASE2":16623,"PHASE3":16637,"PHASE4":16639,"NA":16641},{"trials":16616,"activeCount":98},[],{"trials":16618,"activeCount":98},[16619],{"nctId":4977,"briefTitle":4978,"status":104,"phases":16620,"primaryCompletion":4980,"completion":4980,"start":4981,"enrollment":4982,"conditions":16621,"interventions":16622},[87],[1154],[611,2053,4985,1328,1158,4986],{"trials":16624,"activeCount":98},[16625,16633],{"nctId":16626,"briefTitle":16627,"status":104,"phases":16628,"primaryCompletion":16629,"completion":16629,"start":13036,"conditions":16630,"interventions":16631},"NCT00017043","BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy",[88],"2003-01",[3104,1436],[16632],"ixabepilone",{"nctId":5011,"briefTitle":5012,"status":104,"phases":16634,"primaryCompletion":5014,"completion":5014,"start":4179,"enrollment":5015,"conditions":16635,"interventions":16636},[88],[1223],[4985,1158,1773,2053],{"trials":16638,"activeCount":98},[],{"trials":16640,"activeCount":98},[],{"trials":16642,"activeCount":98},[],{"intervention":16644,"totalTrials":574,"cells":16645},"BMS-582949",{"EARLY_PHASE1":16646,"PHASE1":16648,"PHASE2":16650,"PHASE3":16674,"PHASE4":16676,"NA":16678},{"trials":16647,"activeCount":98},[],{"trials":16649,"activeCount":98},[],{"trials":16651,"activeCount":98},[16652,16658,16665],{"nctId":16653,"briefTitle":16654,"status":104,"phases":16655,"primaryCompletion":7713,"completion":3572,"start":10821,"enrollment":3874,"conditions":16656,"interventions":16657},"NCT00399906","A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis",[88],[749],[16644],{"nctId":16659,"briefTitle":16660,"status":104,"phases":16661,"primaryCompletion":3873,"completion":4038,"start":5023,"enrollment":2028,"conditions":16662,"interventions":16664},"NCT00605735","PoC in Rheumatoid Arthritis With Methotrexate",[88],[16663],"Rheumatoid Arthritis, NOS",[16644],{"nctId":16666,"briefTitle":16667,"status":104,"phases":16668,"primaryCompletion":3904,"completion":6918,"start":6953,"enrollment":534,"conditions":16669,"interventions":16671},"NCT00570752","Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis",[88],[16670],"Vascular Diseases",[16644,16672,16673],"Atorvastatin","Statin",{"trials":16675,"activeCount":98},[],{"trials":16677,"activeCount":98},[],{"trials":16679,"activeCount":98},[],{"intervention":15799,"totalTrials":574,"cells":16681},{"EARLY_PHASE1":16682,"PHASE1":16684,"PHASE2":16686,"PHASE3":16703,"PHASE4":16705,"NA":16707},{"trials":16683,"activeCount":98},[],{"trials":16685,"activeCount":98},[],{"trials":16687,"activeCount":98},[16688,16695,16699],{"nctId":16689,"briefTitle":16690,"status":104,"phases":16691,"primaryCompletion":3017,"completion":3017,"start":7715,"enrollment":3862,"conditions":16692,"interventions":16694},"NCT00696072","Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic",[88],[16693],"Metastatic Breast Cancer",[1197,15799],{"nctId":15600,"briefTitle":15601,"status":963,"phases":16696,"primaryCompletion":15603,"completion":15603,"start":15604,"enrollment":1152,"conditions":16697,"interventions":16698},[88],[1223],[3576,15607],{"nctId":15793,"briefTitle":15794,"status":104,"phases":16700,"primaryCompletion":6918,"completion":6918,"start":11762,"enrollment":4328,"conditions":16701,"interventions":16702},[88],[1223],[15751,15798,15799],{"trials":16704,"activeCount":98},[],{"trials":16706,"activeCount":98},[],{"trials":16708,"activeCount":98},[],{"intervention":16710,"totalTrials":574,"cells":16711},"BMS-919373",{"EARLY_PHASE1":16712,"PHASE1":16714,"PHASE2":16731,"PHASE3":16740,"PHASE4":16742,"NA":16744},{"trials":16713,"activeCount":98},[],{"trials":16715,"activeCount":98},[16716,16722],{"nctId":16717,"briefTitle":16718,"status":104,"phases":16719,"primaryCompletion":4159,"completion":4159,"start":12170,"enrollment":2527,"conditions":16720,"interventions":16721},"NCT02089061","Drug Interaction Statin",[87],[11012],[16710,874,16672],{"nctId":16723,"briefTitle":16724,"status":963,"phases":16725,"primaryCompletion":16726,"completion":16726,"start":16727,"enrollment":1750,"conditions":16728,"interventions":16729},"NCT02153437","Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers",[87],"2016-10-20","2014-10-30",[10858],[16710,16730],"Sotalol",{"trials":16732,"activeCount":98},[16733],{"nctId":16734,"briefTitle":16735,"status":963,"phases":16736,"primaryCompletion":11094,"completion":11094,"start":4262,"enrollment":11,"conditions":16737,"interventions":16739},"NCT02156076","A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation",[88],[16738],"Paroxysmal Atrial Fibrillation",[16710],{"trials":16741,"activeCount":98},[],{"trials":16743,"activeCount":98},[],{"trials":16745,"activeCount":98},[],{"intervention":2053,"totalTrials":574,"cells":16747},{"EARLY_PHASE1":16748,"PHASE1":16750,"PHASE2":16756,"PHASE3":16766,"PHASE4":16768,"NA":16770},{"trials":16749,"activeCount":98},[],{"trials":16751,"activeCount":98},[16752],{"nctId":4977,"briefTitle":4978,"status":104,"phases":16753,"primaryCompletion":4980,"completion":4980,"start":4981,"enrollment":4982,"conditions":16754,"interventions":16755},[87],[1154],[611,2053,4985,1328,1158,4986],{"trials":16757,"activeCount":98},[16758,16762],{"nctId":5011,"briefTitle":5012,"status":104,"phases":16759,"primaryCompletion":5014,"completion":5014,"start":4179,"enrollment":5015,"conditions":16760,"interventions":16761},[88],[1223],[4985,1158,1773,2053],{"nctId":2044,"briefTitle":2045,"status":104,"phases":16763,"primaryCompletion":2047,"completion":1843,"start":2048,"enrollment":2049,"conditions":16764,"interventions":16765},[88],[2051],[43,2053,2054,2055],{"trials":16767,"activeCount":98},[],{"trials":16769,"activeCount":98},[],{"trials":16771,"activeCount":98},[],{"intervention":16242,"totalTrials":574,"cells":16773},{"EARLY_PHASE1":16774,"PHASE1":16776,"PHASE2":16785,"PHASE3":16800,"PHASE4":16802,"NA":16804},{"trials":16775,"activeCount":98},[],{"trials":16777,"activeCount":98},[16778],{"nctId":16779,"briefTitle":16780,"status":963,"phases":16781,"primaryCompletion":4519,"completion":4519,"start":16782,"enrollment":520,"conditions":16783,"interventions":16784},"NCT03058822","Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial",[87],"2017-01-25",[759],[16242],{"trials":16786,"activeCount":98},[16787,16791],{"nctId":16235,"briefTitle":16236,"status":963,"phases":16788,"primaryCompletion":16238,"completion":16238,"start":16239,"enrollment":125,"conditions":16789,"interventions":16790},[88],[3276],[16242,6905],{"nctId":16792,"briefTitle":16793,"status":104,"phases":16794,"primaryCompletion":16795,"completion":2666,"start":16796,"enrollment":16797,"conditions":16798,"interventions":16799},"NCT02265744","Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus",[88],"2017-10-26","2014-11-13",730,[738],[16242],{"trials":16801,"activeCount":98},[],{"trials":16803,"activeCount":98},[],{"trials":16805,"activeCount":98},[],{"intervention":16807,"totalTrials":574,"cells":16808},"Oral Taxane",{"EARLY_PHASE1":16809,"PHASE1":16811,"PHASE2":16825,"PHASE3":16833,"PHASE4":16835,"NA":16837},{"trials":16810,"activeCount":98},[],{"trials":16812,"activeCount":98},[16813,16819],{"nctId":16814,"briefTitle":16815,"status":963,"phases":16816,"primaryCompletion":6968,"start":7846,"enrollment":347,"conditions":16817,"interventions":16818},"NCT00332748","A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer",[87],[606],[16807],{"nctId":16820,"briefTitle":16821,"status":963,"phases":16822,"primaryCompletion":3920,"start":4011,"enrollment":830,"conditions":16823,"interventions":16824},"NCT00326131","A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer",[87],[606],[16807],{"trials":16826,"activeCount":98},[16827],{"nctId":16828,"briefTitle":16829,"status":104,"phases":16830,"primaryCompletion":4665,"conditions":16831,"interventions":16832},"NCT00103831","Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer",[87,88],[1265],[16807],{"trials":16834,"activeCount":98},[],{"trials":16836,"activeCount":98},[],{"trials":16838,"activeCount":98},[],{"intervention":2122,"totalTrials":574,"cells":16840},{"EARLY_PHASE1":16841,"PHASE1":16843,"PHASE2":16845,"PHASE3":16864,"PHASE4":16866,"NA":16868},{"trials":16842,"activeCount":98},[],{"trials":16844,"activeCount":98},[],{"trials":16846,"activeCount":98},[16847,16856,16860],{"nctId":16848,"briefTitle":16849,"status":104,"phases":16850,"primaryCompletion":16851,"completion":16852,"start":16853,"enrollment":1203,"conditions":16854,"interventions":16855},"NCT05134948","A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors",[87,88],"2025-09-01","2025-10-24","2021-11-30",[1132],[2122],{"nctId":2113,"briefTitle":2114,"status":104,"phases":16857,"primaryCompletion":2116,"completion":2117,"start":2118,"enrollment":2119,"conditions":16858,"interventions":16859},[87,88],[1345],[52,43,2122],{"nctId":2195,"briefTitle":2196,"status":104,"phases":16861,"primaryCompletion":2198,"completion":1129,"start":2199,"enrollment":2200,"conditions":16862,"interventions":16863},[88],[1436,1437,2202],[2122,43,2204,2205,2206],{"trials":16865,"activeCount":98},[],{"trials":16867,"activeCount":98},[],{"trials":16869,"activeCount":98},[],{"intervention":16871,"totalTrials":574,"cells":16872},"BMS-986259",{"EARLY_PHASE1":16873,"PHASE1":16875,"PHASE2":16893,"PHASE3":16903,"PHASE4":16905,"NA":16907},{"trials":16874,"activeCount":98},[],{"trials":16876,"activeCount":98},[16877,16885],{"nctId":16878,"briefTitle":16879,"status":104,"phases":16880,"primaryCompletion":16881,"completion":16881,"start":16882,"enrollment":10484,"conditions":16883,"interventions":16884},"NCT04008992","An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants",[87],"2021-01-04","2019-06-18",[18],[16871],{"nctId":16886,"briefTitle":16887,"status":104,"phases":16888,"primaryCompletion":16889,"completion":16889,"start":16890,"enrollment":148,"conditions":16891,"interventions":16892},"NCT04237831","A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function",[87],"2021-07-16","2020-02-26",[16090],[16871],{"trials":16894,"activeCount":98},[16895],{"nctId":16896,"briefTitle":16897,"status":104,"phases":16898,"primaryCompletion":2930,"completion":2930,"start":16899,"enrollment":94,"conditions":16900,"interventions":16902},"NCT04318093","Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure",[88],"2020-11-06",[16901],"Acute Decompensated Heart Failure",[16871],{"trials":16904,"activeCount":98},[],{"trials":16906,"activeCount":98},[],{"trials":16908,"activeCount":98},[],{"intervention":16910,"totalTrials":574,"cells":16911},"MDX-1100",{"EARLY_PHASE1":16912,"PHASE1":16914,"PHASE2":16922,"PHASE3":16938,"PHASE4":16940,"NA":16942},{"trials":16913,"activeCount":98},[],{"trials":16915,"activeCount":98},[16916],{"nctId":16917,"briefTitle":16918,"status":104,"phases":16919,"primaryCompletion":4930,"completion":4930,"start":4995,"enrollment":1203,"conditions":16920,"interventions":16921},"NCT00295282","A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis",[87],[990],[16910],{"trials":16923,"activeCount":98},[16924,16930],{"nctId":16925,"briefTitle":16926,"status":104,"phases":16927,"primaryCompletion":7713,"completion":4459,"start":3680,"enrollment":22,"conditions":16928,"interventions":16929},"NCT01017367","Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)",[88],[15],[16910],{"nctId":16931,"briefTitle":16932,"status":104,"phases":16933,"primaryCompletion":4038,"completion":4038,"start":7811,"enrollment":16934,"conditions":16935,"interventions":16936},"NCT00656890","A Study of MDX-1100 in Subjects With Active Ulcerative Colitis",[88],110,[990],[16937,16910],"sterile saline for",{"trials":16939,"activeCount":98},[],{"trials":16941,"activeCount":98},[],{"trials":16943,"activeCount":98},[],{"intervention":3610,"totalTrials":574,"cells":16945},{"EARLY_PHASE1":16946,"PHASE1":16948,"PHASE2":16954,"PHASE3":16964,"PHASE4":16966,"NA":16968},{"trials":16947,"activeCount":98},[],{"trials":16949,"activeCount":98},[16950],{"nctId":3601,"briefTitle":3602,"status":104,"phases":16951,"primaryCompletion":3604,"completion":3605,"start":3606,"enrollment":3607,"conditions":16952,"interventions":16953},[87],[606],[1158,3610,1157,617,1678,1158,3611],{"trials":16955,"activeCount":98},[16956,16960],{"nctId":1666,"briefTitle":1667,"status":104,"phases":16957,"primaryCompletion":1669,"completion":60,"start":1670,"enrollment":1671,"conditions":16958,"interventions":16959},[87,88],[1673,1674],[1676,43,1225,1267,1677,617,1678],{"nctId":5538,"briefTitle":5539,"status":104,"phases":16961,"primaryCompletion":5541,"completion":5542,"start":3678,"enrollment":5543,"conditions":16962,"interventions":16963},[88],[4875],[1678,3610,3610,5546,3716,612,5547],{"trials":16965,"activeCount":98},[],{"trials":16967,"activeCount":98},[],{"trials":16969,"activeCount":98},[],{"intervention":16971,"totalTrials":574,"cells":16972},"BMS-275183",{"EARLY_PHASE1":16973,"PHASE1":16975,"PHASE2":16983,"PHASE3":16998,"PHASE4":17000,"NA":17002},{"trials":16974,"activeCount":98},[],{"trials":16976,"activeCount":98},[16977],{"nctId":16978,"briefTitle":16979,"status":963,"phases":16980,"primaryCompletion":7750,"start":12468,"enrollment":582,"conditions":16981,"interventions":16982},"NCT00207025","A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies",[87],[1865],[16971],{"trials":16984,"activeCount":98},[16985,16992],{"nctId":16986,"briefTitle":16987,"status":963,"phases":16988,"primaryCompletion":3920,"start":10856,"enrollment":16989,"conditions":16990,"interventions":16991},"NCT00359450","Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)",[88],186,[1265],[16971],{"nctId":16993,"briefTitle":16994,"status":963,"phases":16995,"primaryCompletion":12220,"conditions":16996,"interventions":16997},"NCT00099879","Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer",[88],[1265],[16971],{"trials":16999,"activeCount":98},[],{"trials":17001,"activeCount":98},[],{"trials":17003,"activeCount":98},[],{"intervention":17005,"totalTrials":574,"cells":17006},"BMS-663513",{"EARLY_PHASE1":17007,"PHASE1":17009,"PHASE2":17023,"PHASE3":17031,"PHASE4":17033,"NA":17035},{"trials":17008,"activeCount":98},[],{"trials":17010,"activeCount":98},[17011,17017],{"nctId":17012,"briefTitle":17013,"status":963,"phases":17014,"primaryCompletion":3572,"completion":3572,"start":4930,"enrollment":1063,"conditions":17015,"interventions":17016},"NCT00461110","A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)",[87],[2622],[17005],{"nctId":17018,"briefTitle":17019,"status":963,"phases":17020,"primaryCompletion":4981,"completion":4981,"start":11728,"enrollment":125,"conditions":17021,"interventions":17022},"NCT00351325","A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies",[87],[4874],[17005],{"trials":17024,"activeCount":98},[17025],{"nctId":17026,"briefTitle":17027,"status":963,"phases":17028,"primaryCompletion":6953,"completion":4038,"start":5098,"enrollment":281,"conditions":17029,"interventions":17030},"NCT00309023","Study of BMS-663513 in Patients With Advanced Cancer",[87,88],[1865],[17005],{"trials":17032,"activeCount":98},[],{"trials":17034,"activeCount":98},[],{"trials":17036,"activeCount":98},[],{"intervention":1269,"totalTrials":574,"cells":17038},{"EARLY_PHASE1":17039,"PHASE1":17041,"PHASE2":17047,"PHASE3":17057,"PHASE4":17059,"NA":17061},{"trials":17040,"activeCount":98},[],{"trials":17042,"activeCount":98},[17043],{"nctId":1257,"briefTitle":1258,"status":104,"phases":17044,"primaryCompletion":1260,"completion":1261,"start":1262,"enrollment":1263,"conditions":17045,"interventions":17046},[87],[1265],[43,1267,1268,622,1158,1157,612,1269,608],{"trials":17048,"activeCount":98},[17049,17053],{"nctId":15787,"briefTitle":15788,"status":104,"phases":17050,"primaryCompletion":11998,"completion":1343,"start":4981,"enrollment":3607,"conditions":17051,"interventions":17052},[88],[2622],[15751,1269],{"nctId":2227,"briefTitle":2228,"status":104,"phases":17054,"primaryCompletion":2230,"completion":2230,"start":2231,"enrollment":2232,"conditions":17055,"interventions":17056},[87,88],[36],[43,612,622,2235,1158,1328,1267,1269,2236,1157],{"trials":17058,"activeCount":98},[],{"trials":17060,"activeCount":98},[],{"trials":17062,"activeCount":98},[],{"intervention":1245,"totalTrials":574,"cells":17064},{"EARLY_PHASE1":17065,"PHASE1":17067,"PHASE2":17077,"PHASE3":17083,"PHASE4":17085,"NA":17087},{"trials":17066,"activeCount":98},[],{"trials":17068,"activeCount":98},[17069,17073],{"nctId":1237,"briefTitle":1238,"status":104,"phases":17070,"primaryCompletion":1240,"completion":1241,"start":1242,"enrollment":319,"conditions":17071,"interventions":17072},[87],[1154],[43,52,1245,608,1246],{"nctId":1302,"briefTitle":1303,"status":104,"phases":17074,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1307,"conditions":17075,"interventions":17076},[87],[1309],[1245,43],{"trials":17078,"activeCount":98},[17079],{"nctId":2257,"briefTitle":2258,"status":104,"phases":17080,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":2262,"conditions":17081,"interventions":17082},[88],[2264],[1245,1225,2266,43,618,1267,619,617,2267],{"trials":17084,"activeCount":98},[],{"trials":17086,"activeCount":98},[],{"trials":17088,"activeCount":98},[],{"intervention":12567,"totalTrials":574,"cells":17090},{"EARLY_PHASE1":17091,"PHASE1":17093,"PHASE2":17108,"PHASE3":17114,"PHASE4":17116,"NA":17118},{"trials":17092,"activeCount":98},[],{"trials":17094,"activeCount":98},[17095,17101],{"nctId":17096,"briefTitle":17097,"status":104,"phases":17098,"primaryCompletion":11998,"completion":7706,"start":7944,"enrollment":3986,"conditions":17099,"interventions":17100},"NCT01159808","A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy Subjects",[87],[759],[12567],{"nctId":17102,"briefTitle":17103,"status":104,"phases":17104,"primaryCompletion":11034,"completion":7089,"start":7706,"enrollment":22,"conditions":17105,"interventions":17107},"NCT01250366","Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects",[87],[17106],"HCV (Genotype 1)",[12567,12567,12567,12567,12567,12567,12567,11917],{"trials":17109,"activeCount":98},[17110],{"nctId":12562,"briefTitle":12563,"status":963,"phases":17111,"primaryCompletion":3711,"completion":3711,"start":6225,"enrollment":4255,"conditions":17112,"interventions":17113},[88],[30],[12567,12567,12567,12542,11917,12567,10402],{"trials":17115,"activeCount":98},[],{"trials":17117,"activeCount":98},[],{"trials":17119,"activeCount":98},[],{"intervention":17121,"totalTrials":230,"cells":17122},"BMS-824393",{"EARLY_PHASE1":17123,"PHASE1":17125,"PHASE2":17133,"PHASE3":17143,"PHASE4":17145,"NA":17147},{"trials":17124,"activeCount":98},[],{"trials":17126,"activeCount":98},[17127],{"nctId":17128,"briefTitle":17129,"status":104,"phases":17130,"primaryCompletion":11998,"completion":11998,"start":3678,"enrollment":680,"conditions":17131,"interventions":17132},"NCT00971308","Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus",[87],[11923],[17121,17121,17121,17121,17121],{"trials":17134,"activeCount":98},[17135],{"nctId":17136,"briefTitle":17137,"status":467,"phases":17138,"primaryCompletion":6918,"completion":6918,"start":4348,"enrollment":98,"conditions":17139,"interventions":17141},"NCT01142700","A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I",[88],[17140],"Chronic Hepatitis C Virus Genotype 1",[17121,17121,17121,17142,11917],"Peginterferon Alpha-2a",{"trials":17144,"activeCount":98},[],{"trials":17146,"activeCount":98},[],{"trials":17148,"activeCount":98},[],{"intervention":17150,"totalTrials":230,"cells":17151},"BMS-954561",{"EARLY_PHASE1":17152,"PHASE1":17154,"PHASE2":17156,"PHASE3":17174,"PHASE4":17176,"NA":17178},{"trials":17153,"activeCount":98},[],{"trials":17155,"activeCount":98},[],{"trials":17157,"activeCount":98},[17158,17165],{"nctId":17159,"briefTitle":17160,"status":104,"phases":17161,"primaryCompletion":6437,"completion":1343,"start":11034,"enrollment":660,"conditions":17162,"interventions":17164},"NCT01305538","Crossover Post-herpetic Neuralgia (PHN)",[88],[17163],"Post-Herpetic Neuralgia (PHN)",[17150,17150],{"nctId":17166,"briefTitle":17167,"status":104,"phases":17168,"primaryCompletion":6169,"completion":3902,"start":11034,"enrollment":17169,"conditions":17170,"interventions":17172},"NCT01314222","Diabetic Peripheral Neuropathic Pain (DPNP)",[88],178,[17171],"Diabetic Peripheral Neuropathic Pain",[17150,17173],"Pregabalin",{"trials":17175,"activeCount":98},[],{"trials":17177,"activeCount":98},[],{"trials":17179,"activeCount":98},[],{"intervention":17181,"totalTrials":230,"cells":17182},"Epofolate",{"EARLY_PHASE1":17183,"PHASE1":17185,"PHASE2":17187,"PHASE3":17201,"PHASE4":17203,"NA":17205},{"trials":17184,"activeCount":98},[],{"trials":17186,"activeCount":98},[],{"trials":17188,"activeCount":98},[17189,17195],{"nctId":17190,"briefTitle":17191,"status":963,"phases":17192,"primaryCompletion":7088,"completion":7088,"start":4930,"enrollment":2527,"conditions":17193,"interventions":17194},"NCT00546247","A Phase 1\u002F2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)",[87,88],[1132],[17181],{"nctId":17196,"briefTitle":17197,"status":963,"phases":17198,"primaryCompletion":7088,"completion":7088,"start":6968,"enrollment":4579,"conditions":17199,"interventions":17200},"NCT00550017","A Phase 1\u002F2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)",[87,88],[1132],[17181],{"trials":17202,"activeCount":98},[],{"trials":17204,"activeCount":98},[],{"trials":17206,"activeCount":98},[],{"intervention":17208,"totalTrials":230,"cells":17209},"BMS-914392",{"EARLY_PHASE1":17210,"PHASE1":17212,"PHASE2":17220,"PHASE3":17228,"PHASE4":17230,"NA":17232},{"trials":17211,"activeCount":98},[],{"trials":17213,"activeCount":98},[17214],{"nctId":17215,"briefTitle":17216,"status":104,"phases":17217,"primaryCompletion":3904,"completion":3904,"start":3631,"enrollment":693,"conditions":17218,"interventions":17219},"NCT01211821","Effect of BMS-914392 on Pharmacokinetics of Metoprolol",[87],[10858],[10560,17208],{"trials":17221,"activeCount":98},[17222],{"nctId":17223,"briefTitle":17224,"status":104,"phases":17225,"primaryCompletion":1343,"completion":1343,"start":7776,"enrollment":319,"conditions":17226,"interventions":17227},"NCT01356914","Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation Burden",[88],[10858],[17208,17208,17208],{"trials":17229,"activeCount":98},[],{"trials":17231,"activeCount":98},[],{"trials":17233,"activeCount":98},[],{"intervention":16672,"totalTrials":230,"cells":17235},{"EARLY_PHASE1":17236,"PHASE1":17238,"PHASE2":17244,"PHASE3":17250,"PHASE4":17252,"NA":17254},{"trials":17237,"activeCount":98},[],{"trials":17239,"activeCount":98},[17240],{"nctId":16717,"briefTitle":16718,"status":104,"phases":17241,"primaryCompletion":4159,"completion":4159,"start":12170,"enrollment":2527,"conditions":17242,"interventions":17243},[87],[11012],[16710,874,16672],{"trials":17245,"activeCount":98},[17246],{"nctId":16666,"briefTitle":16667,"status":104,"phases":17247,"primaryCompletion":3904,"completion":6918,"start":6953,"enrollment":534,"conditions":17248,"interventions":17249},[88],[16670],[16644,16672,16673],{"trials":17251,"activeCount":98},[],{"trials":17253,"activeCount":98},[],{"trials":17255,"activeCount":98},[],{"intervention":1442,"totalTrials":230,"cells":17257},{"EARLY_PHASE1":17258,"PHASE1":17260,"PHASE2":17262,"PHASE3":17272,"PHASE4":17274,"NA":17276},{"trials":17259,"activeCount":98},[],{"trials":17261,"activeCount":98},[],{"trials":17263,"activeCount":98},[17264,17268],{"nctId":1429,"briefTitle":1430,"status":467,"phases":17265,"primaryCompletion":1432,"completion":1433,"start":1434,"enrollment":98,"conditions":17266,"interventions":17267},[88],[1436,1437,1438,1439],[1441,43,1158,1442],{"nctId":2057,"briefTitle":2058,"status":467,"phases":17269,"primaryCompletion":2060,"completion":2061,"start":2062,"enrollment":98,"conditions":17270,"interventions":17271},[87,88],[2064],[1123,1122,2066,1981,2067,2068],{"trials":17273,"activeCount":98},[],{"trials":17275,"activeCount":98},[],{"trials":17277,"activeCount":98},[],{"intervention":1474,"totalTrials":230,"cells":17279},{"EARLY_PHASE1":17280,"PHASE1":17282,"PHASE2":17284,"PHASE3":17294,"PHASE4":17296,"NA":17298},{"trials":17281,"activeCount":98},[],{"trials":17283,"activeCount":98},[],{"trials":17285,"activeCount":98},[17286,17290],{"nctId":1464,"briefTitle":1465,"status":104,"phases":17287,"primaryCompletion":1467,"completion":1468,"start":1469,"enrollment":1470,"conditions":17288,"interventions":17289},[87,88],[1472],[43,608,1474],{"nctId":2079,"briefTitle":2080,"status":104,"phases":17291,"primaryCompletion":2082,"completion":2082,"start":2083,"enrollment":2084,"conditions":17292,"interventions":17293},[88],[2086,2087,2088,2089],[608,43,1474,615,2091],{"trials":17295,"activeCount":98},[],{"trials":17297,"activeCount":98},[],{"trials":17299,"activeCount":98},[],{"intervention":3897,"totalTrials":230,"cells":17301},{"EARLY_PHASE1":17302,"PHASE1":17304,"PHASE2":17310,"PHASE3":17316,"PHASE4":17318,"NA":17320},{"trials":17303,"activeCount":98},[],{"trials":17305,"activeCount":98},[17306],{"nctId":3890,"briefTitle":3891,"status":104,"phases":17307,"primaryCompletion":3893,"completion":3893,"start":3894,"enrollment":839,"conditions":17308,"interventions":17309},[87],[21],[3897,3897,608,608],{"trials":17311,"activeCount":98},[17312],{"nctId":5847,"briefTitle":5848,"status":104,"phases":17313,"primaryCompletion":5850,"completion":5850,"start":4348,"enrollment":5543,"conditions":17314,"interventions":17315},[87,88],[1673],[3897,3897,1145],{"trials":17317,"activeCount":98},[],{"trials":17319,"activeCount":98},[],{"trials":17321,"activeCount":98},[],{"intervention":17323,"totalTrials":230,"cells":17324},"Cdc7-inhibitor",{"EARLY_PHASE1":17325,"PHASE1":17327,"PHASE2":17329,"PHASE3":17346,"PHASE4":17348,"NA":17350},{"trials":17326,"activeCount":98},[],{"trials":17328,"activeCount":98},[],{"trials":17330,"activeCount":98},[17331,17339],{"nctId":17332,"briefTitle":17333,"status":963,"phases":17334,"primaryCompletion":17335,"completion":17335,"start":17336,"enrollment":360,"conditions":17337,"interventions":17338},"NCT00886782","A Study of BMS-863233 in Patients With Advanced and\u002For Metastatic Solid Tumors",[87,88],"2010-08-04","2009-05-31",[1375,9803],[17323],{"nctId":17340,"briefTitle":17341,"status":963,"phases":17342,"primaryCompletion":10431,"completion":10431,"start":4981,"enrollment":360,"conditions":17343,"interventions":17345},"NCT00838890","A Study of BMS-863233 in Patients With Hematologic Cancer",[87,88],[17344],"Refractory Hematologic Cancer",[17323,17323],{"trials":17347,"activeCount":98},[],{"trials":17349,"activeCount":98},[],{"trials":17351,"activeCount":98},[],{"intervention":17353,"totalTrials":230,"cells":17354},"Emivirine",{"EARLY_PHASE1":17355,"PHASE1":17357,"PHASE2":17359,"PHASE3":17375,"PHASE4":17377,"NA":17379},{"trials":17356,"activeCount":98},[],{"trials":17358,"activeCount":98},[],{"trials":17360,"activeCount":98},[17361,17369],{"nctId":17362,"briefTitle":17363,"status":963,"phases":17364,"enrollment":94,"conditions":17365,"interventions":17366},"NCT00002420","The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors",[88],[24],[17353,17367,17368,13341,13342],"Hydroxyurea","Delavirdine mesylate",{"nctId":17370,"briefTitle":17371,"status":963,"phases":17372,"enrollment":94,"conditions":17373,"interventions":17374},"NCT00002418","The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors",[88],[24],[17353,17367,13099,13341,13342],{"trials":17376,"activeCount":98},[],{"trials":17378,"activeCount":98},[],{"trials":17380,"activeCount":98},[],{"intervention":15944,"totalTrials":230,"cells":17382},{"EARLY_PHASE1":17383,"PHASE1":17385,"PHASE2":17387,"PHASE3":17399,"PHASE4":17401,"NA":17403},{"trials":17384,"activeCount":98},[],{"trials":17386,"activeCount":98},[],{"trials":17388,"activeCount":98},[17389,17393],{"nctId":15938,"briefTitle":15939,"status":104,"phases":17390,"primaryCompletion":3894,"completion":3894,"start":7944,"enrollment":1686,"conditions":17391,"interventions":17392},[88],[15942],[15944,15944,15944,15944,823],{"nctId":17394,"briefTitle":17395,"status":104,"phases":17396,"primaryCompletion":11034,"completion":11034,"start":7944,"enrollment":12163,"conditions":17397,"interventions":17398},"NCT01058083","Safety Study of BMS-770767 in Subjects With Hypercholesterolemia",[88],[12214],[15944,15944,15944,15944],{"trials":17400,"activeCount":98},[],{"trials":17402,"activeCount":98},[],{"trials":17404,"activeCount":98},[],{"intervention":17406,"totalTrials":230,"cells":17407},"KOS-862",{"EARLY_PHASE1":17408,"PHASE1":17410,"PHASE2":17412,"PHASE3":17427,"PHASE4":17429,"NA":17431},{"trials":17409,"activeCount":98},[],{"trials":17411,"activeCount":98},[],{"trials":17413,"activeCount":98},[17414,17421],{"nctId":17415,"briefTitle":17416,"status":963,"phases":17417,"completion":17418,"start":3640,"enrollment":424,"conditions":17419,"interventions":17420},"NCT00080509","Effectiveness of KOS-862 in the Treatment of Lung Cancer",[88],"2004-11",[1717],[17406],{"nctId":17422,"briefTitle":17423,"status":963,"phases":17424,"completion":7812,"start":10693,"enrollment":28,"conditions":17425,"interventions":17426},"NCT00104130","Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer",[88],[1504],[17406],{"trials":17428,"activeCount":98},[],{"trials":17430,"activeCount":98},[],{"trials":17432,"activeCount":98},[],{"intervention":5092,"totalTrials":230,"cells":17434},{"EARLY_PHASE1":17435,"PHASE1":17437,"PHASE2":17439,"PHASE3":17452,"PHASE4":17454,"NA":17456},{"trials":17436,"activeCount":98},[],{"trials":17438,"activeCount":98},[],{"trials":17440,"activeCount":98},[17441,17448],{"nctId":17442,"briefTitle":17443,"status":963,"phases":17444,"primaryCompletion":17445,"completion":17445,"start":15545,"enrollment":4124,"conditions":17446,"interventions":17447},"NCT05577715","A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)",[88],"2024-08-12",[2781],[5092],{"nctId":5083,"briefTitle":5084,"status":104,"phases":17449,"primaryCompletion":5086,"completion":5087,"start":5088,"enrollment":413,"conditions":17450,"interventions":17451},[88],[5090],[5092,1158,5093,2913],{"trials":17453,"activeCount":98},[],{"trials":17455,"activeCount":98},[],{"trials":17457,"activeCount":98},[],{"intervention":17459,"totalTrials":230,"cells":17460},"BMS-936564",{"EARLY_PHASE1":17461,"PHASE1":17463,"PHASE2":17476,"PHASE3":17487,"PHASE4":17489,"NA":17491},{"trials":17462,"activeCount":98},[],{"trials":17464,"activeCount":98},[17465],{"nctId":17466,"briefTitle":17467,"status":104,"phases":17468,"primaryCompletion":7690,"completion":7690,"start":11998,"enrollment":17469,"conditions":17470,"interventions":17475},"NCT01120457","First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers",[87],96,[17471,17472,17473,17474],"Acute Myelogenous Leukemia","Diffuse Large B-Cell Leukemia","Chronic Lymphocytic Leukemia","Follicular Lymphoma",[17459],{"trials":17477,"activeCount":98},[17478],{"nctId":17479,"briefTitle":17480,"status":963,"phases":17481,"primaryCompletion":17482,"completion":17482,"start":17483,"enrollment":22,"conditions":17484,"interventions":17485},"NCT02305563","An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia",[87,88],"2019-06-04","2015-01-27",[15736],[17459,17486],"Cytarabine",{"trials":17488,"activeCount":98},[],{"trials":17490,"activeCount":98},[],{"trials":17492,"activeCount":98},[],{"intervention":17494,"totalTrials":230,"cells":17495},"MDX-060",{"EARLY_PHASE1":17496,"PHASE1":17498,"PHASE2":17500,"PHASE3":17515,"PHASE4":17517,"NA":17519},{"trials":17497,"activeCount":98},[],{"trials":17499,"activeCount":98},[],{"trials":17501,"activeCount":98},[17502,17509],{"nctId":17503,"briefTitle":17504,"status":467,"phases":17505,"start":13679,"enrollment":125,"conditions":17506,"interventions":17508},"NCT00298467","MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma",[88],[17507],"Lymphoma, Large-Cell",[17494],{"nctId":17510,"briefTitle":17511,"status":104,"phases":17512,"primaryCompletion":5873,"completion":3678,"start":3657,"enrollment":19,"conditions":17513,"interventions":17514},"NCT00284804","A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease",[88],[2760],[17494],{"trials":17516,"activeCount":98},[],{"trials":17518,"activeCount":98},[],{"trials":17520,"activeCount":98},[],{"intervention":1618,"totalTrials":230,"cells":17522},{"EARLY_PHASE1":17523,"PHASE1":17525,"PHASE2":17527,"PHASE3":17537,"PHASE4":17539,"NA":17541},{"trials":17524,"activeCount":98},[],{"trials":17526,"activeCount":98},[],{"trials":17528,"activeCount":98},[17529,17533],{"nctId":1611,"briefTitle":1612,"status":963,"phases":17530,"primaryCompletion":1614,"completion":1614,"start":191,"enrollment":208,"conditions":17531,"interventions":17532},[88],[1616],[1618,43,622,1268,1157,1158],{"nctId":2070,"briefTitle":2071,"status":104,"phases":17534,"primaryCompletion":460,"completion":460,"start":2073,"enrollment":184,"conditions":17535,"interventions":17536},[87,88],[2075],[1618,1123,2077],{"trials":17538,"activeCount":98},[],{"trials":17540,"activeCount":98},[],{"trials":17542,"activeCount":98},[],{"intervention":761,"totalTrials":230,"cells":17544},{"EARLY_PHASE1":17545,"PHASE1":17547,"PHASE2":17553,"PHASE3":17559,"PHASE4":17561,"NA":17563},{"trials":17546,"activeCount":98},[],{"trials":17548,"activeCount":98},[17549],{"nctId":752,"briefTitle":753,"status":104,"phases":17550,"primaryCompletion":755,"completion":755,"start":756,"enrollment":757,"conditions":17551,"interventions":17552},[87],[759],[679,761],{"trials":17554,"activeCount":98},[17555],{"nctId":2133,"briefTitle":2134,"status":104,"phases":17556,"primaryCompletion":460,"completion":2136,"start":2137,"enrollment":25,"conditions":17557,"interventions":17558},[87,88],[1132],[2140,43,608,2141,761],{"trials":17560,"activeCount":98},[],{"trials":17562,"activeCount":98},[],{"trials":17564,"activeCount":98},[],{"intervention":7056,"totalTrials":230,"cells":17566},{"EARLY_PHASE1":17567,"PHASE1":17569,"PHASE2":17571,"PHASE3":17581,"PHASE4":17583,"NA":17585},{"trials":17568,"activeCount":98},[],{"trials":17570,"activeCount":98},[],{"trials":17572,"activeCount":98},[17573,17577],{"nctId":7048,"briefTitle":7049,"status":104,"phases":17574,"primaryCompletion":7051,"completion":7051,"start":7052,"enrollment":2308,"conditions":17575,"interventions":17576},[88],[7054],[7056,7057,7058,7059,2936,7060],{"nctId":7072,"briefTitle":7073,"status":104,"phases":17578,"primaryCompletion":6480,"completion":6479,"start":4010,"enrollment":7075,"conditions":17579,"interventions":17580},[88],[7077],[7056,7057,7079,7060,971],{"trials":17582,"activeCount":98},[],{"trials":17584,"activeCount":98},[],{"trials":17586,"activeCount":98},[],{"intervention":17142,"totalTrials":230,"cells":17588},{"EARLY_PHASE1":17589,"PHASE1":17591,"PHASE2":17593,"PHASE3":17606,"PHASE4":17608,"NA":17610},{"trials":17590,"activeCount":98},[],{"trials":17592,"activeCount":98},[],{"trials":17594,"activeCount":98},[17595,17599],{"nctId":17136,"briefTitle":17137,"status":467,"phases":17596,"primaryCompletion":6918,"completion":6918,"start":4348,"enrollment":98,"conditions":17597,"interventions":17598},[88],[17140],[17121,17121,17121,17142,11917],{"nctId":17600,"briefTitle":17601,"status":104,"phases":17602,"primaryCompletion":3585,"completion":3894,"start":3712,"enrollment":19,"conditions":17603,"interventions":17604},"NCT00874770","Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)",[88],[11904],[10402,10402,10402,17605,12003],"Peginterferon alpha-2a",{"trials":17607,"activeCount":98},[],{"trials":17609,"activeCount":98},[],{"trials":17611,"activeCount":98},[],{"intervention":1708,"totalTrials":230,"cells":17613},{"EARLY_PHASE1":17614,"PHASE1":17616,"PHASE2":17626,"PHASE3":17632,"PHASE4":17634,"NA":17636},{"trials":17615,"activeCount":98},[],{"trials":17617,"activeCount":98},[17618],{"nctId":17619,"briefTitle":17620,"status":104,"phases":17621,"primaryCompletion":17622,"completion":17622,"start":17623,"enrollment":839,"conditions":17624,"interventions":17625},"NCT02884726","Phase 1 Study of Mesothelin-ADC",[87],"2017-09-06","2016-10-14",[1154],[1708],{"trials":17627,"activeCount":98},[17628],{"nctId":1700,"briefTitle":1701,"status":963,"phases":17629,"primaryCompletion":1703,"completion":1704,"start":1448,"enrollment":1705,"conditions":17630,"interventions":17631},[87,88],[1154],[1708,43],{"trials":17633,"activeCount":98},[],{"trials":17635,"activeCount":98},[],{"trials":17637,"activeCount":98},[],{"intervention":17639,"totalTrials":230,"cells":17640},"Aurexis®",{"EARLY_PHASE1":17641,"PHASE1":17643,"PHASE2":17645,"PHASE3":17661,"PHASE4":17663,"NA":17665},{"trials":17642,"activeCount":98},[],{"trials":17644,"activeCount":98},[],{"trials":17646,"activeCount":98},[17647,17654],{"nctId":17648,"briefTitle":17649,"status":104,"phases":17650,"completion":7812,"enrollment":582,"conditions":17651,"interventions":17653},"NCT00198302","Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB)",[88],[17652],"Staphylococcus Aureus Bacteremia",[17639],{"nctId":17655,"briefTitle":17656,"status":104,"phases":17657,"completion":5117,"start":7674,"enrollment":148,"conditions":17658,"interventions":17660},"NCT00198289","Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs",[88],[17659],"Staphylococcus Aureus",[17639],{"trials":17662,"activeCount":98},[],{"trials":17664,"activeCount":98},[],{"trials":17666,"activeCount":98},[],{"intervention":12751,"totalTrials":230,"cells":17668},{"EARLY_PHASE1":17669,"PHASE1":17671,"PHASE2":17673,"PHASE3":17683,"PHASE4":17685,"NA":17687},{"trials":17670,"activeCount":98},[],{"trials":17672,"activeCount":98},[],{"trials":17674,"activeCount":98},[17675,17679],{"nctId":15979,"briefTitle":15980,"status":104,"phases":17676,"primaryCompletion":3903,"completion":3903,"start":15783,"enrollment":15982,"conditions":17677,"interventions":17678},[88],[12749],[12751,12753,12751],{"nctId":12744,"briefTitle":12745,"status":104,"phases":17680,"primaryCompletion":10518,"completion":10518,"start":7714,"enrollment":12747,"conditions":17681,"interventions":17682},[88],[12749],[12751,11906,12752,12753,12753,12753,12753],{"trials":17684,"activeCount":98},[],{"trials":17686,"activeCount":98},[],{"trials":17688,"activeCount":98},[],{"intervention":1771,"totalTrials":230,"cells":17690},{"EARLY_PHASE1":17691,"PHASE1":17693,"PHASE2":17695,"PHASE3":17705,"PHASE4":17707,"NA":17709},{"trials":17692,"activeCount":98},[],{"trials":17694,"activeCount":98},[],{"trials":17696,"activeCount":98},[17697,17701],{"nctId":1763,"briefTitle":1764,"status":104,"phases":17698,"primaryCompletion":1766,"completion":1766,"start":1767,"enrollment":1634,"conditions":17699,"interventions":17700},[87,88],[1154],[1770,43,608,1771,1772,1773],{"nctId":1859,"briefTitle":1860,"status":963,"phases":17702,"primaryCompletion":1862,"completion":1862,"start":789,"enrollment":1863,"conditions":17703,"interventions":17704},[87,88],[606,1865,1866,1867],[1869,43,608,1870],{"trials":17706,"activeCount":98},[],{"trials":17708,"activeCount":98},[],{"trials":17710,"activeCount":98},[],{"intervention":4998,"totalTrials":230,"cells":17712},{"EARLY_PHASE1":17713,"PHASE1":17715,"PHASE2":17721,"PHASE3":17729,"PHASE4":17731,"NA":17733},{"trials":17714,"activeCount":98},[],{"trials":17716,"activeCount":98},[17717],{"nctId":4992,"briefTitle":4993,"status":104,"phases":17718,"primaryCompletion":3873,"completion":3873,"start":4995,"enrollment":3143,"conditions":17719,"interventions":17720},[87],[1482,1223],[4998,4999,1158],{"trials":17722,"activeCount":98},[17723],{"nctId":17724,"briefTitle":17725,"status":963,"phases":17726,"primaryCompletion":11511,"completion":11511,"start":7811,"enrollment":4328,"conditions":17727,"interventions":17728},"NCT00780000","Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer",[88],[1223],[4998],{"trials":17730,"activeCount":98},[],{"trials":17732,"activeCount":98},[],{"trials":17734,"activeCount":98},[],{"intervention":17736,"totalTrials":230,"cells":17737},"BMS-830216",{"EARLY_PHASE1":17738,"PHASE1":17740,"PHASE2":17749,"PHASE3":17757,"PHASE4":17759,"NA":17761},{"trials":17739,"activeCount":98},[],{"trials":17741,"activeCount":98},[17742],{"nctId":17743,"briefTitle":17744,"status":104,"phases":17745,"primaryCompletion":4038,"completion":4038,"start":4459,"enrollment":725,"conditions":17746,"interventions":17748},"NCT00878020","Safety Study to Evaluate BMS-830216 in Healthy Subjects",[87],[17747],"Obesity",[17736,17736],{"trials":17750,"activeCount":98},[17751],{"nctId":17752,"briefTitle":17753,"status":104,"phases":17754,"primaryCompletion":7089,"completion":7089,"start":3873,"enrollment":6961,"conditions":17755,"interventions":17756},"NCT00909766","Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects",[87,88],[17747],[17736,17736,17736,17736,17736,17736],{"trials":17758,"activeCount":98},[],{"trials":17760,"activeCount":98},[],{"trials":17762,"activeCount":98},[],{"intervention":13099,"totalTrials":230,"cells":17764},{"EARLY_PHASE1":17765,"PHASE1":17767,"PHASE2":17773,"PHASE3":17779,"PHASE4":17781,"NA":17783},{"trials":17766,"activeCount":98},[],{"trials":17768,"activeCount":98},[17769],{"nctId":13094,"briefTitle":13095,"status":104,"phases":17770,"primaryCompletion":10856,"completion":10856,"start":5043,"enrollment":6185,"conditions":17771,"interventions":17772},[87],[24],[13099,13100,13100,13081],{"trials":17774,"activeCount":98},[17775],{"nctId":17370,"briefTitle":17371,"status":963,"phases":17776,"enrollment":94,"conditions":17777,"interventions":17778},[88],[24],[17353,17367,13099,13341,13342],{"trials":17780,"activeCount":98},[],{"trials":17782,"activeCount":98},[],{"trials":17784,"activeCount":98},[],{"intervention":1847,"totalTrials":230,"cells":17786},{"EARLY_PHASE1":17787,"PHASE1":17789,"PHASE2":17791,"PHASE3":17801,"PHASE4":17803,"NA":17805},{"trials":17788,"activeCount":98},[],{"trials":17790,"activeCount":98},[],{"trials":17792,"activeCount":98},[17793,17797],{"nctId":1840,"briefTitle":1841,"status":104,"phases":17794,"primaryCompletion":1843,"completion":1843,"start":1844,"enrollment":208,"conditions":17795,"interventions":17796},[88],[36],[43,608,1847],{"nctId":1911,"briefTitle":1912,"status":104,"phases":17798,"primaryCompletion":1914,"completion":1914,"start":1915,"enrollment":1916,"conditions":17799,"interventions":17800},[87,88],[1918],[1847,43,608],{"trials":17802,"activeCount":98},[],{"trials":17804,"activeCount":98},[],{"trials":17806,"activeCount":98},[],{"intervention":16110,"totalTrials":230,"cells":17808},{"EARLY_PHASE1":17809,"PHASE1":17811,"PHASE2":17821,"PHASE3":17827,"PHASE4":17829,"NA":17831},{"trials":17810,"activeCount":98},[],{"trials":17812,"activeCount":98},[17813],{"nctId":17814,"briefTitle":17815,"status":104,"phases":17816,"primaryCompletion":1432,"completion":1432,"start":17817,"enrollment":6185,"conditions":17818,"interventions":17819},"NCT04763226","A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants",[87],"2021-04-14",[18],[17820,16110],"BMS-986308",{"trials":17822,"activeCount":98},[17823],{"nctId":16103,"briefTitle":16104,"status":104,"phases":17824,"primaryCompletion":16106,"completion":16107,"start":2504,"enrollment":2038,"conditions":17825,"interventions":17826},[88],[16079,16078,10867,16080],[16054,16110],{"trials":17828,"activeCount":98},[],{"trials":17830,"activeCount":98},[],{"trials":17832,"activeCount":98},[],{"intervention":3963,"totalTrials":230,"cells":17834},{"EARLY_PHASE1":17835,"PHASE1":17837,"PHASE2":17843,"PHASE3":17849,"PHASE4":17851,"NA":17853},{"trials":17836,"activeCount":98},[],{"trials":17838,"activeCount":98},[17839],{"nctId":3955,"briefTitle":3956,"status":963,"phases":17840,"primaryCompletion":3958,"completion":3959,"start":3960,"enrollment":693,"conditions":17841,"interventions":17842},[87],[21],[608,3963],{"trials":17844,"activeCount":98},[17845],{"nctId":4259,"briefTitle":4260,"status":104,"phases":17846,"primaryCompletion":4262,"completion":4263,"start":4264,"enrollment":22,"conditions":17847,"interventions":17848},[88],[21],[608,3963],{"trials":17850,"activeCount":98},[],{"trials":17852,"activeCount":98},[],{"trials":17854,"activeCount":98},[],{"intervention":2091,"totalTrials":230,"cells":17856},{"EARLY_PHASE1":17857,"PHASE1":17859,"PHASE2":17861,"PHASE3":17871,"PHASE4":17873,"NA":17875},{"trials":17858,"activeCount":98},[],{"trials":17860,"activeCount":98},[],{"trials":17862,"activeCount":98},[17863,17867],{"nctId":12626,"briefTitle":12627,"status":104,"phases":17864,"primaryCompletion":12629,"completion":12629,"start":12630,"enrollment":413,"conditions":17865,"interventions":17866},[87,88],[12632],[2091,3751],{"nctId":2079,"briefTitle":2080,"status":104,"phases":17868,"primaryCompletion":2082,"completion":2082,"start":2083,"enrollment":2084,"conditions":17869,"interventions":17870},[88],[2086,2087,2088,2089],[608,43,1474,615,2091],{"trials":17872,"activeCount":98},[],{"trials":17874,"activeCount":98},[],{"trials":17876,"activeCount":98},[],{"intervention":2100,"totalTrials":230,"cells":17878},{"EARLY_PHASE1":17879,"PHASE1":17881,"PHASE2":17883,"PHASE3":17893,"PHASE4":17895,"NA":17897},{"trials":17880,"activeCount":98},[],{"trials":17882,"activeCount":98},[],{"trials":17884,"activeCount":98},[17885,17889],{"nctId":2093,"briefTitle":2094,"status":963,"phases":17886,"primaryCompletion":2096,"completion":2096,"start":1230,"enrollment":1184,"conditions":17887,"interventions":17888},[88],[2098],[2100,1328,43],{"nctId":2218,"briefTitle":2219,"status":963,"phases":17890,"primaryCompletion":2221,"completion":2221,"start":2222,"enrollment":2223,"conditions":17891,"interventions":17892},[87,88],[1154],[608,2100,43],{"trials":17894,"activeCount":98},[],{"trials":17896,"activeCount":98},[],{"trials":17898,"activeCount":98},[],{"intervention":3646,"totalTrials":230,"cells":17900},{"EARLY_PHASE1":17901,"PHASE1":17903,"PHASE2":17909,"PHASE3":17915,"PHASE4":17917,"NA":17919},{"trials":17902,"activeCount":98},[],{"trials":17904,"activeCount":98},[17905],{"nctId":3637,"briefTitle":3638,"status":104,"phases":17906,"primaryCompletion":3640,"completion":3640,"start":3641,"conditions":17907,"interventions":17908},[87],[3643],[3645,3646],{"trials":17910,"activeCount":98},[17911],{"nctId":2257,"briefTitle":2258,"status":104,"phases":17912,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":2262,"conditions":17913,"interventions":17914},[88],[2264],[1245,1225,2266,43,618,1267,619,617,2267],{"trials":17916,"activeCount":98},[],{"trials":17918,"activeCount":98},[],{"trials":17920,"activeCount":98},[],{"intervention":4999,"totalTrials":230,"cells":17922},{"EARLY_PHASE1":17923,"PHASE1":17925,"PHASE2":17931,"PHASE3":17937,"PHASE4":17939,"NA":17941},{"trials":17924,"activeCount":98},[],{"trials":17926,"activeCount":98},[17927],{"nctId":4992,"briefTitle":4993,"status":104,"phases":17928,"primaryCompletion":3873,"completion":3873,"start":4995,"enrollment":3143,"conditions":17929,"interventions":17930},[87],[1482,1223],[4998,4999,1158],{"trials":17932,"activeCount":98},[17933],{"nctId":15613,"briefTitle":15614,"status":104,"phases":17934,"primaryCompletion":3960,"completion":3960,"start":6170,"enrollment":3562,"conditions":17935,"interventions":17936},[87,88],[1223],[3576,15618],{"trials":17938,"activeCount":98},[],{"trials":17940,"activeCount":98},[],{"trials":17942,"activeCount":98},[],{"intervention":3716,"totalTrials":230,"cells":17944},{"EARLY_PHASE1":17945,"PHASE1":17947,"PHASE2":17949,"PHASE3":17959,"PHASE4":17961,"NA":17963},{"trials":17946,"activeCount":98},[],{"trials":17948,"activeCount":98},[],{"trials":17950,"activeCount":98},[17951,17955],{"nctId":3708,"briefTitle":3709,"status":963,"phases":17952,"primaryCompletion":3711,"completion":3711,"start":3712,"enrollment":3713,"conditions":17953,"interventions":17954},[88],[3131],[1158,1157,3716,612,3717],{"nctId":5538,"briefTitle":5539,"status":104,"phases":17956,"primaryCompletion":5541,"completion":5542,"start":3678,"enrollment":5543,"conditions":17957,"interventions":17958},[88],[4875],[1678,3610,3610,5546,3716,612,5547],{"trials":17960,"activeCount":98},[],{"trials":17962,"activeCount":98},[],{"trials":17964,"activeCount":98},[],{"intervention":3717,"totalTrials":230,"cells":17966},{"EARLY_PHASE1":17967,"PHASE1":17969,"PHASE2":17971,"PHASE3":17981,"PHASE4":17983,"NA":17985},{"trials":17968,"activeCount":98},[],{"trials":17970,"activeCount":98},[],{"trials":17972,"activeCount":98},[17973,17977],{"nctId":3708,"briefTitle":3709,"status":963,"phases":17974,"primaryCompletion":3711,"completion":3711,"start":3712,"enrollment":3713,"conditions":17975,"interventions":17976},[88],[3131],[1158,1157,3716,612,3717],{"nctId":5538,"briefTitle":5539,"status":104,"phases":17978,"primaryCompletion":5541,"completion":5542,"start":3678,"enrollment":5543,"conditions":17979,"interventions":17980},[88],[4875],[1678,3610,3610,5546,3716,612,5547],{"trials":17982,"activeCount":98},[],{"trials":17984,"activeCount":98},[],{"trials":17986,"activeCount":98},[],{"intervention":17988,"totalTrials":230,"cells":17989},"HNO Donor",{"EARLY_PHASE1":17990,"PHASE1":17992,"PHASE2":17994,"PHASE3":18014,"PHASE4":18016,"NA":18018},{"trials":17991,"activeCount":98},[],{"trials":17993,"activeCount":98},[],{"trials":17995,"activeCount":98},[17996,18006],{"nctId":17997,"briefTitle":17998,"status":104,"phases":17999,"primaryCompletion":18000,"completion":18001,"start":18002,"enrollment":18003,"conditions":18004,"interventions":18005},"NCT03016325","Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure",[88],"2019-06-23","2019-11-12","2017-01-13",329,[8277],[17988],{"nctId":18007,"briefTitle":18008,"status":104,"phases":18009,"primaryCompletion":5630,"completion":5630,"start":2666,"enrollment":790,"conditions":18010,"interventions":18012},"NCT03357731","A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function",[88],[8277,16079,18011],"Reduced Ventricular Ejection Fraction",[17988,18013],"Nitroglycerin",{"trials":18015,"activeCount":98},[],{"trials":18017,"activeCount":98},[],{"trials":18019,"activeCount":98},[],{"intervention":1406,"totalTrials":208,"cells":18021},{"EARLY_PHASE1":18022,"PHASE1":18024,"PHASE2":18026,"PHASE3":18032,"PHASE4":18034,"NA":18036},{"trials":18023,"activeCount":98},[],{"trials":18025,"activeCount":98},[],{"trials":18027,"activeCount":98},[18028],{"nctId":1399,"briefTitle":1400,"status":963,"phases":18029,"primaryCompletion":1402,"completion":1402,"start":1403,"enrollment":347,"conditions":18030,"interventions":18031},[87,88],[1132,1265],[1406,43,1328,1157,1407,1158],{"trials":18033,"activeCount":98},[],{"trials":18035,"activeCount":98},[],{"trials":18037,"activeCount":98},[],{"intervention":1407,"totalTrials":208,"cells":18039},{"EARLY_PHASE1":18040,"PHASE1":18042,"PHASE2":18044,"PHASE3":18050,"PHASE4":18052,"NA":18054},{"trials":18041,"activeCount":98},[],{"trials":18043,"activeCount":98},[],{"trials":18045,"activeCount":98},[18046],{"nctId":1399,"briefTitle":1400,"status":963,"phases":18047,"primaryCompletion":1402,"completion":1402,"start":1403,"enrollment":347,"conditions":18048,"interventions":18049},[87,88],[1132,1265],[1406,43,1328,1157,1407,1158],{"trials":18051,"activeCount":98},[],{"trials":18053,"activeCount":98},[],{"trials":18055,"activeCount":98},[],{"intervention":12451,"totalTrials":208,"cells":18057},{"EARLY_PHASE1":18058,"PHASE1":18060,"PHASE2":18062,"PHASE3":18068,"PHASE4":18070,"NA":18072},{"trials":18059,"activeCount":98},[],{"trials":18061,"activeCount":98},[],{"trials":18063,"activeCount":98},[18064],{"nctId":12444,"briefTitle":12445,"status":104,"phases":18065,"primaryCompletion":2687,"completion":2687,"start":12447,"enrollment":34,"conditions":18066,"interventions":18067},[87,88],[12449],[12435,12451,12452],{"trials":18069,"activeCount":98},[],{"trials":18071,"activeCount":98},[],{"trials":18073,"activeCount":98},[],{"intervention":4027,"totalTrials":208,"cells":18075},{"EARLY_PHASE1":18076,"PHASE1":18078,"PHASE2":18080,"PHASE3":18086,"PHASE4":18088,"NA":18090},{"trials":18077,"activeCount":98},[],{"trials":18079,"activeCount":98},[],{"trials":18081,"activeCount":98},[18082],{"nctId":4020,"briefTitle":4021,"status":467,"phases":18083,"start":4023,"enrollment":98,"conditions":18084,"interventions":18085},[88],[4025],[4027,4028,4029,1122],{"trials":18087,"activeCount":98},[],{"trials":18089,"activeCount":98},[],{"trials":18091,"activeCount":98},[],{"intervention":4028,"totalTrials":208,"cells":18093},{"EARLY_PHASE1":18094,"PHASE1":18096,"PHASE2":18098,"PHASE3":18104,"PHASE4":18106,"NA":18108},{"trials":18095,"activeCount":98},[],{"trials":18097,"activeCount":98},[],{"trials":18099,"activeCount":98},[18100],{"nctId":4020,"briefTitle":4021,"status":467,"phases":18101,"start":4023,"enrollment":98,"conditions":18102,"interventions":18103},[88],[4025],[4027,4028,4029,1122],{"trials":18105,"activeCount":98},[],{"trials":18107,"activeCount":98},[],{"trials":18109,"activeCount":98},[],{"intervention":4029,"totalTrials":208,"cells":18111},{"EARLY_PHASE1":18112,"PHASE1":18114,"PHASE2":18116,"PHASE3":18122,"PHASE4":18124,"NA":18126},{"trials":18113,"activeCount":98},[],{"trials":18115,"activeCount":98},[],{"trials":18117,"activeCount":98},[18118],{"nctId":4020,"briefTitle":4021,"status":467,"phases":18119,"start":4023,"enrollment":98,"conditions":18120,"interventions":18121},[88],[4025],[4027,4028,4029,1122],{"trials":18123,"activeCount":98},[],{"trials":18125,"activeCount":98},[],{"trials":18127,"activeCount":98},[],{"intervention":18129,"totalTrials":208,"cells":18130},"Simeprevir",{"EARLY_PHASE1":18131,"PHASE1":18133,"PHASE2":18135,"PHASE3":18143,"PHASE4":18145,"NA":18147},{"trials":18132,"activeCount":98},[],{"trials":18134,"activeCount":98},[],{"trials":18136,"activeCount":98},[18137],{"nctId":18138,"briefTitle":18139,"status":104,"phases":18140,"primaryCompletion":3711,"completion":11742,"start":3902,"enrollment":1597,"conditions":18141,"interventions":18142},"NCT01628692","Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus",[88],[11842],[10402,18129,11917],{"trials":18144,"activeCount":98},[],{"trials":18146,"activeCount":98},[],{"trials":18148,"activeCount":98},[],{"intervention":1441,"totalTrials":208,"cells":18150},{"EARLY_PHASE1":18151,"PHASE1":18153,"PHASE2":18155,"PHASE3":18161,"PHASE4":18163,"NA":18165},{"trials":18152,"activeCount":98},[],{"trials":18154,"activeCount":98},[],{"trials":18156,"activeCount":98},[18157],{"nctId":1429,"briefTitle":1430,"status":467,"phases":18158,"primaryCompletion":1432,"completion":1433,"start":1434,"enrollment":98,"conditions":18159,"interventions":18160},[88],[1436,1437,1438,1439],[1441,43,1158,1442],{"trials":18162,"activeCount":98},[],{"trials":18164,"activeCount":98},[],{"trials":18166,"activeCount":98},[],{"intervention":1484,"totalTrials":208,"cells":18168},{"EARLY_PHASE1":18169,"PHASE1":18171,"PHASE2":18173,"PHASE3":18179,"PHASE4":18181,"NA":18183},{"trials":18170,"activeCount":98},[],{"trials":18172,"activeCount":98},[],{"trials":18174,"activeCount":98},[18175],{"nctId":1476,"briefTitle":1477,"status":963,"phases":18176,"primaryCompletion":1479,"completion":1479,"start":1480,"enrollment":451,"conditions":18177,"interventions":18178},[87,88],[1482],[1484,43],{"trials":18180,"activeCount":98},[],{"trials":18182,"activeCount":98},[],{"trials":18184,"activeCount":98},[],{"intervention":4042,"totalTrials":208,"cells":18186},{"EARLY_PHASE1":18187,"PHASE1":18189,"PHASE2":18191,"PHASE3":18197,"PHASE4":18199,"NA":18201},{"trials":18188,"activeCount":98},[],{"trials":18190,"activeCount":98},[],{"trials":18192,"activeCount":98},[18193],{"nctId":4035,"briefTitle":4036,"status":104,"phases":18194,"primaryCompletion":4038,"completion":3586,"start":4039,"enrollment":3874,"conditions":18195,"interventions":18196},[88],[21],[608,4042,4043,4044,4045,4046,4047,4048,4049,4050],{"trials":18198,"activeCount":98},[],{"trials":18200,"activeCount":98},[],{"trials":18202,"activeCount":98},[],{"intervention":4043,"totalTrials":208,"cells":18204},{"EARLY_PHASE1":18205,"PHASE1":18207,"PHASE2":18209,"PHASE3":18215,"PHASE4":18217,"NA":18219},{"trials":18206,"activeCount":98},[],{"trials":18208,"activeCount":98},[],{"trials":18210,"activeCount":98},[18211],{"nctId":4035,"briefTitle":4036,"status":104,"phases":18212,"primaryCompletion":4038,"completion":3586,"start":4039,"enrollment":3874,"conditions":18213,"interventions":18214},[88],[21],[608,4042,4043,4044,4045,4046,4047,4048,4049,4050],{"trials":18216,"activeCount":98},[],{"trials":18218,"activeCount":98},[],{"trials":18220,"activeCount":98},[],{"intervention":4044,"totalTrials":208,"cells":18222},{"EARLY_PHASE1":18223,"PHASE1":18225,"PHASE2":18227,"PHASE3":18233,"PHASE4":18235,"NA":18237},{"trials":18224,"activeCount":98},[],{"trials":18226,"activeCount":98},[],{"trials":18228,"activeCount":98},[18229],{"nctId":4035,"briefTitle":4036,"status":104,"phases":18230,"primaryCompletion":4038,"completion":3586,"start":4039,"enrollment":3874,"conditions":18231,"interventions":18232},[88],[21],[608,4042,4043,4044,4045,4046,4047,4048,4049,4050],{"trials":18234,"activeCount":98},[],{"trials":18236,"activeCount":98},[],{"trials":18238,"activeCount":98},[],{"intervention":4045,"totalTrials":208,"cells":18240},{"EARLY_PHASE1":18241,"PHASE1":18243,"PHASE2":18245,"PHASE3":18251,"PHASE4":18253,"NA":18255},{"trials":18242,"activeCount":98},[],{"trials":18244,"activeCount":98},[],{"trials":18246,"activeCount":98},[18247],{"nctId":4035,"briefTitle":4036,"status":104,"phases":18248,"primaryCompletion":4038,"completion":3586,"start":4039,"enrollment":3874,"conditions":18249,"interventions":18250},[88],[21],[608,4042,4043,4044,4045,4046,4047,4048,4049,4050],{"trials":18252,"activeCount":98},[],{"trials":18254,"activeCount":98},[],{"trials":18256,"activeCount":98},[],{"intervention":4046,"totalTrials":208,"cells":18258},{"EARLY_PHASE1":18259,"PHASE1":18261,"PHASE2":18263,"PHASE3":18269,"PHASE4":18271,"NA":18273},{"trials":18260,"activeCount":98},[],{"trials":18262,"activeCount":98},[],{"trials":18264,"activeCount":98},[18265],{"nctId":4035,"briefTitle":4036,"status":104,"phases":18266,"primaryCompletion":4038,"completion":3586,"start":4039,"enrollment":3874,"conditions":18267,"interventions":18268},[88],[21],[608,4042,4043,4044,4045,4046,4047,4048,4049,4050],{"trials":18270,"activeCount":98},[],{"trials":18272,"activeCount":98},[],{"trials":18274,"activeCount":98},[],{"intervention":4047,"totalTrials":208,"cells":18276},{"EARLY_PHASE1":18277,"PHASE1":18279,"PHASE2":18281,"PHASE3":18287,"PHASE4":18289,"NA":18291},{"trials":18278,"activeCount":98},[],{"trials":18280,"activeCount":98},[],{"trials":18282,"activeCount":98},[18283],{"nctId":4035,"briefTitle":4036,"status":104,"phases":18284,"primaryCompletion":4038,"completion":3586,"start":4039,"enrollment":3874,"conditions":18285,"interventions":18286},[88],[21],[608,4042,4043,4044,4045,4046,4047,4048,4049,4050],{"trials":18288,"activeCount":98},[],{"trials":18290,"activeCount":98},[],{"trials":18292,"activeCount":98},[],{"intervention":4048,"totalTrials":208,"cells":18294},{"EARLY_PHASE1":18295,"PHASE1":18297,"PHASE2":18299,"PHASE3":18305,"PHASE4":18307,"NA":18309},{"trials":18296,"activeCount":98},[],{"trials":18298,"activeCount":98},[],{"trials":18300,"activeCount":98},[18301],{"nctId":4035,"briefTitle":4036,"status":104,"phases":18302,"primaryCompletion":4038,"completion":3586,"start":4039,"enrollment":3874,"conditions":18303,"interventions":18304},[88],[21],[608,4042,4043,4044,4045,4046,4047,4048,4049,4050],{"trials":18306,"activeCount":98},[],{"trials":18308,"activeCount":98},[],{"trials":18310,"activeCount":98},[],{"intervention":4049,"totalTrials":208,"cells":18312},{"EARLY_PHASE1":18313,"PHASE1":18315,"PHASE2":18317,"PHASE3":18323,"PHASE4":18325,"NA":18327},{"trials":18314,"activeCount":98},[],{"trials":18316,"activeCount":98},[],{"trials":18318,"activeCount":98},[18319],{"nctId":4035,"briefTitle":4036,"status":104,"phases":18320,"primaryCompletion":4038,"completion":3586,"start":4039,"enrollment":3874,"conditions":18321,"interventions":18322},[88],[21],[608,4042,4043,4044,4045,4046,4047,4048,4049,4050],{"trials":18324,"activeCount":98},[],{"trials":18326,"activeCount":98},[],{"trials":18328,"activeCount":98},[],{"intervention":4050,"totalTrials":208,"cells":18330},{"EARLY_PHASE1":18331,"PHASE1":18333,"PHASE2":18335,"PHASE3":18341,"PHASE4":18343,"NA":18345},{"trials":18332,"activeCount":98},[],{"trials":18334,"activeCount":98},[],{"trials":18336,"activeCount":98},[18337],{"nctId":4035,"briefTitle":4036,"status":104,"phases":18338,"primaryCompletion":4038,"completion":3586,"start":4039,"enrollment":3874,"conditions":18339,"interventions":18340},[88],[21],[608,4042,4043,4044,4045,4046,4047,4048,4049,4050],{"trials":18342,"activeCount":98},[],{"trials":18344,"activeCount":98},[],{"trials":18346,"activeCount":98},[],{"intervention":1506,"totalTrials":208,"cells":18348},{"EARLY_PHASE1":18349,"PHASE1":18351,"PHASE2":18353,"PHASE3":18359,"PHASE4":18361,"NA":18363},{"trials":18350,"activeCount":98},[],{"trials":18352,"activeCount":98},[],{"trials":18354,"activeCount":98},[18355],{"nctId":1496,"briefTitle":1497,"status":104,"phases":18356,"primaryCompletion":1499,"completion":1500,"start":1501,"enrollment":1502,"conditions":18357,"interventions":18358},[88],[1504],[43,608,1506,1507],{"trials":18360,"activeCount":98},[],{"trials":18362,"activeCount":98},[],{"trials":18364,"activeCount":98},[],{"intervention":18366,"totalTrials":208,"cells":18367},"INX-08189 50 mg",{"EARLY_PHASE1":18368,"PHASE1":18370,"PHASE2":18372,"PHASE3":18382,"PHASE4":18384,"NA":18386},{"trials":18369,"activeCount":98},[],{"trials":18371,"activeCount":98},[],{"trials":18373,"activeCount":98},[18374],{"nctId":18375,"briefTitle":18376,"status":104,"phases":18377,"primaryCompletion":3960,"completion":3960,"start":5542,"enrollment":1203,"conditions":18378,"interventions":18379},"NCT01471704","Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers",[87,88],[759],[18366,18380,18381],"240 mg verapamil HCL ER","50 mg dose of INX-08189 and 240 mg verapamil HCL ER",{"trials":18383,"activeCount":98},[],{"trials":18385,"activeCount":98},[],{"trials":18387,"activeCount":98},[],{"intervention":18380,"totalTrials":208,"cells":18389},{"EARLY_PHASE1":18390,"PHASE1":18392,"PHASE2":18394,"PHASE3":18400,"PHASE4":18402,"NA":18404},{"trials":18391,"activeCount":98},[],{"trials":18393,"activeCount":98},[],{"trials":18395,"activeCount":98},[18396],{"nctId":18375,"briefTitle":18376,"status":104,"phases":18397,"primaryCompletion":3960,"completion":3960,"start":5542,"enrollment":1203,"conditions":18398,"interventions":18399},[87,88],[759],[18366,18380,18381],{"trials":18401,"activeCount":98},[],{"trials":18403,"activeCount":98},[],{"trials":18405,"activeCount":98},[],{"intervention":18381,"totalTrials":208,"cells":18407},{"EARLY_PHASE1":18408,"PHASE1":18410,"PHASE2":18412,"PHASE3":18418,"PHASE4":18420,"NA":18422},{"trials":18409,"activeCount":98},[],{"trials":18411,"activeCount":98},[],{"trials":18413,"activeCount":98},[18414],{"nctId":18375,"briefTitle":18376,"status":104,"phases":18415,"primaryCompletion":3960,"completion":3960,"start":5542,"enrollment":1203,"conditions":18416,"interventions":18417},[87,88],[759],[18366,18380,18381],{"trials":18419,"activeCount":98},[],{"trials":18421,"activeCount":98},[],{"trials":18423,"activeCount":98},[],{"intervention":18425,"totalTrials":208,"cells":18426},"CXL-1427",{"EARLY_PHASE1":18427,"PHASE1":18429,"PHASE2":18431,"PHASE3":18443,"PHASE4":18445,"NA":18447},{"trials":18428,"activeCount":98},[],{"trials":18430,"activeCount":98},[],{"trials":18432,"activeCount":98},[18433],{"nctId":18434,"briefTitle":18435,"status":104,"phases":18436,"primaryCompletion":18437,"completion":11930,"start":18438,"enrollment":22,"conditions":18439,"interventions":18442},"NCT02157506","A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure",[88],"2015-05-31","2014-06-30",[8277,18440,18441],"Decompensated Heart Failure","Acute Heart Failure",[18425],{"trials":18444,"activeCount":98},[],{"trials":18446,"activeCount":98},[],{"trials":18448,"activeCount":98},[],{"intervention":1517,"totalTrials":208,"cells":18450},{"EARLY_PHASE1":18451,"PHASE1":18453,"PHASE2":18455,"PHASE3":18461,"PHASE4":18463,"NA":18465},{"trials":18452,"activeCount":98},[],{"trials":18454,"activeCount":98},[],{"trials":18456,"activeCount":98},[18457],{"nctId":1509,"briefTitle":1510,"status":104,"phases":18458,"primaryCompletion":1512,"completion":1512,"start":1513,"enrollment":1414,"conditions":18459,"interventions":18460},[87,88],[1515],[1517,43],{"trials":18462,"activeCount":98},[],{"trials":18464,"activeCount":98},[],{"trials":18466,"activeCount":98},[],{"intervention":7158,"totalTrials":208,"cells":18468},{"EARLY_PHASE1":18469,"PHASE1":18471,"PHASE2":18473,"PHASE3":18479,"PHASE4":18481,"NA":18483},{"trials":18470,"activeCount":98},[],{"trials":18472,"activeCount":98},[],{"trials":18474,"activeCount":98},[18475],{"nctId":7150,"briefTitle":7151,"status":104,"phases":18476,"primaryCompletion":7153,"completion":7153,"start":7154,"conditions":18477,"interventions":18478},[88],[7156],[7158,7159],{"trials":18480,"activeCount":98},[],{"trials":18482,"activeCount":98},[],{"trials":18484,"activeCount":98},[],{"intervention":17368,"totalTrials":208,"cells":18486},{"EARLY_PHASE1":18487,"PHASE1":18489,"PHASE2":18491,"PHASE3":18497,"PHASE4":18499,"NA":18501},{"trials":18488,"activeCount":98},[],{"trials":18490,"activeCount":98},[],{"trials":18492,"activeCount":98},[18493],{"nctId":17362,"briefTitle":17363,"status":963,"phases":18494,"enrollment":94,"conditions":18495,"interventions":18496},[88],[24],[17353,17367,17368,13341,13342],{"trials":18498,"activeCount":98},[],{"trials":18500,"activeCount":98},[],{"trials":18502,"activeCount":98},[],{"intervention":1549,"totalTrials":208,"cells":18504},{"EARLY_PHASE1":18505,"PHASE1":18507,"PHASE2":18509,"PHASE3":18515,"PHASE4":18517,"NA":18519},{"trials":18506,"activeCount":98},[],{"trials":18508,"activeCount":98},[],{"trials":18510,"activeCount":98},[18511],{"nctId":1540,"briefTitle":1541,"status":963,"phases":18512,"primaryCompletion":1543,"completion":1544,"start":1545,"enrollment":1492,"conditions":18513,"interventions":18514},[88],[1547],[43,1549,1337],{"trials":18516,"activeCount":98},[],{"trials":18518,"activeCount":98},[],{"trials":18520,"activeCount":98},[],{"intervention":18522,"totalTrials":208,"cells":18523},"BMS-986251",{"EARLY_PHASE1":18524,"PHASE1":18526,"PHASE2":18528,"PHASE3":18539,"PHASE4":18541,"NA":18543},{"trials":18525,"activeCount":98},[],{"trials":18527,"activeCount":98},[],{"trials":18529,"activeCount":98},[18530],{"nctId":18531,"briefTitle":18532,"status":963,"phases":18533,"primaryCompletion":18534,"completion":18534,"start":18535,"enrollment":193,"conditions":18536,"interventions":18538},"NCT03329885","A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis",[87,88],"2018-06-26","2017-11-02",[15,749,18537,794,15408],"Ankylosing Spondylitis",[18522],{"trials":18540,"activeCount":98},[],{"trials":18542,"activeCount":98},[],{"trials":18544,"activeCount":98},[],{"intervention":7745,"totalTrials":208,"cells":18546},{"EARLY_PHASE1":18547,"PHASE1":18549,"PHASE2":18551,"PHASE3":18557,"PHASE4":18559,"NA":18561},{"trials":18548,"activeCount":98},[],{"trials":18550,"activeCount":98},[],{"trials":18552,"activeCount":98},[18553],{"nctId":7739,"briefTitle":7740,"status":104,"phases":18554,"primaryCompletion":7742,"completion":3902,"start":4995,"enrollment":3076,"conditions":18555,"interventions":18556},[87,88],[15],[7745,7745,7745,7745,7745,61],{"trials":18558,"activeCount":98},[],{"trials":18560,"activeCount":98},[],{"trials":18562,"activeCount":98},[],{"intervention":18564,"totalTrials":208,"cells":18565},"CCR2 Antagonist",{"EARLY_PHASE1":18566,"PHASE1":18568,"PHASE2":18570,"PHASE3":18578,"PHASE4":18580,"NA":18582},{"trials":18567,"activeCount":98},[],{"trials":18569,"activeCount":98},[],{"trials":18571,"activeCount":98},[18572],{"nctId":18573,"briefTitle":18574,"status":104,"phases":18575,"primaryCompletion":5014,"completion":5014,"start":3587,"enrollment":2308,"conditions":18576,"interventions":18577},"NCT00699790","Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance",[88],[12248],[18564],{"trials":18579,"activeCount":98},[],{"trials":18581,"activeCount":98},[],{"trials":18583,"activeCount":98},[],{"intervention":18585,"totalTrials":208,"cells":18586},"BMS-817399",{"EARLY_PHASE1":18587,"PHASE1":18589,"PHASE2":18591,"PHASE3":18599,"PHASE4":18601,"NA":18603},{"trials":18588,"activeCount":98},[],{"trials":18590,"activeCount":98},[],{"trials":18592,"activeCount":98},[18593],{"nctId":18594,"briefTitle":18595,"status":104,"phases":18596,"primaryCompletion":4114,"completion":4114,"start":5541,"enrollment":7928,"conditions":18597,"interventions":18598},"NCT01404585","Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis",[88],[15],[18585,18585],{"trials":18600,"activeCount":98},[],{"trials":18602,"activeCount":98},[],{"trials":18604,"activeCount":98},[],{"intervention":18606,"totalTrials":208,"cells":18607},"PSI-7977",{"EARLY_PHASE1":18608,"PHASE1":18610,"PHASE2":18612,"PHASE3":18620,"PHASE4":18622,"NA":18624},{"trials":18609,"activeCount":98},[],{"trials":18611,"activeCount":98},[],{"trials":18613,"activeCount":98},[18614],{"nctId":18615,"briefTitle":18616,"status":104,"phases":18617,"primaryCompletion":3903,"completion":4378,"start":7089,"enrollment":3370,"conditions":18618,"interventions":18619},"NCT01359644","Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care",[88],[11923],[18606,10402,11917],{"trials":18621,"activeCount":98},[],{"trials":18623,"activeCount":98},[],{"trials":18625,"activeCount":98},[],{"intervention":1626,"totalTrials":208,"cells":18627},{"EARLY_PHASE1":18628,"PHASE1":18630,"PHASE2":18632,"PHASE3":18638,"PHASE4":18640,"NA":18642},{"trials":18629,"activeCount":98},[],{"trials":18631,"activeCount":98},[],{"trials":18633,"activeCount":98},[18634],{"nctId":1620,"briefTitle":1621,"status":963,"phases":18635,"primaryCompletion":768,"completion":768,"start":1623,"enrollment":94,"conditions":18636,"interventions":18637},[87,88],[1607],[1626,43],{"trials":18639,"activeCount":98},[],{"trials":18641,"activeCount":98},[],{"trials":18643,"activeCount":98},[],{"intervention":18645,"totalTrials":208,"cells":18646},"HIV Integrase Inhibitor",{"EARLY_PHASE1":18647,"PHASE1":18649,"PHASE2":18651,"PHASE3":18659,"PHASE4":18661,"NA":18663},{"trials":18648,"activeCount":98},[],{"trials":18650,"activeCount":98},[],{"trials":18652,"activeCount":98},[18653],{"nctId":18654,"briefTitle":18655,"status":467,"phases":18656,"completion":7750,"start":7750,"enrollment":98,"conditions":18657,"interventions":18658},"NCT00397566","A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects",[88],[24],[18645],{"trials":18660,"activeCount":98},[],{"trials":18662,"activeCount":98},[],{"trials":18664,"activeCount":98},[],{"intervention":18666,"totalTrials":208,"cells":18667},"Strata 1 CXL-1020",{"EARLY_PHASE1":18668,"PHASE1":18670,"PHASE2":18672,"PHASE3":18682,"PHASE4":18684,"NA":18686},{"trials":18669,"activeCount":98},[],{"trials":18671,"activeCount":98},[],{"trials":18673,"activeCount":98},[18674],{"nctId":18675,"briefTitle":18676,"status":104,"phases":18677,"primaryCompletion":6437,"completion":6437,"start":3872,"enrollment":8039,"conditions":18678,"interventions":18679},"NCT01096043","A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure",[88],[8277],[18666,18680,18681],"Strata 2 CXL-1020","Strata 3 CXL-1020",{"trials":18683,"activeCount":98},[],{"trials":18685,"activeCount":98},[],{"trials":18687,"activeCount":98},[],{"intervention":18680,"totalTrials":208,"cells":18689},{"EARLY_PHASE1":18690,"PHASE1":18692,"PHASE2":18694,"PHASE3":18700,"PHASE4":18702,"NA":18704},{"trials":18691,"activeCount":98},[],{"trials":18693,"activeCount":98},[],{"trials":18695,"activeCount":98},[18696],{"nctId":18675,"briefTitle":18676,"status":104,"phases":18697,"primaryCompletion":6437,"completion":6437,"start":3872,"enrollment":8039,"conditions":18698,"interventions":18699},[88],[8277],[18666,18680,18681],{"trials":18701,"activeCount":98},[],{"trials":18703,"activeCount":98},[],{"trials":18705,"activeCount":98},[],{"intervention":18681,"totalTrials":208,"cells":18707},{"EARLY_PHASE1":18708,"PHASE1":18710,"PHASE2":18712,"PHASE3":18718,"PHASE4":18720,"NA":18722},{"trials":18709,"activeCount":98},[],{"trials":18711,"activeCount":98},[],{"trials":18713,"activeCount":98},[18714],{"nctId":18675,"briefTitle":18676,"status":104,"phases":18715,"primaryCompletion":6437,"completion":6437,"start":3872,"enrollment":8039,"conditions":18716,"interventions":18717},[88],[8277],[18666,18680,18681],{"trials":18719,"activeCount":98},[],{"trials":18721,"activeCount":98},[],{"trials":18723,"activeCount":98},[],{"intervention":18725,"totalTrials":208,"cells":18726},"BMS 587101",{"EARLY_PHASE1":18727,"PHASE1":18729,"PHASE2":18731,"PHASE3":18740,"PHASE4":18742,"NA":18744},{"trials":18728,"activeCount":98},[],{"trials":18730,"activeCount":98},[],{"trials":18732,"activeCount":98},[18733],{"nctId":18734,"briefTitle":18735,"status":963,"phases":18736,"primaryCompletion":5117,"start":7674,"enrollment":3862,"conditions":18737,"interventions":18739},"NCT00162253","Study of BMS-587101 in Patients With Moderate to Severe Psoriasis",[88],[18738],"Psoriasis, Moderate to Severe",[18725],{"trials":18741,"activeCount":98},[],{"trials":18743,"activeCount":98},[],{"trials":18745,"activeCount":98},[],{"intervention":15550,"totalTrials":208,"cells":18747},{"EARLY_PHASE1":18748,"PHASE1":18750,"PHASE2":18752,"PHASE3":18758,"PHASE4":18760,"NA":18762},{"trials":18749,"activeCount":98},[],{"trials":18751,"activeCount":98},[],{"trials":18753,"activeCount":98},[18754],{"nctId":15542,"briefTitle":15543,"status":104,"phases":18755,"primaryCompletion":15545,"completion":15545,"start":15546,"enrollment":2308,"conditions":18756,"interventions":18757},[88],[15548,18],[15550,15528,15199],{"trials":18759,"activeCount":98},[],{"trials":18761,"activeCount":98},[],{"trials":18763,"activeCount":98},[],{"intervention":16673,"totalTrials":208,"cells":18765},{"EARLY_PHASE1":18766,"PHASE1":18768,"PHASE2":18770,"PHASE3":18776,"PHASE4":18778,"NA":18780},{"trials":18767,"activeCount":98},[],{"trials":18769,"activeCount":98},[],{"trials":18771,"activeCount":98},[18772],{"nctId":16666,"briefTitle":16667,"status":104,"phases":18773,"primaryCompletion":3904,"completion":6918,"start":6953,"enrollment":534,"conditions":18774,"interventions":18775},[88],[16670],[16644,16672,16673],{"trials":18777,"activeCount":98},[],{"trials":18779,"activeCount":98},[],{"trials":18781,"activeCount":98},[],{"intervention":18783,"totalTrials":208,"cells":18784},"BMS-911543",{"EARLY_PHASE1":18785,"PHASE1":18787,"PHASE2":18789,"PHASE3":18799,"PHASE4":18801,"NA":18803},{"trials":18786,"activeCount":98},[],{"trials":18788,"activeCount":98},[],{"trials":18790,"activeCount":98},[18791],{"nctId":18792,"briefTitle":18793,"status":963,"phases":18794,"primaryCompletion":6995,"completion":6995,"start":18795,"enrollment":18796,"conditions":18797,"interventions":18798},"NCT01236352","Multiple Ascending Dose of BMS-911543",[87,88],"2011-04-07",98,[606],[18783],{"trials":18800,"activeCount":98},[],{"trials":18802,"activeCount":98},[],{"trials":18804,"activeCount":98},[],{"intervention":18806,"totalTrials":208,"cells":18807},"200 mg INX-08189 Fasted",{"EARLY_PHASE1":18808,"PHASE1":18810,"PHASE2":18812,"PHASE3":18823,"PHASE4":18825,"NA":18827},{"trials":18809,"activeCount":98},[],{"trials":18811,"activeCount":98},[],{"trials":18813,"activeCount":98},[18814],{"nctId":18815,"briefTitle":18816,"status":104,"phases":18817,"primaryCompletion":6225,"completion":6225,"start":5541,"enrollment":217,"conditions":18818,"interventions":18819},"NCT01445795","Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects",[87,88],[30],[18806,18820,18821,18822,12003],"100 mg INX-08189 QD","100 mg INX-08189 with low-fat meal","100 mg INX-08189 BID Fasted",{"trials":18824,"activeCount":98},[],{"trials":18826,"activeCount":98},[],{"trials":18828,"activeCount":98},[],{"intervention":18820,"totalTrials":208,"cells":18830},{"EARLY_PHASE1":18831,"PHASE1":18833,"PHASE2":18835,"PHASE3":18841,"PHASE4":18843,"NA":18845},{"trials":18832,"activeCount":98},[],{"trials":18834,"activeCount":98},[],{"trials":18836,"activeCount":98},[18837],{"nctId":18815,"briefTitle":18816,"status":104,"phases":18838,"primaryCompletion":6225,"completion":6225,"start":5541,"enrollment":217,"conditions":18839,"interventions":18840},[87,88],[30],[18806,18820,18821,18822,12003],{"trials":18842,"activeCount":98},[],{"trials":18844,"activeCount":98},[],{"trials":18846,"activeCount":98},[],{"intervention":18821,"totalTrials":208,"cells":18848},{"EARLY_PHASE1":18849,"PHASE1":18851,"PHASE2":18853,"PHASE3":18859,"PHASE4":18861,"NA":18863},{"trials":18850,"activeCount":98},[],{"trials":18852,"activeCount":98},[],{"trials":18854,"activeCount":98},[18855],{"nctId":18815,"briefTitle":18816,"status":104,"phases":18856,"primaryCompletion":6225,"completion":6225,"start":5541,"enrollment":217,"conditions":18857,"interventions":18858},[87,88],[30],[18806,18820,18821,18822,12003],{"trials":18860,"activeCount":98},[],{"trials":18862,"activeCount":98},[],{"trials":18864,"activeCount":98},[],{"intervention":18822,"totalTrials":208,"cells":18866},{"EARLY_PHASE1":18867,"PHASE1":18869,"PHASE2":18871,"PHASE3":18877,"PHASE4":18879,"NA":18881},{"trials":18868,"activeCount":98},[],{"trials":18870,"activeCount":98},[],{"trials":18872,"activeCount":98},[18873],{"nctId":18815,"briefTitle":18816,"status":104,"phases":18874,"primaryCompletion":6225,"completion":6225,"start":5541,"enrollment":217,"conditions":18875,"interventions":18876},[87,88],[30],[18806,18820,18821,18822,12003],{"trials":18878,"activeCount":98},[],{"trials":18880,"activeCount":98},[],{"trials":18882,"activeCount":98},[],{"intervention":16937,"totalTrials":208,"cells":18884},{"EARLY_PHASE1":18885,"PHASE1":18887,"PHASE2":18889,"PHASE3":18895,"PHASE4":18897,"NA":18899},{"trials":18886,"activeCount":98},[],{"trials":18888,"activeCount":98},[],{"trials":18890,"activeCount":98},[18891],{"nctId":16931,"briefTitle":16932,"status":104,"phases":18892,"primaryCompletion":4038,"completion":4038,"start":7811,"enrollment":16934,"conditions":18893,"interventions":18894},[88],[990],[16937,16910],{"trials":18896,"activeCount":98},[],{"trials":18898,"activeCount":98},[],{"trials":18900,"activeCount":98},[],{"intervention":18902,"totalTrials":208,"cells":18903},"pegIFN",{"EARLY_PHASE1":18904,"PHASE1":18906,"PHASE2":18908,"PHASE3":18919,"PHASE4":18921,"NA":18923},{"trials":18905,"activeCount":98},[],{"trials":18907,"activeCount":98},[],{"trials":18909,"activeCount":98},[18910],{"nctId":18911,"briefTitle":18912,"status":104,"phases":18913,"primaryCompletion":3959,"completion":3959,"start":3904,"enrollment":2969,"conditions":18914,"interventions":18916},"NCT01204762","Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen",[88],[18915],"Hepatitis B Virus",[18902,18917,18918,10680],"pegIFNα-2a","PegIFN lambda",{"trials":18920,"activeCount":98},[],{"trials":18922,"activeCount":98},[],{"trials":18924,"activeCount":98},[],{"intervention":18917,"totalTrials":208,"cells":18926},{"EARLY_PHASE1":18927,"PHASE1":18929,"PHASE2":18931,"PHASE3":18937,"PHASE4":18939,"NA":18941},{"trials":18928,"activeCount":98},[],{"trials":18930,"activeCount":98},[],{"trials":18932,"activeCount":98},[18933],{"nctId":18911,"briefTitle":18912,"status":104,"phases":18934,"primaryCompletion":3959,"completion":3959,"start":3904,"enrollment":2969,"conditions":18935,"interventions":18936},[88],[18915],[18902,18917,18918,10680],{"trials":18938,"activeCount":98},[],{"trials":18940,"activeCount":98},[],{"trials":18942,"activeCount":98},[],{"intervention":18918,"totalTrials":208,"cells":18944},{"EARLY_PHASE1":18945,"PHASE1":18947,"PHASE2":18949,"PHASE3":18955,"PHASE4":18957,"NA":18959},{"trials":18946,"activeCount":98},[],{"trials":18948,"activeCount":98},[],{"trials":18950,"activeCount":98},[18951],{"nctId":18911,"briefTitle":18912,"status":104,"phases":18952,"primaryCompletion":3959,"completion":3959,"start":3904,"enrollment":2969,"conditions":18953,"interventions":18954},[88],[18915],[18902,18917,18918,10680],{"trials":18956,"activeCount":98},[],{"trials":18958,"activeCount":98},[],{"trials":18960,"activeCount":98},[],{"intervention":18962,"totalTrials":208,"cells":18963},"BMS-741672",{"EARLY_PHASE1":18964,"PHASE1":18966,"PHASE2":18968,"PHASE3":18977,"PHASE4":18979,"NA":18981},{"trials":18965,"activeCount":98},[],{"trials":18967,"activeCount":98},[],{"trials":18969,"activeCount":98},[18970],{"nctId":18971,"briefTitle":18972,"status":104,"phases":18973,"primaryCompletion":7713,"completion":3587,"start":4039,"enrollment":217,"conditions":18974,"interventions":18976},"NCT00683423","BMS-741672 for Diabetic Neuropathic Pain",[88],[18975],"Neuropathic Pain",[18962],{"trials":18978,"activeCount":98},[],{"trials":18980,"activeCount":98},[],{"trials":18982,"activeCount":98},[],{"intervention":10755,"totalTrials":208,"cells":18984},{"EARLY_PHASE1":18985,"PHASE1":18987,"PHASE2":18989,"PHASE3":18995,"PHASE4":18997,"NA":18999},{"trials":18986,"activeCount":98},[],{"trials":18988,"activeCount":98},[],{"trials":18990,"activeCount":98},[18991],{"nctId":10748,"briefTitle":10749,"status":963,"phases":18992,"primaryCompletion":4123,"completion":4122,"start":3938,"enrollment":10751,"conditions":18993,"interventions":18994},[88],[10753],[10755,10755,10755,9383,10466,8548],{"trials":18996,"activeCount":98},[],{"trials":18998,"activeCount":98},[],{"trials":19000,"activeCount":98},[],{"intervention":19002,"totalTrials":208,"cells":19003},"INX-08189 50 mg QD X 5 days",{"EARLY_PHASE1":19004,"PHASE1":19006,"PHASE2":19008,"PHASE3":19020,"PHASE4":19022,"NA":19024},{"trials":19005,"activeCount":98},[],{"trials":19007,"activeCount":98},[],{"trials":19009,"activeCount":98},[19010],{"nctId":19011,"briefTitle":19012,"status":104,"phases":19013,"primaryCompletion":3960,"completion":3960,"start":5542,"enrollment":34,"conditions":19014,"interventions":19015},"NCT01471717","Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects",[87,88],[759],[19002,19016,19017,19018,19019],"INX-08189 \u002F Victrelis 800 mg TID X three days","Victrelis 800 mg TID x 3 days","Victrelis 800 mg TID with INX-08189 50 mg QD","Cohort 2: Victrelis 800 mg with Placebo",{"trials":19021,"activeCount":98},[],{"trials":19023,"activeCount":98},[],{"trials":19025,"activeCount":98},[],{"intervention":19016,"totalTrials":208,"cells":19027},{"EARLY_PHASE1":19028,"PHASE1":19030,"PHASE2":19032,"PHASE3":19038,"PHASE4":19040,"NA":19042},{"trials":19029,"activeCount":98},[],{"trials":19031,"activeCount":98},[],{"trials":19033,"activeCount":98},[19034],{"nctId":19011,"briefTitle":19012,"status":104,"phases":19035,"primaryCompletion":3960,"completion":3960,"start":5542,"enrollment":34,"conditions":19036,"interventions":19037},[87,88],[759],[19002,19016,19017,19018,19019],{"trials":19039,"activeCount":98},[],{"trials":19041,"activeCount":98},[],{"trials":19043,"activeCount":98},[],{"intervention":19017,"totalTrials":208,"cells":19045},{"EARLY_PHASE1":19046,"PHASE1":19048,"PHASE2":19050,"PHASE3":19056,"PHASE4":19058,"NA":19060},{"trials":19047,"activeCount":98},[],{"trials":19049,"activeCount":98},[],{"trials":19051,"activeCount":98},[19052],{"nctId":19011,"briefTitle":19012,"status":104,"phases":19053,"primaryCompletion":3960,"completion":3960,"start":5542,"enrollment":34,"conditions":19054,"interventions":19055},[87,88],[759],[19002,19016,19017,19018,19019],{"trials":19057,"activeCount":98},[],{"trials":19059,"activeCount":98},[],{"trials":19061,"activeCount":98},[],{"intervention":19018,"totalTrials":208,"cells":19063},{"EARLY_PHASE1":19064,"PHASE1":19066,"PHASE2":19068,"PHASE3":19074,"PHASE4":19076,"NA":19078},{"trials":19065,"activeCount":98},[],{"trials":19067,"activeCount":98},[],{"trials":19069,"activeCount":98},[19070],{"nctId":19011,"briefTitle":19012,"status":104,"phases":19071,"primaryCompletion":3960,"completion":3960,"start":5542,"enrollment":34,"conditions":19072,"interventions":19073},[87,88],[759],[19002,19016,19017,19018,19019],{"trials":19075,"activeCount":98},[],{"trials":19077,"activeCount":98},[],{"trials":19079,"activeCount":98},[],{"intervention":19019,"totalTrials":208,"cells":19081},{"EARLY_PHASE1":19082,"PHASE1":19084,"PHASE2":19086,"PHASE3":19092,"PHASE4":19094,"NA":19096},{"trials":19083,"activeCount":98},[],{"trials":19085,"activeCount":98},[],{"trials":19087,"activeCount":98},[19088],{"nctId":19011,"briefTitle":19012,"status":104,"phases":19089,"primaryCompletion":3960,"completion":3960,"start":5542,"enrollment":34,"conditions":19090,"interventions":19091},[87,88],[759],[19002,19016,19017,19018,19019],{"trials":19093,"activeCount":98},[],{"trials":19095,"activeCount":98},[],{"trials":19097,"activeCount":98},[],{"intervention":19099,"totalTrials":208,"cells":19100},"BMS-777607",{"EARLY_PHASE1":19101,"PHASE1":19103,"PHASE2":19105,"PHASE3":19113,"PHASE4":19115,"NA":19117},{"trials":19102,"activeCount":98},[],{"trials":19104,"activeCount":98},[],{"trials":19106,"activeCount":98},[19107],{"nctId":19108,"briefTitle":19109,"status":104,"phases":19110,"primaryCompletion":4981,"completion":4981,"start":5023,"enrollment":839,"conditions":19111,"interventions":19112},"NCT00605618","Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors",[87,88],[1132],[19099],{"trials":19114,"activeCount":98},[],{"trials":19116,"activeCount":98},[],{"trials":19118,"activeCount":98},[],{"intervention":1698,"totalTrials":208,"cells":19120},{"EARLY_PHASE1":19121,"PHASE1":19123,"PHASE2":19125,"PHASE3":19131,"PHASE4":19133,"NA":19135},{"trials":19122,"activeCount":98},[],{"trials":19124,"activeCount":98},[],{"trials":19126,"activeCount":98},[19127],{"nctId":1690,"briefTitle":1691,"status":963,"phases":19128,"primaryCompletion":1693,"completion":1693,"start":1694,"enrollment":1695,"conditions":19129,"interventions":19130},[87,88],[1154],[1698,43,636],{"trials":19132,"activeCount":98},[],{"trials":19134,"activeCount":98},[],{"trials":19136,"activeCount":98},[],{"intervention":5093,"totalTrials":208,"cells":19138},{"EARLY_PHASE1":19139,"PHASE1":19141,"PHASE2":19143,"PHASE3":19149,"PHASE4":19151,"NA":19153},{"trials":19140,"activeCount":98},[],{"trials":19142,"activeCount":98},[],{"trials":19144,"activeCount":98},[19145],{"nctId":5083,"briefTitle":5084,"status":104,"phases":19146,"primaryCompletion":5086,"completion":5087,"start":5088,"enrollment":413,"conditions":19147,"interventions":19148},[88],[5090],[5092,1158,5093,2913],{"trials":19150,"activeCount":98},[],{"trials":19152,"activeCount":98},[],{"trials":19154,"activeCount":98},[],{"intervention":1753,"totalTrials":208,"cells":19156},{"EARLY_PHASE1":19157,"PHASE1":19159,"PHASE2":19161,"PHASE3":19167,"PHASE4":19169,"NA":19171},{"trials":19158,"activeCount":98},[],{"trials":19160,"activeCount":98},[],{"trials":19162,"activeCount":98},[19163],{"nctId":1745,"briefTitle":1746,"status":963,"phases":19164,"primaryCompletion":1748,"completion":1748,"start":1749,"enrollment":1750,"conditions":19165,"interventions":19166},[87,88],[606],[1753,43],{"trials":19168,"activeCount":98},[],{"trials":19170,"activeCount":98},[],{"trials":19172,"activeCount":98},[],{"intervention":19174,"totalTrials":208,"cells":19175},"Dasatinib 100 mg",{"EARLY_PHASE1":19176,"PHASE1":19178,"PHASE2":19180,"PHASE3":19188,"PHASE4":19190,"NA":19192},{"trials":19177,"activeCount":98},[],{"trials":19179,"activeCount":98},[],{"trials":19181,"activeCount":98},[19182],{"nctId":19183,"briefTitle":19184,"status":104,"phases":19185,"primaryCompletion":4981,"completion":4459,"start":7846,"enrollment":1695,"conditions":19186,"interventions":19187},"NCT00371345","Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen\u002FProgesterone Receptor-positive (ER+\u002FPR+) or Her2\u002FNeu-positive (Her2\u002FNeu+)Breast Cancer",[88],[1223,4935],[1197,19174],{"trials":19189,"activeCount":98},[],{"trials":19191,"activeCount":98},[],{"trials":19193,"activeCount":98},[],{"intervention":19195,"totalTrials":208,"cells":19196},"Infliximab + Prednisone",{"EARLY_PHASE1":19197,"PHASE1":19199,"PHASE2":19201,"PHASE3":19211,"PHASE4":19213,"NA":19215},{"trials":19198,"activeCount":98},[],{"trials":19200,"activeCount":98},[],{"trials":19202,"activeCount":98},[19203],{"nctId":19204,"briefTitle":19205,"status":467,"phases":19206,"primaryCompletion":15559,"completion":15559,"start":19207,"enrollment":98,"conditions":19208,"interventions":19209},"NCT02763761","An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and\u002For Opdivo",[88],"2016-08-16",[1253,21,1717],[19195,19210],"Methylprednisolone + Prednisone",{"trials":19212,"activeCount":98},[],{"trials":19214,"activeCount":98},[],{"trials":19216,"activeCount":98},[],{"intervention":19210,"totalTrials":208,"cells":19218},{"EARLY_PHASE1":19219,"PHASE1":19221,"PHASE2":19223,"PHASE3":19229,"PHASE4":19231,"NA":19233},{"trials":19220,"activeCount":98},[],{"trials":19222,"activeCount":98},[],{"trials":19224,"activeCount":98},[19225],{"nctId":19204,"briefTitle":19205,"status":467,"phases":19226,"primaryCompletion":15559,"completion":15559,"start":19207,"enrollment":98,"conditions":19227,"interventions":19228},[88],[1253,21,1717],[19195,19210],{"trials":19230,"activeCount":98},[],{"trials":19232,"activeCount":98},[],{"trials":19234,"activeCount":98},[],{"intervention":19236,"totalTrials":208,"cells":19237},"BMS 188667",{"EARLY_PHASE1":19238,"PHASE1":19240,"PHASE2":19242,"PHASE3":19250,"PHASE4":19252,"NA":19254},{"trials":19239,"activeCount":98},[],{"trials":19241,"activeCount":98},[],{"trials":19243,"activeCount":98},[19244],{"nctId":19245,"briefTitle":19246,"status":963,"phases":19247,"primaryCompletion":3640,"completion":3640,"start":14035,"conditions":19248,"interventions":19249},"NCT00035529","A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis",[88],[5446],[19236,19236],{"trials":19251,"activeCount":98},[],{"trials":19253,"activeCount":98},[],{"trials":19255,"activeCount":98},[],{"intervention":19257,"totalTrials":208,"cells":19258},"BMS-986004 75 mg IV",{"EARLY_PHASE1":19259,"PHASE1":19261,"PHASE2":19263,"PHASE3":19275,"PHASE4":19277,"NA":19279},{"trials":19260,"activeCount":98},[],{"trials":19262,"activeCount":98},[],{"trials":19264,"activeCount":98},[19265],{"nctId":19266,"briefTitle":19267,"status":104,"phases":19268,"primaryCompletion":10472,"completion":10472,"start":2846,"enrollment":6185,"conditions":19269,"interventions":19271},"NCT02273960","Study to Evaluate Safety and Efficacy in Adult Subjects With ITP",[87,88],[19270],"Immune Thrombocytopenic Purpura",[19257,19272,19273,19274],"BMS-986004 225 mg IV","BMS-986004 675 mg IV","BMS-986004 1500 mg IV",{"trials":19276,"activeCount":98},[],{"trials":19278,"activeCount":98},[],{"trials":19280,"activeCount":98},[],{"intervention":19272,"totalTrials":208,"cells":19282},{"EARLY_PHASE1":19283,"PHASE1":19285,"PHASE2":19287,"PHASE3":19293,"PHASE4":19295,"NA":19297},{"trials":19284,"activeCount":98},[],{"trials":19286,"activeCount":98},[],{"trials":19288,"activeCount":98},[19289],{"nctId":19266,"briefTitle":19267,"status":104,"phases":19290,"primaryCompletion":10472,"completion":10472,"start":2846,"enrollment":6185,"conditions":19291,"interventions":19292},[87,88],[19270],[19257,19272,19273,19274],{"trials":19294,"activeCount":98},[],{"trials":19296,"activeCount":98},[],{"trials":19298,"activeCount":98},[],{"intervention":19273,"totalTrials":208,"cells":19300},{"EARLY_PHASE1":19301,"PHASE1":19303,"PHASE2":19305,"PHASE3":19311,"PHASE4":19313,"NA":19315},{"trials":19302,"activeCount":98},[],{"trials":19304,"activeCount":98},[],{"trials":19306,"activeCount":98},[19307],{"nctId":19266,"briefTitle":19267,"status":104,"phases":19308,"primaryCompletion":10472,"completion":10472,"start":2846,"enrollment":6185,"conditions":19309,"interventions":19310},[87,88],[19270],[19257,19272,19273,19274],{"trials":19312,"activeCount":98},[],{"trials":19314,"activeCount":98},[],{"trials":19316,"activeCount":98},[],{"intervention":19274,"totalTrials":208,"cells":19318},{"EARLY_PHASE1":19319,"PHASE1":19321,"PHASE2":19323,"PHASE3":19329,"PHASE4":19331,"NA":19333},{"trials":19320,"activeCount":98},[],{"trials":19322,"activeCount":98},[],{"trials":19324,"activeCount":98},[19325],{"nctId":19266,"briefTitle":19267,"status":104,"phases":19326,"primaryCompletion":10472,"completion":10472,"start":2846,"enrollment":6185,"conditions":19327,"interventions":19328},[87,88],[19270],[19257,19272,19273,19274],{"trials":19330,"activeCount":98},[],{"trials":19332,"activeCount":98},[],{"trials":19334,"activeCount":98},[],{"intervention":1770,"totalTrials":208,"cells":19336},{"EARLY_PHASE1":19337,"PHASE1":19339,"PHASE2":19341,"PHASE3":19347,"PHASE4":19349,"NA":19351},{"trials":19338,"activeCount":98},[],{"trials":19340,"activeCount":98},[],{"trials":19342,"activeCount":98},[19343],{"nctId":1763,"briefTitle":1764,"status":104,"phases":19344,"primaryCompletion":1766,"completion":1766,"start":1767,"enrollment":1634,"conditions":19345,"interventions":19346},[87,88],[1154],[1770,43,608,1771,1772,1773],{"trials":19348,"activeCount":98},[],{"trials":19350,"activeCount":98},[],{"trials":19352,"activeCount":98},[],{"intervention":1772,"totalTrials":208,"cells":19354},{"EARLY_PHASE1":19355,"PHASE1":19357,"PHASE2":19359,"PHASE3":19365,"PHASE4":19367,"NA":19369},{"trials":19356,"activeCount":98},[],{"trials":19358,"activeCount":98},[],{"trials":19360,"activeCount":98},[19361],{"nctId":1763,"briefTitle":1764,"status":104,"phases":19362,"primaryCompletion":1766,"completion":1766,"start":1767,"enrollment":1634,"conditions":19363,"interventions":19364},[87,88],[1154],[1770,43,608,1771,1772,1773],{"trials":19366,"activeCount":98},[],{"trials":19368,"activeCount":98},[],{"trials":19370,"activeCount":98},[],{"intervention":1785,"totalTrials":208,"cells":19372},{"EARLY_PHASE1":19373,"PHASE1":19375,"PHASE2":19377,"PHASE3":19383,"PHASE4":19385,"NA":19387},{"trials":19374,"activeCount":98},[],{"trials":19376,"activeCount":98},[],{"trials":19378,"activeCount":98},[19379],{"nctId":1775,"briefTitle":1776,"status":104,"phases":19380,"primaryCompletion":1778,"completion":1779,"start":1780,"enrollment":1781,"conditions":19381,"interventions":19382},[88],[1783],[43,608,1785],{"trials":19384,"activeCount":98},[],{"trials":19386,"activeCount":98},[],{"trials":19388,"activeCount":98},[],{"intervention":19390,"totalTrials":208,"cells":19391},"BMS-936557",{"EARLY_PHASE1":19392,"PHASE1":19394,"PHASE2":19396,"PHASE3":19404,"PHASE4":19406,"NA":19408},{"trials":19393,"activeCount":98},[],{"trials":19395,"activeCount":98},[],{"trials":19397,"activeCount":98},[19398],{"nctId":19399,"briefTitle":19400,"status":104,"phases":19401,"primaryCompletion":3017,"completion":1342,"start":3679,"enrollment":2028,"conditions":19402,"interventions":19403},"NCT01466374","Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease",[88],[1002],[19390,19390,19390,19390,19390],{"trials":19405,"activeCount":98},[],{"trials":19407,"activeCount":98},[],{"trials":19409,"activeCount":98},[],{"intervention":1808,"totalTrials":208,"cells":19411},{"EARLY_PHASE1":19412,"PHASE1":19414,"PHASE2":19416,"PHASE3":19422,"PHASE4":19424,"NA":19426},{"trials":19413,"activeCount":98},[],{"trials":19415,"activeCount":98},[],{"trials":19417,"activeCount":98},[19418],{"nctId":1799,"briefTitle":1800,"status":104,"phases":19419,"primaryCompletion":1802,"completion":1803,"start":1804,"enrollment":1805,"conditions":19420,"interventions":19421},[87,88],[606,21],[1808,43,608],{"trials":19423,"activeCount":98},[],{"trials":19425,"activeCount":98},[],{"trials":19427,"activeCount":98},[],{"intervention":19429,"totalTrials":208,"cells":19430},"Opdivo",{"EARLY_PHASE1":19431,"PHASE1":19433,"PHASE2":19435,"PHASE3":19446,"PHASE4":19448,"NA":19450},{"trials":19432,"activeCount":98},[],{"trials":19434,"activeCount":98},[],{"trials":19436,"activeCount":98},[19437],{"nctId":19438,"briefTitle":19439,"status":104,"phases":19440,"primaryCompletion":1749,"completion":19441,"start":19442,"enrollment":515,"conditions":19443,"interventions":19444},"NCT03029780","An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma",[88],"2021-06-15","2017-02-16",[1253],[19429,19445],"Yervoy",{"trials":19447,"activeCount":98},[],{"trials":19449,"activeCount":98},[],{"trials":19451,"activeCount":98},[],{"intervention":1869,"totalTrials":208,"cells":19453},{"EARLY_PHASE1":19454,"PHASE1":19456,"PHASE2":19458,"PHASE3":19464,"PHASE4":19466,"NA":19468},{"trials":19455,"activeCount":98},[],{"trials":19457,"activeCount":98},[],{"trials":19459,"activeCount":98},[19460],{"nctId":1859,"briefTitle":1860,"status":963,"phases":19461,"primaryCompletion":1862,"completion":1862,"start":789,"enrollment":1863,"conditions":19462,"interventions":19463},[87,88],[606,1865,1866,1867],[1869,43,608,1870],{"trials":19465,"activeCount":98},[],{"trials":19467,"activeCount":98},[],{"trials":19469,"activeCount":98},[],{"intervention":5864,"totalTrials":208,"cells":19471},{"EARLY_PHASE1":19472,"PHASE1":19474,"PHASE2":19476,"PHASE3":19482,"PHASE4":19484,"NA":19486},{"trials":19473,"activeCount":98},[],{"trials":19475,"activeCount":98},[],{"trials":19477,"activeCount":98},[19478],{"nctId":5858,"briefTitle":5859,"status":963,"phases":19479,"primaryCompletion":5861,"completion":5861,"start":135,"enrollment":520,"conditions":19480,"interventions":19481},[87,88],[1132],[5864,1144,1145],{"trials":19483,"activeCount":98},[],{"trials":19485,"activeCount":98},[],{"trials":19487,"activeCount":98},[],{"intervention":19489,"totalTrials":208,"cells":19490},"CXL-1020",{"EARLY_PHASE1":19491,"PHASE1":19493,"PHASE2":19495,"PHASE3":19505,"PHASE4":19507,"NA":19509},{"trials":19492,"activeCount":98},[],{"trials":19494,"activeCount":98},[],{"trials":19496,"activeCount":98},[19497],{"nctId":19498,"briefTitle":19499,"status":104,"phases":19500,"primaryCompletion":7944,"completion":7944,"start":3712,"enrollment":11958,"conditions":19501,"interventions":19502},"NCT01092325","Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure",[87,88],[8277],[19489,19489,19503,19504],"CXL-1020 Dose for Echo Cohort A","CXL-1020 Doses for Echo Cohort B",{"trials":19506,"activeCount":98},[],{"trials":19508,"activeCount":98},[],{"trials":19510,"activeCount":98},[],{"intervention":19503,"totalTrials":208,"cells":19512},{"EARLY_PHASE1":19513,"PHASE1":19515,"PHASE2":19517,"PHASE3":19523,"PHASE4":19525,"NA":19527},{"trials":19514,"activeCount":98},[],{"trials":19516,"activeCount":98},[],{"trials":19518,"activeCount":98},[19519],{"nctId":19498,"briefTitle":19499,"status":104,"phases":19520,"primaryCompletion":7944,"completion":7944,"start":3712,"enrollment":11958,"conditions":19521,"interventions":19522},[87,88],[8277],[19489,19489,19503,19504],{"trials":19524,"activeCount":98},[],{"trials":19526,"activeCount":98},[],{"trials":19528,"activeCount":98},[],{"intervention":19504,"totalTrials":208,"cells":19530},{"EARLY_PHASE1":19531,"PHASE1":19533,"PHASE2":19535,"PHASE3":19541,"PHASE4":19543,"NA":19545},{"trials":19532,"activeCount":98},[],{"trials":19534,"activeCount":98},[],{"trials":19536,"activeCount":98},[19537],{"nctId":19498,"briefTitle":19499,"status":104,"phases":19538,"primaryCompletion":7944,"completion":7944,"start":3712,"enrollment":11958,"conditions":19539,"interventions":19540},[87,88],[8277],[19489,19489,19503,19504],{"trials":19542,"activeCount":98},[],{"trials":19544,"activeCount":98},[],{"trials":19546,"activeCount":98},[],{"intervention":19548,"totalTrials":208,"cells":19549},"BMS-562086",{"EARLY_PHASE1":19550,"PHASE1":19552,"PHASE2":19554,"PHASE3":19563,"PHASE4":19565,"NA":19567},{"trials":19551,"activeCount":98},[],{"trials":19553,"activeCount":98},[],{"trials":19555,"activeCount":98},[19556],{"nctId":19557,"briefTitle":19558,"status":104,"phases":19559,"primaryCompletion":4179,"completion":4930,"start":7846,"enrollment":4579,"conditions":19560,"interventions":19562},"NCT00399438","A Study of BMS-562086 in Patients With Irritable Bowel Syndrome",[88],[19561],"Irritable Bowel Syndrome",[19548],{"trials":19564,"activeCount":98},[],{"trials":19566,"activeCount":98},[],{"trials":19568,"activeCount":98},[],{"intervention":19570,"totalTrials":208,"cells":19571},"MYK-491",{"EARLY_PHASE1":19572,"PHASE1":19574,"PHASE2":19576,"PHASE3":19586,"PHASE4":19588,"NA":19590},{"trials":19573,"activeCount":98},[],{"trials":19575,"activeCount":98},[],{"trials":19577,"activeCount":98},[19578],{"nctId":19579,"briefTitle":19580,"status":104,"phases":19581,"primaryCompletion":7220,"completion":7220,"start":19582,"enrollment":3162,"conditions":19583,"interventions":19585},"NCT03447990","v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491",[87,88],"2018-02-06",[10537,19584],"Dilated Cardiomyopathy",[19570],{"trials":19587,"activeCount":98},[],{"trials":19589,"activeCount":98},[],{"trials":19591,"activeCount":98},[],{"intervention":1909,"totalTrials":208,"cells":19593},{"EARLY_PHASE1":19594,"PHASE1":19596,"PHASE2":19598,"PHASE3":19604,"PHASE4":19606,"NA":19608},{"trials":19595,"activeCount":98},[],{"trials":19597,"activeCount":98},[],{"trials":19599,"activeCount":98},[19600],{"nctId":1902,"briefTitle":1903,"status":963,"phases":19601,"primaryCompletion":1905,"completion":1905,"start":1906,"enrollment":1184,"conditions":19602,"interventions":19603},[87,88],[606],[1909,43],{"trials":19605,"activeCount":98},[],{"trials":19607,"activeCount":98},[],{"trials":19609,"activeCount":98},[],{"intervention":7392,"totalTrials":208,"cells":19611},{"EARLY_PHASE1":19612,"PHASE1":19614,"PHASE2":19616,"PHASE3":19622,"PHASE4":19624,"NA":19626},{"trials":19613,"activeCount":98},[],{"trials":19615,"activeCount":98},[],{"trials":19617,"activeCount":98},[19618],{"nctId":7383,"briefTitle":7384,"status":104,"phases":19619,"primaryCompletion":7386,"completion":7387,"start":3995,"enrollment":7388,"conditions":19620,"interventions":19621},[88],[7390],[7392,7393,3287],{"trials":19623,"activeCount":98},[],{"trials":19625,"activeCount":98},[],{"trials":19627,"activeCount":98},[],{"intervention":7393,"totalTrials":208,"cells":19629},{"EARLY_PHASE1":19630,"PHASE1":19632,"PHASE2":19634,"PHASE3":19640,"PHASE4":19642,"NA":19644},{"trials":19631,"activeCount":98},[],{"trials":19633,"activeCount":98},[],{"trials":19635,"activeCount":98},[19636],{"nctId":7383,"briefTitle":7384,"status":104,"phases":19637,"primaryCompletion":7386,"completion":7387,"start":3995,"enrollment":7388,"conditions":19638,"interventions":19639},[88],[7390],[7392,7393,3287],{"trials":19641,"activeCount":98},[],{"trials":19643,"activeCount":98},[],{"trials":19645,"activeCount":98},[],{"intervention":19647,"totalTrials":208,"cells":19648},"KOS-1584",{"EARLY_PHASE1":19649,"PHASE1":19651,"PHASE2":19653,"PHASE3":19661,"PHASE4":19663,"NA":19665},{"trials":19650,"activeCount":98},[],{"trials":19652,"activeCount":98},[],{"trials":19654,"activeCount":98},[19655],{"nctId":19656,"briefTitle":19657,"status":104,"phases":19658,"primaryCompletion":6480,"completion":6480,"start":7811,"enrollment":208,"conditions":19659,"interventions":19660},"NCT00651508","Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB\u002FIV Non-Small Cell Lung Cancer (NSCLC)",[88],[36],[19647],{"trials":19662,"activeCount":98},[],{"trials":19664,"activeCount":98},[],{"trials":19666,"activeCount":98},[],{"intervention":19668,"totalTrials":208,"cells":19669},"Avagacestat",{"EARLY_PHASE1":19670,"PHASE1":19672,"PHASE2":19674,"PHASE3":19683,"PHASE4":19685,"NA":19687},{"trials":19671,"activeCount":98},[],{"trials":19673,"activeCount":98},[],{"trials":19675,"activeCount":98},[19676],{"nctId":19677,"briefTitle":19678,"status":963,"phases":19679,"primaryCompletion":7691,"completion":7691,"start":4459,"enrollment":19680,"conditions":19681,"interventions":19682},"NCT00890890","A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease",[88],263,[3470],[19668],{"trials":19684,"activeCount":98},[],{"trials":19686,"activeCount":98},[],{"trials":19688,"activeCount":98},[],{"intervention":1948,"totalTrials":208,"cells":19690},{"EARLY_PHASE1":19691,"PHASE1":19693,"PHASE2":19695,"PHASE3":19701,"PHASE4":19703,"NA":19705},{"trials":19692,"activeCount":98},[],{"trials":19694,"activeCount":98},[],{"trials":19696,"activeCount":98},[19697],{"nctId":1940,"briefTitle":1941,"status":104,"phases":19698,"primaryCompletion":1943,"completion":1943,"start":1944,"enrollment":1945,"conditions":19699,"interventions":19700},[87,88],[1154],[1948,43,1949],{"trials":19702,"activeCount":98},[],{"trials":19704,"activeCount":98},[],{"trials":19706,"activeCount":98},[],{"intervention":12014,"totalTrials":208,"cells":19708},{"EARLY_PHASE1":19709,"PHASE1":19711,"PHASE2":19713,"PHASE3":19719,"PHASE4":19721,"NA":19723},{"trials":19710,"activeCount":98},[],{"trials":19712,"activeCount":98},[],{"trials":19714,"activeCount":98},[19715],{"nctId":12009,"briefTitle":12010,"status":104,"phases":19716,"primaryCompletion":3586,"completion":4551,"start":5014,"enrollment":11035,"conditions":19717,"interventions":19718},[88],[11923],[11934,11933,11933,11933,12014,11917],{"trials":19720,"activeCount":98},[],{"trials":19722,"activeCount":98},[],{"trials":19724,"activeCount":98},[],{"intervention":19726,"totalTrials":208,"cells":19727},"Exemestane + Dasatinib",{"EARLY_PHASE1":19728,"PHASE1":19730,"PHASE2":19732,"PHASE3":19741,"PHASE4":19743,"NA":19745},{"trials":19729,"activeCount":98},[],{"trials":19731,"activeCount":98},[],{"trials":19733,"activeCount":98},[19734],{"nctId":19735,"briefTitle":19736,"status":104,"phases":19737,"primaryCompletion":11034,"completion":3977,"start":3587,"enrollment":4012,"conditions":19738,"interventions":19739},"NCT00767520","Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer",[88],[1223],[19726,19740],"Exemestane + Placebo",{"trials":19742,"activeCount":98},[],{"trials":19744,"activeCount":98},[],{"trials":19746,"activeCount":98},[],{"intervention":19740,"totalTrials":208,"cells":19748},{"EARLY_PHASE1":19749,"PHASE1":19751,"PHASE2":19753,"PHASE3":19759,"PHASE4":19761,"NA":19763},{"trials":19750,"activeCount":98},[],{"trials":19752,"activeCount":98},[],{"trials":19754,"activeCount":98},[19755],{"nctId":19735,"briefTitle":19736,"status":104,"phases":19756,"primaryCompletion":11034,"completion":3977,"start":3587,"enrollment":4012,"conditions":19757,"interventions":19758},[88],[1223],[19726,19740],{"trials":19760,"activeCount":98},[],{"trials":19762,"activeCount":98},[],{"trials":19764,"activeCount":98},[],{"intervention":7079,"totalTrials":208,"cells":19766},{"EARLY_PHASE1":19767,"PHASE1":19769,"PHASE2":19771,"PHASE3":19777,"PHASE4":19779,"NA":19781},{"trials":19768,"activeCount":98},[],{"trials":19770,"activeCount":98},[],{"trials":19772,"activeCount":98},[19773],{"nctId":7072,"briefTitle":7073,"status":104,"phases":19774,"primaryCompletion":6480,"completion":6479,"start":4010,"enrollment":7075,"conditions":19775,"interventions":19776},[88],[7077],[7056,7057,7079,7060,971],{"trials":19778,"activeCount":98},[],{"trials":19780,"activeCount":98},[],{"trials":19782,"activeCount":98},[],{"intervention":15798,"totalTrials":208,"cells":19784},{"EARLY_PHASE1":19785,"PHASE1":19787,"PHASE2":19789,"PHASE3":19795,"PHASE4":19797,"NA":19799},{"trials":19786,"activeCount":98},[],{"trials":19788,"activeCount":98},[],{"trials":19790,"activeCount":98},[19791],{"nctId":15793,"briefTitle":15794,"status":104,"phases":19792,"primaryCompletion":6918,"completion":6918,"start":11762,"enrollment":4328,"conditions":19793,"interventions":19794},[88],[1223],[15751,15798,15799],{"trials":19796,"activeCount":98},[],{"trials":19798,"activeCount":98},[],{"trials":19800,"activeCount":98},[],{"intervention":19802,"totalTrials":208,"cells":19803},"Anti-IP-10 Antibody",{"EARLY_PHASE1":19804,"PHASE1":19806,"PHASE2":19808,"PHASE3":19817,"PHASE4":19819,"NA":19821},{"trials":19805,"activeCount":98},[],{"trials":19807,"activeCount":98},[],{"trials":19809,"activeCount":98},[19810],{"nctId":19811,"briefTitle":19812,"status":104,"phases":19813,"primaryCompletion":3977,"completion":1342,"start":11034,"enrollment":19814,"conditions":19815,"interventions":19816},"NCT01294410","Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis",[88],305,[958],[19802,19802,19802,19802,19802,19802],{"trials":19818,"activeCount":98},[],{"trials":19820,"activeCount":98},[],{"trials":19822,"activeCount":98},[],{"intervention":19824,"totalTrials":208,"cells":19825},"Anti-CD137",{"EARLY_PHASE1":19826,"PHASE1":19828,"PHASE2":19830,"PHASE3":19838,"PHASE4":19840,"NA":19842},{"trials":19827,"activeCount":98},[],{"trials":19829,"activeCount":98},[],{"trials":19831,"activeCount":98},[19832],{"nctId":19833,"briefTitle":19834,"status":104,"phases":19835,"primaryCompletion":3678,"completion":3678,"start":5023,"enrollment":11,"conditions":19836,"interventions":19837},"NCT00612664","Phase II, 2nd Line Melanoma - RAND Monotherapy",[88],[21],[19824],{"trials":19839,"activeCount":98},[],{"trials":19841,"activeCount":98},[],{"trials":19843,"activeCount":98},[],{"intervention":2041,"totalTrials":208,"cells":19845},{"EARLY_PHASE1":19846,"PHASE1":19848,"PHASE2":19850,"PHASE3":19856,"PHASE4":19858,"NA":19860},{"trials":19847,"activeCount":98},[],{"trials":19849,"activeCount":98},[],{"trials":19851,"activeCount":98},[19852],{"nctId":2033,"briefTitle":2034,"status":104,"phases":19853,"primaryCompletion":2036,"completion":2036,"start":2037,"enrollment":2038,"conditions":19854,"interventions":19855},[88],[1223,606],[43,2041,2042],{"trials":19857,"activeCount":98},[],{"trials":19859,"activeCount":98},[],{"trials":19861,"activeCount":98},[],{"intervention":2054,"totalTrials":208,"cells":19863},{"EARLY_PHASE1":19864,"PHASE1":19866,"PHASE2":19868,"PHASE3":19874,"PHASE4":19876,"NA":19878},{"trials":19865,"activeCount":98},[],{"trials":19867,"activeCount":98},[],{"trials":19869,"activeCount":98},[19870],{"nctId":2044,"briefTitle":2045,"status":104,"phases":19871,"primaryCompletion":2047,"completion":1843,"start":2048,"enrollment":2049,"conditions":19872,"interventions":19873},[88],[2051],[43,2053,2054,2055],{"trials":19875,"activeCount":98},[],{"trials":19877,"activeCount":98},[],{"trials":19879,"activeCount":98},[],{"intervention":2068,"totalTrials":208,"cells":19881},{"EARLY_PHASE1":19882,"PHASE1":19884,"PHASE2":19886,"PHASE3":19892,"PHASE4":19894,"NA":19896},{"trials":19883,"activeCount":98},[],{"trials":19885,"activeCount":98},[],{"trials":19887,"activeCount":98},[19888],{"nctId":2057,"briefTitle":2058,"status":467,"phases":19889,"primaryCompletion":2060,"completion":2061,"start":2062,"enrollment":98,"conditions":19890,"interventions":19891},[87,88],[2064],[1123,1122,2066,1981,2067,2068],{"trials":19893,"activeCount":98},[],{"trials":19895,"activeCount":98},[],{"trials":19897,"activeCount":98},[],{"intervention":19899,"totalTrials":208,"cells":19900},"BMS-986094",{"EARLY_PHASE1":19901,"PHASE1":19903,"PHASE2":19905,"PHASE3":19913,"PHASE4":19915,"NA":19917},{"trials":19902,"activeCount":98},[],{"trials":19904,"activeCount":98},[],{"trials":19906,"activeCount":98},[19907],{"nctId":19908,"briefTitle":19909,"status":467,"phases":19910,"primaryCompletion":4551,"completion":3017,"start":4123,"enrollment":98,"conditions":19911,"interventions":19912},"NCT01629732","Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C",[88],[11842],[10402,10402,19899,19899,19899,11917],{"trials":19914,"activeCount":98},[],{"trials":19916,"activeCount":98},[],{"trials":19918,"activeCount":98},[],{"intervention":19920,"totalTrials":208,"cells":19921},"valacyclovir",{"EARLY_PHASE1":19922,"PHASE1":19924,"PHASE2":19926,"PHASE3":19939,"PHASE4":19941,"NA":19943},{"trials":19923,"activeCount":98},[],{"trials":19925,"activeCount":98},[],{"trials":19927,"activeCount":98},[19928],{"nctId":19929,"briefTitle":19930,"status":104,"phases":19931,"primaryCompletion":3904,"completion":6918,"start":4459,"enrollment":3370,"conditions":19932,"interventions":19935},"NCT00900783","A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster",[88],[19933,19934],"Herpes Zoster","Shingles",[19920,19936,19936,19937,19938],"FV-100","Valacyclovir placebo","FV-100 placebo",{"trials":19940,"activeCount":98},[],{"trials":19942,"activeCount":98},[],{"trials":19944,"activeCount":98},[],{"intervention":19936,"totalTrials":208,"cells":19946},{"EARLY_PHASE1":19947,"PHASE1":19949,"PHASE2":19951,"PHASE3":19957,"PHASE4":19959,"NA":19961},{"trials":19948,"activeCount":98},[],{"trials":19950,"activeCount":98},[],{"trials":19952,"activeCount":98},[19953],{"nctId":19929,"briefTitle":19930,"status":104,"phases":19954,"primaryCompletion":3904,"completion":6918,"start":4459,"enrollment":3370,"conditions":19955,"interventions":19956},[88],[19933,19934],[19920,19936,19936,19937,19938],{"trials":19958,"activeCount":98},[],{"trials":19960,"activeCount":98},[],{"trials":19962,"activeCount":98},[],{"intervention":19937,"totalTrials":208,"cells":19964},{"EARLY_PHASE1":19965,"PHASE1":19967,"PHASE2":19969,"PHASE3":19975,"PHASE4":19977,"NA":19979},{"trials":19966,"activeCount":98},[],{"trials":19968,"activeCount":98},[],{"trials":19970,"activeCount":98},[19971],{"nctId":19929,"briefTitle":19930,"status":104,"phases":19972,"primaryCompletion":3904,"completion":6918,"start":4459,"enrollment":3370,"conditions":19973,"interventions":19974},[88],[19933,19934],[19920,19936,19936,19937,19938],{"trials":19976,"activeCount":98},[],{"trials":19978,"activeCount":98},[],{"trials":19980,"activeCount":98},[],{"intervention":19938,"totalTrials":208,"cells":19982},{"EARLY_PHASE1":19983,"PHASE1":19985,"PHASE2":19987,"PHASE3":19993,"PHASE4":19995,"NA":19997},{"trials":19984,"activeCount":98},[],{"trials":19986,"activeCount":98},[],{"trials":19988,"activeCount":98},[19989],{"nctId":19929,"briefTitle":19930,"status":104,"phases":19990,"primaryCompletion":3904,"completion":6918,"start":4459,"enrollment":3370,"conditions":19991,"interventions":19992},[88],[19933,19934],[19920,19936,19936,19937,19938],{"trials":19994,"activeCount":98},[],{"trials":19996,"activeCount":98},[],{"trials":19998,"activeCount":98},[],{"intervention":17486,"totalTrials":208,"cells":20000},{"EARLY_PHASE1":20001,"PHASE1":20003,"PHASE2":20005,"PHASE3":20011,"PHASE4":20013,"NA":20015},{"trials":20002,"activeCount":98},[],{"trials":20004,"activeCount":98},[],{"trials":20006,"activeCount":98},[20007],{"nctId":17479,"briefTitle":17480,"status":963,"phases":20008,"primaryCompletion":17482,"completion":17482,"start":17483,"enrollment":22,"conditions":20009,"interventions":20010},[87,88],[15736],[17459,17486],{"trials":20012,"activeCount":98},[],{"trials":20014,"activeCount":98},[],{"trials":20016,"activeCount":98},[],{"intervention":20018,"totalTrials":208,"cells":20019},"BMS-646256",{"EARLY_PHASE1":20020,"PHASE1":20022,"PHASE2":20024,"PHASE3":20033,"PHASE4":20035,"NA":20037},{"trials":20021,"activeCount":98},[],{"trials":20023,"activeCount":98},[],{"trials":20025,"activeCount":98},[20026],{"nctId":20027,"briefTitle":20028,"status":963,"phases":20029,"primaryCompletion":11728,"completion":3572,"start":13061,"enrollment":20030,"conditions":20031,"interventions":20032},"NCT00388609","Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects",[88],705,[17747],[20018],{"trials":20034,"activeCount":98},[],{"trials":20036,"activeCount":98},[],{"trials":20038,"activeCount":98},[],{"intervention":10426,"totalTrials":208,"cells":20040},{"EARLY_PHASE1":20041,"PHASE1":20043,"PHASE2":20045,"PHASE3":20051,"PHASE4":20053,"NA":20055},{"trials":20042,"activeCount":98},[],{"trials":20044,"activeCount":98},[],{"trials":20046,"activeCount":98},[20047],{"nctId":10419,"briefTitle":10420,"status":104,"phases":20048,"primaryCompletion":10422,"completion":10422,"start":10423,"conditions":20049,"interventions":20050},[88],[24],[8547,902,10426],{"trials":20052,"activeCount":98},[],{"trials":20054,"activeCount":98},[],{"trials":20056,"activeCount":98},[],{"intervention":2140,"totalTrials":208,"cells":20058},{"EARLY_PHASE1":20059,"PHASE1":20061,"PHASE2":20063,"PHASE3":20069,"PHASE4":20071,"NA":20073},{"trials":20060,"activeCount":98},[],{"trials":20062,"activeCount":98},[],{"trials":20064,"activeCount":98},[20065],{"nctId":2133,"briefTitle":2134,"status":104,"phases":20066,"primaryCompletion":460,"completion":2136,"start":2137,"enrollment":25,"conditions":20067,"interventions":20068},[87,88],[1132],[2140,43,608,2141,761],{"trials":20070,"activeCount":98},[],{"trials":20072,"activeCount":98},[],{"trials":20074,"activeCount":98},[],{"intervention":2141,"totalTrials":208,"cells":20076},{"EARLY_PHASE1":20077,"PHASE1":20079,"PHASE2":20081,"PHASE3":20087,"PHASE4":20089,"NA":20091},{"trials":20078,"activeCount":98},[],{"trials":20080,"activeCount":98},[],{"trials":20082,"activeCount":98},[20083],{"nctId":2133,"briefTitle":2134,"status":104,"phases":20084,"primaryCompletion":460,"completion":2136,"start":2137,"enrollment":25,"conditions":20085,"interventions":20086},[87,88],[1132],[2140,43,608,2141,761],{"trials":20088,"activeCount":98},[],{"trials":20090,"activeCount":98},[],{"trials":20092,"activeCount":98},[],{"intervention":12021,"totalTrials":208,"cells":20094},{"EARLY_PHASE1":20095,"PHASE1":20097,"PHASE2":20099,"PHASE3":20105,"PHASE4":20107,"NA":20109},{"trials":20096,"activeCount":98},[],{"trials":20098,"activeCount":98},[],{"trials":20100,"activeCount":98},[20101],{"nctId":12016,"briefTitle":12017,"status":104,"phases":20102,"primaryCompletion":3631,"completion":3631,"start":5014,"enrollment":6226,"conditions":20103,"interventions":20104},[88],[11904],[11934,11934,12021,11917],{"trials":20106,"activeCount":98},[],{"trials":20108,"activeCount":98},[],{"trials":20110,"activeCount":98},[],{"intervention":2152,"totalTrials":208,"cells":20112},{"EARLY_PHASE1":20113,"PHASE1":20115,"PHASE2":20117,"PHASE3":20123,"PHASE4":20125,"NA":20127},{"trials":20114,"activeCount":98},[],{"trials":20116,"activeCount":98},[],{"trials":20118,"activeCount":98},[20119],{"nctId":2143,"briefTitle":2144,"status":104,"phases":20120,"primaryCompletion":2146,"completion":2146,"start":2147,"enrollment":2148,"conditions":20121,"interventions":20122},[87,88],[2150],[2152,43,636],{"trials":20124,"activeCount":98},[],{"trials":20126,"activeCount":98},[],{"trials":20128,"activeCount":98},[],{"intervention":13135,"totalTrials":208,"cells":20130},{"EARLY_PHASE1":20131,"PHASE1":20133,"PHASE2":20135,"PHASE3":20141,"PHASE4":20143,"NA":20145},{"trials":20132,"activeCount":98},[],{"trials":20134,"activeCount":98},[],{"trials":20136,"activeCount":98},[20137],{"nctId":13126,"briefTitle":13127,"status":104,"phases":20138,"primaryCompletion":13129,"completion":13130,"start":13131,"enrollment":1063,"conditions":20139,"interventions":20140},[88],[30],[13117,11917,13134,13135],{"trials":20142,"activeCount":98},[],{"trials":20144,"activeCount":98},[],{"trials":20146,"activeCount":98},[],{"intervention":6230,"totalTrials":208,"cells":20148},{"EARLY_PHASE1":20149,"PHASE1":20151,"PHASE2":20153,"PHASE3":20159,"PHASE4":20161,"NA":20163},{"trials":20150,"activeCount":98},[],{"trials":20152,"activeCount":98},[],{"trials":20154,"activeCount":98},[20155],{"nctId":6222,"briefTitle":6223,"status":104,"phases":20156,"primaryCompletion":4378,"completion":6184,"start":6225,"enrollment":6226,"conditions":20157,"interventions":20158},[88],[6228],[1794,6230,1795,1773],{"trials":20160,"activeCount":98},[],{"trials":20162,"activeCount":98},[],{"trials":20164,"activeCount":98},[],{"intervention":12752,"totalTrials":208,"cells":20166},{"EARLY_PHASE1":20167,"PHASE1":20169,"PHASE2":20171,"PHASE3":20177,"PHASE4":20179,"NA":20181},{"trials":20168,"activeCount":98},[],{"trials":20170,"activeCount":98},[],{"trials":20172,"activeCount":98},[20173],{"nctId":12744,"briefTitle":12745,"status":104,"phases":20174,"primaryCompletion":10518,"completion":10518,"start":7714,"enrollment":12747,"conditions":20175,"interventions":20176},[88],[12749],[12751,11906,12752,12753,12753,12753,12753],{"trials":20178,"activeCount":98},[],{"trials":20180,"activeCount":98},[],{"trials":20182,"activeCount":98},[],{"intervention":2204,"totalTrials":208,"cells":20184},{"EARLY_PHASE1":20185,"PHASE1":20187,"PHASE2":20189,"PHASE3":20195,"PHASE4":20197,"NA":20199},{"trials":20186,"activeCount":98},[],{"trials":20188,"activeCount":98},[],{"trials":20190,"activeCount":98},[20191],{"nctId":2195,"briefTitle":2196,"status":104,"phases":20192,"primaryCompletion":2198,"completion":1129,"start":2199,"enrollment":2200,"conditions":20193,"interventions":20194},[88],[1436,1437,2202],[2122,43,2204,2205,2206],{"trials":20196,"activeCount":98},[],{"trials":20198,"activeCount":98},[],{"trials":20200,"activeCount":98},[],{"intervention":2206,"totalTrials":208,"cells":20202},{"EARLY_PHASE1":20203,"PHASE1":20205,"PHASE2":20207,"PHASE3":20213,"PHASE4":20215,"NA":20217},{"trials":20204,"activeCount":98},[],{"trials":20206,"activeCount":98},[],{"trials":20208,"activeCount":98},[20209],{"nctId":2195,"briefTitle":2196,"status":104,"phases":20210,"primaryCompletion":2198,"completion":1129,"start":2199,"enrollment":2200,"conditions":20211,"interventions":20212},[88],[1436,1437,2202],[2122,43,2204,2205,2206],{"trials":20214,"activeCount":98},[],{"trials":20216,"activeCount":98},[],{"trials":20218,"activeCount":98},[],{"intervention":20220,"totalTrials":208,"cells":20221},"CTLA4Ig \u002F Abatacept",{"EARLY_PHASE1":20222,"PHASE1":20224,"PHASE2":20226,"PHASE3":20236,"PHASE4":20238,"NA":20240},{"trials":20223,"activeCount":98},[],{"trials":20225,"activeCount":98},[],{"trials":20227,"activeCount":98},[20228],{"nctId":20229,"briefTitle":20230,"status":104,"phases":20231,"primaryCompletion":20232,"completion":20232,"start":20233,"enrollment":10762,"conditions":20234,"interventions":20235},"NCT00287547","Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris",[88],"1998-01","1997-03",[7653],[20220],{"trials":20237,"activeCount":98},[],{"trials":20239,"activeCount":98},[],{"trials":20241,"activeCount":98},[],{"intervention":20243,"totalTrials":208,"cells":20244},"BMS-275291",{"EARLY_PHASE1":20245,"PHASE1":20247,"PHASE2":20249,"PHASE3":20257,"PHASE4":20259,"NA":20261},{"trials":20246,"activeCount":98},[],{"trials":20248,"activeCount":98},[],{"trials":20250,"activeCount":98},[20251],{"nctId":20252,"briefTitle":20253,"status":963,"phases":20254,"primaryCompletion":7643,"conditions":20255,"interventions":20256},"NCT00036621","A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and\u002For Hormonal Therapy",[88],[1223],[20243],{"trials":20258,"activeCount":98},[],{"trials":20260,"activeCount":98},[],{"trials":20262,"activeCount":98},[],{"intervention":2216,"totalTrials":208,"cells":20264},{"EARLY_PHASE1":20265,"PHASE1":20267,"PHASE2":20269,"PHASE3":20275,"PHASE4":20277,"NA":20279},{"trials":20266,"activeCount":98},[],{"trials":20268,"activeCount":98},[],{"trials":20270,"activeCount":98},[20271],{"nctId":2208,"briefTitle":2209,"status":104,"phases":20272,"primaryCompletion":2211,"completion":2211,"start":2212,"enrollment":534,"conditions":20273,"interventions":20274},[88],[2051],[43,2215,2216],{"trials":20276,"activeCount":98},[],{"trials":20278,"activeCount":98},[],{"trials":20280,"activeCount":98},[],{"intervention":7093,"totalTrials":208,"cells":20282},{"EARLY_PHASE1":20283,"PHASE1":20285,"PHASE2":20287,"PHASE3":20293,"PHASE4":20295,"NA":20297},{"trials":20284,"activeCount":98},[],{"trials":20286,"activeCount":98},[],{"trials":20288,"activeCount":98},[20289],{"nctId":7085,"briefTitle":7086,"status":963,"phases":20290,"primaryCompletion":7088,"completion":7089,"start":4930,"enrollment":3093,"conditions":20291,"interventions":20292},[88],[7091],[7060,7093,7094,7095,971],{"trials":20294,"activeCount":98},[],{"trials":20296,"activeCount":98},[],{"trials":20298,"activeCount":98},[],{"intervention":7094,"totalTrials":208,"cells":20300},{"EARLY_PHASE1":20301,"PHASE1":20303,"PHASE2":20305,"PHASE3":20311,"PHASE4":20313,"NA":20315},{"trials":20302,"activeCount":98},[],{"trials":20304,"activeCount":98},[],{"trials":20306,"activeCount":98},[20307],{"nctId":7085,"briefTitle":7086,"status":963,"phases":20308,"primaryCompletion":7088,"completion":7089,"start":4930,"enrollment":3093,"conditions":20309,"interventions":20310},[88],[7091],[7060,7093,7094,7095,971],{"trials":20312,"activeCount":98},[],{"trials":20314,"activeCount":98},[],{"trials":20316,"activeCount":98},[],{"intervention":7095,"totalTrials":208,"cells":20318},{"EARLY_PHASE1":20319,"PHASE1":20321,"PHASE2":20323,"PHASE3":20329,"PHASE4":20331,"NA":20333},{"trials":20320,"activeCount":98},[],{"trials":20322,"activeCount":98},[],{"trials":20324,"activeCount":98},[20325],{"nctId":7085,"briefTitle":7086,"status":963,"phases":20326,"primaryCompletion":7088,"completion":7089,"start":4930,"enrollment":3093,"conditions":20327,"interventions":20328},[88],[7091],[7060,7093,7094,7095,971],{"trials":20330,"activeCount":98},[],{"trials":20332,"activeCount":98},[],{"trials":20334,"activeCount":98},[],{"intervention":7806,"totalTrials":208,"cells":20336},{"EARLY_PHASE1":20337,"PHASE1":20339,"PHASE2":20341,"PHASE3":20347,"PHASE4":20349,"NA":20351},{"trials":20338,"activeCount":98},[],{"trials":20340,"activeCount":98},[],{"trials":20342,"activeCount":98},[20343],{"nctId":7796,"briefTitle":7797,"status":104,"phases":20344,"primaryCompletion":7799,"completion":7799,"start":7800,"enrollment":1877,"conditions":20345,"interventions":20346},[88],[7802,15,792,7803],[7805,6972,7806],{"trials":20348,"activeCount":98},[],{"trials":20350,"activeCount":98},[],{"trials":20352,"activeCount":98},[],{"intervention":18013,"totalTrials":208,"cells":20354},{"EARLY_PHASE1":20355,"PHASE1":20357,"PHASE2":20359,"PHASE3":20365,"PHASE4":20367,"NA":20369},{"trials":20356,"activeCount":98},[],{"trials":20358,"activeCount":98},[],{"trials":20360,"activeCount":98},[20361],{"nctId":18007,"briefTitle":18008,"status":104,"phases":20362,"primaryCompletion":5630,"completion":5630,"start":2666,"enrollment":790,"conditions":20363,"interventions":20364},[88],[8277,16079,18011],[17988,18013],{"trials":20366,"activeCount":98},[],{"trials":20368,"activeCount":98},[],{"trials":20370,"activeCount":98},[],{"intervention":20372,"totalTrials":208,"cells":20373},"Ipilimumab+ Placebo",{"EARLY_PHASE1":20374,"PHASE1":20376,"PHASE2":20378,"PHASE3":20387,"PHASE4":20389,"NA":20391},{"trials":20375,"activeCount":98},[],{"trials":20377,"activeCount":98},[],{"trials":20379,"activeCount":98},[20380],{"nctId":20381,"briefTitle":20382,"status":104,"phases":20383,"primaryCompletion":4010,"completion":4010,"start":5098,"enrollment":281,"conditions":20384,"interventions":20385},"NCT00135408","A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide",[88],[3035],[20372,20386],"Ipilimumab+ Budesonide",{"trials":20388,"activeCount":98},[],{"trials":20390,"activeCount":98},[],{"trials":20392,"activeCount":98},[],{"intervention":20386,"totalTrials":208,"cells":20394},{"EARLY_PHASE1":20395,"PHASE1":20397,"PHASE2":20399,"PHASE3":20405,"PHASE4":20407,"NA":20409},{"trials":20396,"activeCount":98},[],{"trials":20398,"activeCount":98},[],{"trials":20400,"activeCount":98},[20401],{"nctId":20381,"briefTitle":20382,"status":104,"phases":20402,"primaryCompletion":4010,"completion":4010,"start":5098,"enrollment":281,"conditions":20403,"interventions":20404},[88],[3035],[20372,20386],{"trials":20406,"activeCount":98},[],{"trials":20408,"activeCount":98},[],{"trials":20410,"activeCount":98},[],{"intervention":20412,"totalTrials":208,"cells":20413},"Lomustine",{"EARLY_PHASE1":20414,"PHASE1":20416,"PHASE2":20418,"PHASE3":20427,"PHASE4":20429,"NA":20431},{"trials":20415,"activeCount":98},[],{"trials":20417,"activeCount":98},[],{"trials":20419,"activeCount":98},[20420],{"nctId":20421,"briefTitle":20422,"status":963,"phases":20423,"primaryCompletion":7776,"completion":7776,"start":3678,"enrollment":11958,"conditions":20424,"interventions":20426},"NCT00948389","Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)",[87,88],[20425],"Glioblastoma",[1197,20412],{"trials":20428,"activeCount":98},[],{"trials":20430,"activeCount":98},[],{"trials":20432,"activeCount":98},[],{"intervention":2245,"totalTrials":208,"cells":20434},{"EARLY_PHASE1":20435,"PHASE1":20437,"PHASE2":20439,"PHASE3":20445,"PHASE4":20447,"NA":20449},{"trials":20436,"activeCount":98},[],{"trials":20438,"activeCount":98},[],{"trials":20440,"activeCount":98},[20441],{"nctId":2238,"briefTitle":2239,"status":104,"phases":20442,"primaryCompletion":2241,"completion":2241,"start":1906,"enrollment":2242,"conditions":20443,"interventions":20444},[87,88],[1154],[2245,43,608],{"trials":20446,"activeCount":98},[],{"trials":20448,"activeCount":98},[],{"trials":20450,"activeCount":98},[],{"intervention":4284,"totalTrials":208,"cells":20452},{"EARLY_PHASE1":20453,"PHASE1":20455,"PHASE2":20457,"PHASE3":20463,"PHASE4":20465,"NA":20467},{"trials":20454,"activeCount":98},[],{"trials":20456,"activeCount":98},[],{"trials":20458,"activeCount":98},[20459],{"nctId":4276,"briefTitle":4277,"status":104,"phases":20460,"primaryCompletion":4279,"completion":4279,"start":4280,"enrollment":1152,"conditions":20461,"interventions":20462},[88],[4282,4025],[1122,4284],{"trials":20464,"activeCount":98},[],{"trials":20466,"activeCount":98},[],{"trials":20468,"activeCount":98},[],{"intervention":20470,"totalTrials":208,"cells":20471},"MDX-010 \u002F MDX-010 + Docetaxel",{"EARLY_PHASE1":20472,"PHASE1":20474,"PHASE2":20476,"PHASE3":20485,"PHASE4":20487,"NA":20489},{"trials":20473,"activeCount":98},[],{"trials":20475,"activeCount":98},[],{"trials":20477,"activeCount":98},[20478],{"nctId":20479,"briefTitle":20480,"status":104,"phases":20481,"primaryCompletion":17418,"completion":17418,"start":20482,"conditions":20483,"interventions":20484},"NCT00050596","Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer",[88],"2002-11",[1504],[20470],{"trials":20486,"activeCount":98},[],{"trials":20488,"activeCount":98},[],{"trials":20490,"activeCount":98},[],{"intervention":2266,"totalTrials":208,"cells":20492},{"EARLY_PHASE1":20493,"PHASE1":20495,"PHASE2":20497,"PHASE3":20503,"PHASE4":20505,"NA":20507},{"trials":20494,"activeCount":98},[],{"trials":20496,"activeCount":98},[],{"trials":20498,"activeCount":98},[20499],{"nctId":2257,"briefTitle":2258,"status":104,"phases":20500,"primaryCompletion":2260,"completion":2260,"start":2261,"enrollment":2262,"conditions":20501,"interventions":20502},[88],[2264],[1245,1225,2266,43,618,1267,619,617,2267],{"trials":20504,"activeCount":98},[],{"trials":20506,"activeCount":98},[],{"trials":20508,"activeCount":98},[],{"intervention":5878,"totalTrials":208,"cells":20510},{"EARLY_PHASE1":20511,"PHASE1":20513,"PHASE2":20515,"PHASE3":20521,"PHASE4":20523,"NA":20525},{"trials":20512,"activeCount":98},[],{"trials":20514,"activeCount":98},[],{"trials":20516,"activeCount":98},[20517],{"nctId":5870,"briefTitle":5871,"status":104,"phases":20518,"primaryCompletion":3977,"completion":3977,"start":5873,"enrollment":193,"conditions":20519,"interventions":20520},[87,88],[5875],[1145,1678,5877,5877,5878],{"trials":20522,"activeCount":98},[],{"trials":20524,"activeCount":98},[],{"trials":20526,"activeCount":98},[],{"intervention":20528,"totalTrials":208,"cells":20529},"BMS-650032 or Placebo",{"EARLY_PHASE1":20530,"PHASE1":20532,"PHASE2":20534,"PHASE3":20542,"PHASE4":20544,"NA":20546},{"trials":20531,"activeCount":98},[],{"trials":20533,"activeCount":98},[],{"trials":20535,"activeCount":98},[20536],{"nctId":20537,"briefTitle":20538,"status":104,"phases":20539,"primaryCompletion":4039,"completion":4039,"start":4930,"enrollment":1203,"conditions":20540,"interventions":20541},"NCT00559247","A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects",[87,88],[11923],[20528],{"trials":20543,"activeCount":98},[],{"trials":20545,"activeCount":98},[],{"trials":20547,"activeCount":98},[],{"intervention":17173,"totalTrials":208,"cells":20549},{"EARLY_PHASE1":20550,"PHASE1":20552,"PHASE2":20554,"PHASE3":20560,"PHASE4":20562,"NA":20564},{"trials":20551,"activeCount":98},[],{"trials":20553,"activeCount":98},[],{"trials":20555,"activeCount":98},[20556],{"nctId":17166,"briefTitle":17167,"status":104,"phases":20557,"primaryCompletion":6169,"completion":3902,"start":11034,"enrollment":17169,"conditions":20558,"interventions":20559},[88],[17171],[17150,17173],{"trials":20561,"activeCount":98},[],{"trials":20563,"activeCount":98},[],{"trials":20565,"activeCount":98},[],{"intervention":5546,"totalTrials":208,"cells":20567},{"EARLY_PHASE1":20568,"PHASE1":20570,"PHASE2":20572,"PHASE3":20578,"PHASE4":20580,"NA":20582},{"trials":20569,"activeCount":98},[],{"trials":20571,"activeCount":98},[],{"trials":20573,"activeCount":98},[20574],{"nctId":5538,"briefTitle":5539,"status":104,"phases":20575,"primaryCompletion":5541,"completion":5542,"start":3678,"enrollment":5543,"conditions":20576,"interventions":20577},[88],[4875],[1678,3610,3610,5546,3716,612,5547],{"trials":20579,"activeCount":98},[],{"trials":20581,"activeCount":98},[],{"trials":20583,"activeCount":98},[],{"intervention":11066,"totalTrials":208,"cells":20585},{"EARLY_PHASE1":20586,"PHASE1":20588,"PHASE2":20590,"PHASE3":20596,"PHASE4":20598,"NA":20600},{"trials":20587,"activeCount":98},[],{"trials":20589,"activeCount":98},[],{"trials":20591,"activeCount":98},[20592],{"nctId":11057,"briefTitle":11058,"status":104,"phases":20593,"primaryCompletion":3084,"completion":3084,"start":11060,"enrollment":11061,"conditions":20594,"interventions":20595},[88],[11063],[11001,11065,11066],{"trials":20597,"activeCount":98},[],{"trials":20599,"activeCount":98},[],{"trials":20601,"activeCount":98},[],{"intervention":5584,"totalTrials":360,"cells":20603},{"EARLY_PHASE1":20604,"PHASE1":20606,"PHASE2":20667,"PHASE3":20669,"PHASE4":20671,"NA":20673},{"trials":20605,"activeCount":98},[],{"trials":20607,"activeCount":98},[20608,20612,20621,20625,20629,20633,20641,20645,20649,20653,20657],{"nctId":5578,"briefTitle":5579,"status":104,"phases":20609,"primaryCompletion":997,"completion":997,"start":5581,"enrollment":31,"conditions":20610,"interventions":20611},[87],[18],[5571,5584,5585,5586],{"nctId":20613,"briefTitle":20614,"status":467,"phases":20615,"primaryCompletion":20616,"completion":2561,"start":20617,"enrollment":98,"conditions":20618,"interventions":20619},"NCT04464577","A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235",[87],"2021-06-07","2021-04-01",[18],[15324,6835,5584,20620],"BMS-986235",{"nctId":15185,"briefTitle":15186,"status":104,"phases":20622,"primaryCompletion":8699,"completion":8699,"start":15188,"enrollment":11958,"conditions":20623,"interventions":20624},[87],[11063],[12452,5584,15191],{"nctId":11643,"briefTitle":11644,"status":104,"phases":20626,"primaryCompletion":11646,"completion":11646,"start":11638,"enrollment":28,"conditions":20627,"interventions":20628},[87],[11648],[1337,5584,5658],{"nctId":15658,"briefTitle":15659,"status":104,"phases":20630,"primaryCompletion":15661,"completion":15661,"start":15662,"enrollment":1385,"conditions":20631,"interventions":20632},[87],[18],[15626,5584,15665,5585],{"nctId":20634,"briefTitle":20635,"status":104,"phases":20636,"primaryCompletion":20637,"completion":20638,"start":7051,"enrollment":1385,"conditions":20639,"interventions":20640},"NCT03950960","A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants",[87],"2019-07-31","2019-08-07",[18],[7044,5584],{"nctId":15522,"briefTitle":15523,"status":104,"phases":20642,"primaryCompletion":15510,"completion":15510,"start":11981,"enrollment":15525,"conditions":20643,"interventions":20644},[87],[11063],[15528,15199,5584],{"nctId":8787,"briefTitle":8788,"status":104,"phases":20646,"primaryCompletion":8790,"completion":8790,"start":8791,"enrollment":1203,"conditions":20647,"interventions":20648},[87],[27],[6257,5658,5584,6535,874],{"nctId":16561,"briefTitle":16562,"status":104,"phases":20650,"primaryCompletion":15545,"completion":16564,"start":1533,"enrollment":125,"conditions":20651,"interventions":20652},[87],[18],[16539,5584,16567],{"nctId":16328,"briefTitle":16329,"status":104,"phases":20654,"primaryCompletion":16331,"completion":16331,"start":16332,"enrollment":148,"conditions":20655,"interventions":20656},[87],[18],[10539,5584,16335],{"nctId":20658,"briefTitle":20659,"status":104,"phases":20660,"primaryCompletion":20661,"completion":20661,"start":20662,"enrollment":2425,"conditions":20663,"interventions":20665},"NCT04154800","A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants",[87],"2021-08-31","2019-12-06",[20664],"Health Participants",[20666,5584,16335],"BMS-986209",{"trials":20668,"activeCount":98},[],{"trials":20670,"activeCount":98},[],{"trials":20672,"activeCount":98},[],{"trials":20674,"activeCount":98},[],{"intervention":874,"totalTrials":747,"cells":20676},{"EARLY_PHASE1":20677,"PHASE1":20679,"PHASE2":20722,"PHASE3":20724,"PHASE4":20726,"NA":20728},{"trials":20678,"activeCount":98},[],{"trials":20680,"activeCount":98},[20681,20685,20689,20693,20697,20706,20710,20714,20718],{"nctId":16717,"briefTitle":16718,"status":104,"phases":20682,"primaryCompletion":4159,"completion":4159,"start":12170,"enrollment":2527,"conditions":20683,"interventions":20684},[87],[11012],[16710,874,16672],{"nctId":6512,"briefTitle":6513,"status":104,"phases":20686,"primaryCompletion":6515,"completion":6515,"start":6516,"enrollment":1686,"conditions":20687,"interventions":20688},[87],[18],[6519,874,823,772,617],{"nctId":11845,"briefTitle":11846,"status":104,"phases":20690,"primaryCompletion":4159,"completion":4159,"start":4289,"enrollment":693,"conditions":20691,"interventions":20692},[87],[30],[11850,9391,874],{"nctId":16402,"briefTitle":16403,"status":104,"phases":20694,"primaryCompletion":16405,"completion":16406,"start":16407,"enrollment":3978,"conditions":20695,"interventions":20696},[87],[18],[874,15688],{"nctId":20698,"briefTitle":20699,"status":104,"phases":20700,"primaryCompletion":20701,"completion":20701,"start":2825,"enrollment":11958,"conditions":20702,"interventions":20703},"NCT04124003","A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin",[87],"2020-01-03",[18],[20704,20705],"rosuvastatin","BMS-963272",{"nctId":6829,"briefTitle":6830,"status":104,"phases":20707,"primaryCompletion":5681,"completion":6832,"start":329,"enrollment":148,"conditions":20708,"interventions":20709},[87],[27],[6814,823,6535,874,6835,6532,6533],{"nctId":865,"briefTitle":866,"status":104,"phases":20711,"primaryCompletion":868,"completion":869,"start":870,"enrollment":319,"conditions":20712,"interventions":20713},[87],[705,872],[679,874],{"nctId":16276,"briefTitle":16277,"status":104,"phases":20715,"primaryCompletion":4159,"completion":4159,"start":12170,"enrollment":2527,"conditions":20716,"interventions":20717},[87],[16280],[16254,874],{"nctId":8787,"briefTitle":8788,"status":104,"phases":20719,"primaryCompletion":8790,"completion":8790,"start":8791,"enrollment":1203,"conditions":20720,"interventions":20721},[87],[27],[6257,5658,5584,6535,874],{"trials":20723,"activeCount":98},[],{"trials":20725,"activeCount":98},[],{"trials":20727,"activeCount":98},[],{"trials":20729,"activeCount":98},[],{"intervention":5658,"totalTrials":747,"cells":20731},{"EARLY_PHASE1":20732,"PHASE1":20734,"PHASE2":20786,"PHASE3":20788,"PHASE4":20790,"NA":20792},{"trials":20733,"activeCount":98},[],{"trials":20735,"activeCount":98},[20736,20740,20749,20753,20757,20761,20769,20773,20782],{"nctId":12919,"briefTitle":12920,"status":467,"phases":20737,"primaryCompletion":7784,"completion":7784,"start":11728,"enrollment":98,"conditions":20738,"interventions":20739},[87],[606],[4937,5658],{"nctId":20741,"briefTitle":20742,"status":104,"phases":20743,"primaryCompletion":20744,"completion":20744,"start":20745,"enrollment":3986,"conditions":20746,"interventions":20747},"NCT03563950","An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants",[87],"2018-07-27","2018-06-01",[18],[5658,20748],"BMS-986224",{"nctId":15333,"briefTitle":15334,"status":104,"phases":20750,"primaryCompletion":7706,"completion":7706,"start":11998,"enrollment":319,"conditions":20751,"interventions":20752},[87],[552],[9411,5658,5658],{"nctId":11643,"briefTitle":11644,"status":104,"phases":20754,"primaryCompletion":11646,"completion":11646,"start":11638,"enrollment":28,"conditions":20755,"interventions":20756},[87],[11648],[1337,5584,5658],{"nctId":5651,"briefTitle":5652,"status":104,"phases":20758,"primaryCompletion":5654,"completion":5654,"start":5655,"enrollment":4579,"conditions":20759,"interventions":20760},[87],[18],[5571,5658],{"nctId":20762,"briefTitle":20763,"status":467,"phases":20764,"primaryCompletion":20765,"completion":20765,"start":20766,"enrollment":98,"conditions":20767,"interventions":20768},"NCT04301310","Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants",[87],"2020-03-16","2020-03-09",[18],[20620,5658],{"nctId":8787,"briefTitle":8788,"status":104,"phases":20770,"primaryCompletion":8790,"completion":8790,"start":8791,"enrollment":1203,"conditions":20771,"interventions":20772},[87],[27],[6257,5658,5584,6535,874],{"nctId":20774,"briefTitle":20775,"status":104,"phases":20776,"primaryCompletion":20777,"completion":20777,"start":846,"enrollment":713,"conditions":20778,"interventions":20780},"NCT02957448","A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects",[87],"2017-01",[20779],"Atherothrombotic Diseases",[20781,5658],"BMS 986141",{"nctId":15263,"briefTitle":15264,"status":104,"phases":20783,"primaryCompletion":5841,"completion":5841,"start":846,"enrollment":713,"conditions":20784,"interventions":20785},[87],[11063],[12452,5658],{"trials":20787,"activeCount":98},[],{"trials":20789,"activeCount":98},[],{"trials":20791,"activeCount":98},[],{"trials":20793,"activeCount":98},[],{"intervention":7044,"totalTrials":839,"cells":20795},{"EARLY_PHASE1":20796,"PHASE1":20798,"PHASE2":20847,"PHASE3":20849,"PHASE4":20851,"NA":20853},{"trials":20797,"activeCount":98},[],{"trials":20799,"activeCount":98},[20800,20804,20812,20821,20828,20832,20836,20840],{"nctId":8425,"briefTitle":8426,"status":104,"phases":20801,"primaryCompletion":8428,"completion":8428,"start":8429,"enrollment":3978,"conditions":20802,"interventions":20803},[87],[18],[7044,696],{"nctId":20805,"briefTitle":20806,"status":104,"phases":20807,"primaryCompletion":147,"completion":147,"start":20808,"enrollment":839,"conditions":20809,"interventions":20810},"NCT04269356","Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants",[87],"2020-02-18",[18],[7044,20811],"Milk of magnesia",{"nctId":20813,"briefTitle":20814,"status":104,"phases":20815,"primaryCompletion":20816,"completion":20816,"start":20817,"enrollment":137,"conditions":20818,"interventions":20820},"NCT04493541","A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus",[87],"2023-04-21","2020-08-26",[20819],"Lupus Erythematosus, Cutaneous",[7044],{"nctId":20822,"briefTitle":20823,"status":104,"phases":20824,"primaryCompletion":20825,"completion":20825,"start":859,"enrollment":357,"conditions":20826,"interventions":20827},"NCT03634995","An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants",[87],"2019-10-09",[18],[7044],{"nctId":20634,"briefTitle":20635,"status":104,"phases":20829,"primaryCompletion":20637,"completion":20638,"start":7051,"enrollment":1385,"conditions":20830,"interventions":20831},[87],[18],[7044,5584],{"nctId":8495,"briefTitle":8496,"status":104,"phases":20833,"primaryCompletion":8498,"completion":8499,"start":8500,"enrollment":1063,"conditions":20834,"interventions":20835},[87],[18],[7044,696],{"nctId":7036,"briefTitle":7037,"status":104,"phases":20837,"primaryCompletion":7039,"completion":7040,"start":7041,"enrollment":1385,"conditions":20838,"interventions":20839},[87],[18],[7044,971],{"nctId":20841,"briefTitle":20842,"status":104,"phases":20843,"primaryCompletion":20844,"completion":20844,"start":2837,"enrollment":34,"conditions":20845,"interventions":20846},"NCT04016753","A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants",[87],"2020-02-21",[18],[7044,15885],{"trials":20848,"activeCount":98},[],{"trials":20850,"activeCount":98},[],{"trials":20852,"activeCount":98},[],{"trials":20854,"activeCount":98},[],{"intervention":6535,"totalTrials":830,"cells":20856},{"EARLY_PHASE1":20857,"PHASE1":20859,"PHASE2":20888,"PHASE3":20890,"PHASE4":20892,"NA":20894},{"trials":20858,"activeCount":98},[],{"trials":20860,"activeCount":98},[20861,20865,20872,20876,20880,20884],{"nctId":6521,"briefTitle":6522,"status":104,"phases":20862,"primaryCompletion":6524,"completion":6525,"start":6526,"enrollment":2527,"conditions":20863,"interventions":20864},[87],[15],[6529,772,617,6530,6531,6532,6533,6534,6535,6536],{"nctId":20866,"briefTitle":20867,"status":104,"phases":20868,"primaryCompletion":12220,"completion":12220,"start":4995,"enrollment":1203,"conditions":20869,"interventions":20871},"NCT02262520","Phase 1 Drug Interaction Study of the Effect of Apixaban on the PK of Digoxin in Healthy Subjects",[87],[20870],"N\u002FA - Healthy Subjects",[11001,6535],{"nctId":6829,"briefTitle":6830,"status":104,"phases":20873,"primaryCompletion":5681,"completion":6832,"start":329,"enrollment":148,"conditions":20874,"interventions":20875},[87],[27],[6814,823,6535,874,6835,6532,6533],{"nctId":16269,"briefTitle":16270,"status":104,"phases":20877,"primaryCompletion":7690,"completion":7690,"start":11981,"enrollment":319,"conditions":20878,"interventions":20879},[87],[16273],[16254,6531,6532,6535],{"nctId":8787,"briefTitle":8788,"status":104,"phases":20881,"primaryCompletion":8790,"completion":8790,"start":8791,"enrollment":1203,"conditions":20882,"interventions":20883},[87],[27],[6257,5658,5584,6535,874],{"nctId":10545,"briefTitle":10546,"status":104,"phases":20885,"primaryCompletion":10548,"completion":10548,"start":954,"enrollment":693,"conditions":20886,"interventions":20887},[87],[27],[10551,6530,6531,6532,6533,6534,6535,6536],{"trials":20889,"activeCount":98},[],{"trials":20891,"activeCount":98},[],{"trials":20893,"activeCount":98},[],{"trials":20895,"activeCount":98},[],{"intervention":6532,"totalTrials":520,"cells":20897},{"EARLY_PHASE1":20898,"PHASE1":20900,"PHASE2":20922,"PHASE3":20924,"PHASE4":20926,"NA":20928},{"trials":20899,"activeCount":98},[],{"trials":20901,"activeCount":98},[20902,20906,20910,20914,20918],{"nctId":6521,"briefTitle":6522,"status":104,"phases":20903,"primaryCompletion":6524,"completion":6525,"start":6526,"enrollment":2527,"conditions":20904,"interventions":20905},[87],[15],[6529,772,617,6530,6531,6532,6533,6534,6535,6536],{"nctId":6829,"briefTitle":6830,"status":104,"phases":20907,"primaryCompletion":5681,"completion":6832,"start":329,"enrollment":148,"conditions":20908,"interventions":20909},[87],[27],[6814,823,6535,874,6835,6532,6533],{"nctId":16269,"briefTitle":16270,"status":104,"phases":20911,"primaryCompletion":7690,"completion":7690,"start":11981,"enrollment":319,"conditions":20912,"interventions":20913},[87],[16273],[16254,6531,6532,6535],{"nctId":10545,"briefTitle":10546,"status":104,"phases":20915,"primaryCompletion":10548,"completion":10548,"start":954,"enrollment":693,"conditions":20916,"interventions":20917},[87],[27],[10551,6530,6531,6532,6533,6534,6535,6536],{"nctId":10563,"briefTitle":10564,"status":104,"phases":20919,"primaryCompletion":8187,"completion":8187,"start":10566,"enrollment":3978,"conditions":20920,"interventions":20921},[87],[27],[9403,6530,6835,6532,6533,6534,10569],{"trials":20923,"activeCount":98},[],{"trials":20925,"activeCount":98},[],{"trials":20927,"activeCount":98},[],{"trials":20929,"activeCount":98},[],{"intervention":11858,"totalTrials":520,"cells":20931},{"EARLY_PHASE1":20932,"PHASE1":20934,"PHASE2":20958,"PHASE3":20960,"PHASE4":20962,"NA":20964},{"trials":20933,"activeCount":98},[],{"trials":20935,"activeCount":98},[20936,20940,20946,20950,20954],{"nctId":11852,"briefTitle":11853,"status":104,"phases":20937,"primaryCompletion":4289,"completion":4289,"start":4551,"enrollment":34,"conditions":20938,"interventions":20939},[87],[30],[11857,11858,9391,11859,11860],{"nctId":20941,"briefTitle":20942,"status":104,"phases":20943,"primaryCompletion":4159,"completion":4159,"start":4289,"enrollment":1203,"conditions":20944,"interventions":20945},"NCT02095860","Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325",[87],[30],[11858],{"nctId":11870,"briefTitle":11871,"status":104,"phases":20947,"primaryCompletion":3017,"completion":3017,"start":4289,"enrollment":11873,"conditions":20948,"interventions":20949},[87],[30],[11858,9391],{"nctId":11877,"briefTitle":11878,"status":104,"phases":20951,"primaryCompletion":4289,"completion":4289,"start":4551,"enrollment":713,"conditions":20952,"interventions":20953},[87],[30],[11882,11858,9391],{"nctId":11900,"briefTitle":11901,"status":104,"phases":20955,"primaryCompletion":10525,"start":3017,"enrollment":11873,"conditions":20956,"interventions":20957},[87],[11904],[11906,11907,11858,9391],{"trials":20959,"activeCount":98},[],{"trials":20961,"activeCount":98},[],{"trials":20963,"activeCount":98},[],{"trials":20965,"activeCount":98},[],{"intervention":6529,"totalTrials":4328,"cells":20967},{"EARLY_PHASE1":20968,"PHASE1":20970,"PHASE2":21000,"PHASE3":21002,"PHASE4":21004,"NA":21006},{"trials":20969,"activeCount":98},[],{"trials":20971,"activeCount":98},[20972,20981,20985,20992],{"nctId":20973,"briefTitle":20974,"status":104,"phases":20975,"primaryCompletion":20976,"completion":20976,"start":20977,"enrollment":20978,"conditions":20979,"interventions":20980},"NCT02705989","Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects",[87],"2017-08-16","2016-08-18",439,[15],[6529],{"nctId":6521,"briefTitle":6522,"status":104,"phases":20982,"primaryCompletion":6524,"completion":6525,"start":6526,"enrollment":2527,"conditions":20983,"interventions":20984},[87],[15],[6529,772,617,6530,6531,6532,6533,6534,6535,6536],{"nctId":20986,"briefTitle":20987,"status":104,"phases":20988,"primaryCompletion":788,"completion":20989,"start":10453,"enrollment":2308,"conditions":20990,"interventions":20991},"NCT03262740","The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol\u002FNorethindrone) in Healthy Female Patients",[87],"2018-01-30",[15],[6529,796],{"nctId":20993,"briefTitle":20994,"status":104,"phases":20995,"primaryCompletion":15394,"completion":20996,"start":20997,"enrollment":1203,"conditions":20998,"interventions":20999},"NCT03245515","A Study of BMS-986195 in Healthy Male Subjects",[87],"2017-10-05","2017-08-15",[15],[6529],{"trials":21001,"activeCount":98},[],{"trials":21003,"activeCount":98},[],{"trials":21005,"activeCount":98},[],{"trials":21007,"activeCount":98},[],{"intervention":10551,"totalTrials":4328,"cells":21009},{"EARLY_PHASE1":21010,"PHASE1":21012,"PHASE2":21039,"PHASE3":21041,"PHASE4":21043,"NA":21045},{"trials":21011,"activeCount":98},[],{"trials":21013,"activeCount":98},[21014,21020,21028,21035],{"nctId":21015,"briefTitle":21016,"status":467,"phases":21017,"primaryCompletion":10090,"completion":10090,"start":5691,"enrollment":98,"conditions":21018,"interventions":21019},"NCT06034899","A Study to Evaluate the Effect of Food on the Drug Levels of BMS-986196 in Healthy Adult Participants",[87],[10527],[10551],{"nctId":21021,"briefTitle":21022,"status":104,"phases":21023,"primaryCompletion":21024,"completion":21024,"start":1459,"enrollment":1385,"conditions":21025,"interventions":21027},"NCT05891262","A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Participants",[87],"2023-08-25",[21026],"Healthy Female Volunteers",[10551,15885],{"nctId":21029,"briefTitle":21030,"status":104,"phases":21031,"primaryCompletion":21032,"completion":21032,"start":6421,"enrollment":1586,"conditions":21033,"interventions":21034},"NCT04882150","A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants",[87],"2022-06-10",[18],[10551],{"nctId":10545,"briefTitle":10546,"status":104,"phases":21036,"primaryCompletion":10548,"completion":10548,"start":954,"enrollment":693,"conditions":21037,"interventions":21038},[87],[27],[10551,6530,6531,6532,6533,6534,6535,6536],{"trials":21040,"activeCount":98},[],{"trials":21042,"activeCount":98},[],{"trials":21044,"activeCount":98},[],{"trials":21046,"activeCount":98},[],{"intervention":21048,"totalTrials":4328,"cells":21049},"Cobicistat",{"EARLY_PHASE1":21050,"PHASE1":21052,"PHASE2":21088,"PHASE3":21090,"PHASE4":21092,"NA":21094},{"trials":21051,"activeCount":98},[],{"trials":21053,"activeCount":98},[21054,21064,21073,21080],{"nctId":21055,"briefTitle":21056,"status":104,"phases":21057,"primaryCompletion":21058,"completion":21059,"start":16890,"enrollment":4932,"conditions":21060,"interventions":21061},"NCT04263350","A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time",[87],"2020-11-12","2020-11-17",[18],[21062,21063,21048],"Atazanavir\u002FCobicistat","Reyataz Atazanavir",{"nctId":21065,"briefTitle":21066,"status":104,"phases":21067,"primaryCompletion":21068,"completion":21069,"start":11228,"enrollment":3986,"conditions":21070,"interventions":21071},"NCT05236738","A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions",[87],"2022-07-05","2022-07-26",[18],[8547,21048,21072],"Atazanavir\u002FCobicistat Mini-tablet",{"nctId":21074,"briefTitle":21075,"status":104,"phases":21076,"primaryCompletion":3630,"completion":3630,"start":3958,"enrollment":3102,"conditions":21077,"interventions":21078},"NCT01837719","Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat",[87],[10410],[8547,21048,21079],"Atazanavir\u002FCobicistat FDC",{"nctId":21081,"briefTitle":21082,"status":104,"phases":21083,"primaryCompletion":5375,"completion":5375,"start":21084,"enrollment":830,"conditions":21085,"interventions":21087},"NCT02307656","Taste Properties of Atazanavir and Cobicistat",[87],"2014-12-12",[21086],"HIV in Adults",[8547,21048,883],{"trials":21089,"activeCount":98},[],{"trials":21091,"activeCount":98},[],{"trials":21093,"activeCount":98},[],{"trials":21095,"activeCount":98},[],{"intervention":20705,"totalTrials":4328,"cells":21097},{"EARLY_PHASE1":21098,"PHASE1":21100,"PHASE2":21126,"PHASE3":21128,"PHASE4":21130,"NA":21132},{"trials":21099,"activeCount":98},[],{"trials":21101,"activeCount":98},[21102,21109,21115,21119],{"nctId":21103,"briefTitle":21104,"status":963,"phases":21105,"primaryCompletion":7765,"completion":7765,"start":21106,"enrollment":747,"conditions":21107,"interventions":21108},"NCT04766476","A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease",[87],"2021-02-24",[15407],[20705],{"nctId":21110,"briefTitle":21111,"status":104,"phases":21112,"primaryCompletion":4980,"completion":4980,"start":6917,"enrollment":506,"conditions":21113,"interventions":21114},"NCT02327273","Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects",[87],[759],[20705],{"nctId":20698,"briefTitle":20699,"status":104,"phases":21116,"primaryCompletion":20701,"completion":20701,"start":2825,"enrollment":11958,"conditions":21117,"interventions":21118},[87],[18],[20704,20705],{"nctId":21120,"briefTitle":21121,"status":104,"phases":21122,"primaryCompletion":2446,"completion":2446,"start":2656,"enrollment":347,"conditions":21123,"interventions":21125},"NCT04116632","A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults",[87],[21124],"Obese But Otherwise Healthy Participants",[20705],{"trials":21127,"activeCount":98},[],{"trials":21129,"activeCount":98},[],{"trials":21131,"activeCount":98},[],{"trials":21133,"activeCount":98},[],{"intervention":6835,"totalTrials":574,"cells":21135},{"EARLY_PHASE1":21136,"PHASE1":21138,"PHASE2":21152,"PHASE3":21154,"PHASE4":21156,"NA":21158},{"trials":21137,"activeCount":98},[],{"trials":21139,"activeCount":98},[21140,21144,21148],{"nctId":20613,"briefTitle":20614,"status":467,"phases":21141,"primaryCompletion":20616,"completion":2561,"start":20617,"enrollment":98,"conditions":21142,"interventions":21143},[87],[18],[15324,6835,5584,20620],{"nctId":6829,"briefTitle":6830,"status":104,"phases":21145,"primaryCompletion":5681,"completion":6832,"start":329,"enrollment":148,"conditions":21146,"interventions":21147},[87],[27],[6814,823,6535,874,6835,6532,6533],{"nctId":10563,"briefTitle":10564,"status":104,"phases":21149,"primaryCompletion":8187,"completion":8187,"start":10566,"enrollment":3978,"conditions":21150,"interventions":21151},[87],[27],[9403,6530,6835,6532,6533,6534,10569],{"trials":21153,"activeCount":98},[],{"trials":21155,"activeCount":98},[],{"trials":21157,"activeCount":98},[],{"trials":21159,"activeCount":98},[],{"intervention":20620,"totalTrials":574,"cells":21161},{"EARLY_PHASE1":21162,"PHASE1":21164,"PHASE2":21182,"PHASE3":21184,"PHASE4":21186,"NA":21188},{"trials":21163,"activeCount":98},[],{"trials":21165,"activeCount":98},[21166,21170,21178],{"nctId":20613,"briefTitle":20614,"status":467,"phases":21167,"primaryCompletion":20616,"completion":2561,"start":20617,"enrollment":98,"conditions":21168,"interventions":21169},[87],[18],[15324,6835,5584,20620],{"nctId":21171,"briefTitle":21172,"status":104,"phases":21173,"primaryCompletion":21174,"completion":21174,"start":908,"enrollment":11552,"conditions":21175,"interventions":21177},"NCT03335553","A Study of Experimental Medication BMS-986235 in Healthy Subjects",[87],"2021-07-02",[21176],"Mediators of Inflammation",[20620],{"nctId":20762,"briefTitle":20763,"status":467,"phases":21179,"primaryCompletion":20765,"completion":20765,"start":20766,"enrollment":98,"conditions":21180,"interventions":21181},[87],[18],[20620,5658],{"trials":21183,"activeCount":98},[],{"trials":21185,"activeCount":98},[],{"trials":21187,"activeCount":98},[],{"trials":21189,"activeCount":98},[],{"intervention":21191,"totalTrials":574,"cells":21192},"ND-L02-s0201",{"EARLY_PHASE1":21193,"PHASE1":21195,"PHASE2":21217,"PHASE3":21219,"PHASE4":21221,"NA":21223},{"trials":21194,"activeCount":98},[],{"trials":21196,"activeCount":98},[21197,21203,21210],{"nctId":21198,"briefTitle":21199,"status":104,"phases":21200,"primaryCompletion":4551,"completion":4551,"start":10518,"enrollment":7813,"conditions":21201,"interventions":21202},"NCT01858935","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects",[87],[759],[21191],{"nctId":21204,"briefTitle":21205,"status":104,"phases":21206,"primaryCompletion":16135,"completion":16135,"start":6917,"enrollment":94,"conditions":21207,"interventions":21209},"NCT02227459","Phase 1b\u002F2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)",[87],[21208],"Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)",[21191],{"nctId":21211,"briefTitle":21212,"status":104,"phases":21213,"primaryCompletion":1423,"completion":1423,"start":21214,"enrollment":1221,"conditions":21215,"interventions":21216},"NCT03241264","A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body",[87],"2016-08-28",[8447],[21191],{"trials":21218,"activeCount":98},[],{"trials":21220,"activeCount":98},[],{"trials":21222,"activeCount":98},[],{"trials":21224,"activeCount":98},[],{"intervention":21226,"totalTrials":574,"cells":21227},"BMS-936559",{"EARLY_PHASE1":21228,"PHASE1":21230,"PHASE2":21255,"PHASE3":21257,"PHASE4":21259,"NA":21261},{"trials":21229,"activeCount":98},[],{"trials":21231,"activeCount":98},[21232,21239,21248],{"nctId":21233,"briefTitle":21234,"status":467,"phases":21235,"primaryCompletion":7690,"completion":7690,"start":3960,"enrollment":98,"conditions":21236,"interventions":21238},"NCT01452334","Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy",[87],[1825,1826,33,21237],"Chronic Myelogenous Leukemia",[21226],{"nctId":21240,"briefTitle":21241,"status":963,"phases":21242,"primaryCompletion":21243,"completion":21243,"start":21244,"enrollment":1063,"conditions":21245,"interventions":21247},"NCT02576457","Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis",[87],"2017-03-15","2015-12-02",[1318,21246],"Septic Shock",[21226],{"nctId":21249,"briefTitle":21250,"status":467,"phases":21251,"primaryCompletion":11742,"completion":11742,"start":3960,"enrollment":98,"conditions":21252,"interventions":21254},"NCT01455103","Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma",[87],[21253],"Stage III or IV Melanoma",[21226,21226,21226],{"trials":21256,"activeCount":98},[],{"trials":21258,"activeCount":98},[],{"trials":21260,"activeCount":98},[],{"trials":21262,"activeCount":98},[],{"intervention":15885,"totalTrials":574,"cells":21264},{"EARLY_PHASE1":21265,"PHASE1":21267,"PHASE2":21281,"PHASE3":21283,"PHASE4":21285,"NA":21287},{"trials":21266,"activeCount":98},[],{"trials":21268,"activeCount":98},[21269,21273,21277],{"nctId":21021,"briefTitle":21022,"status":104,"phases":21270,"primaryCompletion":21024,"completion":21024,"start":1459,"enrollment":1385,"conditions":21271,"interventions":21272},[87],[21026],[10551,15885],{"nctId":15879,"briefTitle":15880,"status":104,"phases":21274,"primaryCompletion":2260,"completion":2260,"start":15882,"enrollment":3986,"conditions":21275,"interventions":21276},[87],[18],[6519,15885],{"nctId":20841,"briefTitle":20842,"status":104,"phases":21278,"primaryCompletion":20844,"completion":20844,"start":2837,"enrollment":34,"conditions":21279,"interventions":21280},[87],[18],[7044,15885],{"trials":21282,"activeCount":98},[],{"trials":21284,"activeCount":98},[],{"trials":21286,"activeCount":98},[],{"trials":21288,"activeCount":98},[],{"intervention":6531,"totalTrials":574,"cells":21290},{"EARLY_PHASE1":21291,"PHASE1":21293,"PHASE2":21307,"PHASE3":21309,"PHASE4":21311,"NA":21313},{"trials":21292,"activeCount":98},[],{"trials":21294,"activeCount":98},[21295,21299,21303],{"nctId":6521,"briefTitle":6522,"status":104,"phases":21296,"primaryCompletion":6524,"completion":6525,"start":6526,"enrollment":2527,"conditions":21297,"interventions":21298},[87],[15],[6529,772,617,6530,6531,6532,6533,6534,6535,6536],{"nctId":16269,"briefTitle":16270,"status":104,"phases":21300,"primaryCompletion":7690,"completion":7690,"start":11981,"enrollment":319,"conditions":21301,"interventions":21302},[87],[16273],[16254,6531,6532,6535],{"nctId":10545,"briefTitle":10546,"status":104,"phases":21304,"primaryCompletion":10548,"completion":10548,"start":954,"enrollment":693,"conditions":21305,"interventions":21306},[87],[27],[10551,6530,6531,6532,6533,6534,6535,6536],{"trials":21308,"activeCount":98},[],{"trials":21310,"activeCount":98},[],{"trials":21312,"activeCount":98},[],{"trials":21314,"activeCount":98},[],{"intervention":3611,"totalTrials":574,"cells":21316},{"EARLY_PHASE1":21317,"PHASE1":21319,"PHASE2":21336,"PHASE3":21338,"PHASE4":21340,"NA":21342},{"trials":21318,"activeCount":98},[],{"trials":21320,"activeCount":98},[21321,21328,21332],{"nctId":21322,"briefTitle":21323,"status":104,"phases":21324,"primaryCompletion":16097,"completion":16097,"start":21325,"enrollment":378,"conditions":21326,"interventions":21327},"NCT01292655","Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors",[87],"2011-03-03",[606],[3611],{"nctId":6157,"briefTitle":6158,"status":104,"phases":21329,"primaryCompletion":5640,"completion":5640,"start":6160,"enrollment":4124,"conditions":21330,"interventions":21331},[87],[6162,6163],[3611,1795],{"nctId":3601,"briefTitle":3602,"status":104,"phases":21333,"primaryCompletion":3604,"completion":3605,"start":3606,"enrollment":3607,"conditions":21334,"interventions":21335},[87],[606],[1158,3610,1157,617,1678,1158,3611],{"trials":21337,"activeCount":98},[],{"trials":21339,"activeCount":98},[],{"trials":21341,"activeCount":98},[],{"trials":21343,"activeCount":98},[],{"intervention":20748,"totalTrials":574,"cells":21345},{"EARLY_PHASE1":21346,"PHASE1":21348,"PHASE2":21368,"PHASE3":21370,"PHASE4":21372,"NA":21374},{"trials":21347,"activeCount":98},[],{"trials":21349,"activeCount":98},[21350,21354,21361],{"nctId":20741,"briefTitle":20742,"status":104,"phases":21351,"primaryCompletion":20744,"completion":20744,"start":20745,"enrollment":3986,"conditions":21352,"interventions":21353},[87],[18],[5658,20748],{"nctId":21355,"briefTitle":21356,"status":963,"phases":21357,"primaryCompletion":21358,"completion":21358,"start":15394,"enrollment":13145,"conditions":21359,"interventions":21360},"NCT03281122","A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction",[87],"2019-04-17",[8277],[20748],{"nctId":21362,"briefTitle":21363,"status":104,"phases":21364,"primaryCompletion":21365,"completion":21365,"start":859,"enrollment":217,"conditions":21366,"interventions":21367},"NCT03634969","An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants",[87],"2019-04-30",[16079,16078],[20748],{"trials":21369,"activeCount":98},[],{"trials":21371,"activeCount":98},[],{"trials":21373,"activeCount":98},[],{"trials":21375,"activeCount":98},[],{"intervention":16335,"totalTrials":574,"cells":21377},{"EARLY_PHASE1":21378,"PHASE1":21380,"PHASE2":21397,"PHASE3":21399,"PHASE4":21401,"NA":21403},{"trials":21379,"activeCount":98},[],{"trials":21381,"activeCount":98},[21382,21389,21393],{"nctId":21383,"briefTitle":21384,"status":104,"phases":21385,"primaryCompletion":7706,"completion":7706,"start":3631,"enrollment":1203,"conditions":21386,"interventions":21387},"NCT01211808","Effect of Diltiazem on Pharmacokinetics of BMS-914392",[87],[10858],[21388,16335],"BMS-914832",{"nctId":16328,"briefTitle":16329,"status":104,"phases":21390,"primaryCompletion":16331,"completion":16331,"start":16332,"enrollment":148,"conditions":21391,"interventions":21392},[87],[18],[10539,5584,16335],{"nctId":20658,"briefTitle":20659,"status":104,"phases":21394,"primaryCompletion":20661,"completion":20661,"start":20662,"enrollment":2425,"conditions":21395,"interventions":21396},[87],[20664],[20666,5584,16335],{"trials":21398,"activeCount":98},[],{"trials":21400,"activeCount":98},[],{"trials":21402,"activeCount":98},[],{"trials":21404,"activeCount":98},[],{"intervention":21406,"totalTrials":574,"cells":21407},"BMS-986326",{"EARLY_PHASE1":21408,"PHASE1":21410,"PHASE2":21434,"PHASE3":21436,"PHASE4":21438,"NA":21440},{"trials":21409,"activeCount":98},[],{"trials":21411,"activeCount":98},[21412,21420,21427],{"nctId":21413,"briefTitle":21414,"status":104,"phases":21415,"primaryCompletion":21416,"completion":21416,"start":21417,"enrollment":125,"conditions":21418,"interventions":21419},"NCT06013995","A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus",[87],"2026-04-14","2023-09-21",[738],[21406],{"nctId":21421,"briefTitle":21422,"status":104,"phases":21423,"primaryCompletion":2158,"completion":2158,"start":819,"enrollment":506,"conditions":21424,"interventions":21425},"NCT04736134","A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants",[87],[18],[21406,21426],"Multiple Ascending Dose SC",{"nctId":21428,"briefTitle":21429,"status":104,"phases":21430,"primaryCompletion":658,"completion":658,"start":21431,"enrollment":3102,"conditions":21432,"interventions":21433},"NCT06248814","A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis",[87],"2024-03-06",[15686],[21406],{"trials":21435,"activeCount":98},[],{"trials":21437,"activeCount":98},[],{"trials":21439,"activeCount":98},[],{"trials":21441,"activeCount":98},[],{"intervention":10560,"totalTrials":230,"cells":21443},{"EARLY_PHASE1":21444,"PHASE1":21446,"PHASE2":21456,"PHASE3":21458,"PHASE4":21460,"NA":21462},{"trials":21445,"activeCount":98},[],{"trials":21447,"activeCount":98},[21448,21452],{"nctId":17215,"briefTitle":17216,"status":104,"phases":21449,"primaryCompletion":3904,"completion":3904,"start":3631,"enrollment":693,"conditions":21450,"interventions":21451},[87],[10858],[10560,17208],{"nctId":10553,"briefTitle":10554,"status":104,"phases":21453,"primaryCompletion":4123,"completion":4123,"start":1343,"enrollment":713,"conditions":21454,"interventions":21455},[87],[1482],[10558,10559,10560,10561],{"trials":21457,"activeCount":98},[],{"trials":21459,"activeCount":98},[],{"trials":21461,"activeCount":98},[],{"trials":21463,"activeCount":98},[],{"intervention":11967,"totalTrials":230,"cells":21465},{"EARLY_PHASE1":21466,"PHASE1":21468,"PHASE2":21478,"PHASE3":21480,"PHASE4":21482,"NA":21484},{"trials":21467,"activeCount":98},[],{"trials":21469,"activeCount":98},[21470,21474],{"nctId":12050,"briefTitle":12051,"status":104,"phases":21471,"primaryCompletion":11762,"completion":11762,"start":10431,"enrollment":319,"conditions":21472,"interventions":21473},[87],[11842],[11967,11933],{"nctId":11962,"briefTitle":11963,"status":104,"phases":21475,"primaryCompletion":3617,"completion":3617,"start":3678,"enrollment":31,"conditions":21476,"interventions":21477},[87],[11923],[11934,11967],{"trials":21479,"activeCount":98},[],{"trials":21481,"activeCount":98},[],{"trials":21483,"activeCount":98},[],{"trials":21485,"activeCount":98},[],{"intervention":5585,"totalTrials":230,"cells":21487},{"EARLY_PHASE1":21488,"PHASE1":21490,"PHASE2":21500,"PHASE3":21502,"PHASE4":21504,"NA":21506},{"trials":21489,"activeCount":98},[],{"trials":21491,"activeCount":98},[21492,21496],{"nctId":5578,"briefTitle":5579,"status":104,"phases":21493,"primaryCompletion":997,"completion":997,"start":5581,"enrollment":31,"conditions":21494,"interventions":21495},[87],[18],[5571,5584,5585,5586],{"nctId":15658,"briefTitle":15659,"status":104,"phases":21497,"primaryCompletion":15661,"completion":15661,"start":15662,"enrollment":1385,"conditions":21498,"interventions":21499},[87],[18],[15626,5584,15665,5585],{"trials":21501,"activeCount":98},[],{"trials":21503,"activeCount":98},[],{"trials":21505,"activeCount":98},[],{"trials":21507,"activeCount":98},[],{"intervention":15324,"totalTrials":230,"cells":21509},{"EARLY_PHASE1":21510,"PHASE1":21512,"PHASE2":21522,"PHASE3":21524,"PHASE4":21526,"NA":21528},{"trials":21511,"activeCount":98},[],{"trials":21513,"activeCount":98},[21514,21518],{"nctId":20613,"briefTitle":20614,"status":467,"phases":21515,"primaryCompletion":20616,"completion":2561,"start":20617,"enrollment":98,"conditions":21516,"interventions":21517},[87],[18],[15324,6835,5584,20620],{"nctId":15317,"briefTitle":15318,"status":104,"phases":21519,"primaryCompletion":3712,"completion":3712,"start":3572,"enrollment":148,"conditions":21520,"interventions":21521},[87],[552],[9411,15322,15323,15324,15325],{"trials":21523,"activeCount":98},[],{"trials":21525,"activeCount":98},[],{"trials":21527,"activeCount":98},[],{"trials":21529,"activeCount":98},[],{"intervention":852,"totalTrials":230,"cells":21531},{"EARLY_PHASE1":21532,"PHASE1":21534,"PHASE2":21544,"PHASE3":21546,"PHASE4":21548,"NA":21550},{"trials":21533,"activeCount":98},[],{"trials":21535,"activeCount":98},[21536,21540],{"nctId":7372,"briefTitle":7373,"status":104,"phases":21537,"primaryCompletion":4151,"completion":4151,"start":7375,"enrollment":7376,"conditions":21538,"interventions":21539},[87],[749],[7379,852,696,3287],{"nctId":843,"briefTitle":844,"status":104,"phases":21541,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":21542,"interventions":21543},[87],[850],[679,852,696],{"trials":21545,"activeCount":98},[],{"trials":21547,"activeCount":98},[],{"trials":21549,"activeCount":98},[],{"trials":21551,"activeCount":98},[],{"intervention":21553,"totalTrials":230,"cells":21554},"AVID200",{"EARLY_PHASE1":21555,"PHASE1":21557,"PHASE2":21576,"PHASE3":21578,"PHASE4":21580,"NA":21582},{"trials":21556,"activeCount":98},[],{"trials":21558,"activeCount":98},[21559,21567],{"nctId":21560,"briefTitle":21561,"status":104,"phases":21562,"primaryCompletion":21563,"completion":21563,"start":21564,"enrollment":1307,"conditions":21565,"interventions":21566},"NCT03834662","A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies",[87],"2020-02-19","2019-01-07",[2150],[21553],{"nctId":21568,"briefTitle":21569,"status":104,"phases":21570,"primaryCompletion":21571,"completion":21571,"start":21572,"enrollment":747,"conditions":21573,"interventions":21575},"NCT03831438","Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis",[87],"2020-06-20","2019-01-01",[21574],"Scleroderma, Diffuse",[21553],{"trials":21577,"activeCount":98},[],{"trials":21579,"activeCount":98},[],{"trials":21581,"activeCount":98},[],{"trials":21583,"activeCount":98},[],{"intervention":21585,"totalTrials":230,"cells":21586},"MDX-1342",{"EARLY_PHASE1":21587,"PHASE1":21589,"PHASE2":21603,"PHASE3":21605,"PHASE4":21607,"NA":21609},{"trials":21588,"activeCount":98},[],{"trials":21590,"activeCount":98},[21591,21597],{"nctId":21592,"briefTitle":21593,"status":104,"phases":21594,"primaryCompletion":7944,"completion":7944,"start":7715,"enrollment":1385,"conditions":21595,"interventions":21596},"NCT00593944","Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)",[87],[17473],[21585],{"nctId":21598,"briefTitle":21599,"status":104,"phases":21600,"primaryCompletion":11762,"completion":11762,"start":3680,"enrollment":2527,"conditions":21601,"interventions":21602},"NCT00639834","Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid Arthritis",[87],[15],[21585],{"trials":21604,"activeCount":98},[],{"trials":21606,"activeCount":98},[],{"trials":21608,"activeCount":98},[],{"trials":21610,"activeCount":98},[],{"intervention":10529,"totalTrials":230,"cells":21612},{"EARLY_PHASE1":21613,"PHASE1":21615,"PHASE2":21625,"PHASE3":21627,"PHASE4":21629,"NA":21631},{"trials":21614,"activeCount":98},[],{"trials":21616,"activeCount":98},[21617,21621],{"nctId":15507,"briefTitle":15508,"status":104,"phases":21618,"primaryCompletion":6184,"completion":6184,"start":15510,"enrollment":3986,"conditions":21619,"interventions":21620},[87],[11063],[10529,15199,15215],{"nctId":10522,"briefTitle":10523,"status":104,"phases":21622,"primaryCompletion":4160,"completion":4160,"start":10525,"enrollment":1203,"conditions":21623,"interventions":21624},[87],[10527],[10529,6534],{"trials":21626,"activeCount":98},[],{"trials":21628,"activeCount":98},[],{"trials":21630,"activeCount":98},[],{"trials":21632,"activeCount":98},[],{"intervention":796,"totalTrials":230,"cells":21634},{"EARLY_PHASE1":21635,"PHASE1":21637,"PHASE2":21647,"PHASE3":21649,"PHASE4":21651,"NA":21653},{"trials":21636,"activeCount":98},[],{"trials":21638,"activeCount":98},[21639,21643],{"nctId":20986,"briefTitle":20987,"status":104,"phases":21640,"primaryCompletion":788,"completion":20989,"start":10453,"enrollment":2308,"conditions":21641,"interventions":21642},[87],[15],[6529,796],{"nctId":784,"briefTitle":785,"status":104,"phases":21644,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":21645,"interventions":21646},[87],[792,793,749,794],[679,796],{"trials":21648,"activeCount":98},[],{"trials":21650,"activeCount":98},[],{"trials":21652,"activeCount":98},[],{"trials":21654,"activeCount":98},[],{"intervention":6826,"totalTrials":230,"cells":21656},{"EARLY_PHASE1":21657,"PHASE1":21659,"PHASE2":21669,"PHASE3":21671,"PHASE4":21673,"NA":21675},{"trials":21658,"activeCount":98},[],{"trials":21660,"activeCount":98},[21661,21665],{"nctId":6821,"briefTitle":6822,"status":104,"phases":21662,"primaryCompletion":5610,"completion":5610,"start":5464,"enrollment":34,"conditions":21663,"interventions":21664},[87],[27],[6814,6826,6827],{"nctId":10406,"briefTitle":10407,"status":104,"phases":21666,"primaryCompletion":4348,"completion":3938,"start":4038,"enrollment":12,"conditions":21667,"interventions":21668},[87],[10410,24],[6826,8547,902],{"trials":21670,"activeCount":98},[],{"trials":21672,"activeCount":98},[],{"trials":21674,"activeCount":98},[],{"trials":21676,"activeCount":98},[],{"intervention":21678,"totalTrials":230,"cells":21679},"BMS-866949",{"EARLY_PHASE1":21680,"PHASE1":21682,"PHASE2":21697,"PHASE3":21699,"PHASE4":21701,"NA":21703},{"trials":21681,"activeCount":98},[],{"trials":21683,"activeCount":98},[21684,21690],{"nctId":21685,"briefTitle":21686,"status":104,"phases":21687,"primaryCompletion":7088,"completion":7088,"start":6170,"enrollment":3102,"conditions":21688,"interventions":21689},"NCT00949767","Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy Subjects",[87],[12749],[21678,21678,21678,21678,21678,21678,21678],{"nctId":21691,"briefTitle":21692,"status":963,"phases":21693,"primaryCompletion":3960,"completion":3960,"start":7944,"enrollment":31,"conditions":21694,"interventions":21696},"NCT01124344","Safety and Pharmacology Study of BMS-866949",[87],[21695],"Major Depression",[21678,21678,21678,21678,21678,21678,21678],{"trials":21698,"activeCount":98},[],{"trials":21700,"activeCount":98},[],{"trials":21702,"activeCount":98},[],{"trials":21704,"activeCount":98},[],{"intervention":21706,"totalTrials":230,"cells":21707},"Cendakimab",{"EARLY_PHASE1":21708,"PHASE1":21710,"PHASE2":21728,"PHASE3":21730,"PHASE4":21732,"NA":21734},{"trials":21709,"activeCount":98},[],{"trials":21711,"activeCount":98},[21712,21720],{"nctId":21713,"briefTitle":21714,"status":104,"phases":21715,"primaryCompletion":21716,"completion":21716,"start":21717,"enrollment":94,"conditions":21718,"interventions":21719},"NCT05638282","A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants",[87],"2023-06-27","2023-02-15",[18],[21706],{"nctId":21721,"briefTitle":21722,"status":104,"phases":21723,"primaryCompletion":21724,"completion":21724,"start":21725,"enrollment":515,"conditions":21726,"interventions":21727},"NCT05337345","A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants",[87],"2022-12-15","2022-05-02",[27],[21706],{"trials":21729,"activeCount":98},[],{"trials":21731,"activeCount":98},[],{"trials":21733,"activeCount":98},[],{"trials":21735,"activeCount":98},[],{"intervention":13066,"totalTrials":230,"cells":21737},{"EARLY_PHASE1":21738,"PHASE1":21740,"PHASE2":21753,"PHASE3":21755,"PHASE4":21757,"NA":21759},{"trials":21739,"activeCount":98},[],{"trials":21741,"activeCount":98},[21742,21746],{"nctId":13058,"briefTitle":13059,"status":104,"phases":21743,"primaryCompletion":13061,"completion":13061,"start":13053,"enrollment":363,"conditions":21744,"interventions":21745},[87],[24],[13064,10477,13065,13066,13067],{"nctId":21747,"briefTitle":21748,"status":104,"phases":21749,"primaryCompletion":13053,"completion":13053,"start":10856,"enrollment":3978,"conditions":21750,"interventions":21751},"NCT00357188","Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV\u002FRTV + EFV) in Healthy Subjects",[87],[24,13055],[13066,21752],"Atazanavir Sulphate + Ritonavir + Efavirenz",{"trials":21754,"activeCount":98},[],{"trials":21756,"activeCount":98},[],{"trials":21758,"activeCount":98},[],{"trials":21760,"activeCount":98},[],{"intervention":9403,"totalTrials":230,"cells":21762},{"EARLY_PHASE1":21763,"PHASE1":21765,"PHASE2":21775,"PHASE3":21777,"PHASE4":21779,"NA":21781},{"trials":21764,"activeCount":98},[],{"trials":21766,"activeCount":98},[21767,21771],{"nctId":9397,"briefTitle":9398,"status":104,"phases":21768,"primaryCompletion":9400,"completion":9400,"start":1283,"enrollment":19,"conditions":21769,"interventions":21770},[87],[27],[9403,805],{"nctId":10563,"briefTitle":10564,"status":104,"phases":21772,"primaryCompletion":8187,"completion":8187,"start":10566,"enrollment":3978,"conditions":21773,"interventions":21774},[87],[27],[9403,6530,6835,6532,6533,6534,10569],{"trials":21776,"activeCount":98},[],{"trials":21778,"activeCount":98},[],{"trials":21780,"activeCount":98},[],{"trials":21782,"activeCount":98},[],{"intervention":21784,"totalTrials":230,"cells":21785},"BMS-820132",{"EARLY_PHASE1":21786,"PHASE1":21788,"PHASE2":21802,"PHASE3":21804,"PHASE4":21806,"NA":21808},{"trials":21787,"activeCount":98},[],{"trials":21789,"activeCount":98},[21790,21796],{"nctId":21791,"briefTitle":21792,"status":104,"phases":21793,"primaryCompletion":3960,"completion":3960,"start":3938,"enrollment":1285,"conditions":21794,"interventions":21795},"NCT01290575","Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes",[87],[12248],[21784,21784,21784,21784,21784,21784,21784],{"nctId":21797,"briefTitle":21798,"status":104,"phases":21799,"primaryCompletion":7706,"completion":7706,"start":7944,"enrollment":7813,"conditions":21800,"interventions":21801},"NCT01105429","Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes",[87],[10963],[21784,21784,21784,21784,21784,21784,21784,21784,21784],{"trials":21803,"activeCount":98},[],{"trials":21805,"activeCount":98},[],{"trials":21807,"activeCount":98},[],{"trials":21809,"activeCount":98},[],{"intervention":883,"totalTrials":230,"cells":21811},{"EARLY_PHASE1":21812,"PHASE1":21814,"PHASE2":21824,"PHASE3":21826,"PHASE4":21828,"NA":21830},{"trials":21813,"activeCount":98},[],{"trials":21815,"activeCount":98},[21816,21820],{"nctId":876,"briefTitle":877,"status":104,"phases":21817,"primaryCompletion":879,"completion":879,"start":880,"enrollment":747,"conditions":21818,"interventions":21819},[87],[18],[679,883],{"nctId":21081,"briefTitle":21082,"status":104,"phases":21821,"primaryCompletion":5375,"completion":5375,"start":21084,"enrollment":830,"conditions":21822,"interventions":21823},[87],[21086],[8547,21048,883],{"trials":21825,"activeCount":98},[],{"trials":21827,"activeCount":98},[],{"trials":21829,"activeCount":98},[],{"trials":21831,"activeCount":98},[],{"intervention":21833,"totalTrials":230,"cells":21834},"BMS-986325",{"EARLY_PHASE1":21835,"PHASE1":21837,"PHASE2":21853,"PHASE3":21855,"PHASE4":21857,"NA":21859},{"trials":21836,"activeCount":98},[],{"trials":21838,"activeCount":98},[21839,21847],{"nctId":21840,"briefTitle":21841,"status":104,"phases":21842,"primaryCompletion":21843,"completion":21843,"start":21844,"enrollment":94,"conditions":21845,"interventions":21846},"NCT05813717","A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants",[87],"2023-10-02","2023-04-10",[27],[21833],{"nctId":21848,"briefTitle":21849,"status":963,"phases":21850,"primaryCompletion":114,"completion":114,"start":1574,"enrollment":357,"conditions":21851,"interventions":21852},"NCT04684654","BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome",[87],[18,7803],[21833],{"trials":21854,"activeCount":98},[],{"trials":21856,"activeCount":98},[],{"trials":21858,"activeCount":98},[],{"trials":21860,"activeCount":98},[],{"intervention":21862,"totalTrials":208,"cells":21863},"BMS-986205 reference",{"EARLY_PHASE1":21864,"PHASE1":21866,"PHASE2":21878,"PHASE3":21880,"PHASE4":21882,"NA":21884},{"trials":21865,"activeCount":98},[],{"trials":21867,"activeCount":98},[21868],{"nctId":21869,"briefTitle":21870,"status":104,"phases":21871,"primaryCompletion":21872,"completion":21873,"start":21874,"enrollment":713,"conditions":21875,"interventions":21876},"NCT03378310","A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference Tablet",[87],"2018-02-15","2018-02-22","2017-12-21",[27],[21862,21877],"BMS-986205 tablet with free base",{"trials":21879,"activeCount":98},[],{"trials":21881,"activeCount":98},[],{"trials":21883,"activeCount":98},[],{"trials":21885,"activeCount":98},[],{"intervention":21877,"totalTrials":208,"cells":21887},{"EARLY_PHASE1":21888,"PHASE1":21890,"PHASE2":21896,"PHASE3":21898,"PHASE4":21900,"NA":21902},{"trials":21889,"activeCount":98},[],{"trials":21891,"activeCount":98},[21892],{"nctId":21869,"briefTitle":21870,"status":104,"phases":21893,"primaryCompletion":21872,"completion":21873,"start":21874,"enrollment":713,"conditions":21894,"interventions":21895},[87],[27],[21862,21877],{"trials":21897,"activeCount":98},[],{"trials":21899,"activeCount":98},[],{"trials":21901,"activeCount":98},[],{"trials":21903,"activeCount":98},[],{"intervention":21905,"totalTrials":208,"cells":21906},"BMS-986231 Formulation A",{"EARLY_PHASE1":21907,"PHASE1":21909,"PHASE2":21921,"PHASE3":21923,"PHASE4":21925,"NA":21927},{"trials":21908,"activeCount":98},[],{"trials":21910,"activeCount":98},[21911],{"nctId":21912,"briefTitle":21913,"status":104,"phases":21914,"primaryCompletion":1989,"completion":1989,"start":21915,"enrollment":582,"conditions":21916,"interventions":21917},"NCT03891108","A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants",[87],"2019-02-28",[8277],[21905,21918,21919,21920],"BMS-986231 Formulation B","BMS-986231 Formulation C","BMS-986231 Formulation D",{"trials":21922,"activeCount":98},[],{"trials":21924,"activeCount":98},[],{"trials":21926,"activeCount":98},[],{"trials":21928,"activeCount":98},[],{"intervention":21918,"totalTrials":208,"cells":21930},{"EARLY_PHASE1":21931,"PHASE1":21933,"PHASE2":21939,"PHASE3":21941,"PHASE4":21943,"NA":21945},{"trials":21932,"activeCount":98},[],{"trials":21934,"activeCount":98},[21935],{"nctId":21912,"briefTitle":21913,"status":104,"phases":21936,"primaryCompletion":1989,"completion":1989,"start":21915,"enrollment":582,"conditions":21937,"interventions":21938},[87],[8277],[21905,21918,21919,21920],{"trials":21940,"activeCount":98},[],{"trials":21942,"activeCount":98},[],{"trials":21944,"activeCount":98},[],{"trials":21946,"activeCount":98},[],{"intervention":21919,"totalTrials":208,"cells":21948},{"EARLY_PHASE1":21949,"PHASE1":21951,"PHASE2":21957,"PHASE3":21959,"PHASE4":21961,"NA":21963},{"trials":21950,"activeCount":98},[],{"trials":21952,"activeCount":98},[21953],{"nctId":21912,"briefTitle":21913,"status":104,"phases":21954,"primaryCompletion":1989,"completion":1989,"start":21915,"enrollment":582,"conditions":21955,"interventions":21956},[87],[8277],[21905,21918,21919,21920],{"trials":21958,"activeCount":98},[],{"trials":21960,"activeCount":98},[],{"trials":21962,"activeCount":98},[],{"trials":21964,"activeCount":98},[],{"intervention":21920,"totalTrials":208,"cells":21966},{"EARLY_PHASE1":21967,"PHASE1":21969,"PHASE2":21975,"PHASE3":21977,"PHASE4":21979,"NA":21981},{"trials":21968,"activeCount":98},[],{"trials":21970,"activeCount":98},[21971],{"nctId":21912,"briefTitle":21913,"status":104,"phases":21972,"primaryCompletion":1989,"completion":1989,"start":21915,"enrollment":582,"conditions":21973,"interventions":21974},[87],[8277],[21905,21918,21919,21920],{"trials":21976,"activeCount":98},[],{"trials":21978,"activeCount":98},[],{"trials":21980,"activeCount":98},[],{"trials":21982,"activeCount":98},[],{"intervention":21984,"totalTrials":208,"cells":21985},"Admilparant",{"EARLY_PHASE1":21986,"PHASE1":21988,"PHASE2":21998,"PHASE3":22000,"PHASE4":22002,"NA":22004},{"trials":21987,"activeCount":98},[],{"trials":21989,"activeCount":98},[21990],{"nctId":21991,"briefTitle":21992,"status":104,"phases":21993,"primaryCompletion":21994,"completion":21994,"start":21995,"enrollment":7813,"conditions":21996,"interventions":21997},"NCT07225647","A Study to Assess the Effect of Food on the Drug Levels of Admilparant",[87],"2026-01-05","2025-11-07",[18],[21984],{"trials":21999,"activeCount":98},[],{"trials":22001,"activeCount":98},[],{"trials":22003,"activeCount":98},[],{"trials":22005,"activeCount":98},[],{"intervention":22007,"totalTrials":208,"cells":22008},"Atazanavir\u002FRitonavir\u002FLopinavir\u002Fritonavir",{"EARLY_PHASE1":22009,"PHASE1":22011,"PHASE2":22019,"PHASE3":22021,"PHASE4":22023,"NA":22025},{"trials":22010,"activeCount":98},[],{"trials":22012,"activeCount":98},[22013],{"nctId":22014,"briefTitle":22015,"status":104,"phases":22016,"primaryCompletion":11251,"completion":11251,"start":11405,"enrollment":94,"conditions":22017,"interventions":22018},"NCT00135434","Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism",[87],[24],[22007],{"trials":22020,"activeCount":98},[],{"trials":22022,"activeCount":98},[],{"trials":22024,"activeCount":98},[],{"trials":22026,"activeCount":98},[],{"intervention":22028,"totalTrials":208,"cells":22029},"BMS-986141 Form A",{"EARLY_PHASE1":22030,"PHASE1":22032,"PHASE2":22042,"PHASE3":22044,"PHASE4":22046,"NA":22048},{"trials":22031,"activeCount":98},[],{"trials":22033,"activeCount":98},[22034],{"nctId":22035,"briefTitle":22036,"status":467,"phases":22037,"primaryCompletion":22038,"completion":22038,"start":16782,"enrollment":98,"conditions":22039,"interventions":22040},"NCT03035734","Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants",[87],"2017-02-07",[759],[22028,22041,22041],"BMS-986141 Form B",{"trials":22043,"activeCount":98},[],{"trials":22045,"activeCount":98},[],{"trials":22047,"activeCount":98},[],{"trials":22049,"activeCount":98},[],{"intervention":22041,"totalTrials":208,"cells":22051},{"EARLY_PHASE1":22052,"PHASE1":22054,"PHASE2":22060,"PHASE3":22062,"PHASE4":22064,"NA":22066},{"trials":22053,"activeCount":98},[],{"trials":22055,"activeCount":98},[22056],{"nctId":22035,"briefTitle":22036,"status":467,"phases":22057,"primaryCompletion":22038,"completion":22038,"start":16782,"enrollment":98,"conditions":22058,"interventions":22059},[87],[759],[22028,22041,22041],{"trials":22061,"activeCount":98},[],{"trials":22063,"activeCount":98},[],{"trials":22065,"activeCount":98},[],{"trials":22067,"activeCount":98},[],{"intervention":22069,"totalTrials":208,"cells":22070},"BMS-986165 Tablet formulation 1",{"EARLY_PHASE1":22071,"PHASE1":22073,"PHASE2":22084,"PHASE3":22086,"PHASE4":22088,"NA":22090},{"trials":22072,"activeCount":98},[],{"trials":22074,"activeCount":98},[22075],{"nctId":22076,"briefTitle":22077,"status":104,"phases":22078,"primaryCompletion":22079,"completion":22079,"start":22080,"enrollment":3562,"conditions":22081,"interventions":22082},"NCT04305899","A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants",[87],"2020-11-25","2020-08-31",[18],[22069,22083],"BMS-986165 Tablet formulation 2",{"trials":22085,"activeCount":98},[],{"trials":22087,"activeCount":98},[],{"trials":22089,"activeCount":98},[],{"trials":22091,"activeCount":98},[],{"intervention":22083,"totalTrials":208,"cells":22093},{"EARLY_PHASE1":22094,"PHASE1":22096,"PHASE2":22102,"PHASE3":22104,"PHASE4":22106,"NA":22108},{"trials":22095,"activeCount":98},[],{"trials":22097,"activeCount":98},[22098],{"nctId":22076,"briefTitle":22077,"status":104,"phases":22099,"primaryCompletion":22079,"completion":22079,"start":22080,"enrollment":3562,"conditions":22100,"interventions":22101},[87],[18],[22069,22083],{"trials":22103,"activeCount":98},[],{"trials":22105,"activeCount":98},[],{"trials":22107,"activeCount":98},[],{"trials":22109,"activeCount":98},[],{"intervention":16068,"totalTrials":208,"cells":22111},{"EARLY_PHASE1":22112,"PHASE1":22114,"PHASE2":22120,"PHASE3":22122,"PHASE4":22124,"NA":22126},{"trials":22113,"activeCount":98},[],{"trials":22115,"activeCount":98},[22116],{"nctId":16061,"briefTitle":16062,"status":104,"phases":22117,"primaryCompletion":14097,"completion":14097,"start":16064,"enrollment":7813,"conditions":22118,"interventions":22119},[87],[16066],[16054,16068],{"trials":22121,"activeCount":98},[],{"trials":22123,"activeCount":98},[],{"trials":22125,"activeCount":98},[],{"trials":22127,"activeCount":98},[],{"intervention":5586,"totalTrials":208,"cells":22129},{"EARLY_PHASE1":22130,"PHASE1":22132,"PHASE2":22138,"PHASE3":22140,"PHASE4":22142,"NA":22144},{"trials":22131,"activeCount":98},[],{"trials":22133,"activeCount":98},[22134],{"nctId":5578,"briefTitle":5579,"status":104,"phases":22135,"primaryCompletion":997,"completion":997,"start":5581,"enrollment":31,"conditions":22136,"interventions":22137},[87],[18],[5571,5584,5585,5586],{"trials":22139,"activeCount":98},[],{"trials":22141,"activeCount":98},[],{"trials":22143,"activeCount":98},[],{"trials":22145,"activeCount":98},[],{"intervention":1124,"totalTrials":208,"cells":22147},{"EARLY_PHASE1":22148,"PHASE1":22150,"PHASE2":22156,"PHASE3":22158,"PHASE4":22160,"NA":22162},{"trials":22149,"activeCount":98},[],{"trials":22151,"activeCount":98},[22152],{"nctId":1113,"briefTitle":1114,"status":963,"phases":22153,"primaryCompletion":1116,"completion":1117,"start":1118,"enrollment":757,"conditions":22154,"interventions":22155},[87],[1120],[1122,1123,1124,1123],{"trials":22157,"activeCount":98},[],{"trials":22159,"activeCount":98},[],{"trials":22161,"activeCount":98},[],{"trials":22163,"activeCount":98},[],{"intervention":22165,"totalTrials":208,"cells":22166},"BMS-582664",{"EARLY_PHASE1":22167,"PHASE1":22169,"PHASE2":22178,"PHASE3":22180,"PHASE4":22182,"NA":22184},{"trials":22168,"activeCount":98},[],{"trials":22170,"activeCount":98},[22171],{"nctId":22172,"briefTitle":22173,"status":963,"phases":22174,"primaryCompletion":7846,"start":4011,"enrollment":217,"conditions":22175,"interventions":22177},"NCT00300027","Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies",[87],[22176],"Gastrointestinal Neoplasms",[22165],{"trials":22179,"activeCount":98},[],{"trials":22181,"activeCount":98},[],{"trials":22183,"activeCount":98},[],{"trials":22185,"activeCount":98},[],{"intervention":22187,"totalTrials":208,"cells":22188},"BMS-986447",{"EARLY_PHASE1":22189,"PHASE1":22191,"PHASE2":22200,"PHASE3":22202,"PHASE4":22204,"NA":22206},{"trials":22190,"activeCount":98},[],{"trials":22192,"activeCount":98},[22193],{"nctId":22194,"briefTitle":22195,"status":104,"phases":22196,"primaryCompletion":191,"completion":191,"start":22197,"enrollment":34,"conditions":22198,"interventions":22199},"NCT05760937","A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy Participants",[87],"2023-03-10",[18],[22187],{"trials":22201,"activeCount":98},[],{"trials":22203,"activeCount":98},[],{"trials":22205,"activeCount":98},[],{"trials":22207,"activeCount":98},[],{"intervention":22209,"totalTrials":208,"cells":22210},"BMS-986446 IV",{"EARLY_PHASE1":22211,"PHASE1":22213,"PHASE2":22225,"PHASE3":22227,"PHASE4":22229,"NA":22231},{"trials":22212,"activeCount":98},[],{"trials":22214,"activeCount":98},[22215],{"nctId":22216,"briefTitle":22217,"status":104,"phases":22218,"primaryCompletion":3788,"completion":3788,"start":22219,"enrollment":6185,"conditions":22220,"interventions":22221},"NCT06955741","A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants",[87],"2025-05-05",[928],[22209,22222,22223,22224],"BMS-986446 SC","Acetaminophen","Loratadine",{"trials":22226,"activeCount":98},[],{"trials":22228,"activeCount":98},[],{"trials":22230,"activeCount":98},[],{"trials":22232,"activeCount":98},[],{"intervention":22222,"totalTrials":208,"cells":22234},{"EARLY_PHASE1":22235,"PHASE1":22237,"PHASE2":22243,"PHASE3":22245,"PHASE4":22247,"NA":22249},{"trials":22236,"activeCount":98},[],{"trials":22238,"activeCount":98},[22239],{"nctId":22216,"briefTitle":22217,"status":104,"phases":22240,"primaryCompletion":3788,"completion":3788,"start":22219,"enrollment":6185,"conditions":22241,"interventions":22242},[87],[928],[22209,22222,22223,22224],{"trials":22244,"activeCount":98},[],{"trials":22246,"activeCount":98},[],{"trials":22248,"activeCount":98},[],{"trials":22250,"activeCount":98},[],{"intervention":22223,"totalTrials":208,"cells":22252},{"EARLY_PHASE1":22253,"PHASE1":22255,"PHASE2":22261,"PHASE3":22263,"PHASE4":22265,"NA":22267},{"trials":22254,"activeCount":98},[],{"trials":22256,"activeCount":98},[22257],{"nctId":22216,"briefTitle":22217,"status":104,"phases":22258,"primaryCompletion":3788,"completion":3788,"start":22219,"enrollment":6185,"conditions":22259,"interventions":22260},[87],[928],[22209,22222,22223,22224],{"trials":22262,"activeCount":98},[],{"trials":22264,"activeCount":98},[],{"trials":22266,"activeCount":98},[],{"trials":22268,"activeCount":98},[],{"intervention":22224,"totalTrials":208,"cells":22270},{"EARLY_PHASE1":22271,"PHASE1":22273,"PHASE2":22279,"PHASE3":22281,"PHASE4":22283,"NA":22285},{"trials":22272,"activeCount":98},[],{"trials":22274,"activeCount":98},[22275],{"nctId":22216,"briefTitle":22217,"status":104,"phases":22276,"primaryCompletion":3788,"completion":3788,"start":22219,"enrollment":6185,"conditions":22277,"interventions":22278},[87],[928],[22209,22222,22223,22224],{"trials":22280,"activeCount":98},[],{"trials":22282,"activeCount":98},[],{"trials":22284,"activeCount":98},[],{"trials":22286,"activeCount":98},[],{"intervention":22288,"totalTrials":208,"cells":22289},"BMS-986189",{"EARLY_PHASE1":22290,"PHASE1":22292,"PHASE2":22302,"PHASE3":22304,"PHASE4":22306,"NA":22308},{"trials":22291,"activeCount":98},[],{"trials":22293,"activeCount":98},[22294],{"nctId":22295,"briefTitle":22296,"status":104,"phases":22297,"primaryCompletion":22298,"completion":22298,"start":22299,"enrollment":1686,"conditions":22300,"interventions":22301},"NCT02739373","Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects",[87],"2016-12-14","2016-04-18",[1318],[22288],{"trials":22303,"activeCount":98},[],{"trials":22305,"activeCount":98},[],{"trials":22307,"activeCount":98},[],{"trials":22309,"activeCount":98},[],{"intervention":22311,"totalTrials":208,"cells":22312},"vinflunine + ixabepilone",{"EARLY_PHASE1":22313,"PHASE1":22315,"PHASE2":22323,"PHASE3":22325,"PHASE4":22327,"NA":22329},{"trials":22314,"activeCount":98},[],{"trials":22316,"activeCount":98},[22317],{"nctId":22318,"briefTitle":22319,"status":104,"phases":22320,"primaryCompletion":11728,"completion":11728,"start":4379,"enrollment":582,"conditions":22321,"interventions":22322},"NCT00362830","A Study of the Alternative Administration of Ixabepilone and Vinflunine",[87],[606],[22311],{"trials":22324,"activeCount":98},[],{"trials":22326,"activeCount":98},[],{"trials":22328,"activeCount":98},[],{"trials":22330,"activeCount":98},[],{"intervention":22332,"totalTrials":208,"cells":22333},"Rifabutin",{"EARLY_PHASE1":22334,"PHASE1":22336,"PHASE2":22346,"PHASE3":22348,"PHASE4":22350,"NA":22352},{"trials":22335,"activeCount":98},[],{"trials":22337,"activeCount":98},[22338],{"nctId":22339,"briefTitle":22340,"status":104,"phases":22341,"primaryCompletion":7715,"completion":7715,"start":7811,"enrollment":424,"conditions":22342,"interventions":22344},"NCT00646776","Drug Interaction Study",[87],[22343],"Antivirals\u002FHIV",[22332,22345],"Rifabutin + Atazanavir + Ritonavir",{"trials":22347,"activeCount":98},[],{"trials":22349,"activeCount":98},[],{"trials":22351,"activeCount":98},[],{"trials":22353,"activeCount":98},[],{"intervention":22345,"totalTrials":208,"cells":22355},{"EARLY_PHASE1":22356,"PHASE1":22358,"PHASE2":22364,"PHASE3":22366,"PHASE4":22368,"NA":22370},{"trials":22357,"activeCount":98},[],{"trials":22359,"activeCount":98},[22360],{"nctId":22339,"briefTitle":22340,"status":104,"phases":22361,"primaryCompletion":7715,"completion":7715,"start":7811,"enrollment":424,"conditions":22362,"interventions":22363},[87],[22343],[22332,22345],{"trials":22365,"activeCount":98},[],{"trials":22367,"activeCount":98},[],{"trials":22369,"activeCount":98},[],{"trials":22371,"activeCount":98},[],{"intervention":11850,"totalTrials":208,"cells":22373},{"EARLY_PHASE1":22374,"PHASE1":22376,"PHASE2":22382,"PHASE3":22384,"PHASE4":22386,"NA":22388},{"trials":22375,"activeCount":98},[],{"trials":22377,"activeCount":98},[22378],{"nctId":11845,"briefTitle":11846,"status":104,"phases":22379,"primaryCompletion":4159,"completion":4159,"start":4289,"enrollment":693,"conditions":22380,"interventions":22381},[87],[30],[11850,9391,874],{"trials":22383,"activeCount":98},[],{"trials":22385,"activeCount":98},[],{"trials":22387,"activeCount":98},[],{"trials":22389,"activeCount":98},[],{"intervention":1156,"totalTrials":208,"cells":22391},{"EARLY_PHASE1":22392,"PHASE1":22394,"PHASE2":22400,"PHASE3":22402,"PHASE4":22404,"NA":22406},{"trials":22393,"activeCount":98},[],{"trials":22395,"activeCount":98},[22396],{"nctId":1147,"briefTitle":1148,"status":104,"phases":22397,"primaryCompletion":1150,"completion":1150,"start":1151,"enrollment":1152,"conditions":22398,"interventions":22399},[87],[1154],[1156,43,1157,622,1158],{"trials":22401,"activeCount":98},[],{"trials":22403,"activeCount":98},[],{"trials":22405,"activeCount":98},[],{"trials":22407,"activeCount":98},[],{"intervention":22409,"totalTrials":208,"cells":22410},"BMS-901608 (Elotuzumab) 10 mg",{"EARLY_PHASE1":22411,"PHASE1":22413,"PHASE2":22424,"PHASE3":22426,"PHASE4":22428,"NA":22430},{"trials":22412,"activeCount":98},[],{"trials":22414,"activeCount":98},[22415],{"nctId":22416,"briefTitle":22417,"status":104,"phases":22418,"primaryCompletion":22419,"completion":2977,"start":22420,"enrollment":1750,"conditions":22421,"interventions":22422},"NCT01241292","Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone",[87],"2014-02-14","2011-01-14",[33],[22409,22423],"BMS-901608 (Elotuzumab) 20 mg",{"trials":22425,"activeCount":98},[],{"trials":22427,"activeCount":98},[],{"trials":22429,"activeCount":98},[],{"trials":22431,"activeCount":98},[],{"intervention":22423,"totalTrials":208,"cells":22433},{"EARLY_PHASE1":22434,"PHASE1":22436,"PHASE2":22442,"PHASE3":22444,"PHASE4":22446,"NA":22448},{"trials":22435,"activeCount":98},[],{"trials":22437,"activeCount":98},[22438],{"nctId":22416,"briefTitle":22417,"status":104,"phases":22439,"primaryCompletion":22419,"completion":2977,"start":22420,"enrollment":1750,"conditions":22440,"interventions":22441},[87],[33],[22409,22423],{"trials":22443,"activeCount":98},[],{"trials":22445,"activeCount":98},[],{"trials":22447,"activeCount":98},[],{"trials":22449,"activeCount":98},[],{"intervention":717,"totalTrials":208,"cells":22451},{"EARLY_PHASE1":22452,"PHASE1":22454,"PHASE2":22460,"PHASE3":22462,"PHASE4":22464,"NA":22466},{"trials":22453,"activeCount":98},[],{"trials":22455,"activeCount":98},[22456],{"nctId":708,"briefTitle":709,"status":104,"phases":22457,"primaryCompletion":711,"completion":711,"start":712,"enrollment":713,"conditions":22458,"interventions":22459},[87],[715],[679,717],{"trials":22461,"activeCount":98},[],{"trials":22463,"activeCount":98},[],{"trials":22465,"activeCount":98},[],{"trials":22467,"activeCount":98},[],{"intervention":22469,"totalTrials":208,"cells":22470},"BMS-986090",{"EARLY_PHASE1":22471,"PHASE1":22473,"PHASE2":22482,"PHASE3":22484,"PHASE4":22486,"NA":22488},{"trials":22472,"activeCount":98},[],{"trials":22474,"activeCount":98},[22475],{"nctId":22476,"briefTitle":22477,"status":963,"phases":22478,"primaryCompletion":15836,"completion":15836,"start":4159,"enrollment":3322,"conditions":22479,"interventions":22480},"NCT02079480","Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects",[87],[10527],[22469,22481],"Keyhole limpet hemocyanin",{"trials":22483,"activeCount":98},[],{"trials":22485,"activeCount":98},[],{"trials":22487,"activeCount":98},[],{"trials":22489,"activeCount":98},[],{"intervention":22481,"totalTrials":208,"cells":22491},{"EARLY_PHASE1":22492,"PHASE1":22494,"PHASE2":22500,"PHASE3":22502,"PHASE4":22504,"NA":22506},{"trials":22493,"activeCount":98},[],{"trials":22495,"activeCount":98},[22496],{"nctId":22476,"briefTitle":22477,"status":963,"phases":22497,"primaryCompletion":15836,"completion":15836,"start":4159,"enrollment":3322,"conditions":22498,"interventions":22499},[87],[10527],[22469,22481],{"trials":22501,"activeCount":98},[],{"trials":22503,"activeCount":98},[],{"trials":22505,"activeCount":98},[],{"trials":22507,"activeCount":98},[],{"intervention":22509,"totalTrials":208,"cells":22510},"Atazanavir + Ritonavir + Combivir",{"EARLY_PHASE1":22511,"PHASE1":22513,"PHASE2":22522,"PHASE3":22524,"PHASE4":22526,"NA":22528},{"trials":22512,"activeCount":98},[],{"trials":22514,"activeCount":98},[22515],{"nctId":22516,"briefTitle":22517,"status":104,"phases":22518,"primaryCompletion":7713,"completion":3873,"start":5117,"enrollment":8039,"conditions":22519,"interventions":22521},"NCT00326716","Pharmacokinetics of Atazanavir\u002FRitonavir in HIV-1 Infected Pregnant Women",[87],[22520],"HIV Infection",[22509],{"trials":22523,"activeCount":98},[],{"trials":22525,"activeCount":98},[],{"trials":22527,"activeCount":98},[],{"trials":22529,"activeCount":98},[],{"intervention":7379,"totalTrials":208,"cells":22531},{"EARLY_PHASE1":22532,"PHASE1":22534,"PHASE2":22540,"PHASE3":22542,"PHASE4":22544,"NA":22546},{"trials":22533,"activeCount":98},[],{"trials":22535,"activeCount":98},[22536],{"nctId":7372,"briefTitle":7373,"status":104,"phases":22537,"primaryCompletion":4151,"completion":4151,"start":7375,"enrollment":7376,"conditions":22538,"interventions":22539},[87],[749],[7379,852,696,3287],{"trials":22541,"activeCount":98},[],{"trials":22543,"activeCount":98},[],{"trials":22545,"activeCount":98},[],{"trials":22547,"activeCount":98},[],{"intervention":16218,"totalTrials":208,"cells":22549},{"EARLY_PHASE1":22550,"PHASE1":22552,"PHASE2":22558,"PHASE3":22560,"PHASE4":22562,"NA":22564},{"trials":22551,"activeCount":98},[],{"trials":22553,"activeCount":98},[22554],{"nctId":16211,"briefTitle":16212,"status":104,"phases":22555,"primaryCompletion":16214,"completion":16214,"start":16135,"enrollment":94,"conditions":22556,"interventions":22557},[87],[16216],[16218,6905],{"trials":22559,"activeCount":98},[],{"trials":22561,"activeCount":98},[],{"trials":22563,"activeCount":98},[],{"trials":22565,"activeCount":98},[],{"intervention":22567,"totalTrials":208,"cells":22568},"Process E Belatacept",{"EARLY_PHASE1":22569,"PHASE1":22571,"PHASE2":22582,"PHASE3":22584,"PHASE4":22586,"NA":22588},{"trials":22570,"activeCount":98},[],{"trials":22572,"activeCount":98},[22573],{"nctId":22574,"briefTitle":22575,"status":104,"phases":22576,"primaryCompletion":1479,"completion":1479,"start":22577,"enrollment":22578,"conditions":22579,"interventions":22580},"NCT02564497","A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C",[87],"2015-10-02",491,[7068],[22567,22581],"Process C Belatacept",{"trials":22583,"activeCount":98},[],{"trials":22585,"activeCount":98},[],{"trials":22587,"activeCount":98},[],{"trials":22589,"activeCount":98},[],{"intervention":22581,"totalTrials":208,"cells":22591},{"EARLY_PHASE1":22592,"PHASE1":22594,"PHASE2":22600,"PHASE3":22602,"PHASE4":22604,"NA":22606},{"trials":22593,"activeCount":98},[],{"trials":22595,"activeCount":98},[22596],{"nctId":22574,"briefTitle":22575,"status":104,"phases":22597,"primaryCompletion":1479,"completion":1479,"start":22577,"enrollment":22578,"conditions":22598,"interventions":22599},[87],[7068],[22567,22581],{"trials":22601,"activeCount":98},[],{"trials":22603,"activeCount":98},[],{"trials":22605,"activeCount":98},[],{"trials":22607,"activeCount":98},[],{"intervention":22609,"totalTrials":208,"cells":22610},"BMS-986172",{"EARLY_PHASE1":22611,"PHASE1":22613,"PHASE2":22622,"PHASE3":22624,"PHASE4":22626,"NA":22628},{"trials":22612,"activeCount":98},[],{"trials":22614,"activeCount":98},[22615],{"nctId":22616,"briefTitle":22617,"status":104,"phases":22618,"primaryCompletion":22619,"completion":22619,"start":19441,"enrollment":3562,"conditions":22620,"interventions":22621},"NCT04926051","A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption",[87],"2021-12-28",[18],[22609],{"trials":22623,"activeCount":98},[],{"trials":22625,"activeCount":98},[],{"trials":22627,"activeCount":98},[],{"trials":22629,"activeCount":98},[],{"intervention":22631,"totalTrials":208,"cells":22632},"panHer",{"EARLY_PHASE1":22633,"PHASE1":22635,"PHASE2":22644,"PHASE3":22646,"PHASE4":22648,"NA":22650},{"trials":22634,"activeCount":98},[],{"trials":22636,"activeCount":98},[22637],{"nctId":22638,"briefTitle":22639,"status":104,"phases":22640,"primaryCompletion":4023,"start":22641,"enrollment":582,"conditions":22642,"interventions":22643},"NCT00095537","BMS-599626 in Patients With Advanced Solid Malignancies",[87],"2004-03",[606,13848],[22631],{"trials":22645,"activeCount":98},[],{"trials":22647,"activeCount":98},[],{"trials":22649,"activeCount":98},[],{"trials":22651,"activeCount":98},[],{"intervention":22653,"totalTrials":208,"cells":22654},"Dasatinib + Omeprazole",{"EARLY_PHASE1":22655,"PHASE1":22657,"PHASE2":22665,"PHASE3":22667,"PHASE4":22669,"NA":22671},{"trials":22656,"activeCount":98},[],{"trials":22658,"activeCount":98},[22659],{"nctId":22660,"briefTitle":22661,"status":104,"phases":22662,"primaryCompletion":5873,"completion":5873,"start":7811,"enrollment":363,"conditions":22663,"interventions":22664},"NCT00655746","The Effect of Omeprazole on the Pharmacokinetics of Dasatinib in Healthy Subjects",[87],[759],[22653],{"trials":22666,"activeCount":98},[],{"trials":22668,"activeCount":98},[],{"trials":22670,"activeCount":98},[],{"trials":22672,"activeCount":98},[],{"intervention":21062,"totalTrials":208,"cells":22674},{"EARLY_PHASE1":22675,"PHASE1":22677,"PHASE2":22683,"PHASE3":22685,"PHASE4":22687,"NA":22689},{"trials":22676,"activeCount":98},[],{"trials":22678,"activeCount":98},[22679],{"nctId":21055,"briefTitle":21056,"status":104,"phases":22680,"primaryCompletion":21058,"completion":21059,"start":16890,"enrollment":4932,"conditions":22681,"interventions":22682},[87],[18],[21062,21063,21048],{"trials":22684,"activeCount":98},[],{"trials":22686,"activeCount":98},[],{"trials":22688,"activeCount":98},[],{"trials":22690,"activeCount":98},[],{"intervention":21063,"totalTrials":208,"cells":22692},{"EARLY_PHASE1":22693,"PHASE1":22695,"PHASE2":22701,"PHASE3":22703,"PHASE4":22705,"NA":22707},{"trials":22694,"activeCount":98},[],{"trials":22696,"activeCount":98},[22697],{"nctId":21055,"briefTitle":21056,"status":104,"phases":22698,"primaryCompletion":21058,"completion":21059,"start":16890,"enrollment":4932,"conditions":22699,"interventions":22700},[87],[18],[21062,21063,21048],{"trials":22702,"activeCount":98},[],{"trials":22704,"activeCount":98},[],{"trials":22706,"activeCount":98},[],{"trials":22708,"activeCount":98},[],{"intervention":15308,"totalTrials":208,"cells":22710},{"EARLY_PHASE1":22711,"PHASE1":22713,"PHASE2":22719,"PHASE3":22721,"PHASE4":22723,"NA":22725},{"trials":22712,"activeCount":98},[],{"trials":22714,"activeCount":98},[22715],{"nctId":15303,"briefTitle":15304,"status":104,"phases":22716,"primaryCompletion":6480,"completion":6480,"start":7715,"enrollment":3978,"conditions":22717,"interventions":22718},[87],[552],[15308,9411,15309],{"trials":22720,"activeCount":98},[],{"trials":22722,"activeCount":98},[],{"trials":22724,"activeCount":98},[],{"trials":22726,"activeCount":98},[],{"intervention":15309,"totalTrials":208,"cells":22728},{"EARLY_PHASE1":22729,"PHASE1":22731,"PHASE2":22737,"PHASE3":22739,"PHASE4":22741,"NA":22743},{"trials":22730,"activeCount":98},[],{"trials":22732,"activeCount":98},[22733],{"nctId":15303,"briefTitle":15304,"status":104,"phases":22734,"primaryCompletion":6480,"completion":6480,"start":7715,"enrollment":3978,"conditions":22735,"interventions":22736},[87],[552],[15308,9411,15309],{"trials":22738,"activeCount":98},[],{"trials":22740,"activeCount":98},[],{"trials":22742,"activeCount":98},[],{"trials":22744,"activeCount":98},[],{"intervention":22746,"totalTrials":208,"cells":22747},"Epothilone D",{"EARLY_PHASE1":22748,"PHASE1":22750,"PHASE2":22759,"PHASE3":22761,"PHASE4":22763,"NA":22765},{"trials":22749,"activeCount":98},[],{"trials":22751,"activeCount":98},[22752],{"nctId":22753,"briefTitle":22754,"status":104,"phases":22755,"completion":10973,"start":22756,"enrollment":125,"conditions":22757,"interventions":22758},"NCT00030173","A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors",[87],"2001-10",[7156],[22746],{"trials":22760,"activeCount":98},[],{"trials":22762,"activeCount":98},[],{"trials":22764,"activeCount":98},[],{"trials":22766,"activeCount":98},[],{"intervention":22768,"totalTrials":208,"cells":22769},"BMS-641988",{"EARLY_PHASE1":22770,"PHASE1":22772,"PHASE2":22780,"PHASE3":22782,"PHASE4":22784,"NA":22786},{"trials":22771,"activeCount":98},[],{"trials":22773,"activeCount":98},[22774],{"nctId":22775,"briefTitle":22776,"status":104,"phases":22777,"primaryCompletion":4981,"completion":4981,"start":4039,"enrollment":1750,"conditions":22778,"interventions":22779},"NCT00644488","A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer",[87],[1504],[22768],{"trials":22781,"activeCount":98},[],{"trials":22783,"activeCount":98},[],{"trials":22785,"activeCount":98},[],{"trials":22787,"activeCount":98},[],{"intervention":3907,"totalTrials":208,"cells":22789},{"EARLY_PHASE1":22790,"PHASE1":22792,"PHASE2":22798,"PHASE3":22800,"PHASE4":22802,"NA":22804},{"trials":22791,"activeCount":98},[],{"trials":22793,"activeCount":98},[22794],{"nctId":3899,"briefTitle":3900,"status":467,"phases":22795,"primaryCompletion":3902,"completion":3903,"start":3904,"enrollment":98,"conditions":22796,"interventions":22797},[87],[21],[3907,3907,3907,3907,3907,608],{"trials":22799,"activeCount":98},[],{"trials":22801,"activeCount":98},[],{"trials":22803,"activeCount":98},[],{"trials":22805,"activeCount":98},[],{"intervention":22807,"totalTrials":208,"cells":22808},"BMS-767778 or Placebo",{"EARLY_PHASE1":22809,"PHASE1":22811,"PHASE2":22819,"PHASE3":22821,"PHASE4":22823,"NA":22825},{"trials":22810,"activeCount":98},[],{"trials":22812,"activeCount":98},[22813],{"nctId":22814,"briefTitle":22815,"status":963,"phases":22816,"primaryCompletion":7784,"completion":7784,"start":7715,"enrollment":3862,"conditions":22817,"interventions":22818},"NCT00707590","Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)",[87],[11098],[22807],{"trials":22820,"activeCount":98},[],{"trials":22822,"activeCount":98},[],{"trials":22824,"activeCount":98},[],{"trials":22826,"activeCount":98},[],{"intervention":22828,"totalTrials":208,"cells":22829},"Prenisolone",{"EARLY_PHASE1":22830,"PHASE1":22832,"PHASE2":22842,"PHASE3":22844,"PHASE4":22846,"NA":22848},{"trials":22831,"activeCount":98},[],{"trials":22833,"activeCount":98},[22834],{"nctId":22835,"briefTitle":22836,"status":104,"phases":22837,"primaryCompletion":22838,"completion":22838,"start":5066,"enrollment":1203,"conditions":22839,"interventions":22841},"NCT03196557","A Study to Assess the Pharmacodynamics (PD) of Prednisoline in Healthy Male Subject",[87],"2008-05-05",[22840],"Immunoscience",[22828],{"trials":22843,"activeCount":98},[],{"trials":22845,"activeCount":98},[],{"trials":22847,"activeCount":98},[],{"trials":22849,"activeCount":98},[],{"intervention":728,"totalTrials":208,"cells":22851},{"EARLY_PHASE1":22852,"PHASE1":22854,"PHASE2":22860,"PHASE3":22862,"PHASE4":22864,"NA":22866},{"trials":22853,"activeCount":98},[],{"trials":22855,"activeCount":98},[22856],{"nctId":719,"briefTitle":720,"status":104,"phases":22857,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":22858,"interventions":22859},[87],[18],[679,728],{"trials":22861,"activeCount":98},[],{"trials":22863,"activeCount":98},[],{"trials":22865,"activeCount":98},[],{"trials":22867,"activeCount":98},[],{"intervention":22869,"totalTrials":208,"cells":22870},"[14C]BMS-986419",{"EARLY_PHASE1":22871,"PHASE1":22873,"PHASE2":22883,"PHASE3":22885,"PHASE4":22887,"NA":22889},{"trials":22872,"activeCount":98},[],{"trials":22874,"activeCount":98},[22875],{"nctId":22876,"briefTitle":22877,"status":104,"phases":22878,"primaryCompletion":22879,"completion":22879,"start":22880,"enrollment":839,"conditions":22881,"interventions":22882},"NCT05847439","A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants",[87],"2023-07-05","2023-05-05",[27],[22869],{"trials":22884,"activeCount":98},[],{"trials":22886,"activeCount":98},[],{"trials":22888,"activeCount":98},[],{"trials":22890,"activeCount":98},[],{"intervention":22892,"totalTrials":208,"cells":22893},"BMS-986171",{"EARLY_PHASE1":22894,"PHASE1":22896,"PHASE2":22908,"PHASE3":22910,"PHASE4":22912,"NA":22914},{"trials":22895,"activeCount":98},[],{"trials":22897,"activeCount":98},[22898],{"nctId":22899,"briefTitle":22900,"status":104,"phases":22901,"primaryCompletion":22902,"completion":22903,"start":4415,"enrollment":22904,"conditions":22905,"interventions":22907},"NCT02538874","A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body",[87],"2016-11-04","2016-11-05",275,[22906],"Liver Fibrosis\u002FNASH",[22892],{"trials":22909,"activeCount":98},[],{"trials":22911,"activeCount":98},[],{"trials":22913,"activeCount":98},[],{"trials":22915,"activeCount":98},[],{"intervention":16267,"totalTrials":208,"cells":22917},{"EARLY_PHASE1":22918,"PHASE1":22920,"PHASE2":22926,"PHASE3":22928,"PHASE4":22930,"NA":22932},{"trials":22919,"activeCount":98},[],{"trials":22921,"activeCount":98},[22922],{"nctId":16261,"briefTitle":16262,"status":104,"phases":22923,"primaryCompletion":14959,"completion":14959,"start":9360,"enrollment":319,"conditions":22924,"interventions":22925},[87],[16265],[16254,16267],{"trials":22927,"activeCount":98},[],{"trials":22929,"activeCount":98},[],{"trials":22931,"activeCount":98},[],{"trials":22933,"activeCount":98},[],{"intervention":8450,"totalTrials":208,"cells":22935},{"EARLY_PHASE1":22936,"PHASE1":22938,"PHASE2":22944,"PHASE3":22946,"PHASE4":22948,"NA":22950},{"trials":22937,"activeCount":98},[],{"trials":22939,"activeCount":98},[22940],{"nctId":8441,"briefTitle":8442,"status":104,"phases":22941,"primaryCompletion":8444,"completion":8444,"start":8445,"enrollment":736,"conditions":22942,"interventions":22943},[87],[8447],[8449,8450,696],{"trials":22945,"activeCount":98},[],{"trials":22947,"activeCount":98},[],{"trials":22949,"activeCount":98},[],{"trials":22951,"activeCount":98},[],{"intervention":9287,"totalTrials":208,"cells":22953},{"EARLY_PHASE1":22954,"PHASE1":22956,"PHASE2":22962,"PHASE3":22964,"PHASE4":22966,"NA":22968},{"trials":22955,"activeCount":98},[],{"trials":22957,"activeCount":98},[22958],{"nctId":9281,"briefTitle":9282,"status":963,"phases":22959,"primaryCompletion":3138,"completion":3138,"start":9284,"enrollment":7813,"conditions":22960,"interventions":22961},[87],[8857,404],[9287,9274,9288],{"trials":22963,"activeCount":98},[],{"trials":22965,"activeCount":98},[],{"trials":22967,"activeCount":98},[],{"trials":22969,"activeCount":98},[],{"intervention":22971,"totalTrials":208,"cells":22972},"Anti-PDL-1 antibody",{"EARLY_PHASE1":22973,"PHASE1":22975,"PHASE2":22984,"PHASE3":22986,"PHASE4":22988,"NA":22990},{"trials":22974,"activeCount":98},[],{"trials":22976,"activeCount":98},[22977],{"nctId":22978,"briefTitle":22979,"status":104,"phases":22980,"primaryCompletion":4347,"completion":4347,"start":3587,"enrollment":1805,"conditions":22981,"interventions":22983},"NCT00729664","Multiple Ascending Dose (MDX1105-01)",[87],[22982],"Cancer, Multiple Indications",[22971,22971,22971,22971,22971],{"trials":22985,"activeCount":98},[],{"trials":22987,"activeCount":98},[],{"trials":22989,"activeCount":98},[],{"trials":22991,"activeCount":98},[],{"intervention":16511,"totalTrials":208,"cells":22993},{"EARLY_PHASE1":22994,"PHASE1":22996,"PHASE2":23002,"PHASE3":23004,"PHASE4":23006,"NA":23008},{"trials":22995,"activeCount":98},[],{"trials":22997,"activeCount":98},[22998],{"nctId":16505,"briefTitle":16506,"status":104,"phases":22999,"primaryCompletion":3904,"completion":3904,"start":3617,"enrollment":22,"conditions":23000,"interventions":23001},[87],[16509],[1676,1676,1676,1676,1676,1676,16511,1676,1676],{"trials":23003,"activeCount":98},[],{"trials":23005,"activeCount":98},[],{"trials":23007,"activeCount":98},[],{"trials":23009,"activeCount":98},[],{"intervention":23011,"totalTrials":208,"cells":23012},"BMS-962476",{"EARLY_PHASE1":23013,"PHASE1":23015,"PHASE2":23024,"PHASE3":23026,"PHASE4":23028,"NA":23030},{"trials":23014,"activeCount":98},[],{"trials":23016,"activeCount":98},[23017],{"nctId":23018,"briefTitle":23019,"status":104,"phases":23020,"primaryCompletion":10518,"completion":10518,"start":6225,"enrollment":1424,"conditions":23021,"interventions":23023},"NCT01587365","Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins",[87],[23022],"Atherosclerosis",[23011],{"trials":23025,"activeCount":98},[],{"trials":23027,"activeCount":98},[],{"trials":23029,"activeCount":98},[],{"trials":23031,"activeCount":98},[],{"intervention":23033,"totalTrials":208,"cells":23034},"BMS-844203",{"EARLY_PHASE1":23035,"PHASE1":23037,"PHASE2":23045,"PHASE3":23047,"PHASE4":23049,"NA":23051},{"trials":23036,"activeCount":98},[],{"trials":23038,"activeCount":98},[23039],{"nctId":23040,"briefTitle":23041,"status":467,"phases":23042,"primaryCompletion":14959,"completion":14959,"start":11742,"enrollment":98,"conditions":23043,"interventions":23044},"NCT01146171","Japanese Phase 1 Study of BMS-844203 (CT322)",[87],[7156],[23033],{"trials":23046,"activeCount":98},[],{"trials":23048,"activeCount":98},[],{"trials":23050,"activeCount":98},[],{"trials":23052,"activeCount":98},[],{"intervention":23054,"totalTrials":208,"cells":23055},"MDX-1411",{"EARLY_PHASE1":23056,"PHASE1":23058,"PHASE2":23067,"PHASE3":23069,"PHASE4":23071,"NA":23073},{"trials":23057,"activeCount":98},[],{"trials":23059,"activeCount":98},[23060],{"nctId":23061,"briefTitle":23062,"status":467,"phases":23063,"primaryCompletion":3977,"completion":4123,"start":4459,"enrollment":4932,"conditions":23064,"interventions":23066},"NCT00730652","Study of MDX-1411 in Patients With Relapsed\u002FRefractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma",[87],[23065],"Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma.",[23054],{"trials":23068,"activeCount":98},[],{"trials":23070,"activeCount":98},[],{"trials":23072,"activeCount":98},[],{"trials":23074,"activeCount":98},[],{"intervention":15191,"totalTrials":208,"cells":23076},{"EARLY_PHASE1":23077,"PHASE1":23079,"PHASE2":23085,"PHASE3":23087,"PHASE4":23089,"NA":23091},{"trials":23078,"activeCount":98},[],{"trials":23080,"activeCount":98},[23081],{"nctId":15185,"briefTitle":15186,"status":104,"phases":23082,"primaryCompletion":8699,"completion":8699,"start":15188,"enrollment":11958,"conditions":23083,"interventions":23084},[87],[11063],[12452,5584,15191],{"trials":23086,"activeCount":98},[],{"trials":23088,"activeCount":98},[],{"trials":23090,"activeCount":98},[],{"trials":23092,"activeCount":98},[],{"intervention":740,"totalTrials":208,"cells":23094},{"EARLY_PHASE1":23095,"PHASE1":23097,"PHASE2":23103,"PHASE3":23105,"PHASE4":23107,"NA":23109},{"trials":23096,"activeCount":98},[],{"trials":23098,"activeCount":98},[23099],{"nctId":730,"briefTitle":731,"status":104,"phases":23100,"primaryCompletion":733,"completion":734,"start":735,"enrollment":736,"conditions":23101,"interventions":23102},[87],[738],[740,679,696],{"trials":23104,"activeCount":98},[],{"trials":23106,"activeCount":98},[],{"trials":23108,"activeCount":98},[],{"trials":23110,"activeCount":98},[],{"intervention":3599,"totalTrials":208,"cells":23112},{"EARLY_PHASE1":23113,"PHASE1":23115,"PHASE2":23121,"PHASE3":23123,"PHASE4":23125,"NA":23127},{"trials":23114,"activeCount":98},[],{"trials":23116,"activeCount":98},[23117],{"nctId":3591,"briefTitle":3592,"status":104,"phases":23118,"primaryCompletion":3594,"completion":3595,"start":3596,"enrollment":1221,"conditions":23119,"interventions":23120},[87],[1888],[1890,1268,1929,3599,1157],{"trials":23122,"activeCount":98},[],{"trials":23124,"activeCount":98},[],{"trials":23126,"activeCount":98},[],{"trials":23128,"activeCount":98},[],{"intervention":23130,"totalTrials":208,"cells":23131},"CXL-1427 Ascending Dose",{"EARLY_PHASE1":23132,"PHASE1":23134,"PHASE2":23143,"PHASE3":23145,"PHASE4":23147,"NA":23149},{"trials":23133,"activeCount":98},[],{"trials":23135,"activeCount":98},[23136],{"nctId":23137,"briefTitle":23138,"status":104,"phases":23139,"primaryCompletion":4289,"completion":4289,"start":4551,"enrollment":1863,"conditions":23140,"interventions":23141},"NCT02819271","A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers",[87],[8277],[23130,23142],"CXL-1427 Descending Dose",{"trials":23144,"activeCount":98},[],{"trials":23146,"activeCount":98},[],{"trials":23148,"activeCount":98},[],{"trials":23150,"activeCount":98},[],{"intervention":23142,"totalTrials":208,"cells":23152},{"EARLY_PHASE1":23153,"PHASE1":23155,"PHASE2":23161,"PHASE3":23163,"PHASE4":23165,"NA":23167},{"trials":23154,"activeCount":98},[],{"trials":23156,"activeCount":98},[23157],{"nctId":23137,"briefTitle":23138,"status":104,"phases":23158,"primaryCompletion":4289,"completion":4289,"start":4551,"enrollment":1863,"conditions":23159,"interventions":23160},[87],[8277],[23130,23142],{"trials":23162,"activeCount":98},[],{"trials":23164,"activeCount":98},[],{"trials":23166,"activeCount":98},[],{"trials":23168,"activeCount":98},[],{"intervention":23170,"totalTrials":208,"cells":23171},"MDX-1401",{"EARLY_PHASE1":23172,"PHASE1":23174,"PHASE2":23183,"PHASE3":23185,"PHASE4":23187,"NA":23189},{"trials":23173,"activeCount":98},[],{"trials":23175,"activeCount":98},[23176],{"nctId":23177,"briefTitle":23178,"status":104,"phases":23179,"primaryCompletion":10431,"completion":10431,"start":3680,"enrollment":3978,"conditions":23180,"interventions":23182},"NCT00634452","Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory\u002FRelapsed Hodgkin's Lymphoma",[87],[23181],"Hodgkin's Lymphomas",[23170],{"trials":23184,"activeCount":98},[],{"trials":23186,"activeCount":98},[],{"trials":23188,"activeCount":98},[],{"trials":23190,"activeCount":98},[],{"intervention":23192,"totalTrials":208,"cells":23193},"BMS-986142 200mg",{"EARLY_PHASE1":23194,"PHASE1":23196,"PHASE2":23206,"PHASE3":23208,"PHASE4":23210,"NA":23212},{"trials":23195,"activeCount":98},[],{"trials":23197,"activeCount":98},[23198],{"nctId":23199,"briefTitle":23200,"status":104,"phases":23201,"primaryCompletion":8699,"completion":8699,"start":16135,"enrollment":11958,"conditions":23202,"interventions":23203},"NCT02762123","A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates",[87],[15],[23192,23204,23205],"BMS Drug-drug interaction cocktail","BMS-986142 350mg",{"trials":23207,"activeCount":98},[],{"trials":23209,"activeCount":98},[],{"trials":23211,"activeCount":98},[],{"trials":23213,"activeCount":98},[],{"intervention":23204,"totalTrials":208,"cells":23215},{"EARLY_PHASE1":23216,"PHASE1":23218,"PHASE2":23224,"PHASE3":23226,"PHASE4":23228,"NA":23230},{"trials":23217,"activeCount":98},[],{"trials":23219,"activeCount":98},[23220],{"nctId":23199,"briefTitle":23200,"status":104,"phases":23221,"primaryCompletion":8699,"completion":8699,"start":16135,"enrollment":11958,"conditions":23222,"interventions":23223},[87],[15],[23192,23204,23205],{"trials":23225,"activeCount":98},[],{"trials":23227,"activeCount":98},[],{"trials":23229,"activeCount":98},[],{"trials":23231,"activeCount":98},[],{"intervention":23205,"totalTrials":208,"cells":23233},{"EARLY_PHASE1":23234,"PHASE1":23236,"PHASE2":23242,"PHASE3":23244,"PHASE4":23246,"NA":23248},{"trials":23235,"activeCount":98},[],{"trials":23237,"activeCount":98},[23238],{"nctId":23199,"briefTitle":23200,"status":104,"phases":23239,"primaryCompletion":8699,"completion":8699,"start":16135,"enrollment":11958,"conditions":23240,"interventions":23241},[87],[15],[23192,23204,23205],{"trials":23243,"activeCount":98},[],{"trials":23245,"activeCount":98},[],{"trials":23247,"activeCount":98},[],{"trials":23249,"activeCount":98},[],{"intervention":5595,"totalTrials":208,"cells":23251},{"EARLY_PHASE1":23252,"PHASE1":23254,"PHASE2":23260,"PHASE3":23262,"PHASE4":23264,"NA":23266},{"trials":23253,"activeCount":98},[],{"trials":23255,"activeCount":98},[23256],{"nctId":5588,"briefTitle":5589,"status":104,"phases":23257,"primaryCompletion":5591,"completion":5591,"start":5592,"enrollment":680,"conditions":23258,"interventions":23259},[87],[27],[5571,5595],{"trials":23261,"activeCount":98},[],{"trials":23263,"activeCount":98},[],{"trials":23265,"activeCount":98},[],{"trials":23267,"activeCount":98},[],{"intervention":23269,"totalTrials":208,"cells":23270},"BMS-986177 Oral Solution",{"EARLY_PHASE1":23271,"PHASE1":23273,"PHASE2":23285,"PHASE3":23287,"PHASE4":23289,"NA":23291},{"trials":23272,"activeCount":98},[],{"trials":23274,"activeCount":98},[23275],{"nctId":23276,"briefTitle":23277,"status":104,"phases":23278,"primaryCompletion":23279,"completion":23280,"start":16889,"enrollment":5543,"conditions":23281,"interventions":23282},"NCT04965389","A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants",[87],"2021-08-22","2021-10-01",[27],[23269,23283,23284],"[14C]BMS-986177 Solution for","BMS-986177 Spray-dried Dispersion",{"trials":23286,"activeCount":98},[],{"trials":23288,"activeCount":98},[],{"trials":23290,"activeCount":98},[],{"trials":23292,"activeCount":98},[],{"intervention":23283,"totalTrials":208,"cells":23294},{"EARLY_PHASE1":23295,"PHASE1":23297,"PHASE2":23303,"PHASE3":23305,"PHASE4":23307,"NA":23309},{"trials":23296,"activeCount":98},[],{"trials":23298,"activeCount":98},[23299],{"nctId":23276,"briefTitle":23277,"status":104,"phases":23300,"primaryCompletion":23279,"completion":23280,"start":16889,"enrollment":5543,"conditions":23301,"interventions":23302},[87],[27],[23269,23283,23284],{"trials":23304,"activeCount":98},[],{"trials":23306,"activeCount":98},[],{"trials":23308,"activeCount":98},[],{"trials":23310,"activeCount":98},[],{"intervention":23284,"totalTrials":208,"cells":23312},{"EARLY_PHASE1":23313,"PHASE1":23315,"PHASE2":23321,"PHASE3":23323,"PHASE4":23325,"NA":23327},{"trials":23314,"activeCount":98},[],{"trials":23316,"activeCount":98},[23317],{"nctId":23276,"briefTitle":23277,"status":104,"phases":23318,"primaryCompletion":23279,"completion":23280,"start":16889,"enrollment":5543,"conditions":23319,"interventions":23320},[87],[27],[23269,23283,23284],{"trials":23322,"activeCount":98},[],{"trials":23324,"activeCount":98},[],{"trials":23326,"activeCount":98},[],{"trials":23328,"activeCount":98},[],{"intervention":6546,"totalTrials":208,"cells":23330},{"EARLY_PHASE1":23331,"PHASE1":23333,"PHASE2":23339,"PHASE3":23341,"PHASE4":23343,"NA":23345},{"trials":23332,"activeCount":98},[],{"trials":23334,"activeCount":98},[23335],{"nctId":6538,"briefTitle":6539,"status":104,"phases":23336,"primaryCompletion":6541,"completion":6542,"start":6543,"enrollment":148,"conditions":23337,"interventions":23338},[87],[18],[772,617,6546,6547],{"trials":23340,"activeCount":98},[],{"trials":23342,"activeCount":98},[],{"trials":23344,"activeCount":98},[],{"trials":23346,"activeCount":98},[],{"intervention":6547,"totalTrials":208,"cells":23348},{"EARLY_PHASE1":23349,"PHASE1":23351,"PHASE2":23357,"PHASE3":23359,"PHASE4":23361,"NA":23363},{"trials":23350,"activeCount":98},[],{"trials":23352,"activeCount":98},[23353],{"nctId":6538,"briefTitle":6539,"status":104,"phases":23354,"primaryCompletion":6541,"completion":6542,"start":6543,"enrollment":148,"conditions":23355,"interventions":23356},[87],[18],[772,617,6546,6547],{"trials":23358,"activeCount":98},[],{"trials":23360,"activeCount":98},[],{"trials":23362,"activeCount":98},[],{"trials":23364,"activeCount":98},[],{"intervention":23366,"totalTrials":208,"cells":23367},"FS102",{"EARLY_PHASE1":23368,"PHASE1":23370,"PHASE2":23381,"PHASE3":23383,"PHASE4":23385,"NA":23387},{"trials":23369,"activeCount":98},[],{"trials":23371,"activeCount":98},[23372],{"nctId":23373,"briefTitle":23374,"status":104,"phases":23375,"primaryCompletion":23376,"completion":23376,"start":23377,"enrollment":148,"conditions":23378,"interventions":23380},"NCT02286219","Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)",[87],"2017-06-08","2014-11-04",[23379],"Solid Tumors That Overexpress HER2 (HER2 Positive)",[23366],{"trials":23382,"activeCount":98},[],{"trials":23384,"activeCount":98},[],{"trials":23386,"activeCount":98},[],{"trials":23388,"activeCount":98},[],{"intervention":11857,"totalTrials":208,"cells":23390},{"EARLY_PHASE1":23391,"PHASE1":23393,"PHASE2":23399,"PHASE3":23401,"PHASE4":23403,"NA":23405},{"trials":23392,"activeCount":98},[],{"trials":23394,"activeCount":98},[23395],{"nctId":11852,"briefTitle":11853,"status":104,"phases":23396,"primaryCompletion":4289,"completion":4289,"start":4551,"enrollment":34,"conditions":23397,"interventions":23398},[87],[30],[11857,11858,9391,11859,11860],{"trials":23400,"activeCount":98},[],{"trials":23402,"activeCount":98},[],{"trials":23404,"activeCount":98},[],{"trials":23406,"activeCount":98},[],{"intervention":11859,"totalTrials":208,"cells":23408},{"EARLY_PHASE1":23409,"PHASE1":23411,"PHASE2":23417,"PHASE3":23419,"PHASE4":23421,"NA":23423},{"trials":23410,"activeCount":98},[],{"trials":23412,"activeCount":98},[23413],{"nctId":11852,"briefTitle":11853,"status":104,"phases":23414,"primaryCompletion":4289,"completion":4289,"start":4551,"enrollment":34,"conditions":23415,"interventions":23416},[87],[30],[11857,11858,9391,11859,11860],{"trials":23418,"activeCount":98},[],{"trials":23420,"activeCount":98},[],{"trials":23422,"activeCount":98},[],{"trials":23424,"activeCount":98},[],{"intervention":11860,"totalTrials":208,"cells":23426},{"EARLY_PHASE1":23427,"PHASE1":23429,"PHASE2":23435,"PHASE3":23437,"PHASE4":23439,"NA":23441},{"trials":23428,"activeCount":98},[],{"trials":23430,"activeCount":98},[23431],{"nctId":11852,"briefTitle":11853,"status":104,"phases":23432,"primaryCompletion":4289,"completion":4289,"start":4551,"enrollment":34,"conditions":23433,"interventions":23434},[87],[30],[11857,11858,9391,11859,11860],{"trials":23436,"activeCount":98},[],{"trials":23438,"activeCount":98},[],{"trials":23440,"activeCount":98},[],{"trials":23442,"activeCount":98},[],{"intervention":23444,"totalTrials":208,"cells":23445},"MDX 1411",{"EARLY_PHASE1":23446,"PHASE1":23448,"PHASE2":23456,"PHASE3":23458,"PHASE4":23460,"NA":23462},{"trials":23447,"activeCount":98},[],{"trials":23449,"activeCount":98},[23450],{"nctId":23451,"briefTitle":23452,"status":104,"phases":23453,"primaryCompletion":11762,"completion":11762,"start":7811,"enrollment":37,"conditions":23454,"interventions":23455},"NCT00656734","Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.",[87],[2989],[23444],{"trials":23457,"activeCount":98},[],{"trials":23459,"activeCount":98},[],{"trials":23461,"activeCount":98},[],{"trials":23463,"activeCount":98},[],{"intervention":23465,"totalTrials":208,"cells":23466},"BMS-903452",{"EARLY_PHASE1":23467,"PHASE1":23469,"PHASE2":23478,"PHASE3":23480,"PHASE4":23482,"NA":23484},{"trials":23468,"activeCount":98},[],{"trials":23470,"activeCount":98},[23471],{"nctId":23472,"briefTitle":23473,"status":104,"phases":23474,"primaryCompletion":7927,"completion":7927,"start":3904,"enrollment":515,"conditions":23475,"interventions":23477},"NCT01240980","Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)",[87],[23476],"Diabetes",[23465,23465,23465,23465,23465,23465,23465,23465,23465,23465,23465,23465],{"trials":23479,"activeCount":98},[],{"trials":23481,"activeCount":98},[],{"trials":23483,"activeCount":98},[],{"trials":23485,"activeCount":98},[],{"intervention":15322,"totalTrials":208,"cells":23487},{"EARLY_PHASE1":23488,"PHASE1":23490,"PHASE2":23496,"PHASE3":23498,"PHASE4":23500,"NA":23502},{"trials":23489,"activeCount":98},[],{"trials":23491,"activeCount":98},[23492],{"nctId":15317,"briefTitle":15318,"status":104,"phases":23493,"primaryCompletion":3712,"completion":3712,"start":3572,"enrollment":148,"conditions":23494,"interventions":23495},[87],[552],[9411,15322,15323,15324,15325],{"trials":23497,"activeCount":98},[],{"trials":23499,"activeCount":98},[],{"trials":23501,"activeCount":98},[],{"trials":23503,"activeCount":98},[],{"intervention":15323,"totalTrials":208,"cells":23505},{"EARLY_PHASE1":23506,"PHASE1":23508,"PHASE2":23514,"PHASE3":23516,"PHASE4":23518,"NA":23520},{"trials":23507,"activeCount":98},[],{"trials":23509,"activeCount":98},[23510],{"nctId":15317,"briefTitle":15318,"status":104,"phases":23511,"primaryCompletion":3712,"completion":3712,"start":3572,"enrollment":148,"conditions":23512,"interventions":23513},[87],[552],[9411,15322,15323,15324,15325],{"trials":23515,"activeCount":98},[],{"trials":23517,"activeCount":98},[],{"trials":23519,"activeCount":98},[],{"trials":23521,"activeCount":98},[],{"intervention":15325,"totalTrials":208,"cells":23523},{"EARLY_PHASE1":23524,"PHASE1":23526,"PHASE2":23532,"PHASE3":23534,"PHASE4":23536,"NA":23538},{"trials":23525,"activeCount":98},[],{"trials":23527,"activeCount":98},[23528],{"nctId":15317,"briefTitle":15318,"status":104,"phases":23529,"primaryCompletion":3712,"completion":3712,"start":3572,"enrollment":148,"conditions":23530,"interventions":23531},[87],[552],[9411,15322,15323,15324,15325],{"trials":23533,"activeCount":98},[],{"trials":23535,"activeCount":98},[],{"trials":23537,"activeCount":98},[],{"trials":23539,"activeCount":98},[],{"intervention":20811,"totalTrials":208,"cells":23541},{"EARLY_PHASE1":23542,"PHASE1":23544,"PHASE2":23550,"PHASE3":23552,"PHASE4":23554,"NA":23556},{"trials":23543,"activeCount":98},[],{"trials":23545,"activeCount":98},[23546],{"nctId":20805,"briefTitle":20806,"status":104,"phases":23547,"primaryCompletion":147,"completion":147,"start":20808,"enrollment":839,"conditions":23548,"interventions":23549},[87],[18],[7044,20811],{"trials":23551,"activeCount":98},[],{"trials":23553,"activeCount":98},[],{"trials":23555,"activeCount":98},[],{"trials":23557,"activeCount":98},[],{"intervention":781,"totalTrials":208,"cells":23559},{"EARLY_PHASE1":23560,"PHASE1":23562,"PHASE2":23568,"PHASE3":23570,"PHASE4":23572,"NA":23574},{"trials":23561,"activeCount":98},[],{"trials":23563,"activeCount":98},[23564],{"nctId":774,"briefTitle":775,"status":104,"phases":23565,"primaryCompletion":777,"completion":777,"start":778,"enrollment":693,"conditions":23566,"interventions":23567},[87],[18],[679,781,782],{"trials":23569,"activeCount":98},[],{"trials":23571,"activeCount":98},[],{"trials":23573,"activeCount":98},[],{"trials":23575,"activeCount":98},[],{"intervention":782,"totalTrials":208,"cells":23577},{"EARLY_PHASE1":23578,"PHASE1":23580,"PHASE2":23586,"PHASE3":23588,"PHASE4":23590,"NA":23592},{"trials":23579,"activeCount":98},[],{"trials":23581,"activeCount":98},[23582],{"nctId":774,"briefTitle":775,"status":104,"phases":23583,"primaryCompletion":777,"completion":777,"start":778,"enrollment":693,"conditions":23584,"interventions":23585},[87],[18],[679,781,782],{"trials":23587,"activeCount":98},[],{"trials":23589,"activeCount":98},[],{"trials":23591,"activeCount":98},[],{"trials":23593,"activeCount":98},[],{"intervention":21072,"totalTrials":208,"cells":23595},{"EARLY_PHASE1":23596,"PHASE1":23598,"PHASE2":23604,"PHASE3":23606,"PHASE4":23608,"NA":23610},{"trials":23597,"activeCount":98},[],{"trials":23599,"activeCount":98},[23600],{"nctId":21065,"briefTitle":21066,"status":104,"phases":23601,"primaryCompletion":21068,"completion":21069,"start":11228,"enrollment":3986,"conditions":23602,"interventions":23603},[87],[18],[8547,21048,21072],{"trials":23605,"activeCount":98},[],{"trials":23607,"activeCount":98},[],{"trials":23609,"activeCount":98},[],{"trials":23611,"activeCount":98},[],{"intervention":8466,"totalTrials":208,"cells":23613},{"EARLY_PHASE1":23614,"PHASE1":23616,"PHASE2":23622,"PHASE3":23624,"PHASE4":23626,"NA":23628},{"trials":23615,"activeCount":98},[],{"trials":23617,"activeCount":98},[23618],{"nctId":8460,"briefTitle":8461,"status":104,"phases":23619,"primaryCompletion":819,"completion":819,"start":8463,"enrollment":2527,"conditions":23620,"interventions":23621},[87],[27],[8466,696],{"trials":23623,"activeCount":98},[],{"trials":23625,"activeCount":98},[],{"trials":23627,"activeCount":98},[],{"trials":23629,"activeCount":98},[],{"intervention":5622,"totalTrials":208,"cells":23631},{"EARLY_PHASE1":23632,"PHASE1":23634,"PHASE2":23640,"PHASE3":23642,"PHASE4":23644,"NA":23646},{"trials":23633,"activeCount":98},[],{"trials":23635,"activeCount":98},[23636],{"nctId":5615,"briefTitle":5616,"status":104,"phases":23637,"primaryCompletion":5618,"completion":5618,"start":5619,"enrollment":1203,"conditions":23638,"interventions":23639},[87],[18],[5571,5622,5623],{"trials":23641,"activeCount":98},[],{"trials":23643,"activeCount":98},[],{"trials":23645,"activeCount":98},[],{"trials":23647,"activeCount":98},[],{"intervention":5623,"totalTrials":208,"cells":23649},{"EARLY_PHASE1":23650,"PHASE1":23652,"PHASE2":23658,"PHASE3":23660,"PHASE4":23662,"NA":23664},{"trials":23651,"activeCount":98},[],{"trials":23653,"activeCount":98},[23654],{"nctId":5615,"briefTitle":5616,"status":104,"phases":23655,"primaryCompletion":5618,"completion":5618,"start":5619,"enrollment":1203,"conditions":23656,"interventions":23657},[87],[18],[5571,5622,5623],{"trials":23659,"activeCount":98},[],{"trials":23661,"activeCount":98},[],{"trials":23663,"activeCount":98},[],{"trials":23665,"activeCount":98},[],{"intervention":10824,"totalTrials":208,"cells":23667},{"EARLY_PHASE1":23668,"PHASE1":23670,"PHASE2":23676,"PHASE3":23678,"PHASE4":23680,"NA":23682},{"trials":23669,"activeCount":98},[],{"trials":23671,"activeCount":98},[23672],{"nctId":10818,"briefTitle":10819,"status":104,"phases":23673,"primaryCompletion":6968,"completion":6968,"start":10821,"enrollment":3978,"conditions":23674,"interventions":23675},[87],[24],[10435,8547,10824],{"trials":23677,"activeCount":98},[],{"trials":23679,"activeCount":98},[],{"trials":23681,"activeCount":98},[],{"trials":23683,"activeCount":98},[],{"intervention":15647,"totalTrials":208,"cells":23685},{"EARLY_PHASE1":23686,"PHASE1":23688,"PHASE2":23694,"PHASE3":23696,"PHASE4":23698,"NA":23700},{"trials":23687,"activeCount":98},[],{"trials":23689,"activeCount":98},[23690],{"nctId":15641,"briefTitle":15642,"status":104,"phases":23691,"primaryCompletion":1585,"completion":1585,"start":15644,"enrollment":94,"conditions":23692,"interventions":23693},[87],[18],[15626,15647],{"trials":23695,"activeCount":98},[],{"trials":23697,"activeCount":98},[],{"trials":23699,"activeCount":98},[],{"trials":23701,"activeCount":98},[],{"intervention":23703,"totalTrials":208,"cells":23704},"HuMax-IL8",{"EARLY_PHASE1":23705,"PHASE1":23707,"PHASE2":23715,"PHASE3":23717,"PHASE4":23719,"NA":23721},{"trials":23706,"activeCount":98},[],{"trials":23708,"activeCount":98},[23709],{"nctId":23710,"briefTitle":23711,"status":104,"phases":23712,"primaryCompletion":846,"completion":846,"start":4458,"enrollment":1385,"conditions":23713,"interventions":23714},"NCT02536469","HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors",[87],[1482],[23703],{"trials":23716,"activeCount":98},[],{"trials":23718,"activeCount":98},[],{"trials":23720,"activeCount":98},[],{"trials":23722,"activeCount":98},[],{"intervention":23724,"totalTrials":208,"cells":23725},"BMS-986278 Batched method, Dose A",{"EARLY_PHASE1":23726,"PHASE1":23728,"PHASE2":23740,"PHASE3":23742,"PHASE4":23744,"NA":23746},{"trials":23727,"activeCount":98},[],{"trials":23729,"activeCount":98},[23730],{"nctId":23731,"briefTitle":23732,"status":104,"phases":23733,"primaryCompletion":23734,"completion":23734,"start":23735,"enrollment":725,"conditions":23736,"interventions":23737},"NCT06715683","A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants",[87],"2025-03-16","2024-12-12",[27],[23724,23738,23739],"BMS-986278 Batched method, Dose B","BMS-986278 Continuous method",{"trials":23741,"activeCount":98},[],{"trials":23743,"activeCount":98},[],{"trials":23745,"activeCount":98},[],{"trials":23747,"activeCount":98},[],{"intervention":23738,"totalTrials":208,"cells":23749},{"EARLY_PHASE1":23750,"PHASE1":23752,"PHASE2":23758,"PHASE3":23760,"PHASE4":23762,"NA":23764},{"trials":23751,"activeCount":98},[],{"trials":23753,"activeCount":98},[23754],{"nctId":23731,"briefTitle":23732,"status":104,"phases":23755,"primaryCompletion":23734,"completion":23734,"start":23735,"enrollment":725,"conditions":23756,"interventions":23757},[87],[27],[23724,23738,23739],{"trials":23759,"activeCount":98},[],{"trials":23761,"activeCount":98},[],{"trials":23763,"activeCount":98},[],{"trials":23765,"activeCount":98},[],{"intervention":23739,"totalTrials":208,"cells":23767},{"EARLY_PHASE1":23768,"PHASE1":23770,"PHASE2":23776,"PHASE3":23778,"PHASE4":23780,"NA":23782},{"trials":23769,"activeCount":98},[],{"trials":23771,"activeCount":98},[23772],{"nctId":23731,"briefTitle":23732,"status":104,"phases":23773,"primaryCompletion":23734,"completion":23734,"start":23735,"enrollment":725,"conditions":23774,"interventions":23775},[87],[27],[23724,23738,23739],{"trials":23777,"activeCount":98},[],{"trials":23779,"activeCount":98},[],{"trials":23781,"activeCount":98},[],{"trials":23783,"activeCount":98},[],{"intervention":23785,"totalTrials":208,"cells":23786},"Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg",{"EARLY_PHASE1":23787,"PHASE1":23789,"PHASE2":23801,"PHASE3":23803,"PHASE4":23805,"NA":23807},{"trials":23788,"activeCount":98},[],{"trials":23790,"activeCount":98},[23791],{"nctId":23792,"briefTitle":23793,"status":104,"phases":23794,"primaryCompletion":5542,"completion":3893,"start":5873,"enrollment":1063,"conditions":23795,"interventions":23796},"NCT00560391","Dasatinib in Combination With Revlimid (and Dexamethasone)",[87],[33],[23785,23797,23798,23799,23800],"Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg","Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg","Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg","Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg",{"trials":23802,"activeCount":98},[],{"trials":23804,"activeCount":98},[],{"trials":23806,"activeCount":98},[],{"trials":23808,"activeCount":98},[],{"intervention":23797,"totalTrials":208,"cells":23810},{"EARLY_PHASE1":23811,"PHASE1":23813,"PHASE2":23819,"PHASE3":23821,"PHASE4":23823,"NA":23825},{"trials":23812,"activeCount":98},[],{"trials":23814,"activeCount":98},[23815],{"nctId":23792,"briefTitle":23793,"status":104,"phases":23816,"primaryCompletion":5542,"completion":3893,"start":5873,"enrollment":1063,"conditions":23817,"interventions":23818},[87],[33],[23785,23797,23798,23799,23800],{"trials":23820,"activeCount":98},[],{"trials":23822,"activeCount":98},[],{"trials":23824,"activeCount":98},[],{"trials":23826,"activeCount":98},[],{"intervention":23798,"totalTrials":208,"cells":23828},{"EARLY_PHASE1":23829,"PHASE1":23831,"PHASE2":23837,"PHASE3":23839,"PHASE4":23841,"NA":23843},{"trials":23830,"activeCount":98},[],{"trials":23832,"activeCount":98},[23833],{"nctId":23792,"briefTitle":23793,"status":104,"phases":23834,"primaryCompletion":5542,"completion":3893,"start":5873,"enrollment":1063,"conditions":23835,"interventions":23836},[87],[33],[23785,23797,23798,23799,23800],{"trials":23838,"activeCount":98},[],{"trials":23840,"activeCount":98},[],{"trials":23842,"activeCount":98},[],{"trials":23844,"activeCount":98},[],{"intervention":23799,"totalTrials":208,"cells":23846},{"EARLY_PHASE1":23847,"PHASE1":23849,"PHASE2":23855,"PHASE3":23857,"PHASE4":23859,"NA":23861},{"trials":23848,"activeCount":98},[],{"trials":23850,"activeCount":98},[23851],{"nctId":23792,"briefTitle":23793,"status":104,"phases":23852,"primaryCompletion":5542,"completion":3893,"start":5873,"enrollment":1063,"conditions":23853,"interventions":23854},[87],[33],[23785,23797,23798,23799,23800],{"trials":23856,"activeCount":98},[],{"trials":23858,"activeCount":98},[],{"trials":23860,"activeCount":98},[],{"trials":23862,"activeCount":98},[],{"intervention":23800,"totalTrials":208,"cells":23864},{"EARLY_PHASE1":23865,"PHASE1":23867,"PHASE2":23873,"PHASE3":23875,"PHASE4":23877,"NA":23879},{"trials":23866,"activeCount":98},[],{"trials":23868,"activeCount":98},[23869],{"nctId":23792,"briefTitle":23793,"status":104,"phases":23870,"primaryCompletion":5542,"completion":3893,"start":5873,"enrollment":1063,"conditions":23871,"interventions":23872},[87],[33],[23785,23797,23798,23799,23800],{"trials":23874,"activeCount":98},[],{"trials":23876,"activeCount":98},[],{"trials":23878,"activeCount":98},[],{"trials":23880,"activeCount":98},[],{"intervention":21388,"totalTrials":208,"cells":23882},{"EARLY_PHASE1":23883,"PHASE1":23885,"PHASE2":23891,"PHASE3":23893,"PHASE4":23895,"NA":23897},{"trials":23884,"activeCount":98},[],{"trials":23886,"activeCount":98},[23887],{"nctId":21383,"briefTitle":21384,"status":104,"phases":23888,"primaryCompletion":7706,"completion":7706,"start":3631,"enrollment":1203,"conditions":23889,"interventions":23890},[87],[10858],[21388,16335],{"trials":23892,"activeCount":98},[],{"trials":23894,"activeCount":98},[],{"trials":23896,"activeCount":98},[],{"trials":23898,"activeCount":98},[],{"intervention":23900,"totalTrials":208,"cells":23901},"BMS-241027",{"EARLY_PHASE1":23902,"PHASE1":23904,"PHASE2":23912,"PHASE3":23914,"PHASE4":23916,"NA":23918},{"trials":23903,"activeCount":98},[],{"trials":23905,"activeCount":98},[23906],{"nctId":23907,"briefTitle":23908,"status":104,"phases":23909,"primaryCompletion":4378,"completion":4378,"start":6437,"enrollment":3562,"conditions":23910,"interventions":23911},"NCT01492374","Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease",[87],[3470],[23900,23900,23900],{"trials":23913,"activeCount":98},[],{"trials":23915,"activeCount":98},[],{"trials":23917,"activeCount":98},[],{"trials":23919,"activeCount":98},[],{"intervention":23921,"totalTrials":208,"cells":23922},"MDX1106-02",{"EARLY_PHASE1":23923,"PHASE1":23925,"PHASE2":23933,"PHASE3":23935,"PHASE4":23937,"NA":23939},{"trials":23924,"activeCount":98},[],{"trials":23926,"activeCount":98},[23927],{"nctId":23928,"briefTitle":23929,"status":104,"phases":23930,"primaryCompletion":3678,"completion":3678,"start":6480,"enrollment":890,"conditions":23931,"interventions":23932},"NCT00703469","A Study of MDX-1106 to Treat Patients With Hepatitis C Infection",[87],[30],[23921],{"trials":23934,"activeCount":98},[],{"trials":23936,"activeCount":98},[],{"trials":23938,"activeCount":98},[],{"trials":23940,"activeCount":98},[],{"intervention":23942,"totalTrials":208,"cells":23943},"MDX-1203",{"EARLY_PHASE1":23944,"PHASE1":23946,"PHASE2":23955,"PHASE3":23957,"PHASE4":23959,"NA":23961},{"trials":23945,"activeCount":98},[],{"trials":23947,"activeCount":98},[23948],{"nctId":23949,"briefTitle":23950,"status":104,"phases":23951,"primaryCompletion":3893,"completion":3893,"start":6170,"enrollment":6185,"conditions":23952,"interventions":23954},"NCT00944905","Study of MDX-1203 in Subjects With Advanced\u002FRecurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed\u002FRefractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)",[87],[1253,23953],"Non-hodgkin's Lymphoma",[23942],{"trials":23956,"activeCount":98},[],{"trials":23958,"activeCount":98},[],{"trials":23960,"activeCount":98},[],{"trials":23962,"activeCount":98},[],{"intervention":23964,"totalTrials":208,"cells":23965},"[14C]-BMS-986196",{"EARLY_PHASE1":23966,"PHASE1":23968,"PHASE2":23977,"PHASE3":23979,"PHASE4":23981,"NA":23983},{"trials":23967,"activeCount":98},[],{"trials":23969,"activeCount":98},[23970],{"nctId":23971,"briefTitle":23972,"status":104,"phases":23973,"primaryCompletion":23974,"completion":23974,"start":10535,"enrollment":839,"conditions":23975,"interventions":23976},"NCT05981963","A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants",[87],"2023-10-22",[715],[23964],{"trials":23978,"activeCount":98},[],{"trials":23980,"activeCount":98},[],{"trials":23982,"activeCount":98},[],{"trials":23984,"activeCount":98},[],{"intervention":6827,"totalTrials":208,"cells":23986},{"EARLY_PHASE1":23987,"PHASE1":23989,"PHASE2":23995,"PHASE3":23997,"PHASE4":23999,"NA":24001},{"trials":23988,"activeCount":98},[],{"trials":23990,"activeCount":98},[23991],{"nctId":6821,"briefTitle":6822,"status":104,"phases":23992,"primaryCompletion":5610,"completion":5610,"start":5464,"enrollment":34,"conditions":23993,"interventions":23994},[87],[27],[6814,6826,6827],{"trials":23996,"activeCount":98},[],{"trials":23998,"activeCount":98},[],{"trials":24000,"activeCount":98},[],{"trials":24002,"activeCount":98},[],{"intervention":24004,"totalTrials":208,"cells":24005},"Prednisolone",{"EARLY_PHASE1":24006,"PHASE1":24008,"PHASE2":24019,"PHASE3":24021,"PHASE4":24023,"NA":24025},{"trials":24007,"activeCount":98},[],{"trials":24009,"activeCount":98},[24010],{"nctId":24011,"briefTitle":24012,"status":104,"phases":24013,"primaryCompletion":24014,"completion":24014,"start":24015,"enrollment":3862,"conditions":24016,"interventions":24017},"NCT03198013","A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males",[87],"2009-05-18","2008-11-11",[22840],[24004,24018],"BMS-791826",{"trials":24020,"activeCount":98},[],{"trials":24022,"activeCount":98},[],{"trials":24024,"activeCount":98},[],{"trials":24026,"activeCount":98},[],{"intervention":24018,"totalTrials":208,"cells":24028},{"EARLY_PHASE1":24029,"PHASE1":24031,"PHASE2":24037,"PHASE3":24039,"PHASE4":24041,"NA":24043},{"trials":24030,"activeCount":98},[],{"trials":24032,"activeCount":98},[24033],{"nctId":24011,"briefTitle":24012,"status":104,"phases":24034,"primaryCompletion":24014,"completion":24014,"start":24015,"enrollment":3862,"conditions":24035,"interventions":24036},[87],[22840],[24004,24018],{"trials":24038,"activeCount":98},[],{"trials":24040,"activeCount":98},[],{"trials":24042,"activeCount":98},[],{"trials":24044,"activeCount":98},[],{"intervention":5634,"totalTrials":208,"cells":24046},{"EARLY_PHASE1":24047,"PHASE1":24049,"PHASE2":24055,"PHASE3":24057,"PHASE4":24059,"NA":24061},{"trials":24048,"activeCount":98},[],{"trials":24050,"activeCount":98},[24051],{"nctId":5625,"briefTitle":5626,"status":104,"phases":24052,"primaryCompletion":5628,"completion":5629,"start":5630,"enrollment":3978,"conditions":24053,"interventions":24054},[87],[5632],[5571,5634],{"trials":24056,"activeCount":98},[],{"trials":24058,"activeCount":98},[],{"trials":24060,"activeCount":98},[],{"trials":24062,"activeCount":98},[],{"intervention":24064,"totalTrials":208,"cells":24065},"Dasatinib in combination with imatinib",{"EARLY_PHASE1":24066,"PHASE1":24068,"PHASE2":24077,"PHASE3":24079,"PHASE4":24081,"NA":24083},{"trials":24067,"activeCount":98},[],{"trials":24069,"activeCount":98},[24070],{"nctId":24071,"briefTitle":24072,"status":467,"phases":24073,"primaryCompletion":7750,"start":4379,"enrollment":98,"conditions":24074,"interventions":24076},"NCT00324077","Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase",[87],[24075],"Myeloid Leukemia, Chronic, Chronic-Phase",[24064],{"trials":24078,"activeCount":98},[],{"trials":24080,"activeCount":98},[],{"trials":24082,"activeCount":98},[],{"trials":24084,"activeCount":98},[],{"intervention":24086,"totalTrials":208,"cells":24087},"BMS-907351",{"EARLY_PHASE1":24088,"PHASE1":24090,"PHASE2":24098,"PHASE3":24100,"PHASE4":24102,"NA":24104},{"trials":24089,"activeCount":98},[],{"trials":24091,"activeCount":98},[24092],{"nctId":24093,"briefTitle":24094,"status":104,"phases":24095,"primaryCompletion":4348,"completion":4348,"start":10431,"enrollment":574,"conditions":24096,"interventions":24097},"NCT01018745","Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan",[87],[7156],[24086],{"trials":24099,"activeCount":98},[],{"trials":24101,"activeCount":98},[],{"trials":24103,"activeCount":98},[],{"trials":24105,"activeCount":98},[],{"intervention":24107,"totalTrials":208,"cells":24108},"BMS-394136",{"EARLY_PHASE1":24109,"PHASE1":24111,"PHASE2":24120,"PHASE3":24122,"PHASE4":24124,"NA":24126},{"trials":24110,"activeCount":98},[],{"trials":24112,"activeCount":98},[24113],{"nctId":24114,"briefTitle":24115,"status":104,"phases":24116,"start":12930,"enrollment":347,"conditions":24117,"interventions":24119},"NCT00162448","A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators",[87],[24118],"Heart Diseases",[24107],{"trials":24121,"activeCount":98},[],{"trials":24123,"activeCount":98},[],{"trials":24125,"activeCount":98},[],{"trials":24127,"activeCount":98},[],{"intervention":11757,"totalTrials":208,"cells":24129},{"EARLY_PHASE1":24130,"PHASE1":24132,"PHASE2":24138,"PHASE3":24140,"PHASE4":24142,"NA":24144},{"trials":24131,"activeCount":98},[],{"trials":24133,"activeCount":98},[24134],{"nctId":11752,"briefTitle":11753,"status":104,"phases":24135,"primaryCompletion":4179,"completion":9361,"start":11405,"enrollment":25,"conditions":24136,"interventions":24137},[87],[1865,5884],[5877,5877,5877,5877,5877,11757],{"trials":24139,"activeCount":98},[],{"trials":24141,"activeCount":98},[],{"trials":24143,"activeCount":98},[],{"trials":24145,"activeCount":98},[],{"intervention":24147,"totalTrials":208,"cells":24148},"Treatment A: Mavacamten intact oral",{"EARLY_PHASE1":24149,"PHASE1":24151,"PHASE2":24163,"PHASE3":24165,"PHASE4":24167,"NA":24169},{"trials":24150,"activeCount":98},[],{"trials":24152,"activeCount":98},[24153],{"nctId":24154,"briefTitle":24155,"status":104,"phases":24156,"primaryCompletion":24157,"completion":24157,"start":24158,"enrollment":4932,"conditions":24159,"interventions":24160},"NCT06211179","A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants",[87],"2024-06-13","2024-01-10",[27],[24147,24161,24162],"Treatment B: Mavacamten open capsule in suspension","Treatment C: Mavacamten open capsule in suspension administered via nasogastric tube",{"trials":24164,"activeCount":98},[],{"trials":24166,"activeCount":98},[],{"trials":24168,"activeCount":98},[],{"trials":24170,"activeCount":98},[],{"intervention":24161,"totalTrials":208,"cells":24172},{"EARLY_PHASE1":24173,"PHASE1":24175,"PHASE2":24181,"PHASE3":24183,"PHASE4":24185,"NA":24187},{"trials":24174,"activeCount":98},[],{"trials":24176,"activeCount":98},[24177],{"nctId":24154,"briefTitle":24155,"status":104,"phases":24178,"primaryCompletion":24157,"completion":24157,"start":24158,"enrollment":4932,"conditions":24179,"interventions":24180},[87],[27],[24147,24161,24162],{"trials":24182,"activeCount":98},[],{"trials":24184,"activeCount":98},[],{"trials":24186,"activeCount":98},[],{"trials":24188,"activeCount":98},[],{"intervention":24162,"totalTrials":208,"cells":24190},{"EARLY_PHASE1":24191,"PHASE1":24193,"PHASE2":24199,"PHASE3":24201,"PHASE4":24203,"NA":24205},{"trials":24192,"activeCount":98},[],{"trials":24194,"activeCount":98},[24195],{"nctId":24154,"briefTitle":24155,"status":104,"phases":24196,"primaryCompletion":24157,"completion":24157,"start":24158,"enrollment":4932,"conditions":24197,"interventions":24198},[87],[27],[24147,24161,24162],{"trials":24200,"activeCount":98},[],{"trials":24202,"activeCount":98},[],{"trials":24204,"activeCount":98},[],{"trials":24206,"activeCount":98},[],{"intervention":24208,"totalTrials":208,"cells":24209},"BMS-852927",{"EARLY_PHASE1":24210,"PHASE1":24212,"PHASE2":24220,"PHASE3":24222,"PHASE4":24224,"NA":24226},{"trials":24211,"activeCount":98},[],{"trials":24213,"activeCount":98},[24214],{"nctId":24215,"briefTitle":24216,"status":963,"phases":24217,"primaryCompletion":3630,"completion":3630,"start":3893,"enrollment":12156,"conditions":24218,"interventions":24219},"NCT01651273","A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia",[87],[10942],[24208,24208,24208],{"trials":24221,"activeCount":98},[],{"trials":24223,"activeCount":98},[],{"trials":24225,"activeCount":98},[],{"trials":24227,"activeCount":98},[],{"intervention":15344,"totalTrials":208,"cells":24229},{"EARLY_PHASE1":24230,"PHASE1":24232,"PHASE2":24238,"PHASE3":24240,"PHASE4":24242,"NA":24244},{"trials":24231,"activeCount":98},[],{"trials":24233,"activeCount":98},[24234],{"nctId":15339,"briefTitle":15340,"status":104,"phases":24235,"primaryCompletion":3872,"completion":3872,"start":10431,"enrollment":693,"conditions":24236,"interventions":24237},[87],[552],[15344,9411],{"trials":24239,"activeCount":98},[],{"trials":24241,"activeCount":98},[],{"trials":24243,"activeCount":98},[],{"trials":24245,"activeCount":98},[],{"intervention":24247,"totalTrials":208,"cells":24248},"BMS-779788",{"EARLY_PHASE1":24249,"PHASE1":24251,"PHASE2":24259,"PHASE3":24261,"PHASE4":24263,"NA":24265},{"trials":24250,"activeCount":98},[],{"trials":24252,"activeCount":98},[24253],{"nctId":24254,"briefTitle":24255,"status":104,"phases":24256,"primaryCompletion":6170,"completion":6170,"start":3587,"enrollment":94,"conditions":24257,"interventions":24258},"NCT00836602","Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects",[87],[23022],[24247,24247,24247],{"trials":24260,"activeCount":98},[],{"trials":24262,"activeCount":98},[],{"trials":24264,"activeCount":98},[],{"trials":24266,"activeCount":98},[],{"intervention":24268,"totalTrials":208,"cells":24269},"efavirenz containing antiretroviral regimen",{"EARLY_PHASE1":24270,"PHASE1":24272,"PHASE2":24280,"PHASE3":24282,"PHASE4":24284,"NA":24286},{"trials":24271,"activeCount":98},[],{"trials":24273,"activeCount":98},[24274],{"nctId":24275,"briefTitle":24276,"status":104,"phases":24277,"primaryCompletion":5023,"completion":5023,"start":17418,"enrollment":757,"conditions":24278,"interventions":24279},"NCT00162097","Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment",[87],[24,5603],[24268,24268,24268,24268],{"trials":24281,"activeCount":98},[],{"trials":24283,"activeCount":98},[],{"trials":24285,"activeCount":98},[],{"trials":24287,"activeCount":98},[],{"intervention":1235,"totalTrials":208,"cells":24289},{"EARLY_PHASE1":24290,"PHASE1":24292,"PHASE2":24298,"PHASE3":24300,"PHASE4":24302,"NA":24304},{"trials":24291,"activeCount":98},[],{"trials":24293,"activeCount":98},[24294],{"nctId":1227,"briefTitle":1228,"status":963,"phases":24295,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":1232,"conditions":24296,"interventions":24297},[87],[1154],[1235,43,608],{"trials":24299,"activeCount":98},[],{"trials":24301,"activeCount":98},[],{"trials":24303,"activeCount":98},[],{"trials":24305,"activeCount":98},[],{"intervention":24307,"totalTrials":208,"cells":24308},"Mavacamten Capsule 1",{"EARLY_PHASE1":24309,"PHASE1":24311,"PHASE2":24323,"PHASE3":24325,"PHASE4":24327,"NA":24329},{"trials":24310,"activeCount":98},[],{"trials":24312,"activeCount":98},[24313],{"nctId":24314,"briefTitle":24315,"status":104,"phases":24316,"primaryCompletion":22879,"completion":22879,"start":24317,"enrollment":24318,"conditions":24319,"interventions":24320},"NCT05658146","A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants",[87],"2023-01-06",95,[18],[24307,24321,24322],"Mavacamten Capsule 2","Mavacamten Capsule 3",{"trials":24324,"activeCount":98},[],{"trials":24326,"activeCount":98},[],{"trials":24328,"activeCount":98},[],{"trials":24330,"activeCount":98},[],{"intervention":24321,"totalTrials":208,"cells":24332},{"EARLY_PHASE1":24333,"PHASE1":24335,"PHASE2":24341,"PHASE3":24343,"PHASE4":24345,"NA":24347},{"trials":24334,"activeCount":98},[],{"trials":24336,"activeCount":98},[24337],{"nctId":24314,"briefTitle":24315,"status":104,"phases":24338,"primaryCompletion":22879,"completion":22879,"start":24317,"enrollment":24318,"conditions":24339,"interventions":24340},[87],[18],[24307,24321,24322],{"trials":24342,"activeCount":98},[],{"trials":24344,"activeCount":98},[],{"trials":24346,"activeCount":98},[],{"trials":24348,"activeCount":98},[],{"intervention":24322,"totalTrials":208,"cells":24350},{"EARLY_PHASE1":24351,"PHASE1":24353,"PHASE2":24359,"PHASE3":24361,"PHASE4":24363,"NA":24365},{"trials":24352,"activeCount":98},[],{"trials":24354,"activeCount":98},[24355],{"nctId":24314,"briefTitle":24315,"status":104,"phases":24356,"primaryCompletion":22879,"completion":22879,"start":24317,"enrollment":24318,"conditions":24357,"interventions":24358},[87],[18],[24307,24321,24322],{"trials":24360,"activeCount":98},[],{"trials":24362,"activeCount":98},[],{"trials":24364,"activeCount":98},[],{"trials":24366,"activeCount":98},[],{"intervention":24368,"totalTrials":208,"cells":24369},"Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142",{"EARLY_PHASE1":24370,"PHASE1":24372,"PHASE2":24381,"PHASE3":24383,"PHASE4":24385,"NA":24387},{"trials":24371,"activeCount":98},[],{"trials":24373,"activeCount":98},[24374],{"nctId":24375,"briefTitle":24376,"status":104,"phases":24377,"primaryCompletion":4347,"completion":4347,"start":4980,"enrollment":1203,"conditions":24378,"interventions":24379},"NCT02456844","Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients",[87],[15],[24368,24380],"Methotrexate, Leucovorin and BMS-986142",{"trials":24382,"activeCount":98},[],{"trials":24384,"activeCount":98},[],{"trials":24386,"activeCount":98},[],{"trials":24388,"activeCount":98},[],{"intervention":24380,"totalTrials":208,"cells":24390},{"EARLY_PHASE1":24391,"PHASE1":24393,"PHASE2":24399,"PHASE3":24401,"PHASE4":24403,"NA":24405},{"trials":24392,"activeCount":98},[],{"trials":24394,"activeCount":98},[24395],{"nctId":24375,"briefTitle":24376,"status":104,"phases":24396,"primaryCompletion":4347,"completion":4347,"start":4980,"enrollment":1203,"conditions":24397,"interventions":24398},[87],[15],[24368,24380],{"trials":24400,"activeCount":98},[],{"trials":24402,"activeCount":98},[],{"trials":24404,"activeCount":98},[],{"trials":24406,"activeCount":98},[],{"intervention":24408,"totalTrials":208,"cells":24409},"vinflunine + ketaconazole",{"EARLY_PHASE1":24410,"PHASE1":24412,"PHASE2":24420,"PHASE3":24422,"PHASE4":24424,"NA":24426},{"trials":24411,"activeCount":98},[],{"trials":24413,"activeCount":98},[24414],{"nctId":24415,"briefTitle":24416,"status":104,"phases":24417,"completion":11728,"start":5043,"enrollment":1063,"conditions":24418,"interventions":24419},"NCT00388557","Effect of Ketoconazole on the Pharmacokinetics of Vinflunine",[87],[606],[24408],{"trials":24421,"activeCount":98},[],{"trials":24423,"activeCount":98},[],{"trials":24425,"activeCount":98},[],{"trials":24427,"activeCount":98},[],{"intervention":16183,"totalTrials":208,"cells":24429},{"EARLY_PHASE1":24430,"PHASE1":24432,"PHASE2":24438,"PHASE3":24440,"PHASE4":24442,"NA":24444},{"trials":24431,"activeCount":98},[],{"trials":24433,"activeCount":98},[24434],{"nctId":16176,"briefTitle":16177,"status":104,"phases":24435,"primaryCompletion":846,"completion":846,"start":16179,"enrollment":713,"conditions":24436,"interventions":24437},[87],[16181],[15528,16183],{"trials":24439,"activeCount":98},[],{"trials":24441,"activeCount":98},[],{"trials":24443,"activeCount":98},[],{"trials":24445,"activeCount":98},[],{"intervention":13064,"totalTrials":208,"cells":24447},{"EARLY_PHASE1":24448,"PHASE1":24450,"PHASE2":24456,"PHASE3":24458,"PHASE4":24460,"NA":24462},{"trials":24449,"activeCount":98},[],{"trials":24451,"activeCount":98},[24452],{"nctId":13058,"briefTitle":13059,"status":104,"phases":24453,"primaryCompletion":13061,"completion":13061,"start":13053,"enrollment":363,"conditions":24454,"interventions":24455},[87],[24],[13064,10477,13065,13066,13067],{"trials":24457,"activeCount":98},[],{"trials":24459,"activeCount":98},[],{"trials":24461,"activeCount":98},[],{"trials":24463,"activeCount":98},[],{"intervention":13065,"totalTrials":208,"cells":24465},{"EARLY_PHASE1":24466,"PHASE1":24468,"PHASE2":24474,"PHASE3":24476,"PHASE4":24478,"NA":24480},{"trials":24467,"activeCount":98},[],{"trials":24469,"activeCount":98},[24470],{"nctId":13058,"briefTitle":13059,"status":104,"phases":24471,"primaryCompletion":13061,"completion":13061,"start":13053,"enrollment":363,"conditions":24472,"interventions":24473},[87],[24],[13064,10477,13065,13066,13067],{"trials":24475,"activeCount":98},[],{"trials":24477,"activeCount":98},[],{"trials":24479,"activeCount":98},[],{"trials":24481,"activeCount":98},[],{"intervention":13067,"totalTrials":208,"cells":24483},{"EARLY_PHASE1":24484,"PHASE1":24486,"PHASE2":24492,"PHASE3":24494,"PHASE4":24496,"NA":24498},{"trials":24485,"activeCount":98},[],{"trials":24487,"activeCount":98},[24488],{"nctId":13058,"briefTitle":13059,"status":104,"phases":24489,"primaryCompletion":13061,"completion":13061,"start":13053,"enrollment":363,"conditions":24490,"interventions":24491},[87],[24],[13064,10477,13065,13066,13067],{"trials":24493,"activeCount":98},[],{"trials":24495,"activeCount":98},[],{"trials":24497,"activeCount":98},[],{"trials":24499,"activeCount":98},[],{"intervention":24501,"totalTrials":208,"cells":24502},"Ortho Tri-Cyclen",{"EARLY_PHASE1":24503,"PHASE1":24505,"PHASE2":24514,"PHASE3":24516,"PHASE4":24518,"NA":24520},{"trials":24504,"activeCount":98},[],{"trials":24506,"activeCount":98},[24507],{"nctId":24508,"briefTitle":24509,"status":104,"phases":24510,"primaryCompletion":13061,"completion":13061,"start":10856,"enrollment":3978,"conditions":24511,"interventions":24512},"NCT00357604","Atazanavir and Ritonavir (ATV\u002FRTV) and an Oral Contraceptive in Healthy Females",[87],[24],[24501,24513],"Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir\u002FRitonavir for 14 days then Ortho Tri-Cyclen for 7 days",{"trials":24515,"activeCount":98},[],{"trials":24517,"activeCount":98},[],{"trials":24519,"activeCount":98},[],{"trials":24521,"activeCount":98},[],{"intervention":24513,"totalTrials":208,"cells":24523},{"EARLY_PHASE1":24524,"PHASE1":24526,"PHASE2":24532,"PHASE3":24534,"PHASE4":24536,"NA":24538},{"trials":24525,"activeCount":98},[],{"trials":24527,"activeCount":98},[24528],{"nctId":24508,"briefTitle":24509,"status":104,"phases":24529,"primaryCompletion":13061,"completion":13061,"start":10856,"enrollment":3978,"conditions":24530,"interventions":24531},[87],[24],[24501,24513],{"trials":24533,"activeCount":98},[],{"trials":24535,"activeCount":98},[],{"trials":24537,"activeCount":98},[],{"trials":24539,"activeCount":98},[],{"intervention":16730,"totalTrials":208,"cells":24541},{"EARLY_PHASE1":24542,"PHASE1":24544,"PHASE2":24550,"PHASE3":24552,"PHASE4":24554,"NA":24556},{"trials":24543,"activeCount":98},[],{"trials":24545,"activeCount":98},[24546],{"nctId":16723,"briefTitle":16724,"status":963,"phases":24547,"primaryCompletion":16726,"completion":16726,"start":16727,"enrollment":1750,"conditions":24548,"interventions":24549},[87],[10858],[16710,16730],{"trials":24551,"activeCount":98},[],{"trials":24553,"activeCount":98},[],{"trials":24555,"activeCount":98},[],{"trials":24557,"activeCount":98},[],{"intervention":24559,"totalTrials":208,"cells":24560},"Atenolol",{"EARLY_PHASE1":24561,"PHASE1":24563,"PHASE2":24571,"PHASE3":24573,"PHASE4":24575,"NA":24577},{"trials":24562,"activeCount":98},[],{"trials":24564,"activeCount":98},[24565],{"nctId":24566,"briefTitle":24567,"status":104,"phases":24568,"primaryCompletion":4664,"completion":4664,"start":4664,"enrollment":1385,"conditions":24569,"interventions":24570},"NCT02262533","Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects",[87],[20870],[11001,24559],{"trials":24572,"activeCount":98},[],{"trials":24574,"activeCount":98},[],{"trials":24576,"activeCount":98},[],{"trials":24578,"activeCount":98},[],{"intervention":1246,"totalTrials":208,"cells":24580},{"EARLY_PHASE1":24581,"PHASE1":24583,"PHASE2":24589,"PHASE3":24591,"PHASE4":24593,"NA":24595},{"trials":24582,"activeCount":98},[],{"trials":24584,"activeCount":98},[24585],{"nctId":1237,"briefTitle":1238,"status":104,"phases":24586,"primaryCompletion":1240,"completion":1241,"start":1242,"enrollment":319,"conditions":24587,"interventions":24588},[87],[1154],[43,52,1245,608,1246],{"trials":24590,"activeCount":98},[],{"trials":24592,"activeCount":98},[],{"trials":24594,"activeCount":98},[],{"trials":24596,"activeCount":98},[],{"intervention":24598,"totalTrials":208,"cells":24599},"Smallpox Vaccine",{"EARLY_PHASE1":24600,"PHASE1":24602,"PHASE2":24612,"PHASE3":24614,"PHASE4":24616,"NA":24618},{"trials":24601,"activeCount":98},[],{"trials":24603,"activeCount":98},[24604],{"nctId":24605,"briefTitle":24606,"status":104,"phases":24607,"conditions":24608,"interventions":24609},"NCT00002261","A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers",[87],[24],[24598,24610,24611],"HIVAC-1e","gp160 Vaccine",{"trials":24613,"activeCount":98},[],{"trials":24615,"activeCount":98},[],{"trials":24617,"activeCount":98},[],{"trials":24619,"activeCount":98},[],{"intervention":24610,"totalTrials":208,"cells":24621},{"EARLY_PHASE1":24622,"PHASE1":24624,"PHASE2":24630,"PHASE3":24632,"PHASE4":24634,"NA":24636},{"trials":24623,"activeCount":98},[],{"trials":24625,"activeCount":98},[24626],{"nctId":24605,"briefTitle":24606,"status":104,"phases":24627,"conditions":24628,"interventions":24629},[87],[24],[24598,24610,24611],{"trials":24631,"activeCount":98},[],{"trials":24633,"activeCount":98},[],{"trials":24635,"activeCount":98},[],{"trials":24637,"activeCount":98},[],{"intervention":24611,"totalTrials":208,"cells":24639},{"EARLY_PHASE1":24640,"PHASE1":24642,"PHASE2":24648,"PHASE3":24650,"PHASE4":24652,"NA":24654},{"trials":24641,"activeCount":98},[],{"trials":24643,"activeCount":98},[24644],{"nctId":24605,"briefTitle":24606,"status":104,"phases":24645,"conditions":24646,"interventions":24647},[87],[24],[24598,24610,24611],{"trials":24649,"activeCount":98},[],{"trials":24651,"activeCount":98},[],{"trials":24653,"activeCount":98},[],{"trials":24655,"activeCount":98},[],{"intervention":24657,"totalTrials":208,"cells":24658},"BMS-986104",{"EARLY_PHASE1":24659,"PHASE1":24661,"PHASE2":24669,"PHASE3":24671,"PHASE4":24673,"NA":24675},{"trials":24660,"activeCount":98},[],{"trials":24662,"activeCount":98},[24663],{"nctId":24664,"briefTitle":24665,"status":104,"phases":24666,"primaryCompletion":4347,"completion":4347,"start":10525,"enrollment":11873,"conditions":24667,"interventions":24668},"NCT02211469","A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects",[87],[15],[24657],{"trials":24670,"activeCount":98},[],{"trials":24672,"activeCount":98},[],{"trials":24674,"activeCount":98},[],{"trials":24676,"activeCount":98},[],{"intervention":17820,"totalTrials":208,"cells":24678},{"EARLY_PHASE1":24679,"PHASE1":24681,"PHASE2":24687,"PHASE3":24689,"PHASE4":24691,"NA":24693},{"trials":24680,"activeCount":98},[],{"trials":24682,"activeCount":98},[24683],{"nctId":17814,"briefTitle":17815,"status":104,"phases":24684,"primaryCompletion":1432,"completion":1432,"start":17817,"enrollment":6185,"conditions":24685,"interventions":24686},[87],[18],[17820,16110],{"trials":24688,"activeCount":98},[],{"trials":24690,"activeCount":98},[],{"trials":24692,"activeCount":98},[],{"trials":24694,"activeCount":98},[],{"intervention":8488,"totalTrials":208,"cells":24696},{"EARLY_PHASE1":24697,"PHASE1":24699,"PHASE2":24705,"PHASE3":24707,"PHASE4":24709,"NA":24711},{"trials":24698,"activeCount":98},[],{"trials":24700,"activeCount":98},[24701],{"nctId":8481,"briefTitle":8482,"status":104,"phases":24702,"primaryCompletion":8484,"completion":8484,"start":8485,"enrollment":7813,"conditions":24703,"interventions":24704},[87],[27],[8488,8489,696],{"trials":24706,"activeCount":98},[],{"trials":24708,"activeCount":98},[],{"trials":24710,"activeCount":98},[],{"trials":24712,"activeCount":98},[],{"intervention":8489,"totalTrials":208,"cells":24714},{"EARLY_PHASE1":24715,"PHASE1":24717,"PHASE2":24723,"PHASE3":24725,"PHASE4":24727,"NA":24729},{"trials":24716,"activeCount":98},[],{"trials":24718,"activeCount":98},[24719],{"nctId":8481,"briefTitle":8482,"status":104,"phases":24720,"primaryCompletion":8484,"completion":8484,"start":8485,"enrollment":7813,"conditions":24721,"interventions":24722},[87],[27],[8488,8489,696],{"trials":24724,"activeCount":98},[],{"trials":24726,"activeCount":98},[],{"trials":24728,"activeCount":98},[],{"trials":24730,"activeCount":98},[],{"intervention":24732,"totalTrials":208,"cells":24733},"BMS-986115",{"EARLY_PHASE1":24734,"PHASE1":24736,"PHASE2":24744,"PHASE3":24746,"PHASE4":24748,"NA":24750},{"trials":24735,"activeCount":98},[],{"trials":24737,"activeCount":98},[24738],{"nctId":24739,"briefTitle":24740,"status":963,"phases":24741,"primaryCompletion":6184,"completion":6184,"start":11742,"enrollment":347,"conditions":24742,"interventions":24743},"NCT01986218","Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors",[87],[1636],[24732],{"trials":24745,"activeCount":98},[],{"trials":24747,"activeCount":98},[],{"trials":24749,"activeCount":98},[],{"trials":24751,"activeCount":98},[],{"intervention":24753,"totalTrials":208,"cells":24754},"Ortho Tri-Cyclen LO",{"EARLY_PHASE1":24755,"PHASE1":24757,"PHASE2":24767,"PHASE3":24769,"PHASE4":24771,"NA":24773},{"trials":24756,"activeCount":98},[],{"trials":24758,"activeCount":98},[24759],{"nctId":24760,"briefTitle":24761,"status":104,"phases":24762,"primaryCompletion":10821,"completion":10821,"start":7846,"enrollment":11958,"conditions":24763,"interventions":24764},"NCT00399685","Drug Interaction - Oral Contraceptive",[87],[24],[24753,24765,24766,24765],"Ortho Cyclen","Ortho Cyclen + Efavirenz",{"trials":24768,"activeCount":98},[],{"trials":24770,"activeCount":98},[],{"trials":24772,"activeCount":98},[],{"trials":24774,"activeCount":98},[],{"intervention":24765,"totalTrials":208,"cells":24776},{"EARLY_PHASE1":24777,"PHASE1":24779,"PHASE2":24785,"PHASE3":24787,"PHASE4":24789,"NA":24791},{"trials":24778,"activeCount":98},[],{"trials":24780,"activeCount":98},[24781],{"nctId":24760,"briefTitle":24761,"status":104,"phases":24782,"primaryCompletion":10821,"completion":10821,"start":7846,"enrollment":11958,"conditions":24783,"interventions":24784},[87],[24],[24753,24765,24766,24765],{"trials":24786,"activeCount":98},[],{"trials":24788,"activeCount":98},[],{"trials":24790,"activeCount":98},[],{"trials":24792,"activeCount":98},[],{"intervention":24766,"totalTrials":208,"cells":24794},{"EARLY_PHASE1":24795,"PHASE1":24797,"PHASE2":24803,"PHASE3":24805,"PHASE4":24807,"NA":24809},{"trials":24796,"activeCount":98},[],{"trials":24798,"activeCount":98},[24799],{"nctId":24760,"briefTitle":24761,"status":104,"phases":24800,"primaryCompletion":10821,"completion":10821,"start":7846,"enrollment":11958,"conditions":24801,"interventions":24802},[87],[24],[24753,24765,24766,24765],{"trials":24804,"activeCount":98},[],{"trials":24806,"activeCount":98},[],{"trials":24808,"activeCount":98},[],{"trials":24810,"activeCount":98},[],{"intervention":10790,"totalTrials":208,"cells":24812},{"EARLY_PHASE1":24813,"PHASE1":24815,"PHASE2":24821,"PHASE3":24823,"PHASE4":24825,"NA":24827},{"trials":24814,"activeCount":98},[],{"trials":24816,"activeCount":98},[24817],{"nctId":10785,"briefTitle":10786,"status":104,"phases":24818,"primaryCompletion":4379,"completion":4379,"start":5117,"enrollment":7813,"conditions":24819,"interventions":24820},[87],[24],[8547,10646,10790,10790,8547,10646,10790,10790],{"trials":24822,"activeCount":98},[],{"trials":24824,"activeCount":98},[],{"trials":24826,"activeCount":98},[],{"trials":24828,"activeCount":98},[],{"intervention":24830,"totalTrials":208,"cells":24831},"AR Antagonist",{"EARLY_PHASE1":24832,"PHASE1":24834,"PHASE2":24842,"PHASE3":24844,"PHASE4":24846,"NA":24848},{"trials":24833,"activeCount":98},[],{"trials":24835,"activeCount":98},[24836],{"nctId":24837,"briefTitle":24838,"status":104,"phases":24839,"primaryCompletion":4981,"completion":4981,"start":4023,"enrollment":890,"conditions":24840,"interventions":24841},"NCT00326586","A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer",[87],[1504],[24830],{"trials":24843,"activeCount":98},[],{"trials":24845,"activeCount":98},[],{"trials":24847,"activeCount":98},[],{"trials":24849,"activeCount":98},[],{"intervention":15357,"totalTrials":208,"cells":24851},{"EARLY_PHASE1":24852,"PHASE1":24854,"PHASE2":24860,"PHASE3":24862,"PHASE4":24864,"NA":24866},{"trials":24853,"activeCount":98},[],{"trials":24855,"activeCount":98},[24856],{"nctId":15352,"briefTitle":15353,"status":104,"phases":24857,"primaryCompletion":3872,"completion":3872,"start":10431,"enrollment":693,"conditions":24858,"interventions":24859},[87],[552],[15357,15357,9411],{"trials":24861,"activeCount":98},[],{"trials":24863,"activeCount":98},[],{"trials":24865,"activeCount":98},[],{"trials":24867,"activeCount":98},[],{"intervention":24869,"totalTrials":208,"cells":24870},"BMS-933043",{"EARLY_PHASE1":24871,"PHASE1":24873,"PHASE2":24883,"PHASE3":24885,"PHASE4":24887,"NA":24889},{"trials":24872,"activeCount":98},[],{"trials":24874,"activeCount":98},[24875],{"nctId":24876,"briefTitle":24877,"status":104,"phases":24878,"primaryCompletion":3959,"completion":3959,"start":3902,"enrollment":281,"conditions":24879,"interventions":24881},"NCT01605994","Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects",[87],[24880],"Healthy Adult Normals",[24869,24882],"Antacid Buffer Predose Solution",{"trials":24884,"activeCount":98},[],{"trials":24886,"activeCount":98},[],{"trials":24888,"activeCount":98},[],{"trials":24890,"activeCount":98},[],{"intervention":24882,"totalTrials":208,"cells":24892},{"EARLY_PHASE1":24893,"PHASE1":24895,"PHASE2":24901,"PHASE3":24903,"PHASE4":24905,"NA":24907},{"trials":24894,"activeCount":98},[],{"trials":24896,"activeCount":98},[24897],{"nctId":24876,"briefTitle":24877,"status":104,"phases":24898,"primaryCompletion":3959,"completion":3959,"start":3902,"enrollment":281,"conditions":24899,"interventions":24900},[87],[24880],[24869,24882],{"trials":24902,"activeCount":98},[],{"trials":24904,"activeCount":98},[],{"trials":24906,"activeCount":98},[],{"trials":24908,"activeCount":98},[],{"intervention":1255,"totalTrials":208,"cells":24910},{"EARLY_PHASE1":24911,"PHASE1":24913,"PHASE2":24919,"PHASE3":24921,"PHASE4":24923,"NA":24925},{"trials":24912,"activeCount":98},[],{"trials":24914,"activeCount":98},[24915],{"nctId":1248,"briefTitle":1249,"status":104,"phases":24916,"primaryCompletion":1129,"completion":1129,"start":1251,"enrollment":148,"conditions":24917,"interventions":24918},[87],[1253],[43,1255,609],{"trials":24920,"activeCount":98},[],{"trials":24922,"activeCount":98},[],{"trials":24924,"activeCount":98},[],{"trials":24926,"activeCount":98},[],{"intervention":24928,"totalTrials":208,"cells":24929},"[14C] BMS-986020",{"EARLY_PHASE1":24930,"PHASE1":24932,"PHASE2":24940,"PHASE3":24942,"PHASE4":24944,"NA":24946},{"trials":24931,"activeCount":98},[],{"trials":24933,"activeCount":98},[24934],{"nctId":24935,"briefTitle":24936,"status":104,"phases":24937,"primaryCompletion":4289,"completion":4289,"start":12170,"enrollment":830,"conditions":24938,"interventions":24939},"NCT02068053","Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020",[87],[16280],[24928],{"trials":24941,"activeCount":98},[],{"trials":24943,"activeCount":98},[],{"trials":24945,"activeCount":98},[],{"trials":24947,"activeCount":98},[],{"intervention":863,"totalTrials":208,"cells":24949},{"EARLY_PHASE1":24950,"PHASE1":24952,"PHASE2":24958,"PHASE3":24960,"PHASE4":24962,"NA":24964},{"trials":24951,"activeCount":98},[],{"trials":24953,"activeCount":98},[24954],{"nctId":854,"briefTitle":855,"status":104,"phases":24955,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":24956,"interventions":24957},[87],[18],[679,863],{"trials":24959,"activeCount":98},[],{"trials":24961,"activeCount":98},[],{"trials":24963,"activeCount":98},[],{"trials":24965,"activeCount":98},[],{"intervention":24967,"totalTrials":208,"cells":24968},"[14C] BMS-986278",{"EARLY_PHASE1":24969,"PHASE1":24971,"PHASE2":24982,"PHASE3":24984,"PHASE4":24986,"NA":24988},{"trials":24970,"activeCount":98},[],{"trials":24972,"activeCount":98},[24973],{"nctId":24974,"briefTitle":24975,"status":104,"phases":24976,"primaryCompletion":24977,"completion":24977,"start":24978,"enrollment":747,"conditions":24979,"interventions":24980},"NCT04567667","Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants",[87],"2021-04-11","2020-10-15",[27],[24967,24981],"Kinevac®",{"trials":24983,"activeCount":98},[],{"trials":24985,"activeCount":98},[],{"trials":24987,"activeCount":98},[],{"trials":24989,"activeCount":98},[],{"intervention":24981,"totalTrials":208,"cells":24991},{"EARLY_PHASE1":24992,"PHASE1":24994,"PHASE2":25000,"PHASE3":25002,"PHASE4":25004,"NA":25006},{"trials":24993,"activeCount":98},[],{"trials":24995,"activeCount":98},[24996],{"nctId":24974,"briefTitle":24975,"status":104,"phases":24997,"primaryCompletion":24977,"completion":24977,"start":24978,"enrollment":747,"conditions":24998,"interventions":24999},[87],[27],[24967,24981],{"trials":25001,"activeCount":98},[],{"trials":25003,"activeCount":98},[],{"trials":25005,"activeCount":98},[],{"trials":25007,"activeCount":98},[],{"intervention":25009,"totalTrials":208,"cells":25010},"Brivanib + Cetuximab",{"EARLY_PHASE1":25011,"PHASE1":25013,"PHASE2":25021,"PHASE3":25023,"PHASE4":25025,"NA":25027},{"trials":25012,"activeCount":98},[],{"trials":25014,"activeCount":98},[25015],{"nctId":25016,"briefTitle":25017,"status":104,"phases":25018,"primaryCompletion":6953,"completion":6953,"start":4995,"enrollment":9408,"conditions":25019,"interventions":25020},"NCT00207051","BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies",[87],[1673],[25009],{"trials":25022,"activeCount":98},[],{"trials":25024,"activeCount":98},[],{"trials":25026,"activeCount":98},[],{"trials":25028,"activeCount":98},[],{"intervention":25030,"totalTrials":208,"cells":25031},"Atazanavir, powder for oral use 1",{"EARLY_PHASE1":25032,"PHASE1":25034,"PHASE2":25042,"PHASE3":25044,"PHASE4":25046,"NA":25048},{"trials":25033,"activeCount":98},[],{"trials":25035,"activeCount":98},[25036],{"nctId":25037,"briefTitle":25038,"status":104,"phases":25039,"primaryCompletion":5541,"completion":5541,"start":5850,"enrollment":1221,"conditions":25040,"interventions":25041},"NCT01404572","Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects",[87],[8545],[8547,25030,8547],{"trials":25043,"activeCount":98},[],{"trials":25045,"activeCount":98},[],{"trials":25047,"activeCount":98},[],{"trials":25049,"activeCount":98},[],{"intervention":25051,"totalTrials":208,"cells":25052},"Nintedanib",{"EARLY_PHASE1":25053,"PHASE1":25055,"PHASE2":25065,"PHASE3":25067,"PHASE4":25069,"NA":25071},{"trials":25054,"activeCount":98},[],{"trials":25056,"activeCount":98},[25057],{"nctId":25058,"briefTitle":25059,"status":104,"phases":25060,"primaryCompletion":1283,"completion":1283,"start":25061,"enrollment":14468,"conditions":25062,"interventions":25063},"NCT06568458","A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants",[87],"2024-09-19",[18],[25051,25064],"BMS 986278",{"trials":25066,"activeCount":98},[],{"trials":25068,"activeCount":98},[],{"trials":25070,"activeCount":98},[],{"trials":25072,"activeCount":98},[],{"intervention":25064,"totalTrials":208,"cells":25074},{"EARLY_PHASE1":25075,"PHASE1":25077,"PHASE2":25083,"PHASE3":25085,"PHASE4":25087,"NA":25089},{"trials":25076,"activeCount":98},[],{"trials":25078,"activeCount":98},[25079],{"nctId":25058,"briefTitle":25059,"status":104,"phases":25080,"primaryCompletion":1283,"completion":1283,"start":25061,"enrollment":14468,"conditions":25081,"interventions":25082},[87],[18],[25051,25064],{"trials":25084,"activeCount":98},[],{"trials":25086,"activeCount":98},[],{"trials":25088,"activeCount":98},[],{"trials":25090,"activeCount":98},[],{"intervention":21752,"totalTrials":208,"cells":25092},{"EARLY_PHASE1":25093,"PHASE1":25095,"PHASE2":25101,"PHASE3":25103,"PHASE4":25105,"NA":25107},{"trials":25094,"activeCount":98},[],{"trials":25096,"activeCount":98},[25097],{"nctId":21747,"briefTitle":21748,"status":104,"phases":25098,"primaryCompletion":13053,"completion":13053,"start":10856,"enrollment":3978,"conditions":25099,"interventions":25100},[87],[24,13055],[13066,21752],{"trials":25102,"activeCount":98},[],{"trials":25104,"activeCount":98},[],{"trials":25106,"activeCount":98},[],{"trials":25108,"activeCount":98},[],{"intervention":25110,"totalTrials":208,"cells":25111},"BMS-816336",{"EARLY_PHASE1":25112,"PHASE1":25114,"PHASE2":25122,"PHASE3":25124,"PHASE4":25126,"NA":25128},{"trials":25113,"activeCount":98},[],{"trials":25115,"activeCount":98},[25116],{"nctId":25117,"briefTitle":25118,"status":104,"phases":25119,"primaryCompletion":3617,"completion":3617,"start":3585,"enrollment":3562,"conditions":25120,"interventions":25121},"NCT00979368","Safety Study of BMS-816336 in Healthy Male Subjects",[87],[10963,12214],[25110,25110,25110,25110,25110],{"trials":25123,"activeCount":98},[],{"trials":25125,"activeCount":98},[],{"trials":25127,"activeCount":98},[],{"trials":25129,"activeCount":98},[],{"intervention":25131,"totalTrials":208,"cells":25132},"BMS-929075",{"EARLY_PHASE1":25133,"PHASE1":25135,"PHASE2":25143,"PHASE3":25145,"PHASE4":25147,"NA":25149},{"trials":25134,"activeCount":98},[],{"trials":25136,"activeCount":98},[25137],{"nctId":25138,"briefTitle":25139,"status":467,"phases":25140,"primaryCompletion":4114,"completion":4114,"start":5022,"enrollment":98,"conditions":25141,"interventions":25142},"NCT01525212","Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients",[87],[11923],[25131,25131,25131,25131],{"trials":25144,"activeCount":98},[],{"trials":25146,"activeCount":98},[],{"trials":25148,"activeCount":98},[],{"trials":25150,"activeCount":98},[],{"intervention":25152,"totalTrials":208,"cells":25153},"BMS-981164",{"EARLY_PHASE1":25154,"PHASE1":25156,"PHASE2":25165,"PHASE3":25167,"PHASE4":25169,"NA":25171},{"trials":25155,"activeCount":98},[],{"trials":25157,"activeCount":98},[25158],{"nctId":25159,"briefTitle":25160,"status":104,"phases":25161,"primaryCompletion":3976,"completion":3976,"start":3902,"enrollment":7075,"conditions":25162,"interventions":25164},"NCT01614756","A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis",[87],[25163],"Healthy Subjects and Atopic Dermatitis Subjects",[25152],{"trials":25166,"activeCount":98},[],{"trials":25168,"activeCount":98},[],{"trials":25170,"activeCount":98},[],{"trials":25172,"activeCount":98},[],{"intervention":15656,"totalTrials":208,"cells":25174},{"EARLY_PHASE1":25175,"PHASE1":25177,"PHASE2":25183,"PHASE3":25185,"PHASE4":25187,"NA":25189},{"trials":25176,"activeCount":98},[],{"trials":25178,"activeCount":98},[25179],{"nctId":15649,"briefTitle":15650,"status":104,"phases":25180,"primaryCompletion":15652,"completion":15652,"start":15653,"enrollment":1750,"conditions":25181,"interventions":25182},[87],[18],[15626,15656],{"trials":25184,"activeCount":98},[],{"trials":25186,"activeCount":98},[],{"trials":25188,"activeCount":98},[],{"trials":25190,"activeCount":98},[],{"intervention":11882,"totalTrials":208,"cells":25192},{"EARLY_PHASE1":25193,"PHASE1":25195,"PHASE2":25201,"PHASE3":25203,"PHASE4":25205,"NA":25207},{"trials":25194,"activeCount":98},[],{"trials":25196,"activeCount":98},[25197],{"nctId":11877,"briefTitle":11878,"status":104,"phases":25198,"primaryCompletion":4289,"completion":4289,"start":4551,"enrollment":713,"conditions":25199,"interventions":25200},[87],[30],[11882,11858,9391],{"trials":25202,"activeCount":98},[],{"trials":25204,"activeCount":98},[],{"trials":25206,"activeCount":98},[],{"trials":25208,"activeCount":98},[],{"intervention":25210,"totalTrials":208,"cells":25211},"Tetanus + pnemococcal vaccines alone",{"EARLY_PHASE1":25212,"PHASE1":25214,"PHASE2":25225,"PHASE3":25227,"PHASE4":25229,"NA":25231},{"trials":25213,"activeCount":98},[],{"trials":25215,"activeCount":98},[25216],{"nctId":25217,"briefTitle":25218,"status":104,"phases":25219,"primaryCompletion":12930,"completion":12930,"start":25220,"enrollment":1863,"conditions":25221,"interventions":25222},"NCT00279734","Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers",[87],"2004-08",[15],[25210,25223,25223,25224],"Abatacept + vaccines","Abatacept + Vaccines",{"trials":25226,"activeCount":98},[],{"trials":25228,"activeCount":98},[],{"trials":25230,"activeCount":98},[],{"trials":25232,"activeCount":98},[],{"intervention":25223,"totalTrials":208,"cells":25234},{"EARLY_PHASE1":25235,"PHASE1":25237,"PHASE2":25243,"PHASE3":25245,"PHASE4":25247,"NA":25249},{"trials":25236,"activeCount":98},[],{"trials":25238,"activeCount":98},[25239],{"nctId":25217,"briefTitle":25218,"status":104,"phases":25240,"primaryCompletion":12930,"completion":12930,"start":25220,"enrollment":1863,"conditions":25241,"interventions":25242},[87],[15],[25210,25223,25223,25224],{"trials":25244,"activeCount":98},[],{"trials":25246,"activeCount":98},[],{"trials":25248,"activeCount":98},[],{"trials":25250,"activeCount":98},[],{"intervention":1288,"totalTrials":208,"cells":25252},{"EARLY_PHASE1":25253,"PHASE1":25255,"PHASE2":25261,"PHASE3":25263,"PHASE4":25265,"NA":25267},{"trials":25254,"activeCount":98},[],{"trials":25256,"activeCount":98},[25257],{"nctId":1280,"briefTitle":1281,"status":104,"phases":25258,"primaryCompletion":1283,"completion":1283,"start":1284,"enrollment":1285,"conditions":25259,"interventions":25260},[87],[1132],[1288,43],{"trials":25262,"activeCount":98},[],{"trials":25264,"activeCount":98},[],{"trials":25266,"activeCount":98},[],{"trials":25268,"activeCount":98},[],{"intervention":25270,"totalTrials":208,"cells":25271},"Clarithromycin",{"EARLY_PHASE1":25272,"PHASE1":25274,"PHASE2":25282,"PHASE3":25284,"PHASE4":25286,"NA":25288},{"trials":25273,"activeCount":98},[],{"trials":25275,"activeCount":98},[25276],{"nctId":25277,"briefTitle":25278,"status":104,"phases":25279,"primaryCompletion":16214,"completion":16214,"start":16179,"enrollment":319,"conditions":25280,"interventions":25281},"NCT02912234","Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants",[87],[11130],[11001,25270],{"trials":25283,"activeCount":98},[],{"trials":25285,"activeCount":98},[],{"trials":25287,"activeCount":98},[],{"trials":25289,"activeCount":98},[],{"intervention":21079,"totalTrials":208,"cells":25291},{"EARLY_PHASE1":25292,"PHASE1":25294,"PHASE2":25300,"PHASE3":25302,"PHASE4":25304,"NA":25306},{"trials":25293,"activeCount":98},[],{"trials":25295,"activeCount":98},[25296],{"nctId":21074,"briefTitle":21075,"status":104,"phases":25297,"primaryCompletion":3630,"completion":3630,"start":3958,"enrollment":3102,"conditions":25298,"interventions":25299},[87],[10410],[8547,21048,21079],{"trials":25301,"activeCount":98},[],{"trials":25303,"activeCount":98},[],{"trials":25305,"activeCount":98},[],{"trials":25307,"activeCount":98},[],{"intervention":4986,"totalTrials":208,"cells":25309},{"EARLY_PHASE1":25310,"PHASE1":25312,"PHASE2":25318,"PHASE3":25320,"PHASE4":25322,"NA":25324},{"trials":25311,"activeCount":98},[],{"trials":25313,"activeCount":98},[25314],{"nctId":4977,"briefTitle":4978,"status":104,"phases":25315,"primaryCompletion":4980,"completion":4980,"start":4981,"enrollment":4982,"conditions":25316,"interventions":25317},[87],[1154],[611,2053,4985,1328,1158,4986],{"trials":25319,"activeCount":98},[],{"trials":25321,"activeCount":98},[],{"trials":25323,"activeCount":98},[],{"trials":25325,"activeCount":98},[],{"intervention":25327,"totalTrials":208,"cells":25328},"Dasatinib + Ketoconazole",{"EARLY_PHASE1":25329,"PHASE1":25331,"PHASE2":25339,"PHASE3":25341,"PHASE4":25343,"NA":25345},{"trials":25330,"activeCount":98},[],{"trials":25332,"activeCount":98},[25333],{"nctId":25334,"briefTitle":25335,"status":963,"phases":25336,"primaryCompletion":3920,"completion":3920,"start":12237,"enrollment":582,"conditions":25337,"interventions":25338},"NCT00162214","Study of Dasatinib in Patients With Advanced Solid Tumors",[87],[1865],[25327],{"trials":25340,"activeCount":98},[],{"trials":25342,"activeCount":98},[],{"trials":25344,"activeCount":98},[],{"trials":25346,"activeCount":98},[],{"intervention":25348,"totalTrials":208,"cells":25349},"Onureg",{"EARLY_PHASE1":25350,"PHASE1":25352,"PHASE2":25362,"PHASE3":25364,"PHASE4":25366,"NA":25368},{"trials":25351,"activeCount":98},[],{"trials":25353,"activeCount":98},[25354],{"nctId":25355,"briefTitle":25356,"status":963,"phases":25357,"primaryCompletion":25358,"completion":25358,"start":25359,"enrollment":230,"conditions":25360,"interventions":25361},"NCT05209295","A Study to Evaluate CC-486\u002FOnureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies",[87],"2025-04-20","2024-07-12",[11973,7156],[25348],{"trials":25363,"activeCount":98},[],{"trials":25365,"activeCount":98},[],{"trials":25367,"activeCount":98},[],{"trials":25369,"activeCount":98},[],{"intervention":1300,"totalTrials":208,"cells":25371},{"EARLY_PHASE1":25372,"PHASE1":25374,"PHASE2":25380,"PHASE3":25382,"PHASE4":25384,"NA":25386},{"trials":25373,"activeCount":98},[],{"trials":25375,"activeCount":98},[25376],{"nctId":1290,"briefTitle":1291,"status":104,"phases":25377,"primaryCompletion":1293,"completion":1294,"start":1295,"enrollment":1296,"conditions":25378,"interventions":25379},[87],[1253,1298],[43,1300,621,608],{"trials":25381,"activeCount":98},[],{"trials":25383,"activeCount":98},[],{"trials":25385,"activeCount":98},[],{"trials":25387,"activeCount":98},[],{"intervention":6188,"totalTrials":208,"cells":25389},{"EARLY_PHASE1":25390,"PHASE1":25392,"PHASE2":25398,"PHASE3":25400,"PHASE4":25402,"NA":25404},{"trials":25391,"activeCount":98},[],{"trials":25393,"activeCount":98},[25394],{"nctId":6181,"briefTitle":6182,"status":104,"phases":25395,"primaryCompletion":6184,"completion":6184,"start":5541,"enrollment":6185,"conditions":25396,"interventions":25397},[87],[33],[6188,441,1795,6188,1796,1795],{"trials":25399,"activeCount":98},[],{"trials":25401,"activeCount":98},[],{"trials":25403,"activeCount":98},[],{"trials":25405,"activeCount":98},[],{"intervention":25407,"totalTrials":208,"cells":25408},"11C-BMS-986196",{"EARLY_PHASE1":25409,"PHASE1":25411,"PHASE2":25422,"PHASE3":25424,"PHASE4":25426,"NA":25428},{"trials":25410,"activeCount":98},[],{"trials":25412,"activeCount":98},[25413],{"nctId":25414,"briefTitle":25415,"status":963,"phases":25416,"primaryCompletion":25417,"completion":25417,"start":25418,"enrollment":1184,"conditions":25419,"interventions":25421},"NCT05064436","A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis",[87],"2023-12-18","2021-12-10",[25420],"Multiple Sclerosis (MS)",[25407],{"trials":25423,"activeCount":98},[],{"trials":25425,"activeCount":98},[],{"trials":25427,"activeCount":98},[],{"trials":25429,"activeCount":98},[],{"intervention":25431,"totalTrials":208,"cells":25432},"Baraclude",{"EARLY_PHASE1":25433,"PHASE1":25435,"PHASE2":25444,"PHASE3":25446,"PHASE4":25448,"NA":25450},{"trials":25434,"activeCount":98},[],{"trials":25436,"activeCount":98},[25437],{"nctId":25438,"briefTitle":25439,"status":104,"phases":25440,"primaryCompletion":788,"completion":788,"start":25441,"enrollment":830,"conditions":25442,"interventions":25443},"NCT03083821","A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting",[87],"2017-05-16",[18915],[25431],{"trials":25445,"activeCount":98},[],{"trials":25447,"activeCount":98},[],{"trials":25449,"activeCount":98},[],{"trials":25451,"activeCount":98},[],{"intervention":8666,"totalTrials":208,"cells":25453},{"EARLY_PHASE1":25454,"PHASE1":25456,"PHASE2":25462,"PHASE3":25464,"PHASE4":25466,"NA":25468},{"trials":25455,"activeCount":98},[],{"trials":25457,"activeCount":98},[25458],{"nctId":8659,"briefTitle":8660,"status":104,"phases":25459,"primaryCompletion":8662,"completion":8662,"start":60,"enrollment":8663,"conditions":25460,"interventions":25461},[87],[18],[8521,8666,6534],{"trials":25463,"activeCount":98},[],{"trials":25465,"activeCount":98},[],{"trials":25467,"activeCount":98},[],{"trials":25469,"activeCount":98},[],{"intervention":1327,"totalTrials":208,"cells":25471},{"EARLY_PHASE1":25472,"PHASE1":25474,"PHASE2":25480,"PHASE3":25482,"PHASE4":25484,"NA":25486},{"trials":25473,"activeCount":98},[],{"trials":25475,"activeCount":98},[25476],{"nctId":1321,"briefTitle":1322,"status":104,"phases":25477,"primaryCompletion":1324,"completion":1324,"start":388,"enrollment":22,"conditions":25478,"interventions":25479},[87],[1132],[1327,1328,43,611],{"trials":25481,"activeCount":98},[],{"trials":25483,"activeCount":98},[],{"trials":25485,"activeCount":98},[],{"trials":25487,"activeCount":98},[],{"intervention":21426,"totalTrials":208,"cells":25489},{"EARLY_PHASE1":25490,"PHASE1":25492,"PHASE2":25498,"PHASE3":25500,"PHASE4":25502,"NA":25504},{"trials":25491,"activeCount":98},[],{"trials":25493,"activeCount":98},[25494],{"nctId":21421,"briefTitle":21422,"status":104,"phases":25495,"primaryCompletion":2158,"completion":2158,"start":819,"enrollment":506,"conditions":25496,"interventions":25497},[87],[18],[21406,21426],{"trials":25499,"activeCount":98},[],{"trials":25501,"activeCount":98},[],{"trials":25503,"activeCount":98},[],{"trials":25505,"activeCount":98},[],{"intervention":25507,"totalTrials":208,"cells":25508},"Cofact",{"EARLY_PHASE1":25509,"PHASE1":25511,"PHASE2":25521,"PHASE3":25523,"PHASE4":25525,"NA":25527},{"trials":25510,"activeCount":98},[],{"trials":25512,"activeCount":98},[25513],{"nctId":25514,"briefTitle":25515,"status":104,"phases":25516,"primaryCompletion":4289,"completion":4289,"start":4551,"enrollment":11991,"conditions":25517,"interventions":25519},"NCT02074358","A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects",[87],[25518],"Anticoagulation",[11001,25507,25520],"Beriplex P\u002FN",{"trials":25522,"activeCount":98},[],{"trials":25524,"activeCount":98},[],{"trials":25526,"activeCount":98},[],{"trials":25528,"activeCount":98},[],{"intervention":25520,"totalTrials":208,"cells":25530},{"EARLY_PHASE1":25531,"PHASE1":25533,"PHASE2":25539,"PHASE3":25541,"PHASE4":25543,"NA":25545},{"trials":25532,"activeCount":98},[],{"trials":25534,"activeCount":98},[25535],{"nctId":25514,"briefTitle":25515,"status":104,"phases":25536,"primaryCompletion":4289,"completion":4289,"start":4551,"enrollment":11991,"conditions":25537,"interventions":25538},[87],[25518],[11001,25507,25520],{"trials":25540,"activeCount":98},[],{"trials":25542,"activeCount":98},[],{"trials":25544,"activeCount":98},[],{"trials":25546,"activeCount":98},[],{"intervention":25548,"totalTrials":208,"cells":25549},"BMS-914143",{"EARLY_PHASE1":25550,"PHASE1":25552,"PHASE2":25562,"PHASE3":25564,"PHASE4":25566,"NA":25568},{"trials":25551,"activeCount":98},[],{"trials":25553,"activeCount":98},[25554],{"nctId":25555,"briefTitle":25556,"status":104,"phases":25557,"primaryCompletion":4114,"completion":4114,"start":3616,"enrollment":11991,"conditions":25558,"interventions":25561},"NCT01708889","Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction",[87],[25559,25560],"Chronic Hepatitis B Virus Infection","Chronic Hepatitis C Virus Infection",[25548],{"trials":25563,"activeCount":98},[],{"trials":25565,"activeCount":98},[],{"trials":25567,"activeCount":98},[],{"trials":25569,"activeCount":98},[],{"intervention":25571,"totalTrials":208,"cells":25572},"CC-99677",{"EARLY_PHASE1":25573,"PHASE1":25575,"PHASE2":25585,"PHASE3":25587,"PHASE4":25589,"NA":25591},{"trials":25574,"activeCount":98},[],{"trials":25576,"activeCount":98},[25577],{"nctId":25578,"briefTitle":25579,"status":104,"phases":25580,"primaryCompletion":25581,"completion":25581,"start":25582,"enrollment":839,"conditions":25583,"interventions":25584},"NCT05284890","A Study to Evaluate the Drug Levels of [14C]CC-99677 in Healthy Male Participants",[87],"2022-07-11","2022-05-12",[27],[25571],{"trials":25586,"activeCount":98},[],{"trials":25588,"activeCount":98},[],{"trials":25590,"activeCount":98},[],{"trials":25592,"activeCount":98},[],{"intervention":3634,"totalTrials":208,"cells":25594},{"EARLY_PHASE1":25595,"PHASE1":25597,"PHASE2":25603,"PHASE3":25605,"PHASE4":25607,"NA":25609},{"trials":25596,"activeCount":98},[],{"trials":25598,"activeCount":98},[25599],{"nctId":3627,"briefTitle":3628,"status":104,"phases":25600,"primaryCompletion":3630,"completion":3630,"start":3631,"enrollment":1385,"conditions":25601,"interventions":25602},[87],[36],[3634,3635,1158,1157],{"trials":25604,"activeCount":98},[],{"trials":25606,"activeCount":98},[],{"trials":25608,"activeCount":98},[],{"trials":25610,"activeCount":98},[],{"intervention":3635,"totalTrials":208,"cells":25612},{"EARLY_PHASE1":25613,"PHASE1":25615,"PHASE2":25621,"PHASE3":25623,"PHASE4":25625,"NA":25627},{"trials":25614,"activeCount":98},[],{"trials":25616,"activeCount":98},[25617],{"nctId":3627,"briefTitle":3628,"status":104,"phases":25618,"primaryCompletion":3630,"completion":3630,"start":3631,"enrollment":1385,"conditions":25619,"interventions":25620},[87],[36],[3634,3635,1158,1157],{"trials":25622,"activeCount":98},[],{"trials":25624,"activeCount":98},[],{"trials":25626,"activeCount":98},[],{"trials":25628,"activeCount":98},[],{"intervention":25630,"totalTrials":208,"cells":25631},"BMS-986419 DR",{"EARLY_PHASE1":25632,"PHASE1":25634,"PHASE2":25645,"PHASE3":25647,"PHASE4":25649,"NA":25651},{"trials":25633,"activeCount":98},[],{"trials":25635,"activeCount":98},[25636],{"nctId":25637,"briefTitle":25638,"status":104,"phases":25639,"primaryCompletion":25640,"completion":25640,"start":25641,"enrollment":582,"conditions":25642,"interventions":25643},"NCT05963932","A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants",[87],"2023-10-17","2023-08-08",[27],[25630,25644],"BMS-986419 IR",{"trials":25646,"activeCount":98},[],{"trials":25648,"activeCount":98},[],{"trials":25650,"activeCount":98},[],{"trials":25652,"activeCount":98},[],{"intervention":25644,"totalTrials":208,"cells":25654},{"EARLY_PHASE1":25655,"PHASE1":25657,"PHASE2":25663,"PHASE3":25665,"PHASE4":25667,"NA":25669},{"trials":25656,"activeCount":98},[],{"trials":25658,"activeCount":98},[25659],{"nctId":25637,"briefTitle":25638,"status":104,"phases":25660,"primaryCompletion":25640,"completion":25640,"start":25641,"enrollment":582,"conditions":25661,"interventions":25662},[87],[27],[25630,25644],{"trials":25664,"activeCount":98},[],{"trials":25666,"activeCount":98},[],{"trials":25668,"activeCount":98},[],{"trials":25670,"activeCount":98},[],{"intervention":25672,"totalTrials":208,"cells":25673},"BMS-686117",{"EARLY_PHASE1":25674,"PHASE1":25676,"PHASE2":25685,"PHASE3":25687,"PHASE4":25689,"NA":25691},{"trials":25675,"activeCount":98},[],{"trials":25677,"activeCount":98},[25678],{"nctId":25679,"briefTitle":25680,"status":104,"phases":25681,"primaryCompletion":7758,"completion":7758,"start":10821,"enrollment":347,"conditions":25682,"interventions":25683},"NCT00508287","Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes",[87],[12248],[25672,25684],"Byetta",{"trials":25686,"activeCount":98},[],{"trials":25688,"activeCount":98},[],{"trials":25690,"activeCount":98},[],{"trials":25692,"activeCount":98},[],{"intervention":25684,"totalTrials":208,"cells":25694},{"EARLY_PHASE1":25695,"PHASE1":25697,"PHASE2":25703,"PHASE3":25705,"PHASE4":25707,"NA":25709},{"trials":25696,"activeCount":98},[],{"trials":25698,"activeCount":98},[25699],{"nctId":25679,"briefTitle":25680,"status":104,"phases":25700,"primaryCompletion":7758,"completion":7758,"start":10821,"enrollment":347,"conditions":25701,"interventions":25702},[87],[12248],[25672,25684],{"trials":25704,"activeCount":98},[],{"trials":25706,"activeCount":98},[],{"trials":25708,"activeCount":98},[],{"trials":25710,"activeCount":98},[],{"intervention":5667,"totalTrials":208,"cells":25712},{"EARLY_PHASE1":25713,"PHASE1":25715,"PHASE2":25721,"PHASE3":25723,"PHASE4":25725,"NA":25727},{"trials":25714,"activeCount":98},[],{"trials":25716,"activeCount":98},[25717],{"nctId":5660,"briefTitle":5661,"status":104,"phases":25718,"primaryCompletion":5663,"completion":5663,"start":5664,"enrollment":451,"conditions":25719,"interventions":25720},[87],[18],[5571,5667],{"trials":25722,"activeCount":98},[],{"trials":25724,"activeCount":98},[],{"trials":25726,"activeCount":98},[],{"trials":25728,"activeCount":98},[],{"intervention":13100,"totalTrials":208,"cells":25730},{"EARLY_PHASE1":25731,"PHASE1":25733,"PHASE2":25739,"PHASE3":25741,"PHASE4":25743,"NA":25745},{"trials":25732,"activeCount":98},[],{"trials":25734,"activeCount":98},[25735],{"nctId":13094,"briefTitle":13095,"status":104,"phases":25736,"primaryCompletion":10856,"completion":10856,"start":5043,"enrollment":6185,"conditions":25737,"interventions":25738},[87],[24],[13099,13100,13100,13081],{"trials":25740,"activeCount":98},[],{"trials":25742,"activeCount":98},[],{"trials":25744,"activeCount":98},[],{"trials":25746,"activeCount":98},[],{"intervention":15665,"totalTrials":208,"cells":25748},{"EARLY_PHASE1":25749,"PHASE1":25751,"PHASE2":25757,"PHASE3":25759,"PHASE4":25761,"NA":25763},{"trials":25750,"activeCount":98},[],{"trials":25752,"activeCount":98},[25753],{"nctId":15658,"briefTitle":15659,"status":104,"phases":25754,"primaryCompletion":15661,"completion":15661,"start":15662,"enrollment":1385,"conditions":25755,"interventions":25756},[87],[18],[15626,5584,15665,5585],{"trials":25758,"activeCount":98},[],{"trials":25760,"activeCount":98},[],{"trials":25762,"activeCount":98},[],{"trials":25764,"activeCount":98},[],{"intervention":25766,"totalTrials":208,"cells":25767},"BMS-986318",{"EARLY_PHASE1":25768,"PHASE1":25770,"PHASE2":25779,"PHASE3":25781,"PHASE4":25783,"NA":25785},{"trials":25769,"activeCount":98},[],{"trials":25771,"activeCount":98},[25772],{"nctId":25773,"briefTitle":25774,"status":467,"phases":25775,"primaryCompletion":712,"completion":712,"start":25776,"enrollment":98,"conditions":25777,"interventions":25778},"NCT04082741","A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants",[87],"2019-07-18",[18],[25766],{"trials":25780,"activeCount":98},[],{"trials":25782,"activeCount":98},[],{"trials":25784,"activeCount":98},[],{"trials":25786,"activeCount":98},[],{"intervention":25788,"totalTrials":208,"cells":25789},"BMS-986147",{"EARLY_PHASE1":25790,"PHASE1":25792,"PHASE2":25800,"PHASE3":25802,"PHASE4":25804,"NA":25806},{"trials":25791,"activeCount":98},[],{"trials":25793,"activeCount":98},[25794],{"nctId":25795,"briefTitle":25796,"status":104,"phases":25797,"primaryCompletion":7690,"completion":7690,"start":6917,"enrollment":839,"conditions":25798,"interventions":25799},"NCT02293629","A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects",[87],[759],[25788],{"trials":25801,"activeCount":98},[],{"trials":25803,"activeCount":98},[],{"trials":25805,"activeCount":98},[],{"trials":25807,"activeCount":98},[],{"intervention":919,"totalTrials":208,"cells":25809},{"EARLY_PHASE1":25810,"PHASE1":25812,"PHASE2":25818,"PHASE3":25820,"PHASE4":25822,"NA":25824},{"trials":25811,"activeCount":98},[],{"trials":25813,"activeCount":98},[25814],{"nctId":913,"briefTitle":914,"status":104,"phases":25815,"primaryCompletion":916,"completion":916,"start":745,"enrollment":713,"conditions":25816,"interventions":25817},[87],[759],[679,919],{"trials":25819,"activeCount":98},[],{"trials":25821,"activeCount":98},[],{"trials":25823,"activeCount":98},[],{"trials":25825,"activeCount":98},[],{"intervention":25827,"totalTrials":208,"cells":25828},"Dasatinib as",{"EARLY_PHASE1":25829,"PHASE1":25831,"PHASE2":25842,"PHASE3":25844,"PHASE4":25846,"NA":25848},{"trials":25830,"activeCount":98},[],{"trials":25832,"activeCount":98},[25833],{"nctId":25834,"briefTitle":25835,"status":104,"phases":25836,"primaryCompletion":5541,"completion":5541,"start":7714,"enrollment":3607,"conditions":25837,"interventions":25839},"NCT01392703","Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations",[87],[25838],"Pharmacokinetic Study in Healthy Participants",[25827,25840,25841],"Dasatinib as liquid","Dasatinib as dispersed",{"trials":25843,"activeCount":98},[],{"trials":25845,"activeCount":98},[],{"trials":25847,"activeCount":98},[],{"trials":25849,"activeCount":98},[],{"intervention":25840,"totalTrials":208,"cells":25851},{"EARLY_PHASE1":25852,"PHASE1":25854,"PHASE2":25860,"PHASE3":25862,"PHASE4":25864,"NA":25866},{"trials":25853,"activeCount":98},[],{"trials":25855,"activeCount":98},[25856],{"nctId":25834,"briefTitle":25835,"status":104,"phases":25857,"primaryCompletion":5541,"completion":5541,"start":7714,"enrollment":3607,"conditions":25858,"interventions":25859},[87],[25838],[25827,25840,25841],{"trials":25861,"activeCount":98},[],{"trials":25863,"activeCount":98},[],{"trials":25865,"activeCount":98},[],{"trials":25867,"activeCount":98},[],{"intervention":25841,"totalTrials":208,"cells":25869},{"EARLY_PHASE1":25870,"PHASE1":25872,"PHASE2":25878,"PHASE3":25880,"PHASE4":25882,"NA":25884},{"trials":25871,"activeCount":98},[],{"trials":25873,"activeCount":98},[25874],{"nctId":25834,"briefTitle":25835,"status":104,"phases":25875,"primaryCompletion":5541,"completion":5541,"start":7714,"enrollment":3607,"conditions":25876,"interventions":25877},[87],[25838],[25827,25840,25841],{"trials":25879,"activeCount":98},[],{"trials":25881,"activeCount":98},[],{"trials":25883,"activeCount":98},[],{"trials":25885,"activeCount":98},[],{"intervention":25887,"totalTrials":208,"cells":25888},"Drug: Apixaban sprinkle",{"EARLY_PHASE1":25889,"PHASE1":25891,"PHASE2":25901,"PHASE3":25903,"PHASE4":25905,"NA":25907},{"trials":25890,"activeCount":98},[],{"trials":25892,"activeCount":98},[25893],{"nctId":25894,"briefTitle":25895,"status":104,"phases":25896,"primaryCompletion":25897,"completion":25897,"start":136,"enrollment":378,"conditions":25898,"interventions":25899},"NCT03509883","Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules",[87],"2018-06-15",[27],[25887,25900],"Experimental: Apixaban tablets followed by apixaban sprinkle",{"trials":25902,"activeCount":98},[],{"trials":25904,"activeCount":98},[],{"trials":25906,"activeCount":98},[],{"trials":25908,"activeCount":98},[],{"intervention":25900,"totalTrials":208,"cells":25910},{"EARLY_PHASE1":25911,"PHASE1":25913,"PHASE2":25919,"PHASE3":25921,"PHASE4":25923,"NA":25925},{"trials":25912,"activeCount":98},[],{"trials":25914,"activeCount":98},[25915],{"nctId":25894,"briefTitle":25895,"status":104,"phases":25916,"primaryCompletion":25897,"completion":25897,"start":136,"enrollment":378,"conditions":25917,"interventions":25918},[87],[27],[25887,25900],{"trials":25920,"activeCount":98},[],{"trials":25922,"activeCount":98},[],{"trials":25924,"activeCount":98},[],{"trials":25926,"activeCount":98},[],{"intervention":25928,"totalTrials":208,"cells":25929},"BMS-844421",{"EARLY_PHASE1":25930,"PHASE1":25932,"PHASE2":25941,"PHASE3":25943,"PHASE4":25945,"NA":25947},{"trials":25931,"activeCount":98},[],{"trials":25933,"activeCount":98},[25934],{"nctId":25935,"briefTitle":25936,"status":963,"phases":25937,"primaryCompletion":4348,"completion":4348,"start":3872,"enrollment":3562,"conditions":25938,"interventions":25939},"NCT01082562","Safety Study of BMS-844421 for Treatment of Hypercholesterolemia",[87],[23022,10942],[25928,25940],"0.9% sodium chloride injection solution",{"trials":25942,"activeCount":98},[],{"trials":25944,"activeCount":98},[],{"trials":25946,"activeCount":98},[],{"trials":25948,"activeCount":98},[],{"intervention":25940,"totalTrials":208,"cells":25950},{"EARLY_PHASE1":25951,"PHASE1":25953,"PHASE2":25959,"PHASE3":25961,"PHASE4":25963,"NA":25965},{"trials":25952,"activeCount":98},[],{"trials":25954,"activeCount":98},[25955],{"nctId":25935,"briefTitle":25936,"status":963,"phases":25956,"primaryCompletion":4348,"completion":4348,"start":3872,"enrollment":3562,"conditions":25957,"interventions":25958},[87],[23022,10942],[25928,25940],{"trials":25960,"activeCount":98},[],{"trials":25962,"activeCount":98},[],{"trials":25964,"activeCount":98},[],{"trials":25966,"activeCount":98},[],{"intervention":25968,"totalTrials":208,"cells":25969},"BMS-817378",{"EARLY_PHASE1":25970,"PHASE1":25972,"PHASE2":25980,"PHASE3":25982,"PHASE4":25984,"NA":25986},{"trials":25971,"activeCount":98},[],{"trials":25973,"activeCount":98},[25974],{"nctId":25975,"briefTitle":25976,"status":467,"phases":25977,"primaryCompletion":3904,"completion":3904,"start":7713,"enrollment":98,"conditions":25978,"interventions":25979},"NCT00792558","Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers",[87],[1132],[25968],{"trials":25981,"activeCount":98},[],{"trials":25983,"activeCount":98},[],{"trials":25985,"activeCount":98},[],{"trials":25987,"activeCount":98},[],{"intervention":1347,"totalTrials":208,"cells":25989},{"EARLY_PHASE1":25990,"PHASE1":25992,"PHASE2":25998,"PHASE3":26000,"PHASE4":26002,"NA":26004},{"trials":25991,"activeCount":98},[],{"trials":25993,"activeCount":98},[25994],{"nctId":1339,"briefTitle":1340,"status":104,"phases":25995,"primaryCompletion":1342,"completion":1342,"start":1343,"enrollment":736,"conditions":25996,"interventions":25997},[87],[1345],[1347,43],{"trials":25999,"activeCount":98},[],{"trials":26001,"activeCount":98},[],{"trials":26003,"activeCount":98},[],{"trials":26005,"activeCount":98},[],{"intervention":26007,"totalTrials":208,"cells":26008},"Atazanavir+Ritonavir+Tenofovir",{"EARLY_PHASE1":26009,"PHASE1":26011,"PHASE2":26020,"PHASE3":26022,"PHASE4":26024,"NA":26026},{"trials":26010,"activeCount":98},[],{"trials":26012,"activeCount":98},[26013],{"nctId":26014,"briefTitle":26015,"status":104,"phases":26016,"primaryCompletion":5117,"completion":5117,"start":4011,"enrollment":3562,"conditions":26017,"interventions":26018},"NCT00365339","Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir\u002FRitonavir\u002FTenofovir",[87],[24],[26007,26019,26019,26019,26019],"Atazanavir+Ritonavir+Tenofovir+Famotidine",{"trials":26021,"activeCount":98},[],{"trials":26023,"activeCount":98},[],{"trials":26025,"activeCount":98},[],{"trials":26027,"activeCount":98},[],{"intervention":26019,"totalTrials":208,"cells":26029},{"EARLY_PHASE1":26030,"PHASE1":26032,"PHASE2":26038,"PHASE3":26040,"PHASE4":26042,"NA":26044},{"trials":26031,"activeCount":98},[],{"trials":26033,"activeCount":98},[26034],{"nctId":26014,"briefTitle":26015,"status":104,"phases":26035,"primaryCompletion":5117,"completion":5117,"start":4011,"enrollment":3562,"conditions":26036,"interventions":26037},[87],[24],[26007,26019,26019,26019,26019],{"trials":26039,"activeCount":98},[],{"trials":26041,"activeCount":98},[],{"trials":26043,"activeCount":98},[],{"trials":26045,"activeCount":98},[],{"intervention":26047,"totalTrials":208,"cells":26048},"MDX-1106",{"EARLY_PHASE1":26049,"PHASE1":26051,"PHASE2":26059,"PHASE3":26061,"PHASE4":26063,"NA":26065},{"trials":26050,"activeCount":98},[],{"trials":26052,"activeCount":98},[26053],{"nctId":26054,"briefTitle":26055,"status":104,"phases":26056,"primaryCompletion":3585,"completion":3585,"start":4379,"enrollment":4579,"conditions":26057,"interventions":26058},"NCT00441337","A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies",[87],[2781,1673,3035,2990,1504],[26047],{"trials":26060,"activeCount":98},[],{"trials":26062,"activeCount":98},[],{"trials":26064,"activeCount":98},[],{"trials":26066,"activeCount":98},[],{"intervention":26068,"totalTrials":208,"cells":26069},"BMS-582949 and Methotrexate",{"EARLY_PHASE1":26070,"PHASE1":26072,"PHASE2":26080,"PHASE3":26082,"PHASE4":26084,"NA":26086},{"trials":26071,"activeCount":98},[],{"trials":26073,"activeCount":98},[26074],{"nctId":26075,"briefTitle":26076,"status":104,"phases":26077,"primaryCompletion":4179,"completion":4179,"start":3657,"enrollment":736,"conditions":26078,"interventions":26079},"NCT00162292","Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background",[87],[15],[26068],{"trials":26081,"activeCount":98},[],{"trials":26083,"activeCount":98},[],{"trials":26085,"activeCount":98},[],{"trials":26087,"activeCount":98},[],{"intervention":26089,"totalTrials":208,"cells":26090},"BMS-986184",{"EARLY_PHASE1":26091,"PHASE1":26093,"PHASE2":26103,"PHASE3":26105,"PHASE4":26107,"NA":26109},{"trials":26092,"activeCount":98},[],{"trials":26094,"activeCount":98},[26095],{"nctId":26096,"briefTitle":26097,"status":963,"phases":26098,"primaryCompletion":26099,"completion":26099,"start":26100,"enrollment":1750,"conditions":26101,"interventions":26102},"NCT02864264","Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis",[87],"2017-09-27","2016-09-14",[27,990],[26089],{"trials":26104,"activeCount":98},[],{"trials":26106,"activeCount":98},[],{"trials":26108,"activeCount":98},[],{"trials":26110,"activeCount":98},[],{"intervention":11889,"totalTrials":208,"cells":26112},{"EARLY_PHASE1":26113,"PHASE1":26115,"PHASE2":26121,"PHASE3":26123,"PHASE4":26125,"NA":26127},{"trials":26114,"activeCount":98},[],{"trials":26116,"activeCount":98},[26117],{"nctId":11884,"briefTitle":11885,"status":104,"phases":26118,"primaryCompletion":4122,"completion":4122,"start":4289,"enrollment":319,"conditions":26119,"interventions":26120},[87],[30],[11889,11890,9391],{"trials":26122,"activeCount":98},[],{"trials":26124,"activeCount":98},[],{"trials":26126,"activeCount":98},[],{"trials":26128,"activeCount":98},[],{"intervention":11890,"totalTrials":208,"cells":26130},{"EARLY_PHASE1":26131,"PHASE1":26133,"PHASE2":26139,"PHASE3":26141,"PHASE4":26143,"NA":26145},{"trials":26132,"activeCount":98},[],{"trials":26134,"activeCount":98},[26135],{"nctId":11884,"briefTitle":11885,"status":104,"phases":26136,"primaryCompletion":4122,"completion":4122,"start":4289,"enrollment":319,"conditions":26137,"interventions":26138},[87],[30],[11889,11890,9391],{"trials":26140,"activeCount":98},[],{"trials":26142,"activeCount":98},[],{"trials":26144,"activeCount":98},[],{"trials":26146,"activeCount":98},[],{"intervention":11898,"totalTrials":208,"cells":26148},{"EARLY_PHASE1":26149,"PHASE1":26151,"PHASE2":26157,"PHASE3":26159,"PHASE4":26161,"NA":26163},{"trials":26150,"activeCount":98},[],{"trials":26152,"activeCount":98},[26153],{"nctId":11892,"briefTitle":11893,"status":104,"phases":26154,"primaryCompletion":4159,"completion":4159,"start":4289,"enrollment":839,"conditions":26155,"interventions":26156},[87],[11896],[9391,11898],{"trials":26158,"activeCount":98},[],{"trials":26160,"activeCount":98},[],{"trials":26162,"activeCount":98},[],{"trials":26164,"activeCount":98},[],{"intervention":16567,"totalTrials":208,"cells":26166},{"EARLY_PHASE1":26167,"PHASE1":26169,"PHASE2":26175,"PHASE3":26177,"PHASE4":26179,"NA":26181},{"trials":26168,"activeCount":98},[],{"trials":26170,"activeCount":98},[26171],{"nctId":16561,"briefTitle":16562,"status":104,"phases":26172,"primaryCompletion":15545,"completion":16564,"start":1533,"enrollment":125,"conditions":26173,"interventions":26174},[87],[18],[16539,5584,16567],{"trials":26176,"activeCount":98},[],{"trials":26178,"activeCount":98},[],{"trials":26180,"activeCount":98},[],{"trials":26182,"activeCount":98},[],{"intervention":128,"totalTrials":208,"cells":26184},{"EARLY_PHASE1":26185,"PHASE1":26187,"PHASE2":26193,"PHASE3":26195,"PHASE4":26197,"NA":26199},{"trials":26186,"activeCount":98},[],{"trials":26188,"activeCount":98},[26189],{"nctId":120,"briefTitle":121,"status":104,"phases":26190,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":26191,"interventions":26192},[87],[18],[84,128],{"trials":26194,"activeCount":98},[],{"trials":26196,"activeCount":98},[],{"trials":26198,"activeCount":98},[],{"trials":26200,"activeCount":98},[],{"intervention":12132,"totalTrials":208,"cells":26202},{"EARLY_PHASE1":26203,"PHASE1":26205,"PHASE2":26211,"PHASE3":26213,"PHASE4":26215,"NA":26217},{"trials":26204,"activeCount":98},[],{"trials":26206,"activeCount":98},[26207],{"nctId":12126,"briefTitle":12127,"status":104,"phases":26208,"primaryCompletion":11742,"completion":4159,"start":10518,"enrollment":582,"conditions":26209,"interventions":26210},[87],[12130],[10558,12132],{"trials":26212,"activeCount":98},[],{"trials":26214,"activeCount":98},[],{"trials":26216,"activeCount":98},[],{"trials":26218,"activeCount":98},[],{"intervention":20781,"totalTrials":208,"cells":26220},{"EARLY_PHASE1":26221,"PHASE1":26223,"PHASE2":26229,"PHASE3":26231,"PHASE4":26233,"NA":26235},{"trials":26222,"activeCount":98},[],{"trials":26224,"activeCount":98},[26225],{"nctId":20774,"briefTitle":20775,"status":104,"phases":26226,"primaryCompletion":20777,"completion":20777,"start":846,"enrollment":713,"conditions":26227,"interventions":26228},[87],[20779],[20781,5658],{"trials":26230,"activeCount":98},[],{"trials":26232,"activeCount":98},[],{"trials":26234,"activeCount":98},[],{"trials":26236,"activeCount":98},[],{"intervention":10559,"totalTrials":208,"cells":26238},{"EARLY_PHASE1":26239,"PHASE1":26241,"PHASE2":26247,"PHASE3":26249,"PHASE4":26251,"NA":26253},{"trials":26240,"activeCount":98},[],{"trials":26242,"activeCount":98},[26243],{"nctId":10553,"briefTitle":10554,"status":104,"phases":26244,"primaryCompletion":4123,"completion":4123,"start":1343,"enrollment":713,"conditions":26245,"interventions":26246},[87],[1482],[10558,10559,10560,10561],{"trials":26248,"activeCount":98},[],{"trials":26250,"activeCount":98},[],{"trials":26252,"activeCount":98},[],{"trials":26254,"activeCount":98},[],{"intervention":15538,"totalTrials":208,"cells":26256},{"EARLY_PHASE1":26257,"PHASE1":26259,"PHASE2":26265,"PHASE3":26267,"PHASE4":26269,"NA":26271},{"trials":26258,"activeCount":98},[],{"trials":26260,"activeCount":98},[26261],{"nctId":15530,"briefTitle":15531,"status":104,"phases":26262,"primaryCompletion":1293,"completion":15533,"start":15534,"enrollment":15535,"conditions":26263,"interventions":26264},[87],[11063],[15538,15199],{"trials":26266,"activeCount":98},[],{"trials":26268,"activeCount":98},[],{"trials":26270,"activeCount":98},[],{"trials":26272,"activeCount":98},[],{"intervention":26274,"totalTrials":208,"cells":26275},"Combination of Bendamustine + Dasatinib",{"EARLY_PHASE1":26276,"PHASE1":26278,"PHASE2":26286,"PHASE3":26288,"PHASE4":26290,"NA":26292},{"trials":26277,"activeCount":98},[],{"trials":26279,"activeCount":98},[26280],{"nctId":26281,"briefTitle":26282,"status":467,"phases":26283,"primaryCompletion":3679,"completion":3679,"start":4459,"enrollment":98,"conditions":26284,"interventions":26285},"NCT00872976","Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia",[87],[17473],[1197,26274,1197,26274],{"trials":26287,"activeCount":98},[],{"trials":26289,"activeCount":98},[],{"trials":26291,"activeCount":98},[],{"trials":26293,"activeCount":98},[],{"intervention":3989,"totalTrials":208,"cells":26295},{"EARLY_PHASE1":26296,"PHASE1":26298,"PHASE2":26304,"PHASE3":26306,"PHASE4":26308,"NA":26310},{"trials":26297,"activeCount":98},[],{"trials":26299,"activeCount":98},[26300],{"nctId":3983,"briefTitle":3984,"status":104,"phases":26301,"primaryCompletion":3017,"completion":3017,"start":3679,"enrollment":3986,"conditions":26302,"interventions":26303},[87],[21],[3989,3989,3989,3989,608,608,608],{"trials":26305,"activeCount":98},[],{"trials":26307,"activeCount":98},[],{"trials":26309,"activeCount":98},[],{"trials":26311,"activeCount":98},[],{"intervention":8511,"totalTrials":208,"cells":26313},{"EARLY_PHASE1":26314,"PHASE1":26316,"PHASE2":26322,"PHASE3":26324,"PHASE4":26326,"NA":26328},{"trials":26315,"activeCount":98},[],{"trials":26317,"activeCount":98},[26318],{"nctId":8504,"briefTitle":8505,"status":963,"phases":26319,"primaryCompletion":2628,"completion":2628,"start":8507,"enrollment":8508,"conditions":26320,"interventions":26321},[87],[18],[8511,8512,696],{"trials":26323,"activeCount":98},[],{"trials":26325,"activeCount":98},[],{"trials":26327,"activeCount":98},[],{"trials":26329,"activeCount":98},[],{"intervention":8512,"totalTrials":208,"cells":26331},{"EARLY_PHASE1":26332,"PHASE1":26334,"PHASE2":26340,"PHASE3":26342,"PHASE4":26344,"NA":26346},{"trials":26333,"activeCount":98},[],{"trials":26335,"activeCount":98},[26336],{"nctId":8504,"briefTitle":8505,"status":963,"phases":26337,"primaryCompletion":2628,"completion":2628,"start":8507,"enrollment":8508,"conditions":26338,"interventions":26339},[87],[18],[8511,8512,696],{"trials":26341,"activeCount":98},[],{"trials":26343,"activeCount":98},[],{"trials":26345,"activeCount":98},[],{"trials":26347,"activeCount":98},[],{"intervention":10569,"totalTrials":208,"cells":26349},{"EARLY_PHASE1":26350,"PHASE1":26352,"PHASE2":26358,"PHASE3":26360,"PHASE4":26362,"NA":26364},{"trials":26351,"activeCount":98},[],{"trials":26353,"activeCount":98},[26354],{"nctId":10563,"briefTitle":10564,"status":104,"phases":26355,"primaryCompletion":8187,"completion":8187,"start":10566,"enrollment":3978,"conditions":26356,"interventions":26357},[87],[27],[9403,6530,6835,6532,6533,6534,10569],{"trials":26359,"activeCount":98},[],{"trials":26361,"activeCount":98},[],{"trials":26363,"activeCount":98},[],{"trials":26365,"activeCount":98},[],{"intervention":26367,"totalTrials":208,"cells":26368},"BMS-986331",{"EARLY_PHASE1":26369,"PHASE1":26371,"PHASE2":26381,"PHASE3":26383,"PHASE4":26385,"NA":26387},{"trials":26370,"activeCount":98},[],{"trials":26372,"activeCount":98},[26373],{"nctId":26374,"briefTitle":26375,"status":104,"phases":26376,"primaryCompletion":26377,"completion":26377,"start":26378,"enrollment":725,"conditions":26379,"interventions":26380},"NCT04444050","Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants",[87],"2021-05-19","2020-06-23",[18],[26367],{"trials":26382,"activeCount":98},[],{"trials":26384,"activeCount":98},[],{"trials":26386,"activeCount":98},[],{"trials":26388,"activeCount":98},[],{"intervention":26390,"totalTrials":208,"cells":26391},"BMS-690514 \u002F FOLFIRI",{"EARLY_PHASE1":26392,"PHASE1":26394,"PHASE2":26403,"PHASE3":26405,"PHASE4":26407,"NA":26409},{"trials":26393,"activeCount":98},[],{"trials":26395,"activeCount":98},[26396],{"nctId":26397,"briefTitle":26398,"status":104,"phases":26399,"primaryCompletion":3872,"completion":3872,"start":11728,"enrollment":94,"conditions":26400,"interventions":26401},"NCT00479583","Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX",[87],[606],[26390,26402],"BMS-690514 \u002F FOLFOX",{"trials":26404,"activeCount":98},[],{"trials":26406,"activeCount":98},[],{"trials":26408,"activeCount":98},[],{"trials":26410,"activeCount":98},[],{"intervention":26402,"totalTrials":208,"cells":26412},{"EARLY_PHASE1":26413,"PHASE1":26415,"PHASE2":26421,"PHASE3":26423,"PHASE4":26425,"NA":26427},{"trials":26414,"activeCount":98},[],{"trials":26416,"activeCount":98},[26417],{"nctId":26397,"briefTitle":26398,"status":104,"phases":26418,"primaryCompletion":3872,"completion":3872,"start":11728,"enrollment":94,"conditions":26419,"interventions":26420},[87],[606],[26390,26402],{"trials":26422,"activeCount":98},[],{"trials":26424,"activeCount":98},[],{"trials":26426,"activeCount":98},[],{"trials":26428,"activeCount":98},[],{"intervention":6563,"totalTrials":208,"cells":26430},{"EARLY_PHASE1":26431,"PHASE1":26433,"PHASE2":26439,"PHASE3":26441,"PHASE4":26443,"NA":26445},{"trials":26432,"activeCount":98},[],{"trials":26434,"activeCount":98},[26435],{"nctId":6557,"briefTitle":6558,"status":104,"phases":26436,"primaryCompletion":3017,"completion":3017,"start":3617,"enrollment":790,"conditions":26437,"interventions":26438},[87],[6561],[6563,617,6563,1678,5877,5877,5877],{"trials":26440,"activeCount":98},[],{"trials":26442,"activeCount":98},[],{"trials":26444,"activeCount":98},[],{"trials":26446,"activeCount":98},[],{"intervention":12662,"totalTrials":208,"cells":26448},{"EARLY_PHASE1":26449,"PHASE1":26451,"PHASE2":26457,"PHASE3":26459,"PHASE4":26461,"NA":26463},{"trials":26450,"activeCount":98},[],{"trials":26452,"activeCount":98},[26453],{"nctId":12655,"briefTitle":12656,"status":963,"phases":26454,"primaryCompletion":8597,"completion":8597,"start":12658,"enrollment":520,"conditions":26455,"interventions":26456},[87],[12660,1426],[12662,12663,1773],{"trials":26458,"activeCount":98},[],{"trials":26460,"activeCount":98},[],{"trials":26462,"activeCount":98},[],{"trials":26464,"activeCount":98},[],{"intervention":12663,"totalTrials":208,"cells":26466},{"EARLY_PHASE1":26467,"PHASE1":26469,"PHASE2":26475,"PHASE3":26477,"PHASE4":26479,"NA":26481},{"trials":26468,"activeCount":98},[],{"trials":26470,"activeCount":98},[26471],{"nctId":12655,"briefTitle":12656,"status":963,"phases":26472,"primaryCompletion":8597,"completion":8597,"start":12658,"enrollment":520,"conditions":26473,"interventions":26474},[87],[12660,1426],[12662,12663,1773],{"trials":26476,"activeCount":98},[],{"trials":26478,"activeCount":98},[],{"trials":26480,"activeCount":98},[],{"trials":26482,"activeCount":98},[],{"intervention":26484,"totalTrials":208,"cells":26485},"EVRI",{"EARLY_PHASE1":26486,"PHASE1":26488,"PHASE2":26496,"PHASE3":26498,"PHASE4":26500,"NA":26502},{"trials":26487,"activeCount":98},[],{"trials":26489,"activeCount":98},[26490],{"nctId":26491,"briefTitle":26492,"status":104,"phases":26493,"primaryCompletion":4930,"completion":4930,"start":4930,"enrollment":5543,"conditions":26494,"interventions":26495},"NCT00578916","Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects",[87],[606],[26484],{"trials":26497,"activeCount":98},[],{"trials":26499,"activeCount":98},[],{"trials":26501,"activeCount":98},[],{"trials":26503,"activeCount":98},[],{"intervention":1368,"totalTrials":208,"cells":26505},{"EARLY_PHASE1":26506,"PHASE1":26508,"PHASE2":26514,"PHASE3":26516,"PHASE4":26518,"NA":26520},{"trials":26507,"activeCount":98},[],{"trials":26509,"activeCount":98},[26510],{"nctId":1360,"briefTitle":1361,"status":104,"phases":26511,"primaryCompletion":1363,"completion":1364,"start":1365,"enrollment":37,"conditions":26512,"interventions":26513},[87],[1154],[1368,43],{"trials":26515,"activeCount":98},[],{"trials":26517,"activeCount":98},[],{"trials":26519,"activeCount":98},[],{"trials":26521,"activeCount":98},[],{"intervention":11907,"totalTrials":208,"cells":26523},{"EARLY_PHASE1":26524,"PHASE1":26526,"PHASE2":26532,"PHASE3":26534,"PHASE4":26536,"NA":26538},{"trials":26525,"activeCount":98},[],{"trials":26527,"activeCount":98},[26528],{"nctId":11900,"briefTitle":11901,"status":104,"phases":26529,"primaryCompletion":10525,"start":3017,"enrollment":11873,"conditions":26530,"interventions":26531},[87],[11904],[11906,11907,11858,9391],{"trials":26533,"activeCount":98},[],{"trials":26535,"activeCount":98},[],{"trials":26537,"activeCount":98},[],{"trials":26539,"activeCount":98},[],{"intervention":26541,"totalTrials":208,"cells":26542},"BMS-599626",{"EARLY_PHASE1":26543,"PHASE1":26545,"PHASE2":26554,"PHASE3":26556,"PHASE4":26558,"NA":26560},{"trials":26544,"activeCount":98},[],{"trials":26546,"activeCount":98},[26547],{"nctId":26548,"briefTitle":26549,"status":104,"phases":26550,"primaryCompletion":13679,"start":12230,"enrollment":125,"conditions":26551,"interventions":26553},"NCT00207012","MAD Refractory: Solid Tumor QD w\u002Fo Break",[87],[26552],"HER2 or EGFR Expressing Advanced Solid Malignancies",[26541],{"trials":26555,"activeCount":98},[],{"trials":26557,"activeCount":98},[],{"trials":26559,"activeCount":98},[],{"trials":26561,"activeCount":98},[],{"intervention":20666,"totalTrials":208,"cells":26563},{"EARLY_PHASE1":26564,"PHASE1":26566,"PHASE2":26572,"PHASE3":26574,"PHASE4":26576,"NA":26578},{"trials":26565,"activeCount":98},[],{"trials":26567,"activeCount":98},[26568],{"nctId":20658,"briefTitle":20659,"status":104,"phases":26569,"primaryCompletion":20661,"completion":20661,"start":20662,"enrollment":2425,"conditions":26570,"interventions":26571},[87],[20664],[20666,5584,16335],{"trials":26573,"activeCount":98},[],{"trials":26575,"activeCount":98},[],{"trials":26577,"activeCount":98},[],{"trials":26579,"activeCount":98},[],{"intervention":1377,"totalTrials":208,"cells":26581},{"EARLY_PHASE1":26582,"PHASE1":26584,"PHASE2":26590,"PHASE3":26592,"PHASE4":26594,"NA":26596},{"trials":26583,"activeCount":98},[],{"trials":26585,"activeCount":98},[26586],{"nctId":1370,"briefTitle":1371,"status":104,"phases":26587,"primaryCompletion":183,"completion":1373,"start":937,"enrollment":890,"conditions":26588,"interventions":26589},[87],[1375],[1377,43,608],{"trials":26591,"activeCount":98},[],{"trials":26593,"activeCount":98},[],{"trials":26595,"activeCount":98},[],{"trials":26597,"activeCount":98},[],{"intervention":26599,"totalTrials":208,"cells":26600},"[14C]CC-90010",{"EARLY_PHASE1":26601,"PHASE1":26603,"PHASE2":26613,"PHASE3":26615,"PHASE4":26617,"NA":26619},{"trials":26602,"activeCount":98},[],{"trials":26604,"activeCount":98},[26605],{"nctId":26606,"briefTitle":26607,"status":467,"phases":26608,"primaryCompletion":6840,"completion":6840,"start":26609,"enrollment":98,"conditions":26610,"interventions":26611},"NCT05678283","A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors",[87],"2023-01-09",[1132],[26599,26612],"CC-90010",{"trials":26614,"activeCount":98},[],{"trials":26616,"activeCount":98},[],{"trials":26618,"activeCount":98},[],{"trials":26620,"activeCount":98},[],{"intervention":26612,"totalTrials":208,"cells":26622},{"EARLY_PHASE1":26623,"PHASE1":26625,"PHASE2":26631,"PHASE3":26633,"PHASE4":26635,"NA":26637},{"trials":26624,"activeCount":98},[],{"trials":26626,"activeCount":98},[26627],{"nctId":26606,"briefTitle":26607,"status":467,"phases":26628,"primaryCompletion":6840,"completion":6840,"start":26609,"enrollment":98,"conditions":26629,"interventions":26630},[87],[1132],[26599,26612],{"trials":26632,"activeCount":98},[],{"trials":26634,"activeCount":98},[],{"trials":26636,"activeCount":98},[],{"trials":26638,"activeCount":98},[],{"intervention":26640,"totalTrials":208,"cells":26641},"BMS-986421",{"EARLY_PHASE1":26642,"PHASE1":26651,"PHASE2":26653,"PHASE3":26655,"PHASE4":26657,"NA":26659},{"trials":26643,"activeCount":98},[26644],{"nctId":26645,"briefTitle":26646,"status":963,"phases":26647,"primaryCompletion":26648,"completion":26648,"start":2190,"enrollment":6185,"conditions":26649,"interventions":26650},"NCT05517837","A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants",[86],"2023-07-14",[18],[26640],{"trials":26652,"activeCount":98},[],{"trials":26654,"activeCount":98},[],{"trials":26656,"activeCount":98},[],{"trials":26658,"activeCount":98},[],{"trials":26660,"activeCount":98},[],{"intervention":1197,"totalTrials":217,"cells":26662},{"EARLY_PHASE1":26663,"PHASE1":26665,"PHASE2":26718,"PHASE3":26907,"PHASE4":26950,"NA":26958},{"trials":26664,"activeCount":98},[],{"trials":26666,"activeCount":98},[26667,26674,26680,26689,26693,26699,26703,26707,26711],{"nctId":26668,"briefTitle":26669,"status":104,"phases":26670,"primaryCompletion":2128,"completion":12615,"start":26671,"enrollment":227,"conditions":26672,"interventions":26673},"NCT00306202","Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia",[87],"2006-03-31",[15736],[1197,1197,1197],{"nctId":26675,"briefTitle":26676,"status":104,"phases":26677,"primaryCompletion":9361,"completion":9361,"start":4931,"enrollment":713,"conditions":26678,"interventions":26679},"NCT00339144","Study of Dasatinib (BMS-354825) in Patients With Solid Tumors",[87],[1865],[1197,1197,1197],{"nctId":26681,"briefTitle":26682,"status":104,"phases":26683,"primaryCompletion":12220,"completion":12220,"start":26684,"conditions":26685,"interventions":26688},"NCT00103701","BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia",[87],"2003-11",[26686,26687],"Leukemia, Myeloid, Chronic-phase","Leukemia, Lymphoblastic, Acute, Philadelphia-positive",[1197],{"nctId":5961,"briefTitle":5962,"status":104,"phases":26690,"primaryCompletion":3586,"completion":3586,"start":4664,"enrollment":3162,"conditions":26691,"interventions":26692},[87],[5965],[1197,611],{"nctId":26694,"briefTitle":26695,"status":104,"phases":26696,"primaryCompletion":9361,"completion":9361,"start":5098,"enrollment":6185,"conditions":26697,"interventions":26698},"NCT00978731","Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study",[87],[15736],[1197],{"nctId":1189,"briefTitle":1190,"status":104,"phases":26700,"primaryCompletion":1192,"completion":1192,"start":1193,"enrollment":1063,"conditions":26701,"interventions":26702},[87],[1195],[1197,43],{"nctId":6175,"briefTitle":6176,"status":963,"phases":26704,"primaryCompletion":3938,"completion":3938,"start":3680,"enrollment":713,"conditions":26705,"interventions":26706},[87],[33],[1197,1796,1795],{"nctId":26281,"briefTitle":26282,"status":467,"phases":26708,"primaryCompletion":3679,"completion":3679,"start":4459,"enrollment":98,"conditions":26709,"interventions":26710},[87],[17473],[1197,26274,1197,26274],{"nctId":26712,"briefTitle":26713,"status":104,"phases":26714,"primaryCompletion":4010,"completion":4010,"start":26715,"enrollment":582,"conditions":26716,"interventions":26717},"NCT00099606","Phase I (PH I) Mad Refractory Solid Tumor Study",[87],"2004-07",[7156],[1197],{"trials":26719,"activeCount":98},[26720,26724,26733,26737,26743,26752,26756,26763,26771,26777,26783,26790,26794,26801,26808,26815,26824,26831,26835,26845,26851,26858,26865,26869,26875,26884,26890,26894,26898],{"nctId":1409,"briefTitle":1410,"status":963,"phases":26721,"primaryCompletion":1412,"completion":1412,"start":1413,"enrollment":1414,"conditions":26722,"interventions":26723},[88],[1154],[43,1197,52,608,1337],{"nctId":26725,"briefTitle":26726,"status":104,"phases":26727,"primaryCompletion":26728,"completion":26729,"start":26730,"enrollment":2028,"conditions":26731,"interventions":26732},"NCT00529763","Dasatinib in Imatinib Resistant\u002FIntolerant Chinese CML (Chronic and Advanced Phase) Subjects",[88],"2009-06-17","2022-04-20","2007-11-17",[15736],[1197],{"nctId":16689,"briefTitle":16690,"status":104,"phases":26734,"primaryCompletion":3017,"completion":3017,"start":7715,"enrollment":3862,"conditions":26735,"interventions":26736},[88],[16693],[1197,15799],{"nctId":26738,"briefTitle":26739,"status":104,"phases":26740,"primaryCompletion":9361,"completion":9361,"start":7846,"enrollment":7633,"conditions":26741,"interventions":26742},"NCT00371254","A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer",[88],[1223,4935],[1197,1197],{"nctId":26744,"briefTitle":26745,"status":104,"phases":26746,"primaryCompletion":26747,"completion":6362,"start":26748,"enrollment":26749,"conditions":26750,"interventions":26751},"NCT00777036","A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib",[88],"2016-09-01","2009-03-20",133,[15736],[1197],{"nctId":15732,"briefTitle":15733,"status":104,"phases":26753,"primaryCompletion":3958,"completion":3958,"start":3894,"enrollment":736,"conditions":26754,"interventions":26755},[87,88],[15736],[1197,3621],{"nctId":26757,"briefTitle":26758,"status":104,"phases":26759,"primaryCompletion":11762,"completion":15783,"start":7713,"enrollment":31,"conditions":26760,"interventions":26761},"NCT00764309","Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis",[87,88],[16290],[26762],"dasatinib",{"nctId":26764,"briefTitle":26765,"status":104,"phases":26766,"primaryCompletion":26767,"completion":26767,"start":11930,"enrollment":5543,"conditions":26768,"interventions":26770},"NCT02297139","Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib",[88],"2022-05-15",[26769],"Multiple Indications Cancer",[1197],{"nctId":26772,"briefTitle":26773,"status":104,"phases":26774,"primaryCompletion":6968,"completion":6968,"start":12930,"enrollment":17469,"conditions":26775,"interventions":26776},"NCT00101595","Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",[88],[1195,26687],[1197],{"nctId":26778,"briefTitle":26779,"status":104,"phases":26780,"primaryCompletion":3920,"completion":3920,"start":5078,"enrollment":725,"conditions":26781,"interventions":26782},"NCT00337454","Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan",[87,88],[21237],[1197,1197,1197,1197,1197,1197],{"nctId":26784,"briefTitle":26785,"status":963,"phases":26786,"primaryCompletion":10431,"completion":10431,"start":4379,"enrollment":3162,"conditions":26787,"interventions":26788},"NCT00320190","Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib",[88],[3940],[26789,1197],"Imatinib",{"nctId":19183,"briefTitle":19184,"status":104,"phases":26791,"primaryCompletion":4981,"completion":4459,"start":7846,"enrollment":1695,"conditions":26792,"interventions":26793},[88],[1223,4935],[1197,19174],{"nctId":26795,"briefTitle":26796,"status":104,"phases":26797,"primaryCompletion":3712,"completion":3712,"start":4995,"enrollment":890,"conditions":26798,"interventions":26800},"NCT01030718","Rollover Study of BMS-354825 in Patients With CML and Ph+ALL",[87,88],[21237,26799],"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",[26762],{"nctId":26802,"briefTitle":26803,"status":104,"phases":26804,"primaryCompletion":13053,"completion":7811,"start":7812,"enrollment":14347,"conditions":26805,"interventions":26807},"NCT00101660","Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib",[88],[1195,26806],"Philadelphia-Positive Myeloid Leukemia",[1197],{"nctId":26809,"briefTitle":26810,"status":104,"phases":26811,"primaryCompletion":1342,"completion":1342,"start":4179,"enrollment":26812,"conditions":26813,"interventions":26814},"NCT00982488","Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",[88],238,[15736],[1197,26789],{"nctId":26816,"briefTitle":26817,"status":104,"phases":26818,"primaryCompletion":26819,"completion":26820,"start":1832,"enrollment":116,"conditions":26821,"interventions":26823},"NCT01850004","Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response",[88],"2017-09-20","2021-10-08",[26822],"Chronic Phase Chronic Myeloid Leukemia",[1197],{"nctId":26825,"briefTitle":26826,"status":104,"phases":26827,"primaryCompletion":4459,"completion":4459,"start":7742,"enrollment":2038,"conditions":26828,"interventions":26830},"NCT00482703","A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia",[87,88],[26829],"Myeloid Leukemia, Chronic",[1197,26762],{"nctId":6434,"briefTitle":6435,"status":104,"phases":26832,"primaryCompletion":6437,"completion":3903,"start":4010,"enrollment":790,"conditions":26833,"interventions":26834},[87,88],[6439],[1197,1328],{"nctId":26836,"briefTitle":26837,"status":104,"phases":26838,"primaryCompletion":26839,"completion":26840,"start":26841,"enrollment":26842,"conditions":26843,"interventions":26844},"NCT01593254","Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib",[88],"2017-11-08","2022-04-12","2012-09-12",262,[26822],[26789,1197],{"nctId":26846,"briefTitle":26847,"status":104,"phases":26848,"primaryCompletion":4379,"completion":5023,"start":7812,"enrollment":331,"conditions":26849,"interventions":26850},"NCT00103844","Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia",[88],[1195,26806],[1197,26789],{"nctId":26852,"briefTitle":26853,"status":104,"phases":26854,"primaryCompletion":4664,"completion":4664,"start":13679,"enrollment":2563,"conditions":26855,"interventions":26857},"NCT00298987","A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate",[88],[3940,26856],"Leukemia, Lymphocytic, Acute, L2",[1197],{"nctId":26859,"briefTitle":26860,"status":104,"phases":26861,"primaryCompletion":4379,"completion":5023,"start":10693,"enrollment":15837,"conditions":26862,"interventions":26864},"NCT00101816","Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate",[88],[1195,26863],"Blast Crisis",[1197],{"nctId":15739,"briefTitle":15740,"status":963,"phases":26866,"primaryCompletion":8038,"completion":8038,"start":5541,"enrollment":22,"conditions":26867,"interventions":26868},[88],[15736],[1197,3621],{"nctId":26870,"briefTitle":26871,"status":104,"phases":26872,"primaryCompletion":4379,"completion":5023,"start":10693,"enrollment":2969,"conditions":26873,"interventions":26874},"NCT00101647","Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia",[88],[21237],[1197],{"nctId":26876,"briefTitle":26877,"status":104,"phases":26878,"primaryCompletion":26879,"completion":16470,"start":26880,"enrollment":413,"conditions":26881,"interventions":26883},"NCT01460160","Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia",[88],"2017-05-28","2012-04-13",[26882],"Leukemia, Pediatric",[1197],{"nctId":26885,"briefTitle":26886,"status":104,"phases":26887,"primaryCompletion":6953,"completion":7706,"start":4931,"enrollment":378,"conditions":26888,"interventions":26889},"NCT00385580","Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer",[88],[1504],[26762,26762],{"nctId":20421,"briefTitle":20422,"status":963,"phases":26891,"primaryCompletion":7776,"completion":7776,"start":3678,"enrollment":11958,"conditions":26892,"interventions":26893},[87,88],[20425],[1197,20412],{"nctId":9357,"briefTitle":9358,"status":104,"phases":26895,"primaryCompletion":3960,"completion":9360,"start":9361,"enrollment":660,"conditions":26896,"interventions":26897},[88],[5965],[1197,9331],{"nctId":26899,"briefTitle":26900,"status":963,"phases":26901,"primaryCompletion":26902,"completion":26902,"start":26903,"enrollment":1307,"conditions":26904,"interventions":26906},"NCT01514864","Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation",[88],"2014-07-23","2012-05-31",[26905],"Carcinoma, Non-small Cell Lung",[1197],{"trials":26908,"activeCount":98},[26909,26916,26922,26930,26937,26941],{"nctId":26910,"briefTitle":26911,"status":467,"phases":26912,"primaryCompletion":4931,"start":7846,"enrollment":98,"conditions":26913,"interventions":26915},"NCT00349518","Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL",[88,89],[1195,26914],"Acute Lymphoblastic Leukemia",[1197],{"nctId":26917,"briefTitle":26918,"status":963,"phases":26919,"primaryCompletion":11511,"completion":11511,"start":6960,"enrollment":574,"conditions":26920,"interventions":26921},"NCT00362466","A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy",[89],[15736],[1197,26789],{"nctId":26923,"briefTitle":26924,"status":104,"phases":26925,"primaryCompletion":5014,"completion":26926,"start":11728,"enrollment":26927,"conditions":26928,"interventions":26929},"NCT00481247","A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia",[89],"2015-12",547,[26829],[1197,26789],{"nctId":26931,"briefTitle":26932,"status":104,"phases":26933,"primaryCompletion":13053,"completion":4122,"start":5078,"enrollment":26934,"conditions":26935,"interventions":26936},"NCT00123474","Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML",[89],724,[24075],[26762,26762,26762,26762],{"nctId":6476,"briefTitle":6477,"status":104,"phases":26938,"primaryCompletion":6479,"completion":4347,"start":6480,"enrollment":6481,"conditions":26939,"interventions":26940},[89],[6483],[1197,1328,1507],{"nctId":26942,"briefTitle":26943,"status":104,"phases":26944,"primaryCompletion":13061,"completion":3630,"start":11251,"enrollment":26945,"conditions":26946,"interventions":26949},"NCT00123487","Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML",[89],638,[26947,26948],"Myeloid Leukemia, Chronic, Accelerated Phase","Leukemia, Lymphoblastic, Acute, Philadelphia-Positive",[26762,26762],{"trials":26951,"activeCount":98},[26952],{"nctId":26953,"briefTitle":26954,"status":104,"phases":26955,"primaryCompletion":847,"completion":847,"start":3977,"enrollment":4579,"conditions":26956,"interventions":26957},"NCT01660906","Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib",[90],[26822],[1197],{"trials":26959,"activeCount":98},[26960,26969,26976,26984,26990],{"nctId":26961,"briefTitle":26962,"status":104,"phases":26963,"primaryCompletion":26926,"completion":6184,"start":26926,"enrollment":26964,"conditions":26965,"interventions":26967},"NCT02733445","Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib",[],2650,[26966],"Chronic Myeloid Leukemia (CML)",[26762,26968],"nilotinib",{"nctId":26970,"briefTitle":26971,"status":104,"phases":26972,"primaryCompletion":1915,"completion":1596,"start":26973,"enrollment":1916,"conditions":26974,"interventions":26975},"NCT02546791","Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study",[],"2015-07-22",[15736],[1197],{"nctId":26977,"briefTitle":26978,"status":104,"phases":26979,"primaryCompletion":15251,"completion":15251,"start":6987,"enrollment":26980,"conditions":26981,"interventions":26983},"NCT02389972","Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study",[],128,[26982],"Leukemia, Myelogenous, Chronic, BCR-ABL Positive",[1197],{"nctId":26985,"briefTitle":26986,"status":3014,"phases":26987,"conditions":26988,"interventions":26989},"NCT00454753","Expanded Access for Dasatinib",[],[],[1197],{"nctId":26991,"briefTitle":26992,"status":104,"phases":26993,"primaryCompletion":10821,"completion":10821,"start":5042,"enrollment":3562,"conditions":26994,"interventions":26996},"NCT00382668","A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug",[],[26995],"Liver Diseases",[1197,1197,1197],{"intervention":11001,"totalTrials":3562,"cells":26998},{"EARLY_PHASE1":26999,"PHASE1":27001,"PHASE2":27066,"PHASE3":27094,"PHASE4":27152,"NA":27181},{"trials":27000,"activeCount":98},[],{"trials":27002,"activeCount":98},[27003,27009,27017,27025,27029,27033,27040,27044,27050,27054,27060],{"nctId":27004,"briefTitle":27005,"status":104,"phases":27006,"primaryCompletion":3960,"completion":3960,"start":5542,"enrollment":680,"conditions":27007,"interventions":27008},"NCT02034591","Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects",[87],[850],[11001],{"nctId":27010,"briefTitle":27011,"status":963,"phases":27012,"primaryCompletion":12309,"completion":27013,"start":27014,"enrollment":137,"conditions":27015,"interventions":27016},"NCT01195727","Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter",[87],"2012-07-16","2011-07-26",[11130],[11001],{"nctId":27018,"briefTitle":27019,"status":104,"phases":27020,"primaryCompletion":7914,"completion":7914,"start":27021,"enrollment":790,"conditions":27022,"interventions":27024},"NCT01707394","Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder",[87],"2013-01-10",[27023],"Thromboembolism",[11001],{"nctId":20866,"briefTitle":20867,"status":104,"phases":27026,"primaryCompletion":12220,"completion":12220,"start":4995,"enrollment":1203,"conditions":27027,"interventions":27028},[87],[20870],[11001,6535],{"nctId":24566,"briefTitle":24567,"status":104,"phases":27030,"primaryCompletion":4664,"completion":4664,"start":4664,"enrollment":1385,"conditions":27031,"interventions":27032},[87],[20870],[11001,24559],{"nctId":27034,"briefTitle":27035,"status":104,"phases":27036,"primaryCompletion":5541,"completion":5541,"start":7089,"enrollment":693,"conditions":27037,"interventions":27039},"NCT01340586","Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis",[87],[27038],"End Stage Renal Disease",[11001,11001],{"nctId":25277,"briefTitle":25278,"status":104,"phases":27041,"primaryCompletion":16214,"completion":16214,"start":16179,"enrollment":319,"conditions":27042,"interventions":27043},[87],[11130],[11001,25270],{"nctId":27045,"briefTitle":27046,"status":104,"phases":27047,"primaryCompletion":5850,"completion":5850,"start":7714,"enrollment":16044,"conditions":27048,"interventions":27049},"NCT02034578","Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects",[87],[27],[11001],{"nctId":25514,"briefTitle":25515,"status":104,"phases":27051,"primaryCompletion":4289,"completion":4289,"start":4551,"enrollment":11991,"conditions":27052,"interventions":27053},[87],[25518],[11001,25507,25520],{"nctId":27055,"briefTitle":27056,"status":104,"phases":27057,"primaryCompletion":4159,"completion":4159,"start":12170,"enrollment":8039,"conditions":27058,"interventions":27059},"NCT02101112","Bioavailability of Apixaban Crushed Tablet",[87],[11063],[11001],{"nctId":27061,"briefTitle":27062,"status":104,"phases":27063,"primaryCompletion":7088,"completion":7088,"start":3617,"enrollment":725,"conditions":27064,"interventions":27065},"NCT02034565","Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects",[87],[27],[11001],{"trials":27067,"activeCount":98},[27068,27074,27082,27090],{"nctId":27069,"briefTitle":27070,"status":104,"phases":27071,"primaryCompletion":7713,"completion":7713,"start":5117,"enrollment":3322,"conditions":27072,"interventions":27073},"NCT00320255","A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer",[88],[11063,606,12462],[11001],{"nctId":27075,"briefTitle":27076,"status":104,"phases":27077,"primaryCompletion":7750,"completion":7750,"start":3657,"enrollment":27078,"conditions":27079,"interventions":27081},"NCT00252005","Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study",[88],520,[27080],"Deep-Vein Thrombosis",[11001],{"nctId":27083,"briefTitle":27084,"status":104,"phases":27085,"primaryCompletion":5873,"completion":5873,"start":4023,"enrollment":27086,"conditions":27087,"interventions":27089},"NCT00313300","Safety Study of Apixaban in Recent Acute Coronary Syndrome",[88],1741,[27088],"Acute Coronary Syndrome (ACS)",[11001,11001,11001],{"nctId":11057,"briefTitle":11058,"status":104,"phases":27091,"primaryCompletion":3084,"completion":3084,"start":11060,"enrollment":11061,"conditions":27092,"interventions":27093},[88],[11063],[11001,11065,11066],{"trials":27095,"activeCount":98},[27096,27104,27112,27116,27120,27124,27133,27137,27141,27145],{"nctId":27097,"briefTitle":27098,"status":104,"phases":27099,"primaryCompletion":27100,"completion":27100,"start":27101,"enrollment":11999,"conditions":27102,"interventions":27103},"NCT02369653","A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase",[89],"2021-07-07","2015-10-22",[1426,26914],[11001],{"nctId":27105,"briefTitle":27106,"status":963,"phases":27107,"primaryCompletion":11034,"completion":11034,"start":4981,"enrollment":27108,"conditions":27109,"interventions":27111},"NCT00831441","Phase III Acute Coronary Syndrome",[89],7484,[27110],"Acute Coronary Syndrome",[11001],{"nctId":12456,"briefTitle":12457,"status":104,"phases":27113,"primaryCompletion":7776,"completion":7776,"start":4664,"enrollment":12459,"conditions":27114,"interventions":27115},[89],[12461,12462],[11001,12435],{"nctId":12465,"briefTitle":12466,"status":104,"phases":27117,"primaryCompletion":5098,"completion":5098,"start":12468,"enrollment":12469,"conditions":27118,"interventions":27119},[88,89],[12461,12462],[11001,12435,12472,12473,12474],{"nctId":12476,"briefTitle":12477,"status":104,"phases":27121,"primaryCompletion":7713,"completion":7713,"start":4664,"enrollment":12479,"conditions":27122,"interventions":27123},[89],[12481,12462],[12435,11001],{"nctId":27125,"briefTitle":27126,"status":104,"phases":27127,"primaryCompletion":27128,"completion":27128,"start":11776,"enrollment":27129,"conditions":27130,"interventions":27132},"NCT00412984","Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation",[89],"2011-05-25",20976,[10858,27131],"Atrial Flutter",[12490,12491],{"nctId":10993,"briefTitle":10994,"status":104,"phases":27134,"primaryCompletion":10996,"completion":1306,"start":10997,"enrollment":10998,"conditions":27135,"interventions":27136},[89],[10858],[11001,10982],{"nctId":12484,"briefTitle":12485,"status":104,"phases":27138,"primaryCompletion":4123,"completion":4123,"start":4039,"enrollment":12487,"conditions":27139,"interventions":27140},[89],[12461],[12435,12490,12491],{"nctId":12493,"briefTitle":12494,"status":104,"phases":27142,"primaryCompletion":4038,"completion":4038,"start":3920,"enrollment":12496,"conditions":27143,"interventions":27144},[89],[12481,12462],[12435,11001],{"nctId":27146,"briefTitle":27147,"status":104,"phases":27148,"primaryCompletion":6479,"completion":6479,"start":5873,"enrollment":27149,"conditions":27150,"interventions":27151},"NCT00633893","Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism",[89],2711,[12461],[11001],{"trials":27153,"activeCount":98},[27154,27158,27168,27177],{"nctId":11124,"briefTitle":11125,"status":104,"phases":27155,"primaryCompletion":11127,"completion":11127,"start":11128,"enrollment":2336,"conditions":27156,"interventions":27157},[90],[11130],[11001,11111],{"nctId":27159,"briefTitle":27160,"status":104,"phases":27161,"primaryCompletion":27162,"completion":27162,"start":27163,"enrollment":27164,"conditions":27165,"interventions":27167},"NCT01884350","Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)",[90],"2016-01-20","2013-10-15",1217,[27166],"Non-valvular Atrial Fibrillation",[11001],{"nctId":27169,"briefTitle":27170,"status":104,"phases":27171,"primaryCompletion":27172,"completion":27172,"start":27173,"enrollment":27174,"conditions":27175,"interventions":27176},"NCT01884337","Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery",[90],"2018-06-04","2015-03-24",557,[25518],[11001],{"nctId":11005,"briefTitle":11006,"status":104,"phases":27178,"primaryCompletion":11008,"completion":11008,"start":11009,"enrollment":11010,"conditions":27179,"interventions":27180},[90],[11012],[11001,11014,10982],{"trials":27182,"activeCount":98},[27183,27190,27197,27210,27217,27223,27229,27240,27250,27257,27265],{"nctId":27184,"briefTitle":27185,"status":467,"phases":27186,"primaryCompletion":4528,"completion":4528,"start":4289,"enrollment":98,"conditions":27187,"interventions":27189},"NCT02153424","Early Post-marketing Study of Eliquis (Apixaban)",[],[27188],"Non-valvular Atrial Fibrillation (NVAF)",[11001],{"nctId":27191,"briefTitle":27192,"status":104,"phases":27193,"primaryCompletion":5841,"completion":5841,"start":847,"enrollment":27194,"conditions":27195,"interventions":27196},"NCT02714855","Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France",[],2081,[25518],[11001],{"nctId":27198,"briefTitle":27199,"status":104,"phases":27200,"primaryCompletion":27201,"completion":27202,"start":27203,"enrollment":27204,"conditions":27205,"interventions":27206},"NCT02640222","APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study",[],"2016-12-31","2019-12-31","2014-01-01",321501,[25518],[27207,11001,27208,27209],"VKA","dabigatran","rivaroxaban",{"nctId":27211,"briefTitle":27212,"status":104,"phases":27213,"primaryCompletion":10525,"completion":10525,"start":7927,"enrollment":27214,"conditions":27215,"interventions":27216},"NCT02792335","Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients",[],28000,[10858],[12491,27208,27209,12490],{"nctId":27218,"briefTitle":27219,"status":104,"phases":27220,"primaryCompletion":4980,"completion":4980,"start":4122,"enrollment":660,"conditions":27221,"interventions":27222},"NCT01885585","Eliquis Regulatory Post Marketing Surveillance (rPMS)",[],[11130],[11001],{"nctId":27224,"briefTitle":27225,"status":6870,"phases":27226,"conditions":27227,"interventions":27228},"NCT05187286","Expanded Access for Apixaban",[],[],[11001],{"nctId":27230,"briefTitle":27231,"status":104,"phases":27232,"primaryCompletion":27233,"completion":27233,"start":27234,"enrollment":27235,"conditions":27236,"interventions":27237},"NCT03189069","A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage",[],"2017-05-31","2016-10-06",36000,[10858],[11001,27238,27239,12472],"Dabigatran","Rivaroxaban",{"nctId":27241,"briefTitle":27242,"status":104,"phases":27243,"primaryCompletion":27244,"completion":27244,"start":27245,"enrollment":27246,"conditions":27247,"interventions":27249},"NCT01885598","Eliquis Regulatory Post Marketing Surveillance",[],"2017-09-29","2013-07-10",3335,[27248],"NonValvular Atrial Fibrillation",[11001],{"nctId":27251,"briefTitle":27252,"status":104,"phases":27253,"primaryCompletion":8030,"completion":8030,"start":7690,"enrollment":27254,"conditions":27255,"interventions":27256},"NCT02769078","Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S",[],14201,[10858],[27208,27209,12491,12490],{"nctId":27258,"briefTitle":27259,"status":104,"phases":27260,"primaryCompletion":27261,"completion":27261,"start":27262,"enrollment":660,"conditions":27263,"interventions":27264},"NCT02345343","Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico",[],"2015-10-07","2015-05-04",[12481,12462],[11001],{"nctId":27266,"briefTitle":27267,"status":104,"phases":27268,"primaryCompletion":1192,"completion":1192,"start":27269,"enrollment":27270,"conditions":27271,"interventions":27272},"NCT02754154","Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants",[],"2014-12-31",321182,[10858],[12472,11001,27238,27239],{"intervention":10402,"totalTrials":4579,"cells":27274},{"EARLY_PHASE1":27275,"PHASE1":27277,"PHASE2":27295,"PHASE3":27371,"PHASE4":27465,"NA":27467},{"trials":27276,"activeCount":98},[],{"trials":27278,"activeCount":98},[27279,27285,27289],{"nctId":27280,"briefTitle":27281,"status":104,"phases":27282,"primaryCompletion":3630,"completion":3630,"start":3616,"enrollment":2308,"conditions":27283,"interventions":27284},"NCT01830205","Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment",[87],[30],[10402],{"nctId":10397,"briefTitle":10398,"status":104,"phases":27286,"primaryCompletion":4122,"completion":4122,"start":3017,"enrollment":790,"conditions":27287,"interventions":27288},[87],[30],[10402,10403,902,10404],{"nctId":27290,"briefTitle":27291,"status":104,"phases":27292,"primaryCompletion":4160,"completion":4160,"start":1342,"enrollment":506,"conditions":27293,"interventions":27294},"NCT02323594","A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir",[87],[11904],[10402,10402,11943,10402],{"trials":27296,"activeCount":98},[27297,27301,27305,27309,27315,27323,27327,27335,27341,27345,27349,27353,27359,27363,27367],{"nctId":12778,"briefTitle":11979,"status":104,"phases":27298,"primaryCompletion":4289,"completion":11981,"start":4123,"enrollment":11982,"conditions":27299,"interventions":27300},[88],[30],[11985,12782,10402],{"nctId":18138,"briefTitle":18139,"status":104,"phases":27302,"primaryCompletion":3711,"completion":11742,"start":3902,"enrollment":1597,"conditions":27303,"interventions":27304},[88],[11842],[10402,18129,11917],{"nctId":12845,"briefTitle":12846,"status":104,"phases":27306,"primaryCompletion":5022,"completion":6479,"start":4348,"enrollment":12848,"conditions":27307,"interventions":27308},[88],[11842],[10402,10402,12836,12003],{"nctId":27310,"briefTitle":27311,"status":104,"phases":27312,"primaryCompletion":5873,"completion":5873,"start":7758,"enrollment":24318,"conditions":27313,"interventions":27314},"NCT00546715","A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects",[87,88],[11923],[10402],{"nctId":27316,"briefTitle":27317,"status":963,"phases":27318,"primaryCompletion":858,"completion":8463,"start":27319,"enrollment":520,"conditions":27320,"interventions":27322},"NCT03487848","Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection",[88],"2018-06-25",[30,27321],"Chronic Hepatitis",[10402,13134],{"nctId":18615,"briefTitle":18616,"status":104,"phases":27324,"primaryCompletion":3903,"completion":4378,"start":7089,"enrollment":3370,"conditions":27325,"interventions":27326},[88],[11923],[18606,10402,11917],{"nctId":27328,"briefTitle":27329,"status":467,"phases":27330,"primaryCompletion":27331,"completion":27332,"start":26926,"enrollment":98,"conditions":27333,"interventions":27334},"NCT02556086","A Phase 2b Evaluation of Daclatasvir\u002FSofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)",[88],"2016-06","2017-07",[30],[10402,13134],{"nctId":27336,"briefTitle":27337,"status":467,"phases":27338,"primaryCompletion":27331,"completion":15226,"start":26926,"enrollment":98,"conditions":27339,"interventions":27340},"NCT02551861","A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3",[88],[30],[10402,13134,11917],{"nctId":19908,"briefTitle":19909,"status":467,"phases":27342,"primaryCompletion":4551,"completion":3017,"start":4123,"enrollment":98,"conditions":27343,"interventions":27344},[88],[11842],[10402,10402,19899,19899,19899,11917],{"nctId":12555,"briefTitle":12556,"status":104,"phases":27346,"primaryCompletion":11981,"completion":1342,"start":5541,"enrollment":12558,"conditions":27347,"interventions":27348},[88],[11896],[10402,11943,12542,11917],{"nctId":12562,"briefTitle":12563,"status":963,"phases":27350,"primaryCompletion":3711,"completion":3711,"start":6225,"enrollment":4255,"conditions":27351,"interventions":27352},[88],[30],[12567,12567,12567,12542,11917,12567,10402],{"nctId":27354,"briefTitle":27355,"status":104,"phases":27356,"primaryCompletion":3712,"completion":3712,"start":5873,"enrollment":10432,"conditions":27357,"interventions":27358},"NCT00663208","A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects",[88],[11923],[10402],{"nctId":12295,"briefTitle":12296,"status":104,"phases":27360,"primaryCompletion":5542,"completion":5542,"start":5014,"enrollment":7633,"conditions":27361,"interventions":27362},[88],[11904],[10402,10402,12300,11917],{"nctId":17600,"briefTitle":17601,"status":104,"phases":27364,"primaryCompletion":3585,"completion":3894,"start":3712,"enrollment":19,"conditions":27365,"interventions":27366},[88],[11904],[10402,10402,10402,17605,12003],{"nctId":12569,"briefTitle":12570,"status":104,"phases":27368,"primaryCompletion":6225,"completion":3616,"start":6918,"enrollment":2538,"conditions":27369,"interventions":27370},[88],[11842],[10402,12542,11917],{"trials":27372,"activeCount":98},[27373,27379,27383,27387,27391,27395,27399,27403,27409,27413,27417,27425,27429,27433,27439,27443,27449,27453,27457],{"nctId":27374,"briefTitle":27375,"status":104,"phases":27376,"primaryCompletion":847,"completion":26926,"start":4160,"enrollment":28,"conditions":27377,"interventions":27378},"NCT02319031","Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis",[89],[30],[10402,13134,11917],{"nctId":13254,"briefTitle":13255,"status":963,"phases":27380,"primaryCompletion":13257,"completion":13257,"start":13258,"enrollment":13259,"conditions":27381,"interventions":27382},[89],[13261],[13263,10402,12782],{"nctId":12858,"briefTitle":12859,"status":104,"phases":27384,"primaryCompletion":6916,"completion":3959,"start":6225,"enrollment":12861,"conditions":27385,"interventions":27386},[89],[11842],[11943,10402,12864,11917],{"nctId":12316,"briefTitle":12317,"status":104,"phases":27388,"primaryCompletion":3959,"completion":12170,"start":7927,"enrollment":2517,"conditions":27389,"interventions":27390},[89],[30],[10402,12314,12300,11917],{"nctId":14442,"briefTitle":14443,"status":467,"phases":27392,"primaryCompletion":846,"completion":846,"start":3017,"enrollment":98,"conditions":27393,"interventions":27394},[89],[30],[14431,11917,10402],{"nctId":14463,"briefTitle":14464,"status":104,"phases":27396,"primaryCompletion":14466,"completion":14466,"start":14467,"enrollment":14468,"conditions":27397,"interventions":27398},[89],[11842],[14452,11917,10402],{"nctId":12820,"briefTitle":12821,"status":104,"phases":27400,"primaryCompletion":3959,"completion":1342,"start":3893,"enrollment":12823,"conditions":27401,"interventions":27402},[89],[11896],[10402,11943,11917,12826,12314],{"nctId":27404,"briefTitle":27405,"status":104,"phases":27406,"primaryCompletion":7690,"completion":8038,"start":12170,"enrollment":1898,"conditions":27407,"interventions":27408},"NCT02032875","Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant",[89],[30],[10402,13134,11917],{"nctId":13420,"briefTitle":13421,"status":104,"phases":27410,"primaryCompletion":4378,"completion":11981,"start":6225,"enrollment":6275,"conditions":27411,"interventions":27412},[89],[11842],[11943,10402,12038,11917],{"nctId":11938,"briefTitle":11939,"status":104,"phases":27414,"primaryCompletion":10525,"completion":7690,"start":3959,"enrollment":1096,"conditions":27415,"interventions":27416},[89],[30],[10402,11943,9391,11917],{"nctId":27418,"briefTitle":27419,"status":104,"phases":27420,"primaryCompletion":11930,"completion":11930,"start":27421,"enrollment":27422,"conditions":27423,"interventions":27424},"NCT01995266","Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual",[89],"2014-02-28",218,[30],[11943,10402],{"nctId":14722,"briefTitle":14723,"status":104,"phases":27426,"primaryCompletion":3017,"completion":11981,"start":3679,"enrollment":14725,"conditions":27427,"interventions":27428},[89],[14727],[10402,11917,14711],{"nctId":12577,"briefTitle":12578,"status":104,"phases":27430,"primaryCompletion":3017,"completion":11981,"start":3902,"enrollment":12580,"conditions":27431,"interventions":27432},[89],[12326],[12583,12583,12542,11917,11917,10402],{"nctId":27434,"briefTitle":27435,"status":104,"phases":27436,"primaryCompletion":11981,"completion":1342,"start":9360,"enrollment":7198,"conditions":27437,"interventions":27438},"NCT02032901","Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV",[89],[30],[10402,13134],{"nctId":14956,"briefTitle":14957,"status":104,"phases":27440,"primaryCompletion":14959,"completion":4458,"start":4289,"enrollment":10751,"conditions":27441,"interventions":27442},[89],[11896],[10402,11943,14945],{"nctId":27444,"briefTitle":27445,"status":104,"phases":27446,"primaryCompletion":6917,"completion":14959,"start":4551,"enrollment":26812,"conditions":27447,"interventions":27448},"NCT02032888","A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.",[89],[30],[10402,13134],{"nctId":12866,"briefTitle":12867,"status":104,"phases":27450,"primaryCompletion":6916,"completion":9360,"start":5541,"enrollment":12869,"conditions":27451,"interventions":27452},[89],[30],[10402,12872,11917],{"nctId":12329,"briefTitle":12330,"status":104,"phases":27454,"primaryCompletion":6917,"completion":6917,"start":3903,"enrollment":12332,"conditions":27455,"interventions":27456},[89],[30],[12313,12096,11917,10402,12314],{"nctId":27458,"briefTitle":27459,"status":104,"phases":27460,"primaryCompletion":8699,"completion":27461,"start":4458,"enrollment":27462,"conditions":27463,"interventions":27464},"NCT02496078","A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection",[89],"2017-02",207,[30],[10402,11943],{"trials":27466,"activeCount":98},[],{"trials":27468,"activeCount":98},[27469,27475],{"nctId":27470,"briefTitle":27471,"status":3014,"phases":27472,"conditions":27473,"interventions":27474},"NCT02097966","EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C",[],[11923],[10402,13134,11917],{"nctId":27476,"briefTitle":27477,"status":3014,"phases":27478,"conditions":27479,"interventions":27480},"NCT02161939","A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C",[],[11923],[10402,13134],{"intervention":11917,"totalTrials":4579,"cells":27482},{"EARLY_PHASE1":27483,"PHASE1":27485,"PHASE2":27491,"PHASE3":27573,"PHASE4":27643,"NA":27645},{"trials":27484,"activeCount":98},[],{"trials":27486,"activeCount":98},[27487],{"nctId":17102,"briefTitle":17103,"status":104,"phases":27488,"primaryCompletion":11034,"completion":7089,"start":7706,"enrollment":22,"conditions":27489,"interventions":27490},[87],[17106],[12567,12567,12567,12567,12567,12567,12567,11917],{"trials":27492,"activeCount":98},[27493,27497,27501,27505,27509,27513,27517,27521,27525,27529,27533,27537,27541,27545,27549,27553,27557,27561,27565,27569],{"nctId":18138,"briefTitle":18139,"status":104,"phases":27494,"primaryCompletion":3711,"completion":11742,"start":3902,"enrollment":1597,"conditions":27495,"interventions":27496},[88],[11842],[10402,18129,11917],{"nctId":12845,"briefTitle":12846,"status":104,"phases":27498,"primaryCompletion":5022,"completion":6479,"start":4348,"enrollment":12848,"conditions":27499,"interventions":27500},[88],[11842],[10402,10402,12836,12003],{"nctId":11911,"briefTitle":11912,"status":104,"phases":27502,"primaryCompletion":7089,"completion":3893,"start":7706,"enrollment":4579,"conditions":27503,"interventions":27504},[88],[11842],[9391,9391,11916,11917],{"nctId":11978,"briefTitle":11979,"status":104,"phases":27506,"primaryCompletion":4122,"completion":11981,"start":11034,"enrollment":11982,"conditions":27507,"interventions":27508},[88],[30],[11985,11934,11917,11933,11986,11985,11917,11985,11917,11934,11933],{"nctId":18615,"briefTitle":18616,"status":104,"phases":27510,"primaryCompletion":3903,"completion":4378,"start":7089,"enrollment":3370,"conditions":27511,"interventions":27512},[88],[11923],[18606,10402,11917],{"nctId":18815,"briefTitle":18816,"status":104,"phases":27514,"primaryCompletion":6225,"completion":6225,"start":5541,"enrollment":217,"conditions":27515,"interventions":27516},[87,88],[30],[18806,18820,18821,18822,12003],{"nctId":11995,"briefTitle":11996,"status":104,"phases":27518,"primaryCompletion":1343,"completion":3977,"start":11998,"enrollment":11999,"conditions":27519,"interventions":27520},[88],[11842],[11934,11934,12002,12003],{"nctId":17136,"briefTitle":17137,"status":467,"phases":27522,"primaryCompletion":6918,"completion":6918,"start":4348,"enrollment":98,"conditions":27523,"interventions":27524},[88],[17140],[17121,17121,17121,17142,11917],{"nctId":27336,"briefTitle":27337,"status":467,"phases":27526,"primaryCompletion":27331,"completion":15226,"start":26926,"enrollment":98,"conditions":27527,"interventions":27528},[88],[30],[10402,13134,11917],{"nctId":11926,"briefTitle":11927,"status":104,"phases":27530,"primaryCompletion":11929,"completion":11930,"start":6206,"enrollment":1823,"conditions":27531,"interventions":27532},[88],[11923],[11933,11934,9391,11917],{"nctId":12009,"briefTitle":12010,"status":104,"phases":27534,"primaryCompletion":3586,"completion":4551,"start":5014,"enrollment":11035,"conditions":27535,"interventions":27536},[88],[11923],[11934,11933,11933,11933,12014,11917],{"nctId":19908,"briefTitle":19909,"status":467,"phases":27538,"primaryCompletion":4551,"completion":3017,"start":4123,"enrollment":98,"conditions":27539,"interventions":27540},[88],[11842],[10402,10402,19899,19899,19899,11917],{"nctId":12555,"briefTitle":12556,"status":104,"phases":27542,"primaryCompletion":11981,"completion":1342,"start":5541,"enrollment":12558,"conditions":27543,"interventions":27544},[88],[11896],[10402,11943,12542,11917],{"nctId":12090,"briefTitle":12091,"status":104,"phases":27546,"primaryCompletion":3586,"completion":3586,"start":3617,"enrollment":12093,"conditions":27547,"interventions":27548},[88],[11842],[11933,11933,12096,12096,11917,11917],{"nctId":12562,"briefTitle":12563,"status":963,"phases":27550,"primaryCompletion":3711,"completion":3711,"start":6225,"enrollment":4255,"conditions":27551,"interventions":27552},[88],[30],[12567,12567,12567,12542,11917,12567,10402],{"nctId":12016,"briefTitle":12017,"status":104,"phases":27554,"primaryCompletion":3631,"completion":3631,"start":5014,"enrollment":6226,"conditions":27555,"interventions":27556},[88],[11904],[11934,11934,12021,11917],{"nctId":13126,"briefTitle":13127,"status":104,"phases":27558,"primaryCompletion":13129,"completion":13130,"start":13131,"enrollment":1063,"conditions":27559,"interventions":27560},[88],[30],[13117,11917,13134,13135],{"nctId":12295,"briefTitle":12296,"status":104,"phases":27562,"primaryCompletion":5542,"completion":5542,"start":5014,"enrollment":7633,"conditions":27563,"interventions":27564},[88],[11904],[10402,10402,12300,11917],{"nctId":17600,"briefTitle":17601,"status":104,"phases":27566,"primaryCompletion":3585,"completion":3894,"start":3712,"enrollment":19,"conditions":27567,"interventions":27568},[88],[11904],[10402,10402,10402,17605,12003],{"nctId":12569,"briefTitle":12570,"status":104,"phases":27570,"primaryCompletion":6225,"completion":3616,"start":6918,"enrollment":2538,"conditions":27571,"interventions":27572},[88],[11842],[10402,12542,11917],{"trials":27574,"activeCount":98},[27575,27579,27583,27587,27591,27595,27599,27603,27607,27611,27615,27619,27623,27627,27631,27635,27639],{"nctId":12304,"briefTitle":12305,"status":104,"phases":27576,"primaryCompletion":12307,"completion":12308,"start":12309,"enrollment":12310,"conditions":27577,"interventions":27578},[89],[11842],[12313,12096,11917,12314],{"nctId":27374,"briefTitle":27375,"status":104,"phases":27580,"primaryCompletion":847,"completion":26926,"start":4160,"enrollment":28,"conditions":27581,"interventions":27582},[89],[30],[10402,13134,11917],{"nctId":12858,"briefTitle":12859,"status":104,"phases":27584,"primaryCompletion":6916,"completion":3959,"start":6225,"enrollment":12861,"conditions":27585,"interventions":27586},[89],[11842],[11943,10402,12864,11917],{"nctId":12032,"briefTitle":12033,"status":104,"phases":27588,"primaryCompletion":4378,"completion":9360,"start":3679,"enrollment":12035,"conditions":27589,"interventions":27590},[89],[30],[11934,12038,11917],{"nctId":12316,"briefTitle":12317,"status":104,"phases":27592,"primaryCompletion":3959,"completion":12170,"start":7927,"enrollment":2517,"conditions":27593,"interventions":27594},[89],[30],[10402,12314,12300,11917],{"nctId":14442,"briefTitle":14443,"status":467,"phases":27596,"primaryCompletion":846,"completion":846,"start":3017,"enrollment":98,"conditions":27597,"interventions":27598},[89],[30],[14431,11917,10402],{"nctId":14463,"briefTitle":14464,"status":104,"phases":27600,"primaryCompletion":14466,"completion":14466,"start":14467,"enrollment":14468,"conditions":27601,"interventions":27602},[89],[11842],[14452,11917,10402],{"nctId":12820,"briefTitle":12821,"status":104,"phases":27604,"primaryCompletion":3959,"completion":1342,"start":3893,"enrollment":12823,"conditions":27605,"interventions":27606},[89],[11896],[10402,11943,11917,12826,12314],{"nctId":27404,"briefTitle":27405,"status":104,"phases":27608,"primaryCompletion":7690,"completion":8038,"start":12170,"enrollment":1898,"conditions":27609,"interventions":27610},[89],[30],[10402,13134,11917],{"nctId":13420,"briefTitle":13421,"status":104,"phases":27612,"primaryCompletion":4378,"completion":11981,"start":6225,"enrollment":6275,"conditions":27613,"interventions":27614},[89],[11842],[11943,10402,12038,11917],{"nctId":12322,"briefTitle":12323,"status":104,"phases":27616,"primaryCompletion":11981,"completion":11981,"start":4123,"enrollment":3562,"conditions":27617,"interventions":27618},[89],[12326],[12313,11917,12300],{"nctId":11938,"briefTitle":11939,"status":104,"phases":27620,"primaryCompletion":10525,"completion":7690,"start":3959,"enrollment":1096,"conditions":27621,"interventions":27622},[89],[30],[10402,11943,9391,11917],{"nctId":14722,"briefTitle":14723,"status":104,"phases":27624,"primaryCompletion":3017,"completion":11981,"start":3679,"enrollment":14725,"conditions":27625,"interventions":27626},[89],[14727],[10402,11917,14711],{"nctId":12577,"briefTitle":12578,"status":104,"phases":27628,"primaryCompletion":3017,"completion":11981,"start":3902,"enrollment":12580,"conditions":27629,"interventions":27630},[89],[12326],[12583,12583,12542,11917,11917,10402],{"nctId":12866,"briefTitle":12867,"status":104,"phases":27632,"primaryCompletion":6916,"completion":9360,"start":5541,"enrollment":12869,"conditions":27633,"interventions":27634},[89],[30],[10402,12872,11917],{"nctId":12329,"briefTitle":12330,"status":104,"phases":27636,"primaryCompletion":6917,"completion":6917,"start":3903,"enrollment":12332,"conditions":27637,"interventions":27638},[89],[30],[12313,12096,11917,10402,12314],{"nctId":12585,"briefTitle":12586,"status":467,"phases":27640,"primaryCompletion":12170,"completion":10525,"start":6169,"enrollment":98,"conditions":27641,"interventions":27642},[89],[12326],[11985,11986,11917],{"trials":27644,"activeCount":98},[],{"trials":27646,"activeCount":98},[27647],{"nctId":27470,"briefTitle":27471,"status":3014,"phases":27648,"conditions":27649,"interventions":27650},[],[11923],[10402,13134,11917],{"intervention":10680,"totalTrials":94,"cells":27652},{"EARLY_PHASE1":27653,"PHASE1":27655,"PHASE2":27657,"PHASE3":27704,"PHASE4":27772,"NA":27793},{"trials":27654,"activeCount":98},[],{"trials":27656,"activeCount":98},[],{"trials":27658,"activeCount":98},[27659,27665,27669,27675,27681,27687,27695],{"nctId":27660,"briefTitle":27661,"status":104,"phases":27662,"primaryCompletion":7812,"completion":7812,"start":7154,"enrollment":582,"conditions":27663,"interventions":27664},"NCT01020565","A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection",[88],[10764],[10680],{"nctId":18911,"briefTitle":18912,"status":104,"phases":27666,"primaryCompletion":3959,"completion":3959,"start":3904,"enrollment":2969,"conditions":27667,"interventions":27668},[88],[18915],[18902,18917,18918,10680],{"nctId":27670,"briefTitle":27671,"status":104,"phases":27672,"primaryCompletion":7812,"completion":7812,"start":5051,"enrollment":116,"conditions":27673,"interventions":27674},"NCT01037166","Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy",[88],[10764],[10680],{"nctId":27676,"briefTitle":27677,"status":104,"phases":27678,"primaryCompletion":7846,"completion":7846,"start":3640,"enrollment":9,"conditions":27679,"interventions":27680},"NCT01037062","An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection",[88],[10764],[10680],{"nctId":27682,"briefTitle":27683,"status":104,"phases":27684,"primaryCompletion":5050,"completion":5050,"start":10675,"enrollment":3862,"conditions":27685,"interventions":27686},"NCT01022801","A Phase II Dose Response Study in Japan in Chronic Hepatitis B",[88],[10764],[10680],{"nctId":27688,"briefTitle":27689,"status":104,"phases":27690,"primaryCompletion":5014,"completion":15783,"start":13336,"enrollment":27691,"conditions":27692,"interventions":27694},"NCT01438424","Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials",[88],1053,[18915,27693],"HBV",[10680,10466],{"nctId":27696,"briefTitle":27697,"status":104,"phases":27698,"primaryCompletion":27699,"completion":27700,"start":27701,"enrollment":3102,"conditions":27702,"interventions":27703},"NCT00423891","A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection",[87,88],"2013-08-31","2017-09-04","2007-06-30",[10687],[10680],{"trials":27705,"activeCount":98},[27706,27710,27716,27720,27727,27733,27739,27745,27751,27755,27759,27763],{"nctId":10672,"briefTitle":10673,"status":104,"phases":27707,"primaryCompletion":6480,"completion":10518,"start":10675,"enrollment":10676,"conditions":27708,"interventions":27709},[89],[10678],[10680,10661],{"nctId":27711,"briefTitle":27712,"status":104,"phases":27713,"primaryCompletion":5043,"completion":5043,"start":7643,"conditions":27714,"interventions":27715},"NCT00051038","Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients",[88,89],[10678],[10680],{"nctId":13366,"briefTitle":13367,"status":104,"phases":27717,"primaryCompletion":7706,"completion":7706,"start":6960,"enrollment":13369,"conditions":27718,"interventions":27719},[89],[10687],[10680,13355],{"nctId":27721,"briefTitle":27722,"status":104,"phases":27723,"primaryCompletion":10821,"completion":10821,"start":12230,"enrollment":271,"conditions":27724,"interventions":27726},"NCT00975091","Continue Entecavir Rollover From China",[89],[27725],"Chronic Hepatitis B Virus",[10680,10680],{"nctId":27728,"briefTitle":27729,"status":104,"phases":27730,"primaryCompletion":11034,"completion":11034,"start":6960,"enrollment":15897,"conditions":27731,"interventions":27732},"NCT00395018","Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection",[89],[10687],[10697],{"nctId":27734,"briefTitle":27735,"status":104,"phases":27736,"primaryCompletion":7812,"completion":7812,"start":10422,"conditions":27737,"interventions":27738},"NCT00036608","A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine",[89],[10764],[10680],{"nctId":27740,"briefTitle":27741,"status":104,"phases":27742,"primaryCompletion":4665,"completion":4665,"start":14035,"conditions":27743,"interventions":27744},"NCT00035789","A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen",[89],[10764],[10680],{"nctId":27746,"briefTitle":27747,"status":104,"phases":27748,"primaryCompletion":7812,"completion":7812,"start":10961,"conditions":27749,"interventions":27750},"NCT00035633","A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen",[89],[10764],[10680],{"nctId":10759,"briefTitle":10760,"status":104,"phases":27752,"primaryCompletion":3893,"completion":4551,"start":7944,"enrollment":10762,"conditions":27753,"interventions":27754},[89],[10764],[10680,8548],{"nctId":10682,"briefTitle":10683,"status":104,"phases":27756,"primaryCompletion":3894,"completion":3902,"start":5023,"enrollment":10685,"conditions":27757,"interventions":27758},[89],[10687],[10680,8548,10661,10466],{"nctId":10690,"briefTitle":10691,"status":104,"phases":27760,"primaryCompletion":4995,"completion":7811,"start":10693,"enrollment":8039,"conditions":27761,"interventions":27762},[89],[10678,10695],[10697,10698],{"nctId":27764,"briefTitle":27765,"status":104,"phases":27766,"primaryCompletion":14467,"completion":27767,"start":27768,"enrollment":3313,"conditions":27769,"interventions":27771},"NCT01079806","A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection",[89],"2018-03-31","2010-06-30",[27770],"Chronic Hepatitis B Virus, Pediatric",[10680],{"trials":27773,"activeCount":98},[27774,27778,27782,27786],{"nctId":10702,"briefTitle":10703,"status":467,"phases":27775,"primaryCompletion":3977,"completion":3017,"start":5014,"enrollment":98,"conditions":27776,"interventions":27777},[90],[10687],[10466,10680,10661],{"nctId":11549,"briefTitle":11550,"status":104,"phases":27779,"primaryCompletion":7713,"completion":6916,"start":7750,"enrollment":11552,"conditions":27780,"interventions":27781},[90],[10764],[10680,11536,10466,11555],{"nctId":11590,"briefTitle":11591,"status":104,"phases":27783,"primaryCompletion":5014,"completion":3894,"start":4039,"enrollment":11593,"conditions":27784,"interventions":27785},[90],[10687],[10680,11577],{"nctId":27787,"briefTitle":27788,"status":104,"phases":27789,"primaryCompletion":11034,"completion":11034,"start":13061,"enrollment":860,"conditions":27790,"interventions":27792},"NCT00371150","Effect of Entecavir in Blacks\u002FAfrican Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection",[90],[27791],"Hepatitis B Infection",[10680],{"trials":27794,"activeCount":98},[27795,27805],{"nctId":27796,"briefTitle":27797,"status":104,"phases":27798,"primaryCompletion":27799,"completion":27799,"start":27800,"enrollment":27801,"conditions":27802,"interventions":27803},"NCT00388674","Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection",[],"2016-10-26","2006-12-18",12522,[10764],[10697,27804],"Other anti-HBV medication",{"nctId":27806,"briefTitle":27807,"status":3014,"phases":27808,"primaryCompletion":7715,"completion":7715,"start":13035,"conditions":27809,"interventions":27810},"NCT00096811","Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program",[],[10678,10695],[10680],{"intervention":8547,"totalTrials":1203,"cells":27812},{"EARLY_PHASE1":27813,"PHASE1":27815,"PHASE2":27845,"PHASE3":27862,"PHASE4":27901,"NA":27925},{"trials":27814,"activeCount":98},[],{"trials":27816,"activeCount":98},[27817,27821,27825,27829,27833,27837,27841],{"nctId":21065,"briefTitle":21066,"status":104,"phases":27818,"primaryCompletion":21068,"completion":21069,"start":11228,"enrollment":3986,"conditions":27819,"interventions":27820},[87],[18],[8547,21048,21072],{"nctId":10818,"briefTitle":10819,"status":104,"phases":27822,"primaryCompletion":6968,"completion":6968,"start":10821,"enrollment":3978,"conditions":27823,"interventions":27824},[87],[24],[10435,8547,10824],{"nctId":10406,"briefTitle":10407,"status":104,"phases":27826,"primaryCompletion":4348,"completion":3938,"start":4038,"enrollment":12,"conditions":27827,"interventions":27828},[87],[10410,24],[6826,8547,902],{"nctId":10785,"briefTitle":10786,"status":104,"phases":27830,"primaryCompletion":4379,"completion":4379,"start":5117,"enrollment":7813,"conditions":27831,"interventions":27832},[87],[24],[8547,10646,10790,10790,8547,10646,10790,10790],{"nctId":25037,"briefTitle":25038,"status":104,"phases":27834,"primaryCompletion":5541,"completion":5541,"start":5850,"enrollment":1221,"conditions":27835,"interventions":27836},[87],[8545],[8547,25030,8547],{"nctId":21074,"briefTitle":21075,"status":104,"phases":27838,"primaryCompletion":3630,"completion":3630,"start":3958,"enrollment":3102,"conditions":27839,"interventions":27840},[87],[10410],[8547,21048,21079],{"nctId":21081,"briefTitle":21082,"status":104,"phases":27842,"primaryCompletion":5375,"completion":5375,"start":21084,"enrollment":830,"conditions":27843,"interventions":27844},[87],[21086],[8547,21048,883],{"trials":27846,"activeCount":98},[27847,27854,27858],{"nctId":27848,"briefTitle":27849,"status":104,"phases":27850,"primaryCompletion":10961,"completion":10961,"start":27851,"conditions":27852,"interventions":27853},"NCT00002240","Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs",[88],"1999-03",[24],[8547,13340,13341,13342],{"nctId":10419,"briefTitle":10420,"status":104,"phases":27855,"primaryCompletion":10422,"completion":10422,"start":10423,"conditions":27856,"interventions":27857},[88],[24],[8547,902,10426],{"nctId":10428,"briefTitle":10429,"status":963,"phases":27859,"primaryCompletion":10431,"completion":7944,"start":7784,"enrollment":10432,"conditions":27860,"interventions":27861},[88],[8545],[8547,10435,8547,902,10436],{"trials":27863,"activeCount":98},[27864,27868,27872,27876,27880,27884,27891,27895],{"nctId":10640,"briefTitle":10641,"status":104,"phases":27865,"primaryCompletion":8030,"completion":8030,"start":5079,"enrollment":10643,"conditions":27866,"interventions":27867},[89],[8545],[8547,10646,10436,10647],{"nctId":10440,"briefTitle":10441,"status":467,"phases":27869,"primaryCompletion":10443,"completion":10443,"start":10444,"enrollment":98,"conditions":27870,"interventions":27871},[89],[8545],[8547,10403,902,10447],{"nctId":10449,"briefTitle":10450,"status":104,"phases":27873,"primaryCompletion":10452,"completion":10453,"start":10454,"enrollment":1232,"conditions":27874,"interventions":27875},[89],[24],[10457,10458,8547,902],{"nctId":13344,"briefTitle":13345,"status":104,"phases":27877,"primaryCompletion":13347,"completion":13347,"start":13036,"conditions":27878,"interventions":27879},[89],[24],[8547,13322,9383],{"nctId":13032,"briefTitle":13033,"status":104,"phases":27881,"primaryCompletion":13035,"completion":13035,"start":13036,"conditions":27882,"interventions":27883},[89],[24],[8547,10404],{"nctId":27885,"briefTitle":27886,"status":963,"phases":27887,"primaryCompletion":12211,"completion":12211,"start":27888,"enrollment":290,"conditions":27889,"interventions":27890},"NCT00028067","A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor",[89],"2001-08",[24],[8547,13340],{"nctId":10460,"briefTitle":10461,"status":963,"phases":27892,"primaryCompletion":7114,"completion":7114,"start":10463,"enrollment":574,"conditions":27893,"interventions":27894},[89],[8545],[8547,902,10466,10436],{"nctId":27896,"briefTitle":27897,"status":104,"phases":27898,"primaryCompletion":5050,"completion":5050,"start":5051,"conditions":27899,"interventions":27900},"NCT00067782","A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy",[89],[24],[8547,8547],{"trials":27902,"activeCount":98},[27903,27907,27911,27915,27919],{"nctId":10481,"briefTitle":10482,"status":104,"phases":27904,"primaryCompletion":6916,"completion":4551,"start":5542,"enrollment":10484,"conditions":27905,"interventions":27906},[90],[10486],[8547,902,10435,10436],{"nctId":8541,"briefTitle":8542,"status":104,"phases":27908,"primaryCompletion":7089,"completion":7089,"start":3938,"enrollment":94,"conditions":27909,"interventions":27910},[90],[8545],[8547,8547,902,902,8548,8548,8549,8549,696,696],{"nctId":11508,"briefTitle":11509,"status":104,"phases":27912,"primaryCompletion":4010,"completion":11511,"start":5078,"enrollment":1945,"conditions":27913,"interventions":27914},[90],[11513],[8547,11495],{"nctId":10493,"briefTitle":10494,"status":104,"phases":27916,"primaryCompletion":10496,"completion":10497,"start":10498,"enrollment":7833,"conditions":27917,"interventions":27918},[90],[10500],[8547,902],{"nctId":27920,"briefTitle":27921,"status":963,"phases":27922,"primaryCompletion":6960,"completion":6960,"start":11251,"enrollment":22,"conditions":27923,"interventions":27924},"NCT00312754","A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome",[90],[24],[8547],{"trials":27926,"activeCount":98},[27927],{"nctId":27928,"briefTitle":27929,"status":3014,"phases":27930,"completion":12201,"start":12269,"conditions":27931,"interventions":27932},"NCT00046345","Atazanavir for HIV Infected Individuals: An Early Access Program",[],[24],[8547],{"intervention":13341,"totalTrials":5543,"cells":27934},{"EARLY_PHASE1":27935,"PHASE1":27937,"PHASE2":27939,"PHASE3":27953,"PHASE4":27988,"NA":27990},{"trials":27936,"activeCount":98},[],{"trials":27938,"activeCount":98},[],{"trials":27940,"activeCount":98},[27941,27945,27949],{"nctId":17362,"briefTitle":17363,"status":963,"phases":27942,"enrollment":94,"conditions":27943,"interventions":27944},[88],[24],[17353,17367,17368,13341,13342],{"nctId":27848,"briefTitle":27849,"status":104,"phases":27946,"primaryCompletion":10961,"completion":10961,"start":27851,"conditions":27947,"interventions":27948},[88],[24],[8547,13340,13341,13342],{"nctId":17370,"briefTitle":17371,"status":963,"phases":27950,"enrollment":94,"conditions":27951,"interventions":27952},[88],[24],[17353,17367,13099,13341,13342],{"trials":27954,"activeCount":98},[27955,27959,27968,27974,27982],{"nctId":13333,"briefTitle":13334,"status":104,"phases":27956,"primaryCompletion":13336,"completion":13336,"start":13337,"enrollment":290,"conditions":27957,"interventions":27958},[89],[24],[13322,13340,13341,13342],{"nctId":27960,"briefTitle":27961,"status":104,"phases":27962,"primaryCompletion":27963,"completion":27963,"start":7682,"enrollment":1863,"conditions":27964,"interventions":27965},"NCT00002371","The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine",[89],"1997-12",[24],[27966,10466,13341,27967],"Indinavir sulfate","Zidovudine",{"nctId":27969,"briefTitle":27970,"status":104,"phases":27971,"primaryCompletion":27851,"completion":27851,"start":27851,"enrollment":3862,"conditions":27972,"interventions":27973},"NCT00002224","Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)",[89],[24],[13340,13341,13342],{"nctId":27975,"briefTitle":27976,"status":104,"phases":27977,"primaryCompletion":27851,"completion":27851,"start":27978,"enrollment":319,"conditions":27979,"interventions":27981},"NCT00002246","A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex",[89],"1997-10",[27980,24],"AIDS Dementia Complex",[13341],{"nctId":27983,"briefTitle":27984,"status":104,"phases":27985,"primaryCompletion":12211,"completion":12211,"start":15041,"enrollment":16797,"conditions":27986,"interventions":27987},"NCT00005918","Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients",[89],[24],[9383,10466,13341],{"trials":27989,"activeCount":98},[],{"trials":27991,"activeCount":98},[27992,28000,28006,28013,28019,28025,28032,28040,28047],{"nctId":27993,"briefTitle":27994,"status":104,"phases":27995,"primaryCompletion":27996,"completion":27996,"start":27997,"conditions":27998,"interventions":27999},"NCT00002411","A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs",[91],"1999-09","1998-03",[24],[13340,10466,13341,27967,13342],{"nctId":28001,"briefTitle":28002,"status":104,"phases":28003,"enrollment":311,"conditions":28004,"interventions":28005},"NCT00002168","A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients",[91],[24],[27966,10466,13341,27967,13342],{"nctId":28007,"briefTitle":28008,"status":104,"phases":28009,"completion":28010,"conditions":28011,"interventions":28012},"NCT00002307","A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected Patients",[91],"1994-12",[24],[13341,27967],{"nctId":28014,"briefTitle":28015,"status":104,"phases":28016,"enrollment":311,"conditions":28017,"interventions":28018},"NCT00002369","A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs",[91],[24],[27966,10466,13341,27967],{"nctId":28020,"briefTitle":28021,"status":104,"phases":28022,"primaryCompletion":7153,"completion":7153,"start":7153,"conditions":28023,"interventions":28024},"NCT00002207","A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected Patients",[91],[24],[13341,13342],{"nctId":28026,"briefTitle":28027,"status":104,"phases":28028,"completion":28029,"conditions":28030,"interventions":28031},"NCT00002308","A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs",[91],"1991-11",[24],[13341],{"nctId":28033,"briefTitle":28034,"status":104,"phases":28035,"primaryCompletion":28036,"completion":28036,"start":28037,"enrollment":3562,"conditions":28038,"interventions":28039},"NCT00002349","A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.",[91],"1999-05","1995-01",[24],[13341],{"nctId":28041,"briefTitle":28042,"status":104,"phases":28043,"primaryCompletion":28044,"completion":28044,"start":7650,"conditions":28045,"interventions":28046},"NCT00002176","A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection",[91],"2000-03",[24],[17367,13340,13341,13342],{"nctId":28048,"briefTitle":28049,"status":104,"phases":28050,"primaryCompletion":28044,"completion":28044,"start":7650,"conditions":28051,"interventions":28052},"NCT00002177","A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection",[91],[24],[17367,13340,13341,13342],{"intervention":1794,"totalTrials":713,"cells":28054},{"EARLY_PHASE1":28055,"PHASE1":28057,"PHASE2":28067,"PHASE3":28106,"PHASE4":28124,"NA":28126},{"trials":28056,"activeCount":98},[],{"trials":28058,"activeCount":98},[28059,28063],{"nctId":6138,"briefTitle":6139,"status":104,"phases":28060,"primaryCompletion":6141,"completion":6142,"start":6143,"enrollment":1063,"conditions":28061,"interventions":28062},[87],[33],[441,1795,1795,1795,1794],{"nctId":15825,"briefTitle":15826,"status":104,"phases":28064,"primaryCompletion":15828,"completion":15828,"start":15829,"enrollment":184,"conditions":28065,"interventions":28066},[87],[33],[1794,1187,1111],{"trials":28068,"activeCount":98},[28069,28073,28082,28086,28090,28094,28098,28102],{"nctId":6192,"briefTitle":6193,"status":104,"phases":28070,"primaryCompletion":6195,"completion":6196,"start":6197,"enrollment":116,"conditions":28071,"interventions":28072},[88],[33],[1794,441,1795],{"nctId":28074,"briefTitle":28075,"status":104,"phases":28076,"primaryCompletion":6204,"completion":28077,"start":28078,"enrollment":11873,"conditions":28079,"interventions":28081},"NCT01441973","Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma",[88],"2017-01-17","2011-12-28",[28080],"Smoldering Multiple Myeloma",[1794],{"nctId":6201,"briefTitle":6202,"status":104,"phases":28083,"primaryCompletion":6204,"completion":6205,"start":6206,"enrollment":12,"conditions":28084,"interventions":28085},[88],[33],[1794,1796,1795,1795,1795,1795],{"nctId":1787,"briefTitle":1788,"status":104,"phases":28087,"primaryCompletion":1790,"completion":1790,"start":1791,"enrollment":1285,"conditions":28088,"interventions":28089},[88],[33],[1794,1795,1795,441,1796,1797,43],{"nctId":1986,"briefTitle":1987,"status":104,"phases":28091,"primaryCompletion":1989,"completion":1990,"start":1991,"enrollment":19,"conditions":28092,"interventions":28093},[88],[33],[1794,1797,1795,43],{"nctId":6222,"briefTitle":6223,"status":104,"phases":28095,"primaryCompletion":4378,"completion":6184,"start":6225,"enrollment":6226,"conditions":28096,"interventions":28097},[88],[6228],[1794,6230,1795,1773],{"nctId":6232,"briefTitle":6233,"status":104,"phases":28099,"primaryCompletion":6235,"completion":6236,"start":6237,"enrollment":1835,"conditions":28100,"interventions":28101},[88],[33],[1794,1797,1795],{"nctId":6241,"briefTitle":6242,"status":104,"phases":28103,"primaryCompletion":6244,"completion":6245,"start":6246,"enrollment":1232,"conditions":28104,"interventions":28105},[88],[33],[441,1795,1794],{"trials":28107,"activeCount":98},[28108,28112,28116,28120],{"nctId":6262,"briefTitle":6263,"status":963,"phases":28109,"primaryCompletion":1118,"completion":1118,"start":6265,"enrollment":2038,"conditions":28110,"interventions":28111},[89],[6267],[441,1795,1794],{"nctId":6270,"briefTitle":6271,"status":104,"phases":28113,"primaryCompletion":724,"completion":6273,"start":6274,"enrollment":6275,"conditions":28114,"interventions":28115},[89],[33],[441,1795,1795,1795,1795,1794,1794],{"nctId":6292,"briefTitle":6293,"status":104,"phases":28117,"primaryCompletion":6295,"completion":6296,"start":6297,"enrollment":6298,"conditions":28118,"interventions":28119},[89],[1426,33],[441,1795,1795,1795,1794],{"nctId":2896,"briefTitle":2897,"status":104,"phases":28121,"primaryCompletion":2899,"completion":2899,"start":2900,"enrollment":1175,"conditions":28122,"interventions":28123},[89],[33],[43,1794,1797,1795],{"trials":28125,"activeCount":98},[],{"trials":28127,"activeCount":98},[28128,28134],{"nctId":28129,"briefTitle":28130,"status":3014,"phases":28131,"conditions":28132,"interventions":28133},"NCT03126617","Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma",[],[33],[1794],{"nctId":6310,"briefTitle":6311,"status":3014,"phases":28135,"conditions":28136,"interventions":28137},[],[33],[1794,441,1795],{"intervention":13342,"totalTrials":1385,"cells":28139},{"EARLY_PHASE1":28140,"PHASE1":28142,"PHASE2":28150,"PHASE3":28164,"PHASE4":28174,"NA":28176},{"trials":28141,"activeCount":98},[],{"trials":28143,"activeCount":98},[28144],{"nctId":28145,"briefTitle":28146,"status":104,"phases":28147,"primaryCompletion":27851,"completion":27851,"start":27851,"enrollment":148,"conditions":28148,"interventions":28149},"NCT00002360","A Study Comparing Two Forms of Didanosine in HIV-infected Patients",[87],[24],[13342],{"trials":28151,"activeCount":98},[28152,28156,28160],{"nctId":17362,"briefTitle":17363,"status":963,"phases":28153,"enrollment":94,"conditions":28154,"interventions":28155},[88],[24],[17353,17367,17368,13341,13342],{"nctId":27848,"briefTitle":27849,"status":104,"phases":28157,"primaryCompletion":10961,"completion":10961,"start":27851,"conditions":28158,"interventions":28159},[88],[24],[8547,13340,13341,13342],{"nctId":17370,"briefTitle":17371,"status":963,"phases":28161,"enrollment":94,"conditions":28162,"interventions":28163},[88],[24],[17353,17367,13099,13341,13342],{"trials":28165,"activeCount":98},[28166,28170],{"nctId":13333,"briefTitle":13334,"status":104,"phases":28167,"primaryCompletion":13336,"completion":13336,"start":13337,"enrollment":290,"conditions":28168,"interventions":28169},[89],[24],[13322,13340,13341,13342],{"nctId":27969,"briefTitle":27970,"status":104,"phases":28171,"primaryCompletion":27851,"completion":27851,"start":27851,"enrollment":3862,"conditions":28172,"interventions":28173},[89],[24],[13340,13341,13342],{"trials":28175,"activeCount":98},[],{"trials":28177,"activeCount":98},[28178,28182,28189,28195,28199,28206,28210,28217,28221],{"nctId":27993,"briefTitle":27994,"status":104,"phases":28179,"primaryCompletion":27996,"completion":27996,"start":27997,"conditions":28180,"interventions":28181},[91],[24],[13340,10466,13341,27967,13342],{"nctId":28183,"briefTitle":28184,"status":104,"phases":28185,"completion":28186,"conditions":28187,"interventions":28188},"NCT00002280","A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine",[91],"1994-11",[24],[13342],{"nctId":28190,"briefTitle":28191,"status":104,"phases":28192,"conditions":28193,"interventions":28194},"NCT00002028","A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)",[91],[24],[13342],{"nctId":28001,"briefTitle":28002,"status":104,"phases":28196,"enrollment":311,"conditions":28197,"interventions":28198},[91],[24],[27966,10466,13341,27967,13342],{"nctId":28200,"briefTitle":28201,"status":104,"phases":28202,"conditions":28203,"interventions":28205},"NCT00002274","A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine",[91],[24,28204],"Leukoencephalopathy, Progressive Multifocal",[13342],{"nctId":28020,"briefTitle":28021,"status":104,"phases":28207,"primaryCompletion":7153,"completion":7153,"start":7153,"conditions":28208,"interventions":28209},[91],[24],[13341,13342],{"nctId":28211,"briefTitle":28212,"status":104,"phases":28213,"completion":28214,"enrollment":9852,"conditions":28215,"interventions":28216},"NCT00002035","Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine",[91],"1992-04",[24],[27967,13342],{"nctId":28041,"briefTitle":28042,"status":104,"phases":28218,"primaryCompletion":28044,"completion":28044,"start":7650,"conditions":28219,"interventions":28220},[91],[24],[17367,13340,13341,13342],{"nctId":28048,"briefTitle":28049,"status":104,"phases":28222,"primaryCompletion":28044,"completion":28044,"start":7650,"conditions":28223,"interventions":28224},[91],[24],[17367,13340,13341,13342],{"intervention":11943,"totalTrials":360,"cells":28226},{"EARLY_PHASE1":28227,"PHASE1":28229,"PHASE2":28241,"PHASE3":28247,"PHASE4":28277,"NA":28279},{"trials":28228,"activeCount":98},[],{"trials":28230,"activeCount":98},[28231,28237],{"nctId":28232,"briefTitle":28233,"status":104,"phases":28234,"primaryCompletion":4114,"completion":4114,"start":3893,"enrollment":725,"conditions":28235,"interventions":28236},"NCT01886599","Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease",[87],[30],[11943],{"nctId":27290,"briefTitle":27291,"status":104,"phases":28238,"primaryCompletion":4160,"completion":4160,"start":1342,"enrollment":506,"conditions":28239,"interventions":28240},[87],[11904],[10402,10402,11943,10402],{"trials":28242,"activeCount":98},[28243],{"nctId":12555,"briefTitle":12556,"status":104,"phases":28244,"primaryCompletion":11981,"completion":1342,"start":5541,"enrollment":12558,"conditions":28245,"interventions":28246},[88],[11896],[10402,11943,12542,11917],{"trials":28248,"activeCount":98},[28249,28253,28257,28261,28265,28269,28273],{"nctId":12858,"briefTitle":12859,"status":104,"phases":28250,"primaryCompletion":6916,"completion":3959,"start":6225,"enrollment":12861,"conditions":28251,"interventions":28252},[89],[11842],[11943,10402,12864,11917],{"nctId":12820,"briefTitle":12821,"status":104,"phases":28254,"primaryCompletion":3959,"completion":1342,"start":3893,"enrollment":12823,"conditions":28255,"interventions":28256},[89],[11896],[10402,11943,11917,12826,12314],{"nctId":13420,"briefTitle":13421,"status":104,"phases":28258,"primaryCompletion":4378,"completion":11981,"start":6225,"enrollment":6275,"conditions":28259,"interventions":28260},[89],[11842],[11943,10402,12038,11917],{"nctId":11938,"briefTitle":11939,"status":104,"phases":28262,"primaryCompletion":10525,"completion":7690,"start":3959,"enrollment":1096,"conditions":28263,"interventions":28264},[89],[30],[10402,11943,9391,11917],{"nctId":27418,"briefTitle":27419,"status":104,"phases":28266,"primaryCompletion":11930,"completion":11930,"start":27421,"enrollment":27422,"conditions":28267,"interventions":28268},[89],[30],[11943,10402],{"nctId":14956,"briefTitle":14957,"status":104,"phases":28270,"primaryCompletion":14959,"completion":4458,"start":4289,"enrollment":10751,"conditions":28271,"interventions":28272},[89],[11896],[10402,11943,14945],{"nctId":27458,"briefTitle":27459,"status":104,"phases":28274,"primaryCompletion":8699,"completion":27461,"start":4458,"enrollment":27462,"conditions":28275,"interventions":28276},[89],[30],[10402,11943],{"trials":28278,"activeCount":98},[],{"trials":28280,"activeCount":98},[28281],{"nctId":28282,"briefTitle":28283,"status":104,"phases":28284,"primaryCompletion":28285,"completion":2966,"start":28286,"enrollment":28287,"conditions":28288,"interventions":28289},"NCT01492504","Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and\u002For Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial",[],"2018-03-16","2012-02-07",1850,[30],[11943],{"intervention":10466,"totalTrials":360,"cells":28291},{"EARLY_PHASE1":28292,"PHASE1":28294,"PHASE2":28296,"PHASE3":28306,"PHASE4":28324,"NA":28334},{"trials":28293,"activeCount":98},[],{"trials":28295,"activeCount":98},[],{"trials":28297,"activeCount":98},[28298,28302],{"nctId":10748,"briefTitle":10749,"status":963,"phases":28299,"primaryCompletion":4123,"completion":4122,"start":3938,"enrollment":10751,"conditions":28300,"interventions":28301},[88],[10753],[10755,10755,10755,9383,10466,8548],{"nctId":27688,"briefTitle":27689,"status":104,"phases":28303,"primaryCompletion":5014,"completion":15783,"start":13336,"enrollment":27691,"conditions":28304,"interventions":28305},[88],[18915,27693],[10680,10466],{"trials":28307,"activeCount":98},[28308,28312,28316,28320],{"nctId":27960,"briefTitle":27961,"status":104,"phases":28309,"primaryCompletion":27963,"completion":27963,"start":7682,"enrollment":1863,"conditions":28310,"interventions":28311},[89],[24],[27966,10466,13341,27967],{"nctId":10460,"briefTitle":10461,"status":963,"phases":28313,"primaryCompletion":7114,"completion":7114,"start":10463,"enrollment":574,"conditions":28314,"interventions":28315},[89],[8545],[8547,902,10466,10436],{"nctId":27983,"briefTitle":27984,"status":104,"phases":28317,"primaryCompletion":12211,"completion":12211,"start":15041,"enrollment":16797,"conditions":28318,"interventions":28319},[89],[24],[9383,10466,13341],{"nctId":10682,"briefTitle":10683,"status":104,"phases":28321,"primaryCompletion":3894,"completion":3902,"start":5023,"enrollment":10685,"conditions":28322,"interventions":28323},[89],[10687],[10680,8548,10661,10466],{"trials":28325,"activeCount":98},[28326,28330],{"nctId":10702,"briefTitle":10703,"status":467,"phases":28327,"primaryCompletion":3977,"completion":3017,"start":5014,"enrollment":98,"conditions":28328,"interventions":28329},[90],[10687],[10466,10680,10661],{"nctId":11549,"briefTitle":11550,"status":104,"phases":28331,"primaryCompletion":7713,"completion":6916,"start":7750,"enrollment":11552,"conditions":28332,"interventions":28333},[90],[10764],[10680,11536,10466,11555],{"trials":28335,"activeCount":98},[28336,28340,28344],{"nctId":27993,"briefTitle":27994,"status":104,"phases":28337,"primaryCompletion":27996,"completion":27996,"start":27997,"conditions":28338,"interventions":28339},[91],[24],[13340,10466,13341,27967,13342],{"nctId":28001,"briefTitle":28002,"status":104,"phases":28341,"enrollment":311,"conditions":28342,"interventions":28343},[91],[24],[27966,10466,13341,27967,13342],{"nctId":28014,"briefTitle":28015,"status":104,"phases":28345,"enrollment":311,"conditions":28346,"interventions":28347},[91],[24],[27966,10466,13341,27967],{"intervention":13134,"totalTrials":1184,"cells":28349},{"EARLY_PHASE1":28350,"PHASE1":28352,"PHASE2":28354,"PHASE3":28372,"PHASE4":28390,"NA":28392},{"trials":28351,"activeCount":98},[],{"trials":28353,"activeCount":98},[],{"trials":28355,"activeCount":98},[28356,28360,28364,28368],{"nctId":27316,"briefTitle":27317,"status":963,"phases":28357,"primaryCompletion":858,"completion":8463,"start":27319,"enrollment":520,"conditions":28358,"interventions":28359},[88],[30,27321],[10402,13134],{"nctId":27328,"briefTitle":27329,"status":467,"phases":28361,"primaryCompletion":27331,"completion":27332,"start":26926,"enrollment":98,"conditions":28362,"interventions":28363},[88],[30],[10402,13134],{"nctId":27336,"briefTitle":27337,"status":467,"phases":28365,"primaryCompletion":27331,"completion":15226,"start":26926,"enrollment":98,"conditions":28366,"interventions":28367},[88],[30],[10402,13134,11917],{"nctId":13126,"briefTitle":13127,"status":104,"phases":28369,"primaryCompletion":13129,"completion":13130,"start":13131,"enrollment":1063,"conditions":28370,"interventions":28371},[88],[30],[13117,11917,13134,13135],{"trials":28373,"activeCount":98},[28374,28378,28382,28386],{"nctId":27374,"briefTitle":27375,"status":104,"phases":28375,"primaryCompletion":847,"completion":26926,"start":4160,"enrollment":28,"conditions":28376,"interventions":28377},[89],[30],[10402,13134,11917],{"nctId":27404,"briefTitle":27405,"status":104,"phases":28379,"primaryCompletion":7690,"completion":8038,"start":12170,"enrollment":1898,"conditions":28380,"interventions":28381},[89],[30],[10402,13134,11917],{"nctId":27434,"briefTitle":27435,"status":104,"phases":28383,"primaryCompletion":11981,"completion":1342,"start":9360,"enrollment":7198,"conditions":28384,"interventions":28385},[89],[30],[10402,13134],{"nctId":27444,"briefTitle":27445,"status":104,"phases":28387,"primaryCompletion":6917,"completion":14959,"start":4551,"enrollment":26812,"conditions":28388,"interventions":28389},[89],[30],[10402,13134],{"trials":28391,"activeCount":98},[],{"trials":28393,"activeCount":98},[28394,28398],{"nctId":27470,"briefTitle":27471,"status":3014,"phases":28395,"conditions":28396,"interventions":28397},[],[11923],[10402,13134,11917],{"nctId":27476,"briefTitle":27477,"status":3014,"phases":28399,"conditions":28400,"interventions":28401},[],[11923],[10402,13134],{"intervention":9383,"totalTrials":839,"cells":28403},{"EARLY_PHASE1":28404,"PHASE1":28406,"PHASE2":28412,"PHASE3":28424,"PHASE4":28434,"NA":28436},{"trials":28405,"activeCount":98},[],{"trials":28407,"activeCount":98},[28408],{"nctId":9377,"briefTitle":9378,"status":104,"phases":28409,"primaryCompletion":4458,"completion":4458,"start":4122,"enrollment":2308,"conditions":28410,"interventions":28411},[87],[9381],[805,9383],{"trials":28413,"activeCount":98},[28414,28418],{"nctId":10748,"briefTitle":10749,"status":963,"phases":28415,"primaryCompletion":4123,"completion":4122,"start":3938,"enrollment":10751,"conditions":28416,"interventions":28417},[88],[10753],[10755,10755,10755,9383,10466,8548],{"nctId":28419,"briefTitle":28420,"status":104,"phases":28421,"primaryCompletion":3679,"completion":7691,"start":7750,"enrollment":7813,"conditions":28422,"interventions":28423},"NCT00364793","Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children",[87,88],[24],[9383],{"trials":28425,"activeCount":98},[28426,28430],{"nctId":13344,"briefTitle":13345,"status":104,"phases":28427,"primaryCompletion":13347,"completion":13347,"start":13036,"conditions":28428,"interventions":28429},[89],[24],[8547,13322,9383],{"nctId":27983,"briefTitle":27984,"status":104,"phases":28431,"primaryCompletion":12211,"completion":12211,"start":15041,"enrollment":16797,"conditions":28432,"interventions":28433},[89],[24],[9383,10466,13341],{"trials":28435,"activeCount":98},[],{"trials":28437,"activeCount":98},[28438,28445,28452],{"nctId":28439,"briefTitle":28440,"status":3014,"phases":28441,"primaryCompletion":6918,"completion":6918,"start":28442,"conditions":28443,"interventions":28444},"NCT00162188","An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada",[],"2001-05",[22520],[9383],{"nctId":28446,"briefTitle":28447,"status":104,"phases":28448,"primaryCompletion":14959,"completion":14959,"start":1342,"enrollment":28449,"conditions":28450,"interventions":28451},"NCT02426866","Risk of CV Events With EFV vs. EFV-free Regimens",[],29612,[9381],[9383],{"nctId":28453,"briefTitle":28454,"status":3014,"phases":28455,"primaryCompletion":6918,"completion":6918,"start":28456,"conditions":28457,"interventions":28458},"NCT00162227","An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection",[],"2000-09",[22520],[9383],{"intervention":13340,"totalTrials":1750,"cells":28460},{"EARLY_PHASE1":28461,"PHASE1":28463,"PHASE2":28465,"PHASE3":28471,"PHASE4":28485,"NA":28487},{"trials":28462,"activeCount":98},[],{"trials":28464,"activeCount":98},[],{"trials":28466,"activeCount":98},[28467],{"nctId":27848,"briefTitle":27849,"status":104,"phases":28468,"primaryCompletion":10961,"completion":10961,"start":27851,"conditions":28469,"interventions":28470},[88],[24],[8547,13340,13341,13342],{"trials":28472,"activeCount":98},[28473,28477,28481],{"nctId":13333,"briefTitle":13334,"status":104,"phases":28474,"primaryCompletion":13336,"completion":13336,"start":13337,"enrollment":290,"conditions":28475,"interventions":28476},[89],[24],[13322,13340,13341,13342],{"nctId":27885,"briefTitle":27886,"status":963,"phases":28478,"primaryCompletion":12211,"completion":12211,"start":27888,"enrollment":290,"conditions":28479,"interventions":28480},[89],[24],[8547,13340],{"nctId":27969,"briefTitle":27970,"status":104,"phases":28482,"primaryCompletion":27851,"completion":27851,"start":27851,"enrollment":3862,"conditions":28483,"interventions":28484},[89],[24],[13340,13341,13342],{"trials":28486,"activeCount":98},[],{"trials":28488,"activeCount":98},[28489,28493,28497],{"nctId":27993,"briefTitle":27994,"status":104,"phases":28490,"primaryCompletion":27996,"completion":27996,"start":27997,"conditions":28491,"interventions":28492},[91],[24],[13340,10466,13341,27967,13342],{"nctId":28041,"briefTitle":28042,"status":104,"phases":28494,"primaryCompletion":28044,"completion":28044,"start":7650,"conditions":28495,"interventions":28496},[91],[24],[17367,13340,13341,13342],{"nctId":28048,"briefTitle":28049,"status":104,"phases":28498,"primaryCompletion":28044,"completion":28044,"start":7650,"conditions":28499,"interventions":28500},[91],[24],[17367,13340,13341,13342],{"intervention":26789,"totalTrials":1750,"cells":28502},{"EARLY_PHASE1":28503,"PHASE1":28505,"PHASE2":28507,"PHASE3":28525,"PHASE4":28535,"NA":28537},{"trials":28504,"activeCount":98},[],{"trials":28506,"activeCount":98},[],{"trials":28508,"activeCount":98},[28509,28513,28517,28521],{"nctId":26784,"briefTitle":26785,"status":963,"phases":28510,"primaryCompletion":10431,"completion":10431,"start":4379,"enrollment":3162,"conditions":28511,"interventions":28512},[88],[3940],[26789,1197],{"nctId":26809,"briefTitle":26810,"status":104,"phases":28514,"primaryCompletion":1342,"completion":1342,"start":4179,"enrollment":26812,"conditions":28515,"interventions":28516},[88],[15736],[1197,26789],{"nctId":26836,"briefTitle":26837,"status":104,"phases":28518,"primaryCompletion":26839,"completion":26840,"start":26841,"enrollment":26842,"conditions":28519,"interventions":28520},[88],[26822],[26789,1197],{"nctId":26846,"briefTitle":26847,"status":104,"phases":28522,"primaryCompletion":4379,"completion":5023,"start":7812,"enrollment":331,"conditions":28523,"interventions":28524},[88],[1195,26806],[1197,26789],{"trials":28526,"activeCount":98},[28527,28531],{"nctId":26917,"briefTitle":26918,"status":963,"phases":28528,"primaryCompletion":11511,"completion":11511,"start":6960,"enrollment":574,"conditions":28529,"interventions":28530},[89],[15736],[1197,26789],{"nctId":26923,"briefTitle":26924,"status":104,"phases":28532,"primaryCompletion":5014,"completion":26926,"start":11728,"enrollment":26927,"conditions":28533,"interventions":28534},[89],[26829],[1197,26789],{"trials":28536,"activeCount":98},[],{"trials":28538,"activeCount":98},[28539],{"nctId":28540,"briefTitle":28541,"status":104,"phases":28542,"primaryCompletion":3903,"completion":3903,"start":4348,"enrollment":7198,"conditions":28543,"interventions":28545},"NCT01188278","Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey",[],[28544],"Leukemia, Myeloid, Chronic-Phase (CML-CP)",[26789],{"intervention":12490,"totalTrials":1750,"cells":28547},{"EARLY_PHASE1":28548,"PHASE1":28550,"PHASE2":28552,"PHASE3":28554,"PHASE4":28568,"NA":28570},{"trials":28549,"activeCount":98},[],{"trials":28551,"activeCount":98},[],{"trials":28553,"activeCount":98},[],{"trials":28555,"activeCount":98},[28556,28560,28564],{"nctId":12465,"briefTitle":12466,"status":104,"phases":28557,"primaryCompletion":5098,"completion":5098,"start":12468,"enrollment":12469,"conditions":28558,"interventions":28559},[88,89],[12461,12462],[11001,12435,12472,12473,12474],{"nctId":27125,"briefTitle":27126,"status":104,"phases":28561,"primaryCompletion":27128,"completion":27128,"start":11776,"enrollment":27129,"conditions":28562,"interventions":28563},[89],[10858,27131],[12490,12491],{"nctId":12484,"briefTitle":12485,"status":104,"phases":28565,"primaryCompletion":4123,"completion":4123,"start":4039,"enrollment":12487,"conditions":28566,"interventions":28567},[89],[12461],[12435,12490,12491],{"trials":28569,"activeCount":98},[],{"trials":28571,"activeCount":98},[28572,28576,28580,28584],{"nctId":27211,"briefTitle":27212,"status":104,"phases":28573,"primaryCompletion":10525,"completion":10525,"start":7927,"enrollment":27214,"conditions":28574,"interventions":28575},[],[10858],[12491,27208,27209,12490],{"nctId":27230,"briefTitle":27231,"status":104,"phases":28577,"primaryCompletion":27233,"completion":27233,"start":27234,"enrollment":27235,"conditions":28578,"interventions":28579},[],[10858],[11001,27238,27239,12472],{"nctId":27251,"briefTitle":27252,"status":104,"phases":28581,"primaryCompletion":8030,"completion":8030,"start":7690,"enrollment":27254,"conditions":28582,"interventions":28583},[],[10858],[27208,27209,12491,12490],{"nctId":27266,"briefTitle":27267,"status":104,"phases":28585,"primaryCompletion":1192,"completion":1192,"start":27269,"enrollment":27270,"conditions":28586,"interventions":28587},[],[10858],[12472,11001,27238,27239],{"intervention":27967,"totalTrials":830,"cells":28589},{"EARLY_PHASE1":28590,"PHASE1":28592,"PHASE2":28594,"PHASE3":28596,"PHASE4":28602,"NA":28604},{"trials":28591,"activeCount":98},[],{"trials":28593,"activeCount":98},[],{"trials":28595,"activeCount":98},[],{"trials":28597,"activeCount":98},[28598],{"nctId":27960,"briefTitle":27961,"status":104,"phases":28599,"primaryCompletion":27963,"completion":27963,"start":7682,"enrollment":1863,"conditions":28600,"interventions":28601},[89],[24],[27966,10466,13341,27967],{"trials":28603,"activeCount":98},[],{"trials":28605,"activeCount":98},[28606,28610,28614,28618,28622],{"nctId":27993,"briefTitle":27994,"status":104,"phases":28607,"primaryCompletion":27996,"completion":27996,"start":27997,"conditions":28608,"interventions":28609},[91],[24],[13340,10466,13341,27967,13342],{"nctId":28001,"briefTitle":28002,"status":104,"phases":28611,"enrollment":311,"conditions":28612,"interventions":28613},[91],[24],[27966,10466,13341,27967,13342],{"nctId":28007,"briefTitle":28008,"status":104,"phases":28615,"completion":28010,"conditions":28616,"interventions":28617},[91],[24],[13341,27967],{"nctId":28014,"briefTitle":28015,"status":104,"phases":28619,"enrollment":311,"conditions":28620,"interventions":28621},[91],[24],[27966,10466,13341,27967],{"nctId":28211,"briefTitle":28212,"status":104,"phases":28623,"completion":28214,"enrollment":9852,"conditions":28624,"interventions":28625},[91],[24],[27967,13342],{"intervention":27208,"totalTrials":520,"cells":28627},{"EARLY_PHASE1":28628,"PHASE1":28630,"PHASE2":28632,"PHASE3":28634,"PHASE4":28636,"NA":28638},{"trials":28629,"activeCount":98},[],{"trials":28631,"activeCount":98},[],{"trials":28633,"activeCount":98},[],{"trials":28635,"activeCount":98},[],{"trials":28637,"activeCount":98},[],{"trials":28639,"activeCount":98},[28640,28644,28648,28652,28656],{"nctId":27198,"briefTitle":27199,"status":104,"phases":28641,"primaryCompletion":27201,"completion":27202,"start":27203,"enrollment":27204,"conditions":28642,"interventions":28643},[],[25518],[27207,11001,27208,27209],{"nctId":27211,"briefTitle":27212,"status":104,"phases":28645,"primaryCompletion":10525,"completion":10525,"start":7927,"enrollment":27214,"conditions":28646,"interventions":28647},[],[10858],[12491,27208,27209,12490],{"nctId":27230,"briefTitle":27231,"status":104,"phases":28649,"primaryCompletion":27233,"completion":27233,"start":27234,"enrollment":27235,"conditions":28650,"interventions":28651},[],[10858],[11001,27238,27239,12472],{"nctId":27251,"briefTitle":27252,"status":104,"phases":28653,"primaryCompletion":8030,"completion":8030,"start":7690,"enrollment":27254,"conditions":28654,"interventions":28655},[],[10858],[27208,27209,12491,12490],{"nctId":27266,"briefTitle":27267,"status":104,"phases":28657,"primaryCompletion":1192,"completion":1192,"start":27269,"enrollment":27270,"conditions":28658,"interventions":28659},[],[10858],[12472,11001,27238,27239],{"intervention":27209,"totalTrials":520,"cells":28661},{"EARLY_PHASE1":28662,"PHASE1":28664,"PHASE2":28666,"PHASE3":28668,"PHASE4":28670,"NA":28672},{"trials":28663,"activeCount":98},[],{"trials":28665,"activeCount":98},[],{"trials":28667,"activeCount":98},[],{"trials":28669,"activeCount":98},[],{"trials":28671,"activeCount":98},[],{"trials":28673,"activeCount":98},[28674,28678,28682,28686,28690],{"nctId":27198,"briefTitle":27199,"status":104,"phases":28675,"primaryCompletion":27201,"completion":27202,"start":27203,"enrollment":27204,"conditions":28676,"interventions":28677},[],[25518],[27207,11001,27208,27209],{"nctId":27211,"briefTitle":27212,"status":104,"phases":28679,"primaryCompletion":10525,"completion":10525,"start":7927,"enrollment":27214,"conditions":28680,"interventions":28681},[],[10858],[12491,27208,27209,12490],{"nctId":27230,"briefTitle":27231,"status":104,"phases":28683,"primaryCompletion":27233,"completion":27233,"start":27234,"enrollment":27235,"conditions":28684,"interventions":28685},[],[10858],[11001,27238,27239,12472],{"nctId":27251,"briefTitle":27252,"status":104,"phases":28687,"primaryCompletion":8030,"completion":8030,"start":7690,"enrollment":27254,"conditions":28688,"interventions":28689},[],[10858],[27208,27209,12491,12490],{"nctId":27266,"briefTitle":27267,"status":104,"phases":28691,"primaryCompletion":1192,"completion":1192,"start":27269,"enrollment":27270,"conditions":28692,"interventions":28693},[],[10858],[12472,11001,27238,27239],{"intervention":12313,"totalTrials":4328,"cells":28695},{"EARLY_PHASE1":28696,"PHASE1":28698,"PHASE2":28700,"PHASE3":28702,"PHASE4":28716,"NA":28718},{"trials":28697,"activeCount":98},[],{"trials":28699,"activeCount":98},[],{"trials":28701,"activeCount":98},[],{"trials":28703,"activeCount":98},[28704,28708,28712],{"nctId":12304,"briefTitle":12305,"status":104,"phases":28705,"primaryCompletion":12307,"completion":12308,"start":12309,"enrollment":12310,"conditions":28706,"interventions":28707},[89],[11842],[12313,12096,11917,12314],{"nctId":12322,"briefTitle":12323,"status":104,"phases":28709,"primaryCompletion":11981,"completion":11981,"start":4123,"enrollment":3562,"conditions":28710,"interventions":28711},[89],[12326],[12313,11917,12300],{"nctId":12329,"briefTitle":12330,"status":104,"phases":28713,"primaryCompletion":6917,"completion":6917,"start":3903,"enrollment":12332,"conditions":28714,"interventions":28715},[89],[30],[12313,12096,11917,10402,12314],{"trials":28717,"activeCount":98},[],{"trials":28719,"activeCount":98},[28720],{"nctId":28721,"briefTitle":28722,"status":104,"phases":28723,"primaryCompletion":7690,"completion":7690,"start":6169,"enrollment":27422,"conditions":28724,"interventions":28725},"NCT01525810","Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial",[],[30],[12313],{"intervention":17367,"totalTrials":4328,"cells":28727},{"EARLY_PHASE1":28728,"PHASE1":28730,"PHASE2":28732,"PHASE3":28742,"PHASE4":28744,"NA":28746},{"trials":28729,"activeCount":98},[],{"trials":28731,"activeCount":98},[],{"trials":28733,"activeCount":98},[28734,28738],{"nctId":17362,"briefTitle":17363,"status":963,"phases":28735,"enrollment":94,"conditions":28736,"interventions":28737},[88],[24],[17353,17367,17368,13341,13342],{"nctId":17370,"briefTitle":17371,"status":963,"phases":28739,"enrollment":94,"conditions":28740,"interventions":28741},[88],[24],[17353,17367,13099,13341,13342],{"trials":28743,"activeCount":98},[],{"trials":28745,"activeCount":98},[],{"trials":28747,"activeCount":98},[28748,28752],{"nctId":28041,"briefTitle":28042,"status":104,"phases":28749,"primaryCompletion":28044,"completion":28044,"start":7650,"conditions":28750,"interventions":28751},[91],[24],[17367,13340,13341,13342],{"nctId":28048,"briefTitle":28049,"status":104,"phases":28753,"primaryCompletion":28044,"completion":28044,"start":7650,"conditions":28754,"interventions":28755},[91],[24],[17367,13340,13341,13342],{"intervention":28757,"totalTrials":574,"cells":28758},"Orencia",{"EARLY_PHASE1":28759,"PHASE1":28761,"PHASE2":28763,"PHASE3":28765,"PHASE4":28767,"NA":28769},{"trials":28760,"activeCount":98},[],{"trials":28762,"activeCount":98},[],{"trials":28764,"activeCount":98},[],{"trials":28766,"activeCount":98},[],{"trials":28768,"activeCount":98},[],{"trials":28770,"activeCount":98},[28771,28778,28784],{"nctId":28772,"briefTitle":28773,"status":104,"phases":28774,"primaryCompletion":26926,"completion":26926,"start":6916,"enrollment":28775,"conditions":28776,"interventions":28777},"NCT02600468","Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg",[],671,[15],[28757],{"nctId":28779,"briefTitle":28780,"status":467,"phases":28781,"primaryCompletion":2272,"completion":2272,"start":1965,"enrollment":98,"conditions":28782,"interventions":28783},"NCT01694693","Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study",[],[15],[28757],{"nctId":28785,"briefTitle":28786,"status":104,"phases":28787,"primaryCompletion":27331,"completion":27331,"start":6916,"enrollment":2620,"conditions":28788,"interventions":28789},"NCT02600455","Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL",[],[15],[28757],{"intervention":27966,"totalTrials":574,"cells":28791},{"EARLY_PHASE1":28792,"PHASE1":28794,"PHASE2":28796,"PHASE3":28798,"PHASE4":28804,"NA":28806},{"trials":28793,"activeCount":98},[],{"trials":28795,"activeCount":98},[],{"trials":28797,"activeCount":98},[],{"trials":28799,"activeCount":98},[28800],{"nctId":27960,"briefTitle":27961,"status":104,"phases":28801,"primaryCompletion":27963,"completion":27963,"start":7682,"enrollment":1863,"conditions":28802,"interventions":28803},[89],[24],[27966,10466,13341,27967],{"trials":28805,"activeCount":98},[],{"trials":28807,"activeCount":98},[28808,28812],{"nctId":28001,"briefTitle":28002,"status":104,"phases":28809,"enrollment":311,"conditions":28810,"interventions":28811},[91],[24],[27966,10466,13341,27967,13342],{"nctId":28014,"briefTitle":28015,"status":104,"phases":28813,"enrollment":311,"conditions":28814,"interventions":28815},[91],[24],[27966,10466,13341,27967],{"intervention":28817,"totalTrials":574,"cells":28818},"No Intervention",{"EARLY_PHASE1":28819,"PHASE1":28821,"PHASE2":28823,"PHASE3":28825,"PHASE4":28827,"NA":28829},{"trials":28820,"activeCount":98},[],{"trials":28822,"activeCount":98},[],{"trials":28824,"activeCount":98},[],{"trials":28826,"activeCount":98},[],{"trials":28828,"activeCount":98},[],{"trials":28830,"activeCount":98},[28831,28839,28847],{"nctId":28832,"briefTitle":28833,"status":104,"phases":28834,"primaryCompletion":6184,"completion":6184,"start":3679,"enrollment":28835,"conditions":28836,"interventions":28838},"NCT01450605","Korean Post-marketing Surveillance for Reyataz®",[],601,[28837],"HIV-1",[28817],{"nctId":28840,"briefTitle":28841,"status":104,"phases":28842,"primaryCompletion":21365,"completion":21365,"start":28843,"enrollment":28844,"conditions":28845,"interventions":28846},"NCT01386359","Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant",[],"2012-02-29",914,[7054],[28817],{"nctId":28848,"briefTitle":28849,"status":104,"phases":28850,"primaryCompletion":8030,"completion":8030,"start":7088,"enrollment":2544,"conditions":28851,"interventions":28852},"NCT01583244","Korean Post-marketing Surveillance for Orencia®",[],[15],[28817],{"intervention":28854,"totalTrials":230,"cells":28855},"Systemic therapy",{"EARLY_PHASE1":28856,"PHASE1":28858,"PHASE2":28860,"PHASE3":28862,"PHASE4":28864,"NA":28866},{"trials":28857,"activeCount":98},[],{"trials":28859,"activeCount":98},[],{"trials":28861,"activeCount":98},[],{"trials":28863,"activeCount":98},[],{"trials":28865,"activeCount":98},[],{"trials":28867,"activeCount":98},[28868,28878],{"nctId":28869,"briefTitle":28870,"status":104,"phases":28871,"primaryCompletion":28872,"completion":28872,"start":28873,"enrollment":28874,"conditions":28875,"interventions":28877},"NCT06422247","Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy",[],"2025-02-05","2024-04-05",307,[28876],"Peripheral T-cell Lymphoma",[28854],{"nctId":28879,"briefTitle":28880,"status":104,"phases":28881,"primaryCompletion":28882,"completion":28882,"start":28883,"enrollment":28884,"conditions":28885,"interventions":28886},"NCT06160167","Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs",[],"2024-08-01","2023-10-01",4204,[33],[28887,28888,28854],"IMiD treatment","No IMiD treatment",{"intervention":19445,"totalTrials":230,"cells":28890},{"EARLY_PHASE1":28891,"PHASE1":28893,"PHASE2":28895,"PHASE3":28901,"PHASE4":28903,"NA":28905},{"trials":28892,"activeCount":98},[],{"trials":28894,"activeCount":98},[],{"trials":28896,"activeCount":98},[28897],{"nctId":19438,"briefTitle":19439,"status":104,"phases":28898,"primaryCompletion":1749,"completion":19441,"start":19442,"enrollment":515,"conditions":28899,"interventions":28900},[88],[1253],[19429,19445],{"trials":28902,"activeCount":98},[],{"trials":28904,"activeCount":98},[],{"trials":28906,"activeCount":98},[28907],{"nctId":28908,"briefTitle":28909,"status":467,"phases":28910,"primaryCompletion":28911,"completion":28912,"start":8023,"enrollment":98,"conditions":28913,"interventions":28914},"NCT02854488","Yervoy Pregnancy Surveillance Study",[],"2021-02-05","2021-03-05",[21],[19445],{"intervention":28916,"totalTrials":230,"cells":28917},"Nystatin",{"EARLY_PHASE1":28918,"PHASE1":28920,"PHASE2":28922,"PHASE3":28924,"PHASE4":28926,"NA":28928},{"trials":28919,"activeCount":98},[],{"trials":28921,"activeCount":98},[],{"trials":28923,"activeCount":98},[],{"trials":28925,"activeCount":98},[],{"trials":28927,"activeCount":98},[],{"trials":28929,"activeCount":98},[28930,28937],{"nctId":28931,"briefTitle":28932,"status":104,"phases":28933,"conditions":28934,"interventions":28936},"NCT00002293","A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes",[91],[28935,24],"Candidiasis, Oral",[28916],{"nctId":28938,"briefTitle":28939,"status":104,"phases":28940,"conditions":28941,"interventions":28942},"NCT00002057","Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC",[91],[28935,24],[28916],{"intervention":28944,"totalTrials":230,"cells":28945},"Elotuzumab in combination with Lenalidomide and Dexamethasone",{"EARLY_PHASE1":28946,"PHASE1":28948,"PHASE2":28950,"PHASE3":28952,"PHASE4":28954,"NA":28956},{"trials":28947,"activeCount":98},[],{"trials":28949,"activeCount":98},[],{"trials":28951,"activeCount":98},[],{"trials":28953,"activeCount":98},[],{"trials":28955,"activeCount":98},[],{"trials":28957,"activeCount":98},[28958,28964],{"nctId":28959,"briefTitle":28960,"status":3014,"phases":28961,"conditions":28962,"interventions":28963},"NCT02368301","Expanded Access Treatment Protocol CA204-143",[],[33],[28944],{"nctId":28965,"briefTitle":28966,"status":104,"phases":28967,"primaryCompletion":28968,"completion":28968,"start":330,"enrollment":1750,"conditions":28969,"interventions":28970},"NCT06163040","A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan",[],"2025-03-17",[6287],[28971,28972],"Elotuzumab in combination with pomalidomide and dexamethasone","Elotuzumab in combination with lenalidomide and dexamethasone",{"intervention":28974,"totalTrials":208,"cells":28975},"Amphotericin B",{"EARLY_PHASE1":28976,"PHASE1":28978,"PHASE2":28980,"PHASE3":28982,"PHASE4":28984,"NA":28986},{"trials":28977,"activeCount":98},[],{"trials":28979,"activeCount":98},[],{"trials":28981,"activeCount":98},[],{"trials":28983,"activeCount":98},[],{"trials":28985,"activeCount":98},[],{"trials":28987,"activeCount":98},[28988],{"nctId":28989,"briefTitle":28990,"status":104,"phases":28991,"conditions":28992,"interventions":28994},"NCT00002041","Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients",[91],[28993,24],"Candidiasis, Esophageal",[28974],{"intervention":26968,"totalTrials":208,"cells":28996},{"EARLY_PHASE1":28997,"PHASE1":28999,"PHASE2":29001,"PHASE3":29003,"PHASE4":29005,"NA":29007},{"trials":28998,"activeCount":98},[],{"trials":29000,"activeCount":98},[],{"trials":29002,"activeCount":98},[],{"trials":29004,"activeCount":98},[],{"trials":29006,"activeCount":98},[],{"trials":29008,"activeCount":98},[29009],{"nctId":26961,"briefTitle":26962,"status":104,"phases":29010,"primaryCompletion":26926,"completion":6184,"start":26926,"enrollment":26964,"conditions":29011,"interventions":29012},[],[26966],[26762,26968],{"intervention":27207,"totalTrials":208,"cells":29014},{"EARLY_PHASE1":29015,"PHASE1":29017,"PHASE2":29019,"PHASE3":29021,"PHASE4":29023,"NA":29025},{"trials":29016,"activeCount":98},[],{"trials":29018,"activeCount":98},[],{"trials":29020,"activeCount":98},[],{"trials":29022,"activeCount":98},[],{"trials":29024,"activeCount":98},[],{"trials":29026,"activeCount":98},[29027],{"nctId":27198,"briefTitle":27199,"status":104,"phases":29028,"primaryCompletion":27201,"completion":27202,"start":27203,"enrollment":27204,"conditions":29029,"interventions":29030},[],[25518],[27207,11001,27208,27209],{"intervention":29032,"totalTrials":208,"cells":29033},"LPV\u002FRTV + 2NRTIs",{"EARLY_PHASE1":29034,"PHASE1":29036,"PHASE2":29038,"PHASE3":29040,"PHASE4":29042,"NA":29044},{"trials":29035,"activeCount":98},[],{"trials":29037,"activeCount":98},[],{"trials":29039,"activeCount":98},[],{"trials":29041,"activeCount":98},[],{"trials":29043,"activeCount":98},[],{"trials":29045,"activeCount":98},[29046],{"nctId":29047,"briefTitle":29048,"status":104,"phases":29049,"primaryCompletion":13053,"completion":13053,"start":17418,"enrollment":311,"conditions":29050,"interventions":29051},"NCT00096746","Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects",[],[22520],[29032,29032],{"intervention":29053,"totalTrials":208,"cells":29054},"Anti-IL8",{"EARLY_PHASE1":29055,"PHASE1":29057,"PHASE2":29059,"PHASE3":29061,"PHASE4":29063,"NA":29065},{"trials":29056,"activeCount":98},[],{"trials":29058,"activeCount":98},[],{"trials":29060,"activeCount":98},[],{"trials":29062,"activeCount":98},[],{"trials":29064,"activeCount":98},[],{"trials":29066,"activeCount":98},[29067],{"nctId":29068,"briefTitle":29069,"status":3014,"phases":29070,"conditions":29071,"interventions":29072},"NCT05210894","Expanded Access for Anti-IL8",[],[],[29053],{"intervention":29074,"totalTrials":208,"cells":29075},"Lobucavir",{"EARLY_PHASE1":29076,"PHASE1":29078,"PHASE2":29080,"PHASE3":29082,"PHASE4":29084,"NA":29086},{"trials":29077,"activeCount":98},[],{"trials":29079,"activeCount":98},[],{"trials":29081,"activeCount":98},[],{"trials":29083,"activeCount":98},[],{"trials":29085,"activeCount":98},[],{"trials":29087,"activeCount":98},[29088],{"nctId":29089,"briefTitle":29090,"status":104,"phases":29091,"enrollment":148,"conditions":29092,"interventions":29094},"NCT00002352","A Study of Lobucavir in Patients With AIDS",[91],[29093,24],"Cytomegalovirus Infections",[29074],{"intervention":29096,"totalTrials":208,"cells":29097},"Nivolumab + Ipilimumab combination therapy",{"EARLY_PHASE1":29098,"PHASE1":29100,"PHASE2":29102,"PHASE3":29104,"PHASE4":29106,"NA":29108},{"trials":29099,"activeCount":98},[],{"trials":29101,"activeCount":98},[],{"trials":29103,"activeCount":98},[],{"trials":29105,"activeCount":98},[],{"trials":29107,"activeCount":98},[],{"trials":29109,"activeCount":98},[29110],{"nctId":29111,"briefTitle":29112,"status":104,"phases":29113,"primaryCompletion":2221,"completion":2221,"start":29114,"enrollment":29115,"conditions":29116,"interventions":29118},"NCT06345183","Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients",[],"2024-02-19",327,[29117],"Advanced Renal Cell Carcinoma (aRCC)",[29096,29119],"Pembrolizumab + Lenvatinib combination therapy",{"intervention":29119,"totalTrials":208,"cells":29121},{"EARLY_PHASE1":29122,"PHASE1":29124,"PHASE2":29126,"PHASE3":29128,"PHASE4":29130,"NA":29132},{"trials":29123,"activeCount":98},[],{"trials":29125,"activeCount":98},[],{"trials":29127,"activeCount":98},[],{"trials":29129,"activeCount":98},[],{"trials":29131,"activeCount":98},[],{"trials":29133,"activeCount":98},[29134],{"nctId":29111,"briefTitle":29112,"status":104,"phases":29135,"primaryCompletion":2221,"completion":2221,"start":29114,"enrollment":29115,"conditions":29136,"interventions":29137},[],[29117],[29096,29119],{"intervention":3052,"totalTrials":208,"cells":29139},{"EARLY_PHASE1":29140,"PHASE1":29142,"PHASE2":29144,"PHASE3":29146,"PHASE4":29148,"NA":29150},{"trials":29141,"activeCount":98},[],{"trials":29143,"activeCount":98},[],{"trials":29145,"activeCount":98},[],{"trials":29147,"activeCount":98},[],{"trials":29149,"activeCount":98},[],{"trials":29151,"activeCount":98},[29152],{"nctId":3044,"briefTitle":3045,"status":104,"phases":29153,"primaryCompletion":3047,"completion":3048,"start":3049,"enrollment":660,"conditions":29154,"interventions":29155},[],[21],[3052,43],{"intervention":29157,"totalTrials":208,"cells":29158},"Magnetic Resonance Imaging with Contrast",{"EARLY_PHASE1":29159,"PHASE1":29161,"PHASE2":29163,"PHASE3":29165,"PHASE4":29167,"NA":29169},{"trials":29160,"activeCount":98},[],{"trials":29162,"activeCount":98},[],{"trials":29164,"activeCount":98},[],{"trials":29166,"activeCount":98},[],{"trials":29168,"activeCount":98},[],{"trials":29170,"activeCount":98},[29171],{"nctId":29172,"briefTitle":29173,"status":104,"phases":29174,"primaryCompletion":10518,"completion":10518,"start":3938,"enrollment":29175,"conditions":29176,"interventions":29177},"NCT01137578","Pediatric Catheter-related Thrombosis Imaging Study",[91],151,[11063],[29157],{"intervention":8138,"totalTrials":208,"cells":29179},{"EARLY_PHASE1":29180,"PHASE1":29182,"PHASE2":29184,"PHASE3":29186,"PHASE4":29188,"NA":29190},{"trials":29181,"activeCount":98},[],{"trials":29183,"activeCount":98},[],{"trials":29185,"activeCount":98},[],{"trials":29187,"activeCount":98},[],{"trials":29189,"activeCount":98},[],{"trials":29191,"activeCount":98},[29192],{"nctId":8130,"briefTitle":8131,"status":104,"phases":29193,"primaryCompletion":2837,"completion":2837,"start":8133,"enrollment":8134,"conditions":29194,"interventions":29195},[],[7054,8136],[8138,7057],{"intervention":29197,"totalTrials":208,"cells":29198},"BMS-986094\u002FINX-08189",{"EARLY_PHASE1":29199,"PHASE1":29201,"PHASE2":29203,"PHASE3":29205,"PHASE4":29207,"NA":29209},{"trials":29200,"activeCount":98},[],{"trials":29202,"activeCount":98},[],{"trials":29204,"activeCount":98},[],{"trials":29206,"activeCount":98},[],{"trials":29208,"activeCount":98},[],{"trials":29210,"activeCount":98},[29211],{"nctId":29212,"briefTitle":29213,"status":104,"phases":29214,"primaryCompletion":3017,"completion":3017,"start":3893,"enrollment":6961,"conditions":29215,"interventions":29216},"NCT01732848","A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)",[],[759,30],[29197],{"intervention":27804,"totalTrials":208,"cells":29218},{"EARLY_PHASE1":29219,"PHASE1":29221,"PHASE2":29223,"PHASE3":29225,"PHASE4":29227,"NA":29229},{"trials":29220,"activeCount":98},[],{"trials":29222,"activeCount":98},[],{"trials":29224,"activeCount":98},[],{"trials":29226,"activeCount":98},[],{"trials":29228,"activeCount":98},[],{"trials":29230,"activeCount":98},[29231],{"nctId":27796,"briefTitle":27797,"status":104,"phases":29232,"primaryCompletion":27799,"completion":27799,"start":27800,"enrollment":27801,"conditions":29233,"interventions":29234},[],[10764],[10697,27804],{"intervention":29236,"totalTrials":208,"cells":29237},"Immunotherapy",{"EARLY_PHASE1":29238,"PHASE1":29240,"PHASE2":29242,"PHASE3":29244,"PHASE4":29246,"NA":29248},{"trials":29239,"activeCount":98},[],{"trials":29241,"activeCount":98},[],{"trials":29243,"activeCount":98},[],{"trials":29245,"activeCount":98},[],{"trials":29247,"activeCount":98},[],{"trials":29249,"activeCount":98},[29250],{"nctId":29251,"briefTitle":29252,"status":104,"phases":29253,"primaryCompletion":29254,"completion":29254,"start":3178,"enrollment":790,"conditions":29255,"interventions":29256},"NCT06163053","A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home",[],"2025-06-12",[606,1515],[29236],{"intervention":29258,"totalTrials":208,"cells":29259},"BET Inhibitor",{"EARLY_PHASE1":29260,"PHASE1":29262,"PHASE2":29264,"PHASE3":29266,"PHASE4":29268,"NA":29270},{"trials":29261,"activeCount":98},[],{"trials":29263,"activeCount":98},[],{"trials":29265,"activeCount":98},[],{"trials":29267,"activeCount":98},[],{"trials":29269,"activeCount":98},[],{"trials":29271,"activeCount":98},[29272],{"nctId":29273,"briefTitle":29274,"status":3014,"phases":29275,"conditions":29276,"interventions":29277},"NCT05301972","Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor",[],[],[29258],{"intervention":29279,"totalTrials":208,"cells":29280},"ORENCIA Subcutaneous",{"EARLY_PHASE1":29281,"PHASE1":29283,"PHASE2":29285,"PHASE3":29287,"PHASE4":29289,"NA":29291},{"trials":29282,"activeCount":98},[],{"trials":29284,"activeCount":98},[],{"trials":29286,"activeCount":98},[],{"trials":29288,"activeCount":98},[],{"trials":29290,"activeCount":98},[],{"trials":29292,"activeCount":98},[29293],{"nctId":29294,"briefTitle":29295,"status":104,"phases":29296,"primaryCompletion":6393,"completion":6393,"start":29297,"enrollment":29298,"conditions":29299,"interventions":29300},"NCT02758769","Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings",[],"2016-06-07",303,[15],[29279],{"intervention":29302,"totalTrials":208,"cells":29303},"Veronate",{"EARLY_PHASE1":29304,"PHASE1":29306,"PHASE2":29308,"PHASE3":29310,"PHASE4":29312,"NA":29314},{"trials":29305,"activeCount":98},[],{"trials":29307,"activeCount":98},[],{"trials":29309,"activeCount":98},[],{"trials":29311,"activeCount":98},[],{"trials":29313,"activeCount":98},[],{"trials":29315,"activeCount":98},[29316],{"nctId":29317,"briefTitle":29318,"status":104,"phases":29319,"primaryCompletion":5117,"completion":5117,"start":12230,"enrollment":3360,"conditions":29320,"interventions":29325},"NCT00113191","Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants",[91],[29321,29322,29323,29324],"Nosocomial Infections","Sepsis","Staphylococcal Infections","Candidemia",[29302],{"intervention":29327,"totalTrials":208,"cells":29328},"Sinemet® controlled release",{"EARLY_PHASE1":29329,"PHASE1":29331,"PHASE2":29333,"PHASE3":29335,"PHASE4":29337,"NA":29339},{"trials":29330,"activeCount":98},[],{"trials":29332,"activeCount":98},[],{"trials":29334,"activeCount":98},[],{"trials":29336,"activeCount":98},[],{"trials":29338,"activeCount":98},[],{"trials":29340,"activeCount":98},[29341],{"nctId":29342,"briefTitle":29343,"status":104,"phases":29344,"completion":10821,"start":4664,"enrollment":319,"conditions":29345,"interventions":29347},"NCT00460954","A Multiple-Dose Study of Sinemet® CR (Carbidopa\u002FLevodopa) in Healthy Subjects",[],[29346],"Parkinson's Disease",[29327],{"intervention":29349,"totalTrials":208,"cells":29350},"Nivolumab + platinum-based chemotherapy",{"EARLY_PHASE1":29351,"PHASE1":29353,"PHASE2":29355,"PHASE3":29357,"PHASE4":29359,"NA":29361},{"trials":29352,"activeCount":98},[],{"trials":29354,"activeCount":98},[],{"trials":29356,"activeCount":98},[],{"trials":29358,"activeCount":98},[],{"trials":29360,"activeCount":98},[],{"trials":29362,"activeCount":98},[29363],{"nctId":29364,"briefTitle":29365,"status":104,"phases":29366,"primaryCompletion":1739,"completion":1739,"start":29367,"enrollment":22,"conditions":29368,"interventions":29369},"NCT07141563","A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC",[],"2025-05-26",[3131],[29349],{"intervention":29371,"totalTrials":208,"cells":29372},"metreleptin",{"EARLY_PHASE1":29373,"PHASE1":29375,"PHASE2":29377,"PHASE3":29379,"PHASE4":29381,"NA":29383},{"trials":29374,"activeCount":98},[],{"trials":29376,"activeCount":98},[],{"trials":29378,"activeCount":98},[],{"trials":29380,"activeCount":98},[],{"trials":29382,"activeCount":98},[],{"trials":29384,"activeCount":98},[29385],{"nctId":29386,"briefTitle":29387,"status":104,"phases":29388,"primaryCompletion":14959,"completion":14959,"start":4981,"enrollment":11873,"conditions":29389,"interventions":29391},"NCT00677313","An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and\u002For Hypertriglyceridemia Associated With Lipodystrophy",[91],[29390],"Lipodystrophy",[29371],{"intervention":29393,"totalTrials":208,"cells":29394},"No Interventions",{"EARLY_PHASE1":29395,"PHASE1":29397,"PHASE2":29399,"PHASE3":29401,"PHASE4":29403,"NA":29405},{"trials":29396,"activeCount":98},[],{"trials":29398,"activeCount":98},[],{"trials":29400,"activeCount":98},[],{"trials":29402,"activeCount":98},[],{"trials":29404,"activeCount":98},[],{"trials":29406,"activeCount":98},[29407],{"nctId":29408,"briefTitle":29409,"status":104,"phases":29410,"primaryCompletion":1434,"completion":27202,"start":29411,"enrollment":3986,"conditions":29412,"interventions":29413},"NCT01087125","Abatacept Pregnancy Exposure Registry",[],"2006-09-01",[15],[29393],{"intervention":676,"totalTrials":208,"cells":29415},{"EARLY_PHASE1":29416,"PHASE1":29418,"PHASE2":29420,"PHASE3":29422,"PHASE4":29424,"NA":29426},{"trials":29417,"activeCount":98},[],{"trials":29419,"activeCount":98},[],{"trials":29421,"activeCount":98},[],{"trials":29423,"activeCount":98},[],{"trials":29425,"activeCount":98},[],{"trials":29427,"activeCount":98},[29428],{"nctId":666,"briefTitle":667,"status":104,"phases":29429,"primaryCompletion":669,"completion":669,"start":670,"enrollment":671,"conditions":29430,"interventions":29431},[],[673],[590,675,676,677],{"intervention":677,"totalTrials":208,"cells":29433},{"EARLY_PHASE1":29434,"PHASE1":29436,"PHASE2":29438,"PHASE3":29440,"PHASE4":29442,"NA":29444},{"trials":29435,"activeCount":98},[],{"trials":29437,"activeCount":98},[],{"trials":29439,"activeCount":98},[],{"trials":29441,"activeCount":98},[],{"trials":29443,"activeCount":98},[],{"trials":29445,"activeCount":98},[29446],{"nctId":666,"briefTitle":667,"status":104,"phases":29447,"primaryCompletion":669,"completion":669,"start":670,"enrollment":671,"conditions":29448,"interventions":29449},[],[673],[590,675,676,677],{"intervention":29451,"totalTrials":208,"cells":29452},"Nivolumab + Ipilimumab + Chemotherapy",{"EARLY_PHASE1":29453,"PHASE1":29455,"PHASE2":29457,"PHASE3":29459,"PHASE4":29461,"NA":29463},{"trials":29454,"activeCount":98},[],{"trials":29456,"activeCount":98},[],{"trials":29458,"activeCount":98},[],{"trials":29460,"activeCount":98},[],{"trials":29462,"activeCount":98},[],{"trials":29464,"activeCount":98},[29465],{"nctId":29466,"briefTitle":29467,"status":104,"phases":29468,"primaryCompletion":581,"completion":581,"start":29469,"enrollment":1729,"conditions":29470,"interventions":29471},"NCT07526961","Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland",[],"2025-12-01",[36],[29451],{"intervention":29473,"totalTrials":208,"cells":29474},"efavirenz; didanosine EC; lamivudine",{"EARLY_PHASE1":29475,"PHASE1":29477,"PHASE2":29479,"PHASE3":29481,"PHASE4":29483,"NA":29485},{"trials":29476,"activeCount":98},[],{"trials":29478,"activeCount":98},[],{"trials":29480,"activeCount":98},[],{"trials":29482,"activeCount":98},[],{"trials":29484,"activeCount":98},[],{"trials":29486,"activeCount":98},[29487],{"nctId":29488,"briefTitle":29489,"status":104,"phases":29490,"primaryCompletion":17418,"completion":17418,"start":7724,"enrollment":8663,"conditions":29491,"interventions":29492},"NCT00116415","DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy",[91],[24,11253],[29473],{"intervention":28971,"totalTrials":208,"cells":29494},{"EARLY_PHASE1":29495,"PHASE1":29497,"PHASE2":29499,"PHASE3":29501,"PHASE4":29503,"NA":29505},{"trials":29496,"activeCount":98},[],{"trials":29498,"activeCount":98},[],{"trials":29500,"activeCount":98},[],{"trials":29502,"activeCount":98},[],{"trials":29504,"activeCount":98},[],{"trials":29506,"activeCount":98},[29507],{"nctId":28965,"briefTitle":28966,"status":104,"phases":29508,"primaryCompletion":28968,"completion":28968,"start":330,"enrollment":1750,"conditions":29509,"interventions":29510},[],[6287],[28971,28972],{"intervention":28887,"totalTrials":208,"cells":29512},{"EARLY_PHASE1":29513,"PHASE1":29515,"PHASE2":29517,"PHASE3":29519,"PHASE4":29521,"NA":29523},{"trials":29514,"activeCount":98},[],{"trials":29516,"activeCount":98},[],{"trials":29518,"activeCount":98},[],{"trials":29520,"activeCount":98},[],{"trials":29522,"activeCount":98},[],{"trials":29524,"activeCount":98},[29525],{"nctId":28879,"briefTitle":28880,"status":104,"phases":29526,"primaryCompletion":28882,"completion":28882,"start":28883,"enrollment":28884,"conditions":29527,"interventions":29528},[],[33],[28887,28888,28854],{"intervention":28888,"totalTrials":208,"cells":29530},{"EARLY_PHASE1":29531,"PHASE1":29533,"PHASE2":29535,"PHASE3":29537,"PHASE4":29539,"NA":29541},{"trials":29532,"activeCount":98},[],{"trials":29534,"activeCount":98},[],{"trials":29536,"activeCount":98},[],{"trials":29538,"activeCount":98},[],{"trials":29540,"activeCount":98},[],{"trials":29542,"activeCount":98},[29543],{"nctId":28879,"briefTitle":28880,"status":104,"phases":29544,"primaryCompletion":28882,"completion":28882,"start":28883,"enrollment":28884,"conditions":29545,"interventions":29546},[],[33],[28887,28888,28854],{"intervention":29548,"totalTrials":208,"cells":29549},"Nulojix",{"EARLY_PHASE1":29550,"PHASE1":29552,"PHASE2":29554,"PHASE3":29556,"PHASE4":29558,"NA":29560},{"trials":29551,"activeCount":98},[],{"trials":29553,"activeCount":98},[],{"trials":29555,"activeCount":98},[],{"trials":29557,"activeCount":98},[],{"trials":29559,"activeCount":98},[],{"trials":29561,"activeCount":98},[29562],{"nctId":29563,"briefTitle":29564,"status":104,"phases":29565,"primaryCompletion":29566,"completion":29566,"start":6917,"enrollment":680,"conditions":29567,"interventions":29568},"NCT02500498","Safety Profile of Nulojix in Home Infusion Settings",[],"2015-06",[15],[29548],{"intervention":29570,"totalTrials":208,"cells":29571},"Nivolumab plus Relatlimab FDC",{"EARLY_PHASE1":29572,"PHASE1":29574,"PHASE2":29576,"PHASE3":29578,"PHASE4":29580,"NA":29582},{"trials":29573,"activeCount":98},[],{"trials":29575,"activeCount":98},[],{"trials":29577,"activeCount":98},[],{"trials":29579,"activeCount":98},[],{"trials":29581,"activeCount":98},[],{"trials":29583,"activeCount":98},[29584],{"nctId":29585,"briefTitle":29586,"status":3014,"phases":29587,"conditions":29588,"interventions":29589},"NCT05170685","Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab",[],[],[29570],{"intervention":29591,"totalTrials":208,"cells":29592},"Eliquis",{"EARLY_PHASE1":29593,"PHASE1":29595,"PHASE2":29597,"PHASE3":29599,"PHASE4":29601,"NA":29603},{"trials":29594,"activeCount":98},[],{"trials":29596,"activeCount":98},[],{"trials":29598,"activeCount":98},[],{"trials":29600,"activeCount":98},[],{"trials":29602,"activeCount":98},[],{"trials":29604,"activeCount":98},[29605],{"nctId":29606,"briefTitle":29607,"status":104,"phases":29608,"primaryCompletion":29609,"completion":29609,"start":29610,"enrollment":29611,"conditions":29612,"interventions":29613},"NCT02007655","Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation",[],"2016-08-31","2013-09-01",6372,[27248],[29591]]